Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.7.1.137 - phosphatidylinositol 3-kinase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abortion, Spontaneous
Lnc-HZ08 regulates BPDE-induced trophoblast cell dysfunctions by promoting PI3K ubiquitin degradation and is associated with miscarriage.
Acidosis
Acidosis impairs insulin receptor substrate-1-associated phosphoinositide 3-kinase signaling in muscle cells: consequences on proteolysis.
Acidosis-induced protein tyrosine phosphorylation depends on Ca2+ influx via voltage-dependent Ca2+ channels in SHR aorta.
Extracellular acidosis elevates carbonic anhydrase IX in human glioblastoma cells via transcriptional modulation that does not depend on hypoxia.
Extracellular acidosis induces neutrophil activation by a mechanism dependent on activation of phosphatidylinositol 3-kinase/Akt and ERK pathways.
Inhibition of SNAT2 by metabolic acidosis enhances proteolysis in skeletal muscle.
Mild acidosis delays neutrophil apoptosis via multiple signaling pathways and acts in concert with inflammatory mediators.
Acne Vulgaris
Insulin and insulin-like growth factor-1 can modulate the phosphoinositide-3-kinase/Akt/FoxO1 pathway in SZ95 sebocytes in vitro.
Role of insulin resistance and diet in acne.
Acromegaly
The possible role of mRNA expression changes of GH/IGF-1/insulin axis components in subcutaneous adipose tissue in metabolic disturbances of patients with acromegaly.
Acute Kidney Injury
Mangiferin Ameliorates Cisplatin Induced Acute Kidney Injury by Upregulating Nrf-2 via the Activation of PI3K and Exhibits Synergistic Anticancer Activity With Cisplatin.
Acute Lung Injury
Dexamethasone ameliorates H2S-induced acute lung injury by increasing claudin-5 expression via the PI3K pathway.
Effective attenuation of acute lung injury in vivo and the formyl peptide-induced neutrophil activation in vitro by CYL-26z through the phosphoinositide 3-kinase gamma pathway.
The role of endothelial PI3Kgamma activity in neutrophil trafficking.
Transforming growth factor beta1 inhibits cystic fibrosis transmembrane conductance regulator-dependent cAMP-stimulated alveolar epithelial fluid transport via a phosphatidylinositol 3-kinase-dependent mechanism.
Adenocarcinoma
A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers.
Activation of MUC1 mucin expression by bile acids in human esophageal adenocarcinomatous cells and tissues is mediated by the phosphatidylinositol 3-kinase.
Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung.
Apoptosis initiation of ?-ionone in SGC-7901 gastric carcinoma cancer cells via a PI3K-AKT pathway.
Colon Cancer Tumorigenesis Initiated by the H1047R Mutant PI3K.
Computational Analysis of Drug Resistance Network in Lung Adenocarcinoma.
Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Dedifferentiation of adenocarcinomas by activation of phosphatidylinositol 3-kinase.
Dehydroglyasperin D Inhibits the Proliferation of HT-29 Human Colorectal Cancer Cells Through Direct Interaction With Phosphatidylinositol 3-kinase.
Distinctive Patterns of CTNNB1 (?-Catenin) Alterations in Salivary Gland Basal Cell Adenoma and Basal Cell Adenocarcinoma.
Dysbindin promotes progression of pancreatic ductal adenocarcinoma via direct activation of PI3K.
Elevated phosphatidylinositol 3-kinase activation and its clinicopathological significance in cervical cancer.
ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells.
Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations.
Expression of PI3K, PTEN and Akt in small intestinal adenocarcinoma detected by quantum dots-based immunofluorescence technology.
Expression of PI3K/AKT pathway in gastric cancer and its blockade suppresses tumor growth and metastasis.
FKBP10 functioned as a cancer-promoting factor mediates cell proliferation, invasion, and migration via regulating PI3K signaling pathway in stomach adenocarcinoma.
HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas.
Heterozygous disruption of the PTEN promotes intestinal neoplasia in APCmin/+ mouse: roles of osteopontin.
Impairement of HT29 Cancer Cells Cohesion by the Soluble Form of Neurotensin Receptor-3.
Improved survival associated with somatic PIK3CA mutations in copy-number low endometrioid endometrial adenocarcinoma.
Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer.
Key role of phosphoinositide 3-kinase class IB in pancreatic cancer.
MAPK and PI3K inhibition reduces proliferation of Barrett's adenocarcinoma in vitro.
Mechanisms behind signet ring cell carcinoma formation.
MEK inhibitors in oncology: a patent review (2015-Present).
Mice expressing activated PI3K rapidly develop advanced colon cancer.
Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer.
Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus.
Phosphatidylinositol 3-kinase CB association with preoperative radiotherapy response in rectal adenocarcinoma.
Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics.
Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells.
PI3K inhibition as a novel therapeutic strategy for neoadjuvant chemoradiotherapy resistant oesophageal adenocarcinoma.
PI3K signaling maintains c-myc expression to regulate transcription of E2F1 in pancreatic cancer cells.
PlGF knockdown inhibited tumor survival and migration in gastric cancer cell via PI3K/Akt and p38MAPK pathways.
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Regulation and function of autophagy in pancreatic cancer.
RSK activation via ERK modulates human colon cancer cells response to PTHrP.
Signal transduction mechanism of biased ligands at histamine H2 receptors.
Simultaneous targeting PI3K and PERK pathways promotes cell death and improves the clinical prognosis in esophageal squamous carcinoma.
Stimulation of signal transducer and activator of transcription-1 (STAT1)-dependent gene transcription by lipopolysaccharide and interferon-gamma is regulated by mammalian target of rapamycin.
Synergy between phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung.
Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma.
Targeting autophagy in disease: established and new strategies.
Targeting PI3K and RAD51 in Barrett's Adenocarcinoma: Impact on DNA Damage Checkpoints, Expression Profile and Tumor Growth.
Targeting PI3K Pathway in Pancreatic Ductal Adenocarcinoma: Rationale and Progress.
The regulation of cell motility and chemotaxis by phospholipid signaling.
Vascular endothelial growth factor is an autocrine survival factor for breast tumour cells under hypoxia.
ZSTK474, a PI3K inhibitor, suppresses proliferation and sensitizes human pancreatic adenocarcinoma cells to gemcitabine.
Adenocarcinoma of Lung
Analysis of genomic variation in lung adenocarcinoma patients revealed the critical role of PI3K complex.
Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis.
Different clinical effects upon separate inhibition of coexisting EGFR and PI3KCA mutations in a lung adenocarcinoma patient.
Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma.
Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor.
Effects of BENC-511, a novel PI3K inhibitor, on the proliferation and apoptosis of A549 human lung adenocarcinoma cells.
Effects of PI3K inhibitor NVP-BKM120 on acquired resistance to gefitinib of human lung adenocarcinoma H1975 cells.
ERBB3-Independent Activation of the PI3K Pathway in EGFR-Mutant Lung Adenocarcinomas.
Exploring the importance of cancer pathways by meta-analysis of differential protein expression networks in three different cancers.
Expression and Comparison of Cbl-b in Lung Squamous Cell Carcinoma and Adenocarcinoma.
Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer.
Interleukin-1?-induced interleukin-6 production in A549 cells is mediated by both phosphatidylinositol 3-kinase and interleukin-1 receptor-associated kinase-4.
LncRNA MALAT1 regulates trophoblast cells migration and invasion via miR-206/IGF-1 axis.
mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma.
Naphtho[1,2-b]furan-4,5-dione inactivates EGFR and PI3K/Akt signaling pathways in human lung adenocarcinoma A549 cells.
Neferine augments therapeutic efficacy of cisplatin through ROS- mediated non-canonical autophagy in human lung adenocarcinoma (A549 cells).
Oncogenic activation of the PI3-kinase p110? isoform via the tumor-derived PIK3C?(D1067V) kinase domain mutation.
Oncogenic RIT1 mutations in lung adenocarcinoma.
Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer.
PI3K expression predicts overall survival in lung adenocarcinoma.
Podocalyxin influences malignant potential by controlling epithelial-mesenchymal transition in lung adenocarcinoma.
RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers.
Roles of TP53 gene in the development of resistance to PI3K inhibitor resistances in CRISPR-Cas9-edited lung adenocarcinoma cells.
Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma.
Synergy between phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung.
ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism.
[Advances on driver oncogenes of non-small cell lung cancer].
[Effect of Buzhong Yiqi decoction on PI3K and AKT in spleen, stomach and lung of nude mice with lung adenocarcinoma transplantation tumor].
Adenocarcinoma, Follicular
Nuclear receptor corepressor is a novel regulator of phosphatidylinositol 3-kinase signaling.
The Transcriptional Regulation of FOXO Genes in Thyrocytes.
Adenocarcinoma, Mucinous
PIK3CA and APC mutations are synergistic in the development of intestinal cancers.
Adenoma
Autocrine induction of invasion and metastasis by tumor-associated trypsin inhibitor in human colon cancer cells.
BCL-3 expression promotes colorectal tumorigenesis through activation of AKT signalling.
Diagnostic and Prognostic Biomarkers of Adrenal Cortical Carcinoma.
Distinctive Patterns of CTNNB1 (?-Catenin) Alterations in Salivary Gland Basal Cell Adenoma and Basal Cell Adenocarcinoma.
Expression of Glut-1, HIF-1?, PI3K and p-Akt in a case of ceruminous adenoma.
Genetic and epigenetic aberrations occurring in colorectal tumors associated with serrated pathway.
Heterozygous disruption of the PTEN promotes intestinal neoplasia in APCmin/+ mouse: roles of osteopontin.
Molecular Alterations in Circulating Cell-Free DNA in Patients with Colorectal Adenoma or Carcinoma.
Sclerosing Polycystic "Adenosis" of Salivary Glands: A Neoplasm Characterized by PI3K Pathway Alterations More Correctly Named Sclerosing Polycystic Adenoma.
Sclerosing Polycystic Adenoma: Conclusive Clinical and Molecular Evidence of Its Neoplastic Nature.
Senescence-associated tissue microenvironment promotes colon cancer formation through the secretory factor GDF15.
The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2?×?2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients.
[PI3K p85alpha expression and its role in the progression of colorectal cancer.]
Adenomatous Polyposis Coli
Adenomatous polyposis coli and Asef function downstream of hepatocyte growth factor and phosphatidylinositol 3-kinase.
Clustered DNA lesion sites as a source of mutations during human colorectal tumourigenesis.
Genomic instability and colon carcinogenesis: from the perspective of genes.
Whole-exome sequencing of duodenal adenocarcinoma identifies recurrent Wnt/?-catenin signaling pathway mutations.
Adenomyoepithelioma
Problematic breast tumors reassessed in light of novel molecular data.
Adenomyosis
Loss of PP2A and PTEN immunoexpression coexists with survivin overexpression in adenomyosis.
Adenoviridae Infections
Adenovirus E4-ORF1 Dysregulates Epidermal Growth Factor and Insulin/Insulin-Like Growth Factor Receptors To Mediate Constitutive Myc Expression.
Adrenal Cortex Neoplasms
Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma.
Adrenocortical Carcinoma
AngII induces transient phospholipase D activity in the H295R glomerulosa cell model.
Insulin-Like Growth Factor-Phosphatidylinositol 3 Kinase Signaling in Canine Cortisol-Secreting Adrenocortical Tumors.
Agammaglobulinemia
Agammaglobulinemia and absent B lineage cells in a patient lacking the p85? subunit of PI3K.
aldehyde dehydrogenase (nad+) deficiency
Aldehyde dehydrogenase 2 deficiency blunts compensatory cardiac hypertrophy through modulating Akt phosphorylation early after transverse aorta constriction in mice.
Alveolar Bone Loss
A circRNA-miRNA-mRNA network plays a role in the protective effect of diosgenin on alveolar bone loss in ovariectomized rats.
Alzheimer Disease
"Olfactory three-needle" acupuncture enhances synaptic function in A?1-42-induced Alzheimer's disease via activating PI3K/AKT/GSK-3? signaling pathway.
Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade.
AMPK activation does not enhance autophagy in neurons in contrast to MTORC1 inhibition: different impact on ?-amyloid clearance.
Autophagy: a potential key contributor to the therapeutic action of mesenchymal stem cells.
Bilobalide regulates soluble amyloid precursor protein release via phosphatidyl inositol 3 kinase-dependent pathway.
Crocin protects against beta-amyloid peptide-induced apoptosis in PC12 cells via PI3 K pathway.
Genome-wide analysis reveals mechanisms modulating autophagy in normal brain aging and in Alzheimer's disease.
Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention.
Negative regulation of Vps34 by Cdk mediated phosphorylation.
Neuroprotective effect of Annona muricata-derived polysaccharides in neuronal HT22 cell damage induced by hydrogen peroxide.
PI3 kinase signaling is involved in Abeta-induced memory loss in Drosophila.
PI3K inhibition causes the accumulation of ubiquitinated presenilin 1 without affecting the proteasome activity.
Presenilins mediate phosphatidylinositol 3-kinase/AKT and ERK activation via select signaling receptors. Selectivity of PS2 in platelet-derived growth factor signaling.
Prolonged Alzheimer-like tau hyperphosphorylation induced by simultaneous inhibition of phosphoinositol-3 kinase and protein kinase C in N2a cells.
Ubiquitination status does not affect Vps34 degradation.
Upstream regulators of phosphoinositide 3-kinase and their role in diseases.
[Effects of curcumin on expression of PI3K and p-pI3K in hippocampus of AD mice].
Ameloblastoma
FAK, paxillin, and PI3K in ameloblastoma and adenomatoid odontogenic tumor.
Immunohistochemical detection of phosphorylated Akt, PI3K, and PTEN in ameloblastic tumors.
TNFalpha played a role in induction of Akt and MAPK signals in ameloblastoma.
Amnesia
Clionosterol and Ethyl Cholestan-22-enol Isolated from the Rhizome of Polygala tenuifolia Inhibit Phosphatidylinositol 3-Kinase/Akt Pathway.
Amyloidosis
Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia.
Amyotrophic Lateral Sclerosis
Phosphatidylinositol 3-kinase: increased activity and protein level in amyotrophic lateral sclerosis.
Targeting autophagy in disease: established and new strategies.
Anaphylaxis
Anaphylactic shock depends on PI3K and eNOS-derived NO.
Loss of IL-4R?-mediated PI3K signaling accelerates the progression of IgE/mast cell-mediated reactions.
Phosphoinositide 3-kinase gamma: a key modulator in inflammation and allergy.
Protein kinase CK2/PTEN pathway plays a key role in platelet-activating factor-mediated murine anaphylactic shock.
Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells.
Anemia
Equine lentivirus counteracts SAMHD1 restriction by Rev-mediated degradation of SAMHD1 via the BECN1-dependent lysosomal pathway.
Aneurysm
Abnormal mechanosensing and cofilin activation promote the progression of ascending aortic aneurysms in mice.
Antiphospholipid Syndrome
Inhibition of the mTORC pathway in the antiphospholipid syndrome.
Anus Neoplasms
Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.
Aortic Aneurysm, Abdominal
Astragaloside IV Attenuated 3,4-Benzopyrene-Induced Abdominal Aortic Aneurysm by Ameliorating Macrophage-Mediated Inflammation.
Inhibition of Phosphatidylinositol 3-Kinase ? by IPI-549 Attenuates Abdominal Aortic Aneurysm Formation in Mice.
Inhibition of Phosphatidylinositol 3-kinease suppresses formation and progression of experimental abdominal aortic aneurysms.
Arrhythmias, Cardiac
Cardioprotection by PI3K-mediated signaling is required for anti-arrhythmia and myocardial repair in response to ischemic preconditioning in infarcted pig hearts.
Arteriovenous Malformations
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Somatic Gain of KRAS Function in the Endothelium Is Sufficient to Cause Vascular Malformations That Require MEK but Not PI3K Signaling.
Arteritis
Coronavirus interactions with the cellular autophagy machinery.
Arthritis
Adiponectin Induces Oncostatin M Expression in Osteoblasts through the PI3K/Akt Signaling Pathway.
BAFF/BAFF-R involved in antibodies production of rats with collagen-induced arthritis via PI3K-Akt-mTOR signaling and the regulation of paeoniflorin.
CCN1 induces oncostatin M production in osteoblasts via integrin-dependent signal pathways.
Gastrin-releasing peptide receptor (GRPR) mediates chemotaxis in neutrophils.
Inhibitory effects of ZSTK474, a phosphatidylinositol 3-kinase inhibitor, on adjuvant-induced arthritis in rats.
Interleukin-1?-induced interleukin-6 production in A549 cells is mediated by both phosphatidylinositol 3-kinase and interleukin-1 receptor-associated kinase-4.
Loss of phosphoinositide 3-kinase gamma decreases migration and activation of phagocytes but not T cell activation in antigen-induced arthritis.
MiR-let-7a regulates anti-citrullinated protein antibody-induced macrophage activation and correlates with the development of experimental rheumatoid arthritis.
The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats.
The PI3K/Akt/PTEN/mTOR pathway: a fruitful target for inducing cell death in rheumatoid arthritis?
Thrombin promotes matrix metalloproteinase-13 expression through the PKC? c-Src/EGFR/PI3K/Akt/AP-1 signaling pathway in human chondrocytes.
[Effect of Xinfeng Capsule on Beclin1/PI3K-AKT-mTOR of Adjuvant Arthritis Rats].
[Relations of synovial angiogenesis and PTEN/PI3K/AKT signaling pathway in rats with adjuvant arthritis].
[Therapeutic potential of phosphoinositide 3-kinase inhibitors in rheumatoid arthritis]
Arthritis, Experimental
Relationship between PI3K pathway and angiogenesis in CIA rat synovium.
The PI-3-Kinase P110? Catalytic Subunit of T Lymphocytes Modulates Collagen-Induced Arthritis.
[Effect of Xinfeng Capsule on Beclin1/PI3K-AKT-mTOR of Adjuvant Arthritis Rats].
Arthritis, Psoriatic
The PI3K/Akt/PTEN/mTOR pathway: a fruitful target for inducing cell death in rheumatoid arthritis?
Arthritis, Rheumatoid
Amelioration of collagen-induced arthritis in rats by adenovirus-mediated PTEN gene transfer.
Autophagy promotes citrullination of VIM (vimentin) and its interaction with major histocompatibility complex class II in synovial fibroblasts.
Cytokine-stimulated T cells induce macrophage IL-10 production dependent on phosphatidylinositol 3-kinase and p70S6K: implications for rheumatoid arthritis.
Downregulated microRNA-135a ameliorates rheumatoid arthritis by inactivation of the phosphatidylinositol 3-kinase/AKT signaling pathway via phosphatidylinositol 3-kinase regulatory subunit 2.
Effect of CD95 on inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes.
Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor kappaB pathways in tumor necrosis factor alpha production in rheumatoid arthritis.
META060 inhibits osteoclastogenesis and MMPs in vitro, and reduces bone and cartilage degradation in a mouse model of rheumatoid arthritis.
Necessary role of phosphatidylinositol 3-kinase in transforming growth factor beta-mediated activation of Akt in normal and rheumatoid arthritis synovial fibroblasts.
PI3 kinase ? is a key regulator of synoviocyte function in rheumatoid arthritis.
PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond?
Recent patents of gene sequences relative to the phosphatidylinositol 3-kinase/Akt pathway and their relevance to drug discovery.
Relationship between PI3K pathway and angiogenesis in CIA rat synovium.
Retraction.
Small molecule inhibitors of phosphoinositide 3-kinase (PI3K) delta and gamma.
The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats.
The PI-3-Kinase P110? Catalytic Subunit of T Lymphocytes Modulates Collagen-Induced Arthritis.
Upstream regulators of phosphoinositide 3-kinase and their role in diseases.
[Abnormal signaling activity of phosphatidylinositol 3-kinase pathway in peripheral blood T cells from patients with systemic lupus erythematosus]
[Therapeutic potential of phosphoinositide 3-kinase inhibitors in rheumatoid arthritis]
Asthenozoospermia
Phosphatidylinositol 3-kinase inhibition enhances human sperm motility and sperm-zona pellucida binding.
Phosphatidylinositol 3-kinase inhibition enhances human sperm motility.
[Influence of LY294002 on sperm motility in asthenozoospermia patients in vitro]
Asthma
Advances in development of phosphatidylinositol 3-kinase inhibitors.
Allergic airway hyperresponsiveness, inflammation, and remodeling do not develop in phosphoinositide 3-kinase gamma-deficient mice.
An anti-inflammatory role for a phosphoinositide 3-kinase inhibitor LY294002 in a mouse asthma model.
Anti-inflammatory potential of PI3K? and JAK inhibitors in asthma patients.
Asthma & COPD - SMi's sixth annual conference.
Comprehensive attenuation of IL-25-induced airway hyperresponsiveness, inflammation and remodelling by the PI3K inhibitor LY294002.
Defining Bronchial Asthma with Phosphoinositide 3-Kinase Delta Activation: Towards Endotype-Driven Management.
DEK-targeting aptamer DTA-64 attenuates bronchial EMT-mediated airway remodelling by suppressing TGF-?1/Smad, MAPK and PI3K signalling pathway in asthma.
Differential dependence of eosinophil chemotactic responses on phosphoinositide 3-kinase (PI3K).
Doxycycline reduces airway inflammation and hyperresponsiveness in a murine model of toluene diisocyanate-induced asthma.
Dual ERK and phosphatidylinositol 3-kinase pathways control airway smooth muscle proliferation: differences in asthma.
Enhancement of allergic responses in vivo and in vitro by butylated hydroxytoluene.
IL-17A induces glucocorticoid insensitivity in human bronchial epithelial cells.
Inflammatory cellular phenotypes and molecular mechanisms of glucocorticoid resistance in patients with bronchial asthma.
Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis.
Inhibiting AKT phosphorylation employing non-cytotoxic anthraquinones ameliorates TH2 mediated allergic airways disease and rhinovirus exacerbation.
Investigation into the Role of PI3K and JAK3 Kinase Inhibitors in Murine Models of Asthma.
Involvement of PTEN in airway hyperresponsiveness and inflammation in bronchial asthma.
Mechanisms of BDNF regulation in asthmatic airway smooth muscle.
p110?/? Double-Deficiency Induces Eosinophilia and IgE Production but Protects from OVA-Induced Airway Inflammation.
Phenotypic characterization of lung macrophages in asthmatic patients: Overexpression of CCL17.
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) reduces vascular endothelial growth factor expression in allergen-induced airway inflammation.
Phosphatidylinositol 3-kinase inhibitor suppresses inducible nitric oxide synthase expression in bronchiole epithelial cells in asthmatic rats.
Phosphatidylinositol 3-Kinase Mediates ?-Catenin Dysfunction of Airway Epithelium in a Toluene Diisocyanate-Induced Murine Asthma Model.
Phosphatidylinositol 3-kinase mediates mitogen-induced human airway smooth muscle cell proliferation.
Phosphatidylinositol 3-kinase-? controls endoplasmic reticulum membrane fluidity and permeability in fungus-induced allergic inflammation in mice.
Phosphatidylinositol 3-kinases pathway mediates lung caspase-1 activation and high mobility group box 1 production in a toluene-diisocyanate induced murine asthma model.
Phosphoinositide 3-kinase delta inhibitor as a novel therapeutic agent in asthma.
Phosphoinositide 3-kinase gamma regulates airway smooth muscle contraction by modulating calcium oscillations.
Phosphoinositide 3-Kinase in Asthma: Novel Roles and Therapeutic Approaches.
PI 3-Kinase isoform specific effects in airway mesenchymal cell function.
PI3-Kinase Regulates Eosinophil and Neutrophil Degranulation in Patients with Allergic Rhinitis and Allergic Asthma Irrespective of Allergen Challenge Model.
PI3K and Notch signal pathways coordinately regulate the activation and proliferation of T lymphocytes in asthma.
PI3K inhibitor treatment ameliorates the glucocorticoid insensitivity of PBMCs in severe asthma.
PI3K, p38 and JAK/STAT signalling in bronchial tissue from patients with asthma following allergen challenge.
PI3K/AKT/mTOR and TLR4/MyD88/NF-?B Signaling Inhibitors Attenuate Pathological Mechanisms of Allergic Asthma.
PI3K? contributes to ER stress-associated asthma through ER-redox disturbances: the involvement of the RIDD-RIG-I-NF-?B axis.
Secretory Inositol Polyphosphate 4-Phosphatase Protects Against Airway Inflammation and Remodeling.
Small molecule inhibitors of phosphoinositide 3-kinase (PI3K) delta and gamma.
The anti-malaria drug artesunate inhibits cigarette smoke and ovalbumin concurrent exposure-induced airway inflammation and might reverse glucocorticoid insensitivity.
The pathophysiological roles of PI3Ks and therapeutic potential of selective inhibitors in allergic inflammation.
The phosphatidylinositide 3-kinase (PI3K) signaling pathway is a determinant of zileuton response in adults with asthma.
The phosphoinositide 3'-kinase p110? modulates contractile protein production and IL-6 release in human airway smooth muscle.
[Coordinated regulation of PI3K and Notch signal pathways in the activation and proliferation of CD4(+)T lymphocytes in asthma mice].
[Expression profiles of PI3K, NF-?B, and STAT1 in peripheral blood mononuclear cells in children with bronchial asthma].
[Intervention mechanism of moxa-cone moxibustion at Shu- and Mu-acupoints on the expression of ROR?t/Foxp3 in asthma mice: an analysis based on PI3K signaling pathway].
[The effect of phosphoinositide-3-kinase and signal transducer and activator of transcription-6 on the proliferation of T lymphocytes in bronchial asthma]
Astrocytoma
A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.
Activation of phosphatidylinositol 3 kinase by muscarinic receptors in astrocytoma cells.
Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma therapies.
Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma.
LY294002 and sorafenib as inhibitors of intracellular survival pathways in the elimination of human glioma cells by programmed cell death.
Muscarinic-receptor-mediated inhibition of insulin-like growth factor-1 receptor-stimulated phosphoinositide 3-kinase signalling in 1321N1 astrocytoma cells.
Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma.
Regulation of the pituitary tumor transforming gene by insulin-like-growth factor-I and insulin differs between malignant and non-neoplastic astrocytes.
The Prognostic Significance of RB and PI3K Pathway Alterations in IDH-Mutant Grade II/III Astrocytomas.
Ataxia
An Unusual Case of Metastatic Basal Cell Carcinoma of the Prostate: A Case Report and Literature Review.
Benzo[a]pyrene induces complex H2AX phosphorylation patterns by multiple kinases including ATM, ATR, and DNA-PK.
Effect of ovarian hormones on survival genes in laser captured serotonin neurons from macaques.
Evolving possible link between PI3K and NO pathways in neuroprotective mechanism of ischemic postconditioning in mice.
Induction of H2AX phosphorylation in tumor cells by gossypol acetic acid is mediated by phosphatidylinositol 3-kinase (PI3K) family.
Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase.
Ataxia Telangiectasia
A novel mutation in ATM gene in a Saudi female with ataxia telangiectasia.
Ataxia telangiectasia-mutated gene product inhibits DNA damage-induced apoptosis via ceramide synthase.
ATM, a paradigm for a stress-responsive signal transducer in higher vertebrate cells.
DNA-dependent protein kinase catalytic subunit: a relative of phosphatidylinositol 3-kinase and the ataxia telangiectasia gene product.
DNA-dependent protein kinase regulates lysosomal AMP-dependent protein kinase activation and autophagy.
ERK kinases modulate the activation of PI3 kinase related kinases (PIKKs) in DNA damage response.
Gamma-H2AX - a novel biomarker for DNA double-strand breaks.
Human SMG-1 is Involved in Gemcitabine-Induced Primary microRNA-155/BIC Up-Regulation in Human Pancreatic Cancer PANC-1 Cells.
Inside-Out Signaling Pathways from Nuclear Reactive Oxygen Species Control Pulmonary Innate Immunity.
Nickel carcinogenesis mechanism: cell cycle dysregulation.
Nitric oxide-induced apoptosis in lymphoblastoid and fibroblast cells dependent on the phosphorylation and activation of p53.
Orphan nuclear receptor SHP negatively regulates growth hormone-mediated induction of hepatic gluconeogenesis through inhibition of STAT5 transactivation.
PP2A Regulates Phosphorylation-Dependent Isomerization of Cytoplasmic and Mitochondrial-Associated ATR by Pin1 in DNA Damage Responses.
Protective roles for ATM in cellular response to oxidative stress.
Purification and DNA binding properties of the ataxia-telangiectasia gene product ATM.
Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1.
Six Novel ATM Gene Variants in Sri Lankan Patients with Ataxia Telangiectasia.
The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Wortmannin, a specific inhibitor of phosphatidylinositol-3-kinase, induces accumulation of DNA double-strand breaks.
Atherosclerosis
1alpha,25-dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase.
7?-Hydroxycholesterol induces inflammation by enhancing production of chemokine (C-C motif) ligand 2.
Calcium channel blockers suppress cytokine-induced activation of human neutrophils.
Cardiotrophin-1 stimulates intercellular adhesion molecule-1 and monocyte chemoattractant protein-1 in human aortic endothelial cells.
Critical role for casein kinase 2 and phosphoinositide-3-kinase in the interferon-gamma-induced expression of monocyte chemoattractant protein-1 and other key genes implicated in atherosclerosis.
Heat-killed Staphylococcus aureus reduces atherosclerosis by inducing anti-inflammatory macrophages.
Irisin ameliorates nicotine-mediated atherosclerosis via inhibition of the PI3K pathway.
LncRNA ENST00113 promotes proliferation, survival, and migration by activating PI3K/Akt/mTOR signaling pathway in atherosclerosis.
LRP1 regulates architecture of the vascular wall by controlling PDGFRbeta-dependent phosphatidylinositol 3-kinase activation.
Macrophage SR-BI modulates autophagy via VPS34 complex and PPAR? transcription of Tfeb in atherosclerosis.
Network pharmacology-based exploration of therapeutic mechanism of Liu-Yu-Tang in atypical antipsychotic drug-induced metabolic syndrome.
OxLDL induces mitogen-activated protein kinase activation mediated via PI3-kinase/Akt in vascular smooth muscle cells.
Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets.
Phosphoinositide 3-kinases and their role in inflammation: potential clinical targets in atherosclerosis?
PI3K inhibitors in thrombosis and cardiovascular disease.
PI3K p110? Deletion Attenuates Murine Atherosclerosis by Reducing Macrophage Proliferation but Not Polarization or Apoptosis in Lesions.
PI3K regulates the activation of NLRP3 inflammasome in atherosclerosis through part-dependent AKT signaling pathway.
Potent inhibition of serum-stimulated responses in vascular smooth muscle cell proliferation by 2-chloro-3-(4-hexylphenyl)-amino-1,4-naphthoquinone, a newly synthesized 1,4-naphthoquinone derivative.
Role of PI3K in the Progression and Regression of Atherosclerosis.
Systemic application of 3-methyladenine markedly inhibited atherosclerotic lesion in ApoE(-/-) mice by modulating autophagy, foam cell formation and immune-negative molecules.
The Phosphoinositide 3-Kinase Signaling Pathway is Involved in the Control of Modified Low-Density Lipoprotein Uptake by Human Macrophages.
Transplant atherosclerosis: role of phenotypic modulation of vascular smooth muscle by nitric oxide.
[Hyperinsulinemia induced immune maturation of human monocyte derived dendritic cells: bridging between diabetes and atherosclerosis]
Atrial Fibrillation
Atrial fibrillation risk in patients suffering from type I diabetes mellitus. A review of clinical and experimental evidence.
Laminar shear stress alters endothelial KCa2.3 expression in H9c2 cells partially via regulating the PI3K/Akt/p300 axis.
Autoimmune Diseases
8e Protects against Acute Cerebral Ischemia by Inhibition of PI3K?-Mediated Superoxide Generation in Microglia.
A combined risk score enhances prediction of type 1 diabetes among susceptible children.
An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
Dendritic cell PIK3C3/VPS34 controls the pathogenicity of CNS autoimmunity independently of LC3-associated phagocytosis.
Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation.
Immunomodulatory effects of Nigella sativa seed polysaccharides by gut microbial and proteomic technologies.
Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo.
Loss of Phosphatidylinositol 3-Kinase Activity in Regulatory T Cells Leads to Neuronal Inflammation.
Phosphoinositide 3-Kinase Gamma (PI3Kgamma) Inhibitors for the Treatment of Inflammation and Autoimmune Disease.
Phosphoinositide 3-kinase gamma (PI3Kgamma) inhibitors for the treatment of inflammation and autoimmune disease.
Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond.
PI3K inhibitors as potential therapeutics for autoimmune disease.
PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation.
Pik3c3 deficiency in myeloid cells imparts partial resistance to experimental autoimmune encephalomyelitis associated with reduced IL-1? production.
PIK3IP1/TrIP restricts activation of T cells through inhibition of PI3K/Akt.
Platelet PI3K? Contributes to Carotid Intima-Media Thickening under Severely Reduced Flow Conditions.
Regulation of T-cell responses by PTEN.
Role of phosphoinositide 3-kinase signaling in autoimmunity.
Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia.
The PI-3-Kinase P110? Catalytic Subunit of T Lymphocytes Modulates Collagen-Induced Arthritis.
The Selective Phosphoinoside-3-Kinase p110? Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation.
WITHDRAWN: Phosphoinositide 3-Kinase Gamma (PI3Kgamma) Inhibitors for the Treatment of Inflammation and Autoimmune Disease.
Autoimmune Lymphoproliferative Syndrome
Off-Label Use of Sirolimus and Everolimus in a Pediatric Center: A Case Series and Review of the Literature.
Bacterial Infections
Invasion of HeLa cells by group B streptococcus requires the phosphoinositide-3-kinase signalling pathway and modulates phosphorylation of host-cell Akt and glycogen synthase kinase-3.
Myeloid PTEN promotes inflammation but impairs bactericidal activities during murine pneumococcal pneumonia.
Phosphatidylinositol 3-Kinase p110? Isoform Regulates CD8+ T Cell Responses during Acute Viral and Intracellular Bacterial Infections.
Phosphoinositide 3-kinase in nitric oxide synthesis in macrophage: critical dimerization of inducible nitric-oxide synthase.
Role of EGFR transactivation in preventing apoptosis in Pseudomonas aeruginosa-infected human corneal epithelial cells.
Role of epidermal growth factor receptor transactivation in PPAR gamma-dependent suppression of Helicobacter pylori interference with gastric mucin synthesis.
Tumor suppressor Foxo3a is involved in the regulation of lipopolysaccharide-induced interleukin-8 in intestinal HT-29 cells.
Biliary Tract Neoplasms
Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
Targeting phosphoinositide-3-kinase pathway in biliary tract cancers: A remedial route?
Blister
ADP Ribosylation Factor 6 (Arf6) Acts through FilGAP Protein to Down-regulate Rac Protein and Regulates Plasma Membrane Blebbing.
Na+ influx triggers bleb formation on inner hair cells.
Transcriptomic Repositioning Analysis Identifies mTOR Inhibitor as Potential Therapy for Epidermolysis Bullosa Simplex.
Bone Diseases
The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
The role of mast cells in parathyroid bone disease.
Bone Diseases, Metabolic
Identification of Differential Genes Expression Profiles and Pathways of Bone Marrow Mesenchymal Stem Cells of Adolescent Idiopathic Scoliosis Patients by Microarray and Integrated Gene Network Analysis.
Bone Marrow Failure Disorders
Pivotal role of Pten in the balance between proliferation and differentiation of hematopoietic stem cells in zebrafish.
Bone Neoplasms
Blocking mammalian target of rapamycin alleviates bone cancer pain and morphine tolerance via µ-opioid receptor.
Electroacupuncture Attenuates Morphine Tolerance in Rats with Bone Cancer Pain by Inhibiting PI3K/Akt/JNK1/2 Signaling Pathway in the Spinal Dorsal Horn.
Formaldehyde up-regulates TRPV1 through MAPK and PI3K signaling pathways in a rat model of bone cancer pain.
Neuroinflammation and central PI3K/Akt/mTOR signal pathway contribute to bone cancer pain.
[Effects of intrathecal injection PI3K antagonist on inflammatory cytokines in spinal cord of bone cancer pain model in rats].
Bone Resorption
Cepharanthine Prevents Estrogen Deficiency-Induced Bone Loss by Inhibiting Bone Resorption.
Phosphatidylinositol 3,4,5-trisphosphate directs association of Src homology 2-containing signaling proteins with gelsolin.
Prostate transmembrane protein androgen induced 1 is induced by activation of osteoclasts and regulates bone resorption.
Rho-A is critical for osteoclast podosome organization, motility, and bone resorption.
Role of Cbl-PI3K Interaction during Skeletal Remodeling in a Murine Model of Bone Repair.
The phosphoinositide-3-kinase isoform PI3K? regulates osteoclast-mediated bone resorption.
Wortmannin, a potent inhibitor of phosphatidylinositol 3-kinase, inhibits osteoclastic bone resorption in vitro.
Bradycardia
Vagal stimulation suppresses ischemia-induced myocardial interstitial myoglobin release.
Brain Death
Altered Phosphatidylinositol 3-Kinase and Calcium Signaling in Cardiac Dysfunction After Brain Death in Rats.
Brain Diseases
Impact of ambient temperature on inflammation-induced encephalopathy in endotoxemic mice-role of phosphoinositide 3-kinase gamma.
Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model.
Brain Edema
Activation of the Melanocortin-1 Receptor by NDP-MSH Attenuates Oxidative Stress and Neuronal Apoptosis through PI3K/Akt/Nrf2 Pathway after Intracerebral Hemorrhage in Mice.
Fibroblast growth factors preserve blood-brain barrier integrity through RhoA inhibition after intracerebral hemorrhage in mice.
Pre-ischemic treadmill training alleviates brain damage via GLT-1-mediated signal pathway after ischemic stroke in rats.
[Therapeutic hypothermia reduced brain damage on rats after cardiopulmonary resuscitation by activating III-type PI3K pathway to increase autophagy].
Brain Infarction
Pre-ischemic treadmill training alleviates brain damage via GLT-1-mediated signal pathway after ischemic stroke in rats.
Brain Injuries
Astragaloside IV alleviates the brain damage induced by subarachnoid hemorrhage via PI3K/Akt signaling pathway.
Immunoreactive Akt, PI3-K and ERK protein kinase expression in ischemic rat brain.
Phosphoinositide 3-Kinase Gamma Contributes to Neuroinflammation in a Rat Model of Surgical Brain Injury.
The Role of the PI3K Pathway in the Regeneration of the Damaged Brain by Neural Stem Cells after Cerebral Infarction.
[Gly14]-Humanin Offers Neuroprotection through Glycogen Synthase Kinase-3? Inhibition in a Mouse Model of Intracerebral Hemorrhage.
Brain Injuries, Traumatic
Autophagy: a potential key contributor to the therapeutic action of mesenchymal stem cells.
Regulation of PRKN-independent mitophagy.
Brain Ischemia
Activation of the Akt/GSK3beta signaling pathway mediates survival of vulnerable hippocampal neurons after transient global cerebral ischemia in rats.
Early Activation of Phosphatidylinositol 3-Kinase after Ischemic Stroke Reduces Infarct Volume and Improves Long-Term Behavior.
Emulsified Isoflurane Protects Against Transient Focal Cerebral Ischemia Injury in Rats via the PI3K/Akt Signaling Pathway.
Evidence of phosphorylation of Akt and neuronal survival after transient focal cerebral ischemia in mice.
Icariin and mesenchymal stem cells synergistically promote angiogenesis and neurogenesis after cerebral ischemia via PI3K and ERK1/2 pathways.
Inhibition of MLK3-MKK4/7-JNK1/2 pathway by Akt1 in exogenous estrogen-induced neuroprotection against transient global cerebral ischemia by a non-genomic mechanism in male rats.
Neuroprotection of selenite against ischemic brain injury through negatively regulating early activation of ASK1/JNK cascade via activation of PI3K/AKT pathway.
Neuroprotective effects of bisperoxovanadium on cerebral ischemia by inflammation inhibition.
Oxidative stress affects the integrin-linked kinase signaling pathway after transient focal cerebral ischemia.
PI3K/Akt pathway contributes to neuroprotective effect of Tongxinluo against focal cerebral ischemia and reperfusion injury in rats.
PI3K/Akt Pathway Contributes to Neurovascular Unit Protection of Xiao-Xu-Ming Decoction against Focal Cerebral Ischemia and Reperfusion Injury in Rats.
Possible Involvement of PI3-K/Akt-Dependent GSK-3? Signaling in Proliferation of Neural Progenitor Cells After Hypoxic Exposure.
[Protective effects and mechanisms of Xingnaojing Injection on early global brain ischemic-induced deep coma in rats].
Brain Neoplasms
A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma.
A novel brain tumour model in zebrafish reveals the role of YAP activation in MAPK- and PI3K-induced malignant growth.
A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study.
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.
Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases.
Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma.
Correction: PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.
Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
Impact of blood-brain barrier integrity on tumor growth and therapy response in brain metastases.
Mechanisms of Disease: the PI3K-Akt-PTEN signaling node--an intercept point for the control of angiogenesis in brain tumors.
Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy.
Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma.
Mutation of the PIK3CA gene in anaplastic thyroid cancer.
Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases.
Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma.
Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer.
Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases.
Phosphatidylinositol-3-Kinase Mutations Are Associated With Increased Local Failure in Brain Metastases Treated With Radiation.
Phosphorylated mTOR expression correlates with podoplanin expression and high tumor grade in esophageal squamous cell carcinoma.
PI3K activation in neural stem cells drives tumorigenesis which can be ameliorated by targeting the cAMP response element binding protein.
PI3K pathway inhibition achieves potent antitumor activity in melanoma brain metastases in vitro and in vivo.
PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer.
PI3K: A master regulator of brain metastasis-promoting macrophages/microglia.
Pten loss in Olig2 expressing neural progenitor cells and oligodendrocytes leads to interneuron dysplasia and leukodystrophy.
Quantitating cell-cell interaction functions with applications to glioblastoma multiforme cancer cells.
Rho GTPases in primary brain tumor malignancy and invasion.
Sorafenib/Regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells.
Stand-Sit Microchip for High-Throughput, Multiplexed Analysis of Single Cancer Cells.
Striking the balance between PTEN and PDK1: it all depends on the cell context.
Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier.
The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.
The catalytic phosphoinositol 3-kinase isoform p110? is required for glioma cell migration and invasion.
The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy.
The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors.
Towards Targeting PI3K-Dependent Regulation of Gene Expression in Brain Cancer.
Understanding and exploiting cell signalling convergence nodes and pathway cross-talk in malignant brain cancer.
Breast Neoplasms
"PIKing" the Winner for Phosphatidylinositol 3-Kinase Inhibitors in ErbB2-Positive Breast Cancer: Let's Not "PTENed" It's Easy!
(-)-Liriopein B Suppresses Breast Cancer Progression via Inhibition of Multiple Kinases.
11C-Labeled Pictilisib (GDC-0941) as a Molecular Tracer Targeting Phosphatidylinositol 3-Kinase (PI3K) for Breast Cancer Imaging.
17?-estradiol activates glucose uptake via GLUT4 translocation and PI3K/Akt signaling pathway in MCF-7 cells.
3-phosphoinositide-dependent kinase 1 controls breast tumor growth in a kinase-dependent but akt-independent manner.
3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma.
3D Growth of Cancer Cells Elicits Sensitivity to Kinase Inhibitors but Not Lipid Metabolism Modifiers.
A butterfly effect in cancer.
A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition.
A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach.
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.
A curated resource for phosphosite-specific signature analysis.
A Curated Resource for Phosphosite-specific Signature Analysis.
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
A novel 4-aminoquinazoline derivative, DHW-208, suppresses the growth of human breast cancer cells by targeting the PI3K/AKT/mTOR pathway.
A novel carcinogenic PI3K? mutation suggesting the role of helical domain in transmitting nSH2 regulatory signals to kinase domain.
A novel imidazopyridine analogue as a phosphatidylinositol 3-kinase inhibitor against human breast cancer.
A novel Phosphatidylinositol 3-Kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genes.
A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer.
A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer.
A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies.
A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.
A PI3K p110?-selective inhibitor enhances the efficacy of anti-HER2/neu antibody therapy against breast cancer in mice.
A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib.
A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).
A sensitive HPLC-FLD method for the quantification of alpelisib, a novel phosphatidylinositol 3-kinase inhibitor, in rat plasma: Drug metabolism and pharmacokinetic evaluation in vitro and in vivo.
A systematic review and meta-analysis of selected toxicity endpoints of alpelisib.
Abelson interactor protein-1 positively regulates breast cancer cell proliferation, migration, and invasion.
Abrogating endocrine resistance by targeting ER? and PI3K in breast cancer.
Activation of the phosphatidylinositol 3-kinase/Akt pathway prevents radiation-induced apoptosis in breast cancer cells.
Activation of the PI3 kinase pathway by retinoic acid mediates sodium/iodide symporter induction and iodide transport in MCF-7 breast cancer cells.
Addition of the Akt inhibitor triciribine overcomes antibody resistance in cells from ErbB2/Neu-positive/PTEN-deficient mammary tumors.
Adiponectin induces breast cancer cell migration and growth factor expression.
ADP-ribosylation factor 1 controls the activation of the phosphatidylinositol 3-kinase pathway to regulate epidermal growth factor-dependent growth and migration of breast cancer cells.
Age-specific differences in oncogenic pathway deregulation seen in human breast tumors.
AKR1B10 promotes breast cancer cell proliferation and migration via the PI3K/AKT/NF-?B signaling pathway.
AKT Regulation of Estrogen Receptor {beta} Transcriptional Activity in Breast Cancer.
Akt-dependent T198 phosphorylation of cyclin-dependent kinase inhibitor p27kip1 in breast cancer.
AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival.
Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data.
Alpelisib in the treatment of metastatic HR+ breast cancer with PIK3CA mutations.
Alpelisib to treat breast cancer.
Alpelisib-Induced Diabetic Ketoacidosis: A Case Report and Review of Literature.
Alpelisib: A Novel Therapy for Patients With PIK3CA-Mutated Metastatic Breast Cancer.
Alpelisib: First Global Approval.
Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
Alternative phospholipase D/mTOR survival signal in human breast cancer cells.
Amplification of SOX4 promotes PI3K/Akt signaling in human breast cancer.
An IL6-STAT3 loop mediates resistance to PI3K inhibitors by inducing epithelial-mesenchymal transition and cancer stem cell expansion in human breast cancer cells.
An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer.
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant.
Analysis of molecular markers as predictive factors of lymph node involvement in breast carcinoma.
Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor-Positive, HER2-Negative Early Breast Cancer.
Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria.
Analysis of the ways and methods of signaling pathways in regulating cell cycle of NIH3T3 at transcriptional level.
AND-34 activates phosphatidylinositol 3-kinase and induces anti-estrogen resistance in a SH2 and GDP exchange factor-like domain-dependent manner.
Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review.
Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway.
Anticipating mechanisms of resistance to PI3K inhibition in breast cancer: a challenge in the era of precision medicine.
Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway.
Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy.
Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling.
Assessment of Functional Phosphatidylinositol 3-Kinase Pathway Activity in Cancer Tissue Using Forkhead Box-O Target Gene Expression in a Knowledge-Based Computational Model.
Assessment of PTEN and PI3K status in primary breast cancer and corresponding metastases: is it worthwhile?
Association between the lengths of GT dinucleotide repeat in the PIK3CA gene with breast cancer risk.
Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone.
Association of PI3K Pathway Mutations with Early Positron-Emission Tomography/CT Imaging Response after Radioembolization for Breast Cancer Liver Metastases: Results of a Single-Center Retrospective Pilot Study.
Association of rs1801157 single nucleotide polymorphism of CXCL12 gene in breast cancer in Pakistan and in-silico expression analysis of CXCL12-CXCR4 associated biological regulatory network.
Author Correction: Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-?B signaling.
Autocrine motility factor promotes HER2 cleavage and signaling in breast cancer cells.
Autophagy promotes escape from phosphatidylinositol 3-kinase inhibition in estrogen receptor-positive breast cancer.
AZD8835 inhibits osteoclastogenesis and periodontitis-induced alveolar bone loss in rats.
BC-N102 suppress breast cancer tumorigenesis by interfering with cell cycle regulatory proteins and hormonal signaling, and induction of time-course arrest of cell cycle at G1/G0 phase.
Benchmarking to the Gold Standard: Hyaluronan-Oxime Hydrogels Recapitulate Xenograft Models with In Vitro Breast Cancer Spheroid Culture.
Benefit Mixed with Caution for Buparlisib.
BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC.
Bioinformatics Study of Sea Cucumber Peptides as Antibreast Cancer Through Inhibiting the Activity of Overexpressed Protein (EGFR, PI3K, AKT1, and CDK4).
Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer.
Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors.
Blueberry phytochemicals inhibit growth and metastatic potential of MDA-MB-231 breast cancer cells through modulation of the phosphatidylinositol 3-kinase pathway.
Boosting immune surveillance by low-dose PI3K inhibitor facilitates early intervention of breast cancer.
Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma.
Breast Cancer Special Feature: Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors.
Breast cancer tissue slices as a model for evaluation of response to rapamycin.
Breast cancer.
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.
Breast tumors with elevated expression of 1q candidate genes confer poor clinical outcome and sensitivity to Ras/PI3K inhibition.
Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression.
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Calycosin Suppresses Breast Cancer Cell Growth via ER?-Dependent Regulation of IGF-1R, p38 MAPK and PI3K/Akt Pathways.
Can phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibition ERase them all?
Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes.
Capsaicin suppresses breast cancer cell viability by regulating the CDK8/PI3K/Akt/Wnt/??catenin signaling pathway.
Casticin inhibits breast cancer cell migration and invasion by down-regulation of PI3K/Akt signaling pathway.
Cationic liposome codelivering PI3K pathway regulator improves the response of BRCA1-deficient breast cancer cells to PARP1 inhibition.
CD44/HA signaling mediates acquired resistance to a PI3K? inhibitor.
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
Cell-Cycle Therapeutics Come of Age.
Cellular Plasticity in Breast Cancer Progression and Therapy.
Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment.
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.
Characterization of the Components and Pharmacological Effects of Mountain-Cultivated Ginseng and Garden Ginseng Based on the Integrative Pharmacology Strategy.
Chromatin regulation at the intersection of estrogen receptor and PI3K pathways in breast cancer.
Chromosome band 17q21 in breast cancer: significant association between beclin 1 loss and HER2/NEU amplification.
Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer.
Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer.
Clinical implications of Girdin and PI3K protein expression in breast cancer.
Clinical Implications of Mutations in the PI3K Pathway in HER2+ Breast Cancer: Prognostic or Predictive?
Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
Closing escape routes: inhibition of IL-8 signaling enhances the anti-tumor efficacy of PI3K inhibitors.
CNK1 is a novel Akt interaction partner that promotes cell proliferation through the Akt-FoxO signalling axis.
Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition.
Cohesin modulates transcription of estrogen-responsive genes.
Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases.
Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Combination of zoledronic acid and serine/threonine phosphatase inhibitors induces synergistic cytotoxicity and apoptosis in human breast cancer cells via inhibition of PI3K/Akt pathway.
Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models.
Combined Inhibition of Both p110? and p110? Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER(+) Breast Cancer.
Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells.
Combined targeting of G protein-coupled receptor and EGF receptor signaling overcomes resistance to PI3K pathway inhibitors in PTEN-null triple negative breast cancer.
Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models.
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for a mouse model of BRCA1-related breast cancer.
Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.
Combining flavopiridol with various signal transduction inhibitors.
Comparison of CD4/6 inhibitors, PI3K inhibitors, and mTOR inhibitors for patients with advanced HR+/HER2- Breast cancer: A network meta-analysis of 19 RCTs.
Comprehensive analysis of PTEN status in breast carcinomas.
Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds.
Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.
Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer.
Cooperation between Pik3ca and p53 Mutations in Mouse Mammary Tumor Formation.
Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer.
Cooperative oncogenic effect and cell signaling crosstalk of co?occurring HER2 and mutant PIK3CA in mammary epithelial cells.
Coordinate expression of the PI3-kinase downstream effectors serum and glucocorticoid-induced kinase (SGK-1) and Akt-1 in human breast cancer.
Correction: Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.
Correction: Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer.
Correlation between important genes of mTOR pathway (PI3K and KIT) in Iranian women with sporadic breast cancer.
Correlative studies investigating effects of PI3K inhibition on peripheral leukocytes in metastatic breast cancer: potential implications for immunotherapy.
CSNK1G2 differently sensitizes tamoxifen-induced decrease in PI3K/AKT/mTOR/S6K and ERK signaling according to the estrogen receptor existence in breast cancer cells.
Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer.
Current Status and Future Perspectives of PI3K and mTOR Inhibitor as Anticancer Drugs in Breast Cancer.
CXCR4 drives the metastatic phenotype in breast cancer through induction of CXCR2 and activation of MEK and PI3K pathways.
Cytokines secreted by bone-metastatic breast cancer cells alter the expression pattern of f-actin and reduce focal adhesion plaques in osteoblasts through PI3K.
Cytotoxicity induced by manipulation of signal transduction pathways is associated with down-regulation of Bcl-2 but not Mcl-1 in MCF-7 human breast cancer.
Deciphering the role of phosphatidylinositol 3-kinase mutations in human epidermal growth factor receptor 2-positive breast cancer.
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.
Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer.
Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader.
Development of multiplex digital PCR assays for the detection of PIK3CA mutations in the plasma of metastatic breast cancer patients.
Development of PI3K inhibitors: advances in clinical trials and new strategies (Review).
Development of the CK-MB-1 trastuzumab-resistant HER2-positive breast cancer cell line and xenograft animal models.
Diagnostic Accuracy of PIK3CA Mutation Detection by Circulating Free DNA in Breast Cancer: A Meta-Analysis of Diagnostic Test Accuracy.
Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.
Differential enhancement of the anti-cancer effect of doxorubicin by Akt inhibitors on human breast cancer cells with differing genetic backgrounds.
Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance.
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer.
Discovery, synthesis and molecular corroborations of medicinally important novel pyrazoles; drug efficacy determinations through in silico, in vitro and cytotoxicity validations.
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.
Disulfiram Treatment Facilitates Phosphoinositide 3-Kinase Inhibition in Human Breast Cancer Cells In vitro and In vivo.
DNA damage uncouples the mitogenic response to IGF-I in MCF-7 malignant breast cancer cells by switching the roles of PI3 kinase and p21WAF1/Cip1.
Does the PI3K Pathway Play a Role in Basal Breast Cancer?
Down-regulation of hTERT and Cyclin D1 transcription via PI3K/Akt and TGF-? pathways in MCF-7 Cancer cells with PX-866 and Raloxifene.
Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
Downregulation of wild-type p53 protein by HER-2/neu mediated PI3K pathway activation in human breast cancer cells: its effect on cell proliferation and implication for therapy.
Dual inhibition of PI3K and mTOR mitigates feedback-loop pAkt activation to improve tamoxifen response in breast cancer cells.
Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers.
Dual PDK1/Aurora Kinase A Inhibitors Reduce Pancreatic Cancer Cell Proliferation and Colony Formation.
Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer.
Dysregulation of phosphatidylinositol 3-kinase and downstream effectors in human breast cancer.
Econazole nitrate reversed the resistance of breast cancer cells to Adriamycin through inhibiting the PI3K/AKT signaling pathway.
Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway.
Effect of Taraxacum officinale extract on PI3K/Akt pathway in DMBA induced breast cancer in albino rats.
Effects of PI3K inhibition in AI-resistant breast cancer cell lines: autophagy, apoptosis, and cell cycle progression.
Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells.
Efficacy of buparlisib in treating breast cancer.
Efficacy of PI3K inhibitors in advanced breast cancer.
EGF receptor stimulation shifts breast cancer cell glucose metabolism toward glycolytic flux through PI3 kinase signaling.
Electrochemical assay of the relationship between the inhibition of phosphatidylinositol 3-kinase pathway and estrogen receptor expression in breast cancer.
Elevated PI3K signaling drives multiple breast cancer subtypes.
Elevated V-ATPase Activity Following PTEN Loss Is Required for Enhanced Oncogenic Signaling in Breast Cancer.
Ellagic Acid Enhances the Efficacy of PI3K Inhibitor GDC-0941 in Breast Cancer Cells.
EMT transition alters interstitial fluid flow-induced signaling in ERBB2-positive breast cancer cells.
Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Enhanced anti-cancer effect of a phosphatidylinositol-3 kinase inhibitor and doxorubicin on human breast epithelial cell lines with different p53 and oestrogen receptor status.
Enhanced PI3K p110? signaling confers acquired lapatinib resistance that can be effectively reversed by a p110?-selective PI3K inhibitor.
Enhanced sensitivity to rapamycin following long-term oestrogen deprivation in MCF-7, T-47-D and ZR-75-1 human breast cancer cells.
Epigenetic reversion of breast carcinoma phenotype is accompanied by changes in DNA sequestration as measured by AluI restriction enzyme.
ER and PI3K independently modulate endocrine resistance in ER positive breast cancer.
ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen.
ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth.
Erratum for the Research Article: "The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation" by D. P. Kodack, V. Askoxylakis, G. B. Ferraro, Q. Sheng, M. Badeaux, S. Goel, X. Qi, R. Shankaraiah, Z. A. Cao, R. R. Ramjiawan, D. Bezwada, B. Patel, Y. Song, C. Costa, K. Naxerova, C. S. F. Wong, J. Kloepper, R. Das, A. Tam, J. Tanboon, D. G. Duda, C. R. Miller, M. B. Siegel, C. K. Anders, M. Sanders, M. V. Estrada, R. Schlegel, C. L. Arteaga, E. Brachtel, A. Huang, D. Fukumura, J. A. Engelman, R. K. Jain.
Erufosine suppresses breast cancer in vitro and in vivo for its activity on PI3K, c-Raf and Akt proteins.
Estradiol regulates the insulin-like growth factor-I (IGF-I) signalling pathway: a crucial role of phosphatidylinositol 3-kinase (PI 3-kinase) in estrogens requirement for growth of MCF-7 human breast carcinoma cells.
Estrogen increases Nrf2 activity through activation of the PI3K pathway in MCF-7 breast cancer cells.
Estrogen receptor ? induces down-regulation of PTEN through PI3-kinase activation in breast cancer cells.
Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells.
Ethanol Extracts of Dietary Herb, Alpinia nantoensis, Exhibit Anticancer Potential in Human Breast Cancer Cells.
Etk/Bmx tyrosine kinase activates Pak1 and regulates tumorigenicity of breast cancer cells.
Evaluation of the Expression Level and Hormone Receptor Association of miR-126 in Breast Cancer.
Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk.
Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells.
Expression of PIK3CA, PTEN mRNA and PIK3CA mutations in primary breast cancer: association with lymph node metastases.
Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2(+) Breast Cancer.
Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells.
Feedforward and feedback regulation of the MAPK and PI3K oscillatory circuit in breast cancer.
Fenhexamid induces cancer growth and survival via estrogen receptor-dependent and PI3K-dependent pathways in breast cancer models.
Fibroblast growth factor 8 induced downregulation of thrombospondin 1 is mediated by the MEK/ERK and PI3K pathways in breast cancer cells.
First PI3K Inhibitor for Breast Cancer.
FKBP4 connects mTORC2 and PI3K to activate the PDK1/Akt-dependent cell proliferation signaling in breast cancer.
Focal amplification and oncogene dependency of GAB2 in breast cancer.
Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway.
FOXO1A is a target for HER2-overexpressing breast tumors.
FOXP1 regulation via the PI3K/Akt/p70S6K signaling pathway in breast cancer cells.
Frequency and spectrum of PIK3CA somatic mutations in breast cancer.
Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer.
Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.
Functional analysis of non-hotspot AKT1 mutants found in human breast cancers identifies novel driver mutations: implications for personalized medicine.
Fyn is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration.
Ganoderma lucidum suppresses motility of highly invasive breast and prostate cancer cells.
GDC-0941 and CXCL8 (3-72) K11R/G31P combination therapy confers enhanced efficacy against breast cancer.
GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo.
Gene expression correlation for cancer diagnosis: a pilot study.
Gene expression profiling reveals new aspects of PIK3CA mutation in ERalpha-positive breast cancer: major implication of the Wnt signaling pathway.
Gene signatures and potential therapeutic targets of amino acid metabolism in estrogen receptor-positive breast cancer.
Gene-Expression-Based Predictors for Breast Cancer.
Genetically engineered mouse models of PI3K signaling in breast cancer.
Genetics of breast cancer bone metastasis: a sequential multistep pattern.
Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer.
Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.
GREB1 regulates PI3K/Akt signaling to control hormone-sensitive breast cancer proliferation.
Green tea catechin inhibits fatty acid synthase without stimulating carnitine palmitoyltransferase-1 or inducing weight loss in experimental animals.
Growth factors change nuclear distribution of estrogen receptor-alpha via mitogen-activated protein kinase or phosphatidylinositol 3-kinase cascade in a human breast cancer cell line.
Guizhi Fuling Decoction inhibiting the PI3K and MAPK pathways in breast cancer cells revealed by HTS2 technology and systems pharmacology.
Hepatocyte growth factor enhances CXCR4 expression favoring breast cancer cell invasiveness.
HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression.
Her2 activates NF-kappaB and induces invasion through the canonical pathway involving IKKalpha.
Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase.
Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences.
Hierarchical clustering of PI3K and MAPK pathway proteins in breast cancer intrinsic subtypes.
High-Mobility Group Box 1 (HMGB1) Promotes Angiogenesis and Tumor Migration by Regulating Hypoxia-Inducible Factor 1 (HIF-1?) Expression via the Phosphatidylinositol 3-Kinase (PI3K)/AKT Signaling Pathway in Breast Cancer Cells.
Highlights of the Chemotherapy Foundation Symposium XXVII: therapeutic options for breast cancer.
Highly sensitive profiling of CD44(+)/CD24(-) breast cancer stem cells by combining global mRNA amplification and next generation sequencing: Evidence for a hyperactive PI3K pathway.
hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.
Homotypic gap junctional communication associated with metastasis suppression increases with PKA activity and is unaffected by PI3K inhibition.
Hormone-dependent breast cancer: Targeting autophagy and PI3K overcomes Exemestane-acquired resistance.
How Protein Kinase A Activates Canonical Tyrosine Kinase Signaling Pathways To Promote Granulosa Cell Differentiation.
HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer.
Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression.
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.
Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells.
Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells.
Identification of mTORC2 as a Necessary Component of HRG/ErbB2-dependent Cellular Transformation.
IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors.
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors.
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
ING5 inhibits epithelial-mesenchymal transition in breast cancer by suppressing PI3K/Akt pathway.
Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.
Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma.
Inhibition of ?-enolase affects the biological activity of breast cancer cells by attenuating PI3K/Akt signaling pathway.
Inhibition of BTF3 sensitizes luminal breast cancer cells to PI3K? inhibition through the transcriptional regulation of ER?.
Inhibition of p85, the non-catalytic subunit of phosphatidylinositol 3-kinase, exerts potent antitumor activity in human breast cancer cells.
Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression.
Inhibition of phosphoinositide 3-kinase enhances the cytotoxicity of AG1478, an epidermal growth factor receptor inhibitor, in breast cancer cells.
Inhibition of PI3K pathway using BKM120 intensified the chemo-sensitivity of breast cancer cells to arsenic trioxide (ATO).
Inhibition of PI3K signaling triggered apoptotic potential of curcumin which is hindered by Bcl-2 through activation of autophagy in MCF-7 cells.
Inhibition of the phosphatidylinositol 3-kinase/Akt pathway sensitizes MDA-MB468 human breast cancer cells to cerulenin-induced apoptosis.
Inhibition of the PI3K-AKT-mTOR pathway suppresses the adipocyte-mediated proliferation and migration of breast cancer cells.
Inhibitors of PI3K/ERK 1/2/p38 MAPK Show Preferential Activity Against Endocrine Resistant Breast Cancer Cells.
Inhibitors of STAT3, ?-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review.
INPP4B promotes PI3K?-dependent late endosome formation and Wnt/?-catenin signaling in breast cancer.
Insulin-like growth factor binding protein-3 stimulates phosphatidylinositol 3-kinase in MCF-7 breast carcinoma cells.
Insulin-like growth factor-1 (IGF-1) induces WISP-2/CCN5 via multiple molecular cross-talks and is essential for mitogenic switch by IGF-1 axis in estrogen receptor-positive breast tumor cells.
Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3K?-selective Inhibitors in Breast Cancer.
Integrative genomic approaches identify IKBKE as a breast cancer oncogene.
Involvement of miR-770-5p in trastuzumab response in HER2 positive breast cancer cells.
Jolkinolide B inhibits proliferation or migration and promotes apoptosis of MCF-7 or BT-474 breast cancer cells by downregulating the PI3K-Akt pathway.
KDM6B Counteracts EZH2-Mediated Suppression of IGFBP5 to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast Cancer.
Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.
Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.
Knockdown of lncRNA-HOTAIR downregulates the drug-resistance of breast cancer cells to doxorubicin via the PI3K/AKT/mTOR signaling pathway.
L-plastin Ser5 phosphorylation is modulated by the PI3K/SGK pathway and promotes breast cancer cell invasiveness.
Lactate Lights up PI3K Inhibitor Resistance in Breast Cancer.
Lapatinib inhibits the activation of NF-?B through reducing phosphorylation of I?B-? in breast cancer cells.
Leptin receptor expression and cell signaling in breast cancer.
Leptin signaling in breast cancer: an overview.
LINC00520 is induced by Src, STAT3, and PI3K and plays a functional role in breast cancer.
Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer.
Lipophilic statins limit cancer cell growth and survival, via involvement of Akt signaling.
Lipoxygenase catalyzed metabolites derived from docosahexaenoic acid are promising antitumor agents against breast cancer.
LKB1 when associated with methylatedERa is a marker of bad prognosis in breast cancer.
LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression.
Loss of beta4 integrin subunit reduces the tumorigenicity of MCF7 mammary cells and causes apoptosis upon hormone deprivation.
Low Dose of Acacetin Promotes Breast Cancer MCF-7 Cells Proliferation Through the Activation of ERK/ PI3K /AKT and Cyclin Signaling Pathway.
Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.
Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-?B signaling.
Managing postmenopausal women with hormone receptor-positive advanced breast cancer who progress on endocrine therapies with inhibitors of the PI3K pathway.
Manganese-12 acetate suppresses the migration, invasion, and epithelial-mesenchymal transition by inhibiting Wnt/?-catenin and PI3K/AKT signaling pathways in breast cancer cells.
Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer.
Membrane metallo-endopeptidase mediates cellular senescence induced by oncogenic PIK3CAH1047R accompanied with pro-tumorigenic secretome.
Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer.
Metformin and erlotinib synergize to inhibit basal breast cancer.
Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Microarray phosphatome profiling of breast cancer patients unveils a complex phosphatase regulatory role of the MAPK and PI3K pathways in estrogen receptor-negative breast cancers.
MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
miR-564 acts as a dual inhibitor of PI3K and MAPK signaling networks and inhibits proliferation and invasion in breast cancer.
Mislocalization of the cell polarity protein Scribble promotes mammary tumorigenesis and is associated with basal breast cancer.
Mitogenic activity of estrogens in human breast cancer cells does not rely on direct induction of mitogen-activated protein kinase/extracellularly regulated kinase or phosphatidylinositol 3-kinase.
Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase.
MLL3 Induced by Luteolin Causes Apoptosis in Tamoxifen-Resistant Breast Cancer Cells through H3K4 Monomethylation and Suppression of the PI3K/AKT/mTOR Pathway.
Model-based in silico analysis of the PI3K/Akt pathway: the elucidation of cross-talk between diabetes and breast cancer.
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.
Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer.
Molecular classification of estrogen receptor-positive/luminal breast cancers.
Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients.
Molecular explorations of substituted 2-(4-phenylquinolin-2-yl) phenols as phosphoinositide 3-kinase inhibitors and anticancer agents.
Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.
Molecular Mechanism of Secondary Endocrine Resistance in Luminal Breast Cancer.
More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro.
mTOR function and therapeutic targeting in breast cancer.
mTORC1 inhibition is required for sensitivity to PI3K p110? inhibitors in PIK3CA-mutant breast cancer.
Multiorgan metastasis of human HER-2? breast cancer in Rag2?/?;Il2rg?/? mice and treatment with PI3K inhibitor.
Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes.
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.
MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer.
MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers.
Natural product toosendanin reverses the resistance of human breast cancer cells to adriamycin as a novel PI3K inhibitor.
NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways.
Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).
New anti-cancer role for PDK1 inhibitors: preventing resistance to tamoxifen.
NHERF1: molecular brake on the PI3K pathway in breast cancer.
Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway.
Normal breast epithelial cells induce apoptosis of breast cancer cells via Fas signaling.
Novel Approaches for Molecular Targeted Therapy of Breast Cancer: Interfering with PI3K/AKT/mTOR Signaling.
Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines under Normoxic and Hypoxic Conditions.
Novel strategies for molecular targeting to cancer.
Novel strategy in breast cancer therapy: Revealing the bright side of ginsenosides.
Numerical analysis of intracellular amino acid profiles of breast cancer cells with K-Ras or PI3K mutation in response to kinase inhibitors.
NVP-BEZ235 or JAKi Treatment leads to decreased survival of examined GBM and BBC cells.
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
Obesity and insulin resistance in breast cancer--chemoprevention strategies with a focus on metformin.
Oestrogen Non-Genomic Signalling is Activated in Tamoxifen-Resistant Breast Cancer.
Olaparib and ?-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
Oleate activates phosphatidylinositol 3-kinase and promotes proliferation and reduces apoptosis of MDA-MB-231 breast cancer cells, whereas palmitate has opposite effects.
Oleate promotes the proliferation of breast cancer cells via the G protein-coupled receptor GPR40.
Oncogene PRR14 promotes breast cancer through activation of PI3K signal pathway and inhibition of CHEK2 pathway.
Oncogenic PI3K promotes methionine dependency in breast cancer cells through the cystine-glutamate antiporter xCT.
Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer.
Opposite Prognostic Impact of Single PTEN-loss and PIK3CA Mutations in Early High-risk Breast Cancer.
Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications.
Oral ridaforolimus plus trastuzumab for patients with HER2+ trastuzumab-refractory metastatic breast cancer.
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab.
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Overcoming endocrine resistance in breast cancer: role of the PI3K and the mTOR pathways.
Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis.
Overexpression of seven in absentia homolog 2 protein in human breast cancer tissues is associated with the promotion of tumor cell malignant behavior in in vitro.
Overview of the relevance of PI3K pathway in HR-positive breast cancer.
Oxymatrine Inhibits the Proliferation and Invasion of Breast Cancer Cells via the PI3K Pathway.
P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer.
P-Rex1 directly activates RhoG to regulate GPCR-driven Rac signalling and actin polarity in neutrophils.
p-TSA.H2O mediated one-pot, multi-component synthesis of isatin derived imidazoles as dual-purpose drugs against inflammation and cancer.
Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.
Pathway-based subnetworks enable cross-disease biomarker discovery.
PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3K? Inhibition.
PET Imaging on Dynamic Metabolic Changes after Combination Therapy of Paclitaxel and the Traditional Chinese Medicine in Breast Cancer-Bearing Mice.
Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-? degrader activity in antitumor efficacy.
Pharmacological explorations of eco-friendly amide substituted (Z)-?-enaminones as anti-breast cancer drugs.
Pharmacological inactivation of the PI3K p110? prevents breast tumour progression by targeting cancer cells and macrophages.
Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer.
Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors.
Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.
Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy.
Phase Ib Study of Ribociclib Plus Fulvestrant and Ribociclib Plus Fulvestrant Plus PI3K-Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer.
Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer.
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.
Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts.
Phosphatidylinositol 3-kinase (PI3K?)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells.
Phosphatidylinositol 3-kinase (PI3KCA) oncogene mutation analysis and gene expression profiling in primary breast cancer patients.
Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.
Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator.
Phosphatidylinositol 3-Kinase dependent upregulation of the epidermal growth factor receptor upon Flotillin-1 depletion in breast cancer cells.
Phosphatidylinositol 3-kinase in breast cancer: where from here?
Phosphatidylinositol 3-kinase in the G protein-coupled receptor-induced chemokinesis and chemotaxis of MDA-MB-468 breast carcinoma cells: a comparison with leukocytes.
Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases.
Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
Phosphatidylinositol 3-kinase regulatory subunit 1 and phosphatase and tensin homolog as therapeutic targets in breast cancer.
Phosphatidylinositol 3-kinase/AKT signalling pathway components in human breast cancer: clinicopathological correlations.
Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.
Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K.
Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.
Phospho-PRAS40(Thr246) predicts trastuzumab response in patients with HER2-positive metastatic breast cancer.
Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth.
Phosphoinositide 3-kinase and INPP4B in human breast cancer.
Phosphoinositide 3-kinase mutations in breast cancer: a "good" activating mutation?
Phosphoinositide 3-kinase signaling pathway mediated by p110? regulates invadopodia formation.
Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play?
Phosphoinositide 3-kinase targeting by the beta galactoside binding protein cytokine negates akt gene expression and leads aggressive breast cancer cells to apoptotic death.
Phosphoproteomics reveals that the hVPS34 regulated SGK3 kinase specifically phosphorylates endosomal proteins including Syntaxin-7, Syntaxin-12, RFIP4 and WDR44.
Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment.
Phosphorylation and mRNA Splicing of Collapsin Response Mediator Protein-2 Determine Inhibition of Rho-Associated Protein Kinase (ROCK)-II Function in Carcinoma Cell Migration and Invasion.
Physiology and pathophysiology of IGFBP-1 and IGFBP-2 - consensus and dissent on metabolic control and malignant potential.
Phytochemicals as PI3K/ Akt/ mTOR Inhibitors and Their Role in Breast Cancer Treatment.
PI3-K/AKT regulation of NF-kappaB signaling events in suppression of TNF-induced apoptosis.
PI3K activation is associated with intracellular sodium/iodide symporter protein expression in breast cancer.
PI3K activation promotes resistance to eribulin in HER2-negative breast cancer.
PI3K and ERK-induced Rac1 activation mediates hypoxia-induced HIF-1? expression in MCF-7 breast cancer cells.
PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening.
PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells.
PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression.
PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer.
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA proficient triple negative breast cancer to PARP inhibition.
PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance.
PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses.
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer.
PI3K inhibition to overcome endocrine resistance in breast cancer.
PI3K Inhibitor Improves PFS in BELLE-2 Trial.
PI3K Inhibitors and Adverse Events: Optimizing Patient Care for the Treatment of Advanced Breast Cancer.
PI3K inhibitors are finally coming of age.
PI3K Inhibitors in Breast Cancer Therapy.
PI3K is required for insulin-stimulated but not EGF-stimulated ERK1/2 activation.
PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients.
PI3K mutations in breast cancer: prognostic and therapeutic implications.
PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality.
PI3K Pathway Activation in High-Grade Ductal Carcinoma In Situ--Implications for Progression to Invasive Breast Carcinoma.
PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer.
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.
PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane.
PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D.
PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.
PI3K Regulates YAP/TAZ in Mammary Tumorigenesis through Multiple Signaling Pathways.
PI3K Signaling Regulates ER Activity via KMT2D in ER(+) Breast Cancer.
PI3K targeting in breast cancer: the end of the beginning?
PI3K-based molecular signatures link high PI3K pathway activity with low ER levels in ER+ breast cancer.
PI3K-p110? mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
PI3K/Akt responses to oxytocin stimulation in Caco2BB gut cells.
PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?
PI3K: A master regulator of brain metastasis-promoting macrophages/microglia.
PI3K? inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8+T cells and promoting fatty acid metabolism.
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study.
Pictilisib Plus Anastrozole Reduces Proliferation in ER+ Breast Cancer.
Pictilisib Stalls Advanced ER+/PR+ Breast Cancer.
PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer.
PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.
PIK3CA and PTEN Genes Expressions in Breast Cancer.
PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients.
PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients.
PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis.
PIK3CA gene amplification and PI3K p110? protein expression in breast carcinoma.
PIK3CA gene mutations in breast carcinoma in Malaysian patients.
PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.
PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy.
PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system.
PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.
PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.
PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells.
PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer.
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
PIK3CA mutations define favorable prognostic biomarkers in operable breast cancer: a systematic review and meta-analysis.
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
PIK3R1 targeting by miR-21 suppresses tumor cell migration and invasion by reducing PI3K/AKT signaling and reversing EMT, and predicts clinical outcome of breast cancer.
PIK3R1 underexpression is an independent prognostic marker in breast cancer.
PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
PIKing the right isoform: the emergent role of the p110beta subunit in breast cancer.
Plant cyclopeptide RA-V kills human breast cancer cells by inducing mitochondria-mediated apoptosis through blocking PDK1-AKT interaction.
Plasma PIK3CA Mutation Testing in Advanced Breast Cancer Patients for Personalized Medicine: A Value Proposition.
Poncirin downregulates ATP-binding cassette transporters to enhance cisplatin sensitivity in cisplatin-resistant osteosarcoma cells.
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.
Potential role of PI3K inhibitors in the treatment of breast cancer.
pp60c-Src phosphorylates and activates vacuolar protein sorting 34 to mediate cellular transformation.
Pre-clinical efficacy of Ron kinase inhibitors alone and in combination with PI3K inhibitors for treatment of sfRon-expressing breast cancer patient-derived xenografts.
Pre-existing Cell States Control Heterogeneity of Both EGFR and CXCR4 Signaling.
Precision medicine for metastatic breast cancer.
Precision medicine: PI3K targeting in advanced breast cancer.
Preclinical Evaluation of a Fluorine-18 (18F)-Labeled Phosphatidylinositol 3-Kinase Inhibitor for Breast Cancer Imaging.
Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer.
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models.
Predictive and prognostic significance of p27, Akt, PTEN and PI3K expression in HER2-positive metastatic breast cancer.
Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer.
Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients.
Primary mammary angiosarcomas harbor frequent mutations in KDR and PIK3CA and show evidence of distinct pathogenesis.
Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date.
Profiling the tyrosine phosphoproteome of different mouse mammary tumour models reveals distinct, model-specific signalling networks and conserved oncogenic pathways.
Progesterone receptor-B regulation of insulin-like growth factor-stimulated cell migration in breast cancer cells via insulin receptor substrate-2.
Progress in targeted therapy for breast cancer.
Prolactin and heregulin override DNA damage-induced growth arrest and promote phosphatidylinositol-3 kinase-dependent proliferation in breast cancer cells.
Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer.
Promising rationally derived combination therapy with PI3K and CDK4/6 inhibitors.
Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells.
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.
Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models.
PTEN activation sensitizes breast cancer to PI3-kinase inhibitor through the ?-catenin signaling pathway.
PTEN loss is a predictive marker for HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas.
PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death.
PTEN/PI3K/AKT protein expression is related to clinicopathological features and prognosis in breast cancer with axillary lymph node metastases.
Ramentaceone, a Naphthoquinone Derived from Drosera sp., Induces Apoptosis by Suppressing PI3K/Akt Signaling in Breast Cancer Cells.
Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ.
Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells.
Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling.
Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta.
Regulation of Raf-Akt Cross-talk.
Relationships between signaling pathway usage and sensitivity to a pathway inhibitor: examination of trametinib responses in cultured breast cancer lines.
Responsiveness to PI3K and MEK inhibitors in breast cancer. Use of a 3D culture system to study pathways related to hormone independence in mice.
RGS16 inhibits breast cancer cell growth by mitigating phosphatidylinositol 3-kinase signaling.
RNA interference-mediated depletion of phosphoinositide 3-kinase activates forkhead box class O transcription factors and induces cell cycle arrest and apoptosis in breast carcinoma cells.
Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives.
Role of Aspirin in Breast Cancer Survival.
Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.
RTK-dependent inducible degradation of mutant PI3K? drives GDC-0077 (Inavolisib) efficacy.
Science Signaling Podcast for 21 February 2017: Pentraxin-3 in basal-like breast cancer.
Sequential application of a cytotoxic nanoparticle and a PI3K inhibitor enhances antitumor efficacy.
Serglycin promotes breast cancer cell aggressiveness: Induction of epithelial to mesenchymal transition, proteolytic activity and IL-8 signaling.
Serine phosphorylation of paxillin by heregulin-beta1: role of p38 mitogen activated protein kinase.
Setting the Pick: Can PI3K Inhibitors Circumvent CDK4/6 Inhibitor Resistance?
SGK3 (CISK) may induce tumor angiogenesis (Hypothesis).
SGK3 is an estrogen-inducible kinase promoting estrogen-mediated survival of breast cancer cells.
SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer.
SGLT2 inhibitors as potentially helpful drugs in PI3K inhibitor-induced diabetes: a case report.
Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase.
Signaling Pathway of GP88 (Progranulin) in Breast Cancer Cells: Upregulation and Phosphorylation of c-myc by GP88/Progranulin in Her2-Overexpressing Breast Cancer Cells.
Signaling pathways responsible for cancer cell invasion as targets for cancer therapy.
Signaling through 3',5'-cyclic adenosine monophosphate and phosphoinositide-3 kinase induces sodium/iodide symporter expression in breast cancer.
Signalling mechanisms regulating phenotypic changes in breast cancer cells.
Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase.
Silk fibroin mediated delivery of liposomal emodin to breast cancer cells.
Simultaneous Inhibition of EGFR and PI3K Enhances Radiosensitivity In Human Breast Cancer.
SIRT6 Suppresses Cancer Stem-like Capacity in Tumors with PI3K Activation Independently of Its Deacetylase Activity.
Specific requirement for the p85-p110alpha phosphatidylinositol 3-kinase during epidermal growth factor-stimulated actin nucleation in breast cancer cells.
Sphingosine Kinase 1 in Breast Cancer-A New Molecular Marker and a Therapy Target.
Src family kinases mediate epidermal growth factor receptor signaling from lipid rafts in breast cancer cells.
Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades.
Src mediates prolactin-dependent proliferation of T47D and MCF7 cells via the activation of focal adhesion kinase/Erk1/2 and phosphatidylinositol 3-kinase pathways.
Stabilization of cyclin D1 mRNA via the phosphatidylinositol 3-kinase pathway in MCF-7 human breast cancer cells.
Staged stromal extracellular 3D matrices differentially regulate breast cancer cell responses through PI3K and beta1-integrins.
Standard of care and controversies in the adjuvant endocrine treatment of hormone-responsive early breast cancer.
Stanniocalcin-1 promotes metastasis in a human breast cancer cell line through activation of PI3K.
Stathmin expression associates with vascular and immune responses in aggressive breast cancer subgroups.
Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway.
Strategically timing inhibition of phosphatidylinositol 3-kinase to maximize therapeutic index in estrogen receptor alpha-positive, PIK3CA-mutant breast cancer.
Strong synergism between small molecule inhibitors of HER2, PI3K, mTOR and Bcl-2 in human breast cancer cells.
Suppressing the molecular signaling pathways involved in inflammation and cancer in breast cancer cell lines MDA-MB-231 and MCF-7 by miR-590.
Suppression of epidermal growth factor receptor-mediated ?-catenin nuclear accumulation enhances the anti-tumor activity of phosphoinositide 3-kinase inhibitor in breast cancer.
Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
Surfactin suppresses TPA-induced breast cancer cell invasion through the inhibition of MMP-9 expression.
Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.
Synergistic interactions with PI3K inhibition that induce apoptosis.
Synthesis and Anticancer Activity of the (R,S)-Benzofused 1,5-Oxathiepine Moiety Tethered to Purines through Alkylidenoxy Linkers.
Systematic functional characterization of resistance to PI3K inhibition in breast cancer.
Tackling Resistance to PI3K Inhibition by Targeting the Epigenome.
Tamoxifen and the PI3K Inhibitor: LY294002 Synergistically Induce Apoptosis and Cell Cycle Arrest in Breast Cancer MCF-7 Cells.
Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1.
Tanshinone IIA Induces Mitochondria Dependent Apoptosis in Prostate Cancer Cells in Association with an Inhibition of Phosphoinositide 3-Kinase/AKT Pathway.
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to Sunitinib.
Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.
Targeting PDK1 in cancer.
Targeting PI3K and AMPK? Signaling Alone or in Combination to Enhance Radiosensitivity of Triple Negative Breast Cancer.
Targeting PI3K, HER2 and the IL-8/JAK2 axis in metastatic breast cancer: which combination makes the whole greater than the sum of its parts?
Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer.
Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations.
Targeting PTEN-defined breast cancers with a one-two punch.
Targeting the androgen receptor in triple-negative breast cancer.
Targeting the Phosphatidyl Inositol 3-Kinase Signaling Pathway in Breast Cancer.
Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?
Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
Targeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy.
Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer.
Targeting the PI3K/Akt/mTOR-pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.
TBCRC 032 IB/II Multicenter Study: Molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR+ metastatic triple-negative breast cancer.
Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling.
Testing considerations for phosphatidylinositol-3-kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer.
TGF-beta induces formation of F-actin cores and matrix degradation in human breast cancer cells via distinct signaling pathways.
The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration.
The anticancer activities of Vernonia amygdalina Delile. Leaves on 4T1 breast cancer cells through phosphoinositide 3-kinase (PI3K) pathway.
The antitumor effect of GDC-0941 alone and in combination with rapamycin in breast cancer cells.
The association of diabetes mellitus and insulin treatment with expression of insulin-related proteins in breast tumors.
The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.
The catalytic class I(A) PI3K isoforms play divergent roles in breast cancer cell migration.
The combinatorial activation of the PI3K and Ras/MAPK pathways is sufficient for aggressive tumor formation, while individual pathway activation supports cell persistence.
The Comparison of RhoC and PI3K Gene Expression on the Breast Cancer Tissue and Benign Tumour Tissue.
The Effect of Chrysin Loaded PLGA-PEG on Metalloproteinase Gene Expression in Mouse 4T1 Tumor Model.
The emerging role of BET inhibitors in breast cancer.
The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part II: Metastatic Disease.
The expression and prognosis of Emi1 and Skp2 in breast carcinoma: associated with PI3K/Akt pathway and cell proliferation.
The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer.
The Future of ER+/HER2- Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors.
The H1047R PIK3CA oncogene induces a senescence-like state, pleiotropy and acute HSP90 dependency in HER2+ mammary epithelial cells.
The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth.
The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment.
The inhibition of PI3K and NF?B promoted curcumin-induced cell cycle arrest at G2/M via altering polyamine metabolism in Bcl-2 overexpressing MCF-7 breast cancer cells.
The Interaction of PI3K Inhibition with Homologous Recombination Repair in Triple Negative Breast Cancer Cells.
The lipid metabolism gene FTO influences breast cancer cell energy metabolism via the PI3K/AKT signaling pathway.
The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to the Cytotoxic Effect of Carboplatin in Breast Cancer In Vitro.
The mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3.
The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts.
The outstanding role of miR-132-3p in carcinogenesis of solid tumors.
The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer.
The phosphatidylinositol 3-kinase (PI3K) isoform dependence of tumor formation is determined by the genetic mode of PI3K pathway activation rather than by tissue type.
The PI3K and AIB1 interaction is involved in estrogen treated breast cancer cells.
The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase.
The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.
The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings.
The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis.
The Predictive Role of PIK3CA Mutation Status on PI3K Inhibitors in HR+ Breast Cancer Therapy: A Systematic Review and Meta-Analysis.
The Preparation of Ginsenoside Rg5, Its Antitumor Activity against Breast Cancer Cells and Its Targeting of PI3K.
The PREX1/Rac signaling axis: Potential as a biomarker and therapeutic target in breast cancer.
The prognostic value of PI3K mutational status in breast cancer: A meta-analysis.
The promise of combining inhibition of PI3K and PARP as cancer therapy.
The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells.
The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy.
The Role of PI3K Inhibition in the Treatment of Breast Cancer, Alone or Combined With Immune Checkpoint Inhibitors.
Therapeutic advances in BIG3-PHB2 inhibition targeting the crosstalk between estrogen and growth factors in breast cancer.
Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer.
Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs.
Three-dimensional extracellular matrix culture models of EGFR signalling and drug response.
Thyroid Hormone Receptor Beta Inhibits PI3K-Akt-mTOR Signaling Axis in Anaplastic Thyroid Cancer via Genomic Mechanisms.
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.
Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA (H1047R) in HER2/ER-positive breast cancer.
Transmigration characteristics of breast cancer and melanoma cells through the brain endothelium: Role of Rac and PI3K.
Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors.
Treating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series.
Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway.
Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers.
Tumor lysis Syndrome in a Patient with Metastatic Breast Cancer Treated with Alpelisib.
Two members of the TRiC chaperonin complex, CCT2 and TCP1 are essential for survival of breast cancer cells and are linked to driving oncogenes.
Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells.
Up-regulation of PI3K/Akt signaling by 17beta-estradiol through activation of estrogen receptor-alpha, but not estrogen receptor-beta, and stimulates cell growth in breast cancer cells.
Upregulated WDR26 serves as a scaffold to coordinate PI3K/ AKT pathway-driven breast cancer cell growth, migration, and invasion.
Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer.
Using Tandem Mass Spectrometry in Targeted Mode to Identify Activators of Class IA PI3K in Cancer.
USP35, regulated by estrogen and AKT, promotes breast tumorigenesis by stabilizing and enhancing transcriptional activity of estrogen receptor ?.
Vitamin C sensitizes triple negative breast cancer to PI3K inhibition therapy.
VPS34 stimulation of p62 phosphorylation for cancer progression.
WAVE3 phosphorylation regulates the interplay between PI3K, TGF-?, and EGF signaling pathways in breast cancer.
Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis.
Wortmannin Reduces Metastasis and Angiogenesis of Human Breast Cancer Cells via Nuclear Factor- B-dependent Matrix Metalloproteinase-9 and Interleukin-8 Pathways.
ZSTK474, a specific class I phosphatidylinositol 3-kinase inhibitor, induces G1 arrest and autophagy in human breast cancer MCF-7 cells.
[Activation of phosphatidylinositol 3-kinase in human breast carcinoma]
[New advances in targeted therapy for breast cancer].
[Overexpression of HER2/neu downregulates wild p53 protein expression via PI3K and Ras/Raf/MEK/ERK pathways in human breast cancer cells]
[PI3K/AKT pathway activation and therapeutic consequences in breast cancer].
[The effect of HER2/neu overexpression on p53 gene expression, cell proliferation and sensitivity to gamma-irradiation via the PI3K/Akt pathway in breast cancer cell MCF7]
Bronchitis
Coronavirus interactions with the cellular autophagy machinery.
Bronchitis, Chronic
Phosphatidylinositol 3-kinase mediates mitogen-induced human airway smooth muscle cell proliferation.
Burkitt Lymphoma
BET Inhibition-Induced GSK3? Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors.
Blockade of PI3K/AKT pathway enhances sensitivity of Raji cells to chemotherapy through down-regulation of HSP70.
Dual inhibition of histone deacetylases and phosphoinositide 3-kinases: effects on Burkitt lymphoma cell growth and migration.
ERK-dependent IL-6 positive feedback loop mediates resistance against a combined treatment using danusertib and BKM120 in Burkitt lymphoma cell lines.
Functional role of phosphatidylinositol 3-kinase/Akt pathway on cell growth and lytic cycle of Epstein-Barr virus in the Burkitt's lymphoma cell line, P3HR-1.
Immunocytochemical detection of phosphatidylinositol 3 kinase in Burkitt lymphoma cells.
Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3.
Inhibition of the PI3K/AKT-NF-?B pathway with curcumin enhanced radiation-induced apoptosis in human Burkitt's lymphoma.
Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia.
Nuclear FOXO1 promotes lymphomagenesis in germinal center B cells.
Oncogenic mechanisms in Burkitt lymphoma.
Phosphatidylinositol 3-kinase is essential for the proliferation of lymphoblastoid cells.
Simultaneous inhibition of Vps34 kinase would enhance PI3K? inhibitor cytotoxicity in the B-cell malignancies.
Capsule Opacification
Erufosine, a phosphoinositide-3-kinase inhibitor, to mitigate posterior capsule opacification in the human capsular bag model.
Carcinogenesis
(+)-2-(1-Hydroxyl-4-oxocyclohexyl) ethyl caffeate suppresses solar UV-induced skin carcinogenesis by targeting PI3K, ERK1/2, and p38.
A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.
A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma.
A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic Cancer.
A Kinome-Wide RNAi Screen in Drosophila Glia Reveals That the RIO Kinases Mediate Cell Proliferation and Survival through TORC2-Akt Signaling in Glioblastoma.
A novel PI3K axis selective molecule exhibits potent tumor inhibition in colorectal carcinogenesis.
A Novel PIK3CA Hotspot Mutation in Isfahanian Breast Cancer Patients.
A Selenium Containing Inhibitor for the Treatment of Hepatocellular Cancer.
A susceptibility gene set for early onset colorectal cancer that integrates diverse signaling pathways: implication for tumorigenesis.
A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation.
A Tumor Suppressor Function for the Lipid Phosphatase INPP4B in Melanocytic Neoplasms.
Aberrant PTEN, PIK3CA, pMAPK, and TP53 expression in human scalp and face angiosarcoma.
Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants.
Activation of PDK-1 maintains mouse embryonic stem cell self-renewal in a PKB-dependent manner.
Activation of phosphatidylinositol 3-kinase by membrane localization of p110alpha predisposes mammary glands to neoplastic transformation.
Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor.
Activation of PI3K is associated with reduced survival in renal cell carcinoma.
Activity of BKM120 and BEZ235 against Lymphoma Cells.
Airway PI3K pathway activation is an early and reversible event in lung cancer development.
Akt and mTORC1 Have Different Roles During Liver Tumorigenesis in Mice.
Altered Composition of Fatty Acids Exacerbates Hepatotumorigenesis during Activation of the Phosphatidylinositol 3-kinase Pathway.
Antileukemic activity of the VPS34-IN1 inhibitor in acute myeloid leukemia.
Arsenite-induced stress signaling: Modulation of the phosphoinositide 3'-kinase/Akt/FoxO signaling cascade.
Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors.
Astrocyte elevated gene-1 (AEG-1) functions as an oncogene and regulates angiogenesis.
Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc.
Autophagy inhibition enhances colorectal cancer apoptosis induced by dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
BARgaining membranes for autophagosome formation: Regulation of autophagy and tumorigenesis by Bif-1/Endophilin B1.
BCL-2 in prostate cancer: a minireview.
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis.
Biochemical and biological characterization of tumor-associated mutations of p110alpha.
Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis.
Blocking phosphoinositide 3-kinase activity in colorectal cancer cells reduces proliferation but does not increase apoptosis alone or in combination with cytotoxic drugs.
BMX Acts Downstream of PI3K to Promote Colorectal Cancer Cell Survival and Pathway Inhibition Sensitizes to the BH3 Mimetic ABT-737.
Buparlisib is a brain penetrable pan-PI3K inhibitor.
Caffeine promotes ultraviolet B-induced apoptosis in human keratinocytes without complete DNA repair.
Cellular prostatic acid phosphatase, a PTEN-functional homologue in prostate epithelia, functions as a prostate-specific tumor suppressor.
Challenges in the clinical development of PI3K inhibitors.
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.
Chemoprevention of lung tumorigenesis by intranasally administered diindolylmethane in A/J mice.
Choline kinase: an important target for cancer.
Class 1A PI3K regulates vessel integrity during development and tumorigenesis.
CLDN4 silencing promotes proliferation and reduces chemotherapy sensitivity of gastric cancer cells through activation of the PI3K/Akt signalling pathway.
Clinical value of CagA, c-Met, PI3K and Beclin-1 expressed in gastric cancer and their association with prognosis.
Clustered DNA lesion sites as a source of mutations during human colorectal tumourigenesis.
Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver.
Colon Cancer Tumorigenesis Initiated by the H1047R Mutant PI3K.
Combined targeting of PI3K and MEK effector pathways via CED for DIPG therapy.
Comprehensive analysis of PTEN status in breast carcinomas.
Control of Glucocorticoid Receptor Levels by PTEN Establishes a Failsafe Mechanism for Tumor Suppression.
Correction: Maf1 is a novel target of PTEN and PI3K signaling that negatively regulates oncogenesis and lipid metabolism.
Crosstalk signaling between HER3 and HPV16 E6 and E7 mediates resistance to PI3K inhibitors in head and neck cancer.
Crosstalking between Androgen and PI3K/AKT Signaling Pathways in Prostate Cancer Cells.
Dally Proteoglycan Mediates the Autonomous and Nonautonomous Effects on Tissue Growth Caused by Activation of the PI3K and TOR Pathways.
Depletion of PI3K p85alpha induces cell cycle arrest and apoptosis in colorectal cancer cells.
Development and validation of a novel survival model for head and neck squamous cell carcinoma based on autophagy-related genes.
Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3K? inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancers.
Drugging the PI3 kinome: from chemical tools to drugs in the clinic.
Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations.
Dual roles of hemidesmosomal proteins in the pancreatic epithelium: the phosphoinositide 3-kinase decides.
Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression.
Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer.
Effect of DNAzymes targeting Akt1 on cell proliferation and apoptosis in nasopharyngeal carcinoma.
Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study.
Endometriosis-associated Extraovarian Malignancies: A Challenging Question for the Clinician and the Pathologist.
Enhanced Urinary Bladder, Liver and Colon Carcinogenesis in Zucker Diabetic Fatty Rats in a Multiorgan Carcinogenesis Bioassay: Evidence for Mechanisms Involving Activation of PI3K Signaling and Impairment of p53 on Urinary Bladder Carcinogenesis.
EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway.
Epigenetically silenced LINC02381 functions as a tumor suppressor by regulating PI3K-Akt signaling pathway.
Eupatilin inhibits EGF-induced JB6 cell transformation by targeting PI3K.
Expression cloning of protein targets for 3-phosphorylated phosphoinositides.
Expression of factors and key components associated with the PI3K signaling pathway in colon cancer.
Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancer.
Expression of insulin-like growth factor-1 receptor, p-AKT and p-ERK1/2 protein in extramammary Paget's disease.
Expression of MAPK and PI3K/AKT/mTOR Proteins according to the Chronic Liver Disease Etiology in Hepatocellular Carcinoma.
Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations.
Fangchinoline suppresses the proliferation, invasion and tumorigenesis of human osteosarcoma cells through the inhibition of PI3K and downstream signaling pathways.
Fisetin and 5-fluorouracil: Effective combination for PIK3CA-mutant colorectal cancer.
FLJ10540-elicited cell transformation is through the activation of PI3-kinase/AKT pathway.
FOXO3 Is Inhibited by Oncogenic PI3K/Akt Signaling but Can Be Reactivated by the NSAID Sulindac Sulfide.
Functional genomics reveals that tumors with activating phosphoinositide 3-kinase mutations are dependent on accelerated protein turnover.
Functional inhibition of PI3K by the betaGBP molecule suppresses Ras-MAPK signalling to block cell proliferation.
Functional roles of the phosphatidylinositol 3-kinases (PI3Ks) signaling in the mammalian ovary.
Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer.
G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression--transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway.
Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma.
Genetic deregulation of the PIK3CA oncogene in oral cancer.
Genetically engineered mouse models of PI3K signaling in breast cancer.
Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway.
Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers.
Genomic instability and colon carcinogenesis: from the perspective of genes.
Giant obscurins regulate the PI3K cascade in breast epithelial cells via direct binding to the PI3K/p85 regulatory subunit.
GPCR signaling mediates tumor metastasis via PI3K?.
Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors.
High-throughput screening campaigns against a PI3K? isoform bearing the H1047R mutation identified potential inhibitors with novel scaffolds.
HIV-1 Tat promotes Kaposi's sarcoma-associated herpesvirus (KSHV) vIL-6-induced angiogenesis and tumorigenesis by regulating PI3K/PTEN/AKT/GSK-3? signaling pathway.
Homeobox gene Cdx1 regulates Ras, Rho and PI3 kinase pathways leading to transformation and tumorigenesis of intestinal epithelial cells.
Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells.
Identification of multiple SNT-binding sites on NPM-ALK oncoprotein and their involvement in cell transformation.
Identification of RASAL1 as a major tumor suppressor gene in thyroid cancer.
Identification of survival-related genes of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma multiforme.
Immortalization of primary endothelial cells by the K1 protein of Kaposi's sarcoma-associated herpesvirus.
Immunohistochemical characterisation of molecular subtypes in endometrial cancer.
Immunohistochemical detection of phosphorylated Akt, PI3K, and PTEN in ameloblastic tumors.
Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo.
Inhibitory mechanisms of tea polyphenols on the ultraviolet B-activated phosphatidylinositol 3-kinase-dependent pathway.
Integrate analysis of the promote function of Cell division cycle-associated protein family to pancreatic adenocarcinoma.
Interaction between IGF2-PI3K axis and cancer-associated-fibroblasts promotes anal squamous carcinogenesis.
Kaposi¿s sarcoma-associated herpesvirus G-protein coupled receptor activates the canonical Wnt/ß-catenin signaling pathway.
Key roles for GRB2-associated-binding protein 1, phosphatidylinositol-3-kinase, cyclooxygenase 2, prostaglandin E2 and transforming growth factor alpha in linoleic acid-induced upregulation of lung and breast cancer cell growth.
Key signaling pathways in thyroid cancer.
Kinetic mechanism of AKT/PKB enzyme family.
Krebs medal review. How a lipid mediates tumour suppression: Delivered on 29 June 2010 at the 35th FEBS Congress in Gothenburg, Sweden.
L-Dopa decarboxylase interaction with the major signaling regulator ??3? in tissues and cells of neural and peripheral origin.
Laminin-332 promotes the invasion of oesophageal squamous cell carcinoma via PI3K activation.
LncRNA MEG3 inhibit endometrial carcinoma tumorigenesis and progression through PI3K pathway.
Low Frequency of PIK3CA Gene Mutations in Hepatocellular Carcinoma in Chinese Population.
Maf1 is a novel target of PTEN and PI3K signaling that negatively regulates oncogenesis and lipid metabolism.
Membrane metallo-endopeptidase mediates cellular senescence induced by oncogenic PIK3CAH1047R accompanied with pro-tumorigenic secretome.
Meta-Analysis and Systematic Review of the Genomics of Mucosal Melanoma.
MicroRNA-34A inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression.
Minireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy.
MiR-7-5p inhibits thyroid cell proliferation by targeting the EGFR/MAPK and IRS2/PI3K signaling pathways.
miRNA-Directed Regulation of the Main Signaling Pathways in Thyroid Cancer.
Mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways are not sufficient for insulin-like growth factor I-induced mitogenesis and tumorigenesis.
Modulation of integrin-linked kinase (ILK) expression in human oesophageal squamous cell carcinoma cell lines by the EGF and TGFbeta1 growth factors.
Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines.
Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy.
Molecular perspectives in differentiated thyroid cancer.
Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.
Molecularly targeting the PI3K-Akt-mTOR pathway can sensitize cancer cells to radiotherapy and chemotherapy.
Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma.
Mutation of N-linked glycosylation at Asn548 in CD133 decreases its ability to promote hepatoma cell growth.
Mutation of the PIK3CA oncogene in human cancers.
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.
New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition.
NF-kappaB regulates androgen receptor expression and prostate cancer growth.
Novel mutations of the HRAS gene and absence of hotspot mutations of the BRAF genes in oral squamous cell carcinoma in a Greek population.
Nuclear phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3-kinase, Akt, and PTen: emerging key regulators of anti-apoptotic signaling and carcinogenesis.
Nuclear PI3K signaling in cell growth and tumorigenesis.
Nuclear receptor corepressor is a novel regulator of phosphatidylinositol 3-kinase signaling.
Obesity and thyroid cancer.
Oncogenic mutations of thyroid hormone receptor ?.
Oncogenic PI3K and its role in cancer.
Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN.
Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGF? signaling.
P55PIK Regulates P53-Dependent Apoptosis in Cancer Cells by Interacting with P53 DNA-Specific Domain.
Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma.
Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors.
Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines.
Phosphatidylinositol 3-Kinase Inhibitor LY294002 Suppresses Proliferation and Sensitizes Doxorubicin Chemotherapy in Bladder Cancer Cells.
Phosphatidylinositol 3-kinase isoforms as targets in respiratory disease.
Phosphatidylinositol 3-kinase, a novel target molecule for the inhibitory effects of kaempferol on neoplastic cell transformation.
Phosphoinositide 3-kinases as targets for therapeutic intervention.
Phosphoinositol 3-kinase, a novel target molecule for the inhibitory effects of juglone on TPA-induced cell transformation.
Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis.
Phosphorylation of middle T by pp60c-src: a switch for binding of phosphatidylinositol 3-kinase and optimal tumorigenesis.
PI 3-kinase and cancer: changing accents.
PI3 Kinase in Cancer: From Biology to Clinic.
PI3 kinases in cancer: from oncogene artifact to leading cancer target.
PI3K activation in neural stem cells drives tumorigenesis which can be ameliorated by targeting the cAMP response element binding protein.
PI3K enters beta-testing.
PI3K inhibitors as novel cancer therapies: implications for cardiovascular medicine.
PI3K is required for the physical interaction and functional inhibition of NF-?B by ?-catenin in colorectal cancer cells.
PI3K Regulates YAP/TAZ in Mammary Tumorigenesis through Multiple Signaling Pathways.
PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.
PI3K/Akt Pathway and miR-21 are Involved in N-Ethyl-N-Nitrosourea-Induced F1 Mouse Lung Tumorigenesis: Effect of Inositol Hexaphosphate.
PI3K/PTEN signaling in angiogenesis and tumorigenesis.
PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.
PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations.
PIK3CA is critical for the proliferation, invasiveness, and drug resistance of human tongue carcinoma cells.
PIK3CA Is Regulated by CUX1, Promotes Cell Growth and Metastasis in Bladder Cancer via Activating Epithelial-Mesenchymal Transition.
PIK3CA mutation is predictive of poor survival in patients with colorectal cancer.
PIK3CA mutation occurs in nasopharyngeal carcinoma but does not significantly influence the disease-specific survival.
PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors.
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches.
PIK3IP1, a negative regulator of PI3K, suppresses the development of hepatocellular carcinoma.
PIK3R3, part of the regulatory domain of PI3K, is upregulated in sarcoma stem-like cells and promotes invasion, migration, and chemotherapy resistance.
Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer.
Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways.
PP2A Deficiency Enhances Carcinogenesis of Lgr5+ Intestinal Stem Cells Both in Organoids and In Vivo.
Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Preclinical Rationale for PI3K/Akt/mTOR Pathway Inhibitors as Therapy for Epidermal Growth Factor Receptor Inhibitor-Resistant Non-Small-Cell Lung Cancer.
Predominant Activation of JAK/STAT3 Pathway by Interleukin-6 Is Implicated in Hepatocarcinogenesis.
Prognostic implications of phosphatidylinositol 3-kinase/AKT signaling pathway activation in gastric carcinomas.
PRR14 is a novel activator of the PI3K pathway promoting lung carcinogenesis.
PTEN and the PI3-Kinase Pathway in Cancer.
PTEN inhibits BMI1 function independently of its phosphatase activity.
Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas.
PTEN: from pathology to biology.
Quantitative redox imaging biomarkers for studying tissue metabolic state and its heterogeneity.
Ral activation promotes melanomagenesis.
Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways.
RAS Interaction with PI3K: More Than Just Another Effector Pathway.
REC8 is a novel tumor suppressor gene epigenetically robustly targeted by the PI3K pathway in thyroid cancer.
Recent advances in understanding the molecular role of phosphoinositide-specific phospholipase C gamma 1 as an emerging onco-driver and novel therapeutic target in human carcinogenesis.
Recent Patents Related to Phosphorylation Signaling Pathway on Cancer.
Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression.
Regulation of H-Ras-driven MAPK signaling, transformation and tumorigenesis, but not PI3K signaling and tumor progression, by plasma membrane microdomains.
Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases.
Role of aberrant PI3K pathway activation in gallbladder tumorigenesis.
Role of HGF/MET axis in resistance of lung cancer to contemporary management.
Role of IQGAP1 in Papillomavirus-Associated Head and Neck Tumorigenesis.
Role of phosphatidylinositol-3-kinase pathway in head and neck squamous cell carcinoma.
Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway.
Role of PI3K, mTOR and Akt2 signalling in hepatic tumorigenesis via the control of PKM2 expression.
Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer.
Role of RAS in the Regulation of PI 3-Kinase.
Role of RONS and eIFs in Cancer Progression.
Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.
Romidepsin (FK228) and its analogs directly inhibit PI3K activity and potently induce apoptosis as HDAC/PI3K dual inhibitors.
Second AKT: The rise of SGK in cancer signalling.
Sh-MARCH8 Inhibits Tumorigenesis via PI3K Pathway in Gastric Cancer.
Sh3glb1/Bif-1 and mitophagy: Acquisition of apoptosis resistance during Myc-driven lymphomagenesis.
Should individual PI3 kinase isoforms be targeted in cancer?
SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans.
Simultaneous inhibition of PI3K? and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer.
Small Molecule SOS1 Agonists Modulate MAPK and PI3K Signaling via Independent Cellular Responses.
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.
Somatic mutations of PIK3R1 promote gliomagenesis.
Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.
Src Cooperates with Oncogenic Ras in Tumourigenesis via the JNK and PI3K Pathways in Drosophila epithelial Tissue.
SRF-dependent gene expression is required for PI3-kinase-regulated cell proliferation.
Stopping ras in its tracks.
Structural Perturbations due to Mutation (H1047R) in Phosphoinositide-3-kinase (PI3K?) and Its Involvement in Oncogenesis: An in Silico Insight.
Synthesis and biological evaluation of novel purinyl quinazolinone derivatives as PI3K?-specific inhibitors for the treatment of hematologic malignancies.
TALEN-mediated generation of Nkx3.1 knockout rat model.
Targeted Inhibition of Purine Metabolism Is Effective in Suppressing Hepatocellular Carcinoma Progression.
Targeted RNA interference of phosphatidylinositol 3-kinase p110-beta induces apoptosis and proliferation arrest in endometrial carcinoma cells.
Targeting mTOR network in colorectal cancer therapy.
Targeting neuropilin 1 as an antitumor strategy in lung cancer.
Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs.
Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC).
Targeting the PI3K/AKT pathway for the treatment of prostate cancer.
Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
Taxifolin Suppresses UV-Induced Skin Carcinogenesis by Targeting EGFR and PI3K.
TGF-beta inhibits Akt-induced transformation in intestinal epithelial cells.
The biology of cancer: metabolic reprogramming fuels cell growth and proliferation.
The botanical component p-hydroxycinnamic acid suppresses the growth and bone metastatic activity of human prostate cancer PC-3 cells in vitro.
The combinatorial activation of the PI3K and Ras/MAPK pathways is sufficient for aggressive tumor formation, while individual pathway activation supports cell persistence.
The crosstalk between long non-coding RNAs and PI3K in cancer.
The Frequencies and Clinical Implications of Mutations in 33 Kinase-Related Genes in Locally Advanced Rectal Cancer: A Pilot Study.
The hamster model of sequential oral oncogenesis.
The Iron-Regulated Metastasis Suppressor NDRG1 Targets NEDD4L, PTEN, and SMAD4 and Inhibits the PI3K and Ras Signaling Pathways.
The negative regulation of phosphoinositide 3-kinase signaling by p85 and it's implication in cancer.
The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers.
The p110? and p110? isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis.
The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.
The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling.
The phytochemical p-hydroxycinnamic acid suppresses the growth and stimulates the death in human liver cancer HepG2 cells.
The PI3 Kinase Signaling Pathway in Prostate Cancer.
The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
The PI3K/AKT pathway in the pathogenesis of prostate cancer.
The PI3K/Akt Pathway in Tumors of Endocrine Tissues.
The protein-protein interaction-mediated inactivation of PTEN.
The Rho guanine nucleotide exchange factor ARHGEF5 promotes tumor malignancy via epithelial-mesenchymal transition.
The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy.
The role of hypoxia-inducible factors in cancer.
The role of miR-200a in mammalian epithelial cell transformation.
The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
The role of the PI3K/Akt/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses.
Therapeutics Targeting Mutant KRAS.
Tuberous Sclerosis Complex 1: An Epithelial Tumor Suppressor Essential to Prevent Spontaneous Prostate Cancer in Aged Mice.
Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.
Uncoupling of PI3K from ErbB3 impairs mammary gland development but does not impact on ErbB2-induced mammary tumorigenesis.
Upregulation of FLJ10540, a PI3K-association protein, in rostral ventrolateral medulla impairs brain stem cardiovascular regulation during mevinphos intoxication.
VPS34 stimulation of p62 phosphorylation for cancer progression.
Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.
ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system.
[Activation and significance of the PI3K/Akt pathway in endometrium with polycystic ovary syndrome patients].
[Activation of phosphatidylinositol 3-kinase in human breast carcinoma]
[Clinicopathological Research and Expression of PTEN/PI3K/Akt Signaling Pathway in Non-small Cell Lung Cancer.]
[PIK3CA mutations in the most common types of cancer].
[Screening for mutations in the hotspot mutation regions of PIK3CA gene in nasopharyngeal carcinoma]
Carcinoid Tumor
Increased gastric expression of MMP-7 in hypergastrinemia and significance for epithelial-mesenchymal signaling.
Phosphatidylinositol 3-kinase-Akt signaling in pulmonary carcinoid cells.
Secretin Receptor Promotes the Proliferation of Endocrine Tumor Cells Via the PI3K/AKT Pathway.
Carcinoma
A comprehensive analysis of transcript signatures of the phosphatidylinositol-3 kinase/protein kinase B signal-transduction pathway in prostate cancer.
A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.
A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck.
A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma.
A novel mitogenic signaling pathway of bradykinin in the human colon carcinoma cell line SW-480 involves sequential activation of a Gq/11 protein, phosphatidylinositol 3-kinase beta, and protein kinase Cepsilon.
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma.
A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer.
A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas.
A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells.
Abnormal expression of PI3K isoforms in patients with tobacco-related oral squamous cell carcinoma.
Activation of ErbB3-PI3-kinase pathway is correlated with malignant phenotypes of adenocarcinomas.
Activation of phosphatidylinositol 3-kinase and extracellular signal-regulated kinase is required for glial cell line-derived neurotrophic factor-induced migration and invasion of pancreatic carcinoma cells.
Activation of phosphoinositide 3-OH kinase by the alpha6beta4 integrin promotes carcinoma invasion.
Activation of PI3K is associated with reduced survival in renal cell carcinoma.
Activation of PI3K Signaling in Merkel Cell Carcinoma.
Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.
Adaptive resistance to PI3K?-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells.
Affinity with Raf is sufficient for Ras to efficiently induce rat mammary carcinomas.
Akt-FOXO3a signaling axis dysregulation in human oral squamous cell carcinoma and potent efficacy of FOXO3a-targeted gene therapy.
AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity.
AKT3 is a key regulator of head and neck squamous cell carcinoma.
Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung.
Alternate paths from epidermal growth factor receptor to Akt in malignant versus nontransformed lung epithelial cells: ErbB3 versus Gab1.
Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations.
Analysis of cellular phosphatidylinositol (3,4,5)-trisphosphate levels and distribution using confocal fluorescent microscopy.
Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.
Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway.
Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma.
Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
Arsenic trioxide induces a beclin-1-independent autophagic pathway via modulation of SnoN/SkiL expression in ovarian carcinoma cells.
Arsenite induces HIF-1alpha and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells.
Aspirin reduces the incidence of metastasis in a pre-clinical study of Braf mutant serrated colorectal neoplasia.
Augmentation of Sodium Butyrate-induced Apoptosis by Phosphatidylinositol 3-kinase Inhibition in the Human Cervical Cancer Cell-line.
Autocrine induction of invasion and metastasis by tumor-associated trypsin inhibitor in human colon cancer cells.
Autophagy-related protein PIK3C3/VPS34 controls T cell metabolism and function.
AXL mediates resistance to PI3K? inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.
BCL-3 expression promotes colorectal tumorigenesis through activation of AKT signalling.
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Biallelic ERBB3 loss-of-function variants are associated with a novel multisystem syndrome without congenital contracture.
Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer.
Brassinin enhances the anticancer actions of paclitaxel by targeting multiple signaling pathways in colorectal cancer cells.
Bronchial airway gene expression signatures in mouse lung squamous cell carcinoma and their modulation by cancer chemopreventive agents.
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.
C5aR is frequently expressed in metastatic renal cell carcinoma and plays a crucial role in cell invasion via the ERK and PI3 kinase pathways.
Case Report and Literature Review: Primary Pulmonary NUT-Midline Carcinoma.
CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3K? Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma.
Cell-surface nucleolin is a signal transducing P-selectin binding protein for human colon carcinoma cells.
Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer.
Circ_0015756 promotes proliferation, invasion and migration by microRNA-7-dependent inhibition of FAK in hepatocellular carcinoma.
Clinical significance of immunocytochemistry for PIK3CA as a carcinogenesis-related marker on liquid-based cytology in cervical intraepithelial neoplasia.
Clinicopathological and biological analysis of PIK3CA mutation and amplification in cervical carcinomas.
Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibition.
Contribution of the PI3K/MMPs/Ln-5?2 and EphA2/FAK/Paxillin signaling pathways to tumor growth and vasculogenic mimicry of gallbladder carcinomas.
Cooperative effect of hepatocyte growth factor and fibronectin in anchorage-independent survival of mammary carcinoma cells: requirement for phosphatidylinositol 3-kinase activity.
Cotargeting CHK1 and PI3K Synergistically Suppresses Tumor Growth of Oral Cavity Squamous Cell Carcinoma in Patient-Derived Xenografts.
Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females.
Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.
Diagnostic and Prognostic Biomarkers of Adrenal Cortical Carcinoma.
Differential compensation mechanisms define resistance to PI3K inhibitors in PIK3CA amplified HNSCC.
Differential DNA methylation status between breast carcinomatous and normal tissues.
Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
Disruption of TP63-miR-27a* feedback loop by mutant TP53 in head and neck cancer.
Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
Dual blocking of PI3K and mTOR signaling by NVP-BEZ235 inhibits proliferation in cervical carcinoma cells and enhances therapeutic response.
Dual Inhibition of Autophagy and PI3K/AKT/MTOR Pathway as a Therapeutic Strategy in Head and Neck Squamous Cell Carcinoma.
Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds.
Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma.
E-cadherin directly contributes to PI3K/AKT activation by engaging the PI3K-p85 regulatory subunit to adherens junctions of ovarian carcinoma cells.
Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer.
Effects of LY294002 on the invasiveness of human gastric cancer in vivo in nude mice.
Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines.
EGFR and PI3K Pathway Activities Might Guide Drug Repurposing in HPV-Negative Head and Neck Cancers.
EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer.
Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets-a narrative review.
Enhanced susceptibility to apoptosis of oral squamous cell carcinoma cells subjected to combined treatment with anticancer drugs and phosphatidylinositol 3-kinase inhibitors.
Enhanced susceptibility to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in oral squamous cell carcinoma cells treated with phosphatidylinositol 3-kinase inhibitors.
Enhancement of susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells by phosphatidylinositol 3-kinase inhibitor.
ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth.
ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
Erratum to: Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
Esophageal squamous cell carcinoma transcriptome reveals the effect of FOXM1 on patient outcome through novel PIK3R3 mediated activation of PI3K signaling pathway.
Establishment and preclinical application of a patient-derived xenograft model for uterine cancer.
Establishment of patient-derived xenograft models of adenoid cystic carcinoma to assess pre-clinical efficacy of combination therapy of a PI3K inhibitor and retinoic acid.
Exploring the importance of cancer pathways by meta-analysis of differential protein expression networks in three different cancers.
Expression and clinical significance of the phosphatidylinositol 3-kinase/protein kinase B signal transduction pathway in non-small cell lung carcinoma.
Expression and Comparison of Cbl-b in Lung Squamous Cell Carcinoma and Adenocarcinoma.
Expression of Phosphoinositide 3-Kinase p110? and p110? Subunits and PIK3CA Mutation in Patients With Advanced Gastric Carcinoma.
Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification.
Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells.
Ferulic Acid Induces Apoptosis of HeLa and Caski Cervical Carcinoma Cells by Down-Regulating the Phosphatidylinositol 3-Kinase (PI3K)/Akt Signaling Pathway.
Fibronectin increases matrix metalloproteinase 9 expression through activation of c-Fos via extracellular-regulated kinase and phosphatidylinositol 3-kinase pathways in human lung carcinoma cells.
Fluorodeoxyglucose uptake in laryngeal carcinoma is associated with the expression of glucose transporter-1 and hypoxia-inducible-factor-1? and the phosphoinositide 3-kinase/protein kinase B pathway.
Formal model of the interplay between TGF?1 and MMP-9 and their dynamics in hepatocellular carcinoma.
Frequent activation of AKT2 kinase in human pancreatic carcinomas.
Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.
Functional roles of the phosphatidylinositol 3-kinases (PI3Ks) signaling in the mammalian ovary.
Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells.
Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma.
Genetic mutations in thyroid carcinoma.
Genome-Wide Screen of miRNAs and Targeting mRNAs Reveals the Negatively Regulatory Effect of miR-130b-3p on PTEN by PI3K and Integrin ?1 Signaling Pathways in Bladder Carcinoma.
Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers.
GLI1 Blockade Potentiates the Antitumor Activity of PI3K Antagonists in Lung Squamous Cell Carcinoma.
GSK1059615 kills head and neck squamous cell carcinoma cells possibly via activating mitochondrial programmed necrosis pathway.
Hepatocyte growth factor inhibits anoikis of pancreatic carcinoma cells through phosphatidylinositol 3-kinase pathway.
Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma.
HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma.
High-grade serous ovarian cancer arises from fallopian tube in a mouse model.
High-Throughput Genotyping in Metastatic Esophageal Squamous Cell Carcinoma Identifies Phosphoinositide-3-Kinase and BRAF Mutations.
HS-173, a selective PI3K inhibitor, induces cell death in head and neck squamous cell carcinoma cell lines.
Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells.
Identification of a developmental gene expression signature, including HOX genes, for the normal human colonic crypt stem cell niche - Overexpression of the signature parallels stem cell overpopulation during colon tumorigenesis.
Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide Analyses.
Immunohistochemical Detection and Molecular Characterization of IDH-mutant Sinonasal Undifferentiated Carcinomas.
Immunoprofile of c-MET/PI3K signaling in human salivary gland tumors.
In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002).
In-silico prediction of potential inhibitors against phosphatidylinositol 3-kinase catalytic subunit alpha involved in head and neck squamous cell carcinomas.
Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression.
Inhibition of phosphatidylinositol 3-kinase- and ERK MAPK-regulated protein synthesis reveals the pro-apoptotic properties of CD40 ligation in carcinoma cells.
Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts.
Inhibition of PI3K Isoform p110? Increases Both Anti-Tumor and Immunosuppressive Responses to Aggressive Murine Head and Neck Squamous Cell Carcinoma with Low Immunogenicity.
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.
Inhibition of the PI3K-Akt signaling pathway enhances the sensitivity of Fas-mediated apoptosis in human gastric carcinoma cell line, MKN-45.
Insulin-like growth factor-1 activates different catalytic subunits p110 of PI3K in a cell-type-dependent manner to induce lipogenesis-dependent epithelial-mesenchymal transition through the regulation of ADAM10 and ADAM17.
Involvement of PTEN/Akt signaling in capsular invasive carcinomas developed in a rat two-stage thyroid carcinogenesis model after promotion with sulfadimethoxine.
JQ1 and PI3K inhibition synergistically reduce salivary adenoid cystic carcinoma malignancy by targeting the c-Myc and EGFR signaling pathways.
Knockdown of ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma.
Laminin-332 promotes the invasion of oesophageal squamous cell carcinoma via PI3K activation.
lncRNA MEG3 had anti-cancer effects to suppress pancreatic cancer activity.
Long Non-Coding RNA (lncRNA) Growth Arrest Specific 5 (GAS5) Suppresses Esophageal Squamous Cell Carcinoma Cell Proliferation and Migration by Inactivating Phosphatidylinositol 3-kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.
Long non-coding RNA CCAT1 is a prognostic biomarker for the progression of oral squamous cell carcinoma via miR-181a-mediated Wnt/?-catenin signaling pathway.
Loss of beta4 integrin subunit reduces the tumorigenicity of MCF7 mammary cells and causes apoptosis upon hormone deprivation.
Low-grade Apocrine Intraductal Carcinoma: Expanding the Morphologic and Molecular Spectrum of an Enigmatic Salivary Gland Tumor.
LY294002 enhances inhibitory effect of gemcitabine on proliferation of human pancreatic carcinoma PANC-1 cells.
MAPK and PI3K signalling differentially regulate angiogenic and lymphangiogenic cytokine secretion in squamous cell carcinoma of the head and neck.
Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer.
Metabolic determinants of sensitivity to phosphatidylinositol 3-kinase pathway inhibitor in small-cell lung carcinoma.
MicroRNA?98/PTEN/AKT pathway inhibits cell proliferation and malignant progression of hypopharyngeal carcinoma by MTDH.
MiRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in gastric cancer.
Molecular Alterations in Circulating Cell-Free DNA in Patients with Colorectal Adenoma or Carcinoma.
Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.
Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma.
Molecular pathways of urothelial development and bladder tumorigenesis.
Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma.
Mutation of the PI3' kinase gene in a human colon carcinoma cell line, HCC2998.
Mutation-Driven Signals of ARID1A and PI3K Pathways in Ovarian Carcinomas: Alteration Is An Opportunity.
Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma.
Mutational status of PIK3ca oncogene in oral cancer-In the new age of PI3K inhibitors.
Network Analysis of the Focal Adhesion to Invadopodia Transition Identifies a PI3K-PKC? Invasive Signaling Axis.
NF-kappaB overrides the apoptotic program of TNF receptor 1 but not CD40 in carcinoma cells.
Novel targeting of phosphatidylinositol 3-kinase and mammalian target of rapamycin in renal cell carcinoma.
Omega-3 polyunsaturated fatty acids selectively inhibit growth in neoplastic oral keratinocytes by differentially activating ERK1/2.
Oncogenic activation of the PI3-kinase p110? isoform via the tumor-derived PIK3C?(D1067V) kinase domain mutation.
Oncogenic mutations in gastric cancer with microsatellite instability.
Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
Oral squamous cell carcinoma (OSCC)-derived exosomal MiR-221 targets and regulates phosphoinositide-3-kinase regulatory subunit 1 (PIK3R1) to promote human umbilical vein endothelial cells migration and tube formation.
Overexpression of phosphatidylinositol 3-kinase in human lung cancer.
Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: a role in ovarian pathogenesis.
Overexpression of the N-terminal end of the p55gamma regulatory subunit of phosphatidylinositol 3-kinase blocks cell cycle progression in gastric carcinoma cells.
p120-catenin suppresses proliferation and tumor growth of oral squamous cell carcinoma via inhibiting nuclear phospholipase C-?1 signaling.
p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas.
p62/SQSTM1 Accumulation in Squamous Cell Carcinoma of Head and Neck Predicts Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitors.
p85? phosphoinositide 3-kinase subunit regulates tumor progression.
Parathyroid hormone-related protein induces cell survival in human renal cell carcinoma through the PI3K Akt pathway: evidence for a critical role for integrin-linked kinase and nuclear factor kappa B.
Pathology of endometrioid carcinoma.
Phase I trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck.
Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Phenotypic switching of VEGF and collagen XVIII during hypoxia in head and neck squamous carcinoma cells.
Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells.
Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines.
Phosphatidylinositol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma.
Phosphatidylinositol 3-kinase p110? expression in Merkel cell carcinoma.
Phosphoinositide 3-kinase p85beta regulates invadopodium formation.
PI3K activation is associated with intracellular sodium/iodide symporter protein expression in breast cancer.
PI3k and Stat3: Oncogenes that are Required for Gap Junctional, Intercellular Communication.
PI3K Catalytic Subunits ? and ? Modulate Cell Death and IL-6 Secretion Induced by Talc Particles in Human Lung Carcinoma Cells.
PI3K inhibitor enhances the cytotoxic response to etoposide and cisplatin in a newly established neuroendocrine cervical carcinoma cell line.
PI3K inhibitor provides durable response in metastatic metaplastic carcinoma of the breast: A hidden gem in the BELLE-4 study.
PI3k inhibitors (BKM120 and BYL719) as radiosensitizers for head and neck squamous cell carcinoma during radiotherapy.
PI3K inhibitors curtail MYC-dependent mutant p53 gain-of-function in head and neck squamous cell carcinoma.
PI3K is required for both basal and LPA-induced DNA synthesis in oral carcinoma cells.
PI3K Overexpression and PIK3CA Mutations Are Associated with Age, Tumor Staging, and Other Clinical Characteristics in Chinese Patients with Esophageal Squamous Cell Carcinoma.
PI3K pathway activation and thromboembolism in ovarian clear cell carcinomas.
PI3K Pathway in Gynecologic Malignancies.
PI3K Promotes Basal Cell Carcinoma Growth Through Kinase-Induced p21 Degradation.
PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1alpha from pVHL-independent degradation.
PI3K/AKT pathway regulates phosphorylation of steroid receptors, hormone independence and tumor differentiation in breast cancer.
PI3KCA Mutations in Uterine Cervix Carcinoma.
PIK3C3 Acts as a Tumor Suppressor in Esophageal Squamous Cell Carcinoma and Was Regulated by MiR-340-5p.
PIK3CA, HRAS and KRAS Gene Mutations in Human Penile Cancer.
PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma.
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.
PPARbeta/delta agonist stimulates human lung carcinoma cell growth through inhibition of PTEN expression: the involvement of PI3K and NF-kappaB signals.
Problematic breast tumors reassessed in light of novel molecular data.
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer.
Progranulin expression induced by follicle-stimulating hormone in ovarian cancer cell lines depends on the histological subtype.
Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas.
PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation.
PTEN/PI3K/AKT protein expression is related to clinicopathological features and prognosis in breast cancer with axillary lymph node metastases.
PTHrP increases xenograft growth and promotes integrin alpha6beta4 expression and Akt activation in colon cancer.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Rare PIK3CA hotspot mutations in carcinomas of the biliary tract.
RAS/ PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma.
Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
Recurrent prognostic factors and expression of GLUT-1, PI3K and p-Akt in adenoid cystic carcinomas of the head and neck: Clinicopathological features and biomarkers of adenoid cystic carcinoma.
Reduced expression of E-cadherin and p120-catenin and elevated expression of PLC-?1 and PIKE are associated with aggressiveness of oral squamous cell carcinoma.
Retraction. Fibronectin increases matrix metalloproteinase 9 expression through activation of c-Fos via extracellular-regulated kinase and phosphatidylinositol 3-kinase pathways in human lung carcinoma cells.
Salivary Duct Carcinoma: Targeting the Phosphatidylinositol 3-Kinase Pathway by Blocking Mammalian Target of Rapamycin With Temsirolimus.
Selective inhibition of PI3K110? as a novel therapeutic strategy for cetuximab?resistant oral squamous cell carcinoma.
SETD2 loss sensitizes cells to PI3K? and AKT inhibition.
Signal Transduction Pathway Activity in High-Grade, Serous Ovarian Carcinoma Reveals a More Favorable Prognosis in Tumors with Low PI3K and High NF-?B Pathway Activity: A Novel Approach to a Long-Standing Enigma.
Signaling pathways in follicular cell-derived thyroid carcinomas (review).
Signalling pathways involved in antitumoral effects of VIP in human renal cell carcinoma A498 cells: VIP induction of p53 expression.
Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status.
Simultaneous inhibition of the mitogen-activated protein kinase kinase and phosphatidylinositol 3'-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma.
Simultaneous targeting PI3K and PERK pathways promotes cell death and improves the clinical prognosis in esophageal squamous carcinoma.
SLC39A6 Promotes Aggressiveness of Esophageal Carcinoma Cells by Increasing Intracellular Levels of Zinc, Activating Phosphatidylinositol 3-kinase Signaling, and Upregulating Genes That Regulate Metastasis.
SOX2 and PI3K Cooperate to Induce and Stabilize a Squamous-Committed Stem Cell Injury State during Lung Squamous Cell Carcinoma Pathogenesis.
Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas.
STMN1, a prognostic predictor of esophageal squamous cell carcinoma, is a marker of the activation of the PI3K pathway.
Synergistic inhibition of colon carcinoma cell growth by Hedgehog-Gli1 inhibitor arsenic trioxide and phosphoinositide 3-kinase inhibitor LY294002.
TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3K? inhibition in head and neck squamous cell carcinoma.
Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinoma.
Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cells.
Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: New strategies for overcoming resistance to VEGFR and mTORC1 inhibitors.
Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma.
Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Targeting the PI3K Pathway in Head and Neck Squamous Cell Carcinoma.
Targeting Translation Initiation Bypasses Signaling Crosstalk Mechanisms That Maintain High MYC Levels in Colorectal Cancer.
TGFbeta-induced downregulation of E-cadherin-based cell-cell adhesion depends on PI3-kinase and PTEN.
The alpha6beta4 integrin can regulate ErbB-3 expression: implications for alpha6beta4 signaling and function.
The anti-leishmanial drug miltefosine causes insulin resistance in skeletal muscle cells in vitro.
The anti-tumor activator sMEK1 and paclitaxel additively decrease expression of HIF-1? and VEGF via mTORC1-S6K/4E-BP-dependent signaling pathways.
The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas.
The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR.
The Emerging Molecular Landscape of Urothelial Carcinoma.
The landscape of somatic mutations in Indonesian cervical cancer is predominated by the PI3K pathway.
The p110? and p110? isoforms of class I phosphatidylinositol 3-kinase are involved in toll-like receptor 5 signaling in epithelial cells.
The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel.
The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy.
The phosphoinositide-3-kinase/Akt pathway mediates the transient increase in Nanog expression during differentiation of F9 cells.
The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1.
The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue.
Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors.
Translocation and activation of AKT2 in response to stimulation by insulin.
Transmembrane Collagen XVII Modulates Integrin Dependent Keratinocyte Migration via PI3K/Rac1 Signaling.
Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma.
Using Tandem Mass Spectrometry in Targeted Mode to Identify Activators of Class IA PI3K in Cancer.
Wise Management of Ovarian Cancer: On the Cutting Edge.
[Advances on driver oncogenes of non-small cell lung cancer].
[Corrigendum] STMN1, a prognostic predictor of esophageal squamous cell carcinoma, is a marker of the activation of the PI3K pathway.
[Cyr61 expression influences cancer cell proliferation and apoptosis via PI3K pathway in human ovarian carcinoma cells].
[Effect of licochalcone A on autophagy in renal cell carcinoma via PI3K/Akt/mTOR signaling pathway].
[Effects of class I( phosphatidylinositol-3-kinases inhibitor on gastric cancer cell xenografts in nude mice].
[Expression and clinical significance of phosphatidylinositol 3-kinase and protein kinase B in cervical carcinoma]
[Expression and clinical significance of PI3K in esophageal squamous cell carcinoma].
[Expression and involved signal transduction pathway of autophagy gene Beclin 1 in epithelial ovarian cancer]
[Expression and significance of Ki-67, PI3K and Beclin1 in oral squamous cell carcinoma].
[Expression and significance of PTEN/PI3K signal transduction-related proteins in non-small cell lung cancer]
[Expression of phosphatidylinositol-3 kinase in epithelial ovarian carcinoma]
[Inhibitory effect of tirapazamine combined with phosphatidylinositol 3-kinase inhibitor LY294002 to ovarian cancer cells]
[Research of Feiliuping Gao and its combination with different types of drugs intervention on expression of PI3K/AKT/NF-?B in lung metastatic microenvironment].
Carcinoma in Situ
Molecular pathways of urothelial development and bladder tumorigenesis.
Carcinoma, Adenoid Cystic
Establishment of patient-derived xenograft models of adenoid cystic carcinoma to assess pre-clinical efficacy of combination therapy of a PI3K inhibitor and retinoic acid.
JQ1 and PI3K inhibition synergistically reduce salivary adenoid cystic carcinoma malignancy by targeting the c-Myc and EGFR signaling pathways.
Problematic breast tumors reassessed in light of novel molecular data.
Recurrent prognostic factors and expression of GLUT-1, PI3K and p-Akt in adenoid cystic carcinomas of the head and neck: Clinicopathological features and biomarkers of adenoid cystic carcinoma.
Carcinoma, Basal Cell
PI3K Promotes Basal Cell Carcinoma Growth Through Kinase-Induced p21 Degradation.
Carcinoma, Ductal
Comprehensive analysis of PTEN status in breast carcinomas.
Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases.
Multiplexed imaging reveals heterogeneity of PI3K/MAPK network signaling in breast lesions of known PIK3CA genotype.
Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
PI3K Pathway Activation in High-Grade Ductal Carcinoma In Situ--Implications for Progression to Invasive Breast Carcinoma.
Carcinoma, Endometrioid
Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies.
Mammalian target of rapamycin is a therapeutic target for murine ovarian endometrioid adenocarcinomas with dysregulated Wnt/?-catenin and PTEN.
Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.
PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients.
RNASeq analysis reveals biological processes governing the clinical behaviour of endometrioid and serous endometrial cancers.
Carcinoma, Hepatocellular
A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
A novel role for ABCA1-generated large pre-beta migrating nascent HDL in the regulation of hepatic VLDL triglyceride secretion.
A novel role for ABCA1-generated large pre-beta migrating nascent HDL in the regulationof hepatic VLDL triglyceride secretion.
Ablation of phosphoinositide-3-kinase class II alpha suppresses hepatoma cell proliferation.
Alpha-fetoprotein: A new member of intracellular signal molecules in regulation of the PI3K/AKT signaling in human hepatoma cell lines.
Anticarcinogenic action of quercetin by downregulation of phosphatidylinositol 3-kinase (PI3K) and protein kinase C (PKC) via induction of p53 in hepatocellular carcinoma (HepG2) cell line.
Arctigenin, a Natural Lignan Compound, Induces Apoptotic Death of Hepatocellular Carcinoma Cells via Suppression of PI3-K/Akt Signaling.
Asparagus Polysaccharide inhibits the Hypoxia-induced migration, invasion and angiogenesis of Hepatocellular Carcinoma Cells partly through regulating HIF1?/VEGF expression via MAPK and PI3K signaling pathway.
Author Correction: Novel 2-phenyloxypyrimidine derivative induces apoptosis and autophagy via inhibiting PI3K pathway and activating MAPK/ERK signaling in hepatocellular carcinoma cells.
Basic fibroblast growth factor upregulates survivin expression in hepatocellular carcinoma cells via a protein kinase B-dependent pathway.
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
BRIT1 dysfunction confers synergistic inhibition of hepatocellular carcinoma by targeting poly (ADP-ribose) polymerases and PI3K.
Circ_0015756 promotes proliferation, invasion and migration by microRNA-7-dependent inhibition of FAK in hepatocellular carcinoma.
CK-3, A Novel Methsulfonyl Pyridine Derivative, Suppresses Hepatocellular Carcinoma Proliferation and Invasion by Blocking the PI3K/AKT/mTOR and MAPK/ERK Pathways.
Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver.
Correction to: Loss of PTEN expression is associated with PI3K pathway-dependent metabolic reprogramming in hepatocellular carcinoma.
Detection of a 60 kDa tyrosine-phosphorylated protein in insulin-stimulated hepatoma cells that associates with the SH2 domain of phosphatidylinositol 3-kinase.
Direct association of heat shock protein 20 (HSPB6) with phosphoinositide 3-kinase (PI3K) in human hepatocellular carcinoma: regulation of the PI3K activity.
Down-regulated lncRNA TP73-AS1 reduces radioresistance in hepatocellular carcinoma via the PTEN/Akt signaling pathway.
Effects of PI3K and p42/p44 MAPK on overexpression of vascular endothelial growth factor in hepatocellular carcinoma.
Effects of tyroserleutide on gene expression of calmodulin and PI3K in hepatocellular carcinoma.
GSK-3beta reactivation with LY294002 sensitizes hepatoma cells to chemotherapy-induced apoptosis.
Hepatic ABCA1 and VLDL triglyceride production.
Hepatitis C virus NS5A-mediated activation of phosphoinositide 3-kinase results in stabilization of cellular beta-catenin and stimulation of beta-catenin-responsive transcription.
Hepatocyte growth factor promotes migration of human hepatocellular carcinoma via phosphatidylinositol 3-kinase.
Hepatocyte-specific Pten-deficient mice as a novel model for nonalcoholic steatohepatitis and hepatocellular carcinoma.
Hepatoma-derived growth factor/nucleolin axis as a novel oncogenic pathway in liver carcinogenesis.
Heterogeneous kinetics of AKT signaling in individual cells are accounted for by variable protein concentration.
HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
Hypoxia-independent overexpression of hypoxia-inducible factor 1alpha as an early change in mouse hepatocarcinogenesis.
Ilexgenin A exerts anti-inflammation and anti-angiogenesis effects through inhibition of STAT3 and PI3K pathways and exhibits synergistic effects with Sorafenib on hepatoma growth.
Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation.
Improved synergistic anticancer efficacy of quercetin in combination with PI-103, rottlerin, and G0 6983 against MCF-7 and RAW 264.7 cells.
Increased activity and nuclear localisation of inositol lipid signal transduction enzymes in rat hepatoma cells.
Induction of apoptosis and suppression of angiogenesis of hepatocellular carcinoma by HS-159, a novel phosphatidylinositol 3-kinase inhibitor.
Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling.
Inhibition of B7-H4 promotes hepatocellular carcinoma cell apoptosis and autophagy through the PI3K signaling pathway.
Insulin and dexamethasone regulate insulin receptors, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in Fao hepatoma cells.
Insulin downregulates C3 gene expression in human HepG2 cells through activation of PPAR?.
Interleukin-6 inhibits transforming growth factor-beta-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways.
Involvement of c-Met- and phosphatidylinositol 3-kinase dependent pathways in arsenite-induced downregulation of catalase in hepatoma cells.
Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9.
IPD-196, a novel phosphatidylinositol 3-kinase inhibitor with potent anticancer activity against hepatocellular carcinoma.
L-Dopa decarboxylase interaction with the major signaling regulator ??3? in tissues and cells of neural and peripheral origin.
Lipopolysaccharide inhibition of glucose production through the Toll-like receptor-4, myeloid differentiation factor 88, and nuclear factor kappa b pathway.
Loss of PTEN expression is associated with PI3K pathway-dependent metabolic reprogramming in hepatocellular carcinoma.
Melatonin and (-)-Epigallocatechin-3-Gallate: Partners in Fighting Cancer.
Melatonin reverses tunicamycin-induced endoplasmic reticulum stress in human hepatocellular carcinoma cells and improves cytotoxic response to doxorubicin by increasing CHOP and decreasing Survivin.
Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein alpha by phosphatidylinositol 3-kinase signaling cascade.
Morin fosters apoptosis in experimental hepatocellular carcinogenesis model.
Multi-Drug/Gene NASH Therapy Delivery and Selective Hyperspectral NIR Imaging Using Chirality-Sorted Single-Walled Carbon Nanotubes.
Myricetin induces apoptosis by inhibiting P21 activated kinase 1 (PAK1) signaling cascade in hepatocellular carcinoma.
Nickel and copper ion-induced stress signaling in human hepatoma cells: analysis of phosphoinositide 3'-kinase/Akt signaling.
Normoxic induction of the hypoxia-inducible factor 1alpha by insulin and interleukin-1beta involves the phosphatidylinositol 3-kinase pathway.
Novel 2-phenyloxypyrimidine derivative induces apoptosis and autophagy via inhibiting PI3K pathway and activating MAPK/ERK signaling in hepatocellular carcinoma cells.
Overexpression of integrin beta1 inhibits proliferation of hepatocellular carcinoma cell SMMC-7721 through preventing Skp2-dependent degradation of p27 via PI3K pathway.
Overexpression of PEMT2 downregulates the PI3K/Akt signaling pathway in rat hepatoma cells.
Overexpression of PIK3R1 promotes hepatocellular carcinoma progression.
PF-04691502 triggers cell cycle arrest, apoptosis and inhibits the angiogenesis in hepatocellular carcinoma cells.
Phosphatidylinositol-3-kinase regulates scavenger receptor class B type I subcellular localization and selective lipid uptake in hepatocytes.
Phosphorylated p27(Kip1) on Thr157 is an important prognosis in human hepatocellular carcinoma in vivo and in vitro.
PI3K class 1B controls the cell cycle checkpoint promoting cell proliferation in hepatocellular carcinoma.
PI3K is required for insulin-stimulated but not EGF-stimulated ERK1/2 activation.
PIK3IP1, a negative regulator of PI3K, suppresses the development of hepatocellular carcinoma.
POSSIBLE REGULATION OF LDL-RECEPTOR BY NARINGENIN IN HEPG2 HEPATOMA CELL LINE.
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Rare PIK3CA hotspot mutations in carcinomas of the biliary tract.
Regulation of hepatitis B virus replication by the phosphatidylinositol 3-kinase-akt signal transduction pathway.
Resistance to cisplatin-induced apoptosis via PI3K-dependent survivin expression in a rat hepatoma cell line.
Role of hesperetin in LDL-receptor expression in hepatoma HepG2 cells.
Selective Targeting of ?v?5 Integrin in HepG2 Cell Line by RGDechi15D Peptide.
SGK3 (CISK) may induce tumor angiogenesis (Hypothesis).
Staurosporine suppresses survival of HepG2 cancer cells through Omi/HtrA2-mediated inhibition of PI3K/Akt signaling pathway.
Stimulation of glycogen synthesis by insulin requires S6 kinase and phosphatidylinositol-3-kinase in HTC-IR cells.
STYXL1 promotes malignant progression of hepatocellular carcinoma via downregulating CELF2 through the PI3K/Akt pathway.
Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors.
Synergistic growth inhibition by acyclic retinoid and phosphatidylinositol 3-kinase inhibitor in human hepatoma cells.
The 60-kDa phosphotyrosine protein in insulin-treated adipocytes is a new member of the insulin receptor substrate family.
The bile acid taurochenodeoxycholate activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade.
The essential role of phosphatidylinositol 3-kinase and of p38 mitogen-activated protein kinase activation in the antioxidant response element-mediated rGSTA2 induction by decreased glutathione in H4IIE hepatoma cells.
The hepatitis B virus-X protein activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade.
The hypoglycaemic activity of fenugreek seed extract is mediated through the stimulation of an insulin signalling pathway.
The ménage à trois of autophagy, lipid droplets and liver disease.
The outstanding role of miR-132-3p in carcinogenesis of solid tumors.
The phosphoinositide 3-kinase pathway and glycogen synthase kinase-3 positively regulate the activity of metal-responsive transcription factor-1 in response to zinc ions.
The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma.
The Predictive and Prognostic Significance of c-erb-B2, EGFR, PTEN, mTOR, PI3K, p27, and ERCC1 Expression in Hepatocellular Carcinoma.
The role of different PI3K protein subtypes in the metastasis, angiogenesis and clinical prognosis of hepatocellular carcinoma.
The transmembrane protein-tyrosine phosphatase LAR modulates signaling by multiple receptor tyrosine kinases.
Therapeutic dose of HIV-1 protease inhibitor saquinavir does not permanently influence early insulin signaling.
Tumor necrosis factor alpha-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1.
Two specific inhibitors of the phosphatidylinositol 3-kinase LY294002 and wortmannin up-regulate beta1,4-galactosyltransferase I and thus sensitize SMMC-7721 human hepatocarcinoma cells to cycloheximide-induced apoptosis.
Ubiquitination of UVRAG by SMURF1 promotes autophagosome maturation and inhibits hepatocellular carcinoma growth.
Velvet antler polypeptide prevents the disruption of hepatic tight junctions via inhibiting oxidative stress in cholestatic mice and liver cell lines.
Vps34 Inhibits Hepatocellular Carcinoma Invasion by Regulating Endosome-Lysosome Trafficking via Rab7-RILP and Rab11.
Xmrks the Spot: Fish Models for Investigating Epidermal Growth Factor Receptor Signaling in Cancer Research.
[Insulin/PI3K signalling pathway regulates the expression of survivin in liver cancer HepG2 cells]
[Roles of PIK3R1 gene in development of hepatocellular carcinoma].
Carcinoma, Intraductal, Noninfiltrating
Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases.
Multiplexed imaging reveals heterogeneity of PI3K/MAPK network signaling in breast lesions of known PIK3CA genotype.
PI3K Pathway Activation in High-Grade Ductal Carcinoma In Situ--Implications for Progression to Invasive Breast Carcinoma.
Carcinoma, Lewis Lung
Autophagy-related protein PIK3C3/VPS34 controls T cell metabolism and function.
[Research of Feiliuping Gao and its combination with different types of drugs intervention on expression of PI3K/AKT/NF-?B in lung metastatic microenvironment].
Carcinoma, Lobular
Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system.
Carcinoma, Merkel Cell
Activation of PI3K Signaling in Merkel Cell Carcinoma.
Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts.
Phosphatidylinositol 3-kinase p110? expression in Merkel cell carcinoma.
Carcinoma, Mucoepidermoid
Inhibition of Protein Phosphatase 2A Sensitizes Mucoepidermoid Carcinoma to Chemotherapy via the PI3K-AKT Pathway in Response to Insulin Stimulus.
Carcinoma, Non-Small-Cell Lung
A novel imidazopyridine PI3K inhibitor with anticancer activity in non-small cell lung cancer cells.
A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor.
A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung.
Andrographolide down-regulates hypoxia-inducible factor-1? in human non-small cell lung cancer A549 cells.
Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor.
BENC-511, a novel PI3K inhibitor, suppresses metastasis of non-small cell lung cancer cells by modulating ?-catenin/ZEB1 regulatory loop.
Blockage of Stat3 enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition.
Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.
Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions.
Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
DEPENDENCE ON THE MUC1-C ONCOPROTEIN IN NON-SMALL CELL LUNG CANCER CELLS WITH EGFR AND K-RAS MUTATIONS.
Diprophylline inhibits non-small cell lung cancer A549 cell proliferation and migration, and promotes apoptosis, by downregulating PI3K signaling pathway.
Diverse prognostic roles of Akt isoforms, PTEN and PI3K in tumor epithelial cells and stromal compartment in non-small cell lung cancer.
Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds.
Dual targeting of PI3K and MEK enhances the radiation response of K-RAS mutated non-small cell lung cancer.
Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells.
Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS mutant lung cancers.
Gefitinib-Resistance Is Related to BIM Expression in Non-Small Cell Lung Cancer Cell Lines.
Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway.
HS-173, a selective PI3K inhibitor, induces cell death in head and neck squamous cell carcinoma cell lines.
Identification of a subset of human non-small cell lung cancer patients with high PI3K? and low PTEN expression, more prevalent in squamous cell carcinoma.
Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms.
Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-actiated protein kinase (MAPK) and phosphatidylinositol-3- kinase (PI3K)/AKT pathways.
MicroRNA-217 alleviates development of non-small cell lung cancer by inhibiting AKT3 via PI3K pathway.
MiR-503 targets PI3K p85 and IKK-? and suppresses progression of non-small cell lung cancer.
Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NF kappa B-dependent pathway.
MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.
Notch signaling: a hero or villain in the war against cancer?
PAQR3 suppresses the growth of non-small cell lung cancer cells via modulation of EGFR-mediated autophagy.
Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer.
Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer.
PI3K expression predicts overall survival in lung adenocarcinoma.
PI3K inhibition sensitizes EGFR wild-type NSCLC cell lines to erlotinib chemotherapy.
PI3K Pathway in NSCLC.
PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.
Simultaneous blockade of AP-1 and phosphatidylinositol 3-kinase pathway in non-small cell lung cancer cells.
Survival and prognosis analyses of concurrent PIK3CA mutations in EGFR mutant non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Synergistic antitumor effect of dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with cisplatin on drug-resistant non-small cell lung cancer cell.
Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma.
The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.
The influence of circular RNAs on autophagy and disease progression.
The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling.
The omega-3 polyunsaturated fatty acid docosahexaenoic acid inhibits proliferation and progression of non-small cell lung cancer cells through the reactive oxygen species-mediated inactivation of the PI3K /Akt pathway.
The PI3K subunits, P110? and P110? are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.
TRIM59 regulates autophagy through modulating both the transcription and the ubiquitination of BECN1.
Using Tandem Mass Spectrometry in Targeted Mode to Identify Activators of Class IA PI3K in Cancer.
VPS34 suppression reverses osimertinib resistance via simultaneously inhibiting glycolysis and autophagy.
W941, a new PI3K inhibitor, exhibits preferable anti-proliferative activities against nonsmall cell lung cancer with autophagy inhibitors.
[Clinical Significance and Mechanism of PI3K p110? Overexpression? in Non-small Cell Lung Cancer].
[Clinicopathological Research and Expression of PTEN/PI3K/Akt Signaling Pathway in Non-small Cell Lung Cancer.]
[Enhanced growth inhibition by combined two pathway inhibitors on K-ras mutated non-small cell lung cancer cells].
[Expression and significance of PTEN/PI3K signal transduction-related proteins in non-small cell lung cancer]
[Growth inhibition of combined pathway inhibitors on KRAS mutated non-small cell lung cancer cell line].
[The Relationship between the PI3K/Akt/mTOR Signal Transduction Pathway and Non-small Cell Lung Cancer.]
Carcinoma, Ovarian Epithelial
AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells.
Combination of AKT inhibition with autophagy blockade effectively reduces ascites-derived ovarian cancer cell viability.
Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells.
Induction of galectin-1 by TLR-dependent PI3K activation enhances epithelial-mesenchymal transition of metastatic ovarian cancer cells.
Integrative Genomic Analysis of Phosphatidylinositol 3'-Kinase Family Identifies PIK3R3 as a Potential Therapeutic Target in Epithelial Ovarian Cancer.
Medroxyprogestogen enhances apoptosis of SKOV-3 cells via inhibition of the PI3K/Akt signaling pathway.
Olaparib and ?-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor.
The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy.
[Effects of PI3K/Akt/NF-?B signal pathway on FSH facilitation on cell proliferation and invasion by human epithelial ovarian cancer].
[Expression and involved signal transduction pathway of autophagy gene Beclin 1 in epithelial ovarian cancer]
[Expression of phosphatidylinositol-3 kinase in epithelial ovarian carcinoma]
Carcinoma, Pancreatic Ductal
Role of the phosphatidylinositol 3'-kinase-Akt signal pathway in the proliferation of human pancreatic ductal carcinoma cell lines.
Carcinoma, Papillary
Genetic mutations in thyroid carcinoma.
Carcinoma, Renal Cell
A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma.
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma.
Activation of PI3K is associated with reduced survival in renal cell carcinoma.
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
C5aR is frequently expressed in metastatic renal cell carcinoma and plays a crucial role in cell invasion via the ERK and PI3 kinase pathways.
Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer.
Circ_0015756 promotes proliferation, invasion and migration by microRNA-7-dependent inhibition of FAK in hepatocellular carcinoma.
Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma.
Correction: Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma.
Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma.
Insulin induces heme oxygenase-1 through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in renal cells.
Novel targeting of phosphatidylinositol 3-kinase and mammalian target of rapamycin in renal cell carcinoma.
Parathyroid hormone-related protein induces cell survival in human renal cell carcinoma through the PI3K Akt pathway: evidence for a critical role for integrin-linked kinase and nuclear factor kappa B.
PI3K inhibition potentiates Bcl-2-dependent apoptosis in renal carcinoma cells.
PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1alpha from pVHL-independent degradation.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition.
RLIP76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer.
SETD2 loss sensitizes cells to PI3K? and AKT inhibition.
Signalling pathways involved in antitumoral effects of VIP in human renal cell carcinoma A498 cells: VIP induction of p53 expression.
Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status.
Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: New strategies for overcoming resistance to VEGFR and mTORC1 inhibitors.
The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy.
[Effect of licochalcone A on autophagy in renal cell carcinoma via PI3K/Akt/mTOR signaling pathway].
Carcinoma, Squamous Cell
3q26 Amplifications in Cervical Squamous Carcinomas.
A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.
A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck.
A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer.
AKT3 is a key regulator of head and neck squamous cell carcinoma.
Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung.
Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.
AXL mediates resistance to PI3K? inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.
Bronchial airway gene expression signatures in mouse lung squamous cell carcinoma and their modulation by cancer chemopreventive agents.
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3K? Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma.
Cotargeting CHK1 and PI3K Synergistically Suppresses Tumor Growth of Oral Cavity Squamous Cell Carcinoma in Patient-Derived Xenografts.
Differential compensation mechanisms define resistance to PI3K inhibitors in PIK3CA amplified HNSCC.
Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
Disruption of TP63-miR-27a* feedback loop by mutant TP53 in head and neck cancer.
Dual Inhibition of Autophagy and PI3K/AKT/MTOR Pathway as a Therapeutic Strategy in Head and Neck Squamous Cell Carcinoma.
Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma.
Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines.
EGFR and PI3K Pathway Activities Might Guide Drug Repurposing in HPV-Negative Head and Neck Cancers.
Enforced C-Src Activation Causes Compartmental Dysregulation of PI3K and PTEN Molecules in Lipid Rafts of Tongue Squamous Carcinoma Cells by Attenuating Rac1-Akt-GLUT-1-Mediated Sphingolipid Synthesis.
ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
Erratum to: Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
Exploring the importance of cancer pathways by meta-analysis of differential protein expression networks in three different cancers.
Expression and Comparison of Cbl-b in Lung Squamous Cell Carcinoma and Adenocarcinoma.
Expression of PI3K and ERK in Uygur and Han patients with cervical squamous cancer.
Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification.
FHOD1, a Formin Upregulated in Epithelial-Mesenchymal Transition, Participates in Cancer Cell Migration and Invasion.
Further evidence for the involvement of insulin receptor substrates in epidermal growth factor-induced activation of phosphatidylinositol 3-kinase.
Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers.
GLI1 Blockade Potentiates the Antitumor Activity of PI3K Antagonists in Lung Squamous Cell Carcinoma.
GSK1059615 kills head and neck squamous cell carcinoma cells possibly via activating mitochondrial programmed necrosis pathway.
Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma.
HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma.
HS-173, a selective PI3K inhibitor, induces cell death in head and neck squamous cell carcinoma cell lines.
In-silico prediction of potential inhibitors against phosphatidylinositol 3-kinase catalytic subunit alpha involved in head and neck squamous cell carcinomas.
Inhibition of PI3K Isoform p110? Increases Both Anti-Tumor and Immunosuppressive Responses to Aggressive Murine Head and Neck Squamous Cell Carcinoma with Low Immunogenicity.
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.
Laminin-332 promotes the invasion of oesophageal squamous cell carcinoma via PI3K activation.
MAPK and PI3K signalling differentially regulate angiogenic and lymphangiogenic cytokine secretion in squamous cell carcinoma of the head and neck.
Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma.
Mutational status of PIK3ca oncogene in oral cancer-In the new age of PI3K inhibitors.
p62/SQSTM1 Accumulation in Squamous Cell Carcinoma of Head and Neck Predicts Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitors.
Phase I trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck.
Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Phenotypic switching of VEGF and collagen XVIII during hypoxia in head and neck squamous carcinoma cells.
PI3k inhibitors (BKM120 and BYL719) as radiosensitizers for head and neck squamous cell carcinoma during radiotherapy.
PI3K inhibitors curtail MYC-dependent mutant p53 gain-of-function in head and neck squamous cell carcinoma.
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
RAS/ PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma.
Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
Reduced expression of E-cadherin and p120-catenin and elevated expression of PLC-?1 and PIKE are associated with aggressiveness of oral squamous cell carcinoma.
Selective inhibition of PI3K110? as a novel therapeutic strategy for cetuximab?resistant oral squamous cell carcinoma.
Simultaneous targeting PI3K and PERK pathways promotes cell death and improves the clinical prognosis in esophageal squamous carcinoma.
SOX2 and PI3K Cooperate to Induce and Stabilize a Squamous-Committed Stem Cell Injury State during Lung Squamous Cell Carcinoma Pathogenesis.
TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3K? inhibition in head and neck squamous cell carcinoma.
Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinoma.
Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma.
Targeting the PI3K Pathway in Head and Neck Squamous Cell Carcinoma.
Taselisib (GDC-0032), a Potent ?-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas.
The PI3K subunits, P110? and P110? are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.
The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue.
Transmembrane Collagen XVII Modulates Integrin Dependent Keratinocyte Migration via PI3K/Rac1 Signaling.
Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma.
[Advances on driver oncogenes of non-small cell lung cancer].
Carcinosarcoma
Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition.
The Rho/Rho-kinase and the phosphatidylinositol 3-kinase pathways are essential for spontaneous locomotion of Walker 256 carcinosarcoma cells.
Cardiomegaly
?-Adrenergic receptor-PI3K signaling crosstalk in mouse heart: elucidation of immediate downstream signaling cascades.
A conserved role for phosphatidylinositol 3-kinase but not Akt signaling in mitochondrial adaptations that accompany physiological cardiac hypertrophy.
Adenine decreases hypertrophic effects through interleukin-18 receptor.
Aldehyde dehydrogenase 2 deficiency blunts compensatory cardiac hypertrophy through modulating Akt phosphorylation early after transverse aorta constriction in mice.
Allicin attenuates pathological cardiac hypertrophy by inhibiting autophagy via activation of PI3K/Akt/mTOR and MAPK/ERK/mTOR signaling pathways.
Association of PI3K-Akt signaling pathway with digitalis-induced hypertrophy of cardiac myocytes.
Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy.
Class III PI3K Vps34 plays an essential role in autophagy and in heart and liver function.
Class III PI3K-mediated prolonged activation of autophagy plays a critical role in the transition of cardiac hypertrophy to heart failure.
CpG-ODN attenuates pathological cardiac hypertrophy and heart failure by activation of PI3K?-Akt signaling.
Decreased p110alpha catalytic activity accompanies increased myocyte apoptosis and cardiac hypertrophy in leptin deficient ob/ob mice.
Differential PI3K signal transduction in obesity-associated cardiac hypertrophy and response to ischemia.
Distinct lipidomic profiles in models of physiological and pathological cardiac remodeling, and potential therapeutic strategies.
FoxO1 is required for physiological cardiac hypertrophy induced by exercise but not by constitutively active PI3K.
Identification of Potentially Relevant Genes for Excessive Exercise-Induced Pathological Cardiac Hypertrophy in Zebrafish.
Impaired IGF-I signalling of hypertrophic hearts in the developmental phase of hypertension in genetically hypertensive rats.
Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction.
MicroRNA-200a-3p Is a Positive Regulator in Cardiac Hypertrophy Through Directly Targeting WDR1 as Well as Modulating PTEN/PI3K/AKT/CREB/WDR1 Signaling.
Phosphoinositide dependent protein kinase 1 is required for exercise-induced cardiac hypertrophy but not the associated mitochondrial adaptations.
Pik3ip1 modulates cardiac hypertrophy by inhibiting PI3K pathway.
Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy.
Regulation of L-type inward calcium channel activity by captopril and angiotensin II via the phosphatidyl inositol 3-kinase pathway in cardiomyocytes from volume-overload hypertrophied rat hearts.
Regulation of PI3K and Hand2 gene on physiological hypertrophy of heart following high-intensity interval, and endurance training.
Significance of ERK cascade compared with JAK/STAT and PI3-K pathway in gp130-mediated cardiac hypertrophy.
Cardiomyopathies
Manipulation of cardiac phosphatidylinositol 3-kinase (PI3K)/Akt signaling by apoptosis regulator through modulating IAP expression (ARIA) regulates cardiomyocyte death during doxorubicin-induced cardiomyopathy.
PI3Kinases in Diabetes Mellitus and Its Related Complications.
Resveratrol Protects the Myocardium in Sepsis by Activating the Phosphatidylinositol 3-Kinases (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway and Inhibiting the Nuclear Factor-?B (NF-?B) Signaling Pathway.
Therapeutic targeting of oxidative stress with coenzyme Q10 counteracts exaggerated diabetic cardiomyopathy in a mouse model of diabetes with diminished PI3K(p110?) signaling.
Cardiomyopathy, Dilated
Distinct lipidomic profiles in models of physiological and pathological cardiac remodeling, and potential therapeutic strategies.
Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation.
Cardiomyopathy, Hypertrophic
Vps34 regulates myofibril proteostasis to prevent hypertrophic cardiomyopathy.
Cardiotoxicity
IGF1-PI3K-induced physiological cardiac hypertrophy: Implications for new heart failure therapies, biomarkers, and predicting cardiotoxicity.
Insulin Signaling in Bupivacaine-induced Cardiac Toxicity: Sensitization during Recovery and Potentiation by Lipid Emulsion.
Phosphoinositide 3-Kinase Gamma Inhibition Protects from Anthracycline Cardiotoxicity and Reduces Tumor Growth.
PI3K? is essential for the recovery from Cre/tamoxifen cardiotoxicity and in myocardial insulin signalling but is not required for normal myocardial contractility in the adult heart.
Upregulation of phosphoinositide 3-kinase prevents sunitinib-induced cardiotoxicity in vitro and in vivo.
Cardiovascular Diseases
Association with Longevity of Phosphatidylinositol 3-Kinase Regulatory Subunit 1 Gene Variants Stems from Protection against Mortality Risk in Men with Cardiovascular Disease.
Effect of the Interplay Between Genetic and Behavioral Risks on Survival After Age 75.
IGF1-PI3K-induced physiological cardiac hypertrophy: Implications for new heart failure therapies, biomarkers, and predicting cardiotoxicity.
Inflammation and apoptosis in aortic tissues of aged type II diabetes: Amelioration with alpha-lipoic acid through phosphatidylinositol 3-kinase/Akt- dependent mechanism.
Phosphoinositide 3-kinase in disease: timing, location, and scaffolding.
Phosphoinositide 3-kinase signalling in the vascular system.
PI3K and Calcium Signaling in Cardiovascular Disease.
PI3K Inhibitors in Cardiovascular Disease.
PI3K inhibitors in thrombosis and cardiovascular disease.
Role of PI3K in the Progression and Regression of Atherosclerosis.
The Role of RP105 in Cardiovascular Disease through Regulating TLR4 and PI3K Signaling Pathways.
Therapeutic applications of PI3K inhibitors in cardiovascular diseases.
Tissue-specific impairment of insulin signaling in vasculature and skeletal muscle of fructose-fed rats.
Castleman Disease
Off-Label Use of Sirolimus and Everolimus in a Pediatric Center: A Case Series and Review of the Literature.
Cataract
Alterations in lens protein tyrosine phosphorylation and phosphatidylinositol 3-kinase signaling during selenite cataract formation.
Deletion of autophagy-related 5 (Atg5) and Pik3c3 in the lens causes cataract independent of programmed organelle degradation.
Rapamycin relieves the cataract caused by ablation of Gja8b through stimulating autophagy in zebrafish.
Celiac Disease
Interferon-? Activates Transglutaminase 2 via a Phosphatidylinositol-3-Kinase-Dependent Pathway: Implications for Celiac Sprue Therapy.
Cell Transformation, Neoplastic
Cyanidin suppresses neoplastic cell transformation by directly targeting phosphatidylinositol 3-kinase
Dehydroglyasperin C suppresses TPA-induced cell transformation through direct inhibition of MKK4 and PI3K.
Phosphatidylinositol 3-kinase, a novel target molecule for the inhibitory effects of kaempferol on neoplastic cell transformation.
Species- and cell type-specific requirements for cellular transformation.
Central Nervous System Neoplasms
The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors.
Cerebellar Neoplasms
Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors.
Cerebral Infarction
Activation of the phosphatidylinositol 3-kinase pathway plays important roles in reduction of cerebral infarction by cilnidipine.
Atorvastatin Rejuvenates Neural Stem Cells Injured by Oxygen-Glucose Deprivation and Induces Neuronal Differentiation Through Activating the PI3K/Akt and ERK Pathways.
LncRNA SNHG1 inhibits neuronal apoptosis in cerebral infarction rats through PI3K/Akt signaling pathway.
MicroRNA?634 alters nerve apoptosis via the PI3K/Akt pathway in cerebral infarction.
The Role of the PI3K Pathway in the Regeneration of the Damaged Brain by Neural Stem Cells after Cerebral Infarction.
Cervical Intraepithelial Neoplasia
[Expression and clinical significance of phosphatidylinositol 3-kinase and protein kinase B in cervical carcinoma]
Chagas Disease
Chagas' disease parasite-derived neurotrophic factor activates cholinergic gene expression in neuronal PC12 cells.
Chancre
Recombinant Treponema pallidum protein Tp0136 promotes fibroblast migration by modulating MCP-1/CCR2 through TLR4.
Chemical and Drug Induced Liver Injury
Polygenic architecture informs potential vulnerability to drug-induced liver injury.
Cholangiocarcinoma
Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver.
Human cholangiocarcinoma development is associated with dysregulation of opioidergic modulation of cholangiocyte growth.
Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells.
Inhibitory effect of NVP-BKM120 on cholangiocarcinoma cell growth.
Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion.
Leukemia inhibitory factor protects cholangiocarcinoma cells from drug-induced apoptosis via a PI3K/AKT-dependent Mcl-1 activation.
Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion.
Cholera
Osmosignalling in C6 glioma cells.
Role of cAMP-PKA-PLC signaling cascade on dopamine-induced PKC-mediated inhibition of renal Na(+)-K(+)-ATPase activity.
Cholestasis
Bile acid depletion and repletion regulate cholangiocyte growth and secretion by a phosphatidylinositol 3-kinase-dependent pathway in rats.
ERK1/2 and p38 MAPKs are complementarily involved in estradiol 17ß-D-glucuronide-induced cholestasis: crosstalk with cPKC and PI3K.
Paeonia lactiflora Pall. protects against ANIT-induced cholestasis by activating Nrf2 via PI3K/Akt signaling pathway.
Phosphoinositide 3-kinase/protein kinase B signaling pathway is involved in estradiol 17?-D-glucuronide-induced cholestasis: complementarity with classical protein kinase C.
Rifampicin induces clathrin-dependent endocytosis and ubiquitin-proteasome degradation of MRP2 via oxidative stress-activated PKC-ERK/JNK/p38 and PI3K signaling pathways in HepG2 cells.
Sequential activation of classic PKC and estrogen receptor ? is involved in estradiol 17ß-D-glucuronide-induced cholestasis.
Taurolithocholic acid exerts cholestatic effects via phosphatidylinositol 3-kinase-dependent mechanisms in perfused rat livers and rat hepatocyte couplets.
Chondrosarcoma
?5 integrin up-regulation in brain-derived neurotrophic factor promotes cell motility in human chondrosarcoma.
Adiponectin promotes VEGF-A-dependent angiogenesis in human chondrosarcoma through PI3K, Akt, mTOR, and HIF-? pathway.
Amphiregulin promotes cisplatin chemoresistance by upregulating ABCB1 expression in human chondrosarcoma.
Biological aspects of chondrosarcoma: Leaps and hurdles.
Bone morphogenetic protein-2 enhances the motility of chondrosarcoma cells via activation of matrix metalloproteinase-13.
CCL5 promotes VEGF-dependent angiogenesis by down-regulating miR-200b through PI3K/Akt signaling pathway in human chondrosarcoma cells.
CCN3 increases cell motility and MMP-13 expression in human chondrosarcoma through integrin dependent pathway.
CCN6-mediated MMP-9 activation enhances metastatic potential of human chondrosarcoma.
High hydrostatic pressure induces ERK and PI3 kinase phosphorylation in human HCS-2/8 chondrosarcoma cells.
Interleukin-11 increases cell motility and up-regulates intercellular adhesion molecule-1 expression in human chondrosarcoma cells.
TGF-beta1 increases motility and alphavbeta3 integrin up-regulation via PI3K, Akt and NF-kappaB-dependent pathway in human chondrosarcoma cells.
Chordoma
Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma.
Chordoma characterization of significant changes of the DNA methylation pattern.
Rationale for the advancement of PI3K pathway inhibitors for personalized chordoma therapy.
The driver landscape of sporadic chordoma.
Choriocarcinoma
Angiotensin II augmented migration and invasion of choriocarcinoma cells involves PI3K activation through the AT1 receptor.
c-Rel Promotes Invasion of Choriocarcinoma Cells via PI3K/AKT Signaling.
Inhibition of the PI3K-Akt pathway suppresses sFlt1 expression in human placental hypoxia models in vitro.
Inhibitory Effects of Quercetin on Progression of Human Choriocarcinoma Cells Are Mediated Through PI3K/AKT and MAPK Signal Transduction Cascades.
Low molecular weight hyaluronan induces migration of human choriocarcinoma JEG-3 cells mediated by RHAMM as well as by PI3K and MAPK pathways.
MAPK and PI3K activities are required for leptin stimulation of protein synthesis in human trophoblastic cells.
Overexpressed PAK4 promotes proliferation, migration and invasion of choriocarcinoma.
Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation.
Clonorchiasis
Characterization and identification of differentially expressed microRNAs during the process of the peribiliary fibrosis induced by Clonorchis sinensis.
Coinfection
The Ras/Rac1/Cdc42/SEK/JNK/c-Jun cascade is a key pathway by which agonists stimulate DNA synthesis in primary cultures of rat hepatocytes.
Colitis
Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110?.
Antioxidant properties of mesalamine in colitis inhibit phosphoinositide 3-kinase signaling in progenitor cells.
Arctigenin ameliorates inflammation in vitro and in vivo by inhibiting the PI3K/AKT pathway and polarizing M1 macrophages to M2-like macrophages.
Arginase activity in alternatively activated macrophages protects PI3Kp110? deficient mice from dextran sodium sulfate induced intestinal inflammation.
Citrobacter Infection and Wnt signaling.
Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives.
COX-1/PGE2/EP4 alleviates mucosal injury by upregulating ?-arr1-mediated Akt signaling in colitis.
In vitro and in vivo inhibitory activity of 6-amino-2,4,5-trimethylpyridin-3-ols against inflammatory bowel disease.
Innate PI3K p110? Regulates Th1/Th17 Development and Microbiota-Dependent Colitis.
Interaction between sphingosine kinase/sphingosine 1 phosphate and transforming growth factor-?/Smads pathways in experimental intestinal fibrosis. An in vivo immunohistochemical study.
Loss of Phosphoinositide 3-Kinase p110? is Protective in the Acute Phase but Detrimental in the Resolution Phase of Hapten-Induced Colitis.
Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors.
PI3K p85? Subunit-deficient Macrophages Protect Mice from Acute Colitis due to the Enhancement of IL-10 Production.
PI3K/AKT signaling is essential for communication between tissue infiltrating mast cells, macrophages, and epithelial cells in colitis-induced cancer.
Protective effects of panax notoginseng saponin on dextran sulfate sodium-induced colitis in rats through phosphoinositide-3-kinase protein kinase B signaling pathway inhibition.
Regulation of transient receptor potential cation channel subfamily V1 protein synthesis by the phosphoinositide 3-kinase/Akt pathway in colonic hypersensitivity.
RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.
Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer: A Review.
Colitis, Ulcerative
A study on regulatory mechanism of miR-223 in ulcerative colitis through PI3K/Akt-mTOR signaling pathway.
Emerging views of mitophagy in immunity and autoimmune diseases.
How autophagy controls the intestinal epithelial barrier.
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
PI3KC3 complex subunit NRBF2 is required for apoptotic cell clearance to restrict intestinal inflammation.
RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.
Upregulation of MAPK/Erk and PI3K/Akt pathways in ulcerative colitis-associated colon cancer.
[Effects of PI3K signaling pathway on pathogenesis of ulcerative colitis]
[Expression of phophatidylinositol 3-kinase and effects of wortmannin on the expression of tumor necrosis factor-alpha in ulcerative colitis]
Colonic Neoplasms
?-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer.
A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells.
Activation of mTORC2 by Association with the Ribosome.
Activation of NF-kappaB binding in HT-29 colon cancer cells by inhibition of phosphatidylinositol 3-kinase.
Activation of the PI3K/Akt Pathway Mediates Bone Morphogenetic Protein 2-Induced Invasion of Pancreatic Cancer Cells Panc-1.
Activin and TGF? use diverging mitogenic signaling in advanced colon cancer.
An I?B? phosphorylation inhibitor induces heme oxygenase-1(HO-1) expression through the activation of reactive oxygen species (ROS)-Nrf2-ARE signaling and ROS-PI3K/Akt signaling in an NF-?B-independent mechanism.
Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells.
Antitumor activity of ?-2-himachalen-6-ol in colon cancer is mediated through its inhibition of the PI3K and MAPK pathways.
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
AP-2? Regulates S-Phase and Is a Marker for Sensitivity to PI3K Inhibitor Buparlisib in Colon Cancer.
Association between phosphatidylinositol 3-kinase regulatory subunit p85alpha Met326Ile genetic polymorphism and colon cancer risk.
Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3'-kinase inhibition in the KM20 human colon cancer cell line.
Autophagy delays sulindac sulfide-induced apoptosis in the human intestinal colon cancer cell line HT-29.
Brassinin induces G1 phase arrest through increase of p21 and p27 by inhibition of the phosphatidylinositol 3-kinase signaling pathway in human colon cancer cells.
circCDYL/microRNA-105-5p participates in modulating growth and migration of colon cancer cells.
Colon Cancer Cell Secretes EGF to Promote M2 Polarization of TAM Through EGFR/PI3K/AKT/mTOR Pathway.
Colon Cancer Tumorigenesis Initiated by the H1047R Mutant PI3K.
Curcumol induces cell cycle arrest in colon cancer cells via reactive oxygen species and Akt/ GSK3?/cyclin D1 pathway.
CXCL12 gene silencing down-regulates metastatic potential via blockage of MAPK/PI3K/AP-1 signaling pathway in colon cancer.
CXCL8 induces epithelial-mesenchymal transition in colon cancer cells via the PI3K/Akt/NF-?B signaling pathway.
Daucus carota Pentane-Based Fractions Suppress Proliferation and Induce Apoptosis in Human Colon Adenocarcinoma HT-29 Cells by Inhibiting the MAPK and PI3K Pathways.
Deoxycholyltaurine rescues human colon cancer cells from apoptosis by activating EGFR-dependent PI3K/Akt signaling.
Destruxins: fungal-derived cyclohexadepsipeptides with multifaceted anticancer and antiangiogenic activities.
DIXDC1 activates the Wnt signaling pathway and promotes gastric cancer cell invasion and metastasis.
DIXDC1 targets p21 and cyclin D1 via PI3K pathway activation to promote colon cancer cell proliferation.
Down regulation of the expression of the p110, p85 and p55 subunits of phosphatidylinositol 3-kinase during colon cancer cell anchorage-independent growth.
Down-regulation of PIK3CG, a catalytic subunit of phosphatidylinositol 3-OH kinase, by CpG hypermethylation in human colorectal carcinoma.
Downregulation of PI3-K/Akt/PTEN pathway and activation of mitochondrial intrinsic apoptosis by Diclofenac and Curcumin in colon cancer.
Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations.
Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers.
Effect of bevacizumab on expression level of GLI1 and ING4 in colon cancer animal model.
Ellagic acid prevents rat colon carcinogenesis induced by 1, 2 dimethyl hydrazine through inhibition of AKT-phosphoinositide-3 kinase pathway.
Epidermal growth factor stimulates nuclear factor-?B activation and heme oxygenase-1 expression via c-Src, NADPH oxidase, PI3K, and Akt in human colon cancer cells.
Epigallocatechin-3-gallate inhibits proliferation and triggers apoptosis in colon cancer via the hedgehog/phosphoinositide 3-kinase pathways.
Expression of factors and key components associated with the PI3K signaling pathway in colon cancer.
F-box and leucine-rich repeat protein 5 promotes colon cancer progression by modulating PTEN/PI3K/AKT signaling pathway.
Fibroblast-derived CXCL12 regulates PTEN expression and is associated with the proliferation and invasion of colon cancer cells via PI3k/Akt signaling.
Genomic structure of the PIK3CG gene on chromosome band 7q22 and evaluation as a candidate myeloid tumor suppressor.
Ghrelin induces colon cancer cell proliferation through the GHS-R, Ras, PI3K, Akt, and mTOR signaling pathways.
Hepatocyte growth factor induces colonic cancer cell invasiveness via enhanced motility and protease overproduction. Evidence for PI3 kinase and PKC involvement.
Heregulin-Induced VEGF Expression via the ErbB3 Signaling Pathway in Colon Cancer.
Heterozygous disruption of the PTEN promotes intestinal neoplasia in APCmin/+ mouse: roles of osteopontin.
Human ?-defensin 5 suppressed colon cancer growth by targeting PI3K pathway.
Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc.
IGF-1 induces expression of zinc-finger protein 143 in colon cancer cells through phosphatidylinositide 3-kinase and reactive oxygen species.
IL13 Receptor ?2 Signaling Requires a Scaffold Protein, FAM120A, to Activate the FAK and PI3K Pathways in Colon Cancer Metastasis.
In Vitro and in Vivo antitumor activity and the mechanism of siphonodictyal B in human colon cancer cells.
Induction of cyclooxygenase-2 expression by prostaglandin E2 stimulation of the prostanoid EP4 receptor via coupling to G?i and transactivation of the epidermal growth factor receptor in HCA-7 human colon cancer cells.
Inhibition of alpha5 integrin decreases PI3K activation and cell adhesion of human colon cancers.
Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL.
Inhibition of phosphatidylinositide 3-kinase ameliorates antiproliferation by benzyl isothiocyanate in human colon cancer cells.
Inhibition of phosphatidylinositide 3-kinase impairs the benzyl isothiocyanate-induced accumulation of autophagic molecules and Nrf2 in human colon cancer cells.
Inhibition of the phosphatidylinositol 3-kinase pathway contributes to HT29 and Caco-2 intestinal cell differentiation.
Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells.
Insulin-like growth factor-1 activates different catalytic subunits p110 of PI3K in a cell-type-dependent manner to induce lipogenesis-dependent epithelial-mesenchymal transition through the regulation of ADAM10 and ADAM17.
Kallikrein 6 is a mediator of K-RAS-dependent migration of colon carcinoma cells.
Killing of Kras-Mutant Colon Cancer Cells via Rac-Independent Actin Remodeling by the ?GBP Cytokine, a Physiological PI3K Inhibitor Therapeutically Effective In Vivo.
Knockdown of ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma.
Leptin acts as a mitogenic and antiapoptotic factor for colonic cancer cells.
Leptin promotes motility and invasiveness in human colon cancer cells by activating multiple signal-transduction pathways.
LKB1 is necessary for Akt-mediated phosphorylation of proapoptotic proteins.
LY294002 enhances boswellic acid-induced apoptosis in colon cancer cells.
Mesenchymal-epithelial signalling in tumour microenvironment: role of high-mobility group Box 1.
Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase.
Mice expressing activated PI3K rapidly develop advanced colon cancer.
Modulation of glycolysis and lipogenesis by novel PI3K selective molecule represses tumor angiogenesis and decreases colorectal cancer growth.
mTOR inhibition elicits a dramatic response in PI3K-dependent colon cancers.
Multifunctional Nanodrug Mediates Synergistic Photodynamic Therapy and MDSCs-Targeting Immunotherapy of Colon Cancer.
Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model.
NFkB is essential for activin-induced colorectal cancer migration via upregulation of PI3K-MDM2 pathway.
Novel strategies for molecular targeting to cancer.
Nuclear accumulation of ?-catenin and forkhead box O3a in colon cancer: Dangerous liaison.
Pharmacological Inhibition of Casein Kinase 2 Enhances the Effectiveness of PI3K Inhibition in Colon Cancer Cells.
Phosphatidylinositol 3-kinase (PI3K) signaling does not activate the Wnt cascade.
Phosphoinositide-3-kinase, catalytic, alpha polypeptide RNA interference inhibits growth of colon cancer cell SW948.
PI3K/Akt and GSK-3beta prevents in a differential fashion the malignant phenotype of colorectal cancer cells.
PIK3C3 Inhibition Promotes Sensitivity to Colon Cancer Therapy by Inhibiting Cancer Stem Cells.
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Proteomic analysis of colonic myofibroblasts and effect on colon cancer cell proliferation.
PTEN and TNF-alpha regulation of the intestinal-specific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-kappaB-dependent pathway.
Quercetin may suppress rat aberrant crypt foci formation by suppressing inflammatory mediators that influence proliferation and apoptosis.
Regulation of YAP through an Akt-dependent process by 3, 3'-diindolylmethane in human colon cancer cells.
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
Retinol decreases phosphatidylinositol 3-kinase activity in colon cancer cells.
Robust network inference using response logic.
Roles of phosphatidylinositol 3'-kinase and mammalian target of rapamycin/p70 ribosomal protein S6 kinase in K-Ras-mediated transformation of intestinal epithelial cells.
Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance.
Survival advantages conferred to colon cancer cells by E-selectin-induced activation of the PI3K-NFkappaB survival axis downstream of Death Receptor-3.
Susceptibility to natural killer cell-mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16-binding protein-1 induction.
Synergistic inhibition of colon carcinoma cell growth by Hedgehog-Gli1 inhibitor arsenic trioxide and phosphoinositide 3-kinase inhibitor LY294002.
Targeted inhibition of the phosphoinositide 3-kinase impairs cell proliferation, survival, and invasion in colon cancer.
Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma.
Targeted RNA interference of PI3K pathway components sensitizes colon cancer cells to TNF-related apoptosis-inducing ligand (TRAIL).
Targeting the PI3K signaling pathway in KRAS mutant colon cancer.
The expression and clinical significance of PI3K, pAkt and VEGF in colon cancer.
The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers.
The Novel Benzamide Derivative, VKNG-2, Restores the Efficacy of Chemotherapeutic Drugs in Colon Cancer Cell Lines by Inhibiting the ABCG2 Transporter.
Thioredoxin-Like Protein 2 Is Overexpressed in Colon Cancer and Promotes Cancer Cell Metastasis by Interaction with Ran.
TIMP-3 and Phosphatidylinositol 3-kinase genes were found to be related to the progression of colon cancer in a comparison of pneumoperitoneum and laparotomy in a murine model.
TLR-4 signalling accelerates colon cancer cell adhesion via NF-?B mediated transcriptional up-regulation of Nox-1.
Upregulation of MAPK/Erk and PI3K/Akt pathways in ulcerative colitis-associated colon cancer.
Upregulation of miR-542-3p inhibits the growth and invasion of human colon cancer cells through PI3K/AKT/survivin signaling.
Ursodeoxycholic acid protects colon cancer HCT116 cells from deoxycholic acid-induced apoptosis by inhibiting apoptosome formation.
WNT signaling and distant metastasis in colon cancer through transcriptional activity of nuclear ?-Catenin depend on active PI3K signaling.
[Corrigendum] Brassinin induces G1 phase arrest through increase of p21 and p27 by inhibition of the phosphatidylinositol 3-kinase signaling pathway in human colon cancer cells.
[Effects and mechanisms of phosphatidylinositol 3 kinase B signal pathway on colon cancer cell SW480].
Colorectal Neoplasms
"Squirrel" Primer-Based PCR Assay for Direct and Targeted Sanger Sequencing of Short Genomic Segments.
18 ?-glycyrrhetinic acid exhibits potent antitumor effects against colorectal cancer via inhibition of cell proliferation and migration.
19PPreclinical drug testing and clinical trial planning of palbociclib (CDK4/6 inhibitor) drug combination with a PI3K or MAPK inhibitor for colorectal cancer (CRC).
5-fluorouracil enhances the anti-tumor activity of the glutaminase inhibitor CB-839 against PIK3CA-mutant colorectal cancers.
A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab.
A Deregulated PI3K-AKT Signaling Pathway in Patients with Colorectal Cancer.
A dual-targeted molecular therapy of PP242 and cetuximab plays an anti-tumor effect through EGFR downstream signaling pathways in colorectal cancer.
A Molecular Signature for Oncogenic BRAF in Human Colon Cancer Cells is Revealed by Microarray Analysis.
A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck.
A novel PI3K axis selective molecule exhibits potent tumor inhibition in colorectal carcinogenesis.
A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma.
ABCB1 and ABCG2 restricts the efficacy of gedatolisib (PF-05212384), a PI3K inhibitor in colorectal cancer cells.
Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer.
Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status.
Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS.
Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway.
Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.
Blocking phosphoinositide 3-kinase activity in colorectal cancer cells reduces proliferation but does not increase apoptosis alone or in combination with cytotoxic drugs.
BMX Acts Downstream of PI3K to Promote Colorectal Cancer Cell Survival and Pathway Inhibition Sensitizes to the BH3 Mimetic ABT-737.
Clarithromycin inhibits autophagy in colorectal cancer by regulating the hERG1 potassium channel interaction with PI3K.
Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results.
Combination effects of sorafenib with PI3K inhibitors under hypoxia in colorectal cancer.
Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.
Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer.
Combining Trail with PI3 Kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling.
Correction: Clarithromycin inhibits autophagy in colorectal cancer by regulating the hERG1 potassium channel interaction with PI3K.
Correlation between metastatic potential and variants from colorectal tumor cell line HT-29.
Cripto haploinsufficiency affects in vivo colon tumor development.
Crystal structure of the PTPL1/FAP-1 human tyrosine phosphatase mutated in colorectal cancer: evidence for a second phosphotyrosine substrate recognition pocket.
Current Advances and Trends in KRAS Targeted Therapies for Colorectal Cancer.
Dehydroglyasperin D Inhibits the Proliferation of HT-29 Human Colorectal Cancer Cells Through Direct Interaction With Phosphatidylinositol 3-kinase.
Depletion of PI3K p85alpha induces cell cycle arrest and apoptosis in colorectal cancer cells.
Descriptive profile of PIK3CA-mutated colorectal cancer in postmenopausal women.
Development of siRNA payloads to target KRAS-mutant cancer.
Differential modulation of zinc-stimulated p21(Cip/WAF1) and cyclin D1 induction by inhibition of PI3 kinase in HT-29 colorectal cancer cells.
Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor.
Docosahexaenoic acid induces apoptosis in colorectal carcinoma cells by modulating the PI3 kinase and p38 MAPK pathways.
Dual blockade of phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways overcomes paclitaxel-resistance in colorectal cancer.
Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
Dual PI3K-BRD4 Inhibitor SF1126 Inhibits Colorectal Cancer Cell Growth in Vitro and in Vivo.
Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations.
Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation.
Effects of RAL signal transduction in KRAS- and BRAF-mutated cells and prognostic potential of the RAL signature in colorectal cancer.
Efficacy of the MEK Inhibitor Cobimetinib and its Potential Application to Colorectal Cancer Cells.
Emodin suppresses growth and invasion of colorectal cancer cells by inhibiting VEGFR2.
Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037.
Enhanced efficacy of 5-fluorouracil in combination with a dual histone deacetylase and phosphatidylinositide 3-kinase inhibitor (CUDC-907) in colorectal cancer cells.
Enhancement by Nano-Diamino-Tetrac of Antiproliferative Action of Gefitinib on Colorectal Cancer Cells: Mediation by EGFR Sialylation and PI3K Activation.
Epigenetically silenced LINC02381 functions as a tumor suppressor by regulating PI3K-Akt signaling pathway.
ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer.
Expression profile and biological function of miR-455-5p in colorectal carcinoma.
EYA1 promotes tumor angiogenesis by activating the PI3K pathway in colorectal cancer.
Functional analysis of PIK3CA gene mutations in human colorectal cancer.
Functional genomics reveals that tumors with activating phosphoinositide 3-kinase mutations are dependent on accelerated protein turnover.
Heregulin-Induced VEGF Expression via the ErbB3 Signaling Pathway in Colon Cancer.
How autophagy controls the intestinal epithelial barrier.
Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer.
Identification of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) as a novel downstream target of phosphatidylinositol 3-kinase/AKT/GSK-3beta pathway.
IGF1/IGF1R and microRNA let-7e down-regulate each other and modulate proliferation and migration of colorectal cancer cells.
Inactivating Frameshift Mutation of INPP4B Encoding a PI3K Pathway Phosphatase in Gastric and Colorectal Cancers.
Increased levels of phosphatidylinositol 3-kinase activity in colorectal tumors.
Inducing effects of hepatocyte growth factor on the expression of vascular endothelial growth factor in human colorectal carcinoma cells through MEK and PI3K signaling pathways.
Induction of apoptosis in colorectal cancer cells by peroxisome proliferators-activated receptor gamma activation up-regulating PTEN and inhibiting PI3K activity.
Inhibition of phosphatidylinositide 3-kinase ameliorates antiproliferation by benzyl isothiocyanate in human colon cancer cells.
Integrated analysis of colorectal cancer microRNA datasets: identification of microRNAs associated with tumor development.
Integrated Genetic, Epigenetic, and Transcriptional Profiling Identifies Molecular Pathways in the Development of Laterally Spreading Tumors.
Intestinal epithelial-specific PTEN inactivation results in tumor formation.
Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines.
Justicidin A-induced autophagy flux enhances apoptosis of human colorectal cancer cells via class III PI3K and Atg5 pathway.
Linc02381 Exacerbates Rheumatoid Arthritis Through Adsorbing miR-590-5p and Activating the Mitogen-Activated Protein Kinase Signaling Pathway in Rheumatoid arthritis-fibroblast-like synoviocytes.
Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells.
Lysine-Specific Demethylase 1 Mediates AKT Activity and Promotes Epithelial-to-Mesenchymal Transition in PIK3CA-Mutant Colorectal Cancer.
MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
Mice expressing activated PI3K rapidly develop advanced colon cancer.
MicroRNA-21 promotes phosphatase gene and protein kinase B/phosphatidylinositol 3-kinase expression in colorectal cancer.
miR-18a inhibits CDC42 and plays a tumour suppressor role in colorectal cancer cells.
MiR-27b targets PI3K p110? to inhibit proliferation and migration in colorectal cancer stem cell.
MiR-325 Promotes Oxaliplatin-Induced Cytotoxicity Against Colorectal Cancer Through the HSPA12B/PI3K/AKT/Bcl-2 Pathway.
MiR-338-5p promotes metastasis of colorectal cancer by inhibition of phosphatidylinositol 3-kinase, catalytic subunit type 3-mediated autophagy pathway.
miRs-134 and -370 function as tumor suppressors in colorectal cancer by independently suppressing EGFR and PI3K signalling.
Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids.
Modulation of glycolysis and lipogenesis by novel PI3K selective molecule represses tumor angiogenesis and decreases colorectal cancer growth.
Molecular biomarkers in colorectal carcinoma.
mTORC1 and mTORC2 regulate EMT, motility and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways.
Mutation-Associated Phenotypic Heterogeneity in Novel and Canonical PIK3CA Helical and Kinase Domain Mutants.
Mutations in the RAS and PI3K pathways are associated with metastatic location in colorectal cancers.
Oncogenic PI3K and its role in cancer.
Phosphatidylinositol 3-kinase mediates the ability of retinol to decrease colorectal cancer cell invasion.
Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.
Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: Meta-analysis, co-occurrence and ethnic variation.
Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.
Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma.
PI3K expression and PIK3CA mutations are related to colorectal cancer metastases.
PI3K is required for the physical interaction and functional inhibition of NF-?B by ?-catenin in colorectal cancer cells.
PI3K p110? Blockade Enhances Anti-Tumor Efficacy of Abemaciclib in Human Colorectal Cancer Cells.
PIK3CA in Colorectal Cancer.
PIK3CA Somatic Mutation Status in Relation to Patient and Tumor Factors in Racial/Ethnic Minorities with Colorectal Cancer.
PIK3R3 induces epithelial-to-mesenchymal transition and promotes metastasis in colorectal cancer.
PIK3R3 regulates ZO-1 expression through the NF-kB pathway in inflammatory bowel disease.
Polyamine production is downstream and upstream of oncogenic PI3K signalling and contributes to tumour cell growth.
Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent.
Preclinical drug testing and clinical trial planning of palbociclib (CDK4/6 inhibitor) drug combination with a PI3K or MAPK inhibitor for colorectal cancer (CRC).
Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer.
Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review.
Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.
PTEN-deficient cancers depend on PIK3CB.
Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
Roles of genetic variants in the PI3K/PTEN pathways in susceptibility to colorectal carcinoma and clinical outcomes treated with FOLFOX regimen.
Selective inhibition of PI3K110? as a novel therapeutic strategy for cetuximab?resistant oral squamous cell carcinoma.
Selective inhibition of proliferation in colorectal carcinoma cell lines expressing mutant APC or activated B-Raf.
Selenate induces epithelial-mesenchymal transition in a colorectal carcinoma cell line by AKT activation.
Signal transduction pathway mutations in gastrointestinal (GI) cancers: a systematic review and meta-analysis.
Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells.
Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.
Specific inhibition of p110? subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.
Statistical strategies to improve the efficiency of molecular studies of colorectal cancer prognosis.
Stimulation of proliferation and migration of a colorectal cancer cell line by amidated and glycine-extended gastrin-releasing peptide via the same receptor.
Tankyrase Inhibition Blocks Wnt/?-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
TANKYRASE Inhibition Enhances the Antiproliferative Effect of PI3K and EGFR Inhibition, Mutually Affecting ?-CATENIN and AKT Signaling in Colorectal Cancer.
Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma.
Targeting PI3K signaling as a therapeutic approach for colorectal cancer.
Targeting the PI3K Signalling as a Therapeutic Strategy in Colorectal Cancer.
The association of phosphatase and tensin homolog deleted on chromosome 10 polymorphisms and lifestyle habits with colorectal cancer risk in a Chinese population.
The effects of silencing of PI3K p85? on 5-FU-induced colorectal cancer cells apoptosis.
The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice.
The H1047R point mutation in p110 alpha changes the morphology of human colon HCT116 cancer cells.
The Landscape of PIK3CA Mutations in Colorectal Cancer.
The outstanding role of miR-132-3p in carcinogenesis of solid tumors.
The role of ppar? and autophagy in ros production, lipid droplets biogenesis and its involvement with colorectal cancer cells modulation.
The role of the PI3K pathway in colorectal cancer.
The roles of microbial products in the development of colorectal cancer: a review.
The Safe Soluble Compound Dehydroascorbic Acid Inhibits Various Upstream and Downstream Effectors of PI3K and KRAS Signaling Pathways in Undruggable PIK3CA/KRAS-Mutant Colorectal Cancer Stem-Like Cells.
The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition.
Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: novel targeted therapies and advances in the treatment of colorectal cancer.
Transcriptional modulator ZBED6 affects cell cycle and growth of human colorectal cancer cells.
[Influence of phosphatidylinositol-3-kinases P85? silence by RNA interference on cell cycle and apoptosis of colorectal cancer cells in vitro.]
[PI3K p85alpha expression and its role in the progression of colorectal cancer.]
[PI3K p85alpha gene silencing by RNA interference promotes 5-fluorouracil-induced apoptosis of colorectal cancer LoVo cells]
Communicable Diseases
A Case for Phosphoinositide 3-Kinase-Targeted Therapy for Infectious Disease.
Transcriptomic and Network Analysis Highlight the Association of Diabetes at Different Stages of Alzheimer's Disease.
Confusion
Opposite effects of wortmannin and 2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride on toll-like receptor-mediated nitric oxide production: negative regulation of nuclear factor-{kappa}B by phosphoinositide 3-kinase.
Coronary Artery Disease
Differential Phosphoinositide 3-Kinase Signaling: Implications for PTCA?
Coronary Disease
Advances in development of phosphatidylinositol 3-kinase inhibitors.
Coronary Occlusion
Attenuation of infarction in cynomolgus monkeys: preconditioning and postconditioning.
Isoflurane protects against myocardial infarction during early reperfusion by activation of phosphatidylinositol-3-kinase signal transduction: evidence for anesthetic-induced postconditioning in rabbits.
Morphine enhances isoflurane-induced postconditioning against myocardial infarction: the role of phosphatidylinositol-3-kinase and opioid receptors in rabbits.
Coronavirus Infections
Coronavirus interactions with the cellular autophagy machinery.
Costello Syndrome
Oncogenic HRAS mutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with Costello syndrome.
Cough
Evaluation of WO2013117503 and WO2013117504: the use of PI3K inhibitors to treat cough or idiopathic pulmonary fibrosis.
COVID-19
Coronavirus interactions with the cellular autophagy machinery.
Suppression of SARS-CoV-2 infection in ex-vivo human lung tissues by targeting class III phosphoinositide 3-kinase.
Coxsackievirus Infections
Coxsackievirus infection induces a non-canonical autophagy independent of the ULK and PI3K complexes.
Crohn Disease
Emerging views of mitophagy in immunity and autoimmune diseases.
How autophagy controls the intestinal epithelial barrier.
Integrating genetic and gene expression evidence into genome-wide association analysis of gene sets.
Loss of protein tyrosine phosphatase N2 potentiates epidermal growth factor suppression of intestinal epithelial chloride secretion.
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
PI3KC3 complex subunit NRBF2 is required for apoptotic cell clearance to restrict intestinal inflammation.
RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.
Cryptococcosis
Enhanced innate immune responsiveness to pulmonary Cryptococcus neoformans infection is associated with resistance to progressive infection.
Cystadenoma
Combined VHLH and PTEN mutation causes genital tract cystadenoma and squamous metaplasia.
Cystic Fibrosis
Expression of miR?542?3p in osteosarcoma with miRNA microarray data, and its potential signaling pathways.
How autophagy controls the intestinal epithelial barrier.
Involvement of phosphatidylinositol 3-kinase in cAMP- and cGMP-induced duodenal epithelial CFTR activation in mice.
Transforming growth factor beta1 inhibits cystic fibrosis transmembrane conductance regulator-dependent cAMP-stimulated alveolar epithelial fluid transport via a phosphatidylinositol 3-kinase-dependent mechanism.
Cystitis
Suppression of the PI3K pathway in vivo reduces cystitis-induced bladder hypertrophy and restores bladder capacity examined by magnetic resonance imaging.
Cysts
Epidermal growth factor mediates spermatogonial proliferation in newt testis.
HGF-induced serine 897 phosphorylation of EphA2 regulates epithelial morphogenesis of MDCK cells in 3D culture.
High-Throughput Phenotypic Screening of Kinase Inhibitors to Identify Drug Targets for Polycystic Kidney Disease.
PI3K Signaling in Tissue Hyper-Proliferation: From Overgrowth Syndromes to Kidney Cysts.
pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation.
Rac is essential in the transformation of endothelial cells by polyoma middle T.
The PI3K/Akt/mTOR pathway in polycystic kidney disease: A complex interaction with polycystins and primary cilium.
Decompression Sickness
Structural pathway for allosteric activation of the autophagic PI 3-kinase complex I.
Dehydration
Importance of inositols and their derivatives in cowpea under root dehydration: An omics perspective.
Dementia
Clionosterol and Ethyl Cholestan-22-enol Isolated from the Rhizome of Polygala tenuifolia Inhibit Phosphatidylinositol 3-Kinase/Akt Pathway.
Tumor suppressor PTEN affects tau phosphorylation: deficiency in the phosphatase activity of PTEN increases aggregation of an FTDP-17 mutant Tau.
Dementia, Vascular
Naomaitai Ameliorated Brain Damage in Rats with Vascular Dementia by PI3K/PDK1/AKT Signaling Pathway.
Dengue
Dengue virus enhances thrombomodulin and ICAM-1 expression through the macrophage migration inhibitory factor induction of the MAPK and PI3K signaling pathways.
Dermatitis
Blockade of phosphatidylinositol 3-kinase PI3K? or PI3K? reduces IL-17 and ameliorates imiquimod-induced psoriasis-like dermatitis.
Resveratrol attenuates HMGB1 signaling and inflammation in house dust mite-induced atopic dermatitis in mice.
Dermatitis, Exfoliative
Pityriasis rubra pilaris-like erythroderma secondary to phosphoinositide 3-kinase inhibition.
Diabetes Complications
Increased platelet aggregation in diabetic patients with microangiopathy despite good glycemic control.
Network pharmacology-based exploration of therapeutic mechanism of Liu-Yu-Tang in atypical antipsychotic drug-induced metabolic syndrome.
PI3Kinases in Diabetes Mellitus and Its Related Complications.
Reappraisal of metallothionein: Clinical implications for patients with diabetes mellitus.
[Role of protein kinase C isozymes in cellular functions and pathological conditions]
Diabetes Mellitus
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Bioactive compounds in plant materials for the prevention of diabetesand obesity.
Control of cardiac repolarization by phosphoinositide 3-kinase signaling to ion channels.
Curcumin anti-diabetic effect mainly correlates with its anti-apoptotic actions and PI3K/Akt signal pathway regulation in the liver.
Human umbilical cord mesenchymal stem cells reduce oxidative damage and apoptosis in diabetic nephropathy by activating Nrf2.
Liver paraoxonase 3 expression and the effect of liraglutide treatment in a rat model of diabetes.
PI3Kinases in Diabetes Mellitus and Its Related Complications.
Regulation of gene expression during severe caloric restriction: lack of induction of p85 alpha phosphatidylinositol 3-kinase mRNA in skeletal muscle of patients with type II (non-insulin-dependent) diabetes mellitus.
Regulation of phosphatidylinositol 3-kinase activity in liver and muscle of animal models of insulin-resistant and insulin-deficient diabetes mellitus.
Tacrolimus inhibits insulin release and promotes apoptosis of Min6 cells through the inhibition of the PI3K/Akt/mTOR pathway.
TGF-{beta}1/ALK5-induced monocyte migration involves PI3K and p38 pathways and is not negatively affected by diabetes mellitus.
The association of diabetes mellitus and insulin treatment with expression of insulin-related proteins in breast tumors.
The impact of exposure of diabetic rats to 900 MHz electromagnetic radiation emitted from mobile phone antenna on hepatic oxidative stress.
Type 1 diabetes mellitus associated with activated phosphatidylinositol 3-kinase delta syndrome, type 2.
[Effect of Shenqi compound on PTEN/PI3K signal transduction in GK rats with diabetes mellitus macroangiopathy]
[Effects of Qizhi Jiangtang capsule on protein expressions of InsR, PI3K, GLUT2 and p-JNK in hepatic tissues of rats with type 2 diabetes].
[Mechanism of advanced glycation end products inhibiting the proliferation of peripheral blood mononuclear cells and osteoblasts in rats].
[Role of phosphatidylinositol 3-kinase in platelet aggregation in type 1 diabetes mellitus]
Diabetes Mellitus, Type 1
A combined risk score enhances prediction of type 1 diabetes among susceptible children.
Regulation of the inducible nitric oxide synthase and sodium pump in type 1 diabetes.
Type 1 diabetes mellitus associated with activated phosphatidylinositol 3-kinase delta syndrome, type 2.
[Role of phosphatidylinositol 3-kinase in platelet aggregation in type 1 diabetes mellitus]
Diabetes Mellitus, Type 2
A new layer of phosphoinositide-mediated allosteric regulation uncovered for SHIP2.
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Bioactive compounds in plant materials for the prevention of diabetesand obesity.
Class IA phosphatidylinositol 3-kinase in pancreatic ? cells controls insulin secretion by multiple mechanisms.
Common polymorphisms in the genes regulating the early insulin signalling pathway: effects on weight change and the conversion from impaired glucose tolerance to Type 2 diabetes. The Finnish Diabetes Prevention Study.
Curcumin anti-diabetic effect mainly correlates with its anti-apoptotic actions and PI3K/Akt signal pathway regulation in the liver.
Effect of Aerobic and Resistance Training on Endothelial Progenitor Cells in Mice with Type 2 Diabetes.
Effects of exercise on AMPK signaling and downstream components to PI3K in rat with type 2 diabetes.
Excessive secretion of IL-8 by skeletal muscle in type 2 diabetes impairs tube growth: potential role of PI3K and the Tie2 receptor.
Fatty aldehyde dehydrogenase: potential role in oxidative stress protection and regulation of its gene expression by insulin.
Frequency of mutations of insulin receptor gene in Japanese patients with NIDDM.
Gene encoding the catalytic subunit p110beta of human phosphatidylinositol 3-kinase: cloning, genomic structure, and screening for variants in patients with type 2 diabetes.
Highly bioavailable Berberine formulation improves Glucocorticoid Receptor-mediated Insulin Resistance via reduction in association of the Glucocorticoid Receptor with phosphatidylinositol-3-kinase.
Human umbilical cord mesenchymal stem cells reduce oxidative damage and apoptosis in diabetic nephropathy by activating Nrf2.
Impact of rs361072 in the phosphoinositide 3-kinase p110beta gene on whole-body glucose metabolism and subunit protein expression in skeletal muscle.
Impaired muscle glycogen synthase in type 2 diabetes is associated with diminished phosphatidylinositol 3-kinase activation.
In vitro and in vivo studies of a naturally occurring variant of the human p85alpha regulatory subunit of the phosphoinositide 3-kinase: inhibition of protein kinase B and relationships with type 2 diabetes, insulin secretion, glucose disappearance constant, and insulin sensitivity.
Increased persistent sodium current due to decreased PI3K signaling contributes to QT prolongation in the diabetic heart.
Inhibition of the PI 3-kinase pathway disrupts the unfolded protein response and reduces sensitivity to ER stress-dependent apoptosis.
Insulin receptor substrate (IRS) 1 is reduced and IRS-2 is the main docking protein for phosphatidylinositol 3-kinase in adipocytes from subjects with non-insulin-dependent diabetes mellitus.
Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle from NIDDM subjects after in vivo insulin stimulation.
Insulin-like growth factor 1 regulates growth of endometrial carcinoma through PI3k signaling pathway in insulin-resistant type 2 diabetes.
Loss of class IA PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia.
Macrophage Rewiring by Nutrient Associated PI3K Dependent Pathways.
Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance.
Phosphatidylinositol-3-kinase regulates scavenger receptor class B type I subcellular localization and selective lipid uptake in hepatocytes.
Prevalence of a polymorphism of the phosphatidylinositol 3-kinase p85 alpha regulatory subunit (codon 326 Met-->Ile) in Japanese NIDDM patients.
Restraining PI3K: mTOR signalling goes back to the membrane.
Role of atypical protein kinase C in activation of sterol regulatory element binding protein-1c and nuclear factor kappa B (NFkappaB) in liver of rodents used as a model of diabetes, and relationships to hyperlipidaemia and insulin resistance.
Role of p110a subunit of PI3-kinase in skeletal muscle mitochondrial homeostasis and metabolism.
Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice.
Spinal cord injury causes insulin resistance associated with PI3K signaling pathway in hypothalamus.
The Combined Deletion of S6K1 and Akt2 Deteriorates Glycemic Control in a High-Fat Diet.
The impact of exposure of diabetic rats to 900 MHz electromagnetic radiation emitted from mobile phone antenna on hepatic oxidative stress.
Type 2 diabetes impairs insulin receptor substrate-2-mediated phosphatidylinositol 3-kinase activity in primary macrophages to induce a state of cytokine resistance to IL-4 in association with overexpression of suppressor of cytokine signaling-3.
Variant in the regulatory subunit of phosphatidylinositol 3-kinase (p85alpha): preliminary evidence indicates a potential role of this variant in the acute insulin response and type 2 diabetes in Pima women.
[Effect of "Spleen-Stomach Harmonizing" Needling on Insulin Resistance and Expression of Insulin Receptor Substrate-1, -2, and Glucose Transporter-4 in Insulin Resistance Type 2 Diabetes Rats].
[Effects of Astragalus membranaceus and Potentilla discolor mixture on insulin resistance and its related mRNA expressions in KKAy mice with type 2 diabetes].
[Effects of Qizhi Jiangtang capsule on protein expressions of InsR, PI3K, GLUT2 and p-JNK in hepatic tissues of rats with type 2 diabetes].
Diabetes, Gestational
Analysis of phosphatidylinositol 3-kinase activation in the adipose tissue of gestational diabetes mellitus patients and insulin resistance.
Effect of miR-29b on rats with gestational diabetes mellitus by targeting PI3K/Akt signal.
Expression of PI3-K, PKB and GSK-3 ? in the skeletal muscle tissue of gestational diabetes mellitus.
Phosphatidylinositol 3-kinase redistribution is associated with skeletal muscle insulin resistance in gestational diabetes mellitus.
Relationships of SLC2A4, RBP4, PCK1, and PI3K Gene Polymorphisms with Gestational Diabetes Mellitus in a Chinese Population.
The association of leukocyte phosphatidylinositol 3-kinase delta overexpression with gestational diabetes mellitus (GDM).
Diabetic Angiopathies
[High D-glucose alters PI3K and Akt signaling and leads to endothelial cell migration, proliferation and angiogenesis dysfunction]
Diabetic Cardiomyopathies
Baicalein Protects Rats with Diabetic Cardiomyopathy Against Oxidative Stress and Inflammation Injury via Phosphatidylinositol 3-Kinase (PI3K)/AKT Pathway.
Phosphoinositide 3-kinase (p110?) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction.
Pi3ks In Diabetic Cardiomyopathy.
The heme oxygenase system selectively enhances the anti-inflammatory macrophage-M2 phenotype, reduces pericardial adiposity and ameliorated cardiac injury in diabetic cardiomyopathy in Zucker diabetic fatty rats.
Therapeutic targeting of oxidative stress with coenzyme Q10 counteracts exaggerated diabetic cardiomyopathy in a mouse model of diabetes with diminished PI3K(p110?) signaling.
Diabetic Ketoacidosis
Alpelisib-Induced Diabetic Ketoacidosis: A Case Report and Review of Literature.
Diabetic Nephropathies
Celastrol slows the progression of early diabetic nephropathy in rats via the PI3K/AKT pathway.
KCa3.1 mediates dysfunction of tubular autophagy in diabetic kidneys via PI3k/Akt/mTOR signaling pathways.
Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats.
Sitagliptin improves renal function in diabetic nephropathy in male Sprague Dawley rats through upregulating heme oxygenase-1 expression.
The effects of microRNA-126 reduced inflammation and apoptosis of diabetic nephropathy through PI3K/AKT signalling pathway by VEGF.
[Down-regulation of PTEN expression in kidney and its role in development of diabetic nephropathy in rats].
Diabetic Retinopathy
Increased platelet aggregation in diabetic patients with microangiopathy despite good glycemic control.
[Role of protein kinase C isozymes in cellular functions and pathological conditions]
Diffuse Intrinsic Pontine Glioma
Dual HDAC and PI3K Inhibition Abrogates NF?B- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas.
Digestive System Neoplasms
Novel role of microRNA-126 in digestive system cancers: From bench to bedside.
Disorders of Sex Development
Sex differences in autophagy-mediated diseases: toward precision medicine.
Distemper
Autophagy induction by the pathogen receptor NECTIN4 and sustained autophagy contribute to peste des petits ruminants virus infectivity.
DNA Repair-Deficiency Disorders
Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition.
Drug Resistant Epilepsy
The Putative Role of mTOR Inhibitors in Non-tuberous Sclerosis Complex-Related Epilepsy.
[Expression of PI3K pathway proteins in refractory epilepsy associated with cortical malformation development].
Dyslipidemias
Cellular and Molecular Mechanisms of Chronic Kidney Disease with Diabetes Mellitus and Cardiovascular Diseases as Its Comorbidities.
Cyclocarya paliurus Leaves Tea Improves Dyslipidemia in Diabetic Mice: A Lipidomics-Based Network Pharmacology Study.
Differential Phosphoinositide 3-Kinase Signaling: Implications for PTCA?
Forced internal desynchrony induces cardiometabolic alterations in adult rats.
Dysplastic Nevus Syndrome
Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.
Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions.
Encephalitis, Japanese
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Encephalomyelitis
Antigen-induced pten gene deletion in T cells exacerbates neuropathology in experimental autoimmune encephalomyelitis.
Autophagy-related protein PIK3C3/VPS34 controls T cell metabolism and function.
Autophagy: a potential key contributor to the therapeutic action of mesenchymal stem cells.
Dendritic cell PIK3C3/VPS34 controls the pathogenicity of CNS autoimmunity independently of LC3-associated phagocytosis.
Loss of Phosphatase and Tensin Homolog in APCs Impedes Th17-Mediated Autoimmune Encephalomyelitis.
Pik3c3 deficiency in myeloid cells imparts partial resistance to experimental autoimmune encephalomyelitis associated with reduced IL-1? production.
WLS/wntless is essential in controlling dendritic cell homeostasis via a WNT signaling-independent mechanism.
ZSTK474, a novel PI3K inhibitor, modulates human CD14(+) monocyte-derived dendritic cell functions and suppresses experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Antigen-induced pten gene deletion in T cells exacerbates neuropathology in experimental autoimmune encephalomyelitis.
Autophagy-related protein PIK3C3/VPS34 controls T cell metabolism and function.
Autophagy: a potential key contributor to the therapeutic action of mesenchymal stem cells.
Dendritic cell PIK3C3/VPS34 controls the pathogenicity of CNS autoimmunity independently of LC3-associated phagocytosis.
Loss of Phosphatase and Tensin Homolog in APCs Impedes Th17-Mediated Autoimmune Encephalomyelitis.
Pik3c3 deficiency in myeloid cells imparts partial resistance to experimental autoimmune encephalomyelitis associated with reduced IL-1? production.
WLS/wntless is essential in controlling dendritic cell homeostasis via a WNT signaling-independent mechanism.
ZSTK474, a novel PI3K inhibitor, modulates human CD14(+) monocyte-derived dendritic cell functions and suppresses experimental autoimmune encephalomyelitis.
Endometrial Hyperplasia
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Autophagy in the physiological endometrium and cancer.
Endometrial Neoplasms
A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.
Activation of PI3K/Akt/mTOR pathway and dual inhibitors of PI3K and mTOR in endometrial cancer.
Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
Autophagy in the physiological endometrium and cancer.
Class I Phosphoinositide 3-Kinase PIK3CA/p110? and PIK3CB/p110? Isoforms in Endometrial Cancer.
Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS.
Concomitant activation of AKT with extracellular-regulated kinase 1/2 occurs independently of PTEN or PIK3CA mutations in endometrial cancer and may be associated with favorable prognosiss.
Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations.
Ellagic acid exerts antitumor effects via the PI3K signaling pathway in endometrial cancer.
Endometrial Cancer as a Metabolic Disease with Dysregulated PI3K Signaling: Shedding Light on Novel Therapeutic Strategies.
Endometrial cancer cells exhibit high expression of p110? and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation.
Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations.
Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition.
G protein-coupled estrogen receptor-selective ligands modulate endometrial tumor growth.
Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
Geraniol Inhibits Endometrial Carcinoma via Downregulating Oncogenes and Upregulating Tumour Suppressor Genes.
Hepatocyte growth factor induces anoikis resistance by up-regulation of cyclooxygenase-2 expression in uterine endometrial cancer cells.
High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.
High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability.
High Phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3Kinase inhibition.
Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
Insulin-like growth factor 1 regulates growth of endometrial carcinoma through PI3k signaling pathway in insulin-resistant type 2 diabetes.
Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation.
Kallikrein 4 overexpression in endometrial carcinoma and upregulation by estrogen via mitogen-activated protein kinase signal pathway.
Key factors mediated by PI3K signaling pathway and related genes in endometrial carcinoma.
Lack of Estrogen Receptor-? Is Associated with Epithelial-Mesenchymal Transition and PI3K Alterations in Endometrial Carcinoma.
Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19?784 Diverse Solid Tumors.
Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells.
LncRNA MEG3 inhibit endometrial carcinoma tumorigenesis and progression through PI3K pathway.
LncRNA TDRG1 enhances tumorigenicity in endometrial carcinoma by binding and targeting VEGF-A protein.
Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma.
Metformin is associated with reduced cell proliferation in human endometrial cancer by inbibiting PI3K/AKT/mTOR signaling.
Molecular target therapies in endometrial cancer: from the basic research to the clinic.
Neither ovariectomy nor progestin treatment prevents endometrial neoplasia in pten+/- mice.
New routes to old places: PIK3R1 and PIK3R2 join PIK3CA and PTEN as endometrial cancer genes.
New Strategies in Endometrial Cancer: Targeting the PI3K/mTOR Pathway--The Devil Is in the Details.
Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible.
Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma.
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.
Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.
Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma.
PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2
PI3K pathway dependencies in endometrioid endometrial cancer cell lines.
PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-?/VEGF pathway in endometrial cancer.
PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma.
PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.
PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer.
PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations.
PIK3R1 (p85-alpha/p85{alpha}) is Somatically Mutated at High Frequency in Primary Endometrial Cancer.
PIKing the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas.
Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro.
PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients.
Regulation of epithelial-mesenchymal transition in endometrial cancer: connecting PI3K, estrogen signaling, and microRNAs.
Relevance of lipogenesis and AMPK/Akt/mTOR signaling pathway in endometrial cancer.
RNASeq analysis reveals biological processes governing the clinical behaviour of endometrioid and serous endometrial cancers.
Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.
Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation.
Targeted RNA interference of phosphatidylinositol 3-kinase p110-beta induces apoptosis and proliferation arrest in endometrial carcinoma cells.
Upregulation of estrogen receptor mediates migration, invasion and proliferation of endometrial carcinoma cells by regulating the PI3K/AKT/mTOR pathway.
Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer.
YAP/TAZ-Mediated Upregulation of GAB2 Leads to Increased Sensitivity to Growth Factor-Induced Activation of the PI3K Pathway.
[Activation of phosphatidylinositol 3-kinase-protein kinase B (PI3K-PKB) induced by 17beta-estradiol in endometrial carcinoma cell (Ishikawa)]
[Effect of GPER on the activation of PI3K/Akt induced by 17?-estradiol in endometrial carcinoma cells].
[Influence of pertussis toxin on GPER-mediated activation of phosphatidylinositol 3-kinase/protein kinase B signaling induced by 17?-estradiol in endometrial carcinoma cells].
[Targeting Ras-PI3K/mTOR pathway and the predictive biomarkers in endometrial cancer].
Endometriosis
Activation of mammalian target of rapamycin in postmenopausal ovarian endometriosis.
Differences in autophagy-associated mRNAs in peritoneal fluid of patients with endometriosis and gynecologic cancers.
DNA microarray analysis of gene expression in eutopic endometrium from patients with deep endometriosis using laser capture microdissection.
Effects of inhibiting the PI3K/Akt/mTOR signaling pathway on the pain of sciatic endometriosis in a rat model.
Osteopontin Regulates Endometrial Stromal Cell Migration in Endometriosis through the PI3K Pathway : Osteopontin Regulates Endometrial Cell Migration in Endometriosis.
PI3K/AKT pathway is altered in the endometriosis patient's endometrium and presents differences according to severity stage.
The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive Life.
Transcriptome meta-analysis reveals differences of immune profile between eutopic endometrium from stage I-II and III-IV endometriosis independently of hormonal milieu.
Endotoxemia
Cardiac Specific Expression of Heat Shock Protein 27 Attenuated Endotoxin-Induced Cardiac Dysfunction and Mortality in Mice through a PI3K/Akt Dependent Mechanism.
Insulin hypersensitivity induced by hepatic PTEN gene ablation protects from murine endotoxemia.
Myeloid cell-specific inositol polyphosphate-4-phosphatase type I knockout mice impair bacteria clearance in a murine peritonitis model.
PI3K p110? subunit in leptin receptor expressing cells is required for the acute hypophagia induced by endotoxemia.
Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells.
Sustained endotoxemia leads to marked down-regulation of early steps in the insulin-signaling cascade.
Enteritis
Role of Host Type IA Phosphoinositide 3-Kinase Pathway Components in Invasin-Mediated Internalization of Yersinia enterocolitica.
Enterocolitis, Necrotizing
Effects of oxidative stress on intestinal type I insulin-like growth factor receptor expression.
Phosphatidylinositol 3-kinase pathway regulates hypoxia-inducible factor-1 to protect from intestinal injury during necrotizing enterocolitis.
Eosinophilia
Differential dependence of eosinophil chemotactic responses on phosphoinositide 3-kinase (PI3K).
The p110? subunit of PI3K regulates bone marrow-derived eosinophil trafficking and airway eosinophilia in allergen-challenged mice.
Ependymoma
PI3K pathway activation provides a novel therapeutic target for pediatric ependymoma and is an independent marker of progression free survival.
Ephemeral Fever
Inhibitors of phosphatidylinositol 3-kinase and mTOR but not Akt enhance replication of bovine ephemeral fever virus.
Epidermolysis Bullosa Dystrophica
Finding patients using similarity measures in a rare diseases-oriented clinical data warehouse: Dr. Warehouse and the needle in the needle stack.
Epilepsy
A PI3-kinase-mediated negative feedback regulates neuronal excitability.
Cannabidiol anticonvulsant effect is mediated by the PI3K? pathway.
CB2R induces a protective response for epileptic seizure via the PI3K 110?-AKT signaling pathway.
Gene Expression Profiling of a Hypoxic Seizure Model of Epilepsy Suggests a Role for mTOR and Wnt Signaling in Epileptogenesis.
Geniposide attenuates epilepsy symptoms in a mouse model through the PI3K/Akt/GSK-3? signaling pathway.
MicroRNA?155 contributes to the occurrence of epilepsy through the PI3K/Akt/mTOR signaling pathway.
Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy.
Multi-scale top-down approach for modelling epileptic protein-protein interaction network analysis to identify driver nodes and pathways.
Pentylenetetrazole-induced seizures cause acute, but not chronic, mTOR pathway activation in rat.
Phosphoinositide 3-Kinases Upregulate System xc(-) via Eukaryotic Initiation Factor 2? and Activating Transcription Factor 4?-?A Pathway Active in Glioblastomas and Epilepsy.
PI3K, mTOR and GSK3 modulate cytokines' production in peripheral leukocyte in temporal lobe epilepsy.
Pten loss in Olig2 expressing neural progenitor cells and oligodendrocytes leads to interneuron dysplasia and leukodystrophy.
Target identification, screening and in vivo evaluation of pyrrolone-fused benzosuberene compounds against human epilepsy using Zebrafish model of pentylenetetrazol-induced seizures.
Tau Reduction Prevents Key Features of Autism in Mouse Models.
The Putative Role of mTOR Inhibitors in Non-tuberous Sclerosis Complex-Related Epilepsy.
[Roles and mechanisms of traditional Chinese medicine and its active ingredients in treating epilepsy].
Epilepsy, Temporal Lobe
PI3K, mTOR and GSK3 modulate cytokines' production in peripheral leukocyte in temporal lobe epilepsy.
Epiretinal Membrane
Idelalisib inhibits vitreous-induced Akt activation and proliferation of retinal pigment epithelial cells from epiretinal membranes.
Epstein-Barr Virus Infections
Clinical, phenotypic and genetic similarities and disparities between post-transplant and classical Hodgkin lymphomas with respect to therapeutic targets.
Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation.
Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling.
LMP1 signaling pathway activates IRF4 in latent EBV infection and a positive circuit between PI3K and Src is required.
Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas.
Equine Infectious Anemia
Equine lentivirus counteracts SAMHD1 restriction by Rev-mediated degradation of SAMHD1 via the BECN1-dependent lysosomal pathway.
Esophageal Neoplasms
Id-1 activation of PI3K/Akt/NFkappaB signaling pathway and its significance in promoting survival of esophageal cancer cells.
Id-1 promotes tumorigenicity and metastasis of human esophageal cancer cells through activation of PI3K/AKT signaling pathway.
Itraconazole Exerts Its Antitumor Effect in Esophageal Cancer By Suppressing the HER2/AKT Signaling Pathway.
Long Non-Coding RNA (lncRNA) Growth Arrest Specific 5 (GAS5) Suppresses Esophageal Squamous Cell Carcinoma Cell Proliferation and Migration by Inactivating Phosphatidylinositol 3-kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.
MicroRNA-124 inhibits proliferation and metastasis of esophageal cancer via negatively regulating NRP1.
MicroRNA-21 promotes cell proliferation, migration, and resistance to apoptosis through PTEN/PI3K/AKT signaling pathway in esophageal cancer.
PI3K Overexpression and PIK3CA Mutations Are Associated with Age, Tumor Staging, and Other Clinical Characteristics in Chinese Patients with Esophageal Squamous Cell Carcinoma.
PIK3CA mutation status in Japanese esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Adaptive resistance to PI3K?-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells.
Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
Esophageal squamous cell carcinoma transcriptome reveals the effect of FOXM1 on patient outcome through novel PIK3R3 mediated activation of PI3K signaling pathway.
High-Throughput Genotyping in Metastatic Esophageal Squamous Cell Carcinoma Identifies Phosphoinositide-3-Kinase and BRAF Mutations.
Laminin-332 promotes the invasion of oesophageal squamous cell carcinoma via PI3K activation.
Long Non-Coding RNA (lncRNA) Growth Arrest Specific 5 (GAS5) Suppresses Esophageal Squamous Cell Carcinoma Cell Proliferation and Migration by Inactivating Phosphatidylinositol 3-kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.
PI3K Overexpression and PIK3CA Mutations Are Associated with Age, Tumor Staging, and Other Clinical Characteristics in Chinese Patients with Esophageal Squamous Cell Carcinoma.
PIK3C3 Acts as a Tumor Suppressor in Esophageal Squamous Cell Carcinoma and Was Regulated by MiR-340-5p.
Simultaneous targeting PI3K and PERK pathways promotes cell death and improves the clinical prognosis in esophageal squamous carcinoma.
STMN1, a prognostic predictor of esophageal squamous cell carcinoma, is a marker of the activation of the PI3K pathway.
[Corrigendum] STMN1, a prognostic predictor of esophageal squamous cell carcinoma, is a marker of the activation of the PI3K pathway.
[Expression and clinical significance of PI3K in esophageal squamous cell carcinoma].
Exanthema
PI3K Inhibitors and Adverse Events: Optimizing Patient Care for the Treatment of Advanced Breast Cancer.
Targeting PI3 kinase in cancer.
Extranodal Extension
Prognosis and management of recurrent and/or metastatic head and neck adenoid cystic carcinoma.
Eye Diseases
Selective inhibition of retinal angiogenesis by targeting PI3 kinase.
Fanconi Anemia
Comprehensive Exome Analysis of Immunocompetent Metastatic Head and Neck Cancer Models Reveals Patient Relevant Landscapes.
Fatty Liver
Ablation of PI3K p110-{alpha} Prevents High-Fat Diet-Induced Liver Steatosis.
Data on Lipocalin 2 and phosphatidylinositol 3-kinase signaling in a methionine- and choline-deficient model of non-alcoholic steatohepatitis.
Impaired activation of phosphatidylinositol 3-kinase by leptin is a novel mechanism of hepatic leptin resistance in NAFLD.
Loss of PI3K p110? in the Adipose Tissue Results in Infertility and Delayed Puberty Onset in Male Mice.
Mice Carrying a Dominant-Negative Human PI3K Mutation Are Protected From Obesity and Hepatic Steatosis but Not Diabetes.
PIK3R3 regulates PPAR? expression to stimulate fatty acid ?-oxidation and decrease hepatosteatosis.
The ménage à trois of autophagy, lipid droplets and liver disease.
Fetal Growth Retardation
MiR-199a-5p regulates sirtuin1 and PI3K in the rat hippocampus with intrauterine growth restriction.
Fibrosarcoma
A systematic review of targeted agents for non-small cell lung cancer.
Inhibition of activator protein-1 binding activity and phosphatidylinositol 3-kinase pathway by nobiletin, a polymethoxy flavonoid, results in augmentation of tissue inhibitor of metalloproteinases-1 production and suppression of production of matrix metalloproteinases-1 and -9 in human fibrosarcoma HT-1080 cells.
LY294002 and sorafenib as inhibitors of intracellular survival pathways in the elimination of human glioma cells by programmed cell death.
Microgravity-Induced Transcriptome Adaptation in Mouse Paraspinal longissimus dorsi Muscle Highlights Insulin Resistance-Linked Genes.
PI3K/Akt activity has variable cell-specific effects on expression of HIF target genes, CA9 and VEGF, in human cancer cell lines.
Requirement of phosphoinositide 3-kinase and Akt for interferon-beta-mediated induction of the beta-R1 (SCYB11) gene.
Foot-and-Mouth Disease
Autophagic degradation of SQSTM1 inhibits ovarian cancer motility by decreasing DICER1 and AGO2 to induce MIRLET7A-3P.
Poliovirus induces autophagic signaling independent of the ULK1 complex.
Productive Entry of Foot-and-Mouth Disease Virus via Macropinocytosis Independent of Phosphatidylinositol 3-Kinase.
Fragile X Syndrome
Increased expression of the PI3K enhancer PIKE mediates deficits in synaptic plasticity and behavior in fragile X syndrome.
Selective role of the catalytic PI3K subunit p110? in impaired higher order cognition in fragile X syndrome.
Gallbladder Neoplasms
Regional Differences in Gallbladder Cancer Pathogenesis: Insights from a Comparison of Cell Cycle-Regulatory, PI3K, and Pro-Angiogenic Protein Expression.
Somatic Mutations of PI3K in Early and Advanced Gallbladder Cancer: Further Options for an Orphan Cancer.
Gastritis
A novel gastroprotective effect of zeaxanthin against stress-induced gastritis in male rats targeting the expression of HIF-1?, TFF-1 and MMP-9 through PI3K/Akt/JNK signaling pathway.
Inhibition of phosphoinositide 3-kinase/Akt pathway decreases hypoxia inducible factor-1? expression and increases therapeutic efficacy of paclitaxel in human hypoxic gastric cancer cells.
Gastritis, Atrophic
Gastrin-induced miR-222 promotes gastric tumor development by suppressing p27kip1.
Gastrointestinal Neoplasms
Physiological expression of the PI3K-activating mutation Pik3ca(H1047R) combines with Apc loss to promote development of invasive intestinal adenocarcinomas in mice.
Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.
Therapeutic Potency of PI3K Pharmacological Inhibitors of Gastrointestinal Cancer.
Gastrointestinal Stromal Tumors
A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.
Direct engagement of the PI3K pathway by mutant KIT dominates oncogenic signaling in gastrointestinal stromal tumor.
Expression and phosphorylation of FOXO1 influences cell proliferation and apoptosis in the gastrointestinal stromal tumor cell line GIST-T1.
Inhibition of PI3K and MAPK pathways along with KIT inhibitors as a strategy to overcome drug resistance in gastrointestinal stromal tumors.
Mechanisms of resistance to a PI3K inhibitor in gastrointestinal stromal tumors: an omic approach to identify novel druggable targets.
Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumors: rationale and efficacy.
Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor.
Gastroparesis
Significance of dynamic changes in gastric smooth muscle cell apoptosis, PI3K-AKT-mTOR and AMPK-mTOR signaling in a rat model of diabetic gastroparesis.
Genetic Diseases, Inborn
Genetic disorders: PI3K inhibitor reverses overgrowth syndrome.
Neuropsychological Attention Skills and Related Behaviours in Adults with Tuberous Sclerosis Complex.
Oncogenes on my mind: ERK and MTOR signaling in cognitive diseases.
The role of PI3K/Akt in human herpesvirus infection: From the bench to the bedside.
Two Monogenetic Disorders, Activated PI3-Kinase-? Syndrome 2 and Smith-Magenis Syndrome, in One Patient: Case Report and a Literature Review of Neurodevelopmental Impact in Primary Immunodeficiencies Associated With Disturbed PI3K Signaling.
Germinoma
Molecular Pathology and Targeted Therapies for Personalized Management of Central Nervous System Germinoma.
Gestational Trophoblastic Disease
Whole transcriptome analysis of gestational trophoblastic neoplasms reveals altered PI3K signaling pathway in epithelioid trophoblastic tumor.
Glaucoma
Integrative transcriptomic and proteomic analysis reveals CD9/ITGA4/PI3K-Akt axis mediates trabecular meshwork cell apoptosis in human glaucoma.
Intra-Cellular Calcium Signaling Pathways (PKC, RAS/RAF/MAPK, PI3K) in Lamina Cribrosa Cells in Glaucoma.
Glioblastoma
5' phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells.
A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy.
A Kinome-Wide RNAi Screen in Drosophila Glia Reveals That the RIO Kinases Mediate Cell Proliferation and Survival through TORC2-Akt Signaling in Glioblastoma.
A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.
A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.
A Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration.
Absence of AKT1 Mutations in Glioblastoma.
Absence of AKT1 mutations in glioblastoma.
Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma.
Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway.
Akt2 and Akt3 play a pivotal role in malignant gliomas.
Amalgamation of PI3K and EZH2 blockade synergistically regulates invasion and angiogenesis: combination therapy for glioblastoma multiforme.
Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo.
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.
Autophagy and Akt promote survival in glioma.
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941.
BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma.
BKM120 sensitizes C6 glioma cells to temozolomide via suppression of the PI3K/Akt/NF-?B/MGMT signaling pathway.
Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma.
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.
Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study.
Cadmium induces CCL2 production in glioblastoma cells via activation of MAPK, PI3K, and PKC pathways.
Carnosine inhibits glioblastoma growth independent from PI3K/Akt/mTOR signaling.
Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma.
Characterization of structurally distinct, isoform-selective phosphoinositide 3'-kinase inhibitors in combination with radiation in the treatment of glioblastoma.
Clonal status of actionable driver events and the timing of mutational processes in cancer evolution.
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.
Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.
Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma.
Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis.
Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities.
Cordyceps militaris and mycelial fermentation induced apoptosis and autophagy of human glioblastoma cells.
Correction to: Synergism between the phosphatidylinositol 3-kinase p110? isoform inhibitor AZD6482 and the mixed lineage kinase 3 inhibitor URMC-099 on the blockade of glioblastoma cell motility and focal adhesion formation.
Correction: A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.
Current clinical development of PI3K pathway inhibitors in glioblastoma.
DDR1 (discoidin domain receptor tyrosine kinase 1) drives glioblastoma therapy resistance by modulating autophagy.
Deoxypodophyllotoxin inhibits cell viability and invasion by blocking the PI3K/Akt signaling pathway in human glioblastoma cells.
Differential effects of the Akt inhibitor MK-2206 on migration and radiation sensitivity of glioblastoma cells.
Differential regulation of the pro-inflammatory biomarker, YKL-40/CHI3L1, by PTEN/Phosphoinositide 3-kinase and JAK2/STAT3 pathways in glioblastoma.
Differential response of glioma cells to FOXO1-directed therapy.
Differential sensitivities of glioblastoma cell lines towards metabolic and signaling pathway inhibitions.
Distribution of the phosphatidylinositol 3-kinase inhibitors Pictilisib (GDC-0941) and GNE-317 in U87 and GS2 intracranial glioblastoma models-assessment by matrix-assisted laser desorption ionization imaging.
Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas.
Drosophila melanogaster as a model system for human brain cancers.
Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells.
Dual functional nanoparticles efficiently across the blood-brain barrier to combat glioblastoma via simultaneously inhibit the PI3K pathway and NKG2A axis.
Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Dual targeting of glioblastoma multiforme with a proteasome inhibitor (Velcade) and a phosphatidylinositol 3-kinase inhibitor (ZSTK474).
Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival.
Enhanced antitumor effect of YM872 and AG1296 combination treatment on human glioblastoma xenograft models.
ERK and PI3K signaling cascades induce Nrf2 activation and regulate cell viability partly through Nrf2 in human glioblastoma cells.
Expression of genes belonging to the IGF-system in glial tumors.
GDC-0941 enhances the lysosomal compartment via TFEB and primes glioblastoma cells to lysosomal membrane permeabilization and cell death.
Gene silencing reveals a specific function of hVps34 phosphatidylinositol 3-kinase in late versus early endosomes.
Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas.
Genetic and bioinformatic analyses of the expression and function of PI3K regulatory subunit PIK3R3 in an Asian patient gastric cancer library.
Growth factor receptors signaling in glioblastoma cells: therapeutic implications.
HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells.
Hypoxia and EGF Stimulation Regulate VEGF Expression in Human Glioblastoma Multiforme (GBM) Cells by Differential Regulation of the PI3K/Rho-GTPase and MAPK Pathways.
Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma.
Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM.
In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells.
Inactivation of PI3K/AKT signaling inhibits glioma cell growth through modulation of ?-catenin-mediated transcription.
Infrequent RAS mutation is not associated with specific histological phenotype in gliomas.
Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma.
Inhibition of glycolytic metabolism in glioblastoma cells by Pt3glc combinated with PI3K inhibitor via SIRT3-mediated mitochondrial and PI3K/Akt-MAPK pathway.
Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells.
Inhibition of phosphatidylinositol 3-kinase signaling negates the growth advantage imparted by a mutant epidermal growth factor receptor on human glioblastoma cells.
Inhibition of PI3K signalling increases the efficiency of radiotherapy in glioblastoma cells.
Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs.
Integrating genetic and gene expression evidence into genome-wide association analysis of gene sets.
Interplay of VEGFa and MMP2 regulates invasion of glioblastoma.
Intratumor MAPK and PI3K signaling pathway heterogeneity in glioblastoma tissue correlates with CREB signaling and distinct target gene signatures.
L-Thyroxine vs. 3,5,3'-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase.
Lactate and choline metabolites detected in vitro by nuclear magnetic resonance spectroscopy are potential metabolic biomarkers for PI3K inhibition in pediatric glioblastoma.
Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status.
LY294002 and sorafenib as inhibitors of intracellular survival pathways in the elimination of human glioma cells by programmed cell death.
LY294002 induces differentiation and inhibits invasion of glioblastoma cells by targeting GSK-3beta and MMP.
Mammalian Target of Rapamycin Inhibition Promotes Response to Epidermal Growth Factor Receptor Kinase Inhibitors in PTEN-Deficient and PTEN-Intact Glioblastoma Cells.
MDM2 regulates hypoxic hypoxia-inducible factor 1? stability in an E3 ligase, proteasome, and PTEN-phosphatidylinositol 3-kinase-AKT-dependent manner.
MiRNA-181c inhibits EGFR-signaling-dependent MMP9 activation via suppressing Akt phosphorylation in glioblastoma.
Modulating the tumor microenvironment via oncolytic virus and PI3K inhibition synergistically restores immune checkpoint therapy response in PTEN-deficient glioblastoma.
Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy.
mTOR signaling in glioblastoma: lessons learned from bench to bedside.
Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy.
Novel strategies for molecular targeting to cancer.
Novel targetable FGFR2 and FGFR3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs.
NVP-BEZ235 or JAKi Treatment leads to decreased survival of examined GBM and BBC cells.
Oncogenic dependence of glioma cells on kish/TMEM167A regulation of vesicular trafficking.
Opposing effects of PI3K/Akt and Smad-dependent signaling pathways in NAG-1-induced glioblastoma cell apoptosis.
Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays.
Pharmacokinetics, pharmacodynamics and efficacy on pediatric tumors of the glioma radiosensitizer KU60019.
Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II).
Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir.
Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer.
Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis.
PI3 kinase pathway regulated miRNome in glioblastoma: identification of miR-326 as a tumour suppressor miRNA.
PI3K and Bcl-2 inhibition primes glioblastoma cells to apoptosis through downregulation of Mcl-1 and Phospho-BAD.
PI3K p110? isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition.
PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma.
PI3K signaling in glioma--animal models and therapeutic challenges.
PIK3CA gene mutations in pediatric and adult glioblastoma multiforme.
PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition.
PIP4K2A as a negative regulator of PI3K in PTEN-deficient glioblastoma.
PTEN increases autophagy and inhibits the ubiquitin-proteasome pathway in glioma cells independently of its lipid phosphatase activity.
PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter.
PTEN signaling pathways in glioblastoma.
Radiosensitization of Glioblastoma Cell Lines by the Dual PI3K and mTOR Inhibitor NVP-BEZ235 Depends on Drug-Irradiation Schedule.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
Regorafenib induces lethal autophagy arrest by stabilizing PSAT1 in glioblastoma.
Regulation of GST-MDA-7 toxicity in human glioblastoma cells by ERBB1, ERK1/2, PI3K, and JNK1-3 pathway signaling.
Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma.
Review: Molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies.
Selective Class I Phosphoinositide 3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511.
Stabilization of phosphofructokinase 1 platelet isoform by AKT promotes tumorigenesis.
Synergism between the phosphatidylinositol 3-kinase p110? isoform inhibitor AZD6482 and the mixed lineage kinase 3 inhibitor URMC-099 on the blockade of glioblastoma cell motility and focal adhesion formation.
Targeted inhibition of dominant PI3-kinase catalytic isoforms increase expression of stem cell genes in glioblastoma cancer stem cell models.
Targeting Class IA PI3K Isoforms Selectively Impairs Cell Growth, Survival, and Migration in Glioblastoma.
Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier.
Taxifolin Targets PI3K and mTOR and Inhibits Glioblastoma Multiforme.
TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
Thalidomide attenuates development of morphine dependence in mice by inhibiting PI3K/Akt and nitric oxide signaling pathways.
The catalytic phosphoinositol 3-kinase isoform p110? is required for glioma cell migration and invasion.
The Design and Identification of Brain Penetrant Inhibitors of Phosphoinositide 3-Kinase ?
The effects of PI3K-mediated signalling on glioblastoma cell behaviour.
The Oncogene Addiction Switch from NOTCH to PI3K Requires Simultaneous Targeting of NOTCH and PI3K Pathway Inhibition in Glioblastoma.
The PI3K pathway impacts stem gene expression in a set of glioblastoma cell lines.
The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.
The protein tyrosine phosphatase TCPTP suppresses the tumorigenicity of glioblastoma cells expressing a mutant epidermal growth factor receptor.
The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair.
The RNA helicase DHX33 is required for cancer cell proliferation in human glioblastoma and confers resistance to PI3K/mTOR inhibition.
The Role of Class IA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunits in Glioblastoma.
Three-dimensional Invasion of Human Glioblastoma Cells Remains Unchanged by X-ray and Carbon Ion Irradiation In Vitro.
Tie2-FGFR1 interaction induces adaptive PI3K inhibitor resistance by upregulating Aurora A/PLK1/CDK1 signaling in glioblastoma.
Tivantinib Hampers the Proliferation of Glioblastoma Cells via PI3K/Akt/Mammalian Target of Rapamycin (mTOR) Signaling.
Transcriptomics predicts compound synergy in drug and natural product treated glioblastoma cells.
Understanding and exploiting cell signalling convergence nodes and pathway cross-talk in malignant brain cancer.
Wortmannin sensitizes human glioblastoma cell lines carrying mutant and wild type TP53 gene to radiation.
Yes and PI3K bind CD95 to signal invasion of glioblastoma.
Glioma
A drosophila model for EGFR-Ras and PI3K-dependent human glioma.
A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma.
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.
A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications.
A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma.
A kinase-deficient NTRK2 splice variant predominates in glioma and amplifies several oncogenic signaling pathways.
A novel function of Goalpha: mediation of extracellular signal-regulated kinase activation by opioid receptors in neural cells.
A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study.
ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines.
Akt and autophagy cooperate to promote survival of drug-resistant glioma.
An E3 Ubiquitin Ligase RNF139 Serves as a Tumor-Suppressor in Glioma.
Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells.
ARID1A is a tumour suppressor and inhibits glioma cell proliferation via the PI3K pathwa.
Association of increased phosphatidylinositol 3-kinase signaling with increased invasiveness and gelatinase activity in malignant gliomas.
beta1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury.
Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma.
Cancer stem cells and survival pathways.
Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma.
Cellular stimulation via CD95 involves activation of phospho-inositide-3-kinase.
Characterization of structurally distinct, isoform-selective phosphoinositide 3'-kinase inhibitors in combination with radiation in the treatment of glioblastoma.
Chloroquine or chloroquine-PI3K/Akt pathway inhibitor combinations strongly promote ?-irradiation-induced cell death in primary stem-like glioma cells.
Clinical and biological significance of forkhead class box O 3a expression in glioma: mediation of glioma malignancy by transcriptional regulation of p27(kip1).
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.
Combination therapy for malignant glioma based on PTEN status.
Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach.
Combinatorial therapy with adenoviral-mediated PTEN and a PI3K inhibitor suppresses malignant glioma cell growth in vitro and in vivo by regulating the PI3K/AKT signaling pathway.
Combined targeting of PI3K and MEK effector pathways via CED for DIPG therapy.
Deconstructing the Iboga Alkaloid Skeleton: Potentiation of FGF2-induced Glial Cell Line-Derived Neurotrophic Factor Release by a Novel Compound.
Delayed growth of glioma by Scutellaria flavonoids involve inhibition of Akt, GSK-3 and NF-kappaB signaling.
Deregulated human glioma cell motility: inhibitory effect of somatostatin.
Differential effects of P2Y1 and P2Y12 nucleotide receptors on ERK1/ERK2 and phosphatidylinositol 3-kinase signalling and cell proliferation in serum-deprived and nonstarved glioma C6 cells.
Differentiation antagonizing non-protein coding RNA modulates the proliferation, migration, and angiogenesis of glioma cells by targeting the miR-216a/LGR5 axis and the PI3K/AKT signaling pathway.
Downregulation of PIK3CB by siRNA suppresses malignant glioma cell growth in vitro and in vivo.
Drak/STK17A drives neoplastic glial proliferation through modulation of MRLC signaling.
Dual HDAC and PI3K Inhibition Abrogates NF?B- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas.
Dynamin 2 mediates PDGFR?-SHP-2-promoted glioblastoma growth and invasion.
Effect of saw palmetto extract on PI3K cell signaling transduction in human glioma.
Effect of Tenuifoliside A isolated from Polygala tenuifolia on the ERK and PI3K pathways in C6 glioma cells.
Effects of nonselective cation channels and PI3K on endothelin-1-induced PYK2 tyrosine phosphorylation in C6 glioma cells.
Epigenetic induction of melatonin MT1 receptors by valproate: Neurotherapeutic implications.
Eriodictyol Inhibits Proliferation, Metastasis and Induces Apoptosis of Glioma Cells via PI3K/Akt/NF-?B Signaling Pathway.
Gastrin-Releasing Peptide Receptors Regulate Proliferation of C6 Glioma Cells through a Phosphatidylinositol 3-Kinase-Dependent Mechanism.
Geldanamycin induces mitotic catastrophe and subsequent apoptosis in human glioma cells.
Gene expression changes associated with erlotinib response in glioma cell lines.
Gene of the month: PIK3CA.
Genomic Profiling Identified Novel Prognostic Biomarkers in Chinese Midline Glioma Patients.
Glioblastoma multiforme cells: Expression of erythropoietin receptor and response to erythropoietin.
Glioma biology and molecular markers.
Glioma cells promote the expression of vascular cell adhesion molecule-1 on bone marrow-derived mesenchymal stem cells: a possible mechanism for their tropism toward gliomas.
Glycolytic glioma cells with active glycogen synthase are sensitive to PTEN and inhibitors of PI3K and gluconeogenesis.
High expression of VEGF and PI3K in glioma stem cells provides new criteria for the grading of gliomas.
Identification of survival-related genes of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma multiforme.
IL-17 induces the proliferation and migration of glioma cells through the activation of PI3K/Akt1/NF-?B-p65.
Illuminating Radiogenomic Characteristics of Glioblastoma Multiforme through Integration of MR Imaging, Messenger RNA Expression, and DNA Copy Number Variation.
Increased expression of Akt2 and activity of PI3K and cell proliferation with the ascending of tumor grade of human gliomas.
Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
Inhibiting 4EBP1 in glioblastoma.
Inhibiting PI-3-K for glioma therapy.
Inhibition of Akt kinase signalling and activation of Forkhead are indispensable for upregulation of FasL expression in apoptosis of glioma cells.
Inhibition of phosphatidylinositol 3-kinase/AKT signaling by NVP-BKM120 promotes ABT-737-induced toxicity in a caspase-dependent manner through mitochondrial dysfunction and DNA damage response in established and primary cultured glioblastoma cells.
Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs.
Inhibitory effect of penta-acetyl geniposide on C6 glioma cells metastasis by inhibiting matrix metalloproteinase-2 expression involved in both the PI3K and ERK signaling pathways.
Integrin ?4 is involved in the regulation of glioma-induced motility of bone marrow mesenchymal stem cells.
Investigation of serum proteome alterations in human glioblastoma multiforme.
Involvement of PI3K Pathway in Glioma Cell Resistance to Temozolomide Treatment.
Isoform specific inhibitors of PI3 kinase in glioma.
Kinase inhibitors: vice becomes virtue.
Knockdown of Serine Threonine Tyrosine Kinase 1 (STYK1) Inhibits the Migration and Tumorigenesis in Glioma Cells.
Knockdown of TRIM37 suppresses the proliferation, migration and invasion of glioma cells through the inactivation of PI3K/Akt signaling pathway.
LY294002 and sorafenib as inhibitors of intracellular survival pathways in the elimination of human glioma cells by programmed cell death.
LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway.
MCL1 Gene Silencing Promotes Senescence and Apoptosis of Glioma Cells via Inhibition of the PI3K/Akt Signaling Pathway.
Mechanisms involved in the anti-tumor effects of Toosendanin in glioma cells.
Mechanisms of resistance of human glioma cells to Apo2 ligand/TNF-related apoptosis-inducing ligand.
Metabotropic glutamate receptors as a new therapeutic target for malignant gliomas.
Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma.
MicroRNA-126 acts as a tumor suppressor in glioma cells by targeting insulin receptor substrate 1 (IRS-1).
MicroRNA-21 promotes glioma cell proliferation and inhibits senescence and apoptosis by targeting SPRY1 via the PTEN/PI3K/AKT signaling pathway.
MicroRNA-365 inhibits proliferation, migration and invasion of glioma by targeting PIK3R3.
miR-219-5p inhibits receptor tyrosine kinase pathway by targeting EGFR in glioblastoma.
miR-3175 and miR-134 affect proliferation, invasion and apoptosis of glioma cells through PI3K/AKT signaling pathway.
miR-7 inhibits glioblastoma growth by simultaneously interfering with the PI3K/ATK and Raf/MEK/ERK pathways.
Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma.
NS1619 regulates the expression of caveolin-1 protein in a time-dependent manner via ROS/PI3K/PKB/FoxO1 signaling pathway in brain tumor microvascular endothelial cells.
NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.
NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5.
Overexpression of mTOR and p(240-244)S6 in IDH1 Wild-Type Human Glioblastomas Is Predictive of Low Survival.
Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays.
PCI-24781 down-regulates EZH2 expression and then promotes glioma apoptosis by suppressing the PIK3K/Akt/mTOR pathway.
Phosphatidylinositol 3-kinase activity is required for the expression of glial fibrillary acidic protein upon cAMP-dependent induction of differentiation in rat C6 glioma.
Phosphatidylinositol 3-kinase activity is required for the induction of differentiation in C6 glioma cells by panaxydol.
Phosphoinositide-3-kinase inhibition elevates ferritin level resulting depletion of labile iron pool and blocking of glioma cell proliferation.
PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
PI3K activation in neural stem cells drives tumorigenesis which can be ameliorated by targeting the cAMP response element binding protein.
PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival.
PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma.
Platelet-derived growth factor-mediated gliomagenesis and brain tumor recruitment.
Plausible role of naringenin against cerebrally implanted C6 glioma cells in rats.
Plexin-B1 indirectly affects glioma invasiveness and angiogenesis by regulating the RhoA/?v?3 signaling pathway and SRPK1.
Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis.
Preclinical Pharmacological Evaluation of a Novel Multiple Kinase Inhibitor, ON123300, in Brain Tumor Models.
Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas.
Protein tyrosine kinase-dependent regulation of adenylate cyclase and phosphatidylinositol 3-kinase activates the expression of glial fibrillary acidic protein upon induction of differentiation in rat c6 glioma.
Radiation-induced upregulation of telomerase activity escapes PI3-kinase inhibition in two malignant glioma cell lines.
Reactive blue 2 inhibition of cyclic AMP-dependent differentiation of rat C6 glioma cells by purinergic receptor-independent inactivation of phosphatidylinositol 3-kinase.
Review: Molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies.
Roundabout4 suppresses glioma-induced endothelial cell proliferation, migration and tube formation in vitro by inhibiting VEGR2-mediated PI3K/AKT and FAK signaling pathways.
Selective Class I Phosphoinositide 3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511.
Selective CREB-dependent cyclin expression mediated by the PI3K and MAPK pathways supports glioma cell proliferation.
Sensitization of glioma cells to tamoxifen-induced apoptosis by Pl3-kinase inhibitor through the GSK-3?/?-catenin signaling pathway.
Silibinin-induced glioma cell apoptosis by PI3K-mediated but Akt-independent downregulation of FoxM1 expression.
Sodium vanadate inhibits apoptosis in malignant glioma cells: a role for Akt/PKB.
Sphingosine-1-phosphate stimulates human glioma cell proliferation through Gi-coupled receptors: role of ERK MAP kinase and phosphatidylinositol 3-kinase beta.
STI1 promotes glioma proliferation through MAPK and PI3K pathways.
Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.
Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells.
Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.
Synergistic interaction between 17-AAG and phosphatidylinositol 3-kinase inhibition in human malignant glioma cells.
T11TS immunotherapy repairs PI3K-AKT signaling in T-cells: Clues toward enhanced T-cell survival in rat glioma model.
Tanshinone IIA Affects Autophagy and Apoptosis of Glioma Cells by Inhibiting Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Pathway.
Taxifolin Targets PI3K and mTOR and Inhibits Glioblastoma Multiforme.
Tep1 Regulates Yki Activity in Neural Stem Cells in Drosophila Glioma Model.
The catalytic phosphoinositol 3-kinase isoform p110? is required for glioma cell migration and invasion.
The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.
Thrombin-induced Migration and Matrix Metalloproteinase-9 Expression Are Regulated by MAPK and PI3K Pathways in C6 Glioma Cells.
Tie2-FGFR1 interaction induces adaptive PI3K inhibitor resistance by upregulating Aurora A/PLK1/CDK1 signaling in glioblastoma.
Towards Targeting PI3K-Dependent Regulation of Gene Expression in Brain Cancer.
Twisted gastrulation signaling modulator 1 promotes the ability of glioma cell through activating Akt pathway.
Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway.
V-ATPase controls tumor growth and autophagy in a Drosophila model of gliomagenesis.
Valproic Acid Promotes Human Glioma U87 Cells Apoptosis and Inhibits Glycogen Synthase Kinase-3? Through ERK/Akt Signaling.
[Effect of Brucea Javanica Oil Emulsion on the Invasiveness of Glioma Cells and Its Possible Mechanism].
[Phosphatidylinositide 3-kinase inhibitor BKM120 suppresses proliferation and promotes apoptosis of U251 glioblastoma cells].
Glioma, Subependymal
Therapeutic targets in subependymoma.
Glomerulonephritis
Advances in development of phosphatidylinositol 3-kinase inhibitors.
Glucose Intolerance
3-Deoxyglucosone Induced Acute Glucose Intolerance in Sprague-Dawley Rats: Involvement of Insulin Resistance and Impaired ?-cell Function.
Deletion of Protein Kinase C ? in POMC Neurons Predisposes to Diet-Induced Obesity.
Hepatic deletion of p110α and p85α results in insulin resistance despite sustained IRS1-associated phosphatidylinositol kinase activity.
Loss of PI3K p110? in the Adipose Tissue Results in Infertility and Delayed Puberty Onset in Male Mice.
Maternal Inulin Supplementation Alters Hepatic DNA Methylation Profile and Improves Glucose Metabolism in Offspring Mice.
Graft vs Host Disease
Azole antifungals and new targeted therapies for hematological malignancy.
Gene Expression Profiling-Based Identification of CD28 and PI3K as New Biomarkers for Chronic Graft-Versus-Host Disease.
Granulosa Cell Tumor
Constitutive Activation of PI3K in Oocyte Induces Ovarian Granulosa Cell Tumors.
Dysregulation of WNT/CTNNB1 and PI3K/AKT signaling in testicular stromal cells causes granulosa cell tumor of the testis.
Functional roles of the phosphatidylinositol 3-kinases (PI3Ks) signaling in the mammalian ovary.
Graves Ophthalmopathy
Ganglioside GT1b increases hyaluronic acid synthase 2 via PI3K activation with TLR2 dependence in orbital fibroblasts from thyroid eye disease patients.
Hamartoma
Oncogenes on my mind: ERK and MTOR signaling in cognitive diseases.
PI3K Isoforms Have Spatially Distinct Roles in PTEN Hamartoma Tumor Syndrome.
PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.
Spatially distinct roles of class Ia PI3K isoforms in the development and maintenance of PTEN hamartoma tumor syndrome.
The gene dosage of class Ia PI3K dictates the development of PTEN hamartoma tumor syndrome.
Hamartoma Syndrome, Multiple
PI3K Isoforms Have Spatially Distinct Roles in PTEN Hamartoma Tumor Syndrome.
Sclerosing Polycystic Adenoma: Conclusive Clinical and Molecular Evidence of Its Neoplastic Nature.
Spatially distinct roles of class Ia PI3K isoforms in the development and maintenance of PTEN hamartoma tumor syndrome.
The gene dosage of class Ia PI3K dictates the development of PTEN hamartoma tumor syndrome.
The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.
Head and Neck Neoplasms
A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer.
Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer.
Crosstalk signaling between HER3 and HPV16 E6 and E7 mediates resistance to PI3K inhibitors in head and neck cancer.
Dual blockade of PI3K and MEK in combination with radiation in head and neck cancer.
Efficacy of axitinib in metastatic head and neck cancer with novel radiographic response criteria.
EGFR and PI3K Pathway Activities Might Guide Drug Repurposing in HPV-Negative Head and Neck Cancers.
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.
IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck Cancer.
In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer.
Paracrine Interaction of Cancer Stem Cell Populations Is Regulated by the Senescence-Associated Secretory Phenotype (SASP).
Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.
Phosphorylation of PI3K regulatory subunit p85 contributes to resistance against PI3K inhibitors in radioresistant head and neck cancer.
PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models.
The determinants of head and neck cancer: Unmasking the PI3K pathway mutations.
The influence of PI3K inhibition on the radiotherapy response of head and neck cancer cells.
Hearing Loss
Activation of PI3K signaling prevents aminoglycoside-induced hair cell death in the murine cochlea.
Characterization of EGR-1 Expression in the Auditory Cortex Following Kanamycin-Induced Hearing Loss in Mice.
SOD2 Alleviates Hearing Loss Induced by Noise and Kanamycin in Mitochondrial DNA4834-deficient Rats by Regulating PI3K/MAPK Signaling.
Heart Diseases
Assessment of PI-3 Kinase and Akt in Ischemic Heart Diseases in Diabetes.
Jujuboside A Protects H9C2 Cells from Isoproterenol-Induced Injury via Activating PI3K/Akt/mTOR Signaling Pathway.
LY294002 prevents lipopolysaccharide?induced hepatitis in a murine model by suppressing I?B phosphorylation.
Murine Polyomavirus Cell Surface Receptors Activate Distinct Signaling Pathways Required for Infection.
Phosphoinositide 3-kinase inhibitor LY294002 ameliorates the severity of myosin-induced myocarditis in mice.
Phosphoinositide-3 Kinase Signaling in Cardiac Hypertrophy and Heart Failure.
Role of phosphoinositide 3-kinases in regulating cardiac function.
Role of PI3 kinase gamma in excitation-contraction coupling and heart disease.
Somatic mutations in PI3Kalpha: structural basis for enzyme activation and drug design.
Specific PI3K Isoform Modulation in Heart Failure: Lessons from Transgenic Mice.
Heart Failure
Class III PI3K-mediated prolonged activation of autophagy plays a critical role in the transition of cardiac hypertrophy to heart failure.
CpG-ODN attenuates pathological cardiac hypertrophy and heart failure by activation of PI3K?-Akt signaling.
Differential PI3K signal transduction in obesity-associated cardiac hypertrophy and response to ischemia.
Inhibition of receptor-localized PI3K preserves cardiac beta-adrenergic receptor function and ameliorates pressure overload heart failure.
Pathological role of serum- and glucocorticoid-regulated kinase 1 in adverse ventricular remodeling.
Pharmacological Inhibition of Phosphoinositide 3-Kinase Gamma (PI3K?) Promotes Infarct Resorption and Prevents Adverse Cardiac Remodeling after Myocardial Infarction in Mice.
Phosphoinositide 3-kinases as targets for therapeutic intervention.
Phosphoinositide 3-kinases in health and disease.
PI3K inhibitors in thrombosis and cardiovascular disease.
PI3Kinases in Diabetes Mellitus and Its Related Complications.
Role of phosphoinositide 3-kinase in cardiac function and heart failure.
Specific PI3K Isoform Modulation in Heart Failure: Lessons from Transgenic Mice.
Targeted inhibition of beta-adrenergic receptor kinase-1-associated phosphoinositide-3 kinase activity preserves beta-adrenergic receptor signaling and prolongs survival in heart failure induced by calsequestrin overexpression.
Targeted inhibition of phosphoinositide 3-kinase activity as a novel strategy to normalize beta-adrenergic receptor function in heart failure.
Therapeutic Targeting of PDEs and PI3K in Heart Failure with Preserved Ejection Fraction (HFpEF).
[Novel concepts in beta-adrenergic receptor signaling: therapeutic options for heart failure]
Heart Valve Diseases
[PTEN/PI3K pathways are involved in the signal transduction of myocardial remodeling in patients with congestive heart failure]
Hemangioma
Proanthocyanidins as a Potential Novel Way for the Treatment of Hemangioma.
Propranolol inhibits the activity of PI3K, AKT, and HIF-1? in infantile hemangiomas.
ShcA and Grb2 mediate polyoma middle T antigen-induced endothelial transformation and Gab1 tyrosine phosphorylation.
Hemangiosarcoma
Aberrant PTEN, PIK3CA, pMAPK, and TP53 expression in human scalp and face angiosarcoma.
Active TGF-? signaling and decreased expression of PTEN separates angiosarcoma of bone from its soft tissue counterpart.
Inhibition of MAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells.
Hematologic Neoplasms
A First-in-human Study of Tenalisib (RP6530), a Dual PI3K ?/? Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study.
A Review of PI3K Inhibitors in B-Cell Malignancies.
Activity of BKM120 and BEZ235 against Lymphoma Cells.
Azole antifungals and new targeted therapies for hematological malignancy.
Can Next-Generation PI3K Inhibitors Unlock the Full Potential of the Class in Patients With B-Cell Lymphoma?
Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
Combined inhibition of PI3K-related DNA-damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas.
Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hematological malignancies.
Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1.
Duvelisib, an oral dual PI3K-?, ? inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study.
Duvelisib, an oral dual PI3K-?,? inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.
Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study.
Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies.
Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.
Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies.
Mammalian target of rapamycin as a target in hematological malignancies.
Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
p110? PI3 kinase pathway: emerging roles in cancer.
Pivotal role of Pten in the balance between proliferation and differentiation of hematopoietic stem cells in zebrafish.
Protein kinase B (c-akt) regulates hematopoietic lineage choice decisions during myelopoiesis.
Quassinoid analogs with enhanced efficacy for treatment of hematologic malignancies target the PI3K? isoform.
Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
Somatic mutations in PI3Kalpha: structural basis for enzyme activation and drug design.
Synthesis and biological evaluation of novel purinyl quinazolinone derivatives as PI3K?-specific inhibitors for the treatment of hematologic malignancies.
Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia.
Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies.
The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date.
The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway.
Zydelig (Idelalisib): First-in-Class PI3 Kinase Inhibitor Approved for the Treatment of 3 Hematologic Malignancies.
Hematoma, Subdural, Chronic
Activation of PI3 kinase / Akt signaling in chronic subdural hematoma outer membranes.
Hemorrhagic Stroke
Circulating lncRNAs HIF1A-AS2 and LINLK-A: Role and Relation to Hypoxia-Inducible Factor-1? in Cerebral Stroke Patients.
Hepatic Veno-Occlusive Disease
Chlorogenic acid suppresses monocrotaline-induced sinusoidal obstruction syndrome: The potential contribution of NF?B, Egr1, Nrf2, MAPKs and PI3K signals.
Hepatitis
Coronavirus interactions with the cellular autophagy machinery.
Hepatitis B virus X protein activates a survival signaling by linking SRC to phosphatidylinositol 3-kinase.
LY294002 prevents lipopolysaccharide?induced hepatitis in a murine model by suppressing I?B phosphorylation.
Marmoset Viral Hepatic Inflammation Induced by Hepatitis C Virus Core Protein via IL-32.
Hepatitis B
Clinicopathological characteristics of PIK3CA and HBx mutations in Korean patients with hepatocellular carcinomas.
Hepatitis B virus X protein activates a survival signaling by linking SRC to phosphatidylinositol 3-kinase.
Hepatitis B virus X protein inhibits transforming growth factor-beta -induced apoptosis through the activation of phosphatidylinositol 3-kinase pathway.
Phosphatidylinositol 3-kinase is required for the regulation of hepatitis B surface antigen production and mitogen-activated protein kinase activation by insulin but not by TPA.
Hepatitis C
Hepatitis C virus regulates the production of monocytic myeloid-derived suppressor cells from peripheral blood mononuclear cells through PI3K pathway and autocrine signaling.
Insulin resistance and hepatitis C.
Rab5 and Class III PI-3-Kinase Vps34 Are Involved in Hepatitis C Virus NS4B-Induced Autophagy.
Subversion of cell signaling pathways by hepatitis C virus nonstructural 5A protein via interaction with Grb2 and P85 phosphatidylinositol 3-kinase.
Hepatitis, Alcoholic
Phosphoinositide-3-kinase inhibition with theophylline reverses steroid insensitivity in acute alcoholic hepatitis.
Hepatoblastoma
Activation of phosphatidylinositol-3'-kinase/AKT signaling is essential in hepatoblastoma survival.
Signaling pathway of insulin-like growth factor-II as a target of molecular therapy for hepatoblastoma.
Herpes Simplex
Brain-derived neurotrophic factor induces excitotoxic sensitivity in cultured embryonic rat spinal motor neurons through activation of the phosphatidylinositol 3-kinase pathway.
Coronavirus interactions with the cellular autophagy machinery.
Herpes simplex virus protein kinases US3 and UL13 modulate VP11/12 phosphorylation, virion packaging, and phosphatidylinositol 3-kinase/Akt signaling activity.
Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells.
Phosphatidylinositol 3-kinase confers resistance to encephalomyocarditis and herpes simplex virus-induced cell death through the activation of distinct downstream effectors.
PI3K/Akt signaling mediated apoptosis blockage and viral gene expression in oral epithelial cells during herpes simplex virus infection.
Role of Herpes Simplex Virus VP11/12 Tyrosine-Based Motifs in Binding and Activation of the Src Family Kinase Lck and Recruitment of p85, Grb2, and Shc.
Schizophrenia Susceptibility Genes Directly Implicated in the Life Cycles of Pathogens: Cytomegalovirus, Influenza, Herpes simplex, Rubella, and Toxoplasma gondii.
Herpes Zoster
Oocyte-specific deletion of Pten in mice reveals a stage-specific function of PTEN/PI3K signaling in oocytes in controlling follicular activation.
Herpesviridae Infections
Autoimmune Cytopenia as an Early and Initial Presenting Manifestation in Activated PI3 Kinase Delta Syndrome (APDS): Case Report and Review.
Regulation of PI3K/Akt dependent apoptotic markers during b virus infection of human and macaque fibroblasts.
The role of PI3K/Akt in human herpesvirus infection: From the bench to the bedside.
Histiocytic Sarcoma
Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma.
Multi-omics approach identifies germline regulatory variants associated with hematopoietic malignancies in retriever dog breeds.
Histiocytosis
Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma.
Histiocytosis, Langerhans-Cell
Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma.
HIV Infections
Constitutive activation of phosphatidylinositol 3-kinase signaling pathway down-regulates TLR4-mediated tumor necrosis factor-alpha release in alveolar macrophages from asymptomatic HIV-positive persons in vitro.
Hodgkin Disease
HLXB9 activates IL6 in Hodgkin lymphoma cell lines and is regulated by PI3K signalling involving E2F3.
PI3K? inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma.
Huntington Disease
A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers.
Mutant HTT (huntingtin) impairs mitophagy in a cellular model of Huntington disease.
ULK1-mediated phosphorylation of ATG14 promotes autophagy and is impaired in Huntington's disease models.
Hyperalgesia
A role for adrenomedullin as a pain-related peptide in the rat.
Activation of microglial GLP-1R in the trigeminal nucleus caudalis suppresses central sensitization of chronic migraine after recurrent nitroglycerin stimulation.
Activation of protein kinase B/Akt in the periphery contributes to pain behavior induced by capsaicin in rats.
Beneficial Effects of Electroacupuncture on Neuropathic Pain Evoked by Spinal Cord Injury and Involvement of PI3K-mTOR Mechanisms.
Blocking mammalian target of rapamycin (mTOR) improves neuropathic pain evoked by spinal cord injury.
Blocking mammalian target of rapamycin alleviates bone cancer pain and morphine tolerance via µ-opioid receptor.
Electroacupuncture inhibits phosphorylation of spinal phosphatidylinositol 3-kinase/Akt in a carrageenan-induced inflammatory rat model.
GDNF hyperalgesia is mediated by PLCgamma, MAPK/ERK, PI3K, CDK5 and Src family kinase signaling and dependent on the IB4-binding protein versican.
Involvement of pro-inflammatory cytokines in diabetic neuropathic pain via central PI3K/Akt/mTOR signal pathway.
MCP-1 stimulates spinal microglia via PI3K/Akt pathway in bone cancer pain.
Mechanical allodynia and enhanced responses to capsaicin are mediated by PI3K in a paclitaxel model of peripheral neuropathy.
Mechanisms involved in IL-6-induced muscular mechanical hyperalgesia in mice.
Microglial BDNF, PI3K, and p-ERK in the Spinal Cord Are Suppressed by Pulsed Radiofrequency on Dorsal Root Ganglion to Ease SNI-Induced Neuropathic Pain in Rats.
Neuroinflammation and central PI3K/Akt/mTOR signal pathway contribute to bone cancer pain.
Phosphatidylinositol 3-kinase activates ERK in primary sensory neurons and mediates inflammatory heat hyperalgesia through TRPV1 sensitization.
Phosphoinositide 3-kinase binds to TRPV1 and mediates NGF-stimulated TRPV1 trafficking to the plasma membrane.
Post-surgical inhibition of phosphatidylinositol 3-kinase attenuates the plantar incision-induced postoperative pain behavior via spinal Akt activation in male mice.
Primary afferent nociceptor mechanisms mediating NGF-induced mechanical hyperalgesia.
SDF1-CXCR4 Signaling Contributes to the Transition from Acute to Chronic Pain State.
Spinal cord oligodendrocyte-derived alarmin IL-33 mediates neuropathic pain.
Spinal phosphinositide 3-kinase-Akt-mammalian target of rapamycin signaling cascades in inflammation-induced hyperalgesia.
The Inhibitory Effects of Slow-Releasing Hydrogen Sulfide Donors in the Mechanical Allodynia, Grip Strength Deficits, and Depressive-Like Behaviors Associated with Chronic Osteoarthritis Pain.
Hyperandrogenism
Altered aquaporin expression in women with polycystic ovary syndrome: hyperandrogenism in follicular fluid inhibits aquaporin-9 in granulosa cells through the phosphatidylinositol 3-kinase pathway.
Hypercalcemia
Calcium-sensing receptor induces proliferation through p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase but not extracellularly regulated kinase in a model of humoral hypercalcemia of malignancy.
Hyperglycemia
Acute exercise reduces hepatic glucose production through the inhibition of Foxo1/HNF-4alpha pathway in insulin resistant mice.
Alpha lipoic acid protects against dexamethasone-induced metabolic abnormalities via APPL1 and PGC-1 ? up regulation.
Anti-Apoptotic Effect of IGF1 on Schwann Exposed to Hyperglycemia is Mediated by Neuritin, a Novel Neurotrophic Factor.
Chronic treatment with LY294002, an inhibitor of phosphatidylinositol 3-kinase, attenuates ischemia/reperfusion-induced cardiac dysfunction in normotensive and hypertensive diabetic animals.
Comparison of pancreatic beta cells and alpha cells under hyperglycemia: Inverse coupling in pAkt-FoxO1.
Gamma-glutamyl-carboxylated Gas6 mediates positive role of vitamin K on lowering hyperglycemia in type 2 diabetes.
Hyperglycemia alters PI3k and Akt signaling and leads to endothelial cell proliferative dysfunction.
Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management.
Hyperglycemia inhibits insulin activation of Akt/protein kinase B but not phosphatidylinositol 3-kinase in rat skeletal muscle.
Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation.
Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.
Insulin-like growth factor-I stimulates Shc-dependent phosphatidylinositol 3-kinase activation via Grb2-associated p85 in vascular smooth muscle cells.
Ketoacidosis With Canagliflozin Prescribed for Phosphoinositide 3-Kinase Inhibitor-Induced Hyperglycemia: A Case Report.
Mice Carrying a Dominant-Negative Human PI3K Mutation Are Protected From Obesity and Hepatic Steatosis but Not Diabetes.
Minocycline Effectively Protects the Rabbit's Spinal Cord From Aortic Occlusion-Related Ischemia.
Modification of PI3K- and MAPK-dependent chemotaxis in aortic vascular smooth muscle cells by protein kinase CbetaII.
Novel Miniaturized Drug Conjugate Leverages HSP90-driven Tumor Accumulation to Overcome PI3K Inhibitor Delivery Challenges to Solid Tumors.
Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas.
Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity.
PI3K Inhibitors and Adverse Events: Optimizing Patient Care for the Treatment of Advanced Breast Cancer.
Protective effect of ginsenoside Rg3 on lung injury in diabetic rats.
Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis.
SGLT2 inhibitors as potentially helpful drugs in PI3K inhibitor-induced diabetes: a case report.
Supplementation with Vitis vinifera L. skin extract improves insulin resistance and prevents hepatic lipid accumulation and steatosis in high-fat diet-fed mice.
Targeting PI3 kinase in cancer.
Targeting the glucagon receptor signaling pathway as a novel strategy to counteract PI3K inhibitor induced hyperglycemia while sustaining tumor PI3K inhibition.
The effect of PPAR? agonist on SGLT2 and glucagon expressions in alpha cells under hyperglycemia.
Thyroid Hormone Ameliorates Diabetic Nephropathy in a Mouse Model of Type II Diabetes.
Tributyltin in male mice disrupts glucose homeostasis as well as recovery after exposure: mechanism analysis.
Hyperinsulinism
A link between insulin resistance and hyperinsulinemia: inhibitors of phosphatidylinositol 3-kinase augment glucose-induced insulin secretion from islets of lean, but not obese, rats.
ANG II enhances contractile responses via PI3-kinase p110 delta pathway in aortas from diabetic rats with systemic hyperinsulinemia.
Critical role of atypical protein kinase C in activating hepatic SREBP-1c and NFkappa B in obesity.
Effects of endurance exercise training on insulin signaling in human skeletal muscle: interactions at the level of phosphatidylinositol 3-kinase, Akt, and AS160.
Hepatic deletion of p110α and p85α results in insulin resistance despite sustained IRS1-associated phosphatidylinositol kinase activity.
Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.
Insulin receptor substrate-2-dependent interleukin-4 signaling in macrophages is impaired in two models of type 2 diabetes mellitus.
Insulin regulation of gene expression and concentrations of white adipose tissue-derived proteins in vivo in healthy men: relation to adiponutrin.
Insulin signaling and insulin sensitivity after exercise in human skeletal muscle.
IRS-1 Serine Phosphorylation and Insulin Resistance in Skeletal Muscle From Pancreas Transplant Recipients.
Is daytime insulin more physiologic and less atherogenic than bedtime insulin?
Linkage Between Obesity Leptin and Breast Cancer.
Supplementation with Vitis vinifera L. skin extract improves insulin resistance and prevents hepatic lipid accumulation and steatosis in high-fat diet-fed mice.
Targeting acidity in cancer and diabetes.
The influence of metformin in the etiology of selected cancers.
Tributyltin in male mice disrupts glucose homeostasis as well as recovery after exposure: mechanism analysis.
[Hyperinsulinemia induced immune maturation of human monocyte derived dendritic cells: bridging between diabetes and atherosclerosis]
Hyperlipidemias
Alpha lipoic acid protects against dexamethasone-induced metabolic abnormalities via APPL1 and PGC-1 ? up regulation.
Loss of class IA PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia.
Hyperpigmentation
A novel synthetic Piper amide derivative NED-180 inhibits hyperpigmentation by activating the PI3K and ERK pathways and by regulating Ca2+ influx via TRPM1 channels.
Diosgenin inhibits melanogenesis through the activation of phosphatidylinositol-3-kinase pathway (PI3K) signaling.
Hypersensitivity
Activation of phosphatidylinositol 3-kinase and protein kinase B/Akt in dorsal root ganglia and spinal cord contributes to the neuropathic pain induced by spinal nerve ligation in rats.
Activation of protein kinase B/Akt signaling pathway contributes to mechanical hypersensitivity induced by capsaicin.
Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways.
Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.
Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells.
Dectin-1-Mediated Pathway Contributes to Fusarium proliferatum-Induced CXCL-8 Release from Human Respiratory Epithelial Cells.
Effect and mechanisms of sacral nerve stimulation on visceral hypersensitivity mediated by nerve growth factor.
ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth.
Genetic disruption of the PI3K regulatory subunits, p85?, p55?, and p50?, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF.
Hallway gossip between Ras and PI3K pathways.
Inhibition of lymphocyte kinase Lck and phosphatidylinositol 3-kinase by a novel immunosuppressant, lymphostin.
Insulin hypersensitivity induced by hepatic PTEN gene ablation protects from murine endotoxemia.
Involvement of pro-inflammatory cytokines in diabetic neuropathic pain via central PI3K/Akt/mTOR signal pathway.
Ligand-induced EpoR internalization is mediated by JAK2 and p85 and is impaired by mutations responsible for primary familial and congenital polycythemia.
Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model.
Pharmacological inhibition of PI5P4K?/? disrupts cell energy metabolism and selectively kills p53-null tumor cells.
Phosphatidylinositol 3-kinase activates ERK in primary sensory neurons and mediates inflammatory heat hyperalgesia through TRPV1 sensitization.
Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets.
Phosphoinositide 3-kinase gamma: a key modulator in inflammation and allergy.
Phosphoinositide 3-kinase in disease: timing, location, and scaffolding.
PI3K p110? uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML.
PI3Kgamma adaptor subunits define coupling to degranulation and cell motility by distinct PtdIns(3,4,5)P3 pools in mast cells.
PI3Ks-Drug Targets in Inflammation and Cancer.
Rapamycin alleviates proinflammatory cytokines and nociceptive behavior induced by chemotherapeutic paclitaxel.
Rational Design of Novel Phosphoinositide 3-Kinase Gamma (PI3K?) Selective Inhibitors: A Computational Investigation Integrating 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation.
Recent patents of gene sequences relative to the phosphatidylinositol 3-kinase/Akt pathway and their relevance to drug discovery.
Regulation of p110delta PI 3-kinase gene expression.
Regulation of transient receptor potential cation channel subfamily V1 protein synthesis by the phosphoinositide 3-kinase/Akt pathway in colonic hypersensitivity.
Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.
Spinal SHP2 Contributes to Exaggerated Incisional Pain in Adult Rats Subjected to Neonatal and Adult Incisions via PI3K.
SWAP-70 regulates mast cell FcepsilonRI-mediated signaling and anaphylaxis.
Targeting phosphoinositide 3-kinase: moving towards therapy.
The role of class I phosphoinositide 3-kinase in T-cell function and autoimmunity.
[EXPRESS] Involvement of pro-inflammation signal pathway in inhibitory effects of rapamycin on oxaliplatin-induced neuropathic pain.
Hypertension
Activation of the phosphatidylinositol 3-kinase pathway plays important roles in reduction of cerebral infarction by cilnidipine.
Active Rho kinase (ROK-alpha ) associates with insulin receptor substrate-1 and inhibits insulin signaling in vascular smooth muscle cells.
Chronic blockade of phosphatidylinositol 3-kinase in the nucleus tractus solitarii is prohypertensive in the spontaneously hypertensive rat.
Chronic treatment with LY294002, an inhibitor of phosphatidylinositol 3-kinase, attenuates ischemia/reperfusion-induced cardiac dysfunction in normotensive and hypertensive diabetic animals.
Differential Phosphoinositide 3-Kinase Signaling: Implications for PTCA?
Increased expression and activity of RhoA are associated with increased DNA synthesis and reduced p27(Kip1) expression in the vasculature of hypertensive rats.
Local angiotensin II aggravates cardiac remodeling in hypertension.
Long-term treadmill training ameliorates endothelium-dependent vasorelaxation mediated by insulin and insulin-like growth factor-1 in hypertension.
Low [Mg2+]e enhances arterial spontaneous tone via phosphatidylinositol 3-kinase in DOCA-salt hypertension.
Lower cardiovagal tone and baroreflex sensitivity associated with hepatic insulin resistance and promote cardiovascular disorders in Tibetan minipigs induced by a high fat and high cholesterol diet.
Myeloid PTEN deficiency aggravates renal inflammation and fibrosis in angiotensin II-induced hypertension.
Opposing roles of endothelial and smooth muscle phosphatidylinositol 3-kinase in vasoconstriction: effects of rho-kinase and hypertension.
Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas.
PI3-kinase-induced hyperreactivity in DOCA-salt hypertension is independent of GSK-3 activity.
PI3K signaling: A key pathway in the control of sympathetic traffic and arterial pressure by leptin.
Receptor-independent activation of GABAergic neurotransmission and receptor-dependent nontranscriptional activation of phosphatidylinositol 3-kinase/protein kinase Akt pathway in short-term cardiovascular actions of dexamethasone at the nucleus tractus solitarii of the rat.
Regulation of phosphoinositide 3-kinase expression in health and disease.
Reversal of the Warburg effect with DCA in PDGF?treated human PASMC is potentiated by pyruvate dehydrogenase kinase?1 inhibition mediated through blocking Akt/GSK?3? signalling.
Soluble form of vascular cell adhesion molecule 1 induces migration and proliferation of vascular smooth muscle cells.
SUMOylation of Vps34 by SUMO1 promotes phenotypic switching of vascular smooth muscle cells by activating autophagy in pulmonary arterial hypertension.
Suppression of Phosphatidylinositol 3-Kinase/Akt Signaling Attenuates Hypoxia-Induced Pulmonary Hypertension Through the Downregulation of Lysyl Oxidase.
The Functional Role of PI3K in Maintenance of Blood Pressure and Baroreflex Suppression in (mRen2)27 and mRen2.Lewis Rat.
The phosphoinositide-3 kinase signaling is involved in neuroinflammation in hypertensive rats.
Upregulated function of phosphatidylinositol-3-kinase in genetically hypertensive rats: a moderator of arterial hypercontractility.
Hypertension, Pulmonary
Hypoxic upregulation of preproendothelin-1 gene expression is associated with protein tyrosine kinase-PI3K signaling in cultured lung vascular endothelial cells.
NLRC3 inhibits MCT-induced pulmonary hypertension in rats via attenuating PI3K activation.
[Expression of mitogen-actived protein kinase, phosphatidylinositol 3-kinase and hypoxia-inducible factor-1alpha in pulmonary arteries of patients with chronic obstructive pulmonary disease]
Hypertrophy, Right Ventricular
Inhibition of Phosphatidylinositol-3-kinase/Akt Signaling Attenuates Hypoxia-Induced Pulmonary Artery Remodeling and Suppresses CREB Depletion in Arterial Smooth Muscle Cells.
Ligustrazine Suppresses Platelet-Derived Growth Factor-BB-Induced Pulmonary Artery Smooth Muscle Cell Proliferation and Inflammation by Regulating the PI3K/AKT Signaling Pathway.
Hypoglycemia
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA.
Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer: A Review.
Ubiquitous expression of the Pik3caH1047R mutation promotes hypoglycemia, hypoinsulinemia, and organomegaly.
Hypotension
Activation of PI3K/Akt signaling in rostral ventrolateral medulla impairs brain stem cardiovascular regulation that underpins circulatory depression during mevinphos intoxication.
Advantages of a selective beta-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat.
Cyclosporine counteracts endotoxemia-evoked reductions in blood pressure and cardiac autonomic dysfunction via central sGC/MAPKs signaling in rats.
Phosphatidylinositol 3-kinase inhibition induces vasodilator effect of sevoflurane via reduction of Rho kinase activity.
Hypothyroidism
Class III PI3K Vps34 Controls Thyroid Hormone Production by Regulating Thyroglobulin Iodination, Lysosomal Proteolysis, and Tissue Homeostasis.
Neurotoxicity of developmental hypothyroxinemia and hypothyroidism in rats: Impairments of long-term potentiation are mediated by phosphatidylinositol 3-kinase signaling pathway.
Hypoxia-Ischemia, Brain
Neuroprotective effects of electroacupuncture on hypoxic-ischemic encephalopathy in newborn rats are associated with increased expression of GDNF-RET and protein kinase B.
Idiopathic Pulmonary Fibrosis
Discovery of 4-Methylquinazoline Based PI3K Inhibitors for the Potential Treatment of Idiopathic Pulmonary Fibrosis.
Evaluation of WO2013117503 and WO2013117504: the use of PI3K inhibitors to treat cough or idiopathic pulmonary fibrosis.
PI3K p110? overexpression in idiopathic pulmonary fibrosis lung tissue and fibroblast cells: in vitro effects of its inhibition.
Immune System Diseases
Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies.
p110? PI3 kinase pathway: emerging roles in cancer.
PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances.
Role of PI3K in the Progression and Regression of Atherosclerosis.
Synergy in activating class I PI3Ks.
Infarction, Middle Cerebral Artery
Both PI3K/Akt and ERK1/2 pathways participate in the protection by dexmedetomidine against transient focal cerebral ischemia/reperfusion injury in rats.
Immunoreactive Akt, PI3-K and ERK protein kinase expression in ischemic rat brain.
MiR-124 affects the apoptosis of brain vascular endothelial cells and ROS production through regulating PI3K/AKT signaling pathway.
Infections
A calmodulin-like protein suppresses RNA silencing and promotes geminivirus infection by degrading SGS3 via the autophagy pathway in Nicotiana benthamiana.
A mutation in PIK3CD gene causing pediatric systemic lupus erythematosus: A case report.
A new player in a deadly game: influenza viruses and the PI3K/Akt signalling pathway.
A Peptide Derived from Phosphoinositide 3-kinase Inhibits Endocytosis and Influenza Virus Infection.
Acidosis impairs insulin receptor substrate-1-associated phosphoinositide 3-kinase signaling in muscle cells: consequences on proteolysis.
Activation of EGFR-PI3K-AKT signaling is required for Mycoplasma hyorhinis-promoted gastric cancer cell migration.
Activation of PI3K/Akt signaling has a dominant negative effect on IL-12 production by macrophages infected with Leishmania amazonensis promastigotes.
Activation of the phosphatidylinositol 3-kinase/Akt pathway contributes to survival of primary epithelial cells infected with the periodontal pathogen Porphyromonas gingivalis.
Activation of the phosphatidylinositol 3-kinase/Akt signaling pathway during porcine circovirus type 2 infection facilitates cell survival and viral replication.
Adenovirus infection activates akt1 and induces cell proliferation in pancreatic islets1.
Adrenomedullin induces endothelium-dependent vasorelaxation via the phosphatidylinositol 3-kinase/Akt-dependent pathway in rat aorta.
African swine fever virus infects macrophages, the natural host cells, via clathrin- and cholesterol-dependent endocytosis.
Akt as a mediator of cell death.
Alterations in microRNA expression profile in HCV-infected hepatoma cells: Involvement of miR-491 in regulation of HCV replication via the PI3 kinase/Akt pathway.
An essential role of PI3K in the control of West Nile virus infection.
Analysis of correlation between HP infection and activation of PI3K/Akt pathway in mucosal tissues of gastric cancer and precancerous lesions.
Anti-chlamydial Th17 responses are controlled by the inducible costimulator partially through phosphoinositide 3-kinase signaling.
Antimony-resistant but not antimony-sensitive Leishmania donovani up-regulates host IL-10 to overexpress multidrug-resistant protein 1.
Autoimmune Cytopenia as an Early and Initial Presenting Manifestation in Activated PI3 Kinase Delta Syndrome (APDS): Case Report and Review.
Autophagy induction by the pathogen receptor NECTIN4 and sustained autophagy contribute to peste des petits ruminants virus infectivity.
B cell adaptor for PI3-kinase (BCAP) modulates CD8+ effector and memory T cell differentiation.
Binding of Avibirnavirus VP3 to the PIK3C3-PDPK1 complex inhibits autophagy by activating the AKT-MTOR pathway.
Biphasic activation of PI3K/Akt and MAPK/Erk1/2 signaling pathways in bovine herpesvirus type 1 infection of MDBK cells.
Bivalent role of the phosphatidylinositol-3-kinase (PI3K) during influenza virus infection and host cell defence.
BMI1 promotes cardiac fibrosis in ischemia-induced heart failure via the PTEN-PI3K/Akt-mTOR signaling pathway.
Both PI3K- and mTOR-signaling pathways take part in CVB3-induced apoptosis of Hela cells.
Bovine herpesvirus type 4 infection modulates autophagy in a permissive cell line.
Bta-miR-223 Targeting CBLB Contributes to Resistance to Staphylococcus aureus Mastitis Through the PI3K/AKT/NF-?B Pathway.
BX-795 inhibits HSV-1 and HSV-2 replication by blocking the JNK/p38 pathways without interfering with PDK1 activity in host cells.
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion.
Campylobacter jejuni induces an anti-inflammatory response in human intestinal epithelial cells through activation of phosphatidylinositol 3-kinase/Akt pathway.
Case Study: Mechanism for Increased Follicular Helper T Cell Development in Activated PI3K Delta Syndrome.
CCR5-Dependent Activation of mTORC1 Regulates Translation of Inducible NO Synthase and COX-2 during Encephalomyocarditis Virus Infection.
Cdc42 and the phosphatidylinositol 3-kinase-Akt pathway are essential for PspC-mediated internalization of pneumococci by respiratory epithelial cells.
Cell Surface THY-1 Contributes to Human Cytomegalovirus Entry via a Macropinocytosis-like Process.
Cellular Trans-Differentiation and Morphogenesis Toward the Lymphatic Lineage in Regenerative Medicine.
Centrally acting drug moxonidine decreases reactive oxygen species via inactivation of the phosphoinositide-3 kinase signaling in the rostral ventrolateral medulla in hypertensive rats.
Characterization of entry and infection of monocytic THP-1 cells by Kaposi's sarcoma associated herpesvirus (KSHV): role of heparan sulfate, DC-SIGN, integrins and signaling.
Chlamydia pneumoniae infection induces vascular smooth muscle cell migration via Rac1 activation.
Chlamydia pneumoniae infection promotes vascular smooth muscle cell migration through Toll-like receptor 2-related signaling pathway.
Class III PI3K Vps34 plays an essential role in autophagy and in heart and liver function.
Clinical value of CagA, c-Met, PI3K and Beclin-1 expressed in gastric cancer and their association with prognosis.
Coxsackievirus A2 Leads to Heart Injury in a Neonatal Mouse Model.
Cross-talk between STAT1 and PI3K/AKT signaling in HIV-1-induced blood-brain barrier dysfunction: Role of CCR5 and implications for viral neuropathogenesis.
Dengue virus enhances thrombomodulin and ICAM-1 expression through the macrophage migration inhibitory factor induction of the MAPK and PI3K signaling pathways.
Densovirus infectious pathway requires clathrin-mediated endocytosis followed by trafficking to the nucleus.
Detergent-resistant microdomains mediate activation of host cell signaling in response to attaching-effacing bacteria.
Differential regulation of interleukin-12 and tumour necrosis factor-alpha by phosphatidylinositol 3-kinase and ERK 1/2 pathways during Mycobacterium tuberculosis infection.
Distinct signalling mechanisms mediate neutrophil attraction to bacterial infection and tissue injury.
Divergence of P53, PTEN, PI3K, Akt and mTOR expression in tonsillar cancer.
Down-regulation of MEK/ERK signaling by E-cadherin-dependent PI3K/Akt pathway in differentiating intestinal epithelial cells.
Early diagnosis of PI3K? syndrome in a 2 years old girl with recurrent otitis and enlarged spleen.
Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation.
Enhanced innate immune responsiveness to pulmonary Cryptococcus neoformans infection is associated with resistance to progressive infection.
Enterococcus faecalis infection activates phosphatidylinositol 3-kinase signaling to block apoptotic cell death in macrophages.
Entry of human rhinovirus 89 via ICAM-1 into HeLa epithelial cells is inhibited by actin skeleton disruption and by bafilomycin.
EphrinA2 receptor (EphA2) is an invasion and intracellular signaling receptor for Chlamydia trachomatis.
Epigenetic changes in gastric cancer induction by Helicobacter pylori.
Epithelial PI3K signaling is required for {beta}-catenin activation and host defense against Citrobacter rodentium infection.
Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation.
Equine Herpesvirus Type 1 Enhances Viral Replication in CD172a+ Monocytic Cells upon Adhesion to Endothelial Cells.
Equine lentivirus counteracts SAMHD1 restriction by Rev-mediated degradation of SAMHD1 via the BECN1-dependent lysosomal pathway.
Erythroid cells rendered erythropoietin independent by infection with Friend spleen focus-forming virus show constitutive activation of phosphatidylinositol 3-kinase and Akt kinase: involvement of insulin receptor substrate-related adapter proteins.
Escherichia coli K-1 interaction with human brain micro-vascular endothelial cells triggers phospholipase C-gamma1 activation downstream of phosphatidylinositol 3-kinase.
Expression of PI3K and ERK in Uygur and Han patients with cervical squamous cancer.
Fatty acid synthase and stearoyl-CoA desaturase-1 are conserved druggable cofactors of Old World Alphavirus genome replication.
Fibroblast growth factor 1 regulates signaling via the glycogen synthase kinase-3beta pathway. Implications for neuroprotection.
Flavivirus activates phosphatidylinositol 3-kinase signaling to block caspase-dependent apoptotic cell death at the early stage of virus infection.
Flavone resistant Leishmania donovani over expresses LdMRP2 transporter in the parasite and activates host MRP2 on macrophages to circumvent the flavone-mediated cell death.
Four major factors regulate phosphatidylinositol 3-kinase signaling pathway in cancers induced by infection of human papillomaviruses.
Functional differentiation of three phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) in response to Vibrio anguillarum infection in turbot (Scophthalmus maximus).
Group A Streptococcus modulates RAB1- and PIK3C3 complex-dependent autophagy.
Heat shock protein 20 interacting with phosphorylated Akt reduces doxorubicin-triggered oxidative stress and cardiotoxicity.
Helicobacter pylori activate epidermal growth factor receptor- and phosphatidylinositol 3-OH kinase-dependent Akt and glycogen synthase kinase 3beta phosphorylation.
Helicobacter pylori regulates cellular migration and apoptosis by activation of phosphatidylinositol 3-kinase signaling.
Hepatitis C virus NS5A-mediated activation of phosphoinositide 3-kinase results in stabilization of cellular beta-catenin and stimulation of beta-catenin-responsive transcription.
Hepatitis C Virus Upregulates Beclin1 for Induction of Autophagy and Activates mTOR Signaling.
Herpes simplex virus requires VP11/12 to activate Src family kinase-phosphoinositide 3-kinase-Akt signaling.
Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K.
Higher risk of infections with PI3K-AKT-mTOR pathway inhibitors in patients with advanced solid tumors on Phase I clinical Trials.
Highly pathogenic PRRSV induces IL-17 production via the activation of IRAK1-PI3K-p38MAPK-C/EBP?/CREB pathways.
HIV infection of primary human T cells is determined by tunable thresholds of T cell activation.
Host cell requirements for efficient infection of quiescent primary B lymphocytes by Epstein-Barr virus.
Human adenovirus Ad-36 induces adipogenesis via its E4 orf-1 gene.
Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling.
Human papillomavirus 16 infection predicts poor outcome in patients with esophageal squamous cell carcinoma.
Hydrogen sulfide-induced GAPDH sulfhydration disrupts the CCAR2-SIRT1 interaction to initiate autophagy.
Hypoglycaemia induced by Trichinella infection is due to the increase of glucose uptake in infected muscle cells.
Idelalisib impairs TREM-1 mediated neutrophil inflammatory responses.
IL-10 knockdown with siRNA enhances the efficacy of Doxorubicin chemotherapy in EBV-positive tumors by inducing lytic cycle via PI3K/p38 MAPK/NF-kB pathway.
Impaired B cell function during viral infections due to PTEN-mediated inhibition of the PI3K pathway.
Indoleamine 2,3-dioxygenase expression regulates the survival and proliferation of Fusobacterium nucleatum in THP-1-derived macrophages.
Induction of cyclin D2 in rat granulosa cells requires FSH-dependent relief from FOXO1 repression coupled with positive signals from Smad.
Infection with genotoxin-producing Salmonella enterica synergises with loss of the tumour suppressor APC in promoting genomic instability via the PI3K pathway in colonic epithelial cells.
Infections in activated PI3K delta syndrome (APDS).
Infectious bursal disease virus activates the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway by interaction of VP5 protein with the p85? subunit of PI3K.
Influenza A virus NS1 protein activates the PI3K/Akt pathway to mediate antiapoptotic signaling responses.
Influenza A virus-induced early activation of ERK and PI3K mediates V-ATPase-dependent intracellular pH change required for fusion.
Influenza M2 protein regulates MAVS-mediated signaling pathway through interacting with MAVS and increasing ROS production.
Inhibition of mycobacterial infection by the tumor suppressor PTEN.
Inhibition of Phosphatidylinositol 3-Kinase by Pictilisib Blocks Influenza Virus Propagation in Cells and in Lungs of Infected Mice.
Inhibition of S-phase cyclin-dependent kinase activity blocks expression of Epstein-Barr virus immediate-early and early genes, preventing viral lytic replication.
Insulin resistance and hepatitis C.
Insulin-stimulated phosphorylation of endothelial nitric oxide synthase at serine-615 contributes to nitric oxide synthesis.
Integrating high-content imaging and chemical genetics to probe host cellular pathways critical for Yersinia pestis infection.
Integrative Transcriptomic Analysis Reveals the Immune Mechanism for a CyHV-3-Resistant Common Carp Strain.
Integrin-linked kinase modulates lipopolysaccharide- and Helicobacter pylori-induced nuclear factor ?B-activated tumor necrosis factor-? production via regulation of p65 serine 536 phosphorylation.
Intracellular network of phosphatidylinositol 3-kinase, mammalian target of the rapamycin/70 kDa ribosomal S6 kinase 1, and mitogen-activated protein kinases pathways for regulating mycobacteria-induced IL-23 expression in human macrophages.
Intracellular Networks of the PI3K/AKT and MAPK Pathways for Regulating Toxoplasma gondii-Induced IL-23 and IL-12 Production in Human THP-1 Cells.
Invasion of HeLa cells by group B streptococcus requires the phosphoinositide-3-kinase signalling pathway and modulates phosphorylation of host-cell Akt and glycogen synthase kinase-3.
Involvement of the PI3K and ERK signaling pathways in largemouth bass virus-induced apoptosis and viral replication.
IRS-2 mediates the antiapoptotic effect of insulin in neonatal hepatocytes.
Isofraxidin ameliorated influenza viral inflammation in rodents via inhibiting platelet aggregation.
Kaposi sarcoma in transplantation.
Kaposi's sarcoma-associated herpesvirus confers a survival advantage to endothelial cells.
Legionella pneumophila infection is enhanced in a RacH-null mutant of Dictyostelium.
Life After Death: Are Autophagy Genes Involved in Cell Death and Survival during Plant Innate Immune Responses?
Lipid rafts of primary endothelial cells are essential for Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8-induced phosphatidylinositol 3-kinase and RhoA-GTPases critical for microtubule dynamics and nuclear delivery of viral DNA but dispensable for binding and entry.
LY294002 and Rapamycin promote coxsackievirus-induced cytopathic effect and apoptosis via inhibition of PI3K/AKT/mTOR signaling pathway.
Lysophosphatidylcholine Promotes Phagosome Maturation and Regulates Inflammatory Mediator Production Through the Protein Kinase A-Phosphatidylinositol 3?Kinase-p38 Mitogen-Activated Protein Kinase Signaling Pathway During Mycobacterium tuberculosis Infection in Mouse Macrophages.
M. tuberculosis PknG manipulates host autophagy flux to promote pathogen intracellular survival.
Macrophage pro-inflammatory response to Francisella novicida infection is regulated by SHIP.
Macrophage's proinflammatory response to a mycobacterial infection is dependent on sphingosine kinase-mediated activation of phosphatidylinositol phospholipase C, protein kinase C, ERK1/2, and phosphatidylinositol 3-kinase.
Macrophages target Salmonella by Lc3-associated phagocytosis in a systemic infection model.
Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors.
Marek's Disease Virus Activates the PI3K/Akt Pathway Through Interaction of Its Protein Meq With the P85 Subunit of PI3K to Promote Viral Replication.
Metabolically active CD4+ T cells expressing Glut1 and OX40 preferentially harbor HIV during in vitro infection.
Minocycline differentially modulates macrophage mediated peripheral immune response following Japanese encephalitis virus infection.
MiR-1303 Regulates Mycobacteria Induced Autophagy by Targeting Atg2B.
miRNA-23a has effects to improve lung injury induced by sepsis in vitro and vivo study.
mTOR/p70S6K signaling distinguishes routine, maintenance-level autophagy from autophagic cell death during influenza A infection.
Murine Polyomavirus Cell Surface Receptors Activate Distinct Signaling Pathways Required for Infection.
Mutations in PIK3CD Can Cause Hyper IgM Syndrome (HIGM) Associated with Increased Cancer Susceptibility.
Myeloid cell IL-10 production in response to leishmania involves inactivation of glycogen synthase kinase-3? downstream of phosphatidylinositol-3 kinase.
Neutrophil cell signaling in infection: role of phosphatidylinositide 3-kinase.
NFAT AND CREB REGULATE KAPOSI'S SARCOMA ASSOCIATED HERPES VIRUS (KSHV) INDUCED CYCLOOXYGENASE-2 (COX-2).
Non-opsonic phagocytosis of Legionella pneumophila by macrophages is mediated by phosphatidylinositol 3-kinase.
Novel Roles of Focal Adhesion Kinase in Cytoplasmic Entry and Replication of Influenza A Viruses.
Participation of the phosphatidylinositol 3-kinase/Akt pathway in Junín virus replication in vitro.
PDPK1 regulates autophagosome biogenesis by binding to PIK3C3.
Peroxisome proliferator-activated receptor delta is up-regulated during vascular lesion formation and promotes post-confluent cell proliferation in vascular smooth muscle cells.
Phosphatidylinositol 3-kinase activation attenuates the TLR2-mediated macrophage proinflammatory cytokine response to Francisella tularensis live vaccine strain.
Phosphatidylinositol 3-kinase and frabin mediate Cryptosporidium parvum cellular invasion via activation of Cdc42.
Phosphatidylinositol 3-kinase at The Very Early Symbiont Perception: A Local Nodulation Control under Stress Conditions?
Phosphatidylinositol 3-kinase regulates macrophage responses to double-stranded RNA and encephalomyocarditis virus.
Phosphatidylinositol 3-kinase/Akt signaling controls endothelial cell sensitivity to Fas-mediated apoptosis via regulation of FLICE-inhibitory protein (FLIP).
Phosphoinositide 3'-Kinase ? Facilitates Polyomavirus Infection.
Phosphoinositide 3-kinase family in channel catfish and their regulated expression after bacterial infection.
Phosphoinositide 3-kinase inhibition restores neutrophil accuracy in the elderly: toward targeted treatments for immunosenescence.
Phosphoinositide-3 kinase inhibition modulates responses to rhinovirus by mechanisms that are predominantly independent of autophagy.
Phosphoinositide-3 kinase-Akt pathway controls cellular entry of Ebola virus.
Phosphoinositide-3-kinase-dependent, MyD88-independent induction of CC-type chemokines characterizes the macrophage response to Toxoplasma gondii strains with high virulence.
Phosphoinositides differentially regulate bacterial uptake and Nramp1-induced resistance to Legionella infection in Dictyostelium.
Phosphorylation of PI3K/Akt and MAPK/ERK in an early entry step of enterovirus 71.
PI3K class IB pathway.
PI3K signaling delays Sendai virus-induced apoptosis by preventing XIAP degradation.
PI3K Signaling in Neutrophils.
PI3K signaling of autophagy is required for starvation tolerance and virulenceof Cryptococcus neoformans.
PI3K signaling regulates rapamycin-insensitive translation initiation complex formation in vaccinia virus-infected cells.
PI3K-dependent host cell actin rearrangements are required for Cronobacter sakazakii invasion of human brain microvascular endothelial cells.
PI3K-dependent upregulation of Mcl-1 by human cytomegalovirus is mediated by epidermal growth factor receptor and inhibits apoptosis in short-lived monocytes.
PI3K/Akt signaling mediated apoptosis blockage and viral gene expression in oral epithelial cells during herpes simplex virus infection.
PI3K/Akt-Beclin1 signaling pathway positively regulates phagocytosis and negatively mediates NF-?B-dependent inflammation in Staphylococcus aureus-infected macrophages.
PI3K? Is Critical for Dendritic Cell-Mediated CD8+ T Cell Priming and Viral Clearance during Influenza Virus Infection.
PI3KC3 complex subunit NRBF2 is required for apoptotic cell clearance to restrict intestinal inflammation.
PI3Kgamma is a key regulator of inflammatory responses and cardiovascular homeostasis.
PIK3R1 Mutation Associated with Hyper IgM (APDS2 Syndrome): A Case Report and Review of the Literature.
Platelet-activating factor mediates Porphyromonas gingivalis lipopolysaccharide interference with salivary mucin synthesis via phosphatidylinositol 3-kinase-dependent constitutive nitric-oxide synthase activation.
Poliovirus induces autophagic signaling independent of the ULK1 complex.
Productive Entry of Foot-and-Mouth Disease Virus via Macropinocytosis Independent of Phosphatidylinositol 3-Kinase.
Protein kinase B/Akt regulates coxsackievirus B3 replication through a mechanism which is not caspase dependent.
Protein kinase C isozymes regulate matrix metalloproteinase-1 expression and cell invasion in Helicobacter pylori infection.
Protein phosphatase-2C alpha as a positive regulator of insulin sensitivity through direct activation of phosphatidylinositol 3-kinase in 3T3-L1 adipocytes.
Rab5 activation by Toll-like receptor 2 is required for Trypanosoma cruzi internalization and replication in macrophages.
Rac1-dependent endocytosis and Rab5-dependent intracellular trafficking are required by Enterovirus A71 and Coxsackievirus A10 to establish infections.
Restoration of Akt activity by the bisperoxovanadium compound bpV(pic) attenuates hippocampal apoptosis in experimental neonatal pneumococcal meningitis.
Risk1, a Phosphatidylinositol 3-Kinase Effector, Promotes Rickettsia typhi Intracellular Survival.
Role of cell signaling in poxvirus-mediated foreign gene expression in mammalian cells.
Role of EGFR transactivation in preventing apoptosis in Pseudomonas aeruginosa-infected human corneal epithelial cells.
Role of Herpes Simplex Virus VP11/12 Tyrosine-Based Motifs in Binding and Activation of the Src Family Kinase Lck and Recruitment of p85, Grb2, and Shc.
Role of IQGAP1 in Papillomavirus-Associated Head and Neck Tumorigenesis.
Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis.
Root hair curling and Rhizobium infection in Medicago truncatula are mediated by phosphatidylinositide-regulated endocytosis and reactive oxygen species.
ROS-mediated PI3K activation drives mitochondrial transfer from stromal cells to hematopoietic stem cells in response to infection.
RP105 Engages Phosphatidylinositol 3-Kinase p110? To Facilitate the Trafficking and Secretion of Cytokines in Macrophages during Mycobacterial Infection.
Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils.
Shiga toxin type-2 (Stx2) induces glutamate release via phosphoinositide 3-kinase (PI3K) pathway in murine neurons.
Sindbis virus replication, is insensitive to rapamycin and torin1, and suppresses Akt/mTOR pathway late during infection in HEK cells.
Soluble Egg Antigen Activates M2 Macrophages via the STAT6 and PI3K Pathways, and Schistosoma Japonicum Alternatively Activates Macrophage Polarization to Improve the Survival Rate of Septic Mice.
Sorting nexin (MoVps17) is required for fungal development and plant infection by regulating endosome dynamics in the rice blast fungus.
Spring viraemia of carp virus enters grass carp ovary cells via clathrin-mediated endocytosis and macropinocytosis.
Suppression of host PTEN gene expression for Leishmania donovani survival in Indian visceral leishmaniasis.
Synergistic Interaction between Leptin and Cholecystokinin in the Rat Nodose Ganglia Is Mediated by PI3K and STAT3 Signaling Pathways: IMPLICATIONS FOR LEPTIN AS A REGULATOR OF SHORT TERM SATIETY.
Targeting PI3K-p110? Suppresses Influenza Viral Infection in Chronic Obstructive Pulmonary Disease.
Targeting the PI3K and MAPK pathways to treat Kaposi's-sarcoma-associated herpes virus infection and pathogenesis.
The Chinese herbal prescription JZ-1 induces autophagy to protect against herpes simplex Virus-2 in human vaginal epithelial cells by inhibiting the PI3K/Akt/mTOR pathway.
The Effector TepP Mediates Recruitment and Activation of Phosphoinositide 3-Kinase on Early Chlamydia trachomatis Vacuoles.
The immunity-related GTPase Irgm3 relieves endoplasmic reticulum stress response during coxsackievirus B3 infection via a PI3K/Akt dependent pathway.
The Inhibition of PI3K-Akt Pathway Enhances Gamma-2 Herpesvirus Lytic Replication and Facilitates Reactivation from Latency.
The nuclear protein Sam68 is redistributed to the cytoplasm and is involved in PI3K/Akt activation during EV71 infection.
The p110? isoforme of phosphatidylinositol 3-kinase plays an important role in host defense against chlamydial lung infection through influencing CD4+ T-cell function.
The Phosphatidylinositol 3-Kinase p110?/PTEN Signaling Pathway Is Crucial for HIV-1 Entry.
The PI3K-Akt signaling pathway is important for Staphylococcus aureus internalization by endothelial cells.
The Role of PI3K/AKT Pathway and NADPH Oxidase 4 in Host ROS Manipulation by Toxoplasma gondii.
The role of the PI3K-Akt signal transduction pathway in Autographa californica multiple nucleopolyhedrovirus infection of Spodoptera frugiperda cells.
The study on the role of Hepatitis B virus X protein and apoptosis in HBV intrauterine infection.
Toxoplasma gondii Proliferation Require Down-Regulation of Host Nox4 Expression via Activation of PI3 Kinase/Akt Signaling Pathway.
Transcriptome analysis of liver elucidates key immune-related pathways in Nile tilapia Oreochromis niloticus following infection with tilapia lake virus.
Transcriptome analysis of NF-kappaB- and phosphatidylinositol 3-kinase-regulated genes in human cytomegalovirus-infected monocytes.
Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway.
Transient activation of the PI3K-AKT pathway by hepatitis C virus to enhance viral entry.
Transient activation of the PI3K/Akt pathway promotes Newcastle disease virus replication and enhances anti-apoptotic signaling responses.
Trypanosoma cruzi: phosphatidylinositol 3-kinase and protein kinase B activation is associated with parasite invasion.
Type-2 diabetes, a co-morbidity in Covid-19: does insulin signaling matter?
Unexpected Functional Divergence of Bat Influenza Virus NS1 Proteins.
Variant PIK3R1 Hypermorphic Mutation and Clinical Phenotypes in a Family with Short Statures, Mild Immunodeficiency and Lymphoma.
Varicella-zoster virus requires a functional PI3K/Akt/GSK-3alpha/beta signaling cascade for efficient replication.
VEGF regulation of endothelial nitric oxide synthase in glomerular endothelial cells.
Vibrio parahaemolyticus orchestrates a multifaceted host cell infection by induction of autophagy, cell rounding, and then cell lysis.
[Screening of differentially expressed genes in placentas with hepatitis B virus infection by suppression subtractive hybridization technique]
Infertility
Disorganization of the germ cell pool leads to primary ovarian insufficiency.
Human sperm anatomy: different expression and localization of phosphatidylinositol 3-kinase in normal and varicocele human spermatozoa.
Intraovarian control of early folliculogenesis.
Loss of PI3K p110? in the Adipose Tissue Results in Infertility and Delayed Puberty Onset in Male Mice.
New strategy for in vitro activation of primordial follicles with mTOR and PI3K stimulators.
[Effect of electroacupuncture on levels of serum sex hormones and expression of ovarian auto-phagy related factors in rats with polycystic ovary syndrome].
Infertility, Male
Human sperm anatomy: different expression and localization of phosphatidylinositol 3-kinase in normal and varicocele human spermatozoa.
Inflammatory Bowel Diseases
Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110?.
Emerging views of mitophagy in immunity and autoimmune diseases.
How autophagy controls the intestinal epithelial barrier.
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
PI3K/AKT signaling is essential for communication between tissue infiltrating mast cells, macrophages, and epithelial cells in colitis-induced cancer.
PI3KC3 complex subunit NRBF2 is required for apoptotic cell clearance to restrict intestinal inflammation.
RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.
Sprouty2 limits intestinal tuft and goblet cell numbers through GSK3?-mediated restriction of epithelial IL-33.
The PI3K pathway as a therapeutic intervention point in inflammatory bowel disease.
The role of phosphoinositide 3-kinase signaling in intestinal inflammation.
The roles of microbial products in the development of colorectal cancer: a review.
Influenza, Human
A new player in a deadly game: influenza viruses and the PI3K/Akt signalling pathway.
A Peptide Derived from Phosphoinositide 3-kinase Inhibits Endocytosis and Influenza Virus Infection.
Activation of phosphatidylinositol 3-kinase signaling by the nonstructural NS1 protein is not conserved among type A and B influenza viruses.
An Influenza Virus Entry Inhibitor Targets Class II PI3 Kinase and Synergizes with Oseltamivir.
Binding of influenza A virus NS1 protein to the inter-SH2 domain of p85 suggests a novel mechanism for phosphoinositide 3-kinase activation.
Bivalent role of the phosphatidylinositol-3-kinase (PI3K) during influenza virus infection and host cell defence.
Heterologous SH3-p85beta inhibits influenza A virus replication.
Inability of NS1 protein from an H5N1 influenza virus to activate PI3K/Akt signaling pathway correlates to the enhanced virus replication upon PI3K inhibition.
Influenza A virus NS1 protein activates the phosphatidylinositol 3-kinase (PI3K)/Akt pathway by direct interaction with the p85 subunit of PI3K.
Influenza A virus NS1 protein activates the PI3K/Akt pathway to mediate antiapoptotic signaling responses.
Influenza A virus NS1 protein binds p85beta and activates phosphatidylinositol-3-kinase signaling.
Influenza A virus-induced early activation of ERK and PI3K mediates V-ATPase-dependent intracellular pH change required for fusion.
Influenza A viruses and PI3K: Are there time, place and manner restrictions?
Influenza M2 protein regulates MAVS-mediated signaling pathway through interacting with MAVS and increasing ROS production.
Inhibition of Phosphatidylinositol 3-Kinase by Pictilisib Blocks Influenza Virus Propagation in Cells and in Lungs of Infected Mice.
Innate Immune Response to Influenza A Virus in Differentiated Human Alveolar Type II cells.
Loss of function of the influenza A virus NS1 protein promotes apoptosis but this is not due to a failure to activate phosphatidylinositol 3-kinase (PI3K).
Mechanism of influenza A virus NS1 protein interaction with the p85beta, but not the p85alpha, subunit of phosphatidylinositol 3-kinase (PI3K) and up-regulation of PI3K activity.
Molecular Basis of the Ternary Interaction between NS1 of the 1918 Influenza A Virus, PI3K, and CRK.
Phosphatidylinositol-3-kinase (PI3K) is activated by influenza virus vRNA via the pathogen pattern receptor Rig-I to promote efficient type I interferon production.
PI3K signalling during influenza A virus infections.
PI3K-Akt signaling and viral infection.
PI3K? Is Critical for Dendritic Cell-Mediated CD8+ T Cell Priming and Viral Clearance during Influenza Virus Infection.
Reorganization of the host cell Crk(L)-PI3 kinase signaling complex by the influenza A virus NS1 protein.
Role of G protein and protein kinase signalling in influenza virus budding in MDCK cells.
SH3 binding motif 1 in influenza A virus NS1 protein is essential for PI3K/Akt signaling pathway activation.
Strain-specific contribution of NS1-activated PI3K signaling to influenza A virus replication and virulence.
The human adenovirus E4-ORF1 protein subverts discs large 1 to mediate membrane recruitment and dysregulation of phosphatidylinositol 3-kinase.
Understanding the Binding Transition State After the Conformational Selection Step: The Second Half of the Molecular Recognition Process Between NS1 of the 1918 Influenza Virus and Host p85?.
Insulin Resistance
7-o-methylaromadendrin stimulates glucose uptake and improves insulin resistance in vitro.
A Chinese Herbal Decoction, Dang Gui Bu Xue Tang, Prepared from Radix Astragali and Radix Angelicae sinensis, Ameliorates Insulin Resistance Induced by A High-Fructose Diet in Rats.
A common variation of the PTEN gene is associated with peripheral insulin resistance.
A link between insulin resistance and hyperinsulinemia: inhibitors of phosphatidylinositol 3-kinase augment glucose-induced insulin secretion from islets of lean, but not obese, rats.
A regulatory subunit of phosphoinositide 3-kinase increases the nuclear accumulation of X-box-binding protein-1 to modulate the unfolded protein response.
Abelmoschus esculentus subfractions attenuate beta amyloid-induced neuron apoptosis by regulating DPP-4 with improving insulin resistance signals.
Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction.
Accumulation of endogenous methylglyoxal impaired insulin signaling in adipose tissue of fructose-fed rats.
Acetylation and insulin resistance: a focus on metabolic and mitogenic cascades of insulin signaling.
Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin.
Activation of opioid mu-receptors by loperamide to improve interleukin-6-induced inhibition of insulin signals in myoblast C2C12 cells.
Acute hepatic steatosis in mice by blocking beta-oxidation does not reduce insulin sensitivity of very-low-density lipoprotein production.
Adipocyte-Derived Exosomes Carrying Sonic Hedgehog Mediate M1 Macrophage Polarization-Induced Insulin Resistance via Ptch and PI3K Pathways.
Adipose tissue insulin resistance due to loss of PI3K p110? leads to decreased energy expenditure and obesity.
Adipose tissue insulin sensitivity and macrophage recruitment: Does PI3K pick the pathway?
Alcohol, insulin resistance and the liver-brain axis.
Alterations in the insulin signaling pathway induced by immortalization and H-ras transformation of brown adipocytes.
Amelioration of Insulin Resistance by Scopoletin in High-Glucose-Induced, Insulin-Resistant HepG2 Cells.
Amino acid availability regulates S6K1 and protein synthesis in avian insulin-insensitive QM7 myoblasts.
An Integrated Approach Based on Network Pharmacology Combined with Experimental Verification Reveals AMPK/PI3K/Akt Signaling is an Important Way for the Anti-Type 2 Diabetic Activity of Silkworm Excrement.
Analysis of phosphatidylinositol 3-kinase activation in the adipose tissue of gestational diabetes mellitus patients and insulin resistance.
Anemarrhena saponins attenuate insulin resistance in rats with high-fat diet-induced obesity via the IRS-1/PI3K/AKT pathway.
Antiinsulin receptor autoantibodies induce insulin receptors to constitutively associate with insulin receptor substrate-1 and -2 and cause severe cell resistance to both insulin and insulin-like growth factor I.
Association of impaired phosphatidylinositol 3-kinase activity in GLUT1-containing vesicles with malinsertion of glucose transporters into the plasma membrane of fibroblasts from a patient with severe insulin resistance and clinical features of Werner syndrome.
Astragalus polysaccharides attenuates TNF-?-induced insulin resistance via suppression of miR-721 and activation of PPAR-? and PI3K/AKT in 3T3-L1 adipocytes.
Attenuated Pik3r1 Expression Prevents Insulin Resistance and Adipose Tissue Macrophage Accumulation in Diet-Induced Obese Mice.
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Beneficial effects of Aronia melanocarpa berry extract on hepatic insulin resistance in type 2 diabetes mellitus rats.
Brexpiprazole caused glycolipid metabolic disorder by inhibiting GLP1/GLP1R signaling in rats.
Calorie restriction increases muscle insulin action but not IRS-1-, IRS-2-, or phosphotyrosine-PI 3-kinase.
Calorie restriction prevents the development of insulin resistance and impaired insulin signaling in skeletal muscle of ovariectomized rats.
Calorie Restriction-Induced Increase in Skeletal Muscle Insulin Sensitivity Is Not Prevented by Overexpression of the p55? Subunit of Phosphoinositide 3-Kinase.
Cardiac insulin resistance is associated with an impaired recruitment of phosphatidylinositol 3-kinase to GLUT4 vesicles.
Cardiac PI3K-Akt impairs insulin-stimulated glucose uptake independent of mTORC1 and GLUT4 translocation.
Caulerpa lentillifera extract ameliorates insulin resistance and regulates glucose metabolism in C57BL/KsJ-db/db mice via PI3K/AKT signaling pathway in myocytes.
Cellular mechanism of insulin resistance: potential links with inflammation.
Cellular mechanisms of insulin resistance in humans.
Central GLP-2 enhances hepatic insulin sensitivity via activating PI3K signaling in POMC neurons.
Central insulin-mediated regulation of hepatic glucose production [Review].
Chromium malate alleviates high-glucose and insulin resistance in L6 skeletal muscle cells by regulating glucose uptake and insulin sensitivity signaling pathways.
Chronic ethanol treatment of human hepatocytes inhibits the activation of the insulin signaling pathway by increasing cytosolic free calcium levels.
Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women.
Cinnamon polyphenols regulate multiple metabolic pathways involved in insulin signaling and intestinal lipoprotein metabolism of small intestinal enterocytes.
Class III PI3K regulates organismal glucose homeostasis by providing negative feedback on hepatic insulin signalling.
Coordinated balancing of muscle oxidative metabolism through PGC-1? increases metabolic flexibility and preserves insulin sensitivity.
Crosstalk between 5-HT2cR and PTEN signaling pathway in atypical antipsychotic-induced metabolic syndrome and cognitive dysfunction.
Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome.
Defect in skeletal muscle phosphatidylinositol-3-kinase in obese insulin-resistant mice.
Development of insulin resistance and reversal by thiazolidinediones in C2C12 skeletal muscle cells.
Dexamethasone-induced insulin resistance in 3T3-L1 adipocytes is due to inhibition of glucose transport rather than insulin signal transduction.
DhHP-6 ameliorates hepatic oxidative stress and insulin resistance in type 2 diabetes mellitus through the PI3K/AKT and AMPK pathway.
Diabetes recurrence after metabolic surgeries correlates with re-impaired insulin sensitivity rather than beta-cell function.
Diacerhein attenuates the inflammatory response and improves survival in a model of severe sepsis.
Diet-induced insulin resistance in mice lacking adiponectin/ACRP30.
Dietary Lycium barbarum polysaccharide induces Nrf2/ARE pathway and ameliorates insulin resistance induced by high-fat via activation of PI3K/AKT signaling.
Differential effects of exercise on insulin-signaling gene expression in human skeletal muscle.
Dissecting the mechanism of insulin resistance using a novel heterodimerization strategy to activate Akt.
Down regulation of brain cellular prion protein in an animal model of insulin resistance: possible implication in increased prevalence of stroke in pre-diabetics/diabetics.
Effect of chromium citrate on the mechanism of glucose transport and insulin resistance in Buffalo rat liver cells.
Effect of fetal dexamethasone exposure on the development of adult insulin sensitivity in a rat model.
Effect of phosphotyrosyl-IRS-1 level and insulin receptor tyrosine kinase activity on insulin-stimulated phosphatidylinositol 3, MAP, and S6 kinase activities.
Effect of short-term exercise training on insulin-stimulated PI 3-kinase activity in human skeletal muscle.
Effects of daphnetin on lipid metabolism, insulin resistance and oxidative stress in OA?treated HepG2 cells.
Effects of Insulin on the Vasculature.
Effects of PI3K inhibition and low docosahexaenoic acid on cognition and behavior.
Effects of sleeve gastrectomy plus trunk vagotomy compared with sleeve gastrectomy on glucose metabolism in diabetic rats.
Electroacupuncture mitigates endothelial dysfunction via effects on the PI3K/Akt signalling pathway in high fat diet-induced insulin-resistant rats.
Emodin Regulates Glucose Utilization by Activating AMP-activated Protein Kinase.
Fatty acid-induced insulin resistance: decreased muscle PI3K activation but unchanged Akt phosphorylation.
Fatty aldehyde dehydrogenase: potential role in oxidative stress protection and regulation of its gene expression by insulin.
G-protein coupled receptor 120 is involved in glucose metabolism in fat cells.
Gastric inhibitory peptide controls adipose insulin sensitivity via activation of cAMP-response element-binding protein and p110? isoform of phosphatidylinositol 3-kinase.
Genetic deletion of the angiotensin-(1-7) receptor Mas leads to alterations in gut villi length modulating TLR4/PI3K/AKT and produces microbiome dysbiosis.
Growth hormone induces cellular insulin resistance by uncoupling phosphatidylinositol 3-kinase and its downstream signals in 3T3-L1 adipocytes.
High-fat diet alters PP2A, TC10, and CIP4 expression in visceral adipose tissue of rats.
High-Fat Diet Obesity Associated with Insulin Resistance Increases Cell Proliferation, Estrogen Receptor, and PI3K Proteins in Rat Ventral Prostate.
High-salt diet enhances insulin signaling and induces insulin resistance in Dahl salt-sensitive rats.
Highly bioavailable Berberine formulation improves Glucocorticoid Receptor-mediated Insulin Resistance via reduction in association of the Glucocorticoid Receptor with phosphatidylinositol-3-kinase.
Human insulin receptor substrate-1 (IRS-1) polymorphism G972R causes IRS-1 to associate with the insulin receptor and inhibit receptor autophosphorylation.
Human placental growth hormone increases expression of the p85 regulatory unit of phosphatidylinositol 3-kinase and triggers severe insulin resistance in skeletal muscle.
Hydrogen Sulfide Treatment Promotes Glucose Uptake by Increasing Insulin Receptor Sensitivity and Ameliorates Kidney Lesions in Type 2 Diabetes.
Hypoglycemic Activity and Antioxidative Stress of Extracts and Corymbiferin from Swertia bimaculata In Vitro and In Vivo.
Hypoglycemic activity of the extracts of Belamcanda chinensis leaves (BCLE) on KK-Ay mice.
Hypoglycemic effects of Grifola frondosa (Maitake) polysaccharides F2 and F3 through improvement of insulin resistance in diabetic rats.
Identification of a common amino acid polymorphism in the p85alpha regulatory subunit of phosphatidylinositol 3-kinase: effects on glucose disappearance constant, glucose effectiveness, and the insulin sensitivity index.
Immobilization depresses insulin signaling in skeletal muscle.
Impact of lipid phosphatases SHIP2 and PTEN on the time- and Akt-isoform-specific amelioration of TNF-alpha-induced insulin resistance in 3T3-L1 adipocytes.
Impact of weight cycling on CTRP3 expression, adipose tissue inflammation and insulin sensitivity in C57BL/6J mice.
Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation.
Inducible nitric oxide synthase deficiency ameliorates skeletal muscle insulin resistance but does not alter unexpected lower blood glucose levels after burn injury in C57BL/6 mice.
Influence of the crosstalk between growth hormone and insulin signalling on the modulation of insulin sensitivity.
Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.
Inhibition of 11?-hydroxysteroid dehydrogenase type 1 ameliorates obesity-related insulin resistance.
Inhibition of SNAT2 by metabolic acidosis enhances proteolysis in skeletal muscle.
Inhibition of Soluble Epoxide Hydrolase Limits Mitochondrial Damage and Preserves Function Following Ischemic Injury.
Inhibitors of phosphatidylinositol 3-kinase amplify insulin release from islets of lean but not obese mice.
Insulin action and insulin resistance in vascular endothelium.
Insulin and insulin signaling play a critical role in fat induction of insulin resistance in mouse.
Insulin regulation of gene expression and concentrations of white adipose tissue-derived proteins in vivo in healthy men: relation to adiponutrin.
Insulin resistance and hepatitis C.
Insulin resistance in adult cardiomyocytes undergoing dedifferentiation: role of GLUT4 expression and translocation.
Insulin resistance uncoupled from dyslipidemia due to C-terminal PIK3R1 mutations.
Insulin signal transduction by a mutant human insulin receptor lacking the NPEY sequence. Evidence for an alternate mitogenic signaling pathway that is independent of Shc phosphorylation.
Insulin-mediated pseudoacromegaly in a patient with severe insulin resistance: association of defective insulin-stimulated glucose transport with impaired phosphatidylinositol 3-kinase activity in fibroblasts.
Knockdown of STEAP4 inhibits insulin-stimulated glucose transport and GLUT4 translocation via attenuated phosphorylation of Akt, independent of the effects of EEA1.
Leptin regulates insulin sensitivity via phosphatidylinositol-3-OH kinase signaling in mediobasal hypothalamic neurons.
Leucine reduces the duration of insulin-induced PI 3-kinase activity in rat skeletal muscle.
Link between the renin-angiotensin system and insulin resistance: Implications for cardiovascular disease.
Long-term denervation impairs insulin receptor substrate-1-mediated insulin signaling in skeletal muscle.
Losartan Reduces Insulin Resistance by Inhibiting Oxidative Stress and Enhancing Insulin Signaling Transduction.
Magnesium protects cognitive functions and synaptic plasticity in streptozotocin-induced sporadic Alzheimer's model.
Maternal nicotine exposure aggravates metabolic associated fatty liver disease via PI3K/Akt signaling in adult offspring mice.
Maternal protein restriction affects postnatal growth and the expression of key proteins involved in lifespan regulation in mice.
Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle.
Mechanisms of hemorrhage-induced hepatic insulin resistance: role of tumor necrosis factor-alpha.
Membrane-targeted phosphatidylinositol 3-kinase mimics insulin actions and induces a state of cellular insulin resistance.
Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance.
Metformin paradoxically worsens insulin resistance in SHORT syndrome.
Mice Carrying a Dominant-Negative Human PI3K Mutation Are Protected From Obesity and Hepatic Steatosis but Not Diabetes.
MicroRNA-351 eases insulin resistance and liver gluconeogenesis via the PI3K/AKT pathway by inhibiting FLOT2 in mice of gestational diabetes mellitus.
miR-200s contribute to interleukin-6 (IL-6)-induced insulin resistance in hepatocytes.
MiRNA-21 Reverses High Glucose and High Insulin Induced Insulin Resistance in 3T3-L1 Adipocytes through Targeting Phosphatase and Tensin Homologue.
Mitochondrial dysfunction in insulin resistance: differential contributions of chronic insulin and saturated fatty acid exposure in muscle cells.
Molecular mechanism of insulin resistance in obesity and type 2 diabetes.
Monoclonal antibody to six transmembrane epithelial antigen of prostate-4 influences insulin sensitivity by attenuating phosphorylation of P13K (P85) and Akt: possible mitochondrial mechanism.
Mulberry Bark Alleviates Effect of STZ Inducing Diabetic Mice through Negatively Regulating FoxO1.
Muscular diacylglycerol metabolism and insulin resistance.
Narrow-Leafed Lupin (Lupinus angustifolius L.) Seeds Gamma-Conglutin is an Anti-Inflammatory Protein Promoting Insulin Resistance Improvement and Oxidative Stress Amelioration in PANC-1 Pancreatic Cell-Line.
Network pharmacology-based exploration of therapeutic mechanism of Liu-Yu-Tang in atypical antipsychotic drug-induced metabolic syndrome.
Network Pharmacology-Based Strategy Reveals the Effects of Hedysarum multijugum Maxim.-Radix Salviae Compound on Oxidative Capacity and Cardiomyocyte Apoptosis in Rats with Diabetic Cardiomyopathy.
Neuronal Sirt1 Deficiency Increases Insulin Sensitivity in Both Brain and Peripheral Tissues.
New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
NF-{kappa}B-Inducing Kinase (NIK) Mediates Skeletal Muscle Insulin Resistance: Blockade by Adiponectin.
Nocturnal activation of melatonin receptor type 1 signaling modulates diurnal insulin sensitivity via regulation of PI3K activity.
Non-Alcoholic Fatty Liver Disease.
Normal Akt/PKB with reduced PI3K activation in insulin-resistant mice.
Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1.
Old biliverdin reductase: links to insulin resistance and may be a novel therapeutic target.
Oleic Acid Protects Against Insulin Resistance by Regulating the Genes Related to the PI3K Signaling Pathway.
Opioid ?-receptors as new target for insulin resistance.
Overexpression of uncoupling protein 3 in skeletal muscle protects against fat-induced insulin resistance.
Oxidative stress induces insulin resistance by activating the nuclear factor-kappa B pathway and disrupting normal subcellular distribution of phosphatidylinositol 3-kinase.
Palmitic Acid Induces MicroRNA-221 Expression to Decrease Glucose Uptake in HepG2 Cells via the PI3K/AKT/GLUT4 Pathway.
Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus.
Persistent activation of phosphatidylinositol 3-kinase causes insulin resistance due to accelerated insulin-induced insulin receptor substrate-1 degradation in 3T3-L1 adipocytes.
Phosphatidyl Inositol 3-Kinase Signaling in Hypothalamic Proopiomelanocortin Neurons Contributes to the Regulation of Glucose Homeostasis.
Phosphatidylinositol (3,4) bisphosphate-specific phosphatases and effector proteins: A distinct branch of PI3K signaling.
Phosphatidylinositol 3-kinase and dynamics of insulin resistance in denervated slow and fast muscles in vivo.
Phosphatidylinositol 3-kinase inhibitors reveal a unique mechanism of enhancing insulin secretion in 832/13 rat insulinoma cells.
Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene PIK3R1 haplotype is associated with body fat and serum leptin in a female twin population.
Phosphatidylinositol 3-kinase redistribution is associated with skeletal muscle insulin resistance in gestational diabetes mellitus.
Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice.
Phosphoinositide 3-kinase regulatory subunit p85alpha suppresses insulin action via positive regulation of PTEN.
Physicochemical Characterization of Hizikia fusiforme Polysaccharide and Its Hypoglycemic Activity via Mediating Insulin-Stimulated Blood Glucose Utilization of Skeletal Muscle in Type 2 Diabetic Rats.
Pi 3-kinase and its up- and down-stream modulators as potential targets for the treatment of type II diabetes.
PI3-kinase mutation linked to insulin and growth factor resistance in vivo.
Plasma metabolomic changes following PI3K inhibition as pharmacodynamic biomarkers: preclinical discovery to Phase I trial evaluation.
Prevention of antipsychotic-induced hyperglycaemia by vitamin D: a data mining prediction followed by experimental exploration of the molecular mechanism.
Preventive effect of oleate on palmitate-induced insulin resistance in skeletal muscle and its mechanism of action.
Promoter polymorphisms -359T/C and -303A/G of the catalytic subunit p110beta gene of human phosphatidylinositol 3-kinase are not associated with insulin secretion or insulin sensitivity in finnish subjects.
Protein phosphatase-2C alpha as a positive regulator of insulin sensitivity through direct activation of phosphatidylinositol 3-kinase in 3T3-L1 adipocytes.
Protein tyrosine phosphatase 1B reduction regulates adiposity and expression of genes involved in lipogenesis.
Purple sweet potato color improves hippocampal insulin resistance via down-regulating SOCS3 and galectin-3 in high-fat diet mice.
Randomized clinical trial to compare the effects of preoperative oral carbohydrate versus placebo on insulin resistance after colorectal surgery.
Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation.
Reduction of the PI3K/Akt related signaling activities in skeletal muscle tissues involves insulin resistance in intrauterine growth restriction rats with catch-up growth.
Regulation of insulin receptor substrate 1 (IRS-1)/AKT kinase-mediated insulin signaling by O-Linked beta-N-acetylglucosamine in 3T3-L1 adipocytes.
Regulation of insulin resistance and glucose metabolism by interaction of PIM kinases and insulin receptor substrates.
Rescuing 3T3-L1 adipocytes from insulin resistance induced by stimulation of Akt-mammalian target of rapamycin/p70 S6 kinase (S6K1) pathway and serine phosphorylation of insulin receptor substrate-1: effect of reduced expression of p85alpha subunit of phosphatidylinositol 3-kinase and S6K1 kinase.
Restored insulin-sensitivity in IRS-1-deficient mice treated by adenovirus-mediated gene therapy.
Revealing the Common Mechanisms of Scutellarin in Angina Pectoris and Ischemic Stroke Treatment via a Network Pharmacology Approach.
Reversal of insulin resistance postpartum is linked to enhanced skeletal muscle insulin signaling.
Role of adipocyte-derived factors in enhancing insulin signaling in skeletal muscle and white adipose tissue of mice lacking Acyl CoA:diacylglycerol acyltransferase 1.
Role of miRNAs in the pathogenesis of T2DM, insulin secretion, insulin resistance, and ? cell dysfunction: the story so far.
Role of p110a subunit of PI3-kinase in skeletal muscle mitochondrial homeostasis and metabolism.
Role of retinol-binding protein 4 in the pathogenesis of Type 2 diabetes.
Role of TAPP1 and TAPP2 adaptor binding to PtdIns(3,4)P2 in regulating insulin sensitivity defined by knock-in analysis.
Scopoletin increases glucose uptake through activation of PI3K and AMPK signaling pathway and improves insulin sensitivity in 3T3-L1 cells.
Spinal cord injury causes insulin resistance associated with PI3K signaling pathway in hypothalamus.
Stimulatory effect of docosahexaenoic acid alone or loaded in zinc oxide or silver nanoparticles on the expression of glucose transport pathway.
Structure and in vitro hypoglycemic activity of a homogenous polysaccharide purified from Sargassum pallidum.
Study on the metabolism toxicity, susceptibility and mechanism of di-(2-ethylhexyl) phthalate on rat liver BRL cells with insulin resistance in vitro.
Supplementation with Vitis vinifera L. skin extract improves insulin resistance and prevents hepatic lipid accumulation and steatosis in high-fat diet-fed mice.
Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy.
Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle.
Targeted disruption of ROCK1 causes insulin resistance in vivo.
Tectorigenin Attenuates Palmitate-Induced Endothelial Insulin Resistance via Targeting ROS-Associated Inflammation and IRS-1 Pathway.
The Chinese herbal medicine FTZ attenuates insulin resistance via IRS1 and PI3K in vitro and in rats with metabolic syndrome.
The CNS glucagon-like peptide-2 receptor in the control of energy balance and glucose homeostasis.
The effect of cinnamon extract on insulin resistance parameters in polycystic ovary syndrome: a pilot study.
The ER?-PI3K Cascade in Proopiomelanocortin Progenitor Neurons Regulates Feeding and Glucose Balance in Female Mice.
The influence of metformin in the etiology of selected cancers.
The level of insulin receptor tyrosine kinase activity modulates the activities of phosphatidylinositol 3-kinase, microtubule-associated protein, and S6 kinases.
The p85alpha regulatory subunit of phosphoinositide 3-kinase potentiates c-Jun N-terminal kinase-mediated insulin resistance.
The possible role of mRNA expression changes of GH/IGF-1/insulin axis components in subcutaneous adipose tissue in metabolic disturbances of patients with acromegaly.
Transactivation of ErbB2 and ErbB3 by tumor necrosis factor-alpha and anisomycin leads to impaired insulin signaling through serine/threonine phosphorylation of IRS proteins.
Transcription factor TIP27 regulates glucose homeostasis and insulin sensitivity in a PI3-kinase/Akt-dependent manner in mice.
Trilobatin ameliorates insulin resistance through IRS-AKT-GLUT4 signaling pathway in C2C12 myotubes and ob/ob mice.
Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner.
Tumor necrosis factor-alpha, sphingomyelinase and ceramides activate tyrosine kinase, p21Ras and phosphatidylinositol 3-kinase: implications for glucose transport and insulin resistance.
Understanding the mode-of-action of Cassia auriculata via in silico and in vivo studies towards validating it as a long term therapy for type II diabetes.
Vascular insulin resistance: a potential link between cardiovascular and metabolic diseases.
Verapamil toxicity dysregulates the phosphatidylinositol 3-kinase pathway.
Vps34 PI 3-kinase inactivation enhances insulin sensitivity through reprogramming of mitochondrial metabolism.
Xiao Ke Qing improves glycometabolism and ameliorates insulin resistance by regulating the PI3K/Akt pathway in KKAy mice.
[Cell biological mechanism involved in the effect of sodium selenite on improving insulin sensitivity]
[Correlation between growth hormone/insulin-like growth factor-1 resistance and insulin resistance in non catch-up growth rats born small for gestational age]
[Detection and significance of phosphatidylinositol 3-kinase in adipose tissue of polycystic ovary syndrome patients with insulin resistance]
[Development of insulin resistance in muscle and adipose tissue during obesity in the mouse. Role of phosphatidylinositol 3-kinase]
[Effect of "Spleen-Stomach Harmonizing" Needling on Insulin Resistance and Expression of Insulin Receptor Substrate-1, -2, and Glucose Transporter-4 in Insulin Resistance Type 2 Diabetes Rats].
[Effects of Astragalus membranaceus and Potentilla discolor mixture on insulin resistance and its related mRNA expressions in KKAy mice with type 2 diabetes].
[Effects of electroacupuncture intervention on expression of hypothalamic PI 3 K and p-PI 3 K Proteins in insulin resistance model rats].
[Effects of L-Arg on expression of PI3K and PKB in liver among low-birth-weight newborn rats].
[Effects of retinol binding protein 4 knockdown on the PI3K/Akt pathways in porcine adipocytes].
[Progress in the role of oxidative stress in the pathogenesis of type 2 diabetes].
[Role of protein kinase C isozymes in cellular functions and pathological conditions]
[Study on the mechanism of insulin resistance in rats born with intrauterine growth retardation]
Insulinoma
Antagonism of rat beta-cell voltage-dependent K+ currents by exendin 4 requires dual activation of the cAMP/protein kinase A and phosphatidylinositol 3-kinase signaling pathways.
Differential Signaling by Regulatory Subunits of Phosphoinositide-3-kinase Influences Cell Survival in INS-1E Insulinoma Cells.
Expression and function of the calcium-sensing receptor in pancreatic islets and insulinoma cells.
Impaired glucose-stimulated insulin secretion, enhanced intraperitoneal insulin tolerance, and increased beta-cell mass in mice lacking the p110gamma isoform of phosphoinositide 3-kinase.
Insulin/phosphatidylinositol 3-kinase pathway accelerates the glucose-induced first phase insulin secretion through TrpV2 recruitment in pancreatic beta-cells.
Phosphatidylinositol 3-kinase inhibitors reveal a unique mechanism of enhancing insulin secretion in 832/13 rat insulinoma cells.
Triiodothyronine (T3) induces proinsulin gene expression by activating PI3K: possible roles for GSK-3? and the transcriptional factor PDX-1.
Intellectual Disability
Deletion of PTEN produces deficits in conditioned fear and increases fragile X mental retardation protein.
Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model.
Intervertebral Disc Degeneration
The mechanism of Bushen Huoxue decoction in treating intervertebral disc degeneration based on network pharmacology.
Intracranial Aneurysm
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Intracranial Hemorrhages
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Iron Overload
Zinc induces iron egress from intestinal Caco-2 cells via induction of Hephaestin: A role for PI3K in intestinal iron absorption.
Irritable Bowel Syndrome
From psychology to physicality: how nerve growth factor transduces early life stress into gastrointestinal motility disorders later in life.
Ischemic Stroke
Application of nanostructured lipid carriers: the prolonged protective effects for sesamol in in vitro and in vivo models of ischemic stroke via activation of PI3K signalling pathway.
Biomarkers Associated with Ischemic Stroke in Diabetes Mellitus Patients.
Early Activation of Phosphatidylinositol 3-Kinase after Ischemic Stroke Reduces Infarct Volume and Improves Long-Term Behavior.
Electroacupuncture Inhibits Neuronal Autophagy and Apoptosis via the PI3K/AKT Pathway Following Ischemic Stroke.
Medicarpin Protects Cerebral Microvascular Endothelial Cells Against Oxygen-Glucose Deprivation/Reoxygenation-Induced Injury via the PI3K/Akt/FoxO Pathway: A Study of Network Pharmacology Analysis and Experimental Validation.
Netrin-1 Ameliorates Blood-Brain Barrier Impairment Secondary to Ischemic Stroke via the Activation of PI3K Pathway.
Neuroprotective effects of bisperoxovanadium on cerebral ischemia by inflammation inhibition.
Pre-ischemic treadmill training alleviates brain damage via GLT-1-mediated signal pathway after ischemic stroke in rats.
S-oxiracetam ameliorates ischemic stroke induced neuronal apoptosis through up-regulating ?7 nAChR and PI3K / Akt / GSK3? signal pathway in rats.
Joint Diseases
Synergistic collagenase expression and cartilage collagenolysis are phosphatidylinositol 3-kinase/Akt signaling-dependent.
Kashin-Beck Disease
Role of selenoprotein S (SEPS1) -105G>A polymorphisms and PI3K/Akt signaling pathway in Kashin-Beck disease.
Keloid
Green tea polyphenol epigallocatechin-3-gallate suppresses collagen production and proliferation in keloid fibroblasts via inhibition of the STAT3-signaling pathway.
Interleukin-18 system plays an important role in keloid pathogenesis via epithelial-mesenchymal interactions.
Keloid fibroblasts resist ceramide-induced apoptosis by overexpression of insulin-like growth factor I receptor.
Madecassoside suppresses migration of fibroblasts from keloids: involvement of p38 kinase and PI3K signaling pathways.
Synchronous activation of ERK and phosphatidylinositol 3-kinase pathways is required for collagen and extracellular matrix production in keloids.
Upregulation of microRNA-205 suppresses vascular endothelial growth factor expression-mediated PI3K/Akt signaling transduction in human keloid fibroblasts.
Wubeizi Ointment Suppresses Keloid Formation through Modulation of the mTOR Pathway.
Ketosis
Ketoacidosis With Canagliflozin Prescribed for Phosphoinositide 3-Kinase Inhibitor-Induced Hyperglycemia: A Case Report.
Kidney Neoplasms
CAV2 promotes the growth of renal cell carcinoma through the EGFR/PI3K/Akt pathway.
Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma.
Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer.
Preclinical evaluation of novel PI3K/mTOR dual inhibitor SN202 as potential anti-renal cancer agent.
Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?
Klatskin Tumor
Induction of MKP-1 prevents the cytotoxic effects of PI3K inhibition in hilar cholangiocarcinoma cells.
Klippel-Trenaunay-Weber Syndrome
Haploinsufficiency of Klippel-Trenaunay syndrome gene Aggf1 inhibits developmental and pathological angiogenesis by inactivating PI3K and AKT and disrupts vascular integrity by activating VE-cadherin.
Safety and efficacy of low-dose PI3K inhibitor taselisib in adult patients with CLOVES and Klippel-Trenaunay syndrome (KTS): the TOTEM trial, a phase 1/2 multicenter, open-label, single-arm study.
Laryngeal Neoplasms
Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction.
Latent Infection
Accumulation of cytoplasmic beta-catenin and nuclear glycogen synthase kinase 3beta in Epstein-Barr virus-infected cells.
Phosphatidylinositol 3-kinase is a determinant of responsiveness to B cell antigen receptor-mediated Epstein-Barr virus activation.
Learning Disabilities
Role of Class III phosphoinositide 3-kinase in the brain development: possible involvement in specific learning disorders.
Leiomyoma
All-trans-retinoic acid mediates changes in PI3K and retinoic acid signaling proteins of leiomyomas.
Changes related to phosphatidylinositol 3-kinase/Akt signaling in leiomyomas: possible involvement of glycogen synthase kinase 3alpha and cyclin D2 in the pathophysiology.
Estrogen Receptors and Signaling in Fibroids: Role in Pathobiology and Therapeutic Implications.
Growth factors and pathogenesis.
Progestins activate the AKT pathway in leiomyoma cells and promote survival.
Targeting leiomyomas with all-trans-retinoic acid at phosphoinositide 3-kinase pathway suppression: Effective roles of ?-catenin and of signaling interactions.
Leiomyosarcoma
Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: A pattern distinct from other sarcomas with complex genomics.
Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways.
PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma.
Leishmaniasis
Inhibition of CD40-induced N-Ras activation reduces leishmania major infection.
Pharmacological inhibition of p110? subunit of PI3K confers protection against experimental leishmaniasis.
PI3K signaling in Leishmania infections.
Leishmaniasis, Cutaneous
Critical role for phosphoinositide 3-kinase gamma in parasite invasion and disease progression of cutaneous leishmaniasis.
Leishmaniasis, Visceral
Deficiency of p110? isoform of the phosphoinositide 3 kinase leads to enhanced resistance to Leishmania donovani.
LEOPARD Syndrome
Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1.
Leukemia
A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth.
A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia.
A self-validating quantitative mass spectrometry method for assessing the accuracy of high-content phosphoproteomic experiments.
Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.
Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line.
Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1.
Activation of PDK-1 maintains mouse embryonic stem cell self-renewal in a PKB-dependent manner.
Activation of phosphatidylinositol-3-kinase in Jurkat T cells depends on the presence of the p56lck tyrosine kinase.
Active lipids of Ganoderma lucidum spores-induced apoptosis in human leukemia THP-1 cells via MAPK and PI3K pathways.
Arsenic trioxide reduces the expression of E2F1, cyclin E, and phosphorylation of PI3K signaling molecules in acute leukemia cells.
Association of phosphatidylinositol 3-kinase with SHC in chronic myelogeneous leukemia cells.
Azole antifungals and new targeted therapies for hematological malignancy.
BAD Dephosphorylation and Decreased Expression of MCL-1 Induce Rapid Apoptosis in Prostate Cancer Cells.
Bakkenolide A inhibits leukemia by regulation of HDAC3 and PI3K/Akt-related signaling pathways.
BRAP2 inhibits the Ras/Raf/MEK and PI3K/Akt pathways in leukemia cells, thereby inducing apoptosis and inhibiting cell growth.
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias.
CDK Blockade Using AT7519 Suppresses Acute Myeloid Leukemia Cell Survival through the Inhibition of Autophagy and Intensifies the Anti-leukemic Effect of Arsenic Trioxide.
Chemical modification of santonin into a diacetoxy acetal form confers the ability to induce differentiation of human promyelocytic leukemia cells via the down-regulation of NF-kappaB DNA binding activity.
CK2 and PI3K are direct molecular targets of quercetin in chronic lymphocytic leukaemia.
Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice.
Combined effects of PI3K and SRC kinase inhibitors with imatinib on intracellular calcium levels, autophagy, and apoptosis in CML-PBL cells.
Combined Inhibition of PI3K and mTOR Exerts Synergistic Antiproliferative Effect, but Diminishes Differentiative Properties of Rapamycin in Acute Myeloid Leukemia Cells.
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.
Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice.
Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hematological malignancies.
Dual Inhibition of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin: a Therapeutic Strategy for Acute Leukemias.
Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110? subunit of PI3 kinase.
Effect of wortmannin and 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) on N-formyl-methionyl-leucyl-phenylalanine-induced phospholipase D activation in differentiated HL60 cells: possible involvement of phosphatidylinositol 3-kinase in phospholipase D activation.
Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
Exploration of (S)-3-aminopyrrolidine as a potentially interesting scaffold for discovery of novel Abl and PI3K dual inhibitors.
Genetic disruption of the PI3K regulatory subunits, p85?, p55?, and p50?, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF.
GW5074 and PP2 kinase inhibitors implicate nontraditional c-Raf and Lyn function as drivers of retinoic acid-induced maturation.
Hallway gossip between Ras and PI3K pathways.
Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110?.
Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C.
High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions.
Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization.
Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.
IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia.
Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.
Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells.
Inhibition of phosphatidylinositol 3-kinase causes apoptosis in retinoic acid differentiated hl-60 leukemia cells.
Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias.
Inhibition of PI-3-K and AKT Amplifies Kv1.3 Inhibitor-Induced Death of Human T Leukemia Cells.
Inhibitor of pan class-I PI3K induces differentially apoptotic pathways in acute leukemia cells: Shedding new light on NVP-BKM120 mechanism of action.
Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies.
Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance.
Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.
Mammalian target of rapamycin as a target in hematological malignancies.
MLL3 Induced by Luteolin Causes Apoptosis in Tamoxifen-Resistant Breast Cancer Cells through H3K4 Monomethylation and Suppression of the PI3K/AKT/mTOR Pathway.
Mometasone furoate inhibits growth of acute leukemia cells in childhood by regulating PI3K signaling pathway.
Network model of survival signaling in large granular lymphocyte leukemia.
NF-?B-dependent Mechanism of Action of c-Myc Inhibitor 10058-F4: Highlighting a Promising Effect of c-Myc Inhibition in Leukemia Cells, Irrespective of p53 Status.
Novel pan PI3K inhibitor-induced apoptosis in APL cells correlates with suppression of telomerase: An emerging mechanism of action of BKM120.
Oncogenic kit triggers Shp2/Erk1/2 pathway to down-regulate the pro-apoptotic protein Bim and to promote apoptosis resistance in leukemic cells.
Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas.
Phosphatidylinositol 3-kinase in HL-60 nuclei is bound to the nuclear matrix and increases during granulocytic differentiation.
Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia.
Phosphatidylinositol 3-kinase is required for the induction of ornithine decarboxylase in leukemia cells stimulated to growth.
Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells.
Phosphoinositide 3-kinase: diverse roles in immune cell activation.
PI3-K/Akt-dependent activation of cAMP-response element-binding (CREB) protein in Jurkat T leukemia cells treated with TRAIL.
PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment.
PI3K p110? uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML.
PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL).
PI3K target based novel cyano derivative of betulinic acid induces its signalling inhibition by down-regulation of pGSK3? and cyclin D1 and potentially checks cancer cell proliferation.
Pivotal role of Pten in the balance between proliferation and differentiation of hematopoietic stem cells in zebrafish.
Plasma Hsp90 Level as a Marker of Early Acute Lymphoblastic Leukemia Engraftment and Progression in Mice.
PLC-? and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras.
Positive Effects of PI3K/Akt Signaling Inhibition on PTEN and P53 in Prevention of Acute Lymphoblastic Leukemia Tumor Cells.
Posttranscriptional regulation of the p85? adapter subunit of phosphatidylinositol 3-kinase in human leukemia cells.
Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.
Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Propofol Treatment Inhibits Constitutive Apoptosis in Human Primary Neutrophils and Granulocyte-Differentiated Human HL60 Cells.
Quercetin-induced apoptosis of HL-60 cells by reducing PI3K/Akt.
Rac and phosphatidylinositol 3-kinase regulate the protein kinase B in Fc epsilon RI signaling in RBL 2H3 mast cells.
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.
Semaphorin 4D is a potential biomarker in pediatric leukemia and promotes leukemogenesis by activating PI3K/AKT and ERK signaling pathways.
Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.
Silence of MCL-1 upstream signaling by shRNA abrogates multiple myeloma growth.
Silencing c-Myc translation as a therapeutic strategy through targeting PI3K? and CK1? in hematological malignancies.
Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL.
Small molecule inhibitor of c-Myc 10058-F4 inhibits proliferation and induces apoptosis in acute leukemia cells, irrespective of PTEN status.
SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia.
Specific inhibition of basal mitogen-activated protein kinases and phosphatidylinositol 3 kinase activities in leukemia cells: a possible therapeutic role for the kinase inhibitors.
Synergistic Effects of PI3K and c-Myc Co-targeting in Acute Leukemia: Shedding New Light on Resistance to Selective PI3K-? Inhibitor CAL-101.
Synthesis and biological evaluation of novel pyrimidine-5-carbonitriles featuring morpholine moiety as antitumor agents.
Synthesis and in vitro evaluation of new wortmannin esters: potent inhibitors of phosphatidylinositol 3-kinase.
Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia.
Targeting the MAPK/ERK and PI3K/AKT Signaling Pathways Affects NRF2, Trx and GSH Antioxidant Systems in Leukemia Cells.
Targeting the mTOR Pathway in Leukemia.
Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
The genomic landscape of hypodiploid acute lymphoblastic leukemia.
The Impact of PI3-kinase/RAS Pathway Cooperating Mutations in the Evolution of KMT2A-rearranged Leukemia.
The Inhibitory NKR-P1B:Clr-b Recognition Axis Facilitates Detection of Oncogenic Transformation and Cancer Immunosurveillance.
The IREM-1 (CD300f) inhibitory receptor associates with the p85alpha subunit of phosphoinositide 3-kinase.
The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
The role of autophagy in targeted therapy for acute myeloid leukemia.
Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.
Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML.
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.
Tyrosine phosphorylation of the p85 subunit of phosphatidylinositol 3-kinase correlates with high proliferation rates in sublines derived from the Jurkat leukemia.
[Regulation of All-trans Retinoic Acid and Arsenic Trioxide on CD44v6 Expression in NB4 Cells].
Leukemia, B-Cell
PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL).
Leukemia, Erythroblastic, Acute
Combined inhibition of PI3K and activation of MAPK p38 signaling pathways trigger erythroid alternative splicing switch of 4.1R pre-mRNA in DMSO-induced erythroleukemia cells.
Phosphatidylinositol 3-kinase activity in murine erythroleukemia cells during DMSO-induced differentiation.
Subtle distinct regulations of late erythroid molecular events by PI3K/AKT-mediated activation of Spi-1/PU.1 oncogene autoregulation loop.
[Involvement of regulating the phosphatidylinositol 3-kinase signaling pathway in the process of herbimycin A-induced erythroid cell differentiation in the K562 erythroleukemia cell line]
Leukemia, Large Granular Lymphocytic
Two siblings presenting with novel ADA2 variants, lymphoproliferation, persistence of large granular lymphocytes, and T-cell perturbations.
Leukemia, Lymphocytic, Chronic, B-Cell
A Severe Case of Cutaneous Adverse Drug Reaction Secondary to a Novice Drug: Idelalisib.
Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia.
Approaches for relapsed CLL after chemotherapy-free frontline regimens.
Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.
BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Chronic lymphocytic leukemia patients with heterogeneously or fully methylated LPL promotor display longer time to treatment.
Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
Development of a novel and quick UPLC-MS/MS method for the pharmacokinetic analysis of duvelisib in beagle dogs.
Development of PI3K inhibitors: advances in clinical trials and new strategies (Review).
Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.
Duvelisib, an oral dual PI3K-?,? inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.
Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia.
Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies.
Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia.
Epilepsia partialis continua revealing idelalisib-associated PML-IRIS: clinical and pathological features.
Erratum to: PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL).
Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia.
Expression of Functional Sphingosine-1 Phosphate Receptor-1 Is Reduced by B Cell Receptor Signaling and Increased by Inhibition of PI3 Kinase ? but Not SYK or BTK in Chronic Lymphocytic Leukemia Cells.
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.
GS-1101: A Delta-Specific PI3K Inhibitor in Chronic Lymphocytic Leukemia.
Hedgehog/GLI and PI3K signaling in the initiation and maintenance of chronic lymphocytic leukemia.
High expression of PI3K core complex genes is associated with poor prognosis in chronic lymphocytic leukemia.
Highlights in the treatment of chronic lymphocytic leukemia from the 2014 meeting of the American Society of Hematology.
Ibrutinib inhibits CD20 up-regulation on CLL B cells mediated by the CXCR4/SDF-1 axis.
Idelalisib for the treatment of chronic lymphocytic leukemia.
Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells.
Idelalisib induces PUMA-dependent apoptosis in colon cancer cells.
Idelalisib, an inhibitor of phosphatidylinositol 3 kinase p110?, for relapsed/refractory chronic lymphocytic leukemia.
Idelalisib-associated Enterocolitis: Clinicopathologic Features and Distinction From Other Enterocolitides.
Idelalisib-induced colitis and skin eruption mimicking graft-versus-host disease.
Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
Idelalisib: Targeting the PI3 Kinase Pathway in Non-Hodgkin Lymphoma.
Identification of Candidate Risk Factor Genes for Human Idelalisib Toxicity Using a Collaborative Cross Approach.
IGF1R as druggable target mediating PI3K-? inhibitor resistance in a murine model of chronic lymphocytic leukemia.
IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia.
Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells.
IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells.
Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.
Lessons, Challenges and Future Therapeutic Opportunities for PI3K Inhibition in CLL.
Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia.
Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors.
Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia.
Novel target to kill CLL.
Phosphatidylinositol 3-kinase-? inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.
Phosphatidylinositol-3,4-Bisphosphate and Its Binding Protein Lamellipodin Regulate Chemotaxis of Malignant B Lymphocytes.
Phosphoinositide 3'-kinase delta: turning off BCR signaling in Chronic Lymphocytic Leukemia..
Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia.
Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?
PI3-kinase inhibitors in chronic lymphocytic leukemia.
PI3K Inhibitors: Understanding Toxicity Mechanisms and Management.
PI3K isoform-selective inhibitors: next-generation targeted cancer therapies.
PI3K p110? inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression.
PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL).
PI3K signaling pathway in normal B cells and indolent B-cell malignancies.
Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells.
Retrospective Analysis of the Impact of Adverse Event-Triggered Idelalisib Interruption and Dose Reduction on Clinical Outcomes in Patients With Relapsed/Refractory B-Cell Malignancies.
Targeting the B cell receptor pathway in non-Hodgkin lymphoma.
Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?
The dual PI3K?/CK1? inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells.
The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.
The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions.
The PI3K p110? Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function.
The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia.
The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
Leukemia, Lymphoid
Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.
Leukemia, Mast-Cell
Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line.
Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Anti-leukemic effect of PI3K inhibition on chronic myeloid leukemia (CML) cells: shedding new light on the mitigating effect of c-Myc and autophagy on BKM120 cytotoxicity.
Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations.
BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
BCR/ABL oncogene-induced PI3K signaling pathway leads to chronic myeloid leukemia pathogenesis by impairing immuno-modulatory function of hemangioblasts.
Constitutively activated phosphatidylinositol 3-kinase primes platelets from patients with chronic myelogenous leukemia for thrombopoietin-induced aggregation.
Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Increased galectin-3 facilitates leukemia cell survival from apoptotic stimuli.
NF-?B suppresses ROS levels in BCR-ABL(+) cells to prevent activation of JNK and cell death.
Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells.
Stellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5.
Targeting the MAPK/ERK and PI3K/AKT Signaling Pathways Affects NRF2, Trx and GSH Antioxidant Systems in Leukemia Cells.
[The anti-tumoral effect of PI3K inhibitor and MEK inhibitor combined with STI571 on chronic myeloid leukemia cells in a bone marrow stromal cell co-culture system]
Leukemia, Myeloid
Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110?.
Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias.
Leukemia, Myeloid, Acute
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.
ACLY is the novel signaling target of PIP2/PIP3 and Lyn in acute myeloid leukemia.
Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia.
Arsenic Trioxide and Thalidomide Combination Induces Autophagy Along with Apoptosis in Acute Myeloid Cell Lines.
Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody.
Azole antifungals and new targeted therapies for hematological malignancy.
Camel Whey Protein Disrupts the Cross-Talk Between PI3K and BCL-2 Signals and Mediates Apoptosis in Primary Acute Myeloid Leukemia Cells.
Combined Inhibition of PI3K and mTOR Exerts Synergistic Antiproliferative Effect, but Diminishes Differentiative Properties of Rapamycin in Acute Myeloid Leukemia Cells.
Combined inhibition of the phosphoinosityl-3-kinase (PI3Kinase) P110d subunit and mitogen-extracellular activated protein kinase (MEKinase) shows synergistic cytotoxicity against human acute myeloid leukemia progenitors.
Constitutive activation of PI3K is involved in the spontaneous proliferation of primary acute myeloid leukemia cells: direct evidence of PI3K activation.
Dual inhibition of PI3K and mTORC1/2 signalling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
Dual inhibition of PI3K/Akt signaling and the DNA damage checkpoint in p53-deficient cells with strong survival signaling: implications for cancer therapy.
Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110? subunit of PI3 kinase.
Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells.
Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients.
Gab2 Is Involved in Differential Phosphoinositide 3-Kinase Signaling by Two Splice Forms of c-Kit.
Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis.
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.
mTOR regulates cell survival after etoposide treatment in primary AML cells.
PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.
PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment.
Posttranscriptional regulation of the p85? adapter subunit of phosphatidylinositol 3-kinase in human leukemia cells.
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells.
Puquitinib, a novel orally available PI3K? inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia.
Rheb1 promotes tumor progression through mTORC1 in MLL-AF9-initiated murine acute myeloid leukemia.
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia.
Survival of acute myeloid leukemia cells requires PI3 kinase activation.
Synergistic effects of LY294002 and ABT199 on the cell cycle in K562, HL60 and KG1a cells.
Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription.
Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia.
Targeting the MAPK/ERK and PI3K/AKT Signaling Pathways Affects NRF2, Trx and GSH Antioxidant Systems in Leukemia Cells.
Targeting the mTOR Pathway in Leukemia.
The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia.
The role of autophagy in targeted therapy for acute myeloid leukemia.
The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma.
Upstream regulators of phosphoinositide 3-kinase and their role in diseases.
Leukemia, Myelomonocytic, Juvenile
Genetic disruption of the PI3K regulatory subunits, p85?, p55?, and p50?, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF.
Hallway gossip between Ras and PI3K pathways.
Leukemia, Promyelocytic, Acute
Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.
NF-?B-dependent Mechanism of Action of c-Myc Inhibitor 10058-F4: Highlighting a Promising Effect of c-Myc Inhibition in Leukemia Cells, Irrespective of p53 Status.
The role of autophagy in targeted therapy for acute myeloid leukemia.
[Regulation of All-trans Retinoic Acid and Arsenic Trioxide on CD44v6 Expression in NB4 Cells].
Leukemia, T-Cell
Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.
The human adenovirus E4-ORF1 protein subverts discs large 1 to mediate membrane recruitment and dysregulation of phosphatidylinositol 3-kinase.
The human T-cell leukemia virus type 1 oncoprotein tax controls forkhead box O4 activity through degradation by the proteasome.
The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia.
Leukemia-Lymphoma, Adult T-Cell
Alteration of phosphatidylinositol 3-kinase cascade in the multilobulated nuclear formation of adult T cell leukemia/lymphoma (ATLL).
Novel PRMT5-mediated arginine methylations of HSP90A are essential for maintenance of HSP90A function in NDRG2low ATL and various cancer cells.
Lewy Body Disease
Alteration of Upstream Autophagy-Related Proteins (ULK1, ULK2, Beclin1, VPS34 and AMBRA1) in Lewy Body Disease.
Lipodystrophy
Iris Malformation and Anterior Segment Dysgenesis in Mice and Humans With a Mutation in PI 3-Kinase.
Mice Carrying a Dominant-Negative Human PI3K Mutation Are Protected From Obesity and Hepatic Steatosis but Not Diabetes.
PI3-kinase mutation linked to insulin and growth factor resistance in vivo.
SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling.
Skeletal Muscle Insulin Signaling Defects Downstream of Phosphatidylinositol 3-Kinase at the Level of Akt Are Associated With Impaired Nonoxidative Glucose Disposal in HIV Lipodystrophy.
Lipoma
Sirolimus treatment of severe PTEN hamartoma tumor syndrome: case report and in vitro studies.
The Novel Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Alpelisib Effectively Inhibits Growth of PTEN-Haploinsufficient Lipoma Cells.
Liposarcoma
Novel Dedifferentiated Liposarcoma Xenograft Models Reveal PTEN Down-Regulation as a Malignant Signature and Response to PI3K Pathway Inhibition.
Synergistic Effects of Targeted PI3K Signaling Inhibition and Chemotherapy in Liposarcoma.
Liposarcoma, Myxoid
Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid Liposarcoma.
Liver Cirrhosis
Active Compounds Derived from Fuzheng Huayu Formula Protect Hepatic Parenchymal Cells from Apoptosis Based on Network Pharmacology and Transcriptomic Analysis.
Effect of miR-182 on hepatic fibrosis induced by Schistosomiasis japonica by targeting FOXO1 through PI3K/AKT signaling pathway.
Germacrone improves liver fibrosis by regulating the PI3K/AKT/mTOR signalling pathway.
HS-173, a novel PI3K inhibitor, attenuates the activation of hepatic stellate cells in liver fibrosis.
Multi-Drug/Gene NASH Therapy Delivery and Selective Hyperspectral NIR Imaging Using Chirality-Sorted Single-Walled Carbon Nanotubes.
NF-?B inhibition alleviates carbon tetrachloride-induced liver fibrosis via suppression of activated hepatic stellate cells.
Thymoquinone attenuates liver fibrosis via PI3K and TLR4 signaling pathways in activated hepatic stellate cells.
Liver Cirrhosis, Biliary
Emerging views of mitophagy in immunity and autoimmune diseases.
Liver Diseases
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease.
Impaired activation of phosphatidylinositol 3-kinase by leptin is a novel mechanism of hepatic leptin resistance in NAFLD.
Met signals hepatocyte survival by preventing Fas-triggered FLIP degradation in a PI3k-Akt-dependent manner.
Mice Carrying a Dominant-Negative Human PI3K Mutation Are Protected From Obesity and Hepatic Steatosis but Not Diabetes.
PIK3R3 regulates PPAR? expression to stimulate fatty acid ?-oxidation and decrease hepatosteatosis.
Taurocholic acid feeding prevents tumor necrosis factor-alpha-induced damage of cholangiocytes by a PI3K-mediated pathway.
The ménage à trois of autophagy, lipid droplets and liver disease.
Liver Neoplasms
A combination of Citrus reticulata peel and black tea inhibits migration and invasion of liver cancer via PI3K/AKT and MMPs signaling pathway.
A phosphorylation switch controls the spatiotemporal activation of Rho GTPases in directional cell migration.
Anesthetic effects of isoflurane and the molecular mechanism underlying isoflurane?inhibited aggressiveness of hepatic carcinoma.
Bergapten inhibits liver carcinogenesis by modulating LXR/PI3K/Akt and IDOL/LDLR pathways.
Circ_0000105 promotes liver cancer by regulating miR-498/PIK3R1.
Dynamic interplay of two molecular switches enabled by the MEK1/2-ERK1/2 and IL-6-STAT3 signaling axes controls epithelial cell migration in response to growth factors.
Gomisin N Exerts Anti-liver Cancer Effects and Regulates PI3K-Akt and mTOR-ULK1 Pathways in Vitro.
Inhibition of PI3K/Akt and ERK signaling decreases visfatin-induced invasion in liver cancer cells.
LY?294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF?1? pathway.
MicroRNA-26b inhibits the tumor growth of human liver cancer through the PI3K/Akt and NF-?B/MMP-9/VEGF pathways.
Oncogenic potential of retinoic acid receptor-gamma in hepatocellular carcinoma.
Phthalimide conjugations for the degradation of oncogenic PI3K.
PIK3C3 regulates the expansion of liver CSCs and PIK3C3 inhibition counteracts liver cancer stem cell activity induced by PI3K inhibitor.
PIK3IP1, a negative regulator of PI3K, suppresses the development of hepatocellular carcinoma.
Sedanolide induces autophagy through the PI3K, p53 and NF-?B signaling pathways in human liver cancer cells.
Selective and potent small-molecule inhibitors of PI3Ks.
Signal transduction pathway mutations in gastrointestinal (GI) cancers: a systematic review and meta-analysis.
Sorafenib inhibits liver cancer growth by decreasing mTOR, AKT, and PI3K expression.
Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma.
The Orphan Nuclear Receptor Gene NR0B2 Is a Favorite Prognosis Factor Modulated by Multiple Cellular Signal Pathways in Human Liver Cancers.
Upregulation of EPS8L3 is associated with tumorigenesis and poor prognosis in patients with liver cancer.
[Integrin ?5 silencing inhibits proliferation, invasion and metastasis of human liver cancer Bel-7404 cells in vitro].
Liver Neoplasms, Experimental
Increased activity and nuclear localisation of inositol lipid signal transduction enzymes in rat hepatoma cells.
Lordosis
Participation of growth factor signal transduction pathways in estradiol facilitation of female reproductive behavior.
Lung Diseases
Dual Targeting of MEK and PI3K Pathways Attenuates Established and Progressive Pulmonary Fibrosis.
Genetic Deletion and Pharmacological Inhibition of PI3K ? Reduces Neutrophilic Airway Inflammation and Lung Damage in Mice with Cystic Fibrosis-Like Lung Disease.
MicroRNA-10a controls airway smooth muscle cell proliferation via direct targeting of the PI3 kinase pathway.
Lung Injury
?-Opioid receptor signalling via PI3K/Akt pathway ameliorates lipopolysaccharide-induced acute respiratory distress syndrome.
Anti-malarial drug artesunate protects against cigarette smoke-induced lung injury in mice.
Dexmedetomidine Ameliorates Post-CPB Lung Injury in Rats by Activating the PI3K/Akt Pathway.
Effects of phosphoinositide 3-kinase in protease-induced acute and chronic lung inflammation, remodeling and emphysema in rats.
Expression of phosphatidylinositol-3 kinase and effects of inhibitor Wortmannin on expression of tumor necrosis factor-? in severe acute pancreatitis associated with acute lung injury.
Regulation of phosphatidylinositol 3-kinase by polyisoprenyl phosphates in neutrophil-mediated tissue injury.
Lung Neoplasms
A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
A novel imidazopyridine PI3K inhibitor with anticancer activity in non-small cell lung cancer cells.
A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor.
A peptide that inhibits function of Myristoylated Alanine-Rich C Kinase Substrate (MARCKS) reduces lung cancer metastasis.
A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer.
AC-93253 iodide, a novel Src inhibitor, suppresses NSCLC progression by modulating multiple Src-related signaling pathways.
Aclidinium Bromide holds promising inhibitory effects in A549 lung cancer cells potentials by regulating PI3K / AKT signaling pathway.
Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer.
Adaptive resistance to targeted therapies in cancer.
Airway Microbiota Is Associated with Up-Regulation of the PI3K Pathway in Lung Cancer.
Airway PI3K pathway activation is an early and reversible event in lung cancer development.
Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations.
All-Trans Retinoic Acid Induces Proliferation, Survival, and Migration in A549 Lung Cancer Cells by Activating the ERK Signaling Pathway through a Transcription-Independent Mechanism.
Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung.
Analysis of the Protein-Protein Interaction Network Identifying c-Met as a Target of Gigantol in the Suppression of Lung Cancer Metastasis.
Andrographolide down-regulates hypoxia-inducible factor-1? in human non-small cell lung cancer A549 cells.
Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor.
Assessment of FGFR1 Over-Expression and Over-Activity in Lung Cancer Cells: A Toolkit for Anti-FGFR1 Drug Screening.
BENC-511, a novel PI3K inhibitor, suppresses metastasis of non-small cell lung cancer cells by modulating ?-catenin/ZEB1 regulatory loop.
Blockage of Stat3 enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition.
Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis.
Blocking the PI3K pathway enhances the efficacy of ALK-targeted therapy in EML4-ALK-positive nonsmall-cell lung cancer.
Bone morphogenetic protein-2-induced transformation involves the activation of mammalian target of rapamycin.
CCL5 increases lung cancer migration via PI3K, Akt and NF-kappaB pathways.
Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions.
Characteristics of the PI3K/AKT and MAPK/ERK pathways involved in the maintenance of self-renewal in lung cancer stem-like cells.
cIAP2 Upregulated by E6 Oncoprotein via Epidermal Growth Factor Receptor/Phosphatidylinositol 3-Kinase/AKT Pathway Confers Resistance to Cisplatin in Human Papillomavirus 16/18-Infected Lung Cancer.
Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation.
Clinical Validation of Coexisting Activating Mutations Within EGFR, Mitogen-Activated Protein Kinase, and Phosphatidylinositol 3-Kinase Pathways in Lung Cancers.
Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Codrug Approach for the Potential Treatment of EML4-ALK Positive Lung Cancer.
Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
Comparison of EGFR Signaling Pathway Somatic DNA Mutations Derived From Peripheral Blood and Corresponding Tumor Tissue of Patients with Advanced Non-Small-Cell Lung Cancer Using Liquidchip Technology.
Computational master-regulator search reveals mTOR and PI3K pathways responsible for low sensitivity of NCI-H292 and A427 lung cancer cell lines to cytotoxic action of p53 activator Nutlin-3.
Coordinate direct input of both KRAS and IGF1 receptor to activation of PI 3-kinase in KRAS mutant lung cancer.
Coumarin Derivatives as Anticancer Agents for Lung Cancer Therapy: A Review.
Curcumin inhibited HGF-induced EMT and angiogenesis through regulating c-Met dependent PI3K/Akt/mTOR signaling pathways in lung cancer.
DEPENDENCE ON THE MUC1-C ONCOPROTEIN IN NON-SMALL CELL LUNG CANCER CELLS WITH EGFR AND K-RAS MUTATIONS.
Development and characterisation of a panel of phosphatidylinositide 3-kinase - mammalian target of rapamycin inhibitor resistant lung cancer cell lines.
Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer.
Diprophylline inhibits non-small cell lung cancer A549 cell proliferation and migration, and promotes apoptosis, by downregulating PI3K signaling pathway.
Diverse prognostic roles of Akt isoforms, PTEN and PI3K in tumor epithelial cells and stromal compartment in non-small cell lung cancer.
DIXDC1 activates the Wnt signaling pathway and promotes gastric cancer cell invasion and metastasis.
Dual targeting of PI3K and MEK enhances the radiation response of K-RAS mutated non-small cell lung cancer.
Econazole nitrate inhibits PI3K activity and promotes apoptosis in lung cancer cells.
Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
Effects of direct current electric fields on lung cancer cell electrotaxis in a PMMA-based microfluidic device.
Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS mutant lung cancers.
FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling.
Fibroblast activation protein-? promotes the growth and migration of lung cancer cells via the PI3K and sonic hedgehog pathways.
Fibronectin enhances viability and alters cytoskeletal functions (with effects on the phosphatidylinositol 3-kinase pathway) in small cell lung cancer.
Five genes may predict metastasis in non-small cell lung cancer using bioinformatics analysis.
FOXO3a mediates the cytotoxic effects of cisplatin in lung cancer cells.
Gefitinib-Resistance Is Related to BIM Expression in Non-Small Cell Lung Cancer Cell Lines.
Genome-wide cDNA microarray screening of genes related to survival in patients after curative resection of non-small cell lung cancer.
Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway.
HS-173, a selective PI3K inhibitor, induces cell death in head and neck squamous cell carcinoma cell lines.
Identification of a subset of human non-small cell lung cancer patients with high PI3K? and low PTEN expression, more prevalent in squamous cell carcinoma.
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer.
ING5 knockdown enhances migration and invasion of lung cancer cells by inducing EMT via EGFR/PI3K/Akt and IL-6/STAT3 signaling pathways.
Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms.
Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-actiated protein kinase (MAPK) and phosphatidylinositol-3- kinase (PI3K)/AKT pathways.
Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy.
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.
Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer.
Insulin Receptor Substrate Regulation of Phosphoinositol-3 Kinase.
Ionizing radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-DNA binding and by modulating Ku86 expression via a p38 kinase-dependent mechanism.
Killing tumors by keeping ras and PI3' kinase apart.
Loss of RhoB expression promotes migration and invasion of human bronchial cells via activation of AKT1.
MicroRNA-217 alleviates development of non-small cell lung cancer by inhibiting AKT3 via PI3K pathway.
MicroRNA-7-regulated TLR9 signaling-enhanced growth and metastatic potential of human lung cancer cells by altering the phosphoinositide-3-kinase, regulatory subunit 3/Akt pathway.
miR-212-5p exerts tumor promoter function by regulating the Id3/PI3K/Akt axis in lung adenocarcinoma cells.
MiR-503 targets PI3K p85 and IKK-? and suppresses progression of non-small cell lung cancer.
Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NF kappa B-dependent pathway.
MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells.
Molecular biology of lung cancer.
Molybdenum disulfide-based hyaluronic acid-guided multifunctional theranostic nanoplatform for magnetic resonance imaging and synergetic chemo-photothermal therapy.
Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.
Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases.
Notch signaling: a hero or villain in the war against cancer?
Oncogenic KRAS signaling and YAP1/?-catenin: Similar cell cycle control in tumor initiation.
Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway.
Overexpression of ATP-Binding Cassette Subfamily G Member 2 Confers Resistance to Phosphatidylinositol 3-Kinase Inhibitor PF-4989216 in Cancer Cells.
Overexpression of phosphatidylinositol 3-kinase in human lung cancer.
Overexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivation.
Paclitaxel increases the sensitivity of lung cancer cells to lobaplatin via PI3K/Akt pathway.
PAQR3 suppresses the growth of non-small cell lung cancer cells via modulation of EGFR-mediated autophagy.
Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer.
Phosphatidylinositol 3-kinase could be a promising target in lung cancer therapy.
Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer.
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer.
PI3K expression predicts overall survival in lung adenocarcinoma.
PI3K Inhibition Augments the Therapeutic Efficacy of a 3a-aza-Cyclopenta[?]indene Derivative in Lung Cancer Cells.
PI3K inhibition sensitizes EGFR wild-type NSCLC cell lines to erlotinib chemotherapy.
PI3K Pathway in NSCLC.
PI3K: A Crucial Piece in the RAS Signaling Puzzle.
PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
Potential mechanism of interleukin-8 production from lung cancer cells: An involvement of EGF-EGFR-PI3K-Atk-Erk pathway.
Production of CCL20 from lung cancer cells induces the cell migration and proliferation through PI3K pathway.
Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Regulation of angiogenic factors by the PI3K/Akt pathway in A549 lung cancer cells under hypoxic conditions.
Regulatory roles of OASL in lung cancer cell sensitivity to Actinidia chinensis Planch root extract (acRoots).
Regulatory roles of osteopontin in human lung cancer cell epithelial-to-mesenchymal transitions and responses.
Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
Retraction: Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216.
Reversal of cisplatin resistance by inhibiting PI3K/Akt signal pathway in human lung cancer cells.
Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways.
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.
Schwann cells augment cell spreading and metastasis of lung cancer.
Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLC.
Signaling Networks Associated with AKT Activation in Non-Small Cell Lung Cancer (NSCLC): New Insights on the Role of Phosphatydil-Inositol-3 kinase.
Simultaneous blockade of AP-1 and phosphatidylinositol 3-kinase pathway in non-small cell lung cancer cells.
SPP1 overexpression is associated with poor outcomes in ALK fusion lung cancer patients without receiving targeted therapy.
SRSF1 inhibits autophagy through regulating Bcl-x splicing and interacting with PIK3C3 in lung cancer.
Study of EGCG induced apoptosis in lung cancer cells by inhibiting PI3K/Akt signaling pathway.
Sulindac compounds facilitate the cytotoxicity of ?-lapachone by up-regulation of NAD(P)H quinone oxidoreductase in human lung cancer cells.
Survival and prognosis analyses of concurrent PIK3CA mutations in EGFR mutant non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Synergistic antitumor effect of dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with cisplatin on drug-resistant non-small cell lung cancer cell.
Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment.
Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinoma.
Targeting phosphoinositide 3-kinase signalling in lung cancer.
Targeting RAS and PI3K in lung cancer.
Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.
Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma.
Targeting the effector domain of the myristoylated alanine rich C-kinase substrate enhances lung cancer radiation sensitivity.
Targeting the phosphoinositide 3-kinase p110-? isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer.
The anti-tumor effect of taxifolin on lung cancer via suppressing stemness and epithelial-mesenchymal transition in vitro and oncogenesis in nude mice.
The antipsychotic agent flupentixol is a new PI3K inhibitor and potential anticancer drug for lung cancer.
The Biological Role of PI3K Pathway in Lung Cancer.
The deubiquitylase Ataxin-3 restricts PTEN transcription in lung cancer cells.
The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.
The influence of circular RNAs on autophagy and disease progression.
The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.
The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling.
The omega-3 polyunsaturated fatty acid docosahexaenoic acid inhibits proliferation and progression of non-small cell lung cancer cells through the reactive oxygen species-mediated inactivation of the PI3K /Akt pathway.
The outstanding role of miR-132-3p in carcinogenesis of solid tumors.
The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis.
The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging.
The PI3K subunits, P110? and P110? are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.
The synergistic antitumour effect of multi-components from Pulsatilla chinensis saponins in NCI-H460 lung cancer cell line through induction of apoptosis.
Therapeutic efficacy of hydrogen?rich saline alone and in combination with PI3K inhibitor in non?small cell lung cancer.
Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer.
TRIM59 regulates autophagy through modulating both the transcription and the ubiquitination of BECN1.
Tumours with PI3K activation are resistant to dietary restriction.
VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway.
Volatile Inhibitors of Phosphatidylinositol-3-Kinase (PI3K) Pathway: Anticancer Potential of Aroma Compounds of Plant Essential Oils.
VPS34 suppression reverses osimertinib resistance via simultaneously inhibiting glycolysis and autophagy.
W941, a new PI3K inhibitor, exhibits preferable anti-proliferative activities against nonsmall cell lung cancer with autophagy inhibitors.
Wortmannin inhibits growth of human non-small-cell lung cancer in vitro and in vivo.
ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism.
[Clinical Significance and Mechanism of PI3K p110? Overexpression? in Non-small Cell Lung Cancer].
[Clinicopathological Research and Expression of PTEN/PI3K/Akt Signaling Pathway in Non-small Cell Lung Cancer.]
[Effects of combined therapy of Phosphatidylinositol 3p-Kinase and Paclitaxel in human lung cancer nude mice model.]
[Enhanced growth inhibition by combined two pathway inhibitors on K-ras mutated non-small cell lung cancer cells].
[Growth inhibition of combined pathway inhibitors on KRAS mutated non-small cell lung cancer cell line].
[The Relationship between the PI3K/Akt/mTOR Signal Transduction Pathway and Non-small Cell Lung Cancer.]
Lupus Erythematosus, Cutaneous
Upcoming therapeutic targets in cutaneous lupus erythematous.
Lupus Erythematosus, Systemic
Autophagy: a potential key contributor to the therapeutic action of mesenchymal stem cells.
Emerging views of mitophagy in immunity and autoimmune diseases.
Neutralizing interferon-? blocks inflammation-mediated vascular injury via PI3K and AMPK in systemic lupus erythematosus.
Promoter variant of PIK3C3 is associated with autoimmunity against Ro and Sm epitopes in African-American lupus patients.
[Abnormal signaling activity of phosphatidylinositol 3-kinase pathway in peripheral blood T cells from patients with systemic lupus erythematosus]
Lymphadenitis
Role of Host Type IA Phosphoinositide 3-Kinase Pathway Components in Invasin-Mediated Internalization of Yersinia enterocolitica.
Lymphadenopathy
A mutation in PIK3CD gene causing pediatric systemic lupus erythematosus: A case report.
Case Study: Mechanism for Increased Follicular Helper T Cell Development in Activated PI3K Delta Syndrome.
Early diagnosis of PI3K? syndrome in a 2 years old girl with recurrent otitis and enlarged spleen.
Genetic Defects in Phosphoinositide 3-Kinase ? Influence CD8+ T Cell Survival, Differentiation, and Function.
Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K.
Infections in activated PI3K delta syndrome (APDS).
Mutations in PIK3CD Can Cause Hyper IgM Syndrome (HIGM) Associated with Increased Cancer Susceptibility.
Lymphatic Diseases
Evidence for SH2 domain-containing 5'-inositol phosphatase-2 (SHIP2) contributing to a lymphatic dysfunction.
Lymphatic Metastasis
Acquisition of lymph node, but not distant metastatic potentials, by the overexpression of CXCR4 in human oral squamous cell carcinoma.
Analysis of molecular markers as predictive factors of lymph node involvement in breast carcinoma.
Clinical value of CagA, c-Met, PI3K and Beclin-1 expressed in gastric cancer and their association with prognosis.
Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk.
Inhibition of phosphoinositide 3-kinase/Akt pathway decreases hypoxia inducible factor-1? expression and increases therapeutic efficacy of paclitaxel in human hypoxic gastric cancer cells.
MicroRNA-21 promotes cell proliferation, migration, and resistance to apoptosis through PTEN/PI3K/AKT signaling pathway in esophageal cancer.
PI3K Overexpression and PIK3CA Mutations Are Associated with Age, Tumor Staging, and Other Clinical Characteristics in Chinese Patients with Esophageal Squamous Cell Carcinoma.
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
The expression and clinical significance of PI3K, pAkt and VEGF in colon cancer.
The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance.
[Expression and significance of Ki-67, PI3K and Beclin1 in oral squamous cell carcinoma].
Lymphohistiocytosis, Hemophagocytic
Hemophagocytic Lymphohistiocytosis in Activated PI3K Delta Syndrome: an Illustrative Case Report.
Lymphoma
A mutation in PIK3CD gene causing pediatric systemic lupus erythematosus: A case report.
A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial.
Analyzing synergistic and non-synergistic interactions in signalling pathways using Boolean Nested Effect Models.
Anticancer effect of resibufogenin on gastric carcinoma cells through the phosphoinositide 3-kinase/protein kinase B/glycogen synthase kinase 3? signaling pathway.
Antiglioma Potential of Coumarins Combined with Sorafenib.
Antitumor effects of duvelisib on Epstein-Barr virus-associated lymphoma cells.
Assessment of somatic mutations in phosphatidylinositol 3-kinase gene in human lymphoma and acute leukaemia.
Azole antifungals and new targeted therapies for hematological malignancy.
BET Inhibition-Induced GSK3? Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors.
BRD4 inhibition sensitizes aggressive non-Hodgkin lymphomas to PI3K? inhibitors by suppressing PI3K reactivation and c-MYC expression.
Carcinoma-Associated Fibroblasts Promote Growth of Sox2-Expressing Breast Cancer Cells.
CD40-triggered protein tyrosine phosphorylation on Vav and on phosphatidylinositol 3-kinase correlates with survival of the Ramos-Burkitt lymphoma B cell line.
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Class IA PI3K inhibition inhibits cell growth and proliferation in mantle cell lymphoma.
Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment.
Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in pre-clinical models of aggressive lymphomas.
Comparative RNA-Seq and microarray analysis of gene expression changes in B-cell lymphomas of Canis familiaris.
Concurrent inhibition of PI3-Kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1.
Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
Context-specific BAFF-R signaling by the NF-?B and PI3K pathways.
Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives.
Copanlisib in the treatment of non-Hodgkin lymphoma.
Copanlisib Produces Prolonged Responses in Lymphoma.
Copanlisib: Novel PI3K Inhibitor for Treatment of Lymphoma.
Correction: Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma.
CpG oligodeoxynucleotide 5mer-induced apoptosis in MOLT-4 leukaemia cells does not require caspase 3 or new protein synthesis.
Diosmetin inhibits cell proliferation and induces apoptosis by regulating autophagy via the mammalian target of rapamycin pathway in hepatocellular carcinoma HepG2 cells.
Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hematological malignancies.
Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma.
Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas.
Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.
Early diagnosis of PI3K? syndrome in a 2 years old girl with recurrent otitis and enlarged spleen.
Effects of AS2541019, a novel selective PI3K? inhibitor, on antibody production and hamster to rat xenotransplantation.
Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies.
Epstein-Barr Virus Latent Membrane Protein 1 Regulates Host B Cell MicroRNA-155 and Its Target FOXO3a via PI3K p110? Activation.
ER? targets ZAK and attenuates cellular hypertrophy via SUMO-1 modification in H9c2 cells.
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.
Formaldehyde induces the apoptosis of BMCs of BALB/c mice via the PTEN/PI3K/Akt signal transduction pathway.
Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma.
GCN5 regulates the activation of PI3K/Akt survival pathway in B cells exposed to oxidative stress via controlling gene expressions of Syk and Btk.
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.
Genetic landscape and deregulated pathways in B-cell lymphoid malignancies.
Ibrutinib inhibits CD20 up-regulation on CLL B cells mediated by the CXCR4/SDF-1 axis.
Idelalisib impairs TREM-1 mediated neutrophil inflammatory responses.
Improved synergistic anticancer efficacy of quercetin in combination with PI-103, rottlerin, and G0 6983 against MCF-7 and RAW 264.7 cells.
Incorporating Novel Targeted and Immunotherapeutic Agents in Treatment of B-Cell Lymphomas.
Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo.
Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3K? inhibition through PIK3IP1.
Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies.
Insights into the structural specificity of the cytotoxicity of 3-deoxyphosphatidylinositols.
Integrin CD11b attenuates colitis by strengthening Src-Akt pathway to polarize anti-inflammatory IL-10 expression.
Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.
Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies.
Jak kinase activity is required for lymphoma invasion and metastasis.
Kinetic modeling of hyperpolarized 13C label exchange between pyruvate and lactate in tumor cells.
Ligation of CD40 receptor in human B lymphocytes triggers the 5-lipoxygenase pathway to produce reactive oxygen species and activate p38 MAPK.
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
LY294002-mediated inhibition of phosphatidylinositol 3-kinase activity triggers growth inhibition and apoptosis in CD40-triggered Ramos-Burkitt lymphoma B cells.
Mammalian target of rapamycin as a target in hematological malignancies.
MCL1 Gene Silencing Promotes Senescence and Apoptosis of Glioma Cells via Inhibition of the PI3K/Akt Signaling Pathway.
Membrane Ig cross-linking regulates phosphatidylinositol 3-kinase in B lymphocytes.
Membrane-associated signaling in human B-lymphoma lines.
Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells.
MicroRNA-150 enhances radiosensitivity by inhibiting the AKT pathway in NK/T cell lymphoma.
MicroRNA-17?92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways.
microRNA-212-induced protection of the heart against myocardial infarction occurs via the interplay between AQP9 and PI3K/Akt signaling pathway.
Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy.
Mutations in PIK3CD Can Cause Hyper IgM Syndrome (HIGM) Associated with Increased Cancer Susceptibility.
MYC deregulation in lymphoid tumors: molecular mechanisms, clinical consequences and therapeutic implications.
Novel Agents in the Treatment of Chronic Lymphocytic Leukemia: A Review About the Future.
Novel targeted therapies of T cell lymphomas.
Nuclear FOXO1 promotes lymphomagenesis in germinal center B cells.
On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors.
Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas.
p110? Contributes to p110? Inhibitor Resistance.
P110?-mediated constitutive PI3K signaling limits the efficacy of p110?-selective inhibition in mantle cell lymphoma, particularly with multiple relapse.
PAK1 Mediates Resistance to PI3K Inhibition in Lymphomas.
Pan-class I  PI3-kinase inhibitor BKM120 induces MEK1/2-dependent mitotic catastrophe in non-Hodgkin lymphoma leading to apoptosis or polyploidy determined by Bax/Bak and p53.
Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase ? Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy.
Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma.
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
Phosphatidylinositol-3-kinase activity is required for the anti-ig-mediated growth inhibition of a human B-lymphoma cell line.
Phosphoinositide 3-kinase: diverse roles in immune cell activation.
PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma.
PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL).
PI3K signaling pathway in normal B cells and indolent B-cell malignancies.
PI3K/Akt is involved in bufalin-induced apoptosis in gastric cancer cells.
PI3K?-selective and PI3K?/?-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K ?/? in relapsed refractory B cell lymphoma.
Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors.
Preliminary results of a phase II study of single agent Bay 80-6946, a Novel PI3K inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma.
Primary malignant lymphoma of the brain: analysis of MMAC1 (PTEN) tumor suppressor gene.
Prolactin activates mammalian target-of-rapamycin through phosphatidylinositol 3-kinase and stimulates phosphorylation of p70S6K and 4E-binding protein-1 in lymphoma cells.
PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma.
Putative Roles for PI3K ? and ? Isoforms in Refractory Mantle Cell Lymphoma.
Quantitative MRI establishes the efficacy of PI3K inhibitor (GDC-0941) multi-treatments in PTEN-deficient mice lymphoma.
Quercetin Regresses Dalton's Lymphoma Growth via Suppression of PI3K/AKT Signaling Leading to Upregulation of p53 and Decrease in Energy Metabolism.
Regulation of glucose uptake in lymphoma cell lines by c-MYC- and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability.
Regulation of phosphoinositide 3-kinase signaling by oxidants: hydrogen peroxide selectively enhances immunoreceptor-induced recruitment of phosphatidylinositol (3,4) bisphosphate-binding PH domain proteins.
Regulation of T-cell responses by PTEN.
Role of dephosphorylation of FOXO1 on apoptosis induced by wortmannin for non-Hodgkin's lymphoma cells.
Role of phosphatidylinositol 3-kinase in anti-IgM- and anti-IgD-induced apoptosis in B cell lymphomas.
Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis.
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology.
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Signaling pathways in lymphoma: pathogenesis and therapeutic targets.
Silencing c-Myc translation as a therapeutic strategy through targeting PI3K? and CK1? in hematological malignancies.
Simultaneous pan-PI3K and MEK inhibition as a potential therapeutic strategy in peripheral T cell lymphomas.
Single cell biomass tracking allows identification and isolation of rare targeted therapy-resistant DLBCL cells within a mixed population.
Src Kinase and Syk Activation Initiate PI3K Signaling by a Chimeric Latent Membrane Protein 1 in Epstein-Barr Virus (EBV)+ B Cell Lymphomas.
Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma.
Synergistic suppression of the PI3K inhibitor CAL-101 with bortezomib on mantle cell lymphoma growth.
Targeted therapies for advanced non-small cell lung cancer.
Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A.
Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.
Targeting the B cell receptor pathway in non-Hodgkin lymphoma.
The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax.
The Role of PI3K Inhibition in Lymphoid Malignancies.
The role of PI3K inhibitors in the treatment of malignant lymphomas.
The tumour suppressor FOXO3 is a key regulator of mantle cell lymphoma proliferation and survival.
Therapeutic potential of PI3K signaling in distinct entities of B-cell lymphoma.
Tormentic acid inhibits IL-1?-induced chondrocyte apoptosis by activating the PI3K/Akt signaling pathway.
Truncated ALK derived from chromosomal translocation t(2;5)(p23;q35) binds to the SH3 domain of p85-PI3K.
Uncovering the potential of PI3K inhibitors in cutaneous T cell lymphoma: insights from high throughput in vitro screenings.
[Advances on driver oncogenes of non-small cell lung cancer].
[Study on PI3K inhibitor LY294002 for chemotherapeutic sensitization in diffuse large B cell lymphoma cell lines.]
Lymphoma, B-Cell
A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial.
Absorption, Distribution, and Binding Profile of ME-401, a Potent and Selective Oral Small-Molecule Inhibitor of Phosphatidylinositol 3-Kinase ? (PI3K?) in Animal and B-Cell Lymphoma Models.
Alpinia oxyphylla Miq. fruit extract activates IGFR-PI3K/Akt signaling to induce Schwann cell proliferation and sciatic nerve regeneration.
Annexin A5 inhibits diffuse large B-cell lymphoma cell invasion and chemoresistance through phosphatidylinositol 3-kinase signaling.
Anti-proliferative and apoptosis inducing effect of nimbolide by altering molecules involved in apoptosis and IGF signalling via PI3K/Akt in prostate cancer (PC-3) cell line.
Anwulignan Ameliorates the Intestinal Ischemia/Reperfusion.
Apatinib suppresses the Proliferation and Apoptosis of Gastric Cancer Cells via the PI3K/Akt Signaling Pathway.
AXIN1 protects against testicular germ cell tumors via the PI3K/AKT/mTOR signaling pathway.
BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma.
BET Inhibition-Induced GSK3? Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors.
Blockade of Emodin on Amyloid-? 25-35-Induced Neurotoxicity in A?PP/PS1 Mice and PC12 Cells through Activation of the Class III Phosphatidylinositol 3-Kinase/Beclin-1/B-Cell Lymphoma 2 Pathway.
CB2R induces a protective response for epileptic seizure via the PI3K 110?-AKT signaling pathway.
Cinobufagin Induces Cell Cycle Arrest at the G2/M Phase and Promotes Apoptosis in Malignant Melanoma Cells.
Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in pre-clinical models of aggressive lymphomas.
Comparative RNA-Seq and microarray analysis of gene expression changes in B-cell lymphomas of Canis familiaris.
Concurrent inhibition of PI3-Kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1.
Context-specific BAFF-R signaling by the NF-?B and PI3K pathways.
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells.
Current Treatment of Refractory/Relapsed Chronic Lymphocytic Leukemia: A Focus on Novel Drugs.
Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.
Effect of Huaier on the proliferation and apoptosis of human gastric cancer cells through modulation of the PI3K/AKT signaling pathway.
Effects of AS2541019, a novel selective PI3K? inhibitor, on antibody production and hamster to rat xenotransplantation.
EGFR and PI3K Pathway Activities Might Guide Drug Repurposing in HPV-Negative Head and Neck Cancers.
Epstein-Barr Virus Latent Membrane Protein 1 Regulates Host B Cell MicroRNA-155 and Its Target FOXO3a via PI3K p110? Activation.
Epstein-Barr virus LMP2A utilizes Syk and PI3K to activate NF-?B in B-cell lymphomas to increase MIP-1? production.
Evaluation of the PIK3 pathway in peripheral T-cell lymphoma and NK/T-cell lymphoma.
Exendin-4 improved rat cortical neuron survival under oxygen/glucose deprivation through PKA pathway.
Expression of glucose transporter-1, hypoxia-inducible factor-1?, phosphatidylinositol 3-kinase and protein kinase B (Akt) in relation to [(18)F]fluorodeoxyglucose uptake in nasopharyngeal diffuse large B-cell lymphoma: a case report and literature review.
Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma.
Fibronectin protected bovine preantral follicles from the deleterious effects of kisspeptin.
Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses.
Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma.
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.
Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C.
HIF-?/PKM2 and PI3K-AKT pathways involved in the protection by dexmedetomidine against isoflurane or bupivacaine-induced apoptosis in hippocampal neuronal HT22 cells.
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
Idelalisib: Targeting the PI3 Kinase Pathway in Non-Hodgkin Lymphoma.
Inhibition of phosphatidylinositol 3-kinase-mediated glucose metabolism coincides with resveratrol-induced cell cycle arrest in human diffuse large B-cell lymphomas.
Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3.
Knockdown of lncRNA-HOTAIR downregulates the drug-resistance of breast cancer cells to doxorubicin via the PI3K/AKT/mTOR signaling pathway.
Lens differentiation is controlled by the balance between PDGF and FGF signaling.
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
MCL1 Gene Silencing Promotes Senescence and Apoptosis of Glioma Cells via Inhibition of the PI3K/Akt Signaling Pathway.
Melatonin mitigates the adverse effect of hypoxia during myocardial differentiation in mouse embryonic stem cells.
microRNA-212-induced protection of the heart against myocardial infarction occurs via the interplay between AQP9 and PI3K/Akt signaling pathway.
NF-kappaB/STAT3/PI3K signaling crosstalk in iMycEmu B lymphoma.
Novel Agents in the Treatment of Chronic Lymphocytic Leukemia: A Review About the Future.
PAK1 Mediates Resistance to PI3K Inhibition in Lymphomas.
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
PI3K-AKT Signaling Activation and Icariin: The Potential Effects on the Perimenopausal Depression-Like Rat Model.
Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K ?/? in relapsed refractory B cell lymphoma.
Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Role of phosphatidylinositol 3-kinase in anti-IgM- and anti-IgD-induced apoptosis in B cell lymphomas.
Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma.
Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies.
Single and combined BTK and PI3K? inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas.
Single cell biomass tracking allows identification and isolation of rare targeted therapy-resistant DLBCL cells within a mixed population.
Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.
Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma.
Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma.
Therapeutic potential of PI3K signaling in distinct entities of B-cell lymphoma.
Treadmill exercise reduces spinal cord injury-induced apoptosis by activating the PI3K/Akt pathway in rats.
Upregulated microRNA-132 rescues cardiac fibrosis and restores cardiocyte proliferation in dilated cardiomyopathy through the phosphatase and tensin homolog-mediated PI3K/Akt signal transduction pathway.
[Effects of 7-difluoromethy-5, 4'-dimethoxygenistein on ?stress urinary incontinence model in rats and its mechanisms].
[Study on PI3K inhibitor LY294002 for chemotherapeutic sensitization in diffuse large B cell lymphoma cell lines.]
Lymphoma, B-Cell, Marginal Zone
CpG oligodeoxynucleotide 5mer-induced apoptosis in MOLT-4 leukaemia cells does not require caspase 3 or new protein synthesis.
Lymphoma, Follicular
An analysis of genetic targets for guiding clinical management of follicular lymphoma.
Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Can Next-Generation PI3K Inhibitors Unlock the Full Potential of the Class in Patients With B-Cell Lymphoma?
Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.
Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic.
Copanlisib: An Intravenous Phosphatidylinositol 3-Kinase (PI3K) Inhibitor for the Treatment of Relapsed Follicular Lymphoma.
Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice.
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.
Idelalisib induces PUMA-dependent apoptosis in colon cancer cells.
Idelalisib-associated Enterocolitis: Clinicopathologic Features and Distinction From Other Enterocolitides.
Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
Identification of Candidate Risk Factor Genes for Human Idelalisib Toxicity Using a Collaborative Cross Approach.
Membrane-associated signaling in human B-lymphoma lines.
Novel Agents Beyond Immunomodulatory Agents and Phosphoinositide-3-Kinase for Follicular Lymphoma.
PI3K Inhibitors: Understanding Toxicity Mechanisms and Management.
PI3K? inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax.
Refining the management of relapsed or refractory follicular lymphoma.
Retrospective Analysis of the Impact of Adverse Event-Triggered Idelalisib Interruption and Dose Reduction on Clinical Outcomes in Patients With Relapsed/Refractory B-Cell Malignancies.
The PI3K p110? Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function.
Lymphoma, Large B-Cell, Diffuse
Annexin A5 inhibits diffuse large B-cell lymphoma cell invasion and chemoresistance through phosphatidylinositol 3-kinase signaling.
BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma.
BET Inhibition-Induced GSK3? Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors.
Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in pre-clinical models of aggressive lymphomas.
Concurrent inhibition of PI3-Kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1.
Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells.
Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.
Expression of glucose transporter-1, hypoxia-inducible factor-1?, phosphatidylinositol 3-kinase and protein kinase B (Akt) in relation to [(18)F]fluorodeoxyglucose uptake in nasopharyngeal diffuse large B-cell lymphoma: a case report and literature review.
Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma.
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.
Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3.
Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells.
Single cell biomass tracking allows identification and isolation of rare targeted therapy-resistant DLBCL cells within a mixed population.
Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.
Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma.
[Study on PI3K inhibitor LY294002 for chemotherapeutic sensitization in diffuse large B cell lymphoma cell lines.]
Lymphoma, Large-Cell, Anaplastic
Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis.
Lymphoma, Mantle-Cell
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Class IA PI3K inhibition inhibits cell growth and proliferation in mantle cell lymphoma.
Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in pre-clinical models of aggressive lymphomas.
Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
Correction: Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma.
Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.
p110? Contributes to p110? Inhibitor Resistance.
P110?-mediated constitutive PI3K signaling limits the efficacy of p110?-selective inhibition in mantle cell lymphoma, particularly with multiple relapse.
Putative Roles for PI3K ? and ? Isoforms in Refractory Mantle Cell Lymphoma.
Synergistic suppression of the PI3K inhibitor CAL-101 with bortezomib on mantle cell lymphoma growth.
The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
The tumour suppressor FOXO3 is a key regulator of mantle cell lymphoma proliferation and survival.
Lymphoma, Non-Hodgkin
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma.
Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.
B-cell receptor pathway modulators in NHL.
Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma.
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
Duvelisib, an oral dual PI3K-?, ? inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study.
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.
Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential.
Idelalisib-induced colitis and skin eruption mimicking graft-versus-host disease.
Idelalisib: a rare cause of enterocolitis.
Idelalisib: Targeting the PI3 Kinase Pathway in Non-Hodgkin Lymphoma.
Identification of a potent and selective phosphatidylinositol 3-kinase ? inhibitor for the treatment of non-Hodgkin's lymphoma.
IGF1R as druggable target mediating PI3K-? inhibitor resistance in a murine model of chronic lymphocytic leukemia.
Novel synthetic drugs for the treatment of non-Hodgkin lymphoma.
Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma.
PI3K isoform-selective inhibitors: next-generation targeted cancer therapies.
Puquitinib mesylate, an inhibitor of phosphatidylinositol 3-kinase p110?, for treating relapsed or refractory non-Hodgkin's lymphoma.
Retrospective Analysis of the Impact of Adverse Event-Triggered Idelalisib Interruption and Dose Reduction on Clinical Outcomes in Patients With Relapsed/Refractory B-Cell Malignancies.
Revival of PI3K inhibitors in non-Hodgkin's lymphoma.
Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma.
Lymphoma, T-Cell
GCN5 regulates the activation of PI3K/Akt survival pathway in B cells exposed to oxidative stress via controlling gene expressions of Syk and Btk.
Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K ?/? Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma.
Simultaneous pan-PI3K and MEK inhibition as a potential therapeutic strategy in peripheral T cell lymphomas.
Lymphoma, T-Cell, Cutaneous
Selective inhibition of HDAC6 sensitizes cutaneous T-cell lymphoma to PI3K inhibitors.
Simultaneous pan-PI3K and MEK inhibition as a potential therapeutic strategy in peripheral T cell lymphomas.
Uncovering the potential of PI3K inhibitors in cutaneous T cell lymphoma: insights from high throughput in vitro screenings.
Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma.
Lymphoma, T-Cell, Peripheral
Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: a novel therapeutic strategy.
Lymphopenia
A mutation in PIK3CD gene causing pediatric systemic lupus erythematosus: A case report.
Activated PI3K-delta syndrome in an Egyptian pediatric cohort with primary immune deficiency.
Early diagnosis of PI3K? syndrome in a 2 years old girl with recurrent otitis and enlarged spleen.
Mutations in PIK3CD Can Cause Hyper IgM Syndrome (HIGM) Associated with Increased Cancer Susceptibility.
Lymphoproliferative Disorders
Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo.
Involvement of PI3K in HCV-related lymphoproliferative disorders.
PI3-kinase inhibitors in chronic lymphocytic leukemia.
Macular Degeneration
Activation of type 5 metabotropic glutamate receptor promotes the proliferation of rat retinal progenitor cell via activation of the PI-3-K and MAPK signaling pathways.
Insensitivity of PI3K/Akt/GSK3 signaling in peripheral blood mononuclear cells of age-related macular degeneration patients.
Malaria, Cerebral
Phosphatidylinositol 3-Kinase ? is required for the development of experimental cerebral malaria.
Malnutrition
Impaired insulin secretion and decreased expression of the nutritionally responsive ribosomal kinase protein S6K-1 in pancreatic islets from malnourished rats.
Protein calorie restriction has opposite effects on glucose metabolism and insulin gene expression in fetal and adult rat endocrine pancreas.
Up-regulation of phosphatidylinositol 3-kinase and glucose transporter 4 in muscle of rats subjected to maternal undernutrition.
[Expression of the hepatic insulin signal transduction proteins in the rats with intrauterine growth retardation during the perinatal period.]
Marek Disease
Marek's Disease Virus Activates the PI3K/Akt Pathway Through Interaction of Its Protein Meq With the P85 Subunit of PI3K to Promote Viral Replication.
Marfan Syndrome
LRP1 regulates architecture of the vascular wall by controlling PDGFRbeta-dependent phosphatidylinositol 3-kinase activation.
Mastocytosis
Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade.
PTEN deficiency in mast cells causes a mastocytosis-like proliferative disease that heightens allergic responses and vascular permeability.
Mastocytosis, Systemic
Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis.
Measles
Autophagy induction by the pathogen receptor NECTIN4 and sustained autophagy contribute to peste des petits ruminants virus infectivity.
Medulloblastoma
A Sensitized RNA Interference Screen Identifies a Novel Role for the PI3K p110{gamma} Isoform in Medulloblastoma Cell Proliferation and Chemoresistance.
Apoptosis suppression by somatic cell transfer of Bcl-2 promotes Sonic hedgehog-dependent medulloblastoma formation in mice.
Cancer stem cells and survival pathways.
ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma.
HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma.
Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors.
Inhibition of PI3K Signalling Selectively Affects Medulloblastoma Cancer Stem Cells.
Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.
Modeling medulloblastoma with genetically engineered mice.
mTOR Pathway As a Potential Target In a Subset of Human Medulloblastoma.
Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma.
Phosphatidylinositol 3'-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN.
PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo.
PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibition.
Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.
Targeting HDAC And PI3K Inhibits MYC-Driven Medulloblastoma Growth.
Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration.
The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition.
The FDA approved PI3K inhibitor GDC-0941 enhances in vitro the anti-neoplastic efficacy of Axitinib against c-myc-amplified high-risk medulloblastoma.
The Phosphoinositide 3-Kinase p110? Isoform Regulates Leukemia Inhibitory Factor Receptor Expression via c-Myc and miR-125b to Promote Cell Proliferation in Medulloblastoma.
The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy.
Tumor Growth in the High Frequency Medulloblastoma Mouse Model Ptch1+/-/Tis21KO Has a Specific Activation Signature of the PI3K/AKT/mTOR Pathway and Is Counteracted by the PI3K Inhibitor MEN1611.
Megalencephaly
Identification and Characterization of a Novel Constitutional PIK3CA Mutation in a Child Lacking the Typical Segmental Overgrowth of "PIK3CA-Related Overgrowth Spectrum".
Pten and the brain: sizing up social interaction.
Melanoma
A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma.
A PI3K-Pax3 axis regulates Brn-2 expression in melanoma.
A Tumor Suppressor Function for the Lipid Phosphatase INPP4B in Melanocytic Neoplasms.
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.
Activation of mTORC2 by Association with the Ribosome.
Activation of phosphatidylinositol 3-kinase by a complex of p59fyn and the receptor tyrosine kinase Xmrk is involved in malignant transformation of pigment cells.
Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells.
Active ?-catenin is regulated by the PTEN/PI3 kinase pathway: a role for protein phosphatase PP2A.
Adjuvant treatment of melanoma.
Analysis of Caveolin-1 and Phosphoinositol-3 Kinase expression in primary uveal melanomas.
Anticancer effects of combinational treatment with BRAFV600E siRNA and PI3K pathway inhibitors in melanoma cell lines harboring BRAFV600E.
Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
Autotaxin promotes motility via G protein-coupled phosphoinositide 3-kinase gamma in human melanoma cells.
Berberine suppressed epithelial mesenchymal transition through cross-talk regulation of PI3K/AKT and RAR?/RAR? in melanoma cells.
Bioinformatics-based analysis reveals elevated MFSD12 as a key promoter of cell proliferation and a potential therapeutic target in melanoma.
BRAFV600E Cooperates with PI3K Signaling, Independent of AKT, to Regulate Melanoma Cell Proliferation.
C-Jun drives melanoma progression in PTEN wild type melanoma cells.
C6-ceramide nanoliposome suppresses tumor metastasis by eliciting PI3K and PKC? tumor-suppressive activities and regulating integrin affinity modulation.
Chondroitin Sulfate Proteoglycan-4 Does Not Protect Melanoma Cells During Inhibition of PI3K and mTOR Pathways.
Circular RNA has circ 0001591 promoted cell proliferation and metastasis of human melanoma via ROCK1/PI3K/AKT by targeting miR-431-5p.
Circulating microRNA-194 regulates human melanoma cells via PI3K/AKT/FoxO3a and p53/p21 signaling pathway.
Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment.
Clotrimazole presents anticancer properties against a mouse melanoma model acting as a PI3K inhibitor and inducing repolarization of tumor-associated macrophages.
Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma.
Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ- and GNA11-Dependent Manner.
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.
Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
Concomitant Inhibition of PI3K? and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K?-Selective Inhibitor.
Constitutive Rac Activation Is Not Sufficient to Initiate Melanocyte Neoplasia but Accelerates Malignant Progression.
Contribution of phosphatidylinositol 3-kinase to radiation resistance in human melanoma cells.
Correction: PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.
Cyclin D3 expression in melanoma cells is regulated by adhesion-dependent phosphatidylinositol 3-kinase signaling and contributes to G1-S progression.
Decatenation checkpoint-defective melanomas are dependent on PI3K for survival.
Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in Pten(LoxP/LoxP);Braf(CA/+) Mice.
Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.
Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma.
Dissecting the roles of Raf- and PI3K-signalling pathways in melanoma formation and progression in a zebrafish model.
Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.
Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.
Dual MAPK / PI3K pathway inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS mutant and wild type melanoma.
Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors.
Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.
Embryonic Stem Cells Modulate the Cancer-Permissive Microenvironment of Human Uveal Melanoma.
Emerging views of mitophagy in immunity and autoimmune diseases.
Endothelin signaling axis activates osteopontin expression through PI3 kinase pathway in A375 melanoma cells.
Enhanced chemosensitization of anoikis-resistant melanoma cells through syndecan-2 upregulation upon anchorage independency.
Enhancing the evaluation of PI3K inhibitors through 3D melanoma models.
ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis.
Euphorbia fischeriana Steud inhibits malignant melanoma via modulation of the phosphoinositide-3-kinase/Akt signaling pathway.
Evidence of the involvement of phosphatidylinositol 3-kinase in the migration, actin stress fiber formation, and alpha v beta 3-integrin-mediated adherence of human melanoma cells.
Evodiamine-induced human melanoma A375-S2 cell death was mediated by PI3K/Akt/caspase and Fas-L/NF-kappaB signaling pathways and augmented by ubiquitin-proteasome inhibition.
Firing up the cold tumors by targeting Vps34.
Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanoma.
Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
FMNL2/FMNL3 formins are linked with oncogenic pathways and predict melanoma outcome.
FTY720 and cisplatin synergistically induce the death of cisplatin-resistant melanoma cells through the downregulation of the PI3K pathway and the decrease in epidermal growth factor receptor expression.
G1 phase arrest by the phosphatidylinositol 3-kinase inhibitor LY 294002 is correlated to up-regulation of p27Kip1 and inhibition of G1 CDKs in choroidal melanoma cells.
Genomic and Transcriptomic Analysis Reveals Incremental Disruption of Key Signaling Pathways during Melanoma Evolution.
GM3 suppresses anchorage-independent growth via Rho GDP dissociation inhibitor beta in melanoma B16 cells.
GM3 Upregulation of matrix metalloproteinase-9 possibly through PI3K, AKT, RICTOR, RHOGDI-2, and TNF-A pathways in mouse melanoma B16 cells.
H3K27 Demethylase JMJD3 Employs the NF-?B and BMP Signaling Pathways to Modulate the Tumor Microenvironment and Promote Melanoma Progression and Metastasis.
Harnessing autophagy to overcome mitogen-activated protein kinase kinase inhibitor-induced resistance in metastatic melanoma.
HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma.
Impact of blood-brain barrier integrity on tumor growth and therapy response in brain metastases.
Impact of phosphoinositide-3-kinase and vitamin D3 nuclear receptor single-nucleotide polymorphisms on the outcome of malignant melanoma patients.
In vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways.
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.
Induction of melanogenesis by rapamycin in human MNT-1 melanoma cells.
Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitises melanoma cells to Bortezomib by blocking Akt pathway.
Inhibition of the phosphatidylinositol 3-kinase/p70(S6)-kinase pathway induces B16 melanoma cell differentiation.
Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy.
Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.
Inosine Strongly Enhances Proliferation of Human C32 Melanoma Cells through PLC-PKC-MEK1/2-ERK1/2 and PI3K Pathways.
Interplay between PREX2 mutations and the PI3K pathway and its effect on epigenetic regulation of gene expression in NRAS-mutant melanoma.
Involvement of phospholipase C signaling in melanoma cell-induced endothelial junction disassembly.
Involvement of PI3K and MAPK signaling in bcl-2-induced vascular endothelial growth factor expression in melanoma cells.
Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells.
Knockdown of thrombospondin 2 inhibits metastasis through modulation of PI3K signaling pathway in uveal melanoma cell line M23.
Loss of MiR-664 Expression Enhances Cutaneous Malignant Melanoma Proliferation by Upregulating PLP2.
Loss of PI(4,5)P2 5-Phosphatase A Contributes to Resistance of Human Melanoma Cells to RAF/MEK Inhibitors.
Low Mutational Burden of Eight Genes Involved in the MAPK/ERK, PI3K/AKT, and GNAQ/11 Pathways in Female Genital Tract Primary Melanomas.
Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.
MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21.
Mechanism of miR-137 regulating migration and invasion of melanoma cells by targeting PIK3R3 gene.
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
MEK inhibitors in oncology: a patent review (2015-Present).
Melanoma cell-derived factors stimulate hyaluronan synthesis in dermal fibroblasts by upregulating HAS2 through PDGFR-PI3K-AKT and p38 signaling.
Melanoma stem cell maintenance and chemo-resistance are mediated by CD133 signal to PI3K-dependent pathways.
MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma.
MiR-21: an environmental driver of malignant melanoma?
Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells.
Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy.
Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target.
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases.
Mutations of the KIT gene and loss of heterozygosity of the PTEN region in a primary malignant melanoma arising from a mature cystic teratoma of the ovary.
Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis.
Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma.
Neural cell adhesion molecule potentiates invasion and metastasis of melanoma cells through CAMP-dependent protein kinase and phosphatidylinositol 3-kinase pathways.
Novel Somatic Mutations to PI3K Pathway Genes in Metastatic Melanoma.
Novel targeted therapies for the treatment of metastatic melanoma.
NPS - 2143 (hydrochloride) inhibits melanoma cancer cell proliferation and induces autophagy and apoptosis.
NUAK2 Amplification Coupled with PTEN Deficiency Promotes Melanoma Development via CDK Activation.
Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN.
Overexpression of Akt converts radial growth melanoma to vertical growth melanoma.
Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling.
P-Rex1 directly activates RhoG to regulate GPCR-driven Rac signalling and actin polarity in neutrophils.
p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
Phosphatidylinositol-3-kinase as a therapeutic target in melanoma.
Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions.
Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry.
PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cells.
PI3'-Kinase Inhibition Forestalls the Onset of MEK1/2 Inhibitor Resistance in BRAF-Mutated Melanoma.
PI3K pathway inhibition achieves potent antitumor activity in melanoma brain metastases in vitro and in vivo.
PI3K signalling is required for a TGF?-induced epithelial-mesenchymal-like transition (EMT-like) in human melanoma cells.
PIK3CA-Mutated Melanoma Cells Rely on Cooperative Signaling through mTORC1/2 for Sustained Proliferation.
PLK1 and NOTCH Positively Correlate in Melanoma and Their Combined Inhibition Results in Synergistic Modulations of Key Melanoma Pathways.
Positive Feedback Loop Between PI3K-Akt-mTORC1 Signaling and the Lipogenic Pathway Boosts Akt Signaling: Induction of the Lipogenic Pathway by a Melanoma Antigen.
Protein kinase C-betaII represses hepatocyte growth factor-induced invasion by preventing the association of adapter protein Gab1 and phosphatidylinositol 3-kinase in melanoma cells.
Ral activation promotes melanomagenesis.
Rational targeting of BRAF and PI3-Kinase signaling for melanoma therapy.
Regulation of melanogenesis through phosphatidylinositol 3-kinase-Akt pathway in human G361 melanoma cells.
Resistance to c-Kit inhibitors in melanoma: insights for future therapies.
Resistance to Molecularly Targeted Therapies in Melanoma.
RIAM controls invasion and growth of melanoma cells.
RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanoma.
RMEL3, a novel BRAFV600E-associated long noncoding RNA, is required for MAPK and PI3K signaling in melanoma.
Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.
Selenium-containing histone deacetylase inhibitors for melanoma management.
Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: A rationale to combine targeted drugs based on protein expression inhibition profiles.
Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis.
Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment.
Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity.
Studies of NVP-BEZ235 in Melanoma.
Subcutaneous adipocytes promote melanoma cell growth by activating the Akt signaling pathway: role of palmitic acid.
Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.
Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma.
Targeting BRAF(V600E) in an Inducible Murine Model of Melanoma.
Targeting CDK4/6 in patients with cancer.
Targeting effector pathways in RAC1P29S-driven malignant melanoma.
Targeting Glutamatergic Signaling and the PI3 Kinase Pathway to Halt Melanoma Progression.
Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors.
Targeting Multiple Key Signaling Pathways in Melanoma using Leelamine.
Targeting TBK1 Inhibits Migration and Resistance to MEK Inhibitors in Mutant NRAS Melanoma.
Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.
TBX3 Promotes Melanoma Migration by Transcriptional Activation of ID1, which Prevents Activation of E-Cadherin by MITF.
The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
The Antitumor Effect of Lipophilic Bisphosphonate BPH1222 in Melanoma Models: The Role of the PI3K/Akt Pathway and the Small G Protein Rheb.
The Ashitaba (Angelica keiskei) Chalcones 4-hydroxyderricin and Xanthoangelol Suppress Melanomagenesis By Targeting BRAF and PI3K.
The dual PI3K/mTOR inhibitor (PI-103) promotes immunosupression, in vivo tumor growth and increases survival of sorafenib treated melanoma cells.
The inhibition of invasion of human melanoma cells through N-cadherin knock-down.
The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma.
The molecular pathology of cutaneous melanoma.
The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma.
The mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3.
The novel PI3 kinase inhibitor, BAY 80-6946, impairs melanoma growth in vivo and in vitro.
The phosphatidyl inositol 3-kinase pathway is central to the pathogenesis of Kit-activated melanoma.
The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.
The Small GTPase ARF6 Activates PI3K in Melanoma to Induce a Prometastatic State.
Timp1 Promotes Cell Survival by Activating the PDK1 Signaling Pathway in Melanoma.
Transmigration characteristics of breast cancer and melanoma cells through the brain endothelium: Role of Rac and PI3K.
Transposon mutagenesis identifies genetic drivers of Braf(V600E) melanoma.
Treatment Following Progression in Metastatic Melanoma: the State of the Art from Scientific Literature to Clinical Need.
Treatment of melanoma with selected inhibitors of signaling kinases effectively reduces proliferation and induces expression of cell cycle inhibitors.
Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF.
VEGF Induce Vasculogenic Mimicry of Choroidal Melanoma through the PI3k Signal Pathway.
Vertical Inhibition of the mTORC1/mTORC2/PI3K Pathway Shows Synergistic Effects against Melanoma In Vitro and In Vivo.
Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma.
VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo.
Xmrks the Spot: Fish Models for Investigating Epidermal Growth Factor Receptor Signaling in Cancer Research.
[Molecular background of the melanoma and the brain metastasis].
Memory Disorders
Aluminum-Induced Cognitive Impairment and PI3K/Akt/mTOR Signaling Pathway Involvement in Occupational Aluminum Workers.
Hyperactivity, memory deficit and anxiety-related behaviors in mice lacking the p85alpha subunit of phosphoinositide-3 kinase.
PI3 kinase signaling is involved in Abeta-induced memory loss in Drosophila.
Remifentanil postconditioning improves global cerebral ischemia-induced spatial learning and memory deficit in rats via inhibition of neuronal apoptosis through the PI3K signaling pathway.
Wortmannin Attenuates Seizure-Induced Hyperactive PI3K/Akt/mTOR Signaling, Impaired Memory, and Spine Dysmorphology in Rats.
Meningioma
Associations of meningioma molecular subgroup and tumor recurrence.
Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development.
Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas.
Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas.
EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas.
Evidence for phosphatidylinositol 3-kinase-Akt-p7S6K pathway activation and transduction of mitogenic signals by platelet-derived growth factor in meningioma cells.
Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis.
The spatial phenotype of genotypically distinct meningiomas demonstrate potential implications of the embryology of the meninges.
Meningitis
Escherichia coli K-1 interaction with human brain micro-vascular endothelial cells triggers phospholipase C-gamma1 activation downstream of phosphatidylinositol 3-kinase.
Restoration of Akt activity by the bisperoxovanadium compound bpV(pic) attenuates hippocampal apoptosis in experimental neonatal pneumococcal meningitis.
Meningitis, Bacterial
Inhibition of meningitis-associated neutrophil apoptosis by TNF-? depends on functional PI3-kinase in monocytes.
Mesothelioma
Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma.
Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo.
Mitochondrial ROS Induce Partial Dedifferentiation of Human Mesothelioma via Upregulation of NANOG.
Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
PI3K/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy.
Suppression of pro-metastasis phenotypes expression in malignant pleural mesothelioma by the PI3K inhibitor LY294002 or the MEK inhibitor UO126.
Mesothelioma, Malignant
A novel combination: ranpirnase and rosiglitazone induce a synergistic apoptotic effect by down-regulating Fra-1 and Survivin in cancer cells.
Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo.
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
PI3K/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy.
Suppression of pro-metastasis phenotypes expression in malignant pleural mesothelioma by the PI3K inhibitor LY294002 or the MEK inhibitor UO126.
Metabolic Diseases
Endometrial Cancer as a Metabolic Disease with Dysregulated PI3K Signaling: Shedding Light on Novel Therapeutic Strategies.
Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets.
PI-3-K and AKT: Onto the mitochondria.
PI3K signaling in the pathogenesis of obesity: The cause and the cure.
The PI3K pathway preserves metabolic health through MARCO-dependent lipid uptake by adipose tissue macrophages.
Metabolic Syndrome
Differential Phosphoinositide 3-Kinase Signaling: Implications for PTCA?
Insulin resistance uncoupled from dyslipidemia due to C-terminal PIK3R1 mutations.
Metabolic effects of RUBCN/Rubicon deficiency in kidney proximal tubular epithelial cells.
Pharmacological inhibition of PI3K reduces adiposity and metabolic syndrome in obese mice and rhesus monkeys.
Phosphatidylinositol-3-kinase regulates scavenger receptor class B type I subcellular localization and selective lipid uptake in hepatocytes.
Roles for PI3K/AKT/PTEN Pathway in Cell Signaling of Nonalcoholic Fatty Liver Disease.
The Chinese herbal medicine FTZ attenuates insulin resistance via IRS1 and PI3K in vitro and in rats with metabolic syndrome.
Microcephaly
Deletion of PDK1 in oligodendrocyte lineage cells causes white matter abnormality and myelination defect in the central nervous system.
Mouth Diseases
Poliovirus induces autophagic signaling independent of the ULK1 complex.
Mouth Neoplasms
CTGF inhibits cell motility and COX-2 expression in oral cancer cells.
Detection of two novel mutations and relatively high incidence of H-RAS mutations in Vietnamese oral cancer.
Evaluating the role of microRNAs alterations in oral squamous cell carcinoma.
Genetic deregulation of the PIK3CA oncogene in oral cancer.
Is there a pAkt between VEGF and oral cancer cell migration?
Kalopanaxsaponin a inhibits the invasion of human oral squamous cell carcinoma by reducing metalloproteinase-9 mRNA stability and protein trafficking.
Nimbolide, a neem limonoid inhibits cytoprotective autophagy to activate apoptosis via modulation of the PI3K/Akt/GSK-3? signalling pathway in oral cancer.
Nimbolide, a neem limonoid inhibits Phosphatidyl Inositol-3 Kinase to activate Glycogen Synthase Kinase-3? in a hamster model of oral oncogenesis.
Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cells.
The novel pterostilbene derivative ANK-199 induces autophagic cell death through regulating PI3 kinase class III/beclin 1/Atg?related proteins in cisplatin?resistant CAR human oral cancer cells.
Multiple Endocrine Neoplasia
Biochemical and biological responses induced by coupling of Gab1 to phosphatidylinositol 3-kinase in RET-expressing cells.
UPDATE ON THE CLINICOPATHOLOGY OF PITUITARY ADENOMAS.
Multiple Endocrine Neoplasia Type 2a
Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation.
Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway.
Multiple Endocrine Neoplasia Type 2b
Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation.
Multiple Myeloma
A Cross-Species Study of PI3K Protein-Protein Interactions Reveals the Direct Interaction of P85 and SHP2.
A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma.
A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo.
A virtual screen identified C96 as a novel inhibitor of phosphatidylinositol 3-kinase that displays potent preclinical activity against multiple myeloma in vitro and in vivo.
Anticancer effect of pan-PI3K inhibitor on multiple myeloma cells: Shedding new light on the mechanisms involved in BKM120 resistance.
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice.
Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma.
Correction: A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma.
Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation and survival of multiple myeloma cells.
Cytokines prevent dexamethasone-induced apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in a new multiple myeloma cell line.
Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myeloma.
Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hematological malignancies.
Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization.
Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance.
PI3K as a Target for Therapy in Haematological Malignancies.
PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus.
PI3K-dependent multiple myeloma cell survival is mediated by the PIK3CA isoform.
PI3K? and PI3K? isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment.
PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance.
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma.
Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis.
Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model.
Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib.
Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma.
Targeting the phosphatidylinositol 3-kinase/AKT pathway for the treatment of multiple myeloma.
The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.
The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma.
Multiple Sclerosis
Autophagy-related protein PIK3C3/VPS34 controls T cell metabolism and function.
Dendritic cell PIK3C3/VPS34 controls the pathogenicity of CNS autoimmunity independently of LC3-associated phagocytosis.
Transendothelial migratory pathways of V delta 1+TCR gamma delta+ and V delta 2+TCR gamma delta+ T lymphocytes from healthy donors and multiple sclerosis patients: involvement of phosphatidylinositol 3 kinase and calcium calmodulin-dependent kinase II.
ZSTK474, a novel PI3K inhibitor, modulates human CD14(+) monocyte-derived dendritic cell functions and suppresses experimental autoimmune encephalomyelitis.
Muscle Spasticity
ZFYVE26/SPASTIZIN and SPG11/SPATACSIN mutations in hereditary spastic paraplegia types AR-SPG15 and AR-SPG11 have different effects on autophagy and endocytosis.
Muscular Atrophy
Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice.
Icaritin requires Phosphatidylinositol 3 kinase (PI3K)/Akt signaling to counteract skeletal muscle atrophy following mechanical unloading.
Microgravity-Induced Transcriptome Adaptation in Mouse Paraspinal longissimus dorsi Muscle Highlights Insulin Resistance-Linked Genes.
Myostatin Activates the Ubiquitin-Proteasome and Autophagy-Lysosome Systems Contributing to Muscle Wasting in Chronic Kidney Disease.
Muscular Dystrophies
Conditional Knockout of Pik3c3 Causes a Murine Muscular Dystrophy.
PTEN contributes to profound PI3K/Akt signaling pathway deregulation in dystrophin-deficient dog muscle.
Mycosis Fungoides
In situ assessment of PI3K and PTEN alterations in mycosis fungoides: correlation with clinicopathological features.
Myelodysplastic Syndromes
ON 01910.Na is selectively cytotoxic for Chronic Lymphocytic Leukemia cells through a dual mechanism involving PI3K/AKT inhibition and induction of oxidative stress.
Polo-like kinase inhibitors in hematologic malignancies.
Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes.
The role of autophagy in targeted therapy for acute myeloid leukemia.
Myeloproliferative Disorders
Anemia, thrombocytopenia, leukocytosis, extramedullary hematopoiesis, and impaired progenitor function in Pten+/-SHIP-/- mice: a novel model of myelodysplasia.
Myocardial Infarction
Apelin shorten QT interval by inhibiting Kir2.1/IK1 via a PI3K way in acute myocardial infarction.
Attenuation of cardiac dysfunction and remodeling of myocardial infarction by microRNA-130a are mediated by suppression of PTEN and activation of PI3K dependent signaling.
Crucial lncRNAs associated with adipocyte differentiation from human adipose-derived stem cells based on co-expression and ceRNA network analyses.
Dexmedetomidine preconditioning activates pro-survival kinases and attenuates regional ischemia/reperfusion injury in rat heart.
Differential role of PI3K/Akt pathway in the infarct size limitation and antiarrhythmic protection in the rat heart.
Discovery of 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol as an isozyme-selective inhibitor of PI3K for the treatment of ischemia reperfusion injury associated with myocardial infarction.
Effect of lithium on ventricular remodelling in infarcted rats via the Akt/mTOR signalling pathways.
Endocrine Protection of Ischemic Myocardium by FGF21 from the Liver and Adipose Tissue.
Fibrauretine reduces ischemia/reperfusion injury via RISK/eNOS activation.
Impact of age and sex on response to ischemic preconditioning in the rat heart: differential role of the PI3K-AKT pathway.
Involvement of phosphoinositide 3-kinase gamma in angiogenesis and healing of experimental myocardial infarction in mice.
Ischemic postconditioning protects both adult and aged Sprague Dawley rat hearts from ischemia/reperfusion injury through the PI3-K/Akt and GSK-3beta pathway.
Isoflurane-induced myocardial preconditioning is dependent on phosphatidylinositol-3-kinase/Akt signalling.
Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction.
Long-term aerobic exercise protects the heart against ischemia/reperfusion injury via PI3 kinase-dependent and Akt-mediated mechanism.
LY294002 prevents lipopolysaccharide?induced hepatitis in a murine model by suppressing I?B phosphorylation.
Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening.
MicroRNA-146b induces the PI3K/Akt/NF-?B signaling pathway to reduce vascular inflammation and apoptosis in myocardial infarction by targeting PTEN.
Pharmacological Inhibition of Phosphoinositide 3-Kinase Gamma (PI3K?) Promotes Infarct Resorption and Prevents Adverse Cardiac Remodeling after Myocardial Infarction in Mice.
Pharmacological preconditioning in type 2 diabetic rat hearts: the roles of mitochondrial ATP-sensitive potassium channels and the phosphatidylinositol 3-kinase-Akt pathway.
Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury.
Phosphoinositide 3-kinase inhibitor LY294002 ameliorates the severity of myosin-induced myocarditis in mice.
Phosphoinositide 3-kinases in health and disease.
Post-ischemic cardioprotection by A2A adenosine receptors: dependent of phosphatidylinositol 3-kinase pathway.
Research on protective mechanism of ibuprofen in myocardial ischemia-reperfusion injury in rats through the PI3K/Akt/mTOR signaling pathway.
Targeting phosphatidylinositol 3-kinase-Akt through hepatocyte growth factor for cardioprotection.
Targeting phosphoinositide 3-kinase: moving towards therapy.
The novel adipocytokine visfatin exerts direct cardioprotective effects.
The PI3K/Akt pathway mediates the protection of SO2 preconditioning against myocardial ischemia/reperfusion injury in rats.
The role of PI3K? isoform in cardioprotection.
Myocardial Ischemia
(?)?Epicatechin protects against myocardial ischemia?induced cardiac injury via activation of the PTEN/PI3K/AKT pathway.
(S)-1-(alpha-naphthylmethyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (CKD712) reduces rat myocardial apoptosis against ischemia and reperfusion injury by activation of phosphatidylinositol 3-kinase/Akt signaling and anti-inflammatory action in vivo.
Ginsenoside Rb1 preconditioning protects against myocardial infarction after regional ischemia and reperfusion by activation of phosphatidylinositol-3-kinase signal transduction.
Investigating the Signal Transduction Pathways Underlying Remote Ischemic Conditioning in the Porcine Heart.
Remifentanil Preconditioning Reduces Postischemic Myocardial Infarction and Improves Left Ventricular Performance via Activation of the Janus Activated Kinase-2/Signal Transducers and Activators of Transcription-3 Signal Pathway and Subsequent Inhibition of Glycogen Synthase Kinase-3? in Rats.
SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia/reperfusion injury in rat hearts.
U50,488H postconditioning reduces apoptosis after myocardial ischemia and reperfusion.
Vagal stimulation suppresses ischemia-induced myocardial interstitial myoglobin release.
Volatile anesthetic preconditioning attenuates myocardial apoptosis in rabbits after regional ischemia and reperfusion via Akt signaling and modulation of Bcl-2 family proteins.
Myocarditis
Phosphoinositide 3-kinase inhibitor LY294002 ameliorates the severity of myosin-induced myocarditis in mice.
Myopathies, Structural, Congenital
Myotubularin, a phosphatase deficient in myotubular myopathy, acts on phosphatidylinositol 3-kinase and phosphatidylinositol 3-phosphate pathway.
Myxoma
Innate immune response of human plasmacytoid dendritic cells to poxvirus infection is subverted by vaccinia E3 via its Z-DNA/RNA binding domain.
Myxoma virus induces type I IFN production in murine plasmacytoid dendritic cells via a TLR9/MyD88, IRF5/IRF7, and IFNAR-dependent pathway.
Nasal Polyps
Expression of galectin-9 by IFN-? stimulated human nasal polyp fibroblasts through MAPK, PI3K, and JAK/STAT signaling pathways.
Nasopharyngeal Carcinoma
Casticin inhibits nasopharyngeal carcinoma growth by targeting phosphoinositide 3-kinase.
Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 Has a Therapeutic Potential and Sensitizes Cisplatin in Nasopharyngeal Carcinoma.
Human nasopharyngeal carcinoma can be radiosensitized by trichosanthin via inhibition of the PI3K pathway.
Increased Expression of Phosphatidylinositol 3-Kinase p110? and Gene Amplification of PIK3CA in Nasopharyngeal Carcinoma.
Nuclear Klf4 accumulation is associated with cetuximab drug-resistance and predicts poor prognosis of nasopharyngeal carcinoma.
Phosphatidylinositol 3-kinase inhibitor(LY294002) induces apoptosis of human nasopharyngeal carcinoma in vitro and in vivo.
Preclinical evaluation of PI3K inhibitor BYL719 as a single agent and its synergism in combination with cisplatin or MEK inhibitor in nasopharyngeal carcinoma (NPC).
Prognostic significance of the EGFR pathway in nasopharyngeal carcinoma: a systematic review and meta-analysis.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Nasopharyngeal Neoplasms
Hepatocyte growth factor enhances proteolysis and invasiveness of human nasopharyngeal cancer cells through activation of PI3K and JNK.
Neoplasm Metastasis
(-)-4-O-(4-O-?-D-glucopyranosylcaffeoyl) quinic acid exerts anti-tumour effects against uveal melanoma through PI3K/AKT pathway.
(-)-Kusunokinin inhibits breast cancer in N-nitrosomethylurea-induced mammary tumor rats.
17?-Oestradiol activates proteolysis and increases invasion through phosphatidylinositol 3-kinase pathway in human cervical cancer cells.
5-Azacytidine promotes invadopodia formation and tumor metastasis through the upregulation of PI3K in ovarian cancer cells.
?-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer.
?ig-h3 Promotes Human Osteosarcoma Cells Metastasis by Interacting with Integrin ?2?1 and Activating PI3K Signaling Pathway.
?Np63? is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis.
A genome-wide survey of RAS transformation targets.
A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1? and HIF2? stability and tumor growth, angiogenesis, and metastasis.
A role for PI3K-Akt signaling in pulmonary metastatic nodule formation of the osteosarcoma cell line, LM8.
Aclidinium bromide inhibits the growth and metastasis of gastric cancer MKN?28 cells via the PI3K signaling pathway.
Acquisition of lymph node, but not distant metastatic potentials, by the overexpression of CXCR4 in human oral squamous cell carcinoma.
Acquisition of paclitaxel resistance via PI3K?dependent epithelial?mesenchymal transition in A2780 human ovarian cancer cells.
Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma.
Activation of the RalGEF/Ral Pathway Promotes Prostate Cancer Metastasis to Bone.
Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes.
Akt Isoforms: A Family Affair in Breast Cancer.
Amalgamation of PI3K and EZH2 blockade synergistically regulates invasion and angiogenesis: combination therapy for glioblastoma multiforme.
Analysis of molecular markers as predictive factors of lymph node involvement in breast carcinoma.
Androgen deprivation-induced NCoA2 promotes metastatic and castration-resistant prostate cancer.
Andrographolide and its analogues: versatile bioactive molecules for combating inflammation and cancer.
Anti-metastasis effects of gallic acid on gastric cancer cells involves inhibition of NF-kappaB activity and downregulation of PI3K/AKT/small GTPase signals.
Anti-metastatic Effects of Cationic KT2 Peptide (a Lysine/Tryptophan-rich Peptide) on Human Melanoma A375.S2 Cells.
AP4 modulated by the PI3K/AKT pathway promotes prostate cancer proliferation and metastasis of prostate cancer via upregulating L-plastin.
Aromatic Hydrocarbon Receptor Suppresses Prostate Cancer Bone Metastasis Cells-Induced Vasculogenesis of Endothelial Progenitor Cells under Hypoxia.
Aspirin reduces the incidence of metastasis in a pre-clinical study of Braf mutant serrated colorectal neoplasia.
Assessment of PTEN and PI3K status in primary breast cancer and corresponding metastases: is it worthwhile?
Association of PI3K Pathway Mutations with Early Positron-Emission Tomography/CT Imaging Response after Radioembolization for Breast Cancer Liver Metastases: Results of a Single-Center Retrospective Pilot Study.
Association of rs1801157 single nucleotide polymorphism of CXCL12 gene in breast cancer in Pakistan and in-silico expression analysis of CXCL12-CXCR4 associated biological regulatory network.
Astragaloside IV inhibits the invasion and metastasis of SiHa cervical cancer cells via the TGF??1?mediated PI3K and MAPK pathways.
Autophagy-related protein PIK3C3/VPS34 controls T cell metabolism and function.
BENC-511, a novel PI3K inhibitor, suppresses metastasis of non-small cell lung cancer cells by modulating ?-catenin/ZEB1 regulatory loop.
C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits.
C6-ceramide nanoliposome suppresses tumor metastasis by eliciting PI3K and PKC? tumor-suppressive activities and regulating integrin affinity modulation.
Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2.
CDX2 enhances HTR-8/SVneo trophoblast cell invasion by altering the expression of matrix metalloproteinases.
Chemokine (C-X-C motif) receptor 4 RNA interference inhibits bone metastasis in breast cancer.
Clinical implications of Girdin and PI3K protein expression in breast cancer.
Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
Clinical value of CagA, c-Met, PI3K and Beclin-1 expressed in gastric cancer and their association with prognosis.
Colorectal cancer lung metastasis treatment with polymer-drug nanoparticles.
Connective tissue growth factor stimulates osteosarcoma cell migration and induces osteosarcoma metastasis by upregulating VCAM-1 expression.
CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12.
CXCL8 induces epithelial-mesenchymal transition in colon cancer cells via the PI3K/Akt/NF-?B signaling pathway.
Cytochrome b5 reductase 2 suppresses tumor formation in nasopharyngeal carcinoma by attenuating angiogenesis.
Cytochrome P450 ?-hydroxylase promotes angiogenesis and metastasis by upregulation of VEGF and MMP-9 in non-small cell lung cancer.
Deregulation of EGFR/PI3K and activation of PTEN by photodynamic therapy combined with carboplatin in human anaplastic thyroid cancer cells and xenograft tumors in nude mice.
Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3K?.
DOC-2/DAB2 interactive protein regulates proliferation and mobility of nasopharyngeal carcinoma cells by targeting PI3K/Akt pathway.
Down-regulated lncRNA TP73-AS1 reduces radioresistance in hepatocellular carcinoma via the PTEN/Akt signaling pathway.
Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis.
EBV latent membrane protein 1 effects on plakoglobin, cell growth, and migration.
Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors.
EGF promotes DKK1 transcription in hepatocellular carcinoma by enhancing the phosphorylation and acetylation of histone H3.
Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways.
Eupatilin induces human renal cancer cell apoptosis via ROS-mediated MAPK and PI3K/AKT signaling pathways.
Euphorbia fischeriana Steud inhibits malignant melanoma via modulation of the phosphoinositide-3-kinase/Akt signaling pathway.
Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk.
Expression of PI3K/AKT pathway in gastric cancer and its blockade suppresses tumor growth and metastasis.
Focal adhesion kinase regulates syndecan-2-mediated tumorigenic activity of HT1080 fibrosarcoma cells.
Formal model of the interplay between TGF?1 and MMP-9 and their dynamics in hepatocellular carcinoma.
Functional vinorelbine plus schisandrin B liposomes destroying tumor metastasis in treatment of gastric cancer.
Furanodiene, a natural small molecule suppresses metastatic breast cancer cell migration and invasion in vitro.
Gelidiella acerosa inhibits lung cancer proliferation.
Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review).
Genetic alterations of the PIK3CA oncogene in human oral squamous cell carcinoma in an Indian population.
Genetic downregulation of pregnancy-associated plasma protein-A (PAPP-A) by bikunin reduces IGF-I-dependent Akt and ERK1/2 activation and subsequently reduces ovarian cancer cell growth, invasion and metastasis.
Genetics of breast cancer bone metastasis: a sequential multistep pattern.
Genome-Wide Mapping of the Binding Sites and Structural Analysis of Kaposi's Sarcoma-Associated Herpesvirus Viral Interferon Regulatory Factor 2 Reveal that It Is a DNA-Binding Transcription Factor.
Genomic Sequencing and Insight into Clinical Heterogeneity and Prognostic Pathway Genes in Patients with Metastatic Colorectal Cancer.
Giant obscurins regulate the PI3K cascade in breast epithelial cells via direct binding to the PI3K/p85 regulatory subunit.
Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells.
GPER1 Silencing Suppresses the Proliferation, Migration, and Invasion of Gastric Cancer Cells by Inhibiting PI3K/AKT-Mediated EMT.
High metastatic efficiency of human sarcoma cells in Rag2/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy.
Homotypic gap junctional communication associated with metastasis suppression increases with PKA activity and is unaffected by PI3K inhibition.
HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer.
Human ?-defensin 5 suppressed colon cancer growth by targeting PI3K pathway.
Id-1 promotes tumorigenicity and metastasis of human esophageal cancer cells through activation of PI3K/AKT signaling pathway.
Identification of tyrosine-phosphorylated proteins associated with metastasis and functional analysis of FER in human hepatocellular carcinoma cells.
IL13 Receptor ?2 Signaling Requires a Scaffold Protein, FAM120A, to Activate the FAK and PI3K Pathways in Colon Cancer Metastasis.
In vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways.
Induction of galectin-1 by TLR-dependent PI3K activation enhances epithelial-mesenchymal transition of metastatic ovarian cancer cells.
Influence and mechanism of 5-aminolevulinic acid-photodynamic therapy on the metastasis of esophageal carcinoma.
ING5 knockdown enhances migration and invasion of lung cancer cells by inducing EMT via EGFR/PI3K/Akt and IL-6/STAT3 signaling pathways.
Inhibiting the phosphatidylinositide 3-kinase pathway blocks radiation-induced metastasis associated with Rho-GTPase and Hypoxia-inducible factor-1 activity.
Inhibition of phosphoinositide 3-kinase/Akt pathway decreases hypoxia inducible factor-1? expression and increases therapeutic efficacy of paclitaxel in human hypoxic gastric cancer cells.
Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention.
Inhibitory effect of penta-acetyl geniposide on C6 glioma cells metastasis by inhibiting matrix metalloproteinase-2 expression involved in both the PI3K and ERK signaling pathways.
Inhibitory effects of Chanling Gao on the proliferation and liver metastasis of transplanted colorectal cancer in nude mice.
Integrated bioinformatic analysis and experiment confirmation of the antagonistic effect and molecular mechanism of ginsenoside Rh2 in metastatic osteosarcoma.
IRS-1 regulates proliferation, invasion and metastasis of pancreatic cancer cells through MAPK and PI3K signaling pathways.
ITGA6 and RPSA synergistically promote pancreatic cancer invasion and metastasis via PI3K and MAPK signaling pathways.
Jak kinase activity is required for lymphoma invasion and metastasis.
JTC-801 inhibits the proliferation and metastasis of ovarian cancer cell SKOV3 through inhibition of the PI3K - AKT signaling pathway.
Knockdown of ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma.
Knockdown of thrombospondin 2 inhibits metastasis through modulation of PI3K signaling pathway in uveal melanoma cell line M23.
L-Dopa decarboxylase interaction with the major signaling regulator ??3? in tissues and cells of neural and peripheral origin.
Licochalcone A-induced human gastric cancer BGC-823 cells apoptosis by regulating ROS-mediated MAPKs and PI3K/AKT signaling pathways.
Liquiritigenin Potentiates the Inhibitory Effects of Cisplatin on Invasion and Metastasis Via Downregulation MMP-2/9 and PI3 K/AKT Signaling Pathway in B16F10 Melanoma Cells and Mice Model.
LY404039 Inhibits Proliferation and Metastasis of Osteosarcoma Cells via PI3K Signaling Pathway.
Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion.
Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model.
Mapping protein signal pathway interaction in sarcoma bone metastasis: linkage between rank, metalloproteinases turnover and growth factor signaling pathways.
MARCH8 is associated with poor prognosis in non-small cell lung cancers patients.
Mechanisms in epithelial plasticity and metastasis: insights from 3D cultures and expression profiling.
MicroRNA-153-5p promotes the proliferation and metastasis of renal cell carcinoma via direct targeting of AGO1.
MicroRNA-21 promotes cell proliferation, migration, and resistance to apoptosis through PTEN/PI3K/AKT signaling pathway in esophageal cancer.
MicroRNA-34A inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression.
MicroRNA-552 Accelerates the Progression of Gastric Cancer by Targeting FOXO1 and Regulating PI3K/AKT Pathway.
MiR-21: an environmental driver of malignant melanoma?
MiR-328-3p inhibits cell proliferation and metastasis in colorectal cancer by targeting Girdin and inhibiting the PI3K/Akt signaling pathway.
MiR-338-5p promotes metastasis of colorectal cancer by inhibition of phosphatidylinositol 3-kinase, catalytic subunit type 3-mediated autophagy pathway.
miR-564 acts as a dual inhibitor of PI3K and MAPK signaling networks and inhibits proliferation and invasion in breast cancer.
miRNA-487a Promotes Proliferation and Metastasis in Hepatocellular Carcinoma.
miRNA?148a inhibits cell growth of papillary thyroid cancer through STAT3 and PI3K/AKT signaling pathways.
Modulation of glycolysis and lipogenesis by novel PI3K selective molecule represses tumor angiogenesis and decreases colorectal cancer growth.
Molecular differential analysis of uterine leiomyomas and leiomyosarcomas through weighted gene network and pathway tracing approaches.
Molecular mechanisms of action of Trehalose in cancer: A comprehensive review.
Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target.
Monoclonal Antibody against Cell Surface GRP78 as a Novel Agent in Suppressing PI3K/AKT Signaling, Tumor Growth and Metastasis.
Multiorgan metastasis of human HER-2? breast cancer in Rag2?/?;Il2rg?/? mice and treatment with PI3K inhibitor.
Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell-Level PI3K Pathway Activation.
Neural cell adhesion molecule potentiates invasion and metastasis of melanoma cells through CAMP-dependent protein kinase and phosphatidylinositol 3-kinase pathways.
Nitric oxide increases the invasion of pancreatic cancer cells via activation of the PI3K-AKT and RhoA pathways after carbon ion irradiation.
Nongenomic activation of phosphatidylinositol 3-kinase signaling by thyroid hormone receptors.
Novel functions of thyroid hormone receptor mutants: beyond nucleus-initiated transcription.
Novel non-genomic signaling of thyroid hormone receptors in thyroid carcinogenesis.
Novel strategies for molecular targeting to cancer.
Obesity and Obese-related Chronic Low-grade Inflammation in Promotion of Colorectal Cancer Development.
Oncogenic PIK3CA mutations in lobular breast cancer progression.
Orthotopic Patient-Derived Xenografts of Gastric Cancer to Decipher Drugs Effects on Cancer Stem Cells and Metastatic Dissemination.
Overexpression of phosphatidylinositol 3-kinase in human lung cancer.
Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGF? signaling.
Overview of Protein Kinase B Enzyme:a Potential Target for breast and Prostate Cancer.
P-Rex1 directly activates RhoG to regulate GPCR-driven Rac signalling and actin polarity in neutrophils.
P-Rex1 Expression in Invasive Breast Cancer in relation to Receptor Status and Distant Metastatic Site.
P53 suppresses cell proliferation, metastasis, and angiogenesis of osteosarcoma through inhibition of the PI3K/AKT/mTOR pathway.
Phosphatidylinositol 3-kinase ? and ? isoforms play key roles in metastasis of prostate cancer DU145 cells.
Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association.
Phosphatidylinositol 3-kinase in the G protein-coupled receptor-induced chemokinesis and chemotaxis of MDA-MB-468 breast carcinoma cells: a comparison with leukocytes.
Phosphatidylinositol 3-kinase mediates the ability of retinol to decrease colorectal cancer cell invasion.
Phosphatidylinositol 3-kinase/Akt signaling as a key mediator of tumor cell responsiveness to radiation.
Phosphoinositide 3-kinase in disease: timing, location, and scaffolding.
Phosphoinositide 3-kinase inhibitor (wortmannin) inhibits pancreatic cancer cell motility and migration induced by hyaluronan in vitro and peritoneal metastasis in vivo.
Phosphoinositide 3-kinases as drug targets in cancer.
PI3K and MAPK pathways mediate the BDNF/TrkB-increased metastasis in neuroblastoma.
PI3K Catalytic Isoform Alteration Promotes the LIMK1-related Metastasis Through the PAK1 or ROCK1/2 Activation in Cigarette Smoke-exposed Ovarian Cancer Cells.
PI3K expression and PIK3CA mutations are related to colorectal cancer metastases.
PI3K in cancer-stroma interactions: bad in seed and ugly in soil.
PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses.
PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects.
PI3K Overexpression and PIK3CA Mutations Are Associated with Age, Tumor Staging, and Other Clinical Characteristics in Chinese Patients with Esophageal Squamous Cell Carcinoma.
PI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases.
PI3K-PKB-mTOR hyperactivation in relation to nasopharyngeal carcinoma progression and prognosis.
PI3K: A master regulator of brain metastasis-promoting macrophages/microglia.
PI3Ks-Drug Targets in Inflammation and Cancer.
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches.
PIK3R3 induces epithelial-to-mesenchymal transition and promotes metastasis in colorectal cancer.
PIK3R3 Promotes Metastasis of Pancreatic Cancer via ZEB1 Induced Epithelial-Mesenchymal Transition.
PIK3R3, part of the regulatory domain of PI3K, is upregulated in sarcoma stem-like cells and promotes invasion, migration, and chemotherapy resistance.
PKB/Akt-Dependent Regulation of Cell Motility.
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.
PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway.
Pre-clinical efficacy of Ron kinase inhibitors alone and in combination with PI3K inhibitors for treatment of sfRon-expressing breast cancer patient-derived xenografts.
PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition.
Prognosis and management of recurrent and/or metastatic head and neck adenoid cystic carcinoma.
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Promotion of invasion by mutant RAS is dependent on activation of the WASF3 metastasis promoter gene.
Protein Phosphorylation in Cancer: Role of Nitric Oxide Signaling Pathway.
PTEN/MAPK pathways play a key role in platelet-activating factor-induced experimental pulmonary tumor metastasis.
Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways.
Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway.
Role of phosphatidylinositol-3-kinase pathway in head and neck squamous cell carcinoma.
Role of phosphoinositide 3-kinase in cardiac function and heart failure.
Rosmarinic Acid Induces Proliferation Suppression of Hepatoma Cells Associated with NF-?B Signaling Pathway.
SEMA4b inhibits MMP9 to prevent metastasis of non-small cell lung cancer.
SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer.
Shikonin attenuates lung cancer cell adhesion to extracellular matrix and metastasis by inhibiting integrin ?1 expression and the ERK1/2 signaling pathway.
Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase.
Simultaneous blockade of AP-1 and phosphatidylinositol 3-kinase pathway in non-small cell lung cancer cells.
Sinomenine inhibits hypoxia induced breast cancer side population cells metastasis by PI3K/Akt/mTOR pathway.
SLC39A6 Promotes Aggressiveness of Esophageal Carcinoma Cells by Increasing Intracellular Levels of Zinc, Activating Phosphatidylinositol 3-kinase Signaling, and Upregulating Genes That Regulate Metastasis.
Small in Size, but Large in Action: microRNAs as Potential Modulators of PTEN in Breast and Lung Cancers.
Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.
Stanniocalcin-1 promotes metastasis in a human breast cancer cell line through activation of PI3K.
Suppressing effects of dietary supplementation of soybean trypsin inhibitor on spontaneous, experimental and peritoneal disseminated metastasis in mouse model.
Sur8/Shoc2 promotes cell motility and metastasis through activation of Ras-PI3K signaling.
Synergistic Therapeutic Effect of Cisplatin and Phosphatidylinositol 3-Kinase (PI3K) Inhibitors in Cancer Growth and Metastasis of Brca1 Mutant Tumors.
Targeting the PI3K/Akt/mTOR Pathway in Malignancy: Rationale and Clinical Outlook.
Targeting the PI3K/Akt/mTOR-pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.
TGF-beta specifically enhances the metastatic attributes of murine lung adenocarcinoma: implications for human non-small cell lung cancer.
The antipsychotic agent flupentixol is a new PI3K inhibitor and potential anticancer drug for lung cancer.
The Cytoplasmic Expression Of CLDN12 Predicts An Unfavorable Prognosis And Promotes Proliferation And Migration Of Osteosarcoma.
The H1047R point mutation in p110 alpha changes the morphology of human colon HCT116 cancer cells.
The in vitro and in vivo experimental evidences disclose the chemopreventive effects of Ganoderma lucidum on cancer invasion and metastasis.
The Iron-Regulated Metastasis Suppressor NDRG1 Targets NEDD4L, PTEN, and SMAD4 and Inhibits the PI3K and Ras Signaling Pathways.
The mechanisms of renin-angiotensin system in hepatocellular carcinoma: From the perspective of liver fibrosis, HCC cell proliferation, metastasis and angiogenesis, and corresponding protection measures.
The omega-3 polyunsaturated fatty acid docosahexaenoic acid inhibits proliferation and progression of non-small cell lung cancer cells through the reactive oxygen species-mediated inactivation of the PI3K /Akt pathway.
The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging.
The PI3K/AKT/mTOR interactive pathway.
The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance.
The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings.
The Ras-ERK pathway modulates cytoskeleton organization, cell motility and lung metastasis signature genes in MDA-MB-231 LM2.
The role of different PI3K protein subtypes in the metastasis, angiogenesis and clinical prognosis of hepatocellular carcinoma.
The Small GTPase ARF6 Activates PI3K in Melanoma to Induce a Prometastatic State.
The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2.
Therapeutic perspective of thymoquinone: A mechanistic treatise.
Thioredoxin-Like Protein 2 Is Overexpressed in Colon Cancer and Promotes Cancer Cell Metastasis by Interaction with Ran.
Thymoquinone: A novel strategy to combat cancer: A review.
Transcriptome Analysis Reveals Key Genes and Pathways Associated with Metastasis in Breast Cancer.
Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery.
Tumor-derived exosomal microRNA-7-5p enhanced by verbascoside inhibits biological behaviors of glioblastoma in vitro and in vivo.
UNBS5162 inhibits the proliferation of human A549 non-small-cell lung cancer cells by promoting apoptosis.
Up-regulation of PIK3CA promotes metastasis in gastric carcinoma.
uPA and PAI-1-Related Signaling Pathways Differ between Primary Breast Cancers and Lymph Node Metastases.
Vinorelbine cationic liposomes modified with wheat germ agglutinin for inhibiting tumor metastasis in treatment of brain glioma.
WNT signaling and distant metastasis in colon cancer through transcriptional activity of nuclear ?-Catenin depend on active PI3K signaling.
Wortmannin Reduces Metastasis and Angiogenesis of Human Breast Cancer Cells via Nuclear Factor- B-dependent Matrix Metalloproteinase-9 and Interleukin-8 Pathways.
Xmrks the Spot: Fish Models for Investigating Epidermal Growth Factor Receptor Signaling in Cancer Research.
ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism.
[Clinicopathological Research and Expression of PTEN/PI3K/Akt Signaling Pathway in Non-small Cell Lung Cancer.]
[Expression and clinical significance of phosphatidylinositol 3-kinase and protein kinase B in cervical carcinoma]
[Expression and significance of Ki-67, PI3K and Beclin1 in oral squamous cell carcinoma].
[Expression and significance of PTEN/PI3K signal transduction-related proteins in non-small cell lung cancer]
[Integrin ?5 silencing inhibits proliferation, invasion and metastasis of human liver cancer Bel-7404 cells in vitro].
Neoplasm, Residual
SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia.
Neoplasms
'Decoy' and 'non-decoy' functions of DcR3 promote malignant potential in human malignant fibrous histiocytoma cells.
(-)-Kusunokinin inhibits breast cancer in N-nitrosomethylurea-induced mammary tumor rats.
10D1F, an Anti-HER3 Antibody that Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models.
16-Hydroxycleroda-3,13-dien-15,16-olide deregulates PI3K and Aurora B activities that involve in cancer cell apoptosis.
17 ?-Estradiol Reverses Leptin-Inducing Ovarian Cancer Cell Migration by the PI3K/Akt Signaling Pathway.
17ß-Estradiol regulates mTORC2 sensitivity to rapamycin in adaptive cardiac remodeling.
18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer.
2-Methoxyestradiol attenuates phosphatidylinositol 3-kinase/Akt pathway-mediated metastasis of gastric cancer.
20(S)-ginsenoside Rh2 induces caspase-dependent promyelocytic leukemia-retinoic acid receptor A degradation in NB4 cells via Akt/Bax/caspase9 and TNF-?/caspase8 signaling cascades.
3,3'-Diindolylmethane downregulates pro-survival pathway in hormone independent prostate cancer.
3-Deoxy-3-substituted-D-myo-inositol imidazolyl ether lipid phosphates and carbonate as inhibitors of the phosphatidylinositol 3-kinase pathway and cancer cell growth.
3-Methyladenine prevents energy stress-induced necrotic death of melanoma cells through autophagy-independent mechanisms.
3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma.
3-phosphoinositide-dependent protein kinase-1 regulates proliferation and survival of cancer cells with an activated mitogen-activated protein kinase pathway.
3D tumour spheroids as a model to assess the suitability of [18F]FDG-PET as an early indicator of response to PI3K inhibition.
3D-QSAR, Virtual Screening, Docking and Design of Dual PI3K/mTOR Inhibitors with Enhanced Antiproliferative Activity.
5-Azacytidine promotes invadopodia formation and tumor metastasis through the upregulation of PI3K in ovarian cancer cells.
5-fluorouracil enhances the anti-tumor activity of the glutaminase inhibitor CB-839 against PIK3CA-mutant colorectal cancers.
?-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer.
?2-AR blockade potentiates MEK1/2 inhibitor effect on HNSCC by regulating the Nrf2-mediated defense mechanism.
?4-integrin/PI3K Signaling Promotes Tumor Progression through Galectin-3-N-glycan Complex.
?5?1-integrinpromotes tension-dependent mammary epithelial cell invasion by engaging the fibronectin synergy site.
?Np63? is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis.
A beta version of life: p110? takes center stage.
A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/Akt/mTOR signaling pathway.
A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition.
A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer.
A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach.
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.
A Computational Approach Identifies Immunogenic Features of Prognosis in Human Cancers.
A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy.
A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3K? inhibition in controlling tumor growth.
A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.
A Cross-Species Study of PI3K Protein-Protein Interactions Reveals the Direct Interaction of P85 and SHP2.
A Discovery of Clinically Approved Formula FBRP for Repositioning to Treat HCC by Inhibiting PI3K/AKT/NF-?B Activation.
A drug targeting only p110? can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types.
A dual PI3 kinase/mTOR inhibitor BEZ235 reverses doxorubicin resistance in ABCB1 overexpressing ovarian and pancreatic cancer cell lines.
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.
A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
A gain-of-function mutant p53-HSF1 feed forward circuit governs adaptation of cancer cells to proteotoxic stress.
A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
A general prodrug nanohydrogel platform for reduction-triggered drug activation and treatment of taxane-resistant malignancies.
A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.
A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy.
A humanized yeast-based toolkit for monitoring phosphatidylinositol 3-kinase activity at both single cell and population levels.
A Kinome-Wide RNAi Screen in Drosophila Glia Reveals That the RIO Kinases Mediate Cell Proliferation and Survival through TORC2-Akt Signaling in Glioblastoma.
A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas.
A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1? and HIF2? stability and tumor growth, angiogenesis, and metastasis.
A mechanism for synergy with combined mTOR and PI3 kinase inhibitors.
A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.
A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors.
A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors.
A new evaluation method for quantifying PI3K activity by HTRF assay.
A new layer of phosphoinositide-mediated allosteric regulation uncovered for SHIP2.
A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
A Noncoding Regulatory RNAs Network Driven by Circ-CDYL Acts Specifically in the Early Stages Hepatocellular Carcinoma.
A novel brain tumour model in zebrafish reveals the role of YAP activation in MAPK- and PI3K-induced malignant growth.
A novel imidazopyridine derivative, HS-106, induces apoptosis of breast cancer cells and represses angiogenesis by targeting the PI3K/mTOR pathway.
A novel mutation of the PTEN gene in a Japanese patient with Cowden syndrome and bilateral breast cancer.
A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67,000 Patient Samples.
A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death.
A novel pathway for tumor necrosis factor-alpha and ceramide signaling involving sequential activation of tyrosine kinase, p21(ras), and phosphatidylinositol 3-kinase.
A novel PI3K axis selective molecule exhibits potent tumor inhibition in colorectal carcinogenesis.
A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma.
A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo.
A novel sLRP6E1E2 inhibits canonical Wnt signaling, epithelial-to-mesenchymal transition, and induces mitochondria-dependent apoptosis in lung cancer.
A p110?-specific inhibitor combined with bortezomib blocks drug resistance properties of EBV-related B cell origin cancer cells via regulation of NF-?B.
A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins.
A peptide inhibitor derived from p55PIK phosphatidylinositol 3-kinase regulatory subunit: a novel cancer therapy.
A Personalized Medicine Approach to Treat Malignant Proliferating Trichilemmal Tumors.
A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth.
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors.
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.
A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.
A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors.
A Phase I study of safety, pharmacokinetics, and pharmacodynamics of concurrent everolimus and buparlisib treatment in advanced solid tumors.
A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study.
A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies.
A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors.
A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours.
A Phase Ib Study of Single-Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors.
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma.
A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity.
A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1.
A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations.
A PI3K inhibitor-induced growth inhibition of cancer cells is linked to MEK-ERK pathway.
A PI3K p110?-Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis.
A PI3K p110?-selective inhibitor enhances the efficacy of anti-HER2/neu antibody therapy against breast cancer in mice.
A PI3K/AKT Scaffolding Protein, IQ Motif-Containing GTPase Associating Protein 1 (IQGAP1), Promotes Head and Neck Carcinogenesis.
A positive feedback loop between GRP78 and VPS34 is critical for GRP78-mediated autophagy in cancer cells.
A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.
A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.
A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.
A preclinical report of a cobimetinib-inspired novel anticancer small-molecule scaffold of isoflavones, NSC777213, for targeting PI3K/AKT/mTOR/MEK in multiple cancers.
A primary splenic angiosarcoma hepatic metastasis after splenectomy and its genomic alteration profile.
A Probabilistic Boolean Network Approach for the Analysis of Cancer-Specific Signalling: A Case Study of Deregulated PDGF Signalling in GIST.
A Prospective Pilot Study of Target-guided Personalized Chemotherapy with Intensity-modulated Radiotherapy in Patients With Early Rectal Cancer.
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).
A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
A Ras-LSD1 axis activates PI3K signaling through PIK3IP1 suppression.
A Review of PI3K Inhibitors in B-Cell Malignancies.
A secreted PTEN phosphatase that enters cells to alter signaling and survival.
A selectivity study on mTOR/PI3K? inhibitors by homology modeling and 3D-QSAR.
A Selenium Containing Inhibitor for the Treatment of Hepatocellular Cancer.
A SNP-mediated lncRNA (LOC146880) and microRNA (miR-539-5p) interaction and its potential impact on the NSCLC risk.
A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells.
A Structurally Optimized Celecoxib Derivative Inhibits Human Pancreatic Cancer Cell Growth.
A switch of G protein-coupled receptor binding preference from phosphoinositide 3-kinase (PI3K)-p85 to filamin A negatively controls the PI3K pathway.
A synthetic peptide hijacks the catalytic subunit of class I PI3K to suppress the growth of cancer cells.
A Tumor initiating cell-enriched prognostic signature for HER2+:ER?- breast cancer; rationale, new features, controversies and future directions.
A Tumor Suppressor Function for the Lipid Phosphatase INPP4B in Melanocytic Neoplasms.
A Tumor-Associated Mutation of FYVE-CENT Prevents Its Interaction with Beclin 1 and Interferes with Cytokinesis.
A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.
Abelson interactor protein-1 positively regulates breast cancer cell proliferation, migration, and invasion.
Aberrant PTEN, PIK3CA, pMAPK, and TP53 expression in human scalp and face angiosarcoma.
Ablation of phosphoinositide-3-kinase class II alpha suppresses hepatoma cell proliferation.
Abrogating endocrine resistance by targeting ER? and PI3K in breast cancer.
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.
Abrogation of histone deacetylases (HDACs) decreases survival of chronic myeloid leukemia cells: New insight into attenuating effects of the PI3K/c-Myc axis on panobinostat cytotoxicity.
Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients.
Acetylsalicylic acid suppression of the PI3K pathway as a novel medical therapy for head and neck lymphatic malformations.
Acid Ceramidase Promotes Nuclear Export of PTEN through Sphingosine 1-Phosphate Mediated Akt Signaling.
Activated PI3K signaling as an endogenous inducer of p53 in human cancer.
Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.
Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110?.
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
Activation of Akt independent of PTEN and CTMP tumor-suppressor gene mutations in epilepsy-associated Taylor-type focal cortical dysplasias.
Activation of Akt predicts poor outcome in neuroblastoma.
Activation of cAMP-responsive-element-binding protein by PI3 kinase and p38 MAPK is essential for elevated expression of transforming growth factor ?2 in cancer cells.
Activation of human neutrophils by granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor alpha: role of phosphatidylinositol 3-kinase.
Activation of IGF1R/p110?/AKT/mTOR confers resistance to ?-specific PI3K inhibition.
Activation of integrin alpha(V)beta(3) regulates cell adhesion and migration to bone sialoprotein.
Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA.
Activation of phosphatidylinositol 3-kinase and extracellular signal-regulated kinase is required for glial cell line-derived neurotrophic factor-induced migration and invasion of pancreatic carcinoma cells.
Activation of phosphatidylinositol 3-kinase by membrane localization of p110alpha predisposes mammary glands to neoplastic transformation.
Activation of phosphatidylinositol 3-kinase is required for tumor necrosis factor-alpha-induced upregulation of matrix metalloproteinase-9: its direct inhibition by quercetin.
Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor.
Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma.
Activation of phosphatidylinositol-3'-kinase/AKT signaling is essential in hepatoblastoma survival.
Activation of PI3K is associated with reduced survival in renal cell carcinoma.
Activation of PI3K-AKT pathway in oral epithelial dysplasia and early cancer of tongue.
Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
Activation of PI3K/Akt/HIF-1? Signaling is Involved in Lung Protection of Dexmedetomidine in Patients Undergoing Video-Assisted Thoracoscopic Surgery: A Pilot Study.
Activation of PPARgamma increases PTEN expression in pancreatic cancer cells.
Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells.
Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma.
Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a.
Activation of the PI3K-AKT pathway in human malignant mesothelioma cells.
Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models.
Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis.
Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma.
Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes.
Active TGF-? signaling and decreased expression of PTEN separates angiosarcoma of bone from its soft tissue counterpart.
Activity of any class IA PI3K isoform can sustain cell proliferation and survival.
Activity of BKM120 and BEZ235 against Lymphoma Cells.
ADAMTS9-AS2: A Functional Long Non-coding RNA in Tumorigenesis.
Adaphostin toxicity in a sensitive non-small cell lung cancer model is mediated through Nrf2 signaling and heme oxygenase 1.
Addition of the p110? inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer.
Adenocarcinoma in Crohn's disease: the pathologist's experience in a tertiary referral centre of inflammatory bowel disease.
Adenoviral-mediated expression of a kinase-dead mutant of Akt induces apoptosis selectively in tumor cells and suppresses tumor growth in mice.
Adenovirus E4-ORF1 Dysregulates Epidermal Growth Factor and Insulin/Insulin-Like Growth Factor Receptors To Mediate Constitutive Myc Expression.
Adenovirus mediated knockdown of bone morphogenetic protein 2 inhibits human lung cancer growth and invasion in vitro and in vivo.
Adenovirus-mediated PTEN treatment combined with caffeine produces a synergistic therapeutic effect in colorectal cancer cells.
Adenovirus-mediated transfer of the PTEN gene inhibits human colorectal cancer growth in vitro and in vivo.
Adhesion-independent alpha6beta4 integrin clustering is mediated by phosphatidylinositol 3-kinase.
ADORA1 Promotes Hepatocellular Carcinoma Progression via PI3K/AKT Pathway.
ADORA1 promotes nasopharyngeal carcinoma cell progression through regulation of PI3K/AKT/GSK-3?/?-catenin signaling.
Advances in development of phosphatidylinositol 3-kinase inhibitors.
Advances in subunits of PI3K class I in cancer.
Advances in the use of PARP inhibitor therapy for breast cancer.
Affinity with Raf is sufficient for Ras to efficiently induce rat mammary carcinomas.
Age-specific differences in oncogenic pathway deregulation seen in human breast tumors.
Airway Microbiota Is Associated with Up-Regulation of the PI3K Pathway in Lung Cancer.
AKT activation controls cell survival in response to HDAC6 inhibition.
Akt and ERK Control the Proliferative Response of Mammary Epithelial Cells to the Growth Factors IGF-1 and EGF Through the Cell Cycle Inhibitor p57Kip2.
Akt and mTORC1 Have Different Roles During Liver Tumorigenesis in Mice.
Akt determines cell fate through inhibition of the PERK-eIF2? phosphorylation pathway.
AKT hyper-phosphorylation associated with PI3K mutations in lymphatic endothelial cells from a patient with lymphatic malformation.
AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy.
AKT is a therapeutic target in myeloproliferative neoplasms.
Akt Isoforms: A Family Affair in Breast Cancer.
Akt protects mouse hepatocytes from TNF-alpha- and Fas-mediated apoptosis through NK-kappa B activation.
AKT regulates NPM dependent ARF localization and p53mut stability in tumors.
Akt regulates TPP1 homodimerization and telomere protection.
AKT signaling in regulating angiogenesis.
Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK.
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.
Akt-mediated regulation of autophagy and tumorigenesis through Beclin 1 phosphorylation.
AKT-phosphorylated FOXO1 suppresses ERK activation and chemoresistance by disrupting IQGAP1-MAPK interaction.
Akt/protein kinase b and glycogen synthase kinase-3beta signaling pathway regulates cell migration through the NFAT1 transcription factor.
Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression.
Akt1 enhances CA916798 expression through mTOR pathway.
AKT1(E17K) in human solid tumours.
Akt2 and Akt3 play a pivotal role in malignant gliomas.
AKT2 expression in histopathologic grading and recurrence of meningiomas.
AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells.
AKT3 is a key regulator of head and neck squamous cell carcinoma.
ALK positively regulates MYCN activity through repression of HBP1 expression.
Alkylsulfonamide-containing quinazoline derivatives as potent and orally bioavailable PI3Ks inhibitors.
All in the family: Clueing into the link between metabolic syndrome and hematologic malignancies.
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
Alleviating the suppression of glycogen synthase kinase-3beta by Akt leads to the phosphorylation of cAMP-response element-binding protein and its transactivation in intact cell nuclei.
Alpelisib and radiotherapy treatment enhances Alisertib-mediated cervical cancer tumor killing.
Alpelisib for the treatment of PIK3CA-mutated, hormone receptor-positive, HER2-negative metastatic breast cancer.
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
Alpelisib: A Novel Therapy for Patients With PIK3CA-Mutated Metastatic Breast Cancer.
Alphavbeta3 integrin blocking inhibits apoptosis and induces autophagy in murine breast tumor cells.
Alternative dosing of dual PI3K and MEK inhibition in cancer therapy.
Amalgamation of PI3K and EZH2 blockade synergistically regulates invasion and angiogenesis: combination therapy for glioblastoma multiforme.
Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition.
AMPK and cell proliferation--AMPK as a therapeutic target for atherosclerosis and cancer.
An acetyl-histone vulnerability in PI3K/AKT inhibition-resistant cancers is targetable by both BET and HDAC inhibitors.
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.
An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo.
An IL6-STAT3 loop mediates resistance to PI3K inhibitors by inducing epithelial-mesenchymal transition and cancer stem cell expansion in human breast cancer cells.
An In Silico Investigation of Potential EGFR Inhibitors for the Clinical Treatment of Colorectal Cancer.
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice.
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
An inverted CAV1 (caveolin 1) topology defines novel autophagy-dependent exosome secretion from prostate cancer cells.
An LXR agonist promotes GBM cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.
An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells.
An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
An overview on the role of dietary phenolics for the treatment of cancers.
Analyses of FGFR3 and PIK3CA mutations in neuroblastomas and the effects of the corresponding inhibitors on neuroblastoma cell lines.
Analysis of cellular phosphatidylinositol (3,4,5)-trisphosphate levels and distribution using confocal fluorescent microscopy.
Analysis of correlation between HP infection and activation of PI3K/Akt pathway in mucosal tissues of gastric cancer and precancerous lesions.
Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant.
Analysis of intracellular PTEN signaling and secretion.
Analysis of molecular markers as predictive factors of lymph node involvement in breast carcinoma.
Analysis of PI3K pathway components in human cancers.
Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.
Analysis of PIK3CA mutations in breast cancer subtypes.
Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS.
Analysis of the Internal Hypoxic Environment in Solid Tumor Tissue Using a Folding Paper System.
Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo.
Analysis of the ways and methods of signaling pathways in regulating cell cycle of NIH3T3 at transcriptional level.
Androgen blockade based clinical trials landscape in triple negative breast cancer.
Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a PTEN-deficient mouse model of prostate cancer.
Androgen receptor-induced integrin ?6?1 and Bnip3 promote survival and resistance to PI3K inhibitors in castration-resistant prostate cancer.
Andrographolide and its analogues: versatile bioactive molecules for combating inflammation and cancer.
Annexin A2 is involved in activation of extracellular signal-regulated kinase upon endothelin-1 stimulation.
Another Surprise from Metformin: Novel Mechanism of Action via K-Ras Influences Endometrial Cancer Response to Therapy.
Antagonistic effect of selenium on lead-induced neutrophil apoptosis in chickens via miR-16-5p targeting of PiK3R1 and IGF1R.
Anti-breast-Cancer Activity Exerted by ?-Sitosterol-d-glucoside from Sweet Potato via Upregulation of MicroRNA-10a and via the PI3K-Akt Signaling Pathway.
Anti-cancer effects of Tranilast: An update.
Anti-Cancer Properties of Theaflavins.
Anti-HER3 Domain 1 and 3 Antibodies Reduce Tumor Growth by Hindering HER2/HER3 Dimerization and AKT-Induced MDM2, XIAP, and FoxO1 Phosphorylation.
Anti-tumor effects of NVP-BKM120 alone or in combination with MEK162 in biliary tract cancer.
Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma.
Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor.
Anticancer Mammalian Target of Rapamycin (mTOR) Signaling Pathway Inhibitors: Current Status, Challenges and Future Prospects in Management of Epilepsy.
Anticancer potential of novel ?,?-unsaturated ?-lactam derivatives targeting the PI3K/AKT signaling pathway.
Anticipating mechanisms of resistance to PI3K inhibition in breast cancer: a challenge in the era of precision medicine.
Antinociceptive and anti-inflammatory effects of cryptotanshinone through PI3K/Akt signaling pathway in a rat model of neuropathic pain.
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors.
Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo.
Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor.
Antitumor and Anti-Invasive Effect of Apigenin on Human Breast Carcinoma through Suppression of IL-6 Expression.
Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H22 murine hepatocarcinoma model.
Antitumor effects of ?-elemene via targeting the phosphorylation of insulin receptor.
Antitumor effects of the silencing of programmed cell death ligand 1 in colorectal cancer via immunoregulation.
Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor.
Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor.
Anwulignan Ameliorates the Intestinal Ischemia/Reperfusion.
AP-2? Regulates S-Phase and Is a Marker for Sensitivity to PI3K Inhibitor Buparlisib in Colon Cancer.
APOBEC3B Gene Expression in Ductal Carcinoma In Situ and Synchronous Invasive Breast Cancer.
Apoptosis initiation of ?-ionone in SGC-7901 gastric carcinoma cancer cells via a PI3K-AKT pathway.
Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002.
Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy.
Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Architecture and dynamics of the autophagic phosphatidylinositol 3-kinase complex.
Are we on the brink of nonsurgical treatment for ameloblastoma?
ARID1A is a tumour suppressor and inhibits glioma cell proliferation via the PI3K pathwa.
Artesunate Attenuates Pro-Inflammatory Cytokine Release from Macrophages by Inhibiting TLR4-Mediated Autophagic Activation via the TRAF6-Beclin1-PI3KC3 Pathway.
ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors.
Asparagus Polysaccharide inhibits the Hypoxia-induced migration, invasion and angiogenesis of Hepatocellular Carcinoma Cells partly through regulating HIF1?/VEGF expression via MAPK and PI3K signaling pathway.
Aspirin and colorectal cancer: back to the future.
Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling.
Assessment of Functional Phosphatidylinositol 3-Kinase Pathway Activity in Cancer Tissue Using Forkhead Box-O Target Gene Expression in a Knowledge-Based Computational Model.
Assessment of PTEN tumor suppressor activity in nonmammalian models: the year of the yeast.
Assessment of tris (1, 3-dichloro-2-propyl) phosphate toxicology in PC12 cells by using digital gene expression profiling.
Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
Association between phosphatidylinositol 3-kinase regulatory subunit p85alpha Met326Ile genetic polymorphism and colon cancer risk.
Association of increased phosphatidylinositol 3-kinase signaling with increased invasiveness and gelatinase activity in malignant gliomas.
Association of PIK3CA gene mutations with head and neck squamous cell carcinomas.
Association of polyomavirus middle tumor antigen with 14-3-3 proteins.
Association of PTEN expression with biochemical recurrence in prostate cancer: results based on previous reports.
Associations of meningioma molecular subgroup and tumor recurrence.
Astaxanthin inhibits hallmarks of cancer by targeting the PI3K/NF-??/STAT3 signalling axis in oral squamous cell carcinoma models.
Astilbin-induced inhibition of the PI3K/AKT signaling pathway decelerates the progression of osteoarthritis.
Astragaloside IV inhibits the invasion and metastasis of SiHa cervical cancer cells via the TGF??1?mediated PI3K and MAPK pathways.
Astrocyte elevated gene-1 (AEG-1) functions as an oncogene and regulates angiogenesis.
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.
Attenuating PI3K isoforms in pancreatic cancer: Focus on immune PI3K?.
Augmented Antitumor Activity for Novel Dual PI3K/BDR4 Inhibitors, SF2523 and SF1126 in Ewing Sarcoma.
Aurora-A down-regulates IkappaBalpha via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival.
Author Correction: Tumours with PI3K activation are resistant to dietary restriction.
Autocrine effects of tumor-derived complement.
Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody.
Autocrine signaling through Ras regulates cell survival activity in human glioma cells: potential cross-talk between Ras and the phosphatidylinositol 3-kinase-Akt pathway.
Autoimmune Cytopenia as an Early and Initial Presenting Manifestation in Activated PI3 Kinase Delta Syndrome (APDS): Case Report and Review.
Autophagic pathways as new targets for cancer drug development.
Autophagy and Akt promote survival in glioma.
Autophagy and autophagy-related proteins in cancer.
Autophagy drives fibroblast senescence through MTORC2 regulation.
Autophagy in the physiological endometrium and cancer.
Autophagy inhibition enhances colorectal cancer apoptosis induced by dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
Autophagy inhibition specifically promotes epithelial-mesenchymal transition and invasion in RAS-mutated cancer cells.
Autophagy is required for the activation of NF?B.
Autophagy modulation as a potential targeted cancer therapy: From drug repurposing to new drug development.
Autophagy-based unconventional secretion of HMGB1 by keratinocytes plays a pivotal role in psoriatic skin in?ammation.
Autophagy-related protein PIK3C3/VPS34 controls T cell metabolism and function.
Autophagy: a potential key contributor to the therapeutic action of mesenchymal stem cells.
Autotaxin promotes motility via G protein-coupled phosphoinositide 3-kinase gamma in human melanoma cells.
B-Raf Activation Cooperates with PTEN Loss to Drive c-Myc Expression in Advanced Prostate Cancer.
Baicalein induces autophagic cell death through AMPK/ULK1 activation and downregulation of mTORC1 complex components in human cancer cells.
Baicalin attenuates myocardial ischemia-reperfusion injury through Akt/NF-?B pathway.
BAP1 antagonizes WWP1-mediated transcription factor KLF5 ubiquitination and inhibits autophagy to promote melanoma progression.
Basal expression of insulin-like growth factor 1 receptor determines intrinsic resistance of cancer cells to a phosphatidylinositol 3-kinase inhibitor ZSTK474.
BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110? and p110? activities in tumor cell lines and xenograft models.
Bcl-2 family members: dual regulators of apoptosis and autophagy.
Bcl-2 family members: Dual regulators of apoptosis and autophagy.
BCL-2 in prostate cancer: a minireview.
Bcl-2/Bcl-xL Inhibition Increases the Efficacy of Mek Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models.
BCL-3 expression promotes colorectal tumorigenesis through activation of AKT signalling.
Bcl-xl and Mcl-1 are the major determinants of the apoptotic response to dual PI3K and MEK blockage.
BDNF: An Oncogene or Tumor Suppressor?
Behavioral stress accelerates prostate cancer development in mice.
BENC-511, a novel PI3K inhibitor, suppresses metastasis of non-small cell lung cancer cells by modulating ?-catenin/ZEB1 regulatory loop.
Benefit Mixed with Caution for Buparlisib.
Berberine-induced autophagic cell death by elevating GRP78 levels in cancer cells.
beta-amyloid activates the O-2 forming NADPH oxidase in microglia, monocytes, and neutrophils. A possible inflammatory mechanism of neuronal damage in Alzheimer's disease.
Between bench and bed side: PI3K inhibitors.
Beyond adenocarcinoma: current treatments and future directions for squamous, small cell, and rare lung cancer histologies.
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis.
Beyond the endoplasmic reticulum: atypical GRP78 in cell viability, signalling and therapeutic targeting.
Bi2 S3 -Tween 20 Nanodots Loading PI3K Inhibitor, LY294002, for Mild Photothermal Therapy of LoVo Cells In Vitro and In Vivo.
BIM expression in treatment naïve cancers predicts responsiveness to kinase inhibitors.
Bioactive compounds in plant materials for the prevention of diabetesand obesity.
Biochemical and biological characterization of tumor-associated mutations of p110alpha.
Biochemical and biological responses induced by coupling of Gab1 to phosphatidylinositol 3-kinase in RET-expressing cells.
Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors.
Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.
Biochemistry and Biology of ARHI (DIRAS3), an Imprinted Tumor Suppressor Gene Whose Expression Is Lost in Ovarian and Breast Cancers.
Bioinformatics Study of Sea Cucumber Peptides as Antibreast Cancer Through Inhibiting the Activity of Overexpressed Protein (EGFR, PI3K, AKT1, and CDK4).
Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases.
Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3K?, in comparison to established pan PI3K inhibitors.
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941.
Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer.
Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras.
Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis.
Blocking phosphoinositide 3-kinase activity in colorectal cancer cells reduces proliferation but does not increase apoptosis alone or in combination with cytotoxic drugs.
Blocking the PI3K/PKB pathway in tumor cells.
Blocking Y-Box Binding Protein-1 through Simultaneous Targeting of PI3K and MAPK in Triple Negative Breast Cancers.
Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways.
Bmal1 suppresses cancer cell invasion by blocking the phosphoinositide 3-kinase-Akt-MMP-2 signaling pathway.
BMP4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice.
BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer.
Bone marrow-derived mesenchymal stromal cells promote colorectal cancer cell death under low-dose irradiation.
Boosting immune surveillance by low-dose PI3K inhibitor facilitates early intervention of breast cancer.
Both p110? and p110? isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor.
Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma.
BRAF/MAPK and GSK3 signaling converges to control MITF nuclear export.
Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma.
Brain pericytes among cells constituting the blood-brain barrier are highly sensitive to tumor necrosis factor-alpha, releasing matrix metalloproteinase-9 and migrating in vitro.
Brain-Derived Neurotrophic Factor Activation of TrkB Induces Vascular Endothelial Growth Factor Expression via Hypoxia-Inducible Factor-1{alpha} in Neuroblastoma Cells.
Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3'-kinase pathway.
Brassinin induces G1 phase arrest through increase of p21 and p27 by inhibition of the phosphatidylinositol 3-kinase signaling pathway in human colon cancer cells.
Brassinin Represses Invasive Potential of Lung Carcinoma Cells through Deactivation of PI3K/Akt/mTOR Signaling Cascade.
BRD7, a Tumor Suppressor, Interacts with p85? and Regulates PI3K Activity.
Breaking up is hard to do: PI3K isoforms on the rebound.
Breast Cancer Update 2014 - Focus on the Patient and the Tumour.
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.
Breast cancer.
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.
BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions.
Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer.
Buparlisib in breast cancer.
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.
Buparlisib is a brain penetrable pan-PI3K inhibitor.
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.
Burkitt Lymphoma: Much More than MYC.
Butein suppresses cervical cancer growth through the PI3K/AKT/mTOR pathway.
Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer.
C-Jun drives melanoma progression in PTEN wild type melanoma cells.
C-terminal domain of p42 Ebp1 is essential for down regulation of p85 subunit of PI3K, inhibiting tumor growth.
C6-ceramide nanoliposome suppresses tumor metastasis by eliciting PI3K and PKC? tumor-suppressive activities and regulating integrin affinity modulation.
Caffeine activates tumor suppressor PTEN in sarcoma cells.
Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway.
CAL-101, a p110{delta} selective phosphatidylinositol-3-kinase inhibitor (PI3K) for the treatment of B cell malignancies inhibits PI3K signaling and cellular viability.
CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies.
Calcium-sensing receptor induces proliferation through p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase but not extracellularly regulated kinase in a model of humoral hypercalcemia of malignancy.
Calming down T cell acute leukemia.
Calmodulin and PI3K Signaling in KRAS Cancers.
Can phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibition ERase them all?
Cancer biomarkers for targeted therapy.
Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/?-catenin/CBP pathway.
Cancer cells dysregulate PI3K/AKT/mTOR pathway activation to ensure their survival and proliferation: mimicking them is a smart strategy of gammaherpesviruses.
Cancer cells exploit adaptive mitochondrial dynamics to increase tumor cell invasion.
Cancer cells regulate biomechanical properties of human microvascular endothelial cells.
Cancer cells resistant to therapy promote cell surface relocalization of GRP78 which complexes with PI3K and enhances PI(3,4,5)P3 production.
Cancer chemoprevention by tea polyphenols through modulating signal transduction pathways.
Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal.
Cancer invasion and resistance: interconnected processes of disease progression and therapy failure.
Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K.
Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
Cancer stem cells and survival pathways.
Cancer-associated fibroblasts-derived IL-8 mediates resistance to cisplatin in human gastric cancer.
Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes.
Cancer-specific mutations in phosphatidylinositol 3-kinase.
Canine tumor mutational burden is correlated with TP53 mutation across tumor types and breeds.
Capitalizing on Tumor genotyping: Towards the design of mutation specific inhibitors of Phosphoinsitide-3-Kinase.
Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR.
Carcinogenesis of PIK3CA.
Cardamonin inhibits the progression of oesophageal cancer by inhibiting the PI3K/AKT signalling pathway.
Cardiovascular toxicity of PI3K? inhibitors.
Carnosine inhibits glioblastoma growth independent from PI3K/Akt/mTOR signaling.
Catalogue, cause, complexity and cure; the many uses of cancer genome sequence.
Cationic liposome codelivering PI3K pathway regulator improves the response of BRCA1-deficient breast cancer cells to PARP1 inhibition.
CDC25 as a common therapeutic target for triple-negative breast cancer - the challenges ahead.
Cdh1 and Pik3ca Mutations Cooperate to Induce Immune-Related Invasive Lobular Carcinoma of the Breast.
CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3K? Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma.
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
Cdk5-mediated regulation of the PIKE-A-Akt pathway and glioblastoma cell invasion.
Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.
Cell cycle-dependent nuclear export of phosphatase and tensin homologue tumor suppressor is regulated by the phosphoinositide-3-kinase signaling cascade.
Cell signalling of glucagon-like peptide-1 action in rat skeletal muscle.
Cell size regulation by the human TSC tumor suppressor proteins depends on PI3K and FKBP38.
Cell type-specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors.
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Cell-Cycle Therapeutics Come of Age.
Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma.
Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer.
Cellular stimulation via CD95 involves activation of phospho-inositide-3-kinase.
Central role of PI3K in transcriptional activation of hTERT in HTLV-I-infected cells.
Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors.
Challenges in the clinical development of PI3K inhibitors.
Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions.
Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor.
Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling.
Characterization of genomic alterations in Chinese colorectal cancer patients with liver metastases.
Characterization of molecular recognition of Phosphoinositide-3-kinase ? inhibitor through molecular dynamics simulation.
Characterization of PI3K class IA isoforms with regulatory subunit p55alpha using a scintillation proximity assay.
Characterization of pomiferin triacetate as a novel mTOR and translation inhibitor.
Characterization of selective and potent PI3K? inhibitor (PI3KDIN- 015) for B-Cell malignances.
Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Impacting the PI3K Pathway.
Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies.
Chemically targeting the PI3K family.
Chemo-sensitisation of HeLa cells to Etoposide by a Benzoxazine in the absence of DNA-PK inhibition.
Chemokine axes in breast cancer: factors of the tumor microenvironment reshape the CCR7-driven metastatic spread of luminal-A breast tumors.
Chimeric antigen receptors that trigger phagocytosis.
Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas.
Chimeric Nanoparticle: A Platform for Simultaneous Targeting of Phosphatidylinositol-3-Kinase Signaling and Damaging DNA in Cancer Cells.
Chloroform fraction of Serratulae chinensis S. Moore suppresses proliferation and induces apoptosis via the phosphatidylinositide 3-kinase/Akt pathway in human gastric cancer cells.
Chloroquine or chloroquine-PI3K/Akt pathway inhibitor combinations strongly promote ?-irradiation-induced cell death in primary stem-like glioma cells.
Chromosome localization analysis of genes strongly expressed in human visceral adipose tissue.
Circadian Clock Protein PERIOD2 Suppresses the PI3K/Akt Pathway and Promotes Cisplatin Sensitivity in Ovarian Cancer.
Circular RNA hsa_circ_0005046 and hsa_circ_0001791 May Become Diagnostic Biomarkers for Breast Cancer Early Detection.
Circulating tumor DNA as a novel tool to shape clinical trial designs with the potential to impact outcomes: a focus on PI3K inhibitors.
CK-3, A Novel Methsulfonyl Pyridine Derivative, Suppresses Hepatocellular Carcinoma Proliferation and Invasion by Blocking the PI3K/AKT/mTOR and MAPK/ERK Pathways.
CKAP4 is a Dickkopf1 receptor and is involved in tumor progression.
Class (I) Phosphoinositide 3-Kinases in the Tumor Microenvironment.
Class 1A PI3K regulates vessel integrity during development and tumorigenesis.
Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy.
Class I phosphoinositide 3-kinase (PI3K) regulatory subunits and their roles in signaling and disease.
Class I Phosphoinositide 3-Kinase PIK3CA/p110? and PIK3CB/p110? Isoforms in Endometrial Cancer.
Class I PI 3-kinases signaling in platelet activation and thrombosis: PDK1/Akt/GSK3 axis and impact of PTEN and SHIP1.
Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity.
Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discovery.
Class IA PI3K regulatory subunits: p110-independent roles and structures.
Class II phosphoinositide 3-kinase C2? regulates a novel signaling pathway involved in breast cancer progression.
Class reunion: PTEN joins the nuclear crew.
Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization.
Cleavage of Syndecan-1 Promotes the Proliferation of the Basal-Like Breast Cancer Cell Line BT-549 Via Akt SUMOylation.
Clinical activity of mammalian target of rapamycin inhibitors in solid tumors.
Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment.
Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma.
Clinical development of phosphatidylinositol-3 kinase pathway inhibitors.
Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers.
Clinical implications of Girdin and PI3K protein expression in breast cancer.
Clinical outcomes and differential effects of PI3K pathway mutation in obese versus non-obese patients with cervical cancer.
Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
Clinical Trial of Oral Nelfinavir before and during Radiation Therapy for Advanced Rectal Cancer.
Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
Clinical, diagnostic significance and theranostic interest of PIK3CA gene mutations in breast cancer.
Clinical, phenotypic and genetic similarities and disparities between post-transplant and classical Hodgkin lymphomas with respect to therapeutic targets.
Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population.
Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.
Clionosterol and Ethyl Cholestan-22-enol Isolated from the Rhizome of Polygala tenuifolia Inhibit Phosphatidylinositol 3-Kinase/Akt Pathway.
Clonal status of actionable driver events and the timing of mutational processes in cancer evolution.
Closing escape routes: inhibition of IL-8 signaling enhances the anti-tumor efficacy of PI3K inhibitors.
Clotrimazole presents anticancer properties against a mouse melanoma model acting as a PI3K inhibitor and inducing repolarization of tumor-associated macrophages.
Clustered DNA lesion sites as a source of mutations during human colorectal tumourigenesis.
Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver.
Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs.
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.
Codelivery of HIF-1? siRNA and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression.
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
CoGAPS matrix factorization algorithm identifies transcriptional changes in AP-2alpha target genes in feedback from therapeutic inhibition of the EGFR network.
Coincident signals from GPCRs and receptor tyrosine kinases are uniquely transduced by PI3K? in myeloid cells.
Colon Cancer Tumorigenesis Initiated by the H1047R Mutant PI3K.
Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis.
Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype.
Colorectal Carcinogenesis: Connecting K-RAS-Induced Transformation and CREB Activity In Vitro and In Vivo.
Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review.
Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases.
Combination Nanopreparations of a Novel Proapoptotic Drug - NCL-240, TRAIL and siRNA.
Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice.
Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110? Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers.
Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer.
Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice.
Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells.
Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer.
Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.
Combination therapy for malignant glioma based on PTEN status.
Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.
Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach.
Combinatorial screening using orthotopic patient derived xenograft-expanded early phase cultures of osteosarcoma identify novel therapeutic drug combinations.
Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma.
Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice.
Combined effect of sCD40L and PI3K siRNA on transplanted tumours growth and microenvironment in nude mice with gastric cancer.
Combined effects of PI3K and SRC kinase inhibitors with imatinib on intracellular calcium levels, autophagy, and apoptosis in CML-PBL cells.
Combined Inhibition of Both p110? and p110? Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER(+) Breast Cancer.
Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations.
Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma.
Combined inhibition of PI3K? and mTOR inhibits growth of PTEN null tumours.
Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells.
Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
Combined MEK and PI3K/p110? Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features.
Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer.
Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors.
Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.
Combined targeting of G protein-coupled receptor and EGF receptor signaling overcomes resistance to PI3K pathway inhibitors in PTEN-null triple negative breast cancer.
Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors.
Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models.
Combined treatment of XIAP-targeting shRNA and celecoxib synergistically inhibits the tumor growth of non?small cell lung cancer cells in vitro and in vivo.
Combined treatment with PI3K inhibitor BKM120 and PARP inhibitor olaparib is effective in inhibiting the gastric cancer cells with ARID1A deficiency.
Combined VHLH and PTEN mutation causes genital tract cystadenoma and squamous metaplasia.
Combining targeted drugs to overcome and prevent resistance of solid cancers with some stem-like cell features.
Common and distinct features of mammary tumors driven by Pten-deletion or activating Pik3ca mutation.
Comparative effect of two pan-class I PI3K inhibitors used as anticancer drugs on human T cell function.
Comparative Genomics Reveals Shared Mutational Landscape in Canine Hemangiosarcoma and Human Angiosarcoma.
Comparative transcriptome analysis of transcultured human skin-derived precursors (tSKPs) from adherent monolayer culture system and tSKPs-derived fibroblasts (tFBs) by RNA-Seq.
Comparing the Roles of the p110? and p110? Isoforms of PI3K in Signaling and Cancer.
Comparison between endothelial and tumor cells in the response to verteporfin-photodynamic therapy and a PI3K pathway inhibitor.
Comparison of CD28-B7.1 and B7.2 functional interaction in resting human T cells: phosphatidylinositol 3-kinase association to CD28 and cytokine production.
Comparison of EGFR Signaling Pathway Somatic DNA Mutations Derived From Peripheral Blood and Corresponding Tumor Tissue of Patients with Advanced Non-Small-Cell Lung Cancer Using Liquidchip Technology.
Comparison of PI3K Pathway in HPV-Associated Oropharyngeal Cancer With and Without Tobacco Exposure.
Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer.
Compartmentalization and Insulin-Induced Translocations of Insulin Receptor Substrates, Phosphatidylinositol 3-Kinase, and Protein Kinase B in Rat Liver* * This work was supported by grants from the Medical Research Council and from the National Cancer Institute of Canada, and by the Cleghorn Fund at McGill University and the M. Pollack Foundation of Montreal.
Complementation of human papillomavirus type 16 E6 and E7 by Jagged1-specific Notch1-phosphatidylinositol 3-kinase signaling involves pleiotropic oncogenic functions independent of CBF1;Su(H);Lag-1 activation.
Comprehensive analysis of PTEN status in breast carcinomas.
Comprehensive Exome Analysis of Immunocompetent Metastatic Head and Neck Cancer Models Reveals Patient Relevant Landscapes.
Comprehensive investigation of aberrant microRNA profiling in bladder cancer tissues.
Concomitant activation of AKT with extracellular-regulated kinase 1/2 occurs independently of PTEN or PIK3CA mutations in endometrial cancer and may be associated with favorable prognosiss.
Concomitant Inhibition of PI3K? and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K?-Selective Inhibitor.
Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations.
Conditional drug screening shows that mitotic inhibitors induce AKT/PKB-insensitive apoptosis.
Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
Conditional loss of PTEN leads to testicular teratoma and enhances embryonic germ cell production.
Connecting with an old partner in a new way.
Connection between Tumor Suppressor BRCA1 and PTEN in Damaged DNA Repair.
Constitutive activation of phosphatidylinositol 3-kinase signaling pathway down-regulates TLR4-mediated tumor necrosis factor-alpha release in alveolar macrophages from asymptomatic HIV-positive persons in vitro.
Constitutive Activation of PI3K in Oocyte Induces Ovarian Granulosa Cell Tumors.
Constitutive and interleukin-1-inducible phosphorylation of p65 NF-{kappa}B at serine 536 is mediated by multiple protein kinases including I{kappa}B kinase (IKK)-{alpha}, IKK{beta}, IKK{epsilon}, TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription.
Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance.
Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer.
Contactin 1: An Important and Emerging Oncogenic Protein Promoting Cancer Progression and Metastasis.
Contributions of the RhoA guanine nucleotide exchange factor Net1 to polyoma middle T antigen-mediated mammary gland tumorigenesis and metastasis.
Control of autophagy by oncogenes and tumor suppressor genes.
Control of Glucocorticoid Receptor Levels by PTEN Establishes a Failsafe Mechanism for Tumor Suppression.
Control of T lymphocyte fate decisions by PI3K signaling.
Controversies in the Management of Early-stage Serous Endometrial Cancer.
Cooperation Between Pten and Smad4 in Murine Salivary Gland Tumor Formation and Progression.
Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta.
Cooperativity within and among Pten, p53, and Rb Pathways Induces High-Grade Astrocytoma in Adult Brain.
Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities.
Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases.
Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.
Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer.
Correction: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.
Correction: PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses.
Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations.
Correlation between important genes of mTOR pathway (PI3K and KIT) in Iranian women with sporadic breast cancer.
Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma.
Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines.
Correlative studies investigating effects of PI3K inhibition on peripheral leukocytes in metastatic breast cancer: potential implications for immunotherapy.
Correspondence re: M. Tresini et al. A phosphatidylinositol 3-kinase inhibitor induces a senescent-like growth arrest in human diploid fibroblasts. Cancer Res., 58: 1-4, 1998.
Cotargeting CHK1 and PI3K Synergistically Suppresses Tumor Growth of Oral Cavity Squamous Cell Carcinoma in Patient-Derived Xenografts.
Cripto haploinsufficiency affects in vivo colon tumor development.
Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma.
CRKL Mediates p110?-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells.
Cross-regulation between protein L-isoaspartyl O-methyltransferase and ERK in epithelial mesenchymal transition of MDA-MB-231 cells.
Cross-species proteomics reveals specific modulation of signaling in cancer and stromal cells by PI3K inhibitors.
Cross-talk between phosphatidylinositol 3-kinase and sphingomyelinase pathways as a mechanism for cell survival/death decisions.
Crosslink among phosphatidylinositol-3 kinase/Akt, PTEN and STAT-5A signaling pathways post liposomal galactomannan hepatocellular carcinoma therapy.
Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.
Crosstalk signaling between HER3 and HPV16 E6 and E7 mediates resistance to PI3K inhibitors in head and neck cancer.
Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer.
CRYAB inhibits migration and invasion of bladder cancer cells through the PI3K/AKT and ERK pathways.
Crystal Structures of PI3K? Complexed with PI103 and Its Derivatives: New Directions for Inhibitors Design.
CTRP3 improves the insulin sensitivity of 3T3-L1 adipocytes by inhibiting inflammation and ameliorating insulin signalling transduction.
CUL3 (cullin 3)-mediated ubiquitination and degradation of BECN1 (beclin 1) inhibit autophagy and promote tumor progression.
Curcumin attenuates high glucose-induced inflammatory injury through the reactive oxygen species-phosphoinositide 3-kinase/protein kinase B-nuclear factor-?B signaling pathway in rat thoracic aorta endothelial cells.
Current and future management strategies for relapsed or progressive hepatoblastoma.
Current clinical development of PI3K pathway inhibitors in glioblastoma.
Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3K?/? and HDAC.
Cyclin A2 confers cisplatin resistance to endometrial carcinoma cells via up-regulation of an Akt-binding protein, periplakin.
Cyclotherapy: protection of normal cells and unshielding of cancer cells.
Cytochrome P450 ?-hydroxylase promotes angiogenesis and metastasis by upregulation of VEGF and MMP-9 in non-small cell lung cancer.
Cytotoxicity of PEGylated liposomes co-loaded with novel pro-apoptotic drug NCL-240 and the MEK inhibitor cobimetinib against colon carcinoma in vitro.
Dally Proteoglycan Mediates the Autonomous and Nonautonomous Effects on Tissue Growth Caused by Activation of the PI3K and TOR Pathways.
De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.
Deciphering the Role of PI3K/Akt/mTOR Pathway in Breast Cancer Biology and Pathogenesis.
Decursinol angelate blocks transmigration and inflammatory activation of cancer cells through inhibition of PI3K, ERK and NF-kappaB activation.
Defects in cytochrome c oxidase expression induce a metabolic shift to glycolysis and carcinogenesis.
Defining How Oncogenic and Developmental Mutations of PIK3R1 Alter the Regulation of Class IA Phosphoinositide 3-Kinases.
Defining Key Signaling Nodes and Therapeutic Biomarkers in NF1-Mutant Cancers.
Defining the blueprint of the cancer genome.
Definition of the binding mode of phosphoinositide 3-kinase ?-selective inhibitor A-66S through molecular dynamics simulation.
Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway.
Dehydroglyasperin C suppresses TPA-induced cell transformation through direct inhibition of MKK4 and PI3K.
Delineating the mechanism by which selenium deactivates Akt in prostate cancer cells.
Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation.
Deoxyshikonin isolated from Arnebia euchroma inhibits colorectal cancer by down-regulating the PI3K/Akt/mTOR pathway.
Deregulated activity of Akt in epithelial basal cells induces spontaneous tumors and heightened sensitivity to skin carcinogenesis.
Deregulation of EGFR/PI3K and activation of PTEN by photodynamic therapy combined with carboplatin in human anaplastic thyroid cancer cells and xenograft tumors in nude mice.
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.
Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader.
Design and synthesis of imidazopyridine analogues as inhibitors of phosphoinositide 3-kinase signaling and angiogenesis.
Design of thienopyranone-based BET inhibitors that bind multiple synthetic lethality targets.
Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3K?.
Design, synthesis and biological evaluation of novel series of 2H-benzo[b][1,4]oxazin-3(4H)-one and 2H-benzo[b][1,4]oxazine scaffold derivatives as PI3K? inhibitors.
Design, synthesis and biological evaluation of novel urea and thiourea bearing thieno[3,2-d]-pyrimidines as PI3 kinase inhibitors.
Design, synthesis and biological evaluation of thieno[3,2-d]pyrimidine derivatives containing aroyl hydrazone or aryl hydrazide moieties for PI3K and mTOR dual inhibition.
Design, synthesis and evaluation of some 1,6-disubstituted-1H-benzo[d]imidazoles derivatives targeted PI3K as anticancer agents.
Design, Synthesis and Preliminary Biological Evaluation of Benzylsulfone Coumarin Derivatives as Anti-Cancer Agents.
Design, Synthesis and SAR in 2,4,7-Trisubstituted Pyrido[3,2-d]Pyrimidine Series as Novel PI3K/mTOR Inhibitors.
Design, Synthesis, and Biological Evaluation of a Novel Photocaged PI3K Inhibitor toward Precise Cancer Treatment.
Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3K? inhibitors.
Design, Synthesis, and Structure-Activity Relationships of 3-Ethynyl-1H-indazoles as Inhibitors of the Phosphatidylinositol 3-Kinase Signaling Pathway.
Detection of functional PTEN lipid phosphatase protein and enzyme activity in squamous cell carcinomas of the head and neck, despite loss of heterozygosity at this locus.
Detection of PI3K inhibition in human neuroblastoma using multiplex luminex bead immunoassay: a targeted approach for pathway analysis.
Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer.
Developing a Novel Embryo-Larval Zebrafish Xenograft Assay to Prioritize Human Glioblastoma Therapeutics.
Development and application of PI3K assays for novel drug discovery.
Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers.
Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myeloma.
Development of an immunohistochemical protein quantification system in conjunction with tissue microarray technology for identifying predictive biomarkers for phosphatidylinositol 3-kinase inhibitors.
Development of New Molecular Markers for Cancer: A Highly Sensitive Assay for Detecting Mutations of Phosphatidylinositol 3-kinase and p53.
Development of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates bearing sulfonylpiperazine as antitumor inhibitors targeting PI3K?.
Development of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates containing piperazine as inhibitors of PI3K?.
Development of novel PET probes targeting phosphatidylinositol 3-kinase (PI3K) in tumors.
Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer.
Development of PI3K inhibitors: lessons learned from early clinical trials.
Developments in Selective Small Molecule ATP-Targeting the Serine/Threonine Kinase Akt/PKB.
Dexamethasone enhances the lung metastasis of breast cancer via a PI3K-SGK1-CTGF pathway.
DHEA inhibits proliferation, migration and alters mesenchymal-epithelial transition proteins through the PI3K/Akt pathway in MDA-MB-231 cells.
Diagnostic and Prognostic Biomarkers of Adrenal Cortical Carcinoma.
Dietary isothiocyanates inhibit cancer progression by modulation of epigenome.
Differences in autophagy-associated mRNAs in peritoneal fluid of patients with endometriosis and gynecologic cancers.
Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers.
Differences in the molecular profile of endometrial cancers from British White and British South Asian women.
Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas.
Different correlations between tumor size and cancer-related gene profiles according to histologic type of salivary gland tumor.
Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS.
Different PI 3-kinase inhibitors have distinct effects on endothelial permeability and leukocyte transmigration.
Different Response of Ptch Mutant and Ptch Wildtype Rhabdomyosarcoma Toward SMO and PI3K Inhibitors.
Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma.
Differential compensation mechanisms define resistance to PI3K inhibitors in PIK3CA amplified HNSCC.
Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas.
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status.
Differential radio-adaptive responses in BALB/c and C57BL/6 mice: pivotal role of calcium and nitric oxide signalling.
Differential regulation of interleukin-12 and tumour necrosis factor-alpha by phosphatidylinositol 3-kinase and ERK 1/2 pathways during Mycobacterium tuberculosis infection.
Differential response of neuroblastoma cells to TRAIL is independent of PI3K/AKT.
Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers.
Difuran-substituted quinoxalines as a novel class of PI3K? H1047R mutant inhibitors: Synthesis, biological evaluation and structure-activity relationship.
Dimethylsulfoxide induces upregulation of tumor suppressor protein PTEN through nuclear factor-kappaB activation in HL-60 cells.
Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma.
Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway.
Direct engagement of the PI3K pathway by mutant KIT dominates oncogenic signaling in gastrointestinal stromal tumor.
Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase.
Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant-driven tumor growth.
Disabling mitochondrial reprogramming in cancer.
Discovering and developing PI3 kinase inhibitors for cancer: rapid progress through academic-biotech-pharma interactions.
Discovery and bioactivity of 4-(2-arylpyrido[3',2':3,4]pyrrolo[1,2-f][1,2,4]triazin-4-yl) morpholine derivatives as novel PI3K inhibitors.
Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799.
Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3-Kinase Inhibitors for Cancer Treatment.
Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3K? inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancers.
Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders.
Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946).
Discovery of (2S)-8-[(3R)-3-methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one: a novel potent and selective inhibitor of Vps34 for the treatment of solid tumors.
Discovery of a Novel Series of 7-Azaindole Scaffold Derivatives as PI3K Inhibitors with Potent Activity.
Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer.
Discovery of Bifunctional Oncogenic Target Inhibitors against Allosteric Mitogen-Activated Protein Kinase (MEK1) and Phosphatidylinositol 3-Kinase (PI3K).
Discovery of nanomolar phosphoinositide 3-kinase gamma (PI3K?) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis.
Discovery of new thieno[2,3-d]pyrimidine and thiazolo[5,4-d]pyrimidine derivatives as orally active phosphoinositide 3-kinase inhibitors.
Discovery of novel and potent PARP/PI3K dual inhibitors for the treatment of cancer.
Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway.
Discovery of Novel Dual Extracellular Regulated Protein Kinases (ERK) and Phosphoinositide 3-Kinase (PI3K) Inhibitors as a Promising Strategy for Cancer Therapy.
Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy.
Discovery of phosphatidylinositol 3-kinase inhibitory compounds from the Screening Committee of Anticancer Drugs (SCADS) library.
Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hematological malignancies.
Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design.
Discovery of the novel mTOR inhibitor and its antitumor activities in vitro and in vivo.
Discovery of the PTEN Tumor Suppressor and Its Connection to the PI3K and AKT Oncogenes.
Disease-related mutations in PI3K? disrupt regulatory C-terminal dynamics and reveal a path to selective inhibitors.
Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
Disruption of TP63-miR-27a* feedback loop by mutant TP53 in head and neck cancer.
Dissecting Pin1 and phospho-pRb regulation.
Dissecting the different biological effects of oncogenic Ras isoforms in cancer cell lines: Could stimulation of oxidative stress be the one more weapon of H-Ras?: Regulation of oxidative stress and Ras biological effects.
Dissecting the PI3K Signaling Axis in Pediatric Solid Tumors: Novel Targets for Clinical Integration.
Dissecting the roles of Ephrin-A3 in malignant peripheral nerve sheath tumor by TALENs.
Dissecting the roles of Raf- and PI3K-signalling pathways in melanoma formation and progression in a zebrafish model.
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.
Distinct regulation of autophagic activity by Atg14L and Rubicon associated with Beclin 1-phosphatidylinositol-3-kinase complex.
Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages.
Distribution of the phosphatidylinositol 3-kinase inhibitors Pictilisib (GDC-0941) and GNE-317 in U87 and GS2 intracranial glioblastoma models-assessment by matrix-assisted laser desorption ionization imaging.
Diverse prognostic roles of Akt isoforms, PTEN and PI3K in tumor epithelial cells and stromal compartment in non-small cell lung cancer.
DJ-1 promotes survival of human colon cancer cells under hypoxia by modulating HIF-1? expression through the PI3K-AKT pathway.
DNA-dependent protein kinase regulates lysosomal AMP-dependent protein kinase activation and autophagy.
Do Wortmannin and Thalidomide induce apoptosis by autophagy inhibition in 4T1 breast cancer cells in vitro and in vivo?
Does the PI3K Pathway Play a Role in Basal Breast Cancer?
Dominant negative inhibitors of signalling through the phosphoinositol 3-kinase pathway for gene therapy of pancreatic cancer.
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K? inhibitors.
Down-regulated lncRNA TP73-AS1 reduces radioresistance in hepatocellular carcinoma via the PTEN/Akt signaling pathway.
Down-regulated microRNA-223 or elevated ZIC1 inhibits the development of pancreatic cancer via inhibiting PI3K/Akt/mTOR signaling pathway activation.
Down-regulation of class II phosphoinositide 3-kinase alpha expression below a critical threshold induces apoptotic cell death.
Down-regulation of Inositol Polyphosphate 4-Phosphatase Type II Expression in Colorectal Carcinoma.
Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
Down-regulation of the tumor suppressor PTEN by the tumor necrosis factor-alpha/nuclear factor-kappaB (NF-kappaB)-inducing kinase/NF-kappaB pathway is linked to a default IkappaB-alpha autoregulatory loop.
Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer.
Downregulation of PI3-K/Akt/PTEN pathway and activation of mitochondrial intrinsic apoptosis by Diclofenac and Curcumin in colon cancer.
Downregulation of PTEN expression in psoriatic lesions.
Downregulation of uPA inhibits migration and PI3k/Akt signaling in glioblastoma cells.
Drosophila melanogaster as a model system for human brain cancers.
Drug discovery approaches targeting the PI3K/Akt pathway in cancer.
Drug-resistant phosphatidylinositol 3-kinase: guidance for the preemptive strike.
Drugging PI3K in cancer: refining targets and therapeutic strategies.
Drugging the Phosphoinositide 3-Kinase (PI3K) and Phosphatidylinositol 4-Kinase (PI4K) Family of Enzymes for Treatment of Cancer, Immune Disorders, and Viral/Parasitic Infections.
Drugging the PI3 kinome: from chemical tools to drugs in the clinic.
Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.
Dual effects of the PI3K inhibitor ZSTK474 on multidrug efflux pumps in resistant cancer cells.
Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.
Dual Inhibition of Autophagy and PI3K/AKT/MTOR Pathway as a Therapeutic Strategy in Head and Neck Squamous Cell Carcinoma.
Dual inhibition of BRD4 and PI3K by SF2523 suppresses human prostate cancer cell growth in vitro and in vivo.
Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer.
Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas.
Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature.
Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers.
Dual Inhibiton of Bruton's Tyrosine Kinase and Phosphoinositide-3-Kinase p110? as a Therapeutic Approach to Treat non-Hodgkin's B cell Malignancies.
Dual inhibitor of phosphoinositide 3-kinase/mammalian target of rapamycin NVP-BEZ235 effectively inhibits cisplatin-resistant urothelial cancer cell growth through autophagic flux.
Dual inhibitor of PI3K and mTOR (NVP-BEZ235) augments the efficacy of fluorouracil on gastric cancer chemotherapy.
Dual PDK1/Aurora Kinase A Inhibitors Reduce Pancreatic Cancer Cell Proliferation and Colony Formation.
Dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 synergizes with chloroquine to induce apoptosis in embryonal rhabdomyosarcoma.
Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations.
Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations.
Dual PI3K/mTORC1 Targeting Suppresses HER2+ Brain Metastasis Xenografts.
Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma.
Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance.
Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis.
Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation.
Duvelisib, a new PI3K inhibitor for lymphoid malignancies.
Duvelisib: a phosphoinositide-3 kinase ?/? inhibitor for chronic lymphocytic leukemia.
Dynamic palmitoylation controls the microdomain localization of the DKK1 receptors CKAP4 and LRP6.
Dynamics of GFP-Fusion p110? and p110? Isoforms of PI3K Signaling Pathway in Normal and Cancer Cells.
Dynamin 2 mediates PDGFR?-SHP-2-promoted glioblastoma growth and invasion.
Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival.
Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia.
Dysregulation of WNT/CTNNB1 and PI3K/AKT signaling in testicular stromal cells causes granulosa cell tumor of the testis.
E-cadherin downregulation sensitizes PTEN-mutant tumors to PI3K? silencing.
E17K substitution in AKT1 in prostate cancer.
E1A inhibition of radiation-induced NF-kappaB activity through suppression of IKK activity and IkappaB degradation, independent of Akt activation.
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.
Early changes in [18F]FDG incorporation by breast cancer cells treated with trastuzumab in normoxic conditions: role of the Akt-pathway, glucose transport and HIF-1?.
Early Changes in [18F]FDG Uptake as a Readout for PI3K/Akt/mTOR Targeted Drugs in HER-2-Positive Cancer Xenografts.
Early-Life Body Adiposity and the Breast Tumor Transcriptome.
Efemp1 and p27Kip1 modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models.
Effect of Atorvastatin on Wound Healing in Rats.
Effect of bevacizumab on expression level of GLI1 and ING4 in colon cancer animal model.
Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer.
Effect of combined inhibition of p110 alpha PI3K isoform and STAT3 pathway in ovarian cancer platinum-based resistance.
Effect of dexmedetomidine on the cognitive function of patients undergoing gastric cancer surgery by regulating the PI3K/AKT signaling pathway.
Effect of early-stage autophagy inhibition in BRAFV600E autophagy-dependent brain tumor cells.
Effect of nutrient intake on intramuscular glucose metabolism during the early growth stage in cross-bred steers (Japanese Black male?×?Holstein female).
Effect of PI3K gene silencing on growth, migration and related proteins expression of CD40 signal-mediated gastric cancer cells.
Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice.
Effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor, on DNA-dependent protein kinase.
Effective PI3K modulators for improved therapy against malignant tumors and for neuroprotection of brain damage after tumor therapy (Review).
Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease.
Effective treatment of HER2-amplified breast cancer by targeting HER3 and ?1 integrin.
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
Effects of an inhibitor of the gamma-secretase complex on proliferation and apoptotic parameters in a FOXL2-mutated granulosa tumor cell line (KGN).
Effects of chitosan and oligochitosans on the phosphatidylinositol 3-kinase-AKT pathway in cancer therapy.
Effects of inhibitors of vascular endothelial growth factor receptor 2 and downstream pathways of receptor tyrosine kinases involving phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin or mitogen-activated protein kinase in canine hemangiosarcoma cell lines.
Effects of LY294002 on the invasiveness of human gastric cancer in vivo in nude mice.
Effects of Macrothele raven venom on intrarenal invasion and metastasis of H22 liver cancer cells in mice.
Effects of mutations in Wnt/?-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer.
Effects of Natural Products on Fructose-Induced Nonalcoholic Fatty Liver Disease (NAFLD).
Effects of PI3K Inhibition on Afucosylated Antibody-Driven Fc?RIIIa Events and Phospho-S6 Activity in NK Cells.
Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells.
Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells.
Effects of PTEN Loss and Activated KRAS Overexpression on Mechanical Properties of Breast Epithelial Cells.
Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging.
Effects of tyroserleutide on gene expression of calmodulin and PI3K in hepatocellular carcinoma.
Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study.
Efficacy of PI3K inhibitors in advanced breast cancer.
Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomised control trials.
Efficacy of Providing the PI3K p110? Inhibitor BYL719 (Alpelisib) to Middle-Aged Mice in Their Diet.
Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma.
EGCG inhibited bladder cancer T24 and 5637 cell proliferation and migration via PI3K/AKT pathway.
EGCG inhibits growth of human pancreatic tumors orthotopically implanted in Balb C nude mice through modulation of FKHRL1/FOXO3a and neuropilin.
EGF promotes DKK1 transcription in hepatocellular carcinoma by enhancing the phosphorylation and acetylation of histone H3.
EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma.
EGFR and PI3K Pathway Activities Might Guide Drug Repurposing in HPV-Negative Head and Neck Cancers.
EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells.
EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release.
EGFR/Notch Antagonists Enhance the Response to Inhibitors of the PI3K-Akt Pathway by Decreasing Tumour-Initiating Cell Frequency.
Electronegative low-density lipoprotein induces cardiomyocyte apoptosis indirectly through endothelial cell-released chemokines.
Elevated phosphatidylinositol 3-kinase activation and its clinicopathological significance in cervical cancer.
Elevated PI3K signaling drives multiple breast cancer subtypes.
Embryonic Stem Cells Modulate the Cancer-Permissive Microenvironment of Human Uveal Melanoma.
Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation.
Emerging role of PI3K/AKT in tumor-related epigenetic regulation.
Emerging Roles for AKT Isoform Preference in Cancer Progression Pathways.
Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity.
Emerging strategies for targeting PI3K in gynecologic cancer.
Emerging views of mitophagy in immunity and autoimmune diseases.
Emodin suppresses growth and invasion of colorectal cancer cells by inhibiting VEGFR2.
Endothelial Barrier Protection by Local Anesthetics: Ropivacaine and Lidocaine Block Tumor Necrosis Factor-?-Induced Endothelial Cell Src Activation.
Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037.
Enhanced antitumor efficacy by blocking activation of the phosphatidylinositol 3-kinase/Akt pathway during anti-angiogenesis therapy.
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN.
Enhanced Phosphoinositide 3-Kinase {delta} Activity Is a Frequent Event in Systemic Lupus Erythematosus That Confers Resistance to Activation-Induced T Cell Death.
Enhanced radiation damage of tumor vasculature by mTOR inhibitors.
Enhanced susceptibility to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in oral squamous cell carcinoma cells treated with phosphatidylinositol 3-kinase inhibitors.
Enhancement of tumor cell susceptibility to natural killer cell activity through inhibition of the PI3K signaling pathway.
Enhancement of tumor radioresponse by wortmannin in C3H/HeJ hepatocarcinoma.
Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.
ENTPD5, an Endoplasmic Reticulum UDPase, Alleviates ER Stress Induced by Protein Overloading in ATK-Activated Cancer Cells.
Enzymatic and non-enzymatic activities of SHIP-1 in signal transduction and cancer.
EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway.
Ephs and ephrins in cancer: Ephrin-A1 signalling.
Epidermal growth factor protects fibroblasts from apoptosis via PI3 kinase and Rac signaling pathways.
Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model.
Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor.
Epigallocatechin-3-gallate inhibits proliferation and triggers apoptosis in colon cancer via the hedgehog/phosphoinositide 3-kinase pathways.
Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.
Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling.
Epstein-Barr virus latent membrane protein 1 represses DNA repair through the PI3K/Akt/FOXO3a pathway in human epithelial cells.
ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted future.
ER?-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.
Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells.
ErbB antagonists patenting: "playing chess with cancer".
ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth.
ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis.
ERBB3-Independent Activation of the PI3K Pathway in EGFR-Mutant Lung Adenocarcinomas.
ERBB4 is over-expressed in human colon cancer and enhances cellular transformation.
Erinacine Facilitates the Opening of the Mitochondrial Permeability Transition Pore Through the Inhibition of the PI3K/ Akt/GSK-3? Signaling Pathway in Human Hepatocellular Carcinoma.
ERK and PI3K regulate different aspects of the epithelial to mesenchymal transition of mammary tumor cells induced by truncated MUC1.
ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition.
Erratum for the Research Article: "Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy".
Erratum to: Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.
Essential role of Stat3 in PI3K-induced oncogenic transformation.
Establishment and Characterization of Cell Lines from a Novel Mouse Model of Poorly Differentiated Thyroid Carcinoma: Powerful Tools for Basic and Preclinical Research.
Establishment and preclinical application of a patient-derived xenograft model for uterine cancer.
Establishment of a Choriocarcinoma Model from Immortalized Normal Extravillous Trophoblast Cells Transduced with HRASV12.
Establishment of patient-derived xenograft models of adenoid cystic carcinoma to assess pre-clinical efficacy of combination therapy of a PI3K inhibitor and retinoic acid.
Establishment of PI3K inhibitor-resistant cancer cell lines and the therapeutic strategies for overcoming the resistance.
Estrogen receptor ? induces down-regulation of PTEN through PI3-kinase activation in breast cancer cells.
Estrogen sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3.
Estrogen-induced activation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor expression, and edema in the uterus are mediated by the phosphatidylinositol 3-kinase/Akt pathway.
Etk/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathway.
ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells.
ETV6/RUNX1 Fusion Gene Abrogation Decreases the Oncogenicity of Tumour Cells in a Preclinical Model of Acute Lymphoblastic Leukaemia.
Eupatilin induces human renal cancer cell apoptosis via ROS-mediated MAPK and PI3K/AKT signaling pathways.
Eupatilin inhibits EGF-induced JB6 cell transformation by targeting PI3K.
Evaluating many treatments and biomarkers in oncology: a new design.
Evaluating the therapeutic potential of mTOR inhibitors using mouse genetics.
Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [(18)F] FDG-PET imaging combined with proteomic approaches.
Evaluation of the role of hexokinase type II in cellular proliferation and apoptosis using human hepatocellular carcinoma cell lines.
Evaluation of type 2 diabetic mellitus animal models via interactions between insulin and mitogen?activated protein kinase signaling pathways induced by a high fat and sugar diet and streptozotocin.
Evidence of a role for phosphatidylinositol 3-kinase activation in the blocking of apoptosis by polyomavirus middle T antigen.
Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling.
Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent Pathways cooperate to maintain lung cancer cell survival.
Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor kappaB pathways in tumor necrosis factor alpha production in rheumatoid arthritis.
Evolving Strategies for Overcoming Resistance to HER2-Directed Therapy: Targeting the PI3K/Akt/mTOR Pathway.
Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (review).
Exceptional response to cetuximab monotherapy in a patient with metastatic oropharyngeal squamous cell carcinoma: a molecular insight.
Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer.
Exosomal microRNA concentrations in colorectal cancer: A mathematical model.
Exploring the importance of cancer pathways by meta-analysis of differential protein expression networks in three different cancers.
Exploring the Pharmacological Mechanisms of Tripterygium wilfordii Hook F against Cardiovascular Disease Using Network Pharmacology and Molecular Docking.
Exploring the potential of PI3K inhibitors for inflammation and cancer.
Exposure of breast cancer cells to a subcytotoxic dose of apigenin causes growth inhibition, oxidative stress, and hypophosphorylation of Akt.
Expression Analysis of GRHL3 and PHLDA3 in Head and Neck Squamous Cell Carcinoma.
Expression and clinical significance of the phosphatidylinositol 3-kinase/protein kinase B signal transduction pathway in non-small cell lung carcinoma.
Expression and phosphorylation of FOXO1 influences cell proliferation and apoptosis in the gastrointestinal stromal tumor cell line GIST-T1.
Expression and purification of PI3 kinase alpha and development of an ATP depletion and an alphascreen PI3 kinase activity assay.
Expression microarray meta-analysis identifies genes associated with Ras/MAPK and related pathways in progression of muscle-invasive bladder transition cell carcinoma.
Expression of biomarkers in the AKT pathway correlates with malignancy and recurrence in phyllodes tumours of the breast.
Expression of factors and key components associated with the PI3K signaling pathway in colon cancer.
Expression of fibroblast growth factor receptor 1, fibroblast growth factor 2, phosphatidyl inositol 3 phosphate kinase and their clinical and prognostic significance in early and advanced stage of squamous cell carcinoma of the lung.
Expression of genes belonging to the IGF-system in glial tumors.
Expression of interleukin (IL)-11 and IL-11 receptor in human colorectal adenocarcinoma: IL-11 up-regulation of the invasive and proliferative activity of human colorectal carcinoma cells.
Expression of MAPK and PI3K/AKT/mTOR Proteins according to the Chronic Liver Disease Etiology in Hepatocellular Carcinoma.
Expression of phosphorylated-mTOR during the development of prostate cancer.
Expression of PI3K and ERK in Uygur and Han patients with cervical squamous cancer.
Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R.
Expression of PIK3CA, PTEN mRNA and PIK3CA mutations in primary breast cancer: association with lymph node metastases.
Expression of PTEN and phosphorylated Akt in human cholesteatoma epithelium.
Expression of PTEN, p27, p21 and AKT mRNA and protein in human BEL-7402 hepatocarcinoma cells in transplanted tumors of nude mice treated with the tripeptide tyroservatide (YSV).
Expression of the RAE-1 family of stimulatory NK-cell ligands requires activation of the PI3K pathway during viral infection and transformation.
Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells.
Expression status and mutational analysis of the PTEN and P13K subunit genes in ovarian granulosa cell tumors.
Extracellular and subcellular regulation of the PI3K/Akt cassette: new mechanisms for controlling insulin and growth factor signalling.
Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2(+) Breast Cancer.
Extracellular-signal-regulated kinase/mitogen-activated protein kinase signaling as a target for cancer therapy: an updated review.
Extramammary Paget's disease: analysis of growth signal pathway from the human epidermal growth factor receptor 2 protein.
EYA1 promotes tumor angiogenesis by activating the PI3K pathway in colorectal cancer.
Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS mutant lung cancers.
FAK, paxillin, and PI3K in ameloblastoma and adenomatoid odontogenic tumor.
Familial Intracranial Hypertension in 2 Brothers With PTEN Mutation: Expansion of the Phenotypic Spectrum.
Fangchinoline targets PI3K and suppresses PI3K/AKT signaling pathway in SGC7901 cells.
Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition.
Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.
Feedback autophagy activation as a key resistance factor of Ku-0060648 in colorectal cancer cells.
Feedback suppression of PI3K? signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3K?.
Firing up the cold tumors by targeting Vps34.
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial.
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.
First-In-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR In Patients With Advanced Cancer.
First-in-human trial of the PI3K?-selective inhibitor SAR260301 in patients with advanced solid tumors.
Fisetin and 5-fluorouracil: Effective combination for PIK3CA-mutant colorectal cancer.
Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanoma.
Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
Fluorodeoxyglucose uptake in laryngeal carcinoma is associated with the expression of glucose transporter-1 and hypoxia-inducible-factor-1? and the phosphoinositide 3-kinase/protein kinase B pathway.
Force engages vinculin and promotes tumor progression by enhancing PI3K activation of phosphatidylinositol (3,4,5)-triphosphate.
Forkhead transcription factors: new insights into protein kinase B (c-akt) signaling.
Form and flexibility in phosphoinositide 3-kinases.
Formal Modeling of mTOR Associated Biological Regulatory Network Reveals Novel Therapeutic Strategy for the Treatment of Cancer.
Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma.
Four major factors regulate phosphatidylinositol 3-kinase signaling pathway in cancers induced by infection of human papillomaviruses.
FoxO proteins' nuclear retention and BH3-only protein Bim induction evoke mitochondrial dysfunction-mediated apoptosis in berberine-treated HepG2 cells.
FOXO1 controls thyroid cell proliferation in response to TSH and IGF-I and is involved in thyroid tumorigenesis.
FOXO1 promotes tumor progression by increased M2 macrophage infiltration in esophageal squamous cell carcinoma.
FOXO1 regulates expression of a microRNA cluster on X chromosome.
FOXOs in the maintenance of vascular homoeostasis.
FOXOs Maintaining the Equilibrium for Better or for Worse.
Frequency and clinicopathologic profile of PIK3CA mutant GISTs: molecular genetic study of 529 cases.
Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients.
Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases.
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.
Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.
Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.
Fucoxanthin induces apoptosis in human cervical cancer cell line HeLa via PI3K/Akt pathway.
Functional analysis of PIK3CA gene mutations in human colorectal cancer.
Functional characterization of an isoform-selective inhibitor of PI3K-p110? as a potential anticancer agent.
Functional genomics reveals that tumors with activating phosphoinositide 3-kinase mutations are dependent on accelerated protein turnover.
Functional interaction of phosphatase and tensin homologue (PTEN) with the E3 ligase NEDD4-1 during neuronal response to zinc.
Functional role of phosphatidylinositol 3-kinase in direct tumor lysis by human natural killer cells.
Functional role of phosphatidylinositol 3-kinase/Akt pathway on cell growth and lytic cycle of Epstein-Barr virus in the Burkitt's lymphoma cell line, P3HR-1.
Functional roles of the phosphatidylinositol 3-kinases (PI3Ks) signaling in the mammalian ovary.
Functional specificity of the mammalian Beclin-Vps34 PI 3-kinase complex in macroautophagy versus endocytosis and lysosomal enzyme trafficking.
Functional vinorelbine plus schisandrin B liposomes destroying tumor metastasis in treatment of gastric cancer.
Furanodiene, a natural small molecule suppresses metastatic breast cancer cell migration and invasion in vitro.
G-Protein-Coupled Lysophosphatidic Acid Receptors and Their Regulation of AKT Signaling.
Gab2 Is Involved in Differential Phosphoinositide 3-Kinase Signaling by Two Splice Forms of c-Kit.
Gain of interaction with IRS1 by p110?-helical domain mutants is crucial for their oncogenic functions.
Galectin binding to Mgat5-modified N-glycans regulates fibronectin matrix remodeling in tumor cells.
Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression--transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway.
Gastric cancer management: Kinases as a target therapy.
GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
Geldanamycin induces mitotic catastrophe and subsequent apoptosis in human glioma cells.
Gelidiella acerosa inhibits lung cancer proliferation.
Gene amplifications associated with the development of hormone-resistant prostate cancer.
Gene expression correlation for cancer diagnosis: a pilot study.
Gene expression profiling demonstrates WNT/?-catenin pathway genes alteration in Mexican patients with colorectal cancer and diabetes mellitus.
Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance.
Gene of the month: PIK3CA.
Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannoma.
Generation and functional characterization of murine mammary organoids.
Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas.
Genetic alterations and PIK3CA gene mutations and amplifications analysis in cervical cancer by racial groups in the United States.
Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.
Genetic Alterations in the PI3K Pathway in Prostate Cancer.
Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas.
Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology.
Genetic and bioinformatic analyses of the expression and function of PI3K regulatory subunit PIK3R3 in an Asian patient gastric cancer library.
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.
Genetic Basis and Therapies for Vascular Anomalies.
Genetic deregulation of the PIK3CA oncogene in oral cancer.
Genetic down-regulation of phosphoinositide 3-kinase by bikunin correlates with suppression of invasion and metastasis in human ovarian cancer HRA cells.
Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation.
Genetic mutations in thyroid carcinoma.
Genetic polymorphisms involved in insulin-like growth factor (IGF) pathway in relation to mammographic breast density and IGF levels.
Genetic profile of GNAQ-mutated blue melanocytic neoplasms reveals mutations in genes linked to genomic instability and the PI3K pathway.
Genetic removal of Smad3 from inhibin-null mice attenuates tumor progression by uncoupling extracellular mitogenic signals from the cell cycle machinery.
Genetically engineered mouse models of PI3K signaling in breast cancer.
Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway.
Genome sequencing analysis of blood cells identifies germline haplotypes strongly associated with drug resistance in osteosarcoma patients.
Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer.
Genome-wide association study in esophageal cancer using GeneChip mapping 10K array.
Genome-wide cDNA microarray screening of genes related to survival in patients after curative resection of non-small cell lung cancer.
Genome-Wide Mapping of the Binding Sites and Structural Analysis of Kaposi's Sarcoma-Associated Herpesvirus Viral Interferon Regulatory Factor 2 Reveal that It Is a DNA-Binding Transcription Factor.
Genome-wide screen for serum microRNA expression profile in mfat-1 transgenic mice.
Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion.
Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma.
Genomic Characterization of Primary Invasive Lobular Breast Cancer.
Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer.
Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers.
Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer.
Genomic landscape of a metastatic malignant proliferating tricholemmal tumor and its response to PI3K inhibition.
Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.
Genomic Landscapes of EBV-Associated Nasopharyngeal Carcinoma vs. HPV-Associated Head and Neck Cancer.
Genomic Profiling and Prognostic Value Analysis of Genetic Alterations in Chinese Resected Lung Cancer With Invasive Mucinous Adenocarcinoma.
Genomic profiling of high-grade large-cell neuroendocrine carcinoma of the colon.
Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers.
Germline disruption of Pten localization causes enhanced sex-dependent social motivation and increased glial production.
Girding for migratory cues: roles of the Akt substrate Girdin in cancer progression and angiogenesis.
GIV/Girdin Creates a Positive Feedback Loop that Potentiates Outside-in Integrin Signaling in Cancer Cells.
GLI1 Blockade Potentiates the Antitumor Activity of PI3K Antagonists in Lung Squamous Cell Carcinoma.
Glucocorticoid adrenal steroids and glucocorticoid-inducible kinase isoforms in the regulation of GluR6 expression.
Glucocorticoid Receptor Counteracts Tumorigenic Activity of Akt in Skin through Interference with the Phosphatidylinositol 3-Kinase Signaling Pathway.
Glucose Metabolism Measured by [F]Fluorodeoxyglucose Positron Emission Tomography Is Independent of PTEN/AKT Status in Human Colon Carcinoma Cells.
Glutaminase Inhibitors Induce Thiol-Mediated Oxidative Stress and Radiosensitization in Treatment-Resistant Cervical Cancers.
Glycine-extended gastrin activates two independent tyrosine-kinases in upstream of p85/p110 phosphatidylinositol 3-kinase in human colonic tumour cells.
Glycyrrhizic Acid and 18?-Glycyrrhetinic Acid Modulate Lipopolysaccharide-Induced Inflammatory Response by Suppression of NF-?B through PI3K p110? and p110? Inhibitions.
GPCR signaling mediates tumor metastasis via PI3K?.
Grape Proanthocyanidin Inhibit Pancreatic Cancer Cell Growth In Vitro and In Vivo through Induction of Apoptosis and by Targeting the PI3K/Akt Pathway.
Growth inhibition of human malignant glioma cells induced by the PI3-K-specific inhibitor.
GSK-3beta reactivation with LY294002 sensitizes hepatoma cells to chemotherapy-induced apoptosis.
H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3.
H3K27 Demethylase JMJD3 Employs the NF-?B and BMP Signaling Pathways to Modulate the Tumor Microenvironment and Promote Melanoma Progression and Metastasis.
Ha-ras overexpression mediated cell apoptosis in the presence of 5-fluorouracil.
Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway.
Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression.
HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma.
HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer.
Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia.
Heat shock protein Hsp72 controls oncogene-induced senescence pathways in cancer cells.
Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms.
Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110?.
Heparin co-factor II enhances cell motility and promotes metastasis in non-small cell lung cancer.
Hepatic stellate cell coculture enables sorafenib resistance in Huh7 cells through HGF/c-Met/Akt and Jak2/Stat3 pathways.
Hepatitis C virus NS5A-mediated activation of phosphoinositide 3-kinase results in stabilization of cellular beta-catenin and stimulation of beta-catenin-responsive transcription.
Hepatoprotective effect of forsythiaside a against acetaminophen-induced liver injury in zebrafish: Coupling network pharmacology with biochemical pharmacology.
HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3.
HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B.
HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment.
HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma.
Herbal cake-partitioned moxibustion inhibits colonic autophagy in Crohn's disease via signaling involving distinct classes of phosphatidylinositol 3-kinases.
Heregulin-ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells.
Heterogeneity of Phosphatidylinositol-3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin Activation in Cancer: Is PI3K Isoform Specificity Important?
Heterogeneous kinetics of AKT signaling in individual cells are accounted for by variable protein concentration.
Heterozygous disruption of the PTEN promotes intestinal neoplasia in APCmin/+ mouse: roles of osteopontin.
Heterozygous expression of the oncogenic Pik3ca(H1047R) mutation during murine development results in fatal embryonic and extraembryonic defects.
High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.
High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability.
High level of p37?-mRNA relative to p110?-mRNA in neuroblastoma tumors correlates with poor patient survival.
High levels of p110? PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110? inhibitors through PTEN activation.
High throughput chemical library screening identifies a novel p110-? inhibitor that potentiates the anti-myeloma effect of bortezomib.
High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions.
High-fat diet feeding promotes stemness and precancerous changes in murine gastric mucosa mediated by leptin receptor signaling pathway.
High-Mobility Group Box 1 (HMGB1) Promotes Angiogenesis and Tumor Migration by Regulating Hypoxia-Inducible Factor 1 (HIF-1?) Expression via the Phosphatidylinositol 3-Kinase (PI3K)/AKT Signaling Pathway in Breast Cancer Cells.
High-Throughput Detection of Clinically Relevant Mutations in Archived Tumor Samples by Multiplexed PCR and Next-Generation Sequencing.
High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes.
High-throughput screening campaigns against a PI3K? isoform bearing the H1047R mutation identified potential inhibitors with novel scaffolds.
Highly infiltrative brain tumours show reduced chemosensitivity associated with a stem cell-like phenotype.
Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity.
Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach.
HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo.
hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.
Honokiol, a phytochemical from the Magnolia plant, inhibits photocarcinogenesis by targeting UVB-induced inflammatory mediators and cell cycle regulators: development of topical formulation.
Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations.
Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.
Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma.
How autophagy controls the intestinal epithelial barrier.
HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
HS-133, a novel fluorescent phosphatidylinositol 3-kinase inhibitor as a potential imaging and anticancer agent for targeted therapy.
HS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis.
Hsa_circ_CSPP1/MiR-361-5p/ITGB1 Regulates Proliferation and Migration of Cervical Cancer (CC) by Modulating the PI3K-Akt Signaling Pathway.
Hsp90 inhibitor gedunin causes apoptosis in A549 lung cancer cells by disrupting Hsp90:Beclin-1:Bcl-2 interaction and downregulating autophagy.
Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth.
Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase.
Human papillomavirus 16 infection predicts poor outcome in patients with esophageal squamous cell carcinoma.
Human tumor mutants in the p110alpha subunit of PI3K.
Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates.
Hyperhomocysteinemia inhibits tibial fracture healing in rats through PI3K/AKT signaling pathway.
Hyperoside exerts potent anticancer activity in skin cancer.
Hypoxia-induced PIM kinase and laminin-activated integrin ?6 mediate resistance to PI3K inhibitors in bone-metastatic CRPC.
Hypoxic microenvironment induced spatial transcriptome changes in pancreatic cancer.
ICAM3 mediates inflammatory signaling to promote cancer cell stemness.
Icariside II ameliorates myocardial ischemia and reperfusion injury by attenuating inflammation and apoptosis through the regulation of the PI3K/AKT signaling pathway.
Id-1 promotes tumorigenicity and metastasis of human esophageal cancer cells through activation of PI3K/AKT signaling pathway.
Idelalisib for treatment of B-cell malignancies.
Idelalisib impacts cell growth through inhibiting translation regulatory mechanisms in mantle cell lymphoma.
Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas.
Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
Idelalisib: Targeting the PI3 Kinase Pathway in Non-Hodgkin Lymphoma.
Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase.
Identification and characterization of HPV-independent cervical cancers.
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.
Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples.
Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors.
Identification and treatment of T2-low asthma in the era of biologics.
Identification of 4-phenylquinolin-2(1H)-one as a specific allosteric inhibitor of Akt.
Identification of a New RXR? Antagonist Targeting the Coregulator-Binding Site.
Identification of a potent and selective phosphatidylinositol 3-kinase ? inhibitor for the treatment of non-Hodgkin's lymphoma.
Identification of a subset of human non-small cell lung cancer patients with high PI3K? and low PTEN expression, more prevalent in squamous cell carcinoma.
Identification of allosteric binding sites for PI3K? oncogenic mutant specific inhibitor design.
Identification of cancer genes by mutational profiling of tumor genomes.
Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen.
Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma.
Identification of dysregulated pathways associated with pancreatic cancer by survival analysis.
Identification of E545k mutation in plasma from a PIK3CA wild-type metastatic breast cancer patient by array-based digital polymerase chain reaction: Circulating-free DNA a powerful tool for biomarker testing in advance disease.
Identification of ETP-46321, a potent and orally bioavailable PI3K ?, ? inhibitor.
Identification of key pathways and hub genes in the myogenic differentiation of pluripotent stem cell: a bioinformatics and experimental study.
Identification of MALT1 Feedback Mechanisms Enables Rational Design of Potent Anti-Lymphoma Regimens for ABC-DLBCL.
Identification of methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) as an orally bioavailable, highly potent, PI3K alpha inhibitor for the treatment of advanced solid tumors.
Identification of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) as a novel downstream target of phosphatidylinositol 3-kinase/AKT/GSK-3beta pathway.
Identification of novel PI3K? inhibitors by docking, ADMET prediction and molecular dynamics simulations.
Identification of novel potential PI3K? inhibitors for cancer therapy.
Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer.
Identification of small-molecule inhibitors of protein kinase B (PKB/AKT) in an AlphaScreenTM high-throughput screen.
Identification of the PTEN-ARID4B-PI3K pathway reveals the dependency on ARID4B by PTEN-deficient prostate cancer.
Identifying actionable targets through integrative analyses of GEM model and human prostate cancer genomic profiling.
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer.
IFITM3 Enhances PI3K Pathway Signaling to Promote B-cell Malignancies.
IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer.
IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck Cancer.
IL-17 induces the proliferation and migration of glioma cells through the activation of PI3K/Akt1/NF-?B-p65.
IL-33 suppresses GSK-3? activation through an ST2-independent MyD88/TRAF6/RIP/PI3K/Akt pathway.
IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer.
IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors.
ILEI requires oncogenic Ras for the epithelial to mesenchymal transition of hepatocytes and liver carcinoma progression.
Illuminating Radiogenomic Characteristics of Glioblastoma Multiforme through Integration of MR Imaging, Messenger RNA Expression, and DNA Copy Number Variation.
Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.
Imidazo[1,2-a]pyridines: promising drug candidate for antitumor therapy.
Immune escape as a fundamental trait of cancer: focus on IDO.
Immune signaling-based Cascade Propagation approach re-stratifies HNSCC patients.
Immuno-Matrix-Assisted Laser Desorption/Ionization Assays for Quantifying AKT1 and AKT2 in Breast and Colorectal Cancer Cell Lines and Tumors.
Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo.
Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity.
Immunohistochemical detection of phosphorylated Akt, PI3K, and PTEN in ameloblastic tumors.
Immunohistochemical study of correlation between histologic subtype and expression of epithelial-mesenchymal transition-related proteins in synovial sarcomas.
Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-?+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.
Impact of blood-brain barrier integrity on tumor growth and therapy response in brain metastases.
Impact of E6-associated protein on the proliferation and invasion of prostate cancer cells in bone metastasis.
Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation.
Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.
Impact of p85? Alterations in Cancer.
Impact of phosphoinositide-3-kinase and vitamin D3 nuclear receptor single-nucleotide polymorphisms on the outcome of malignant melanoma patients.
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Impaired caudal fin-fold regeneration in zebrafish deficient for the tumor suppressor Pten.
In silico docking of phytocompounds to identify potent inhibitors of signaling pathways involved in prostate cancer.
In situ assessment of PI3K and PTEN alterations in mycosis fungoides: correlation with clinicopathological features.
In vitro and in vivo anti-malignant melanoma activity of Alocasia cucullata via modulation of the phosphatase and tensin homolog/phosphoinositide 3-kinase/AKT pathway.
In Vitro Antimetastatic Effect of Phosphatidylinositol 3-Kinase Inhibitor ZSTK474 on Prostate Cancer PC3 Cells.
In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA.
In vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways.
In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer.
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
In vivo functional analysis of the counterbalance of hyperactive phosphatidylinositol 3-kinase p110 catalytic oncoproteins by the tumor suppressor PTEN.
In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene.
In vivo selection for metastasis promoting genes in the mouse.
In-depth molecular profiling of the biphasic components of uterine carcinosarcomas.
Inactivating CUX1 mutations promote tumorigenesis.
Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase.
Inactivation of Pten in osteo-chondroprogenitor cells leads to epiphyseal growth plate abnormalities and skeletal overgrowth.
Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition.
Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.
Increased apoptosis is associated with robust immune cell infiltration and cytolytic activity in breast cancer.
Increased expression of Akt2 and activity of PI3K and cell proliferation with the ascending of tumor grade of human gliomas.
Increased Expression of Phosphatidylinositol 3-Kinase p110? and Gene Amplification of PIK3CA in Nasopharyngeal Carcinoma.
Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo.
Increased radioresistance via G12S K-Ras by compensatory upregulation of MAPK and PI3K pathways in epithelial cancer.
Increased visfatin expression is associated with nuclear factor-kappa B and phosphatidylinositol 3-kinase in periodontal inflammation.
Individual and combined soy isoflavones exert differential effects on metastatic cancer progression.
Indole-3-carbinol inhibits cell proliferation and induces apoptosis in Hep-2 laryngeal cancer cells.
Induction of apoptosis and suppression of angiogenesis of hepatocellular carcinoma by HS-159, a novel phosphatidylinositol 3-kinase inhibitor.
Induction of galectin-1 by TLR-dependent PI3K activation enhances epithelial-mesenchymal transition of metastatic ovarian cancer cells.
Induction of H2AX phosphorylation in tumor cells by gossypol acetic acid is mediated by phosphatidylinositol 3-kinase (PI3K) family.
Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3K? inhibition through PIK3IP1.
Infection with genotoxin-producing Salmonella enterica synergises with loss of the tumour suppressor APC in promoting genomic instability via the PI3K pathway in colonic epithelial cells.
Inflammation-induced GluA1 trafficking and membrane insertion of Ca(2+) permeable AMPA receptors in dorsal horn neurons is dependent on spinal tumor necrosis factor, PI3 kinase and protein kinase A.
Influence and mechanism of 5-aminolevulinic acid-photodynamic therapy on the metastasis of esophageal carcinoma.
ING5 knockdown enhances migration and invasion of lung cancer cells by inducing EMT via EGFR/PI3K/Akt and IL-6/STAT3 signaling pathways.
Inhibiting effect of Endostar combined with ginsenoside Rg3 on breast cancer tumor growth in tumor-bearing mice.
Inhibiting PI3K as a therapeutic strategy against cancer.
Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.
Inhibiting the phosphatidylinositide 3-kinase pathway blocks radiation-induced metastasis associated with Rho-GTPase and Hypoxia-inducible factor-1 activity.
Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer.
Inhibiting the RAS-PI3K pathway in cancer therapy.
Inhibition of AKT sensitizes chemoresistant ovarian cancer cells to cisplatin by abrogating S and G2/M arrest.
Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma.
Inhibition of BTF3 sensitizes luminal breast cancer cells to PI3K? inhibition through the transcriptional regulation of ER?.
Inhibition of cell cycle progression by dual phosphatidylinositol-3-kinase and mTOR blockade in cyclin D2 positive multiple myeloma bearing IgH translocations.
Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms.
Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors.
Inhibition of fatty acid synthase induces pro-survival Akt and ERK signaling in K-Ras-driven cancer cells.
Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.
Inhibition of MAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells.
Inhibition of p110? PI3K prevents inflammatory response and restenosis after artery injury.
Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
Inhibition of Phosphatidylinositol 3-kinase (PI3K) Signaling Synergistically Potentiates Antitumor Efficacy of Paclitaxel and Overcomes Paclitaxel-Mediated Resistance in Cervical Cancer.
Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer.
Inhibition of Phosphatidylinositol 3-Kinase Destabilizes Mycn Protein and Blocks Malignant Progression in Neuroblastoma.
Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression.
Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment.
Inhibition of phosphatidylinositol-3-kinase synergizes with gemcitabine in low-passage tumor cell lines correlating with Bax translocation to the mitochondria.
Inhibition of phosphoinositide 3-kinase enhances the cytotoxicity of AG1478, an epidermal growth factor receptor inhibitor, in breast cancer cells.
Inhibition of phosphoinositide 3-kinase is associated with reduced angiogenesis and an altered expression of angiogenic markers in endothelioma cells.
Inhibition of phosphoinositide 3-kinase/Akt pathway decreases hypoxia inducible factor-1? expression and increases therapeutic efficacy of paclitaxel in human hypoxic gastric cancer cells.
Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy.
Inhibition of PI3K and MAPK pathways along with KIT inhibitors as a strategy to overcome drug resistance in gastrointestinal stromal tumors.
Inhibition of PI3K and MEK: it is all about combinations and biomarkers.
Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts.
Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest.
Inhibition of PI3K Isoform p110? Increases Both Anti-Tumor and Immunosuppressive Responses to Aggressive Murine Head and Neck Squamous Cell Carcinoma with Low Immunogenicity.
Inhibition of PI3K signalling increases the efficiency of radiotherapy in glioblastoma cells.
Inhibition of PI3K Signalling Selectively Affects Medulloblastoma Cancer Stem Cells.
Inhibition of PI3K suppresses propagation of drug-tolerant cancer cell subpopulations enriched by 5-fluorouracil.
Inhibition of PI3K-AKT Signaling Blocks PGE2-Induced COX-2 Expression in Lung Adenocarcinoma.
Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC.
Inhibition of PI3K? signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.
Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer.
Inhibition of the p110? isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis.
Inhibition of the phosphatidylinositol 3'-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells.
Inhibition of the phosphatidylinositol 3-kinase pathway contributes to HT29 and Caco-2 intestinal cell differentiation.
Inhibition of the phosphatidylinositol 3-kinase/Akt pathway sensitizes MDA-MB468 human breast cancer cells to cerulenin-induced apoptosis.
Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma.
Inhibition of the PI 3-kinase pathway disrupts the unfolded protein response and reduces sensitivity to ER stress-dependent apoptosis.
Inhibition of the PI3 kinase/Akt pathway enhances doxorubicin-induced apoptotic cell death in tumor cells in a p53-dependent manner.
Inhibition of the PI3K Pathway: Hope We Can Believe in?
Inhibition of the PI3K/AKT Pathway Reduces Tumor Necrosis Factor-Alpha Production in the Cellular Response to Wear Particles In Vitro.
Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3.
Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy.
Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39.
Inhibitors in AKTion: ATP-competitive vs allosteric.
Inhibitors of phosphatidylinositol 3'-kinases promote mitotic cell death in HeLa cells.
Inhibitors of PI3K/ERK 1/2/p38 MAPK Show Preferential Activity Against Endocrine Resistant Breast Cancer Cells.
Inhibitors of STAT3, ?-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention.
Inhibitory effect of NVP-BKM120 on cholangiocarcinoma cell growth.
Inhibitory effects of adenovirus mediated Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo.
Inhibitory effects of adenovirus mediated COX-2, Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo.
Inhibitory effects of Chanling Gao on the proliferation and liver metastasis of transplanted colorectal cancer in nude mice.
Inhibitory Potential of Dietary Nutraceuticals on Cellular PI3K/Akt Signaling: Implications in Cancer Prevention and Therapy.
Inhibitory role of focal adhesion kinase on anoikis in the lung cancer cell A549.
Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.
Initiating breast cancer by PIK3CA mutation.
Innovative Therapeutic Strategies for Effective Treatment of Brain Metastases.
Inosine Strongly Enhances Proliferation of Human C32 Melanoma Cells through PLC-PKC-MEK1/2-ERK1/2 and PI3K Pathways.
INPP4B is an oncogenic regulator in human colon cancer.
INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells.
INPP4B promotes PI3K?-dependent late endosome formation and Wnt/?-catenin signaling in breast cancer.
Inpp5f Is a Polyphosphoinositide Phosphatase That Regulates Cardiac Hypertrophic Responsiveness.
Insight into the PTEN - p85? interaction and lipid binding properties of the p85? BH domain.
Insights into the pathological mechanisms of p85? mutations using a yeast-based phosphatidylinositol 3-kinase model.
Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer.
Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer.
Insulin receptor substrate 2-mediated phosphatidylinositol 3-kinase signaling selectively inhibits glycogen synthase kinase 3? to regulate aerobic glycolysis.
Insulin Receptor Substrate Regulation of Phosphoinositol-3 Kinase.
Insulin receptor substrate-1 deficiency drives a proinflammatory phenotype in KRAS mutant lung adenocarcinoma.
Insulin signalling, exercise and cellular integrity.
Insulin-Driven PI3K-AKT Signaling in the Hepatocyte Is Mediated by Redundant PI3K? and PI3K? Activities and Is Promoted by RAS.
Insulin-like Growth Factor Binding Protein 2 (IGFBP-2) Promotes Growth and Survival of Breast Epithelial Cells: Novel Regulation of the Estrogen Receptor.
Insulin-like growth factor ligands, receptors, and binding proteins in cancer.
Intake of high-fat diet stimulates the risk of ultraviolet radiation-induced skin tumors and malignant progression of papillomas to carcinoma in SKH-1 hairless mice.
Intake of red wine increases the number and functional capacity of circulating endothelial progenitor cells by enhancing nitric oxide bioavailability.
Integrated analysis of colorectal cancer microRNA datasets: identification of microRNAs associated with tumor development.
Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers.
Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation.
Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines.
Integrated Genomics Identifies miR-32/MCL-1 Pathway as a Critical Driver of Melanomagenesis: Implications for miR-Replacement and Combination Therapy.
Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
Integrated molecular signaling involving mitochondrial dysfunction and alteration of cell metabolism induced by tyrosine kinase inhibitors in cancer.
Integrated tumor and germline whole-exome sequencing identifies mutations in MAPK and PI3K pathway genes in an adolescent with rosette-forming glioneuronal tumor of the fourth ventricle.
Integrating genomics in head and neck cancer treatment: Promises and pitfalls.
Integration of cell attachment, cytoskeletal localization, and signaling by integrin-linked kinase (ILK), CH-ILKBP, and the tumor suppressor PTEN.
Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.
Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors.
Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.
Integrin-linked kinase activity is associated with interleukin-1 alpha-induced progressive behavior of pancreatic cancer and poor patient survival.
Interactions between Ras1, dMyc, and dPI3K signaling in the developing Drosophila wing.
Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.
Interleukin-10-induced gene expression and suppressive function are selectively modulated by the PI3K-Akt-GSK3 pathway.
Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.
Interplay Among PI3K/AKT, PTEN/FOXO and AR Signaling in Prostate Cancer.
Intracellular paired agent imaging enables improved evaluation of tyrosine kinase inhibitor target engagement.
Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy.
Introduction.
Invention of a novel photodynamic therapy for tumors using a photosensitizing PI3K inhibitor.
Involvement of adipokines, AMPK, PI3K and the PPAR signaling pathways in ovarian follicle development and cancer.
Involvement of autophagy in the response of tumor cells to PtdIns3K inhibitors: Therapeutic implications.
Involvement of neutral endopeptidase in neoplastic progression.
Involvement of phosphatidylinositol 3-kinase/Akt pathway in gemcitabine-induced apoptosis-like cell death in insulinoma cell line INS-1.
Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma.
Involvement of the serine/threonine p70S6 kinase in TGF-beta1-induced ADAM12 expression in cultured human hepatic stellate cells.
Iodine catalyzed three component synthesis of 1-((2-hydroxy naphthalen-1-yl)(phenyl)(methyl))pyrrolidin-2-one derivatives: Rationale as potent PI3K inhibitors and anticancer agents.
IPD-196, a novel phosphatidylinositol 3-kinase inhibitor with potent anticancer activity against hepatocellular carcinoma.
Irs2 inactivation suppresses tumor progression in Pten+/- mice.
Is Emodin with Anticancer Effects Completely Innocent? Two Sides of the Coin.
Is the cancer stem cell population "a player" in multi-drug resistance?
Isoform specific inhibitors of PI3 kinase in glioma.
Isoform-Selective Phosphatidylinositol 3-Kinase Inhibition in Cancer.
Isoform-Selective PI3K Inhibitors for Various Diseases.
Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
Isoliquiritigenin inhibits the proliferation, apoptosis and migration of osteosarcoma cells.
Isoquercitrin inhibits bladder cancer progression in vivo and in vitro by regulating the PI3K/Akt and PKC signaling pathways.
Isorhamnetin inhibited the proliferation and metastasis of androgen-independent prostate cancer cells by targeting the mitochondrion-dependent intrinsic apoptotic and PI3K/Akt/mTOR pathway.
Jab1/CSN5 mediates E2F dependent expression of mitotic and apoptotic but not DNA replication targets.
Jiedu Sangen decoction inhibits chemoresistance to 5-fluorouracil of colorectal cancer cells by suppressing glycolysis via PI3K/AKT/HIF-1? signaling pathway.
JQ1 and PI3K inhibition synergistically reduce salivary adenoid cystic carcinoma malignancy by targeting the c-Myc and EGFR signaling pathways.
K-RAS Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In Vivo.
Kaposi¿s sarcoma-associated herpesvirus G-protein coupled receptor activates the canonical Wnt/ß-catenin signaling pathway.
Kathon Induces Fibrotic Inflammation in Lungs: The First Animal Study Revealing a Causal Relationship between Humidifier Disinfectant Exposure and Eosinophil and Th2-Mediated Fibrosis Induction.
Ketoacidosis With Canagliflozin Prescribed for Phosphoinositide 3-Kinase Inhibitor-Induced Hyperglycemia: A Case Report.
Key autophagic targets and relevant small-molecule compounds in cancer therapy.
Key factors mediated by PI3K signaling pathway and related genes in endometrial carcinoma.
Key role of phosphoinositide 3-kinase class IB in pancreatic cancer.
Key signalling nodes in mammary gland development and cancer. Signalling downstream of PI3 kinase in mammary epithelium: a play in 3 Akts.
Killing tumors by keeping ras and PI3' kinase apart.
Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.
Kinase inhibitors: vice becomes virtue.
Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells.
Kinetic analysis of PI3K reactions with fluorescent PIP(2) derivatives.
Kinetic mechanism of AKT/PKB enzyme family.
Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer.
Kirenol inhibited the cell survival and induced apoptosis in human thyroid cancer cells by altering PI3K/AKT and MAP kinase signaling pathways.
KLHL18 inhibits the proliferation, migration, and invasion of non-small cell lung cancer by inhibiting PI3K/PD-L1 axis activity.
Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations.
Knockdown of hTERT by siRNA inhibits cervical cancer cell growth in vitro and in vivo.
Knockdown of toll-like receptor 4 inhibits human NSCLC cancer cell growth and inflammatory cytokine secretion in vitro and in vivo.
Knockin of mutant PIK3CA activates multiple oncogenic pathways.
KRAS-related proteins in pancreatic cancer.
KRASQ61H Preferentially Signals through MAPK in a RAF Dimer-Dependent Manner in Non-Small Cell Lung Cancer.
Krebs medal review. How a lipid mediates tumour suppression: Delivered on 29 June 2010 at the 35th FEBS Congress in Gothenburg, Sweden.
Lactate and choline metabolites detected in vitro by nuclear magnetic resonance spectroscopy are potential metabolic biomarkers for PI3K inhibition in pediatric glioblastoma.
Lactate Lights up PI3K Inhibitor Resistance in Breast Cancer.
Lactate promotes resistance to glucose starvation via upregulation of Bcl-2 mediated by mTOR activation.
Laminin-332 promotes the invasion of oesophageal squamous cell carcinoma via PI3K activation.
Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19?784 Diverse Solid Tumors.
LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling.
Lethality of Drosophila lacking TSC tumor suppressor function rescued by reducing dS6K signaling.
Levels of p27 Sensitize to Dual PI3K/mTOR Inhibition.
Licochalcone A-induced human gastric cancer BGC-823 cells apoptosis by regulating ROS-mediated MAPKs and PI3K/AKT signaling pathways.
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.
Linarin inhibits radiation-induced cancer invasion by downregulating MMP-9 expression via the suppression of NF-?B activation in human non-small-cell lung cancer A549.
Liquiritigenin Potentiates the Inhibitory Effects of Cisplatin on Invasion and Metastasis Via Downregulation MMP-2/9 and PI3 K/AKT Signaling Pathway in B16F10 Melanoma Cells and Mice Model.
Live or let die: E2F1 and PI3K pathways intersect to make life or death decisions.
LMP1 signaling and activation of NF-kappaB in LMP1 transgenic mice.
lncRNA LOC102724169 plus cisplatin exhibit the synergistic anti-tumor effect in ovarian cancer with chronic stress.
Localization of Fas/CD95 into the lipid rafts on down-modulation of the phosphatidylinositol 3-kinase signaling pathway.
Long Non-Coding RNA (lncRNA) Growth Arrest Specific 5 (GAS5) Suppresses Esophageal Squamous Cell Carcinoma Cell Proliferation and Migration by Inactivating Phosphatidylinositol 3-kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.
Long-term p110? PI3K inactivation exerts a beneficial effect on metabolism.
Losartan metabolite EXP3179 activates Akt and endothelial nitric oxide synthase via vascular endothelial growth factor receptor-2 in endothelial cells: angiotensin II type 1 receptor-independent effects of EXP3179.
Loss of beta4 integrin subunit reduces the tumorigenicity of MCF7 mammary cells and causes apoptosis upon hormone deprivation.
Loss of endogenous interleukin-12 activates survival signals in ultraviolet-exposed mouse skin and skin tumors.
Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway.
Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/Snf5-mediated tumorigenesis.
Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers.
Loss of phosphatase activity in PTEN (phosphatase and tensin homolog deleted on chromosome ten) results in endometrial carcinoma in humans: An in-silico study.
Loss of Phosphatidylinositol 3-Kinase Activity in Regulatory T Cells Leads to Neuronal Inflammation.
Loss of PI3 kinase association improves the sensitivity of secondary mutation of KIT to Imatinib.
Loss of PI3K blocks cell-cycle progression in a Drosophila tumor model.
Loss of PTEN expression is associated with PI3K pathway-dependent metabolic reprogramming in hepatocellular carcinoma.
Loss of PTEN induces microtentacles through PI3K-independent activation of cofilin.
Loss of RhoB expression promotes migration and invasion of human bronchial cells via activation of AKT1.
Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
Loss of tumor suppressor p53 decreases PTEN expression and enhances signaling pathways leading to activation of activator protein 1 and nuclear factor kappaB induced by UV radiation.
Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status.
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
Low-dose testosterone alleviates vascular damage caused by castration in male rats in puberty via modulation of the PI3K/AKT signaling pathway.
Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
Lowered Expression of Tumor Suppressor Candidate MYO1C Stimulates Cell Proliferation, Suppresses Cell Adhesion and Activates AKT.
LPIN1 downregulation enhances anticancer activity of the novel HDAC/PI3K dual inhibitor FK-A11.
LRP1B mutation is associated with tumor HPV status and promotes poor disease outcomes with a higher mutation count in HPV-related cervical carcinoma and head & neck squamous cell carcinoma.
Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors.
LY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-Akt pathway.
LY294002 induces G0/G1 cell cycle arrest and apoptosis of cancer stem-like cells from human osteosarcoma via down-regulation of PI3K activity.
LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells.
LY3023414 inhibits both osteogenesis and osteoclastogenesis through the PI3K/Akt/GSK3 signalling pathway.
Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion.
Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity.
Macrophage migration inhibitory factor induces phosphorylation of Mdm2 mediated by phosphatidylinositol 3-kinase/Akt kinase: Role of this pathway in decidual cell survival.
Macrophage PTEN regulates expression and secretion of arginase I modulating innate and adaptive immune responses.
Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-?B signaling.
Macropinocytosis Renders a Subset of Pancreatic Tumor Cells Resistant to mTOR Inhibition.
Macropinocytosis: Insights from immunology and cancer.
MADD is a downstream target of PTEN in triggering apoptosis.
Mammalian Target of Rapamycin Inhibition Promotes Response to Epidermal Growth Factor Receptor Kinase Inhibitors in PTEN-Deficient and PTEN-Intact Glioblastoma Cells.
Mammalian target of rapamycin.
Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.
Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model.
Management of adverse events associated with idelalisib treatment - expert panel opinion.
Management of toxicity to isoform ?-specific PI3K inhibitors.
Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors.
Mapping the Germline and Somatic Mutation Interaction Landscape in Indolent and Aggressive Prostate Cancers.
Markers CD40, VEGF, AKT, PI3K, and S100 Correlate with Tumor Stage in Gastric Cancer.
Mass spectrometry-based proteomics reveals potential roles of NEK9 and MAP2K4 in resistance to PI3K inhibitors in triple negative breast cancers.
Mast cells are directly activated by contact with cancer cells by a mechanism involving autocrine formation of adenosine and autocrine/paracrine signaling of the adenosine A3 receptor.
Matrine inhibits the development and progression of ovarian cancer by repressing cancer associated phosphorylation signaling pathways.
Matrix crosslinking forces tumor progression by enhancing integrin signaling.
MDA-7 negatively regulates the beta-catenin and PI3K signaling pathways in breast and lung tumor cells.
mda-7/IL24 kills pancreatic cancer cells by inhibition of the Wnt/PI3K signaling pathways: identification of IL-20 receptor-mediated bystander activity against pancreatic cancer.
MDM2 regulates hypoxic hypoxia-inducible factor 1? stability in an E3 ligase, proteasome, and PTEN-phosphatidylinositol 3-kinase-AKT-dependent manner.
Measurement of PIP3 levels reveals an unexpected role for p110? in early adaptive responses to p110?-specific inhibitors in luminal breast cancer.
Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer.
Measuring PI3K lipid kinase activity.
Mechanism of activation of SGK3 by growth factors via the Class 1 and Class 3 PI3Ks.
Mechanisms behind COX-1 and COX-2 inhibition of tumor growth in vivo.
Mechanisms behind resistance to PI3K Inhibitor treatment induced by the PIM kinase.
Mechanisms in epithelial plasticity and metastasis: insights from 3D cultures and expression profiling.
Mechanisms of PI3K?-Selective Inhibition Revealed by Reciprocal Mutagenesis.
Mechanisms of resistance to a PI3K inhibitor in gastrointestinal stromal tumors: an omic approach to identify novel druggable targets.
Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity.
Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer.
Medicinal Plants in the Prevention and Treatment of Colon Cancer.
MEK and PI3K inhibition in solid tumors: rationale and evidence to date.
MEK inhibitors in oncology: a patent review (2015-Present).
MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
MEK1 Is Required for PTEN Membrane Recruitment, AKT Regulation, and the Maintenance of Peripheral Tolerance.
Melatonin overcomes apoptosis resistance in human hepatocellular carcinoma by targeting Survivin and XIAP.
Membrane androgen receptor sensitive Na(+)/H(+) exchanger activity in prostate cancer cells.
MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type EGFR Family Members.
Mesenchymal-epithelial signalling in tumour microenvironment: role of high-mobility group Box 1.
Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer.
Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFN? receptor signaling.
Metabolic switching of PI3K-dependent lipid signals.
Metastases and their microenvironments: linking pathogenesis and therapy.
Metformin and erlotinib synergize to inhibit basal breast cancer.
Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase.
Methionine-stress: A pleiotropic approach in enhancing the efficacy of chemotherapy.
Methylseleninic acid promotes antitumour effects via nuclear FOXO3a translocation through Akt inhibition.
Mice expressing activated PI3K rapidly develop advanced colon cancer.
Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy.
Microarray phosphatome profiling of breast cancer patients unveils a complex phosphatase regulatory role of the MAPK and PI3K pathways in estrogen receptor-negative breast cancers.
Microarray-based identification of differentially expressed genes associated with andrographolide derivatives-induced resistance in colon and prostate cancer cell lines.
Microcystin-leucine arginine exhibits immunomodulatory roles in testicular cells resulting in orchitis.
MicroRNA Deregulation in Anaplastic Thyroid Cancer Biology.
MicroRNA-100 regulates IGF1-receptor expression in metastatic pancreatic cancer cells.
MicroRNA-124-3p inhibited progression of nasopharyngeal carcinoma by interaction with PCDH8 and the inactivation of PI3K/AKT/mTOR pathway.
MicroRNA-126 acts as a tumor suppressor in glioma cells by targeting insulin receptor substrate 1 (IRS-1).
microRNA-128 plays a critical role in human non-small cell lung cancer tumourigenesis, angiogenesis and lymphangiogenesis by directly targeting vascular endothelial growth factor-C.
MicroRNA-145 inhibits growth of laryngeal squamous cell carcinoma by targeting the PI3K/Akt signaling pathway.
MicroRNA-17?92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways.
MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2.
MicroRNA-2053 overexpression inhibits the development and progression of hepatocellular carcinoma.
MicroRNA-34A inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression.
MicroRNA-492 expression promotes the progression of hepatic cancer by targeting PTEN.
Mild chronic hypoxia-induced HIF-2? interacts with c-MYC through competition with HIF-1? to induce hepatocellular carcinoma cell proliferation.
Minimum regions of genomic imbalance in stage I testicular embryonal carcinoma and association of 22q loss with relapse.
Minireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy.
miR-126 in human cancers: clinical roles and current perspectives.
MiR-126-3p-Enriched Extracellular Vesicles from Hypoxia-Preconditioned VSC 4.1 Neurons Attenuate Ischaemia-Reperfusion-Induced Pain Hypersensitivity by Regulating the PIK3R2-Mediated Pathway.
MiR-142-3p targeting NUCKS1 inhibits proliferation and invasion of pancreatic cancer cells.
Mir-190b negatively contributes to the Trypanosoma cruzi- infected cell survival by repressing PTEN protein expression.
miR-21 targets and inhibits tumor suppressor gene PTEN to promote prostate cancer cell proliferation and invasion: An experimental study.
miR-218 suppresses tumor growth and enhances the chemosensitivity of esophageal squamous cell carcinoma to cisplatin.
miR-27b expression in diagnosis and evaluation prognosis of prostate cancer.
MiR-338-5p promotes metastasis of colorectal cancer by inhibition of phosphatidylinositol 3-kinase, catalytic subunit type 3-mediated autophagy pathway.
MiR-374b Promotes Proliferation and Inhibits Apoptosis of Human GIST Cells by Inhibiting PTEN through Activation of the PI3K/Akt Pathway.
miR-940 is a new biomarker with tumor diagnostic and prognostic value.
miRs-134 and -370 function as tumor suppressors in colorectal cancer by independently suppressing EGFR and PI3K signalling.
Mislocalization of the cell polarity protein Scribble promotes mammary tumorigenesis and is associated with basal breast cancer.
MLL3 Induced by Luteolin Causes Apoptosis in Tamoxifen-Resistant Breast Cancer Cells through H3K4 Monomethylation and Suppression of the PI3K/AKT/mTOR Pathway.
Model free approach to kinetic analysis of real-time hyperpolarized (13)c magnetic resonance spectroscopy data.
Modeling human disease in yeast: recreating the PI3K-PTEN-Akt signaling pathway in Saccharomyces cerevisiae.
Modeling medulloblastoma with genetically engineered mice.
Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer.
Modification of a dihydropyrrolopyrimidine phosphoinositide 3-kinase (PI3K) inhibitor to improve oral bioavailability.
Modulating apoptosis as a target for effective therapy.
Modulating the tumor microenvironment via oncolytic virus and PI3K inhibition synergistically restores immune checkpoint therapy response in PTEN-deficient glioblastoma.
Modulation of cell sensitivity to antitumor agents by targeting survival pathways.
Modulation of cell signaling pathways by Phyllanthus amarus and its major constituents: potential role in the prevention and treatment of inflammation and cancer.
Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family.
Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase.
Modulation of glycolysis and lipogenesis by novel PI3K selective molecule represses tumor angiogenesis and decreases colorectal cancer growth.
Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
Modulation of Matrix Metalloproteinases by Plant-derived Products.
Modulation of mitochondrial apoptosis by PI3K inhibitors.
Modulation of nongenomic activation of PI3K signalling by tetramerization of N-terminally-cleaved RXR?.
Modulation of sodium iodide symporter expression and function by LY294002, Akti-1/2 and rapamycin in thyroid cells.
Modulation of telomere protection by the PI3K/AKT pathway.
Modulation of the activity of certain genes involved in tumor cell metabolism in the presence of the cytotoxic peptides defensin and cathelicidin LL37.
Modulators of sensitivity and resistance to inhibition of PI3K identified in a pharmacogenomic screen of the NCI-60 human tumor cell line collection.
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.
Molecular alterations associated with prostate cancer.
Molecular alterations in uterine serous carcinoma.
Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma.
Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: Frequent PIK3CA amplification and AKT phosphorylation.
Molecular changes in the phosphatidylinositide 3-kinase (PI3K) pathway are common in gastric cancer.
Molecular characterization of DICER1-mutated pituitary blastoma.
Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.
Molecular determinants of PI3K?-mediated activation downstream of G-protein-coupled receptors (GPCRs).
Molecular Determinants of Thyroid Nodules with Indeterminate Cytology and RAS Mutations.
Molecular differential analysis of uterine leiomyomas and leiomyosarcomas through weighted gene network and pathway tracing approaches.
Molecular explorations of substituted 2-(4-phenylquinolin-2-yl) phenols as phosphoinositide 3-kinase inhibitors and anticancer agents.
Molecular genetics of bladder cancer: an update.
Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.
Molecular landscape of head and neck cancer and implications for therapy.
Molecular Mechanism Exploration of Potent Fluorinated PI3K Inhibitors with a Triazine Scaffold: Unveiling the Unusual Synergistic Effect of Pyridine-to-Pyrimidine Ring Interconversion and CF3 Defluorination.
Molecular mechanisms of action of Trehalose in cancer: A comprehensive review.
Molecular mechanisms of anticancer activity of deoxyelephantopin in cancer cells.
Molecular mechanisms of platelet activation and aggregation induced by breast cancer cells.
Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy.
Molecular Modeling, Synthesis and Biological Evaluation of N-Phenyl-4-Hydroxy-6-Methyl-2-Quinolone-3-CarboxAmides as Anticancer Agents.
Molecular pathology of skin adnexal tumors.
Molecular pathways associated with aggressiveness of papillary thyroid cancer.
Molecular pathways of urothelial development and bladder tumorigenesis.
Molecular pathways: intercellular PTEN and the potential of PTEN restoration therapy.
Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy.
Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy.
Molecular pathways: PI3K pathway targets in triple-negative breast cancers.
Molecular Pathways: Targeting the PI3K Pathway in Cancer-BET Inhibitors to the Rescue.
Molecular pathways: VCAM-1 as a potential therapeutic target in metastasis.
Molecular patterns in salivary duct carcinoma identify prognostic subgroups.
Molecular Profiling Establishes Genetic Features Predictive of the Efficacy of the p110? Inhibitor KIN-193.
Molecular profiling of lung adenosquamous carcinoma: hybrid or genuine type?
Molecular profiling of sinonasal undifferentiated carcinoma.
Molecular Profiling Reveals Common and Specific Development Processes in Different Types of Gynecologic Cancers.
Molecular target therapies in endometrial cancer: from the basic research to the clinic.
Molecular target: pan-AKT in gastric cancer.
Molecular targets of curcumin for cancer therapy: an updated review.
Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.
Molecularly targeting the PI3K-Akt-mTOR pathway can sensitize cancer cells to radiotherapy and chemotherapy.
Molecules in medicine mini-review: isoforms of PI3K in biology and disease.
Molybdenum disulfide-based hyaluronic acid-guided multifunctional theranostic nanoplatform for magnetic resonance imaging and synergetic chemo-photothermal therapy.
Monoclonal Antibody against Cell Surface GRP78 as a Novel Agent in Suppressing PI3K/AKT Signaling, Tumor Growth and Metastasis.
More Than Just Kinases: The Scaffolding Function of PI3K.
Morphine inhibits the promotion of inflammatory microenvironment on chronic tibial cancer pain through the PI3K-Akt-NF-?B pathway.
Morphine-3-glucuronide upregulates PD-L1 expression via TLR4 and promotes the immune escape of non-small cell lung cancer.
Motility-related proteins as markers for head and neck squamous cell cancer.
Mouse ER+/PIK3CAH1047R breast cancers caused by exogenous estrogen are heterogeneously dependent on estrogen and undergo BIM-dependent apoptosis with BH3 and PI3K agents.
Mouse Models for Exploring the Biological Consequences and Clinical Significance of PIK3CA Mutations.
Mouse models of PIK3CA mutations: one mutation initiates heterogeneous mammary tumors.
Mouse models to decipher the PI3K signaling network in human cancer.
mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma.
mTOR inhibition elicits a dramatic response in PI3K-dependent colon cancers.
mTOR inhibitor temsirolimus and MEK1/2 inhibitor U0126 promote chromosomal instability and cell type-dependent phenotype changes of glioblastoma cells.
mTOR kinase inhibitor potentiates apoptosis of PI3K and MEK inhibitors in diagnostically defined subpopulations.
mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids.
mTORC1 inhibition is required for sensitivity to PI3K p110? inhibitors in PIK3CA-mutant breast cancer.
mTORC1 promotes survival through translational control of Mcl-1.
mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers.
Multi-ancestral origin of intestinal tumors: Impact on growth, progression, and drug efficacy.
Multimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular response.
Multiple defects of cell cycle checkpoints in U937-ASPI3K, an U937 cell mutant stably expressing anti-sense ATM gene cDNA.
Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma.
Multiple metabolic alterations exist in mutant PI3K cancers, but only glucose is essential as a nutrient source.
Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell-Level PI3K Pathway Activation.
Murine Polyomavirus Cell Surface Receptors Activate Distinct Signaling Pathways Required for Infection.
Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway.
Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas.
Mutant ras-induced proliferation of human thyroid epithelial cells requires three effector pathways.
Mutated PI 3-kinases: cancer targets on a silver platter.
Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus.
Mutation analysis of tumor suppressor gene PTEN in patients with gastric carcinomas and its impact on PI3K/AKT pathway.
Mutation and genomic amplification of the PIK3CA proto-oncogene in pituitary adenomas.
Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer.
Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness.
Mutation of the PIK3CA oncogene in human cancers.
Mutation of the PTEN gene in a human hepatic angiosarcoma.
Mutation-Driven Signals of ARID1A and PI3K Pathways in Ovarian Carcinomas: Alteration Is An Opportunity.
Mutational and immunohistochemical analysis of ezrin-, radixin-, moesin (ERM) molecules in epilepsy-associated glioneuronal lesions.
Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes.
Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group.
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.
Mutations in the RAS and PI3K pathways are associated with metastatic location in colorectal cancers.
Mutations of PIK3CA in gastric adenocarcinoma.
MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer.
MYC-nick promotes cell migration by inducing fascin expression and Cdc42 activation.
MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers.
Myeloid PTEN deficiency impairs tumor-immune surveillance via immune-checkpoint inhibition.
Myricetin induces apoptosis by inhibiting P21 activated kinase 1 (PAK1) signaling cascade in hepatocellular carcinoma.
Myristoylated p110? Causes Embryonic Death Due to Developmental and Vascular Defects.
Myristoylation confers noncanonical AMPK functions in autophagy selectivity and mitochondrial surveillance.
Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis.
Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid Malignancies.
Naproxen induces cell-cycle arrest and apoptosis in human urinary bladder cancer cell lines and chemically induced cancers by targeting PI3K.
Natural forms of vitamin E and metabolites-regulation of cancer cell death and underlying mechanisms.
NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer.
Ndfip1 regulates nuclear Pten import in vivo to promote neuronal survival following cerebral ischemia.
Necessity to evaluate PI3K/Akt signalling pathway in proarrhythmia.
Nedd4-dependent lysine-11-linked polyubiquitination of the tumour suppressor Beclin 1.
NEDD4L Protein Catalyzes Ubiquitination of PIK3CA Protein and Regulates PI3K-AKT Signaling.
Neferine augments therapeutic efficacy of cisplatin through ROS- mediated non-canonical autophagy in human lung adenocarcinoma (A549 cells).
Negative cross talk between LIMK2 and PTEN promotes castration resistant prostate cancer pathogenesis in cells and in vivo.
Negative feedback regulation of the tumor suppressor PTEN by phosphoinositide-induced serine phosphorylation.
Negative regulation of Vps34 by Cdk mediated phosphorylation.
Neither ovariectomy nor progestin treatment prevents endometrial neoplasia in pten+/- mice.
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Nerve growth factor protects oligodendrocytes from tumor necrosis factor-alpha-induced injury through Akt-mediated signaling mechanisms.
Network Pharmacology Analysis of Traditional Chinese Medicine Formula Xiao Ke Yin Shui Treating Type 2 Diabetes Mellitus.
Network Pharmacology-Based Study on the Mechanism of Bushen-Jianpi Decoction in Liver Cancer Treatment.
Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes.
Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L.
Neurofibromatosis-like phenotype in Drosophila caused by lack of glucosylceramide extension.
Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth.
New anti-cancer role for PDK1 inhibitors: preventing resistance to tamoxifen.
New Cellular Dimensions on Glioblastoma Progression.
New functions for PI3K in the control of cell division.
New Insights into PI3K Inhibitor Design using X-ray Structures of PI3K? Complexed with a Potent Lead Compound.
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
New Mechanisms of mTOR Pathway Activation in KIT-mutant Malignant GISTs.
New molecular targets in the treatment of NSCLC.
New perspective for an old antidiabetic drug: metformin as anticancer agent.
New phosphatidylinositol 3-kinase inhibitors for cancer.
New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?pi.
Next generation sequencing of progressive colorectal liver metastases after portal vein embolization.
Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma.
Next-generation sequencing reveals heterogeneous genetic alterations in key signaling pathways of mismatch repair deficient colorectal carcinomas.
Niaspan treatment induces neuroprotection after stroke.
Nicotine Stimulated Dendritic Cells Could Achieve Anti-Tumor Effects in Mouse Lung and Liver Cancer.
Nitric oxide increases the invasion of pancreatic cancer cells via activation of the PI3K-AKT and RhoA pathways after carbon ion irradiation.
NLRC3 inhibits MCT-induced pulmonary hypertension in rats via attenuating PI3K activation.
Nobiletin Inhibits Helicobacterium pylori Infection-Induced Gastric Carcinogenic Signaling by Blocking Inflammation, Apoptosis, and Mitogen-Activated Protein Kinase Events in Gastric Epithelial-1 Cells.
Non-coding RNAs in Wilms' tumor: biological function, mechanism, and clinical implications.
Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway.
Non-invasive (89)Zr-Transferrin PET Shows Improved Tumor Targeting Compared to (18)F-FDG PET in MYC-overexpressing Human Triple Negative Breast Cancer.
Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Nongenomic activation of phosphatidylinositol 3-kinase signaling by thyroid hormone receptors.
Nongenomic effects of thyroid hormones on the immune system cells: New targets, old players.
Notch signaling: a hero or villain in the war against cancer?
Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer.
Notch1 Signaling Promotes Primary Melanoma Progression by Activating Mitogen-Activated Protein Kinase/Phosphatidylinositol 3-Kinase-Akt Pathways and Up-regulating N-Cadherin Expression.
Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3K? inhibition.
Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma.
Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers.
Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer.
Novel inhibitors of the PI3K family.
Novel Miniaturized Drug Conjugate Leverages HSP90-driven Tumor Accumulation to Overcome PI3K Inhibitor Delivery Challenges to Solid Tumors.
Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer.
Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone.
Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines under Normoxic and Hypoxic Conditions.
Novel PRMT5-mediated arginine methylations of HSP90A are essential for maintenance of HSP90A function in NDRG2low ATL and various cancer cells.
Novel role of microRNA-126 in digestive system cancers: From bench to bedside.
Novel roles of the autocrine motility factor/phosphoglucose isomerase in tumor malignancy.
Novel strategy in breast cancer therapy: Revealing the bright side of ginsenosides.
Novel targetable FGFR2 and FGFR3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs.
Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity In Vitro and In Vivo.
NSAID therapy for PIK3CA-Altered colorectal, breast, and head and neck cancer.
NTRK3 kinase fusions in Spitz tumours.
Nuclear accumulation of ?-catenin and forkhead box O3a in colon cancer: Dangerous liaison.
Nuclear FOXO1 promotes lymphomagenesis in germinal center B cells.
Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer.
Nuclear PTEN interferes with binding of Ku70 at double-strand breaks through post-translational poly(ADP-ribosyl)ation.
Nuclear receptor corepressor is a novel regulator of phosphatidylinositol 3-kinase signaling.
Nuclear trafficking of EGFR by Vps34 represses Arf expression to promote lung tumor cell survival.
Nutrient restriction enhances the proliferative potential of cells lacking the tumor suppressor PTEN in mitotic tissues.
NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity.
NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells.
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.
Obesity and Obese-related Chronic Low-grade Inflammation in Promotion of Colorectal Cancer Development.
Occurrence of low frequency PIK3CA and AKT2 mutations in gastric cancer.
Ocular Toxicity Profile of ST-162 and ST-168 as Novel Bifunctional MEK/PI3K Inhibitors.
Omipalisib inspired macrocycles as dual PI3K/mTOR inhibitors.
On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors.
Oncogene alterations in endometrial carcinosarcomas.
Oncogenes and tumor suppressor genes.
Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis.
Oncogenic activation of the PI3-kinase p110? isoform via the tumor-derived PIK3C?(D1067V) kinase domain mutation.
Oncogenic dependence of glioma cells on kish/TMEM167A regulation of vesicular trafficking.
Oncogenic driver mutations predict outcome in a cohort of head and neck squamous cell carcinoma (HNSCC) patients within a clinical trial.
Oncogenic function for the Dlg1 mammalian homolog of the Drosophila discs-large tumor suppressor.
Oncogenic Fusion Gene CD74-NRG1 Confers Cancer Stem Cell-like Properties in Lung Cancer through a IGF2 Autocrine/Paracrine Circuit.
Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor.
Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo.
Oncogenic met receptor induces cell-cycle progression in Xenopus oocytes independent of direct Grb2 and Shc binding or mos synthesis, but requires phosphatidylinositol 3-kinase and raf signaling.
Oncogenic mutations in gastric cancer with microsatellite instability.
Oncogenic mutations of PIK3CA in human cancers.
Oncogenic Mutations of PIK3CA in Human Cancers.
Oncogenic PI3K and its role in cancer.
Oncogenic PI3K deregulates transcription and translation.
Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling.
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern.
Oncogenic PIK3CA promotes cellular stemness in an allele dose-dependent manner.
Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms.
Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
Oncogenic Ras/Her-2 mediate hyperproliferation of polarized epithelial cells in 3D cultures and rapid tumor growth via the PI3K pathway.
Oncogenic regulation of tumor metabolic reprogramming.
Oncogenic role of neurotensin and neurotensin receptors in various cancers.
Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells.
Only a subset of Met-activated pathways are required to sustain oncogene addiction.
Only a subset of met-activated pathways are required to sustain oncogene addiction.
Opposing roles of the two isoforms of ErbB3 binding protein 1 in human cancer cells.
Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.
Optogenetic control of epithelial-mesenchymal transition in cancer cells.
Oral ridaforolimus plus trastuzumab for patients with HER2+ trastuzumab-refractory metastatic breast cancer.
Oridonin inhibits oral cancer growth and PI3K/Akt signaling pathway.
Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN.
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.
Ovatodiolide Suppresses Oral Cancer Malignancy by Down-Regulating Exosomal Mir-21/STAT3/?-Catenin Cargo and Preventing Oncogenic Transformation of Normal Gingival Fibroblasts.
Overexpression of 14-3-3? in cancer cells activates PI3K via binding the p85 regulatory subunit.
Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines.
Overexpression of ATP-Binding Cassette Subfamily G Member 2 Confers Resistance to Phosphatidylinositol 3-Kinase Inhibitor PF-4989216 in Cancer Cells.
Overexpression of DJ-1 and HSP90?, and loss of PTEN associated with invasive urothelial carcinoma of urinary bladder: Possible prognostic markers.
Overexpression of Long Noncoding RNA H19 Downregulates miR-140-5p and Activates PI3K/AKT Signaling Pathway to Promote Invasion, Migration and Epithelial-Mesenchymal Transition of Ovarian Cancer Cells.
Overexpression of phosphatidylinositol 3-kinase in human lung cancer.
Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway.
Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGF? signaling.
Overexpression of PIK3R1 promotes hepatocellular carcinoma progression.
Overexpression of Suppressor of Cytokine Signaling 3 in Adipose Tissue Causes Local but Not Systemic Insulin Resistance.
Overexpression of the N-terminal end of the p55gamma regulatory subunit of phosphatidylinositol 3-kinase blocks cell cycle progression in gastric carcinoma cells.
Overshoot during phenotypic switching of cancer cell populations.
Oxidative stress downstream of mTORC1 but not AKT causes a proliferative defect in cancer cells resistant to PI3K inhibition.
Oxytocin effects on the inhibition of the NF-?B/miR195 pathway in mice breast cancer.
P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer.
P-Rex1 Expression in Invasive Breast Cancer in relation to Receptor Status and Distant Metastatic Site.
p110? and p110? isoforms of PI3K are involved in protection against H2O2 induced oxidative stress in cancer cells.
p110? deficiency protects against pancreatic carcinogenesis yet predisposes to diet-induced hepatotoxicity.
p110? PI3 kinase pathway: emerging roles in cancer.
p110? PI3K as a therapeutic target of solid tumours.
p120-Catenin Downregulation and PIK3CA Mutations Cooperate to Induce Invasion through MMP1 in HNSCC.
p27 as Jekyll and Hyde: Regulation of cell cycle and cell motility.
P300/CBP inhibition sensitizes mantle cell lymphoma to PI3K? inhibitor idelalisib.
p37? is a new isoform of PI3K p110? that increases cell proliferation and is overexpressed in tumors.
P42 Ebp1 regulates the proteasomal degradation of the p85 regulatory subunit of PI3K by recruiting a chaperone-E3 ligase complex HSP70/CHIP.
P450-mediated O-demethylated metabolite is responsible for rat hepatobiliary toxicity of pyridyltriazine-containing PI3K inhibitors.
p53 and NF 1 loss plays distinct but complementary roles in glioma initiation and progression.
p55PIK-PI3K stimulates angiogenesis in colorectal cancer cell by activating NF-?B pathway.
p85? phosphoinositide 3-kinase subunit regulates tumor progression.
p85? regulates autophagic degradation of AXL to activate oncogenic signaling.
p85alpha acts as a novel signal transducer for mediation of cellular apoptotic response to UV radiation.
Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability.
Pan-Cancer Multiomics Analysis of TC2N Gene Suggests its Important Role(s) in Tumourigenesis of Many Cancers.
Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma.
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.
Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy.
Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase ? Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy.
Parsaclisib, a potent and highly selective PI3K? inhibitor, in patients with relapsed or refractory B-cell malignancies.
Particular molecular and ultrastructural aspects in invasive mammary carcinoma.
Past, Present, and Future of Targeting Ras for Cancer Therapies.
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.
Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma.
PDGF regulated migration of mesenchymal stem cells towards malignancy acts via the PI3K signaling pathway.
PDK1 inhibitors.
Pentraxin-3 is a PI3K signaling target that promotes stem cell-like traits in basal-like breast cancers.
Peripheral axon regrowth: New molecular approaches.
Peroxiredoxin 1 silencing inhibited the growth and promoted apoptosis of pancreatic cancer cells via targeting FOXO3 gene.
Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity.
Perspective: Potential Impact and Therapeutic Implications of Oncogenic PI3K Activation on Chromosomal Instability.
Perspectives on the role of PTEN in diabetic nephropathy: an update.
PF-04691502 triggers cell cycle arrest, apoptosis and inhibits the angiogenesis in hepatocellular carcinoma cells.
PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.
Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics.
Pharmacogenomic profiling of the PI3K/PTEN pathway in sporadic breast cancer.
Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.
Pharmacologic characterization of SHR8443, a novel dual inhibitor of phosphatidylinositol 3-kinase and mammalian target of rapamycin.
Pharmacological inactivation of the PI3K p110? prevents breast tumour progression by targeting cancer cells and macrophages.
Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer.
Phase 1 clinical trial of the PI3K? inhibitor YY-20394 in patients with B-cell hematological malignancies.
Phase 1 study of rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
Phase 1 study of the PI3K? inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma.
Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.
Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations.
Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08).
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers.
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors.
Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors.
Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147), a Pan-Class I PI3K Inhibitor, in Combination With Erlotinib in Patients With Solid Tumors.
Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.
Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma.
Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors.
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors.
Phase I study of alpelisib (BYL719), an ?-specific PI3K inhibitor, in Japanese patients with advanced solid tumors.
Phase I study of BGT226, a pan-PI3K and mTOR inhibitor, in Japanese patients with advanced solid cancers.
Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.
Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies.
Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies.
Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.
Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II).
Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer.
Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets.
Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.
Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors.
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.
Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer.
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.
Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study.
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma.
PHLDA2 regulates EMT and autophagy in colorectal cancer via the PI3K/AKT signaling pathway.
Phosphatase and tensin homologue (PTEN) regulates synaptic plasticity independently of its effect on neuronal morphology and migration.
Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.
Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer.
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.
Phosphatidylinositol 3-kinase (PI3K) signaling does not activate the Wnt cascade.
Phosphatidylinositol 3-kinase ? and ? isoforms play key roles in metastasis of prostate cancer DU145 cells.
Phosphatidylinositol 3-Kinase ?-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association.
Phosphatidylinositol 3-kinase affects mitochondrial function in part through inducing peroxisome proliferator-activated receptor ? coactivator-1? expression.
Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.
Phosphatidylinositol 3-kinase binding to polyoma virus middle tumor antigen mediates elevation of glucose transport by increasing translocation of the GLUT1 transporter.
Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren's syndrome.
Phosphatidylinositol 3-kinase gamma inhibition ameliorates inflammation and tumor growth in a model of colitis-associated cancer.
Phosphatidylinositol 3-kinase in the G protein-coupled receptor-induced chemokinesis and chemotaxis of MDA-MB-468 breast carcinoma cells: a comparison with leukocytes.
Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines.
Phosphatidylinositol 3-kinase inhibition down-regulates survivin and facilitates TRAIL-mediated apoptosis in neuroblastomas.
Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy.
Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets.
Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer.
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.
Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.
Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
Phosphatidylinositol 3-kinase regulation of gastrin-releasing peptide-induced cell cycle progression in neuroblastoma cells.
Phosphatidylinositol 3-kinase regulatory subunit 1 and phosphatase and tensin homolog as therapeutic targets in breast cancer.
Phosphatidylinositol 3-kinase related kinases.
Phosphatidylinositol 3-kinase signaling and immune regulation: insights into disease pathogenesis and clinical implications.
Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1.
Phosphatidylinositol 3-kinase translocates to the nucleus of osteoblast-like MC3T3-E1 cells in response to insulin-like growth factor I and platelet-derived growth factor but not to the proapoptotic cytokine tumor necrosis factor alpha.
Phosphatidylinositol 3-kinase, class 2 beta (PI3KC2?) isoform contributes to neuroblastoma tumorigenesis.
Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer.
Phosphatidylinositol 3-kinase-Akt signaling in pulmonary carcinoid cells.
Phosphatidylinositol 3-kinase/Akt activation by integrin-tumor matrix interaction suppresses Fas-mediated apoptosis in T cells.
Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation.
Phosphatidylinositol 3-kinase/AKT signalling pathway components in human breast cancer: clinicopathological correlations.
Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation.
Phosphatidylinositol 3-Kinase: A Link Between Inflammation and Pancreatic Cancer.
Phosphatidylinositol 3-kinases in tumor progression.
Phosphatidylinositol 4,5-bisphosphate (PIP(2))-specific AKT1 is oncogenic.
Phosphatidylinositol Phosphate 5-Kinase I? and Phosphoinositide 3-Kinase/Akt Signaling Couple to Promote Oncogenic Growth.
Phosphatidylinositol-3 kinase p85 enhances expression from the myelin basic protein promoter in oligodendrocytes.
Phosphatidylinositol-3,4-Bisphosphate and Its Binding Protein Lamellipodin Regulate Chemotaxis of Malignant B Lymphocytes.
Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.
Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: Meta-analysis, co-occurrence and ethnic variation.
Phosphatidylinositol-3-Kinase-AKT Pathway, Phospho-JUN and Phospho-JNK Expression in Spontaneously Arising Bovine Urinary Bladder Tumours.
Phospho-PRAS40(Thr246) predicts trastuzumab response in patients with HER2-positive metastatic breast cancer.
Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy.
Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies.
Phosphoinositide 3'-kinase delta: turning off BCR signaling in Chronic Lymphocytic Leukemia..
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients.
Phosphoinositide 3-kinase ? regulates chromosome segregation in mitosis.
Phosphoinositide 3-kinase accelerates postoperative tumor growth by inhibiting apoptosis and enhancing resistance to chemotherapy-induced apoptosis. Novel role for an old enemy.
Phosphoinositide 3-kinase and INPP4B in human breast cancer.
Phosphoinositide 3-kinase assay in breast cancer cell extracts.
Phosphoinositide 3-kinase controls early and late events in mammalian cell division.
Phosphoinositide 3-Kinase Gamma Inhibition Protects from Anthracycline Cardiotoxicity and Reduces Tumor Growth.
Phosphoinositide 3-kinase in disease: timing, location, and scaffolding.
Phosphoinositide 3-kinase inhibition in cancer treatment.
Phosphoinositide 3-kinase inhibitor (wortmannin) inhibits pancreatic cancer cell motility and migration induced by hyaluronan in vitro and peritoneal metastasis in vivo.
Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumors: rationale and efficacy.
Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis.
Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion.
Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions.
Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry.
Phosphoinositide 3-kinase signaling can modulate MHC class I and II expression.
Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?
Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics.
Phosphoinositide 3-kinase signaling pathway mediated by p110? regulates invadopodia formation.
Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play?
Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis.
Phosphoinositide 3-kinase-related overgrowth: cellular phenotype and future therapeutic options.
Phosphoinositide 3-kinase: from viral oncoprotein to drug target.
Phosphoinositide 3-kinases as drug targets in cancer.
Phosphoinositide 3-kinases as targets for therapeutic intervention.
Phosphoinositide 3-kinases in health and disease.
Phosphoinositide 3?kinase/protein kinase B regulates inflammation severity via signaling of Toll?like receptor 4 in severe acute pancreatitis.
Phosphoinositide phosphatases in cancer cell dynamics-Beyond PI3K and PTEN.
Phosphoinositide signalling in cancer: beyond PI3K and PTEN.
Phosphoinositide-3-Kinase Enhancers, PIKEs: Their Biological Functions and Roles in Cancer.
Phosphoinositide-3-kinase inhibition enhances radiosensitization of cervical cancer in vivo.
Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells.
Phosphoinositides signalling in cancer: Focus on PI3K and PLC.
Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition.
Phosphoproteomic comparison of Pik3ca and Pten signalling identifies the nucleotidase NT5C as a novel AKT substrate.
Phosphoproteomics reveals that the hVPS34 regulated SGK3 kinase specifically phosphorylates endosomal proteins including Syntaxin-7, Syntaxin-12, RFIP4 and WDR44.
Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients.
Phosphorylated T567 ezrin is associated with merlin expression in KIT-mutant gastrointestinal stromal tumors.
Phosphorylation and Driver Mutations in PI3K? and PTEN Autoinhibition.
Phosphorylation of CSF-1R Y721 mediates its association with PI3K to regulate macrophage motility and enhancement of tumor cell invasion.
Phosphorylation of PI3K regulatory subunit p85 contributes to resistance against PI3K inhibitors in radioresistant head and neck cancer.
Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: discovery and structure-activity relationships of a series of quinoline and quinoxaline derivatives.
Phytochemicals and PI3K Inhibitors in Cancer-An Insight.
PI(3)king apart PTEN's role in cancer.
PI-3-K and AKT: Onto the mitochondria.
PI-3-kinase is an essential anti-apoptotic effector in the proliferative response of primary human epithelial cells to mutant RAS.
PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance?
PI3 kinase alpha and delta promote hematopoietic stem cell activation.
PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cells.
PI3 Kinase in Cancer: From Biology to Clinic.
PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancer.
PI3 kinase is indispensable for oncogenic transformation by the V560D mutant of c-Kit in a kinase-independent manner.
PI3 Kinase Pathway Mutations in Human Cancers.
PI3 kinase pathway regulated miRNome in glioblastoma: identification of miR-326 as a tumour suppressor miRNA.
PI3 kinase signaling pathway in hematopoietic cancers: A glance in miRNA's role.
PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma.
PI3 kinases in cancer: from oncogene artifact to leading cancer target.
PI3-K/AKT regulation of NF-kappaB signaling events in suppression of TNF-induced apoptosis.
PI3-K/Akt-dependent activation of cAMP-response element-binding (CREB) protein in Jurkat T leukemia cells treated with TRAIL.
PI3-kinase and TOR: PIKTORing cell growth.
PI3-kinase: a new kid on the block in vascular anomalies.
PI3K abrogation using pan PI3K inhibitor BKM120 give rise to a weighty anti-cancer effect on AML-derived KG-1 cells by inducing apoptosis and G2/M arrest
PI3K activation in neural stem cells drives tumorigenesis which can be ameliorated by targeting the cAMP response element binding protein.
PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes.
PI3K and AKT: Unfaithful Partners in Cancer.
PI3K and BET Inhibition Overcomes RTK-Driven Resistance in Cancer.
PI3K and cancer: lessons, challenges and opportunities.
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types.
PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies.
PI3K and RAC signalling in leukocyte and cancer cell migration.
PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors.
PI3K as a Target for Therapy in Haematological Malignancies.
PI3K at the crossroads of tumor angiogenesis signaling pathways.
PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer.
PI3K Catalytic Isoform Alteration Promotes the LIMK1-related Metastasis Through the PAK1 or ROCK1/2 Activation in Cigarette Smoke-exposed Ovarian Cancer Cells.
PI3K expression predicts overall survival in lung adenocarcinoma.
PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors.
PI3K in cancer-stroma interactions: bad in seed and ugly in soil.
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.
PI3K in cancer: its structure, activation modes and role in shaping tumor microenvironment.
PI3K in stemness regulation: from development to cancer.
PI3K inhibition enhances doxorubicin-induced apoptosis in sarcoma cells.
PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer.
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA proficient triple negative breast cancer to PARP inhibition.
PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance.
PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough.
PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses.
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.
PI3K inhibition sensitizes EGFR wild-type NSCLC cell lines to erlotinib chemotherapy.
PI3K Inhibitor Combined With Chemotherapy Can Enhance the Apoptosis of Neuroblastoma Cells In Vitro and In Vivo.
PI3K inhibitor combined with miR-125b inhibitor sensitize TMZ-induced anti-glioma stem cancer effects through inactivation of Wnt/?-catenin signaling pathway.
PI3K Inhibitors and Adverse Events: Optimizing Patient Care for the Treatment of Advanced Breast Cancer.
PI3K inhibitors are finally coming of age.
PI3K inhibitors as new cancer therapeutics: implications for clinical trial design.
PI3K inhibitors as novel cancer therapies: implications for cardiovascular medicine.
PI3K inhibitors for cancer therapy: what has been achieved so far?
PI3K inhibitors for cancer treatment: five years of preclinical and clinical research after BEZ235.
PI3K inhibitors for cancer treatment: where do we stand?
PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects.
PI3K inhibitors in inflammation, autoimmunity and cancer.
PI3K Inhibitors: Understanding Toxicity Mechanisms and Management.
PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation.
PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.
PI3K Isoform-Selective Inhibitors in Cancer.
PI3K isoform-selective inhibitors: next-generation targeted cancer therapies.
PI3K Isoforms Have Spatially Distinct Roles in PTEN Hamartoma Tumor Syndrome.
PI3K keeps the balance between metabolism and cancer.
PI3K mediates tumor necrosis factor induced-necroptosis through initiating RIP1-RIP3-MLKL signaling pathway activation.
PI3K mutations in breast cancer: prognostic and therapeutic implications.
PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells.
PI3K Overexpression and PIK3CA Mutations Are Associated with Age, Tumor Staging, and Other Clinical Characteristics in Chinese Patients with Esophageal Squamous Cell Carcinoma.
PI3K p110? isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition.
PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality.
PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers.
PI3K pathway alterations in cancer: variations on a theme.
PI3K pathway and Bcl-2 family. Clinicopathological features in prostate cancer.
PI3K Pathway Effectors pAKT and FOXO1 as Novel Markers of Endometrioid Intraepithelial Neoplasia.
PI3K Pathway in Gynecologic Malignancies.
PI3K Pathway in NSCLC.
PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer.
PI3K pathway inhibitors: better not left alone.
PI3K pathway is involved in ERK signaling cascade activation by histamine H2R agonist in HEK293T cells.
PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo.
PI3K pathway-directed therapeutic strategies in cancer.
PI3K Plays an Essential Role in Planarian Regeneration and Tissue Maintenance.
PI3K Promotes Basal Cell Carcinoma Growth Through Kinase-Induced p21 Degradation.
PI3K regulates intraepithelial cell positioning through Rho GTP-ases in the developing neural tube.
PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.
PI3K regulatory subunits lose control in cancer.
PI3K signaling in cancer: beyond AKT.
PI3K signaling in glioma--animal models and therapeutic challenges.
PI3K signaling maintains c-myc expression to regulate transcription of E2F1 in pancreatic cancer cells.
PI3K signaling pathway in normal B cells and indolent B-cell malignancies.
PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events.
PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances.
PI3K signalling: the path to discovery and understanding.
PI3K target based novel cyano derivative of betulinic acid induces its signalling inhibition by down-regulation of pGSK3? and cyclin D1 and potentially checks cancer cell proliferation.
PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion.
PI3K(p110alpha) inhibitors as anti-cancer agents: minding the heart.
PI3K, Rac1 and pPAK1 are overexpressed in extramammary Paget's disease.
PI3K-based molecular signatures link high PI3K pathway activity with low ER levels in ER+ breast cancer.
PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells.
PI3K-independent AKT activation in cancers: A treasure trove for novel therapeutics.
PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition.
PI3K-mTORC2 but not PI3K-mTORC1 regulates transcription of HIF2A/EPAS1 and vascularization in neuroblastoma.
PI3K-p110? mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85?.
PI3K-PTEN dysregulation leads to mTOR-driven upregulation of the core clock gene BMAL1 in normal and malignant epithelial cells.
PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis.
PI3K/Akt inhibition modulates multidrug resistance and activates NF-kappaB in murine lymphoma cell lines.
PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma.
PI3K/Akt pathway activation attenuates the cytotoxic effect of methyl jasmonate toward sarcoma cells.
PI3K/AKT pathway regulates phosphorylation of steroid receptors, hormone independence and tumor differentiation in breast cancer.
PI3K/Akt Pathway: The Indestructible Role of a Vintage Target as a Support to the Most Recent Immunotherapeutic Approaches.
PI3K/Akt signaling in osteosarcoma.
PI3K/AKT signaling is essential for communication between tissue infiltrating mast cells, macrophages, and epithelial cells in colitis-induced cancer.
PI3K/Akt-mediated regulation of p53 in cancer.
PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
PI3K/AKT/mTOR inhibitors in ovarian cancer.
PI3K/AKT/mTOR Pathway in Angiogenesis.
PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress.
PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?
PI3K/Akt/mTOR signaling and plasma membrane proteins are implicated in responsiveness to adjuvant dendritic cell vaccination for metastatic colorectal cancer.
PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer.
PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response.
PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases.
PI3K/PTEN signaling in angiogenesis and tumorigenesis.
PI3K/PTEN signaling in tumorigenesis and angiogenesis.
PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
PI3K: A Crucial Piece in the RAS Signaling Puzzle.
PI3K: A potential therapeutic target for cancer.
PI3K: From the Bench to the Clinic and Back.
PI3K: Missense Mutation Motivates Malignancy.
PI3K? Inhibition Hits a Sensitive Spot in B Cell Malignancies.
PI3K? inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response.
PI3K? inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8+T cells and promoting fatty acid metabolism.
PI3K? inhibitors in cancer: rationale and serendipity merge in the clinic.
PI3K? Is a Therapeutic Target in Hepatocellular Carcinoma.
PI3K? is essential for the recovery from Cre/tamoxifen cardiotoxicity and in myocardial insulin signalling but is not required for normal myocardial contractility in the adult heart.
PI3K?/? inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity.
PI3KCA Mutations in Uterine Cervix Carcinoma.
PI3Kinase signaling in glioblastoma.
PI3Ks-Drug Targets in Inflammation and Cancer.
Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study.
Pieces of the complex puzzle of cancer cell energy metabolism: an overview of energy metabolism and alternatives for targeted cancer therapy.
PIK3C3 Acts as a Tumor Suppressor in Esophageal Squamous Cell Carcinoma and Was Regulated by MiR-340-5p.
PIK3C3 Inhibition Promotes Sensitivity to Colon Cancer Therapy by Inhibiting Cancer Stem Cells.
PIK3C3 regulates the expansion of liver CSCs and PIK3C3 inhibition counteracts liver cancer stem cell activity induced by PI3K inhibitor.
PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma.
PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients.
PIK3CA and AKT1 Mutations Have Distinct Effects on Sensitivity to Targeted Pathway Inhibitors in an Isogenic Luminal Breast Cancer Model System.
PIK3CA and APC mutations are synergistic in the development of intestinal cancers.
PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001.
PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer.
PIK3CA and p53 mutations promote 4NQO-initated head and neck tumor progression and metastasis in mice.
PIK3CA and PTEN mutations in adenoid cystic carcinoma of the breast metastatic to kidney.
PIK3CA cancer mutations display gender and tissue specificity patterns.
PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.
PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma.
PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients.
PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.
PIK3CA gene mutations in breast carcinoma in Malaysian patients.
PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations.
PIK3CA gene mutations in pediatric and adult glioblastoma multiforme.
PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models.
PIK3CA in cancer: The past 30 years.
PIK3CA in Colorectal Cancer.
PIK3CA is critical for the proliferation, invasiveness, and drug resistance of human tongue carcinoma cells.
PIK3CA is implicated as an oncogene in ovarian cancer.
PIK3CA mutant tumors depend on oxoglutarate dehydrogenase.
PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma.
PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.
PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.
PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells.
PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors.
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
PIK3CA mutations in breast cancer are associated with poor outcome.
PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.
PIK3CA mutations in hepatocellular carcinoma in Korea.
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches.
PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas.
PIK3CA Mutations in Resected Small Cell Lung Cancer.
PIK3CA mutations in small bowel adenocarcinoma.
PIK3CA mutations in vascular malformations.
PIK3CA mutations matter for cancer in dogs.
PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling.
PIK3CA, a hotspot for postzygotic mutations in nonhereditary overgrowth syndromes.
PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas.
PIK3CB/p110? is a selective survival factor for glioblastoma.
PIK3IP1/TrIP restricts activation of T cells through inhibition of PI3K/Akt.
PIK3R1 (p85-alpha/p85{alpha}) is Somatically Mutated at High Frequency in Primary Endometrial Cancer.
PIK3R3 induces epithelial-to-mesenchymal transition and promotes metastasis in colorectal cancer.
PIK3R3 promotes chemotherapeutic sensitivity of colorectal cancer through PIK3R3/NF-kB/TP pathway.
PIK3R3 Promotes Metastasis of Pancreatic Cancer via ZEB1 Induced Epithelial-Mesenchymal Transition.
PIKing the right isoform: the emergent role of the p110beta subunit in breast cancer.
PIKing the right patient.
Pilocytic astrocytoma: a review of genetic and molecular factors, diagnostic and prognostic markers.
Piperlongumine, a piper alkaloid targets Ras/PI3K/Akt/mTOR signaling axis to inhibit tumor cell growth and proliferation in DMH/DSS induced experimental colon cancer.
Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent.
PIPPing on AKT1: How Many Phosphatases Does It Take to Turn off PI3K?
Pityriasis rubra pilaris-like erythroderma secondary to phosphoinositide 3-kinase inhibition.
Pivotal role of Pten in the balance between proliferation and differentiation of hematopoietic stem cells in zebrafish.
PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts.
PKB/Akt-Dependent Regulation of Cell Motility.
PKN3 is required for malignant prostate cell growth downstream of activated PI 3-kinase.
Plasma metabolomic changes following PI3K inhibition as pharmacodynamic biomarkers: preclinical discovery to Phase I trial evaluation.
Platelet releasate promotes breast cancer growth and angiogenesis via VEGF-integrin cooperative signalling.
Plk1 phosphorylates PTEN and regulates its mitotic activity during the cell cycle.
Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin.
Polyamine production is downstream and upstream of oncogenic PI3K signalling and contributes to tumour cell growth.
Polymorphic GT dinucleotide repeat in the PIK3CA gene and risk of colorectal cancer.
Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
Polyunsaturated fatty acids inhibit PI3K activity in a yeast-based model system.
Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer.
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.
Positive Effects of PI3K/Akt Signaling Inhibition on PTEN and P53 in Prevention of Acute Lymphoblastic Leukemia Tumor Cells.
Potential role of PI3K inhibitors in the treatment of breast cancer.
pp60c-Src phosphorylates and activates vacuolar protein sorting 34 to mediate cellular transformation.
Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor.
Preclinical Assessment of the Absorption and Disposition of the Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor GDC-0980 and Prediction of Its Pharmacokinetics and Efficacy in Human.
Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl-Pyrimidine Moiety.
Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer.
Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro.
Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells.
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Preclinical Rationale for PI3K/Akt/mTOR Pathway Inhibitors as Therapy for Epidermal Growth Factor Receptor Inhibitor-Resistant Non-Small-Cell Lung Cancer.
Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
Predictability, efficacy and safety of radiosensitization of glioblastoma-initiating cells by the ATM inhibitor KU-60019.
Predictive and prognostic significance of p27, Akt, PTEN and PI3K expression in HER2-positive metastatic breast cancer.
Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors.
Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors.
Predictive value of FHIT, p27, and pERK1/ERK2 in salivary gland carcinomas: a retrospective study.
Present and Future of PI3K Pathway Inhibition in Cancer: Perspectives and Limitations.
Present and future of PI3K pathway inhibition in cancer: perspectives and limitations.
Prevalence and prognostic role of PIK3CA E545K mutation in Iranian colorectal cancer patients.
Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients.
Primary mammary angiosarcomas harbor frequent mutations in KDR and PIK3CA and show evidence of distinct pathogenesis.
PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition.
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells.
Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas.
Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date.
Profiling the tyrosine phosphoproteome of different mouse mammary tumour models reveals distinct, model-specific signalling networks and conserved oncogenic pathways.
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Proliferation and polarity in breast cancer: untying the gordian knot.
Proliferation of PTEN-deficient haematopoietic tumour cells is not affected by isoform-selective inhibition of p110 PI3-kinase and requires blockade of all class 1 PI3K activity.
Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer.
Prolonged inhibition of class I PI3K promotes liver cancer stem cell expansion by augmenting SGK3/GSK-3?/?-catenin signalling.
Promising rationally derived combination therapy with PI3K and CDK4/6 inhibitors.
Promotion of cancer cell invasiveness and metastasis emergence caused by olfactory receptor stimulation.
Promotion of Tumor Invasion by Tumor-Associated Macrophages: The Role of CSF-1-Activated Phosphatidylinositol 3 Kinase and Src Family Kinase Motility Signaling.
Pronounced induction of endoplasmic reticulum stress and tumor suppression by surfactant-free poly(lactic-co-glycolic acid) nanoparticles via modulation of the PI3K signaling pathway.
Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies.
Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways.
Prostatic adenocarcinoma with novel NTRK3 gene fusion: a case report.
Protective Effects of Geniposide on Hepatic Ischemia/Reperfusion Injury.
Protein Arginine Methyltransferase 5 (PRMT5) and the ERK1/2 & PI3K Pathways: A Case for PRMT5 Inhibition and Combination Therapies in Cancer.
Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival.
Protein kinase B phosphorylation correlates with vascular endothelial growth factor a and microvessel density in gastric adenocarcinoma.
Protein kinase C ? regulates survivin expression and inhibits apoptosis in colon cancer.
Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells.
Protein Phosphorylation in Cancer: Role of Nitric Oxide Signaling Pathway.
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.
Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models.
Psoralidin, an herbal molecule, inhibits phosphatidylinositol 3-kinase-mediated Akt signaling in androgen-independent prostate cancer cells.
PTEN activation sensitizes breast cancer to PI3-kinase inhibitor through the ?-catenin signaling pathway.
PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition.
PTEN and phosphatidylinositol 3'-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment.
PTEN and the PI3-Kinase Pathway in Cancer.
PTEN and TNF-alpha regulation of the intestinal-specific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-kappaB-dependent pathway.
PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise?
PTEN couples Sema3A signalling to growth cone collapse.
PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer.
PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.
PTEN deletion potentiates invasion of colorectal cancer spheroidal cells through 3D Matrigel.
PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting.
PTEN function in normal and neoplastic growth.
PTEN genomic deletion defines favorable prognostic biomarkers in localized prostate cancer: a systematic review and meta-analysis.
PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity.
PTEN Hamartoma Tumor Syndrome: Clinical Risk Assessment and Management Protocol.
PTEN in brain tumors.
PTEN in Hereditary and Sporadic Cancer.
PTEN in osteosarcoma: Recent advances and the therapeutic potential.
PTEN increases autophagy and inhibits the ubiquitin-proteasome pathway in glioma cells independently of its lipid phosphatase activity.
PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model.
PTEN inhibits PREX2-catalyzed activation of RAC1 to restrain tumor cell invasion.
PTEN inhibits the migration and invasion of HepG2 cells by coordinately decreasing MMP expression via the PI3K/Akt pathway.
PTEN loss correlates with T cell exclusion across human cancers.
Pten loss in CD4 T cells enhances their helper function but does not lead to autoimmunity or lymphoma.
PTEN Loss in E-Cadherin-Deficient Mouse Mammary Epithelial Cells Rescues Apoptosis and Results in Development of Classical Invasive Lobular Carcinoma.
PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients.
Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas.
PTEN Methylation by NSD2 Controls Cellular Sensitivity to DNA Damage.
PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects.
PTEN on Chromosome 10 Is Phosphorylated in Primary Effusion Lymphoma and Kaposi's Sarcoma.
PTEN opposes negative selection and enables oncogenic transformation of pre-B cells.
PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy.
PTEN regulates angiogenesis and VEGF expression through phosphatase-dependent and -independent mechanisms in HepG2 cells: PTEN regulates angiogenesis in HepG2.
PTEN regulates apoptotic cell death through PI3-K/Akt/GSK3? signaling pathway in DMH induced early colon carcinogenesis in rat.
PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a).
PTEN Regulates PI(3,4)P
PTEN represses RNA polymerase III-dependent transcription by targeting the TFIIIB complex.
PTEN signaling in brain: neuropathology and tumorigenesis.
PTEN signaling pathways in glioblastoma.
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer.
PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control.
PTEN, more than the AKT pathway.
PTEN-deficient cancers depend on PIK3CB.
PTEN/PI3K/AKT protein expression is related to clinicopathological features and prognosis in breast cancer with axillary lymph node metastases.
PTEN/PTENP1: 'Regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy.
PTEN: a promising pharmacological target to enhance epithelial wound healing.
PTEN: a yin-yang master regulator protein in health and disease.
PTEN: Bridging Endocytosis and Signaling.
PTEN: its deregulation and tumorigenesis.
PTEN: life as a tumor suppressor.
PTEN: Multiple Functions in Human Malignant Tumors.
PTENless means more.
Puquitinib mesylate (XC-302) induces autophagy via inhibiting the PI3K/AKT/mTOR signaling pathway in nasopharyngeal cancer cells.
pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation.
PWT-458, A Novel Pegylated-17-Hydroxywortmannin, Inhibits Phosphatidylinositol 3-Kinase Signaling and Suppresses Growth of Solid Tumors.
Pyrazolopyrimidines as dual Akt/p70S6K inhibitors.
Quantification of Idelalisib in Human Plasma by Ultra-Performance Liquid Chromatography Coupled to Mass Spectrometry in Negative Ionization Mode.
Quantitation of class IA PI3Ks in mice reveals p110-free-p85s and isoform-selective subunit associations and recruitment to receptors.
Quantitative Measurement of Functional Activity of the PI3K Signaling Pathway in Cancer.
Quantitative phosphoproteomic analysis of the PI3K-regulated signaling network.
Quantitative phosphoproteomics reveals Wee1 kinase as a therapeutic target in a model of proneural glioblastoma.
Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma.
Quantitative redox imaging biomarkers for studying tissue metabolic state and its heterogeneity.
Quercetin Regresses Dalton's Lymphoma Growth via Suppression of PI3K/AKT Signaling Leading to Upregulation of p53 and Decrease in Energy Metabolism.
Quinazoline based small molecule exerts potent tumour suppressive properties by inhibiting PI3K/Akt/FoxO3a signalling in experimental colon cancer.
R-spondin3 promotes the tumor growth of choriocarcinoma JEG-3 cells.
Rac is activated by tumor necrosis factor alpha and is involved in activation of Erk.
Rac signaling in breast cancer: a tale of GEFs and GAPs.
Rac1-mediated membrane raft localization of PI3K/p110? is required for its activation by GPCRs or PTEN loss.
Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002.
Radiosensitization of cervical cancer cells via double-strand DNA break repair inhibition.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Raf kinases in signal transduction and interaction with translation machinery.
RAF-1 promotes survival of thyroid cancer cells harboring RET/PTC1 rearrangement independently of ERK activation.
RAKing in AKT: a tumor suppressor function for the intracellular tyrosine kinase FRK.
Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells.
Rapamycin is a potent inhibitor of skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate.
Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells.
Rapamycin: an anti-cancer immunosuppressant?
Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR.
Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RAS-ERK Signaling.
RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition.
Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition.
Rare PIK3CA hotspot mutations in carcinomas of the biliary tract.
RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms.
RAS GTPase signalling to alternative effector pathways.
RAS interaction with PI3K p110? is required for tumor-induced angiogenesis.
Ras oncoprotein induces CD44 cleavage through phosphoinositide 3-OH kinase and the rho family of small G proteins.
RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
RAS unplugged: negative feedback and oncogene-induced senescence.
Ras, PI3K and mTORC2 - three's a crowd?
Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling.
Ras-related C3 Botulinum Toxin Substrate (Rac) and Src Family Kinases (SFK) Are Proximal and Essential for Phosphatidylinositol 3-Kinase (PI3K) Activation in Natural Killer (NK) Cell-mediated Direct Cytotoxicity against Cryptococcus neoformans.
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.
Rational application of targeted therapeutics in mucinous colon/appendix cancers with positive predictive factors.
Rational Design of Novel Phosphoinositide 3-Kinase Gamma (PI3K?) Selective Inhibitors: A Computational Investigation Integrating 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation.
Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment.
RB independent G1-phase arrest by flavone, phosphatidylinositol 3-kinase inhibitor and histone deacetylase inhibitor.
RCE?4, a potential anti?cervical cancer drug isolated from Reineckia carnea, induces autophagy via the dual blockade of PI3K and ERK pathways in cervical cancer CaSki cells.
Re-evaluating AKT regulation: role of TOR complex 2 in tissue growth.
Reactivation of AKT signaling following treatment of cancer cells with PI3K inhibitors attenuates their antitumor effects.
Rebound pathway overactivation by cancer cells following discontinuation of PI3K or mTOR inhibition promotes cancer cell growth.
REC8 is a novel tumor suppressor gene epigenetically robustly targeted by the PI3K pathway in thyroid cancer.
Recent advances in antimultiple myeloma drug development.
Recent advances in the management of anaplastic thyroid cancer.
Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
Recent Development in Targeting PI3K-Akt-Mtor Signaling for Anticancer Therapeutic Strategies.
Recent Developments in Anti-Cancer Agents Targeting PI3K, Akt and mTORC1/2.
Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway.
Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma.
Recent patents of gene sequences relative to the phosphatidylinositol 3-kinase/Akt pathway and their relevance to drug discovery.
Recent progress in mouse models for tumor suppressor genes and its implications in human cancer.
Recent therapeutic advances in the treatment of colorectal cancer.
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer.
Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC).
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.
Recurrent prognostic factors and expression of GLUT-1, PI3K and p-Akt in adenoid cystic carcinomas of the head and neck: Clinicopathological features and biomarkers of adenoid cystic carcinoma.
Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance.
Regulation and function of autophagy in pancreatic cancer.
Regulation and repurposing of nutrient sensing and autophagy in innate immunity.
Regulation and signaling of human bombesin receptors and their biological effects.
Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression.
Regulation of apoptosis by androgens in prostate cancer cells.
Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta.
Regulation of cancer metabolism by oncogenes and tumor suppressors.
Regulation of cell signaling pathways by dietary agents for cancer prevention and treatment.
Regulation of H-Ras-driven MAPK signaling, transformation and tumorigenesis, but not PI3K signaling and tumor progression, by plasma membrane microdomains.
Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2.
Regulation of hepatitis B virus replication by the phosphatidylinositol 3-kinase-akt signal transduction pathway.
Regulation of mTOR by phosphatidic acid?
Regulation of nuclear factor kappa B transactivation. Implication of phosphatidylinositol 3-kinase and protein kinase C zeta in c-Rel activation by tumor necrosis factor alpha.
Regulation of O2 consumption by the PI3K and mTOR pathways contributes to tumor hypoxia.
Regulation of phosphoinositide 3-kinase expression in health and disease.
Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases.
Regulation of PI3K signaling in T-cell acute lymphoblastic leukemia: a novel PTEN/Ikaros/miR-26b mechanism reveals a critical targetable role for PIK3CD.
Regulation of PTEN expression in intestinal epithelial cells by c-Jun NH2-terminal kinase activation and nuclear factor-kappaB inhibition.
Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis.
Regulation of SHP2 by PTEN/AKT/GSK-3? signaling facilitates IFN-? resistance in hyperproliferating gastric cancer.
Regulation of survivin by PI3K/Akt/p70S6K1 pathway.
Regulation of T cell homeostasis and responses by pten.
Regulation of the tumor suppressor PTEN by natural anticancer compounds.
Relative quantification of PIK3CA gene expression level in fine-needle aspiration biopsy thyroid specimens collected from patients with papillary thyroid carcinoma and non-toxic goitre by real-time RT-PCR.
Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy.
Repositioning compounds from cancer drug discovery to IPF: PI3K inhibition.
Repositioning metformin in cancer: genetics, drug targets, and new ways of delivery.
Repression of BIRC5/survivin by FOXO3/FKHRL1 sensitizes human neuroblastoma cells to DNA damage-induced apoptosis.
Repurposing dasatinib for diffuse large B cell lymphoma.
Requirement for Ras and phosphatidylinositol 3-kinase signaling uncouples the glucocorticoid-induced junctional organization and transepithelial electrical resistance in mammary tumor cells.
Research on protective mechanism of ibuprofen in myocardial ischemia-reperfusion injury in rats through the PI3K/Akt/mTOR signaling pathway.
Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
Response and determinants of cancer cell susceptibility to PI3K inhibitors: Combined targeting of PI3K and Mek1 as an effective anticancer strategy.
Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer.
Resveratrol attenuates HMGB1 signaling and inflammation in house dust mite-induced atopic dermatitis in mice.
Resveratrol is a class IA phosphoinositide 3-kinase inhibitor.
Resveratrol mediated cell death in cigarette smoke transformed breast epithelial cells is through induction of p21Waf1/Cip1 and inhibition of long patch base excision repair pathway.
Retinoblastoma cells activate the AKT pathway and are vulnerable to the PI3K/mTOR inhibitor NVP-BEZ235.
Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer.
Retroviral oncogenes: a historical primer.
Revealing the Common Mechanisms of Scutellarin in Angina Pectoris and Ischemic Stroke Treatment via a Network Pharmacology Approach.
Reversal of boswellic acid analog BA145 induced caspase dependent apoptosis by PI3K inhibitor LY294002 and MEK inhibitor PD98059.
Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers.
Review: Molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies.
Revisiting PI3-kinase signalling in angiogenesis.
RGS16 inhibits breast cancer cell growth by mitigating phosphatidylinositol 3-kinase signaling.
RhoC Mediates Epidermal Growth Factor-Stimulated Migration and Invasion in Head and Neck Squamous Cell Carcinoma.
Rigosertib potently protects against colitis-associated intestinal fibrosis and inflammation by regulating PI3K/AKT and NF-?B signaling pathways.
RIP1 Activates PI3K-Akt via a Dual Mechanism Involving NF-{kappa}B-Mediated Inhibition of the mTOR-S6K-IRS1 Negative Feedback Loop and Down-regulation of PTEN.
RNA interference-mediated depletion of phosphoinositide 3-kinase activates forkhead box class O transcription factors and induces cell cycle arrest and apoptosis in breast carcinoma cells.
RNASeq analysis reveals biological processes governing the clinical behaviour of endometrioid and serous endometrial cancers.
RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.
Role and Mechanisms of RAGE-Ligand Complexes and RAGE-Inhibitors in Cancer Progression.
Role of aberrant PI3K pathway activation in gallbladder tumorigenesis.
Role of Akt signaling in resistance to DNA-targeted therapy.
Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia.
Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor.
Role of estrogen in lung cancer based on the estrogen receptor-epithelial mesenchymal transduction signaling pathways.
Role of HER2/HER3 co-receptor in breast carcinogenesis.
Role of IQGAP1 in Papillomavirus-Associated Head and Neck Tumorigenesis.
Role of keratinocytes in the development of vitiligo.
Role of phosphatidylinositol signaling pathway in the development of cross-resistance of tumor cells to hormonal cytostatics and hypoxia.
Role of phosphatidylinositol-3-kinase pathway in head and neck squamous cell carcinoma.
Role of PI3K in the Progression and Regression of Atherosclerosis.
Role of PI3K/Akt signaling in insulin-like growth factor-1 (IGF-1) skin tumor promotion.
Role of PTEN in neutrophil extracellular trap formation.
Role of PTEN/PI3K pathway in endothelial cells.
Role of Rac1 and Cdc42 in hypoxia induced p53 and von Hippel-Lindau suppression and HIF1alpha activation.
Role of RAS in the Regulation of PI 3-Kinase.
Role of the E3 ubiquitin ligase RNF157 as a novel downstream effector linking PI3K and MAPK signaling pathways to the cell cycle.
Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells.
Role of the phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways in the secretion of tumor necrosis factor-alpha and interleukin-10 by the PPD antigen of Mycobacterium tuberculosis.
Role of triptolide as an adjunct chemotherapy for ovarian cancer.
Roles of autophagy in cetuximab-mediated cancer therapy against EGFR.
Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells.
Roles of EGFR, PI3K, AKT, and mTOR in Heavy Metal-Induced Cancer.
Roles of ERK, PI3 kinase, and PLC-gamma pathways induced by overexpression of translationally controlled tumor protein in HeLa cells.
Roles of genetic variants in the PI3K/PTEN pathways in susceptibility to colorectal carcinoma and clinical outcomes treated with FOLFOX regimen.
Roles of phosphatidylinositol 3-kinase and Rac in the nuclear signaling by tumor necrosis factor-alpha in rat-2 fibroblasts.
Roles of phosphatidylinositol 3-kinase in interferon-gamma-dependent phosphorylation of STAT1 on serine 727 and activation of gene expression.
Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications.
Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours.
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
Romidepsin (FK228) and its analogs directly inhibit PI3K activity and potently induce apoptosis as HDAC/PI3K dual inhibitors.
Ron-receptor tyrosine kinase in tumorigenesis and metastasis.
RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility.
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.
S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer.
SABCS 2016: systemic therapy for metastatic breast cancer.
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.
Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology.
Safety, Pharmacokinetics, and Pharmacodynamics of ME-401, an Oral, Potent, and Selective Inhibitor of Phosphatidylinositol 3-Kinase P110?, Following Single Ascending Dose Administration to Healthy Volunteers.
Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer: A Review.
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study.
Salidroside Mitigates Sepsis-Induced Myocarditis in Rats by Regulating IGF-1/PI3K/Akt/GSK-3? Signaling.
SAMHD1 modulates in vitro proliferation of acute myeloid leukemia-derived THP-1 cells through the PI3K-Akt-p27 axis.
SAR405, a PIK3C3/Vps34 inhibitor that prevents autophagy and synergizes with MTOR inhibition in tumor cells.
Schwann cells augment cell spreading and metastasis of lung cancer.
Science Signaling Podcast for 21 February 2017: Pentraxin-3 in basal-like breast cancer.
Sclerosing Polycystic "Adenosis" of Salivary Glands: A Neoplasm Characterized by PI3K Pathway Alterations More Correctly Named Sclerosing Polycystic Adenoma.
Sclerosing Polycystic Adenoma of Salivary Glands: A Novel Neoplasm Characterized by PI3K-AKT Pathway Alterations-New Insights Into a Challenging Entity.
Sclerosing Polycystic Adenoma: Conclusive Clinical and Molecular Evidence of Its Neoplastic Nature.
Scutellarin Inhibits the Growth and EMT of Gastric Cancer Cells through Regulating PTEN/PI3K Pathway.
Se-methylselenocysteine inhibits phosphatidylinositol 3-kinase activity of mouse mammary epithelial tumor cells in vitro.
Secretin Receptor Promotes the Proliferation of Endocrine Tumor Cells Via the PI3K/AKT Pathway.
SECTM1 Produced by Tumor Cells Attracts Human Monocytes via CD7-Mediated Activation of the PI3K Pathway.
Seeking out the sweet spot in cancer therapeutics: an interview with Lewis Cantley.
Selective and potent small-molecule inhibitors of PI3Ks.
Selective Class I Phosphoinositide 3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511.
Selective inhibition of mTORC1 in tumor vessels increases antitumor immunity.
Selective Inhibition of Phosphoinositide 3-Kinase p110? Preserves Lymphocyte Function.
Selective inhibition of PI3K110? as a novel therapeutic strategy for cetuximab?resistant oral squamous cell carcinoma.
Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines.
Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival.
Selective PDZ protein-dependent stimulation of phosphatidylinositol 3-kinase by the adenovirus E4-ORF1 oncoprotein.
Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.
Selective PI3K? inhibitors, a review of the patent literature.
Sensitivity of Human Malignant Melanoma Cell Lines to Newcastle Disease Virus.
Sensitization of Cancers Resistant to HER2 Antibodies.
Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas.
Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils.
SETD2 loss sensitizes cells to PI3K? and AKT inhibition.
SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer.
SGK1 Is a Critical Component of an AKT-Independent Pathway Essential for PI3K-Mediated Tumor Development and Maintenance.
SGK2 is overexpressed in colon cancer and promotes epithelial-mesenchymal transition in colon cancer cells.
SGK3 (CISK) may induce tumor angiogenesis (Hypothesis).
SGLT2 inhibitors as potentially helpful drugs in PI3K inhibitor-induced diabetes: a case report.
Shen-Yuan-Dan Capsule Inhibiting Inflammatory Reaction by Regulating Insulin Receptor Substrate 1/PI3K/Akt/NF-?B Signaling Pathway in Apoliprotein E Knockout Mice Fed with a High-Fat Diet.
Shiga toxin 1-induced proinflammatory cytokine production is regulated by the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling pathway.
Shikonin attenuates lung cancer cell adhesion to extracellular matrix and metastasis by inhibiting integrin ?1 expression and the ERK1/2 signaling pathway.
Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase.
Should individual PI3 kinase isoforms be targeted in cancer?
Signal Transduction Pathway Activity in High-Grade, Serous Ovarian Carcinoma Reveals a More Favorable Prognosis in Tumors with Low PI3K and High NF-?B Pathway Activity: A Novel Approach to a Long-Standing Enigma.
Signaling inhibition with radiation in colorectal cancer: clinical trials.
Signaling Networks Associated with AKT Activation in Non-Small Cell Lung Cancer (NSCLC): New Insights on the Role of Phosphatydil-Inositol-3 kinase.
Signaling pathways and inhibitors of cells from patients with kaposiform lymphangiomatosis.
Signaling pathways responsible for cancer cell invasion as targets for cancer therapy.
Signalling pathways involved in antitumoral effects of VIP in human renal cell carcinoma A498 cells: VIP induction of p53 expression.
Signalling through phosphoinositide 3-kinases: the lipids take centre stage.
Signals Controlling Un-Differentiated States in Embryonic Stem and Cancer Cells: Role of the Phosphatidylinositol 3' Kinase Pathway.
Signatures of drug sensitivity in nonsmall cell lung cancer.
Significance of p85 expression as a prognostic factor for patients with breast cancer.
Significant benefit of everolimus in a patient with urothelial bladder cancer harboring a rare M1043I mutation of PIK3CA.
Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway.
Silencing p110? prevents rapid depletion of nuclear pAkt.
Silibinin suppresses bladder cancer through down-regulation of actin cytoskeleton and PI3K/Akt signaling pathways.
Silimarin and Cancer.
Simultaneous Inhibition of EGFR and PI3K Enhances Radiosensitivity In Human Breast Cancer.
Simultaneous inhibition of Vps34 kinase would enhance PI3K? inhibitor cytotoxicity in the B-cell malignancies.
Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.
Single-cell resolved imaging reveals intra-tumor heterogeneity in glycolysis, transitions between metabolic states, and their regulatory mechanisms.
siRNA Knockdown of REDD1 Facilitates Aspirin-Mediated Dephosphorylation of mTORC1 Target 4E-BP1 in MDA-MB-468 Human Breast Cancer Cell Line.
Sirt2 deacetylase is a novel AKT binding partner critical for AKT activation by insulin.
SIRT4 suppresses the PI3K/Akt/NF??B signaling pathway and attenuates HUVEC injury induced by oxLDL.
SIRT6 Suppresses Cancer Stem-like Capacity in Tumors with PI3K Activation Independently of Its Deacetylase Activity.
Small in Size, but Large in Action: microRNAs as Potential Modulators of PTEN in Breast and Lung Cancers.
Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance.
Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells.
Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis.
Soluble E-cadherin: a critical oncogene modulating receptor tyrosine kinases, MAPK and PI3K/Akt/mTOR signaling.
Soluble klotho binds monosialoganglioside to regulate membrane microdomains and growth factor signaling.
Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway.
Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome.
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.
Somatic Mutations of PI3K in Early and Advanced Gallbladder Cancer: Further Options for an Orphan Cancer.
Sorafenib/Regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells.
SOX4 and SMARCA4 cooperatively regulate PI3k signaling through transcriptional activation of TGFBR2.
Spatially distinct roles of class Ia PI3K isoforms in the development and maintenance of PTEN hamartoma tumor syndrome.
Specific inhibition of PI3K p110? inhibits CSF-1-induced macrophage spreading and invasive capacity.
Sphingosine Kinase 1 in Breast Cancer-A New Molecular Marker and a Therapy Target.
Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date.
SPR965, a Dual PI3K/mTOR Inhibitor, as a Targeted Therapy in Ovarian Cancer.
SPRY2 loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and mouse prostate carcinogenesis.
Src activation regulates anoikis in human colon tumor cell lines.
Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades.
Stable tumor vessel normalization with pO2 increase and endothelial PTEN activation by inositol trispyrophosphate brings novel tumor treatment.
Stathmin expression associates with vascular and immune responses in aggressive breast cancer subgroups.
Stathmin in pancreatic neuroendocrine neoplasms: a marker of proliferation and PI3K signaling.
Stathmin is dispensable for tumor onset in mice.
Statistical method on nonrandom clustering with application to somatic mutations in cancer.
Status of PI3K inhibition and biomarker development in cancer therapeutics.
Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma.
Stem cell factor (SCF)-kit mediated phosphatidylinositol 3 (PI3) kinase signaling during mammalian oocyte growth and early follicular development.
STI1 promotes glioma proliferation through MAPK and PI3K pathways.
Stopping ras in its tracks.
Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer.
Strong synergism between small molecule inhibitors of HER2, PI3K, mTOR and Bcl-2 in human breast cancer cells.
Structural analysis of a glucoglucuronan derived from laminarin and the mechanisms of its anti-lung cancer activity.
Structural and functional analysis of the natural JNK1 inhibitor quercetagetin.
Structural Insights into the Interactions of Digoxin and Na+/K+-ATPase and Other Targets for the Inhibition of Cancer Cell Proliferation.
Structure guided optimization of a fragment hit to imidazopyridine inhibitors of PI3K.
Structure, function and inhibition of the phosphoinositide 3-kinase p110? enzyme.
Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity.
Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series.
Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K/mTOR inhibitor.
Study of the CD95-Mediated Non-apoptotic Signaling Pathway: PI3K.
Study on the anti-hepatocarcinoma effect and molecular mechanism of Prunella vulgaris total flavonoids.
STYK1 promotes autophagy through enhancing the assembly of autophagy-specific class III phosphatidylinositol 3-kinase complex I.
Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells.
Substrate specificity and acute regulation of the tumour suppressor phosphatase, PTEN.
Sulforaphane inhibits growth of phenotypically different breast cancer cells.
SUMOylation modulates the stability and function of PI3K-p110?.
Suppressing effects of dietary supplementation of soybean trypsin inhibitor on spontaneous, experimental and peritoneal disseminated metastasis in mouse model.
Suppression of cell migration by phospholipase C-related catalytically inactive protein-dependent modulation of PI3K signalling.
Suppression of Egr-1 transcription through targeting of the serum response factor by oncogenic H-Ras.
Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
Suppression of insulin feedback enhances the efficacy of PI3K inhibitors.
Suppression of phospho-p85?-GTP-Rac1 lipid raft interaction by bichalcone analog attenuates cancer cell invasion.
Suppression of prometastatic phenotype of highly metastatic androgen-independent rat prostate cancer MLL cell line by PI3K inhibitor LY294002.
Suppression of Survival Signalling Pathways by the Phosphatase PHLPP.
Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling.
Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy.
Survival pathways regulating the apoptosis induced by tumour necrosis factor-alpha in primary cultured bovine endothelial cells.
Sustained release of PI3K inhibitor from PHA nanoparticles and in vitro growth inhibition of cancer cell lines.
SWATH-MS proteomics of PANC-1 and MIA PaCa-2 pancreatic cancer cells allows identification of drug targets alternative to MEK and PI3K inhibition.
Synergism between altered cortical polarity and the PI3K/TOR pathway in the suppression of tumour growth.
Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
Synergistic effects of SHP2 and PI3K pathway inhibitors in GAB2-overexpressing ovarian cancer.
Synergistic induction of cancer cell migration regulated by G?? and phosphatidylinositol 3-kinase.
Synergistic induction of cell death in haematological malignancies by combined phosphoinositide-3-kinase and BET bromodomain inhibition.
Synergistic inhibition of colon carcinoma cell growth by Hedgehog-Gli1 inhibitor arsenic trioxide and phosphoinositide 3-kinase inhibitor LY294002.
Synergistic interactions with PI3K inhibition that induce apoptosis.
Synergistic Therapeutic Effect of Cisplatin and Phosphatidylinositol 3-Kinase (PI3K) Inhibitors in Cancer Growth and Metastasis of Brca1 Mutant Tumors.
Synergy between PI3K Signaling and MYC in Burkitt Lymphomagenesis.
Synergy in activating class I PI3Ks.
Synthesis and activity of C11-modified wortmannin probes for PI3 kinase.
Synthesis and anti-metastatic effects of pregn-17(20)-en-3-amine derivatives.
Synthesis and anticancer evaluation of novel 1H-benzo[d]imidazole derivatives of dehydroabietic acid as PI3K? inhibitors.
Synthesis and biological activity of Akt/PI3K inhibitors.
Synthesis and biological evaluation of new 5-benzylated 4-oxo-3,4-dihydro-5H-pyridazino[4,5-b]indoles as PI3K? inhibitors.
Synthesis and biological evaluation of novel purinyl quinazolinone derivatives as PI3K?-specific inhibitors for the treatment of hematologic malignancies.
Synthesis and Cancer Stem Cell-Based Activity of Substituted 5-Morpholino-7H-thieno[3,2-b]pyran-7-ones Designed as Next Generation PI3K Inhibitors.
Synthesis and Characterization of a Novel Prostate Cancer-Targeted Phosphatidylinositol-3-kinase Inhibitor Prodrug.
Synthesis and evaluation of indazole based analog sensitive Akt inhibitors.
Synthesis and evaluation of pyrrolotriazine based molecules as PI3 kinase inhibitors.
Synthesis and in Vitro and in Vivo Evaluation of Phosphoinositide-3-kinase Inhibitors.
Synthesis and SAR of novel 4-morpholinopyrrolopyrimidine derivatives as potent phosphatidylinositol 3-kinase inhibitors.
Synthesis, biological evaluation and structure-activity relationship of a novel class of PI3K? H1047R mutant inhibitors.
Synthetic Lethality in PTEN-mutant Prostate Cancer is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.
Synthetic peptides containing ITIM-like domains block expression of inflammatory mediators and migration/invasion of cancer cells through activation of SHP-1 and PI3K.
Systematic functional characterization of resistance to PI3K inhibition in breast cancer.
Tackling Resistance to PI3K Inhibition by Targeting the Epigenome.
Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy.
TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3K? inhibition in head and neck squamous cell carcinoma.
Taming the PI3K team to hold inflammation and cancer at bay.
Tankyrase Inhibition Blocks Wnt/?-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression.
Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cells.
Targeted inhibition of dominant PI3-kinase catalytic isoforms increase expression of stem cell genes in glioblastoma cancer stem cell models.
Targeted inhibition of phosphatidyl inositol-3-kinase p110?, but not p110?, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.
Targeted Inhibition of Purine Metabolism Is Effective in Suppressing Hepatocellular Carcinoma Progression.
Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma.
Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.
Targeted RNA interference of phosphatidylinositol 3-kinase p110-beta induces apoptosis and proliferation arrest in endometrial carcinoma cells.
Targeted small-molecule inhibitors of protein kinase B as anticancer agents.
Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.
Targeting a common collaborator in cancer development.
Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma.
Targeting Akt in cancer therapy.
Targeting autophagic pathways for cancer drug discovery.
Targeting Autophagy by MPT0L145, a Highly Potent PIK3C3 Inhibitor, Provides Synergistic Interaction to Targeted or Chemotherapeutic Agents in Cancer Cells.
Targeting B cell receptor signalling in cancer: preclinical and clinical advances.
Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3K?/? Inhibitor RP6530.
Targeting CDK4/6 in patients with cancer.
Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant.
Targeting Class IA PI3K Isoforms Selectively Impairs Cell Growth, Survival, and Migration in Glioblastoma.
Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer.
Targeting drug-resistant prostate cancer with dual PI3K/mTOR inhibition.
Targeting EGFR and PI3K pathways in ovarian cancer.
Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.
Targeting Endocrine Resistance: Is There a Role for mTOR Inhibition?
Targeting Epirubicin Plus Quinacrine Liposomes Modified with DSPE-PEG2000-C(RGDfK) Conjugate for Eliminating Invasive Breast Cancer.
Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors.
Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.
Targeting mTOR: Evaluating the Therapeutic Potential of Resveratrol for Cancer Treatment.
Targeting Multiple Key Signaling Pathways in Melanoma using Leelamine.
Targeting neuropilin 1 as an antitumor strategy in lung cancer.
Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110? inhibition.
Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development.
Targeting PDK1 in cancer.
Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma.
Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs.
Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia.
Targeting phosphoinositide 3-kinase signalling in lung cancer.
Targeting phosphoinositide 3-kinase: moving towards therapy.
Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma.
Targeting phosphoinositide-3-kinase pathway in biliary tract cancers: A remedial route?
Targeting PI3 kinase in cancer.
Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.
Targeting PI3K and RAD51 in Barrett's Adenocarcinoma: Impact on DNA Damage Checkpoints, Expression Profile and Tumor Growth.
Targeting PI3K in Cancer: Any Good News?
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy.
Targeting PI3K in cancer: mechanisms and advances in clinical trials.
Targeting PI3K in neuroblastoma.
Targeting PI3K Pathway in Pancreatic Ductal Adenocarcinoma: Rationale and Progress.
Targeting PI3K signaling as a therapeutic approach for colorectal cancer.
Targeting PI3K Signaling in Cancer: A Cautionary Tale of Two AKTs.
Targeting PI3K signaling in cancer: Challenges and advances.
Targeting PI3K Signaling in Combination Cancer Therapy.
Targeting PI3K signalling in cancer: opportunities, challenges and limitations.
Targeting PTEN-defined breast cancers with a one-two punch.
Targeting RTK Signaling Pathways in Cancer.
Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.
Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib.
Targeting the Autophagy Specific Lipid Kinase VPS34 for Cancer Treatment: An Integrative Repurposing Strategy.
Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma.
Targeting the cell cycle and the PI3K pathway: a possible universal strategy to reactivate innate tumor suppressor programmes in cancer cells.
Targeting the glucagon receptor signaling pathway as a novel strategy to counteract PI3K inhibitor induced hyperglycemia while sustaining tumor PI3K inhibition.
Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.
Targeting the mTOR pathway using deforolimus in cancer therapy.
Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Targeting the phosphatidylinositol 3-kinase pathway in airway smooth muscle: rationale and promise.
Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma.
Targeting the phosphatidylinositol-3 kinase/Akt pathway for the treatment of cancer.
Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?
Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells.
Targeting the phosphoinositide 3-kinase pathway in cancer.
Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.
Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration.
Targeting the PI3K pathway for cancer therapy.
Targeting the PI3K pathway in cancer: are we making headway?
Targeting the PI3K signaling pathway in cancer therapy.
Targeting the PI3K signaling pathway in cancer.
Targeting the PI3K-AKT-mTOR Pathway in Castration Resistant Prostate Cancer: A Review Article.
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
Targeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy.
Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC).
Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.
Targeting the protein-protein interaction between IRS1 and mutant p110? for cancer therapy.
Targeting tumor cells by enhancing radiation sensitivity.
Targetome Analysis Revealed Involvement of MiR-126 in Neurotrophin Signaling Pathway: A Possible Role in Prevention of Glioma Development.
TCP1 regulates PI3K/AKT/mTOR signaling pathway to promote proliferation of ovarian cancer cells.
Telomerase is regulated by c-Jun NH2-terminal kinase in ovarian surface epithelial cells.
Tenacigenin B Has Anti-Tumor Effect in Lymphoma by In Vitro and In Vivo Study.
TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
TGF-? promotes PI3K-AKT signaling and prostate cancer cell migration through the TRAF6-mediated ubiquitylation of p85?.
TGF-?/PI3K/AKT/mTOR/NF-kB pathway. Clinicopathological features in prostate cancer.
The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration.
The Adherens Junction Protein Afadin Is an AKT Substrate that Regulates Breast Cancer Cell Migration.
The adhesion of anti-CD3-activated mouse T cells to syngeneic colon adenocarcinoma cells is differentially regulated by protein tyrosine kinase-, protein kinase C-, and cAMP-dependent pathways in the effector cell.
The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells.
The Akt-mTOR tango and its relevance to cancer.
The alternative reading frame tumor suppressor antagonizes hypoxia-induced cancer cell migration via interaction with the COOH-terminal binding protein corepressor.
The Androgen Receptor Induces Integrin {alpha}6{beta}1 to Promote Prostate Tumor Cell Survival via NF-{kappa}B and Bcl-xL Independently of PI3K Signaling.
The anti-tumor effect of taxifolin on lung cancer via suppressing stemness and epithelial-mesenchymal transition in vitro and oncogenesis in nude mice.
The anti-tumorigenic activity of A2M-A lesson from the naked mole-rat.
The antitumor effect of GDC-0941 alone and in combination with rapamycin in breast cancer cells.
The Antitumor Effect of Xihuang Pill on Treg Cells Decreased in Tumor Microenvironment of 4T1 Breast Tumor-Bearing Mice by PI3K/AKT~AP-1 Signaling Pathway.
The apoptotic effects of the flavonoid N101-2 in human cervical cancer cells.
The application and prospect of CDK4/6 inhibitors in malignant solid tumors.
The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2?×?2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients.
The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive Life.
The association of phosphatase and tensin homolog deleted on chromosome 10 polymorphisms and lifestyle habits with colorectal cancer risk in a Chinese population.
The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.
The biology and clinical relevance of the PTEN tumor suppressor pathway.
The biology behind PI3K inhibition in chronic lymphocytic leukaemia.
The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.
The cell biology behind the oncogenic PIP3 lipids.
The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor.
The Class I PI3K inhibitor S14161 induces autophagy in malignant blood cells by modulating the Beclin 1/Vps34 complex.
The class I PI3K/Akt pathway is critical for cancer cell survival in dogs and offers an opportunity for therapeutic intervention.
The class III PI(3)K Vps34 promotes autophagy and endocytosis but not TOR signaling in Drosophila.
The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
The combinatorial activation of the PI3K and Ras/MAPK pathways is sufficient for aggressive tumor formation, while individual pathway activation supports cell persistence.
The Comparison of RhoC and PI3K Gene Expression on the Breast Cancer Tissue and Benign Tumour Tissue.
The crosstalk between long non-coding RNAs and PI3K in cancer.
The Design and Identification of Brain Penetrant Inhibitors of Phosphoinositide 3-Kinase ?
The determinants of head and neck cancer: Unmasking the PI3K pathway mutations.
The driver landscape of sporadic chordoma.
The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells.
The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma.
The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
The dual PI3K/mTOR inhibitor BEZ235 is effective in lung cancer cell lines.
The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity
The dual PI3K/mTOR inhibitor GSK2126458 is effective for treating solid renal tumours in Tsc2(+/-) mice through suppression of cell proliferation and induction of apoptosis.
The dual PI3K?/CK1? inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells.
The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
The effects of PI3K-mediated signalling on glioblastoma cell behaviour.
The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
The emerging mechanisms of isoform-specific PI3K signalling.
The Emerging Molecular Landscape of Urothelial Carcinoma.
The emerging roles of WBP2 oncogene in human cancers.
The end of KRAS, and other, cancers? A new way forward.
The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice.
The EphB2 tumor suppressor induces autophagic cell death via concomitant activation of the ERK1/2 and PI3K pathways.
The Essential Role of Phosphoinositide 3-Kinases (PI3Ks) in Regulating Pro-Inflammatory Responses and the Progression of Cancer.
The Evolutionarily Conserved Domain of Beclin 1 is Required for Vps34 Binding, Autophagy and Tumor Suppressor Function.
The expression and clinical significance of PI3K, pAkt and VEGF in colon cancer.
The forkhead transcription factor FOXO4 induces the down-regulation of hypoxia-inducible factor 1 alpha by a von Hippel-Lindau protein-independent mechanism.
The Function of RAS Mutation in Cancer and Advances in its Drug Research.
The functions of Atg8-family proteins in autophagy and cancer: linked or unrelated?
The Future of ER+/HER2- Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors.
The gene dosage of class Ia PI3K dictates the development of PTEN hamartoma tumor syndrome.
The Genetic and Molecular Basis for Canine Models of Human Leukemia and Lymphoma.
The genetic landscapes of urological cancers and their clinical implications in the era of high-throughput genome analysis.
The genomic architecture of EBV and infected gastric tissue from precursor lesions to carcinoma.
The H1047R point mutation in p110 alpha changes the morphology of human colon HCT116 cancer cells.
The hexosamine biosynthesis pathway and O-GlcNAcylation maintain insulin-stimulated PI3K-PKB phosphorylation and tumour cell growth after short-term glucose deprivation.
The Hidden Conundrum of Phosphoinositide Signaling in Cancer.
The histone demethylase KDM2B activates FAK and PI3K that control tumor cell motility.
The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth.
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .
The impact of heterogeneity in Phosphoinositide 3-Kinase pathway in human cancer and possible therapeutic treatments.
The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment.
The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer.
The Importance of Being PI3K in the RAS Signaling Network.
The in vitro and in vivo effects of human umbilical cord mesenchymal stem cells on the growth of breast cancer cells.
The in vitro and in vivo experimental evidences disclose the chemopreventive effects of Ganoderma lucidum on cancer invasion and metastasis.
The influence of circular RNAs on autophagy and disease progression.
The interaction of HAb18G/CD147 with integrin alpha6beta1 and its implications for the invasion potential of human hepatoma cells.
The intra-tumor heterogeneity of cell signaling factors in breast cancer: p4E-BP1 and peIF4E are diffusely expressed and are real potential targets.
The K1 Protein of Kaposi's Sarcoma-Associated Herpesvirus Augments Viral Lytic Replication.
The lipid phosphatase activity of PTEN is critical for its tumor supressor function.
The lipid products of phosphoinositide 3-kinase isoforms in cancer and thrombosis.
The Marine-Derived Kinase Inhibitor Fascaplysin Exerts Anti-Thrombotic Activity.
The Mechanism by Which Amentoflavone Improves Insulin Resistance in HepG2 Cells.
The Mechanism of Trivalent Inorganic Arsenic on HIF-1?: a Systematic Review and Meta-analysis.
The Mechanisms Underlying PTEN Loss in Human Tumors Suggest Potential Therapeutic Opportunities.
The metastasis suppressor protein NM23-H1 modulates the PI3K-AKT axis through interaction with the p110? catalytic subunit.
The Mitotic Kinase Aurora-A Induces Mammary Cell Migration and Breast Cancer Metastasis by Activating the Cofilin-F-actin Pathway.
The molecular landscape of glioma in patients with Neurofibromatosis 1.
The molecular therapy of colorectal cancer.
The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to the Cytotoxic Effect of Carboplatin in Breast Cancer In Vitro.
The mTOR pathway and its role in human genetic diseases.
The N-terminal Phosphodegron Targets TAZ/WWTR1 Protein for SCF?-TrCP-dependent Degradation in Response to Phosphatidylinositol 3-Kinase Inhibition.
The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers.
The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism.
The novel non-immunological role and underlying mechanisms of B7-H3 in tumorigenesis.
The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.
The old and the new in p53 functional regulation.
The outstanding role of miR-132-3p in carcinogenesis of solid tumors.
The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours.
The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision.
The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.
The phosphatidylinositol 3-kinase (PI3K) isoform dependence of tumor formation is determined by the genetic mode of PI3K pathway activation rather than by tissue type.
The phosphatidylinositol 3-Kinase AKT pathway in human cancer.
The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage.
The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes quiescent but not proliferating MG-63 human osteosarcoma cells to radiation.
The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures.
The Phosphatidylinositol 3-kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.
The Phosphatidylinositol 3-kinase/Akt Signaling Pathway in Neuroendocrine Tumors.
The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy.
The phosphoinositide 3-kinase pathway and therapy resistance in cancer.
The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications.
The phosphoinositide 3-kinase pathway.
The Phosphoinositide 3-Kinase Signaling Pathway as a Therapeutic Target in Grade IV Brain Tumors.
The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions.
The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer.
The PI3 Kinase Signaling Pathway in Prostate Cancer.
The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging.
The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy.
The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
The PI3K inhibitor LY294002 prevents p53 induction by DNA damage and attenuates chemotherapy-induced apoptosis.
The PI3k inhibitors: new hopes in the battle against advanced NSCLC.
The PI3K pathway as drug target in human cancer.
The PI3K pathway at the crossroads of cancer and the immune system: strategies for next generation immunotherapy combinations.
The PI3K pathway impacts stem gene expression in a set of glioblastoma cell lines.
The PI3K Pathway in Human Disease.
The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia.
The PI3K subunits, P110? and P110? are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.
The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism.
The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.
The PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis.
The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
The PI3K/AKT Pathway and Renal Cell Carcinoma.
The PI3K/Akt pathway as a target in the treatment of hematologic malignancies.
The PI3K/Akt Pathway Contributes To Arenavirus Budding.
The PI3K/Akt pathway in colitis associated colon cancer and its chemoprevention with celecoxib, a Cox-2 selective inhibitor.
The PI3K/Akt Pathway in Tumors of Endocrine Tissues.
The PI3K/Akt Pathway Regulates Oxygen Metabolism via Pyruvate Dehydrogenase (PDH)-E1? Phosphorylation.
The PI3K/AKT/mTOR interactive pathway.
The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers.
The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges.
The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance.
The PI3K/AKT/mTOR signaling pathway inhibitors enhance radiosensitivity in cancer cell lines.
The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation.
The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies.
The PI3K/Akt/PTEN/mTOR pathway: a fruitful target for inducing cell death in rheumatoid arthritis?
The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.
The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the ?-catenin/SIRT3 signaling pathway in cervical cancer.
The PIK3CA gene is mutated with high frequency in human breast cancers.
The PKB/AKT pathway in cancer.
The positive is inside the negative: HER2-negative tumors can express the HER2 intracellular domain and present a HER2-positive phenotype.
The possible roles of B-cell novel protein-1 (BCNP1) in cellular signalling pathways and in cancer.
The Prevention and Inhibition Effect of Anthocyanins on Colorectal Cancer.
The pro-atherogenic cytokine interleukin-18 induces CXCL16 expression in rat aortic smooth muscle cells via MyD88, interleukin-1 receptor-associated kinase, tumor necrosis factor receptor-associated factor 6, c-Src, phosphatidylinositol 3-kinase, Akt, c-Jun N-terminal kinase, and activator protein-1 signaling.
The prognostic impact of Akt isoforms, PI3K and PTEN related to female steroid hormone receptors in soft tissue sarcomas.
The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.
The promise of combining inhibition of PI3K and PARP as cancer therapy.
The prospect of serum and glucocorticoid-inducible kinase 1 (SGK1) in cancer therapy: a rising star.
The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration.
The PtdIns 3-kinase/Akt pathway regulates macrophage-mediated ADCC against B cell lymphoma.
The PTEN Tumor Suppressor Forms Homodimers in Solution.
The Pten-Parkin Axis: At the Nexus of Cancer and Neurodegeneration.
The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.
The PTEN?PI3K Axis in Cancer.
The putative tumor suppressor gene PTPN13/PTPL1 induces apoptosis through insulin receptor substrate-1 dephosphorylation.
The pyrazolyl-urea GeGe3 inhibits tumor angiogenesis and reveals dystrophia myotonica protein kinase (DMPK)1 as a novel angiogenesis target.
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers.
The Ras radiation resistance pathway.
The RAS signal transduction pathway and its role in radiation sensitivity.
The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches.
The regulation of cell migration by PTEN.
The relation between PI3K/AKT signalling pathway and cancer.
The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
The response of PIK3CA/KRAS-mutant colorectal cancer stem-like cells to RGD-peptide FraC produced by the strawberry anemone: A promising water-soluble peptide-based inhibitor of metastasis-driver gene CXCR4, stem cell regulatory genes and self-renewal.
The Rho guanine nucleotide exchange factor ARHGEF5 promotes tumor malignancy via epithelial-mesenchymal transition.
The role and therapeutic implications of PI3K signaling pathway in cancer.
The role of autophagy in targeted therapy for acute myeloid leukemia.
The Role of Breast Cancer Stem Cells and Some Related Molecular Biomarkers in Metastatic and Nonmetastatic Breast Cancer.
The role of different PI3K protein subtypes in the metastasis, angiogenesis and clinical prognosis of hepatocellular carcinoma.
The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy.
The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy.
The role of hypoxia-inducible factors in cancer.
The role of insulin-like growth factors signaling in merlin-deficient human schwannomas.
The role of mechanistic target of rapamycin (mTOR) complexes signaling in the immune responses.
The Role of p110? in the Development and Activation of B Lymphocytes.
The role of phosphatidylinositol 3-kinase signaling pathways in pancreatic cancer.
The Role of PI3K in Met Driven Cancer: A Recap.
The Role of PI3K Inhibition in Lymphoid Malignancies.
The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma.
The role of PI3K/Akt in human herpesvirus infection: From the bench to the bedside.
The role of PI3K/Akt/mTOR signaling in dose-dependent biphasic effects of glycine on vascular development.
The role of PP2A A subunits in tumor suppression.
The role of the PI3K-AKT pathway in melanoma.
The roles of microbial products in the development of colorectal cancer: a review.
The roles of ubiquitin modifying enzymes in neoplastic disease.
The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.
The Selective Phosphoinoside-3-Kinase p110? Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation.
The selective PI3K inhibitor XL147 (SAR245408) inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.
The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling.
The Small GTPase ARF6 Activates PI3K in Melanoma to Induce a Prometastatic State.
The structural basis of PI3K cancer mutations: from mechanism to therapy.
The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.
The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition.
The targeting of phosphoinositide-3 kinase attenuates pulmonary metastatic tumor growth following laparotomy.
The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors.
The times they are a-changin': prognostic markers in the new era of BCR-targeting therapies for CLL.
The TLR3, PI3K, survivin, FasL, and Fas genes as major risk factors of occurrence and development of cervical cancer disease.
The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2.
The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins.
The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.
The tumor suppressor DiRas3 forms a complex with H-Ras and C-RAF proteins and regulates localization, dimerization, and kinase activity of C-RAF.
The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells.
The Tumor Suppressor p53 Fine-Tunes Reactive Oxygen Species Levels and Neurogenesis via PI3 Kinase Signaling.
The tumor suppressor PTEN interacts with p53 in hereditary cancer (Review).
The tumour suppressor FOXO3 is a key regulator of mantle cell lymphoma proliferation and survival.
The turtle and the rabbit story in a modern (PI3)key.
The type of KRAS mutation drives PI3K?/? signalling dependency: Implication for the choice of targeted therapy in pancreatic adenocarcinoma patients.
The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma.
The unfolded protein response is a major mechanism by which LRP1 regulates Schwann cell survival after injury.
The Unique Non-Catalytic C-Terminus of P37delta-PI3K Adds Proliferative Properties In Vitro and In Vivo.
The uremic toxin p-cresol promotes the invasion and migration on carcinoma cells via Ras and mTOR signaling.
The use of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3K?/? inhibitor.
The Zinc Finger Protein Zbtb18 Represses Expression of Class I Phosphatidylinositol 3-Kinase Subunits and Inhibits Plasma Cell Differentiation.
Theoretical studies on beta and delta isoform-specific binding mechanisms of phosphoinositide 3-kinase inhibitors.
Therapeutic benefit of selective inhibition of p110? PI3-kinase in pancreatic neuroendocrine tumors.
Therapeutic Effects of Curcumin against Bladder Cancer: A Review of Possible Molecular Pathways.
Therapeutic Potential of PI3K/AKT/mTOR Pathway in Gastrointestinal Stromal Tumors: Rationale and Progress.
Therapeutic Potential of SH2 Domain-Containing Inositol-5'-Phosphatase 1 (SHIP1) and SHIP2 Inhibition in Cancer.
Therapeutic targeting of cancers with loss of PTEN function.
Therapeutic targeting of replicative immortality.
Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: novel targeted therapies and advances in the treatment of colorectal cancer.
Therapeutic targets in subependymoma.
Thioredoxin-Like Protein 2 Is Overexpressed in Colon Cancer and Promotes Cancer Cell Metastasis by Interaction with Ran.
Tie2-FGFR1 interaction induces adaptive PI3K inhibitor resistance by upregulating Aurora A/PLK1/CDK1 signaling in glioblastoma.
Tim-3 Hampers Tumor Surveillance of Liver-Resident and Conventional NK Cells by Disrupting PI3K Signaling.
Timosaponin AIII, a steroidal saponin, exhibits anti-tumor effect on taxol-resistant cells in vitro and in vivo.
Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes.
Tissue-specific signaling networks rewired by major somatic mutations in human cancer revealed by proteome-wide discovery.
TNF-induced necroptosis initiates early autophagy events via RIPK3-dependent AMPK activation, but inhibits late autophagy.
Topological Tumor Graphs: A Graph-Based Spatial Model to Infer Stromal Recruitment for Immunosuppression in Melanoma Histology.
Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells.
Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells.
Towards Targeting PI3K-Dependent Regulation of Gene Expression in Brain Cancer.
Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma.
TP53INP2 contributes to autophagosome formation by promoting LC3-ATG7 interaction.
TRAF6 interacts with and ubiquitinates PIK3CA to enhance PI3K activation.
TRAIL-induced apoptosis in human vascular endothelium is regulated by phosphatidylinositol 3-kinase/Akt through the short form of cellular FLIP and Bcl-2.
Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase.
Transcriptional co-factor Transducin beta-like (TBL) 1 acts as a checkpoint in pancreatic cancer malignancy.
Transcriptional regulation of human mucin MUC4 by bile acids in oesophageal cancer cells is promoter-dependent and involves activation of the phosphatidylinositol 3-kinase signalling pathway.
Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype.
Transcriptome Analysis Reveals Key Genes and Pathways Associated with Metastasis in Breast Cancer.
Transcriptome sequencing identifies genes associated with invasion of ovarian cancer.
Transcriptome-Wide Effects of Sphingosine Kinases Knockdown in Metastatic Prostate and Breast Cancer Cells: Implications for Therapeutic Targeting.
Transcriptomic metaanalyses of autistic brains reveals shared gene expression and biological pathway abnormalities with cancer.
Transforming acidic coiled coil 1 promotes transformation and mammary tumorigenesis.
Transforming growth factor-beta (TGF-beta)-inducible gene TMEPAI converts TGF-beta from a tumor suppressor to a tumor promoter in breast cancer.
Translating PI3K-Delta Inhibitors to the Clinic in Chronic Lymphocytic Leukemia: The Story of CAL-101 (GS1101).
Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis.
Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors.
Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway.
Treating cancer with phosphatidylinositol-3-kinase inhibitors: increasing efficacy and overcoming resistance.
Treatment Following Progression in Metastatic Melanoma: the State of the Art from Scientific Literature to Clinical Need.
Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats.
TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT.
Triggering PIK3CA mutations in PI3K/AKT/mTOR axis: Exploration of newer inhibitors and rational preventive strategies.
TRIM21 and PHLDA3 negatively regulate the crosstalk between the PI3K/AKT pathway and PPP metabolism.
Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers.
Triptolide, a diterpenoid triepoxide, induces antitumor proliferation via activation of c-Jun NH2-terminal kinase 1 by decreasing phosphatidylinositol 3-kinase activity in human tumor cells.
TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer.
Tuberous Sclerosis Complex 1: An Epithelial Tumor Suppressor Essential to Prevent Spontaneous Prostate Cancer in Aged Mice.
Tubers and tumors: rapamycin therapy for benign and malignant tumors.
Tumor educated platelets, a promising source for early detection of hepatocellular carcinoma: Liquid biopsy an alternative approach to tissue biopsy.
Tumor Genetic Testing for Patient Selection in Phase I Clinical Trials: The Case of PI3K Inhibitors.
Tumor Growth in the High Frequency Medulloblastoma Mouse Model Ptch1+/-/Tis21KO Has a Specific Activation Signature of the PI3K/AKT/mTOR Pathway and Is Counteracted by the PI3K Inhibitor MEN1611.
Tumor heterogeneity, aggressiveness, and immune cell composition in a novel syngeneic PSA-targeted Pten knockout mouse prostate cancer (MuCaP) model.
Tumor induction by a transformation-defective polyoma virus mutant blocked in signaling through Shc.
Tumor lysis Syndrome in a Patient with Metastatic Breast Cancer Treated with Alpelisib.
Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner.
Tumor necrosis factor promotes phosphorylation and binding of insulin receptor substrate 1 to phosphatidylinositol 3-kinase in 3T3-L1 adipocytes.
Tumor necrosis factor-alpha, sphingomyelinase and ceramides activate tyrosine kinase, p21Ras and phosphatidylinositol 3-kinase: implications for glucose transport and insulin resistance.
Tumor necrosis factor-related apoptosis-inducing ligand promotes microvascular endothelial cell hyperpermeability through phosphatidylinositol 3-kinase pathway.
Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: Opportunities for signaling-adapted therapies.
Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas.
Tumor suppression by PTEN requires the activation of the PKR-eIF2alpha phosphorylation pathway.
Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN.
Tumor suppressor Hippo/MST1 kinase mediates chemotaxis by regulating spreading and adhesion.
Tumor suppressor PTEN affects tau phosphorylation: deficiency in the phosphatase activity of PTEN increases aggregation of an FTDP-17 mutant Tau.
Tumor vascular changes mediated by inhibition of oncogenic signaling.
Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery.
Tumor-derived CSF-1 induces the NKG2D ligand RAE-1? on tumor-infiltrating macrophages.
Tumor-derived exosomal microRNA-7-5p enhanced by verbascoside inhibits biological behaviors of glioblastoma in vitro and in vivo.
Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.
Tumor-Targeted Synergistic Blockade of MAPK and PI3K from a Layer-by-Layer Nanoparticle.
Tumour maintenance is mediated by eNOS.
Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS.
Tumours with PI3K activation are resistant to dietary restriction.
Two distinct phosphoinositide 3-kinases mediate polypeptide growth factor-stimulated PKB activation.
Ubiquitination and phosphorylation of Beclin 1 and its binding partners: Tuning class III phosphatidylinositol 3-kinase activity and tumor suppression.
Ubiquitous expression of the Pik3caH1047R mutation promotes hypoglycemia, hypoinsulinemia, and organomegaly.
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry.
Umbralisib: First Approval.
Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors.
Uncoupling of PI3K from ErbB3 impairs mammary gland development but does not impact on ErbB2-induced mammary tumorigenesis.
Uncovering the PI3Ksome: phosphoinositide 3-kinases and counteracting PTEN form a signaling complex with intrinsic regulatory properties.
Understanding and exploiting cell signalling convergence nodes and pathway cross-talk in malignant brain cancer.
United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling.
Unravelling the molecular mechanisms of prostate cancer evolution from genotype to phenotype.
Unsaturated fatty acids induce non-canonical autophagy.
Up-regulation of interleukin-17 expression by human papillomavirus type 16 E6 in nonsmall cell lung cancer.
Up-regulation of Skp2 after prostate cancer cell adhesion to basement membranes results in BRCA2 degradation and cell proliferation.
uPA and PAI-1-Related Signaling Pathways Differ between Primary Breast Cancers and Lymph Node Metastases.
Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice.
Update Breast Cancer 2019 Part 5 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer.
Update on Molecular Genetic Alterations of Cutaneous Adnexal Neoplasms.
UPDATE ON THE CLINICOPATHOLOGY OF PITUITARY ADENOMAS.
Update on the role of copanlisib in hematologic malignancies.
Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer.
Upregulation of phosphoinositide 3-kinase prevents sunitinib-induced cardiotoxicity in vitro and in vivo.
Upregulation of polymeric immunoglobulin receptor expression in flounder (Paralichthys olivaceus) gill cells by cytokine tumor necrosis factor-? via activating PI3K and NF-?B signaling pathways.
Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway.
Upstream regulators of phosphoinositide 3-kinase and their role in diseases.
Ursolic Acid Induces Apoptosis of Prostate Cancer Cells via the PI3K/Akt/mTOR Pathway.
Using Molecular Docking Analysis to Discovery Dregea sinensis Hemsl. Potential Mechanism of Anticancer, Antidepression, and Immunoregulation.
Using Tandem Mass Spectrometry in Targeted Mode to Identify Activators of Class IA PI3K in Cancer.
UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas.
V-ATPase controls tumor growth and autophagy in a Drosophila model of gliomagenesis.
Validated HPLC-UV method for simultaneous quantification of phosphatidylinositol 3-kinase inhibitors, copanlisib, duvelisib and idelalisib, in rat plasma: Application to a pharmacokinetic study in rats.
Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors.
Vanillin suppresses metastatic potential of human cancer cells through PI3K inhibition and decreases angiogenesis in vivo.
Variable expression of PIK3R3 and PTEN in Ewing Sarcoma impacts oncogenic phenotypes.
Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer.
Versatile inhibitory effects of the flavonoid-derived PI3K/Akt inhibitor, LY294002, on ATP-binding cassette transporters that characterize stem cells.
VGLL1 phosphorylation and activation promotes gastric cancer malignancy via TGF-?/ERK/RSK2 signaling.
Vinorelbine cationic liposomes modified with wheat germ agglutinin for inhibiting tumor metastasis in treatment of brain glioma.
Virtual docking screening and QSAR studies to explore AKT and mTOR inhibitors acting on PI3K in cancers.
Volatile Inhibitors of Phosphatidylinositol-3-Kinase (PI3K) Pathway: Anticancer Potential of Aroma Compounds of Plant Essential Oils.
VPS34 regulates TSC1/TSC2 heterodimer to mediate RheB and mTORC1/S6K1 activation and cellular transformation.
VPS34 stimulation of p62 phosphorylation for cancer progression.
Vps34-mediated macropinocytosis in Tuberous Sclerosis Complex 2-deficient cells supports tumorigenesis.
W941, a new PI3K inhibitor, exhibits preferable anti-proliferative activities against nonsmall cell lung cancer with autophagy inhibitors.
What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway.
When less is more: the PI3K pathway as a determinant of tumor response to dietary restriction.
Whole Genome Resequencing of Arkansas Progressor and Regressor Line Chickens to Identify SNPs Associated with Tumor Regression.
Whole transcriptome analysis of gestational trophoblastic neoplasms reveals altered PI3K signaling pathway in epithelioid trophoblastic tumor.
Whole-exome sequencing of duodenal adenocarcinoma identifies recurrent Wnt/?-catenin signaling pathway mutations.
Whole-genome profiling of primary cutaneous anaplastic large cell lymphoma.
Will PI3K pathway inhibitors be effective as single agents in patients with cancer?
Withholding of M-CSF Supplement Reprograms Macrophages to M2-Like via Endogenous CSF-1 Activation.
WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant.
WLS/wntless is essential in controlling dendritic cell homeostasis via a WNT signaling-independent mechanism.
Wnt3a regulates tumor necrosis factor-?-stimulated interleukin-6 release in osteoblasts.
Wogonin induced calreticulin/annexin A1 exposure dictates the immunogenicity of cancer cells in a PERK/AKT dependent manner.
Wogonoside Shows Antifibrotic Effects in an Experimental Regression Model of Hepatic Fibrosis.
Wortmannin inhibits growth of human non-small-cell lung cancer in vitro and in vivo.
Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase.
Wortmannin, a specific inhibitor of phosphatidylinositol-3-kinase, enhances LPS-induced NO production from murine peritoneal macrophages.
WWP2 is a physiological ubiquitin ligase for phosphatase and tensin homolog (PTEN) in mice.
XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.
YM155 exerts a growth inhibitory effect on human osteosarcoma in vitro and in vivo.
ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms.
ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system.
ZSTK474, a specific phosphatidylinositol 3-kinase inhibitor, induces G1 arrest of the cell cycle in vivo.
[11C]GSK2126458 and [18F]GSK2126458, the first radiosynthesis of new potential PET agents for imaging of PI3K and mTOR in cancers.
[18F]-FLT Positron Emission Tomography can be used to image the response of sensitive tumors to PI3-Kinase inhibition with the novel agent GDC-0941.
[Advances in Lung Stem Cells and Lung Cancer Stem Cells].
[Akt kinase: a key regulator of metabolism and progression of tumors].
[Anti-tumor effect and its related mechanisms of cinobufotalin combined with cisplatin on H22 liver cancer mice].
[Clinical Significance and Mechanism of PI3K p110? Overexpression? in Non-small Cell Lung Cancer].
[Correlation of PI3K-Akt Signal Pathway to Apoptosis of Tumor Cells.]
[Cyr61 expression influences cancer cell proliferation and apoptosis via PI3K pathway in human ovarian carcinoma cells].
[Dynamic analysis of modification of peripheral neutrophils functional activity and its regulation during tumor growth in vivo]
[Effect of Buzhong Yiqi decoction on PI3K and AKT in spleen, stomach and lung of nude mice with lung adenocarcinoma transplantation tumor].
[Effects of combined therapy of LY294002 and SN50 on nude mice model with gastric cancer].
[Expression and clinical significance of phosphatidylinositol 3-kinase and protein kinase B in cervical carcinoma]
[Expression and involved signal transduction pathway of autophagy gene Beclin 1 in epithelial ovarian cancer]
[Expression of phosphatidylinositol-3 kinase in epithelial ovarian carcinoma]
[Impact of molecular targeting therapy on tumor immunity].
[Integrin ?5 silencing inhibits proliferation, invasion and metastasis of human liver cancer Bel-7404 cells in vitro].
[Molecular pathogenesis of thyroid tumors].
[PI3 kinases and the control of autophagia]
[PI3K and mTOR pathway and molecular targeted agents].
[PI3K inhibitor].
[PI3K p85alpha expression and its role in the progression of colorectal cancer.]
[PI3K/AKT pathway activation and therapeutic consequences in breast cancer].
[PI3K/p110?-specific inhibitors in castration-resistant prostate cancer].
[PIK3CA mutation is an independent indicator of malignant phenotype and prognosis in breast cancer].
[Relationship between the inhibitory effect of fraxetin on breast cancer and estrogen signaling pathway].
[Research of reversal effect of PESV to multi-drug resistance of leukemia stem cell].
[Screening for mutations in the hotspot mutation regions of PIK3CA gene in nasopharyngeal carcinoma]
[Studies of betuionic acid on cell cycle and related protein expressions on mice of bearing H22 tumor cells]
[Targeted molecular strategies for cancer therapy based on the blockage of oncogenic pathways in human tumor cells]
[The kinome and glucocorticoid-induced apoptosis]
[The molecular mechanism responsible for the adaptation of malignant tumors to hormonal drugs: a role of phophatidylinositol-3-kinase and phosphoinositide-dependent proteins]
[Therapeutic effect of IGF-1R-targeting inhibitor (TAE226) on malignant pleural effusion in nude mice].
Neoplasms, Germ Cell and Embryonal
Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study.
Neoplasms, Squamous Cell
A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins.
A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
Motility-related proteins as markers for head and neck squamous cell cancer.
Neoplastic Cells, Circulating
Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer.
Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients.
Neoplastic Processes
Serum- and glucocorticoid-inducible kinase 3 is a potential oncogene in nasopharyngeal carcinoma.
Nervous System Diseases
A PI3-kinase-mediated negative feedback regulates neuronal excitability.
Age-independent synaptogenesis by phosphoinositide 3 kinase.
PI3K? deficiency enhances seizures severity and associated outcomes in a mouse model of convulsions induced by intrahippocampal injection of pilocarpine.
Target identification, screening and in vivo evaluation of pyrrolone-fused benzosuberene compounds against human epilepsy using Zebrafish model of pentylenetetrazol-induced seizures.
Neuralgia
Activation of phosphatidylinositol 3-kinase and protein kinase B/Akt in dorsal root ganglia and spinal cord contributes to the neuropathic pain induced by spinal nerve ligation in rats.
Blocking Mammalian Target of Rapamycin (mTOR) Alleviates Neuropathic Pain Induced by Chemotherapeutic Bortezomib.
Blocking mammalian target of rapamycin (mTOR) improves neuropathic pain evoked by spinal cord injury.
Microglial BDNF, PI3K, and p-ERK in the Spinal Cord Are Suppressed by Pulsed Radiofrequency on Dorsal Root Ganglion to Ease SNI-Induced Neuropathic Pain in Rats.
MiR-1906 Attenuates Neuropathic Pain in Rats by Regulating the TLR4/mTOR/ Akt Signaling Pathway.
PI3K/Akt Pathway is Required for Spinal Central Sensitization in Neuropathic Pain.
Neurilemmoma
Changes in the mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling associated with the induction of apoptosis.
Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannoma.
Schwannoma development is mediated by Hippo pathway dysregulation and modified by RAS/MAPK signaling.
The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours.
The role of insulin-like growth factors signaling in merlin-deficient human schwannomas.
Neuroacanthocytosis
Chorein-sensitive polymerization of cortical actin and suicidal cell death in chorea-acanthocytosis.
Neuroaxonal Dystrophies
Risk of false positive genetic associations in complex traits with underlying population structure: a case study.
Neuroblastoma
15-Deoxy-?(12,14)-prostaglandin J2 induced neurotoxicity via suppressing phosphoinositide 3-kinase.
A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy.
A novel function of Goalpha: mediation of extracellular signal-regulated kinase activation by opioid receptors in neural cells.
Activation of Akt predicts poor outcome in neuroblastoma.
Age-independent synaptogenesis by phosphoinositide 3 kinase.
Aggressive neuroblastomas have high p110alpha but low p110delta and p55alpha/p50alpha protein levels compared to low stage neuroblastomas.
ALK positively regulates MYCN activity through repression of HBP1 expression.
Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma.
Association of high microvessel ?v?3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126.
Brain-Derived Neurotrophic Factor Activation of TrkB Induces Vascular Endothelial Growth Factor Expression via Hypoxia-Inducible Factor-1{alpha} in Neuroblastoma Cells.
Carbachol inhibits insulin-stimulated phosphatidylinositol 3-kinase activity in SH-SY5Y neuroblastoma cells.
Clioquinol inhibits peroxide-mediated toxicity through up-regulation of phosphoinositol-3-kinase and inhibition of p53 activity.
Cross down-regulation of leptin and insulin receptor expression and signalling in a human neuronal cell line.
Cyclic AMP protects against staurosporine and wortmannin-induced apoptosis and opioid-enhanced apoptosis in both embryonic and immortalized (F-11kappa7) neurons.
Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay.
Detection of PI3K inhibition in human neuroblastoma using multiplex luminex bead immunoassay: a targeted approach for pathway analysis.
Differential regulation of insulin receptor substrate-2 and mitogen-activated protein kinase tyrosine phosphorylation by phosphatidylinositol 3-kinase inhibitors in SH-SY5Y human neuroblastoma cells.
Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines.
Extracellular-regulated kinases and phosphatidylinositol 3-kinase are involved in brain-derived neurotrophic factor-mediated survival and neuritogenesis of the neuroblastoma cell line SH-SY5Y.
Gli1 Transcriptional Activity is Negatively Regulated by AKT2 in Neuroblastoma.
High level of p37?-mRNA relative to p110?-mRNA in neuroblastoma tumors correlates with poor patient survival.
HspB8 mediates neuroprotection against OGD/R in N2A cells through the phosphoinositide 3-kinase/Akt pathway.
IGF-1 alleviates serum IgG-induced neuronal cytolysis through PI3K signaling in children with opsoclonus-myoclonus syndrome and neuroblastoma.
Inactivation of glycogen synthase kinase-3 by protein kinase C delta: implications for regulation of tau phosphorylation.
Inhibition of neuroblastoma cell phosphatidylinositol 3-kinase by CDP-diacylglycerol and phosphatidate.
Inhibition of Phosphatidylinositol 3-Kinase Destabilizes Mycn Protein and Blocks Malignant Progression in Neuroblastoma.
Inhibition of PI3k class III-dependent autophagy prevents apoptosis and necrosis by oxidative stress in dopaminergic neuroblastoma cells.
Insulin-like growth factor I induces preferential degradation of insulin receptor substrate-2 through the phosphatidylinositol 3-kinase pathway in human neuroblastoma cells.
L-Dopa decarboxylase interaction with the major signaling regulator ??3? in tissues and cells of neural and peripheral origin.
Mechanism of zinc-induced phosphorylation of p70 S6 kinase and glycogen synthase kinase 3beta in SH-SY5Y neuroblastoma cells.
Mechanisms of platelet-derived growth factor-mediated neuroprotection--implications in HIV dementia.
Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model.
Neuroprotective properties of ciliary neurotrophic factor on retinoic acid (RA)-predifferentiated SH-SY5Y neuroblastoma cells.
Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma.
Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity In Vitro and In Vivo.
Nuclear estrogen receptor activation by insulin-like growth factor-1 in Neuro-2A neuroblastoma cells requires endogenous estrogen synthesis and is mediated by mutually repressive MAPK and PI3K cascades.
Orexin-A Protects Human Neuroblastoma SH-SY5Y Cells Against 6-Hydroxydopamine-Induced Neurotoxicity: Involvement of PKC and PI3K Signaling Pathways.
Oridonin enhances the anticancer activity of NVP-BEZ235 against neuroblastoma cells in vitro and in vivo through autophagy.
Ouabain-Induced Signaling and Cell Survival in SK-N-SH Neuroblastoma Cells Differentiated by Retinoic Acid.
Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma.
Phosphatidylinositol 3-kinase and glycogen synthase kinase 3 regulate estrogen receptor-mediated transcription in neuronal cells.
Phosphatidylinositol 3-kinase inhibition down-regulates survivin and facilitates TRAIL-mediated apoptosis in neuroblastomas.
Phosphatidylinositol 3-kinase regulation of gastrin-releasing peptide-induced cell cycle progression in neuroblastoma cells.
Phosphatidylinositol 3-kinase, Cdc42, and Rac1 act downstream of Ras in integrin-dependent neurite outgrowth in N1E-115 neuroblastoma cells.
Phosphatidylinositol 3-kinase, class 2 beta (PI3KC2?) isoform contributes to neuroblastoma tumorigenesis.
Phosphatidylinositol 3-kinase, not extracellular signal-regulated kinase, regulates activation of the antioxidant-responsive element in IMR-32 human neuroblastoma cells.
PI3K activation prevents A?42-induced synapse loss and favors insoluble amyloid deposit formation.
PI3K and MAPK pathways mediate the BDNF/TrkB-increased metastasis in neuroblastoma.
PI3K Inhibitor Combined With Chemotherapy Can Enhance the Apoptosis of Neuroblastoma Cells In Vitro and In Vivo.
PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis.
PI3K is a key molecule in the Nrf2-mediated regulation of antioxidative proteins by hemin in human neuroblastoma cells.
PI3K-mTORC2 but not PI3K-mTORC1 regulates transcription of HIF2A/EPAS1 and vascularization in neuroblastoma.
Possible involvement of rapamycin-sensitive pathway in Bcl-2 expression in human neuroblastoma SH-SY5Y cells.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Repression of BIRC5/survivin by FOXO3/FKHRL1 sensitizes human neuroblastoma cells to DNA damage-induced apoptosis.
Role of gastrointestinal hormones in neuroblastoma.
Signalling pathways leading to neuroblastoma differentiation after serum withdrawal: HDL blocks neuroblastoma differentiation by inhibition of EGFR.
Stage-dependent expression of PI3K/Akt?pathway genes in neuroblastoma.
Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma.
Targeting PI3K in neuroblastoma.
The inhibition of phosphatidylinositol-3-kinase induces neurite retraction and activates GSK3.
Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells.
Type I interferons impair BDNF-induced cell signaling and neurotrophic activity in differentiated human SH-SY5Y neuroblastoma cells and mouse primary cortical neurons.
Tyrosine 251 at the C-terminus of neuronal glycoprotein M6a is critical for neurite outgrowth.
[Exogenous HSP70 and Signaling Pathways Involved in the Inhibition of LPS-Induced Neurotoxicity of Neuroblastoma Cells].
Neurodegenerative Diseases
Application of nanostructured lipid carriers: the prolonged protective effects for sesamol in in vitro and in vivo models of ischemic stroke via activation of PI3K signalling pathway.
Biochemical re-programming of human dermal stem cells to neurons by increasing mitochondrial membrane potential.
Cadmium induction of reactive oxygen species activates the mTOR pathway, leading to neuronal cell death.
Derivatives of caffeic acid, a natural antioxidant, as the basis for the discovery of novel nonpeptidic neurotrophic agents.
Microglia Mediated Neuroinflammation: Focus on PI3K Modulation.
Structure-Based Exploration of Selectivity for ATM Inhibitors in Huntington's Disease.
Targeting autophagy in disease: established and new strategies.
Neuroectodermal Tumors, Primitive
PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors.
Neuroendocrine Tumors
Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors.
Dual inhibition of PI3K and mTOR signaling pathways decreases human pancreatic neuroendocrine tumor metastatic progression.
Identification and chromosome assignment of a human gene encoding a novel phosphatidylinositol-3 kinase.
Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.
Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.
PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors.
Signaling Pathways as Specific Pharmacologic Targets for Neuroendocrine Tumor Therapy: RET, PI3K, MEK, Growth Factors, and Notch.
Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?
UPDATE ON THE CLINICOPATHOLOGY OF PITUITARY ADENOMAS.
Neurofibromatoses
A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2.
A PI3-kinase-mediated negative feedback regulates neuronal excitability.
Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions.
Neurofibromatosis 2
A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2.
Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L.
Neurofibrosarcoma
Dual targeting of AKT and mammalian target of rapamycin: A potential therapeutic approach for malignant peripheral nerve sheath tumor.
Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft.
Neuroinflammatory Diseases
Berberine enhances survival and axonal regeneration of motoneurons following spinal root avulsion and re-implantation in rats.
CircRNA 001372 Reduces Inflammation in Propofol-Induced Neuroinflammation and Neural Apoptosis through PIK3CA/Akt/NF-?B by miRNA-148b-3p.
Lipopolysaccharide induces neuroinflammation in microglia by activating the MTOR pathway and downregulating Vps34 to inhibit autophagosome formation.
Mechanism underlying ?2-AR agonist-mediated phenotypic conversion of LPS-activated microglial cells.
Microglia Mediated Neuroinflammation: Focus on PI3K Modulation.
Phosphoinositide 3-Kinase Gamma Contributes to Neuroinflammation in a Rat Model of Surgical Brain Injury.
Role of hydrogen sulfide in cognitive deficits: Evidences and mechanisms.
Sodium orthovanadate improves learning and memory in intracerebroventricular-streptozotocin rat model of Alzheimer's disease through modulation of brain insulin resistance induced tau pathology.
The expression pattern of Nischarin after lipopolysaccharides (LPS)-induced neuroinflammation in rats brain cortex.
The phosphoinositide-3 kinase signaling is involved in neuroinflammation in hypertensive rats.
Neurologic Manifestations
?-Caryophyllene Pretreatment Alleviates Focal Cerebral Ischemia-Reperfusion Injury by Activating PI3K/Akt Signaling Pathway.
Isorhapontigenin alleviates cerebral ischemia/reperfusion injuries in rats and modulated the PI3K/Akt signaling pathway.
The Role of the PI3K Pathway in the Regeneration of the Damaged Brain by Neural Stem Cells after Cerebral Infarction.
Two Monogenetic Disorders, Activated PI3-Kinase-? Syndrome 2 and Smith-Magenis Syndrome, in One Patient: Case Report and a Literature Review of Neurodevelopmental Impact in Primary Immunodeficiencies Associated With Disturbed PI3K Signaling.
Neutropenia
Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis.
Nevi and Melanomas
Phosphatidylinositol-3-kinase as a therapeutic target in melanoma.
Nevus
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.
Phosphatidylinositol-3-kinase as a therapeutic target in melanoma.
Prenatal diagnosis of CLOVES syndrome confirmed by detection of a mosaic PIK3CA mutation in cultured amniocytes.
Nevus, Pigmented
Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.
Newcastle Disease
Autophagy in farm animals: current knowledge and future challenges.
Niemann-Pick Disease, Type C
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
Niemann-Pick Diseases
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
Non-alcoholic Fatty Liver Disease
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Effects of Natural Products on Fructose-Induced Nonalcoholic Fatty Liver Disease (NAFLD).
Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease.
Folic Acid Reduced Triglycerides Deposition in Primary Chicken Hepatocytes.
Granulocyte colony stimulating factor treatment in non-alcoholic fatty liver disease: beyond marrow cell mobilization.
Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C.
High Glucose Induces Lipid Accumulation via 25-Hydroxycholesterol DNA-CpG Methylation.
Impaired activation of phosphatidylinositol 3-kinase by leptin is a novel mechanism of hepatic leptin resistance in NAFLD.
Multi-Drug/Gene NASH Therapy Delivery and Selective Hyperspectral NIR Imaging Using Chirality-Sorted Single-Walled Carbon Nanotubes.
PI3K inhibition protects mice from NAFLD by down-regulating CMKLR1 and NLRP3 in Kupffer cells.
PIK3R3 regulates PPAR? expression to stimulate fatty acid ?-oxidation and decrease hepatosteatosis.
PPAR ? inhibition protects against palmitic acid-LPS induced lipidosis and injury in cultured hepatocyte L02 cell.
Quercetin ameliorates dysregulation of lipid metabolism genes via the PI3K/AKT pathway in a diet-induced mouse model of non-alcoholic fatty liver disease.
Roles and mechanisms of NRG1 in modulating the pathogenesis of NAFLD through ErbB3 signaling in hepatocytes (NRG1 modulates NAFLD through ErbB3 signaling).
Roles for PI3K/AKT/PTEN Pathway in Cell Signaling of Nonalcoholic Fatty Liver Disease.
The ménage à trois of autophagy, lipid droplets and liver disease.
non-specific protein-tyrosine kinase deficiency
Novel mechanism for Fc{epsilon}RI-mediated signal transducer and activator of transcription 5 (STAT5) tyrosine phosphorylation and the selective influence of STAT5B over mast cell cytokine production.
Obesity
Adipose tissue insulin resistance due to loss of PI3K p110? leads to decreased energy expenditure and obesity.
Both insulin signaling defects in the liver and obesity contribute to insulin resistance and cause diabetes in Irs2(-/-) mice.
Central insulin-mediated regulation of hepatic glucose production [Review].
Central leptin action improves skeletal muscle AKT, AMPK, and PGC1alpha activation by hypothalamic PI3K-dependent mechanism.
Creatine Inhibits Adipogenesis by Downregulating Insulin-Induced Activation of the Phosphatidylinositol 3-Kinase Signaling Pathway.
Differential effects of insulin on sympathetic nerve activity in agouti obese mice.
Differential Phosphoinositide 3-Kinase Signaling: Implications for PTCA?
Differential PI3K signal transduction in obesity-associated cardiac hypertrophy and response to ischemia.
Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase.
Energy balancing by fat Pik3ca.
Enhanced ?-adrenergic signalling underlies an age-dependent beneficial metabolic effect of PI3K p110? inactivation in adipose tissue.
High fat diet induced obesity alters ovarian phosphatidylinositol-3 kinase signaling gene expression.
High-Fat Diet Obesity Associated with Insulin Resistance Increases Cell Proliferation, Estrogen Receptor, and PI3K Proteins in Rat Ventral Prostate.
High-fat feeding promotes obesity via insulin receptor/PI3K-dependent inhibition of SF-1 VMH neurons.
High-salt diet enhances insulin signaling and induces insulin resistance in Dahl salt-sensitive rats.
Hirsutenone Directly Targets PI3K and ERK to Inhibit Adipogenesis in 3T3-L1 Preadipocytes.
Hypothalamic miR-103 protects from hyperphagic obesity in mice.
Hypothalamic phosphatidylinositol 3-kinase pathway of leptin signaling is impaired during the development of diet-induced obesity in FVB/N mice.
Impact of Obesity on Ovotoxicity Induced by 7,12-dimethylbenz[a]anthracene in Mice.
Impaired activation of phosphatidylinositol 3-kinase by leptin is a novel mechanism of hepatic leptin resistance in diet-induced obesity.
Impaired activation of phosphatidylinositol 3-kinase by leptin is a novel mechanism of hepatic leptin resistance in NAFLD.
Impairment of central leptin-mediated PI3K signaling manifested as hepatic steatosis independent of hyperphagia and obesity.
Inhibition of 11?-hydroxysteroid dehydrogenase type 1 ameliorates obesity-related insulin resistance.
Inhibition of the aryl hydrocarbon receptor prevents Western diet-induced obesity. Model for AHR activation by kynurenine via oxidized-LDL, TLR2/4, TGF?, and IDO1.
Inhibitors of VPS34 and lipid metabolism suppress SARS-CoV-2 replication.
Insulin and leptin revisited: adiposity signals with overlapping physiological and intracellular signaling capabilities.
Insulin-Dependent Activation of MCH Neurons Impairs Locomotor Activity and Insulin Sensitivity in Obesity.
Intracellular Leptin-Signaling Pathways in Hypothalamic Neurons: The Emerging Role of Phosphatidylinositol-3 Kinase-Phosphodiesterase-3B-cAMP Pathway.
Leptin acts as a mitogenic and antiapoptotic factor for colonic cancer cells.
Leptin and the Regulation of Renal Sodium Handling and Renal Na-Transporting ATPases: Role in the Pathogenesis of Arterial Hypertension.
Macrophage Rewiring by Nutrient Associated PI3K Dependent Pathways.
Mechanisms mediating renal sympathetic activation to leptin in obesity.
Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance.
Mice Carrying a Dominant-Negative Human PI3K Mutation Are Protected From Obesity and Hepatic Steatosis but Not Diabetes.
Neuronal suppressor of cytokine signaling-3 (Socs3) deficiency enhances hypothalamic leptin-dependent phosphatidylinositol 3-kinase (PI3K) signaling.
Obesity and thyroid cancer.
Obesity: Inhibiting PI3K reduces body weight in obese mice.
Pharmacological inhibition of PI3K reduces adiposity and metabolic syndrome in obese mice and rhesus monkeys.
Phosphatidylinositol-3-kinase regulates scavenger receptor class B type I subcellular localization and selective lipid uptake in hepatocytes.
PI3K signaling in the pathogenesis of obesity: The cause and the cure.
PI3K signaling in the ventromedial hypothalamic nucleus is required for normal energy homeostasis.
PI3K/Akt pathway expression in children with different obesity degrees and its relationship with glucolipid metabolism and insulin resistance.
PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis.
PI3K: An Attractive Candidate for the Central Integration of Metabolism and Reproduction.
PI3K? inhibition reduces obesity in mice.
Progressive obesity alters ovarian insulin, phosphatidylinositol-3 kinase, and chemical metabolism signaling pathways and potentiates ovotoxicity induced by phosphoramide mustard in mice.
Progressive obesity alters ovarian insulin, phosphatidylinositol-3 kinase, and chemical metabolism signaling pathways and potentiates ovotoxicity induced by phosphoramide mustard in mice†.
Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation.
Retraction notice to: Impairment of central leptin-mediated PI3K signaling manifested as hepatic steatosis independent of hyperphagia and obesity.
Roles for PI3K/AKT/PTEN Pathway in Cell Signaling of Nonalcoholic Fatty Liver Disease.
Structural and functional analysis of the natural JNK1 inhibitor quercetagetin.
Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle.
The PI3K pathway preserves metabolic health through MARCO-dependent lipid uptake by adipose tissue macrophages.
Time-Series Expression Analysis of Epidermal Stem Cells from High Fat Diet Mice.
[Development of insulin resistance in muscle and adipose tissue during obesity in the mouse. Role of phosphatidylinositol 3-kinase]
Obesity, Maternal
Maternal obesity and increased neonatal adiposity correspond with altered infant mesenchymal stem cell metabolism.
Maternal obesity is associated with ovarian inflammation and upregulation of early growth response factor 1.
Obstetric Labor, Premature
Decrease in SHP-1 enhances myometrium remodeling via FAK activation leading to labor.
Oculocerebrorenal Syndrome
Finding patients using similarity measures in a rare diseases-oriented clinical data warehouse: Dr. Warehouse and the needle in the needle stack.
Odontogenic Tumors
FAK, paxillin, and PI3K in ameloblastoma and adenomatoid odontogenic tumor.
Immunohistochemical detection of phosphorylated Akt, PI3K, and PTEN in ameloblastic tumors.
Oligodendroglioma
Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics.
Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways.
Oncogene Addiction
Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.
The Oncogene Addiction Switch from NOTCH to PI3K Requires Simultaneous Targeting of NOTCH and PI3K Pathway Inhibition in Glioblastoma.
Opportunistic Infections
Phosphatidylinositol 3-Kinase ? Inhibitor-Induced Immunomodulation and Secondary Opportunistic Infection in the Cynomolgus Monkey (Macaca fascicularis).
Opsoclonus-Myoclonus Syndrome
IGF-1 alleviates serum IgG-induced neuronal cytolysis through PI3K signaling in children with opsoclonus-myoclonus syndrome and neuroblastoma.
Optic Nerve Injuries
The upregulation of GLAST-1 is an indirect antiapoptotic mechanism of GDNF and neurturin in the adult CNS.
Oropharyngeal Neoplasms
A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer.
Comparison of PI3K Pathway in HPV-Associated Oropharyngeal Cancer With and Without Tobacco Exposure.
Difference in expression of EGFR, pAkt, and PTEN between oropharyngeal and oral cavity squamous cell carcinoma.
Osteitis
The role of mast cells in parathyroid bone disease.
Osteoarthritis
Autophagy promotes citrullination of VIM (vimentin) and its interaction with major histocompatibility complex class II in synovial fibroblasts.
Discoidin domain receptor 2 mediates the collagen II-dependent release of interleukin-6 in primary human chondrocytes.
Downregulation of miR-34a Promotes Proliferation and Inhibits Apoptosis of Rat Osteoarthritic Cartilage Cells by Activating PI3K/Akt Pathway.
MicroRNA-130a regulates chondrocyte proliferation and alleviates osteoarthritis through PTEN/PI3K/Akt signaling pathway.
MiRNA-132 regulates the development of osteoarthritis in correlation with the modulation of PTEN/PI3K/AKT signaling.
The effects of amphiregulin induced MMP-13 production in human osteoarthritis synovial fibroblast.
The Inhibitory Effects of Slow-Releasing Hydrogen Sulfide Donors in the Mechanical Allodynia, Grip Strength Deficits, and Depressive-Like Behaviors Associated with Chronic Osteoarthritis Pain.
TNF-? increases the expression of inflammatory factors in synovial fibroblasts by inhibiting the PI3K/AKT pathway in a rat model of monosodium iodoacetate-induced osteoarthritis.
Upregulation of urokinase-type plasminogen activator and inhibitor and gelatinase expression via 3 mitogen-activated protein kinases and PI3K pathways during the early development of osteoarthritis.
Osteoarthritis, Knee
Upregulation of urokinase-type plasminogen activator and inhibitor and gelatinase expression via 3 mitogen-activated protein kinases and PI3K pathways during the early development of osteoarthritis.
Osteochondritis Dissecans
Autophagy in farm animals: current knowledge and future challenges.
Osteolysis
PI3K? deletion reduces variability in the in vivo osteolytic response induced by orthopaedic wear particles.
Pictilisib Enhances the Antitumor Effect of Doxorubicin and Prevents Tumor-Mediated Bone Destruction by Blockade of PI3K/AKT Pathway.
RNA Interference Targeting p110? Reduces Tumor Necrosis Factor-Alpha Production in Cellular Response to Wear Particles In vitro and Osteolysis In vivo.
Osteopetrosis
Proteomic Profiling of the First Human Dental Pulp Mesenchymal Stem/Stromal Cells from Carbonic Anhydrase II Deficiency Osteopetrosis Patients.
Osteoporosis
PSMC6 promotes osteoblast apoptosis through inhibiting PI3K/AKT signaling pathway activation in ovariectomy-induced osteoporosis mouse model.
TAZ accelerates osteogenesis differentiation of mesenchymal stem cells via targeting PI3K/Akt.
The PI3K/AKT cell signaling pathway is involved in regulation of osteoporosis.
Osteoporosis, Postmenopausal
Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene.
Osteosarcoma
?ig-h3 Promotes Human Osteosarcoma Cells Metastasis by Interacting with Integrin ?2?1 and Activating PI3K Signaling Pathway.
Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.
An affinity-directed protein missile system for targeted proteolysis.
BTG2 inhibits the proliferation and metastasis of osteosarcoma cells by suppressing the PI3K/AKT pathway.
BYL719, a new ?-specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma.
Calycosin, a Phytoestrogen Isoflavone, Induces Apoptosis of Estrogen Receptor-Positive MG-63 Osteosarcoma Cells via the Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
Connective tissue growth factor stimulates osteosarcoma cell migration and induces osteosarcoma metastasis by upregulating VCAM-1 expression.
Cytochrome b5 reductase 2 suppresses tumor formation in nasopharyngeal carcinoma by attenuating angiogenesis.
Cytoplasmic and nuclear localization sites of phosphatidylinositol 3-kinase in human osteosarcoma sensitive and multidrug-resistant Saos-2 cells.
Digital expression profiling identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma.
Downregulation of lncRNA H19 inhibits migration and invasion of human osteosarcoma through the NF-?B pathway.
Examination of the signal transduction pathways leading to activation of gelatinolytic activity by interleukin-1alpha and Porphyromonas gingivalis in human osteosarcoma cells.
Fangchinoline suppresses the proliferation, invasion and tumorigenesis of human osteosarcoma cells through the inhibition of PI3K and downstream signaling pathways.
Galangin suppresses human osteosarcoma cells: An exploration of its underlying mechanism.
High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes.
Honokiol induces autophagy and apoptosis of osteosarcoma through PI3K/Akt/mTOR signaling pathway.
Inhibition of miRNA-21 attenuates the proliferation and metastasis of human osteosarcoma by upregulating PTEN.
Long non-coding RNA phosphatase and tensin homolog pseudogene 1 suppresses osteosarcoma cell growth via the phosphoinositide 3-kinase/protein kinase B signaling pathway.
LY294002 induces G0/G1 cell cycle arrest and apoptosis of cancer stem-like cells from human osteosarcoma via down-regulation of PI3K activity.
LY294002 inhibits the malignant phenotype of osteosarcoma cells by modulating the phosphatidylinositol 3?kinase/Akt/fatty acid synthase signaling pathway in vitro.
LY404039 Inhibits Proliferation and Metastasis of Osteosarcoma Cells via PI3K Signaling Pathway.
Mechanism of miR-122-5p regulating the activation of PI3K-Akt-mTOR signaling pathway on the cell proliferation and apoptosis of osteosarcoma cells through targeting TP53 gene.
P53 suppresses cell proliferation, metastasis, and angiogenesis of osteosarcoma through inhibition of the PI3K/AKT/mTOR pathway.
Phosphatidylinositol 3-kinase translocation to the nucleus is an early event in the interleukin-1 signalling mechanism in human osteosarcoma Saos-2 cells.
Phosphatidylinositol 3-kinase translocation to the nucleus is induced by interleukin 1 and prevented by mutation of interleukin 1 receptor in human osteosarcoma Saos-2 cells.
PI3K? isoform-dependent activation of RhoA regulates Wnt5a-induced osteosarcoma cell migration.
Pictilisib Enhances the Antitumor Effect of Doxorubicin and Prevents Tumor-Mediated Bone Destruction by Blockade of PI3K/AKT Pathway.
Podocalyxin promotes cisplatin chemoresistance in osteosarcoma cells through phosphatidylinositide 3-kinase signaling.
Possible involvement of PI3K-dependent pathways in the increased VEGF120 release from osteoblastic cells preloaded with palmitate in vitro.
Regulation of phosphoinositide-3-kinase by G protein beta gamma subunits in a rat osteosarcoma cell line.
ROR2 receptor promotes the migration of osteosarcoma cells in response to Wnt5a.
Signal transduction pathways involved in the stimulation of tissue type plasminogen activator by interleukin-1alpha and Porphyromonas gingivalis in human osteosarcoma cells.
Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma.
The outstanding role of miR-132-3p in carcinogenesis of solid tumors.
The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes quiescent but not proliferating MG-63 human osteosarcoma cells to radiation.
Transforming growth factor alpha promotes osteosarcoma metastasis by ICAM-1 and PI3K/Akt signaling pathway.
Up-regulation of LINC00619 promotes apoptosis and inhibits proliferation, migration and invasion while promoting apoptosis of osteosarcoma cells through inactivation of the HGF-mediated PI3K-Akt signalling pathway.
VPS34 regulates dynamin to determine the endocytosis of mitochondria-targeted zinc oxide nanoparticles in human osteosarcoma cells.
Ototoxicity
Dexamethasone protects auditory hair cells against TNFalpha-initiated apoptosis via activation of PI3K/Akt and NFkappaB signaling.
Ovarian Diseases
Functional roles of the phosphatidylinositol 3-kinases (PI3Ks) signaling in the mammalian ovary.
Ovarian Neoplasms
17 ?-Estradiol Reverses Leptin-Inducing Ovarian Cancer Cell Migration by the PI3K/Akt Signaling Pathway.
5-Azacytidine promotes invadopodia formation and tumor metastasis through the upregulation of PI3K in ovarian cancer cells.
A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer.
A specific role for AKT3 in the genesis of ovarian cancer through modulation of G(2)-M phase transition.
Activation of mammalian target of rapamycin in postmenopausal ovarian endometriosis.
Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDX.
AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance.
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.
Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS-126 in models of ovarian cancer.
ARHI (DIRAS3) induces autophagy in ovarian cancer cells by downregulating the epidermal growth factor receptor, inhibiting PI3K and Ras/MAP signaling and activating the FOXo3a-mediated induction of Rab7.
Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer.
c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2.
Ceramide limits phosphatidylinositol-3-kinase C2?-controlled cell motility in ovarian cancer: potential of ceramide as a metastasis-suppressor lipid.
Chrysin Attenuates Progression of Ovarian Cancer Cells by Regulating Signaling Cascades and Mitochondrial Dysfunction.
Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression.
CNDP2 Acts as an Activator for Human Ovarian Cancer Growth and Metastasis via the PI3K/AKT Pathway.
Combination of KRAS gene silencing and PI3K inhibition for ovarian cancer treatment.
Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Combining PI3K and PARP inhibitors for breast and ovarian cancer treatment.
Correction: Enhanced GAB2 Expression Is Associated with Improved Survival in High-grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition.
Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer.
Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma.
Effect of combined inhibition of p110 alpha PI3K isoform and STAT3 pathway in ovarian cancer platinum-based resistance.
Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.
Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition.
Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors.
Formation of E-cadherin-mediated cell-cell adhesion activates AKT and mitogen activated protein kinase via phosphatidylinositol 3 kinase and ligand-independent activation of epidermal growth factor receptor in ovarian cancer cells.
Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome.
Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
Gab2 promotes cancer stem cell like properties and metastatic growth of ovarian cancer via downregulation of miR-200c.
Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells.
Gene expression correlation for cancer diagnosis: a pilot study.
Genetic and bioinformatic analyses of the expression and function of PI3K regulatory subunit PIK3R3 in an Asian patient gastric cancer library.
Genetic down-regulation of phosphoinositide 3-kinase by bikunin correlates with suppression of invasion and metastasis in human ovarian cancer HRA cells.
Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer.
Gonadotropin-releasing hormone-II increases membrane type I metalloproteinase production via beta-catenin signaling in ovarian cancer cells.
Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells.
GSG2 Promotes Development and Predicts Poor Prognosis of Ovarian Cancer.
HER-2/neu signal transduction in human breast and ovarian cancer.
Highly efficient Gab2 siRNA delivery to ovarian cancer cells mediated by chitosan-polyethyleneimine nanoparticles.
HOXB4 knockdown enhances the cytotoxic effect of paclitaxel and cisplatin by downregulating ABC transporters in ovarian cancer cells.
Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells.
IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer.
IL-13 regulates cancer invasion and metastasis through IL-13R?2 via ERK/AP-1 pathway in mouse model of human ovarian cancer.
In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene.
Induction of galectin-1 by TLR-dependent PI3K activation enhances epithelial-mesenchymal transition of metastatic ovarian cancer cells.
Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin.
Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models.
Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment.
Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel.
Inhibition of PI3K/Akt/mTOR signaling pathway enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin in vitro.
Insulin-like growth factor-I induces cyclooxygenase-2 expression via PI3K, MAPK and PKC signaling pathways in human ovarian cancer cells.
Integrative Genomic Analysis of Phosphatidylinositol 3'-Kinase Family Identifies PIK3R3 as a Potential Therapeutic Target in Epithelial Ovarian Cancer.
Integrin alpha x stimulates cancer angiogenesis through PI3K/Akt signaling-mediated VEGFR2/VEGF-A overexpression in blood vessel endothelial cells.
JTC-801 inhibits the proliferation and metastasis of ovarian cancer cell SKOV3 through inhibition of the PI3K - AKT signaling pathway.
Knockdown of Hypoxia-Inducible Factor 1? (HIF-1?) Promotes Autophagy and Inhibits Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Ovarian Cancer Cells.
KRAS-Mutated, Estrogen Receptor-Positive Low-Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery.
Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial?mesenchymal transition.
Lysophosphatidic acid activates telomerase in ovarian cancer cells through hypoxia-inducible factor-1alpha and the PI3K pathway.
Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway.
Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways.
Microenvironment mesenchymal cells protect ovarian cancer cell lines from apoptosis by inhibiting XIAP inactivation.
MicroRNA-301a Promotes Cell Proliferation and Resistance to Apoptosis through PTEN/PI3K/Akt Signaling Pathway in Human Ovarian Cancer.
MiR-200b-5p inhibits proliferation of ovarian cancer cells by targeting ATAD2 and regulating PI3K/AKT signaling pathway.
miR?338?3p suppresses tumor growth of ovarian epithelial carcinoma by targeting Runx2.
MRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity.
Mutation of the PIK3CA gene in anaplastic thyroid cancer.
Mutation-Driven Signals of ARID1A and PI3K Pathways in Ovarian Carcinomas: Alteration Is An Opportunity.
Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer.
Omental macrophages secrete chemokine ligands that promote ovarian cancer colonization of the omentum via CCR1.
Overexpression of ARF1 is associated with cell proliferation and migration through PI3K signal pathway in ovarian cancer.
Overexpression of GAB2 in ovarian cancer cells promotes tumor growth and angiogenesis by upregulating chemokine expression.
Overexpression of glycosyltransferase 8 domain containing 2 confers ovarian cancer to CDDP resistance by activating FGFR/PI3K signalling axis.
p70 S6 kinase promotes epithelial to mesenchymal transition through snail induction in ovarian cancer cells.
p85? alters response to EGFR inhibitor in ovarian cancer through p38 MAPK-mediated regulation of DNA repair.
PAK5 Induces EMT and Promotes Cell Migration and Invasion by Activating the PI3K/AKT Pathway in Ovarian Cancer.
Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.
Phosphatidylinositol 3-kinase Inhibitor (PIK75) Containing Surface Functionalized Nanoemulsion for Enhanced Drug Delivery, Cytotoxicity and Pro-apoptotic Activity in Ovarian Cancer Cells.
Phosphatidylinositol 3-kinase inhibitors are a triple threat to ovarian cancer.
PI3K Catalytic Isoform Alteration Promotes the LIMK1-related Metastasis Through the PAK1 or ROCK1/2 Activation in Cigarette Smoke-exposed Ovarian Cancer Cells.
PI3K inhibitor D-116883 is effective in in vitro models of ovarian cancer.
PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer.
PI3K: A rational target for ovarian cancer therapy?
PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients.
Profiling of protein kinases in the neoplastic transformation of human ovarian surface epithelium.
Progesterone protects ovarian cancer cells from cisplatin-induced inhibitory effects through progesterone receptor membrane component 1/2 as well as AKT signaling.
Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer.
Progranulin expression induced by follicle-stimulating hormone in ovarian cancer cell lines depends on the histological subtype.
Protein chip discovery of secreted proteins regulated by the phosphatidylinositol 3-kinase pathway in ovarian cancer cell lines.
Prucalopride Inhibits Proliferation of Ovarian Cancer Cells via Phosphatidylinositol 3-Kinase (PI3K) Signaling Pathway.
RNA Interference-Mediated Silencing of the Phosphatidylinositol 3-Kinase Catalytic Subunit Attenuates Growth of Human Ovarian Cancer Cells in vitroand in vivo.
RNA interference: a potential strategy for isoform-specific phosphatidylinositol 3-kinase targeted therapy in ovarian cancer.
Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway.
Role of TGF alpha stimulation of the ERK, PI3 kinase and PLC gamma pathways in ovarian cancer growth and migration.
Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells.
Role of triptolide as an adjunct chemotherapy for ovarian cancer.
Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer.
Serum bioactive lysophospholipids prevent TRAIL-induced apoptosis via PI3K/Akt-dependent cFLIP expression and Bad phosphorylation.
SGK3 (CISK) may induce tumor angiogenesis (Hypothesis).
Simultaneous inhibition of the mitogen-activated protein kinase kinase and phosphatidylinositol 3'-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma.
Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis.
Suppressing effects of dietary supplementation of soybean trypsin inhibitor on spontaneous, experimental and peritoneal disseminated metastasis in mouse model.
Synergistic effects of SHP2 and PI3K pathway inhibitors in GAB2-overexpressing ovarian cancer.
Synergistic lethality of mifepristone and LY294002 in ovarian cancer cells.
Tanshinone IIA induces apoptosis of ovarian cancer cells in vitro and in vivo through attenuation of PI3K/AKT/JNK signaling pathways.
Targeted inhibition of phosphatidyl inositol-3-kinase p110?, but not p110?, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.
Targeting EGFR and PI3K pathways in ovarian cancer.
Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer.
TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer.
The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive Life.
The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.
The circadian rhythm and core gene Period2 regulate the chemotherapy effect and multidrug resistance of ovarian cancer through the PI3K signaling pathway.
The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.
The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma.
The outstanding role of miR-132-3p in carcinogenesis of solid tumors.
The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges.
The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy.
The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells.
TLR5/7-mediated PI3K activation triggers epithelial-mesenchymal transition of ovarian cancer cells through WAVE3-dependent mesothelin or OCT4/SOX2 expression.
TMEFF1 overexpression and its mechanism for tumor promotion in ovarian cancer.
Transforming growth factor-beta1-dependent activation of Smad2/3 and up-regulation of PAI-1 expression is negatively regulated by Src in SKOV-3 human ovarian cancer cells.
Translational Highlights in Breast and Ovarian Cancer 2019 - Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy.
TRPM7 promotes the epithelial-mesenchymal transition in ovarian cancer through the calcium-related PI3K / AKT oncogenic signaling.
Upregulated microRNA-15b alleviates ovarian cancer through inhitbition of the PI3K/Akt pathway by targeting LPAR3.
Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling.
Wogonin Increases Cisplatin Sensitivity in Ovarian Cancer Cells Through Inhibition of the Phosphatidylinositol 3-Kinase (PI3K)/Akt Pathway.
[Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
[Expression of phosphatidylinositol-3 kinase in epithelial ovarian carcinoma]
[Inhibitory effect of tirapazamine combined with phosphatidylinositol 3-kinase inhibitor LY294002 to ovarian cancer cells]
Overweight
Obesity-induced metabolic stresses in breast and colon cancer.
Paget Disease, Extramammary
PI3K, Rac1 and pPAK1 are overexpressed in extramammary Paget's disease.
Pancreatic Neoplasms
A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic Cancer.
A Structurally Optimized Celecoxib Derivative Inhibits Human Pancreatic Cancer Cell Growth.
A study on the mechanism of rapamycin mediating the sensitivity of pancreatic cancer cells to cisplatin through PI3K/AKT/mTOR signaling pathway.
Activation of PPARgamma increases PTEN expression in pancreatic cancer cells.
Activation of the PI3K/Akt Pathway Mediates Bone Morphogenetic Protein 2-Induced Invasion of Pancreatic Cancer Cells Panc-1.
Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer.
Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells.
Associations of novel variants in PIK3C3, INSR and MAP3K4 of the ATM pathway genes with pancreatic cancer risk.
Attenuating PI3K isoforms in pancreatic cancer: Focus on immune PI3K?.
Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer.
Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras.
BxPC3 pancreatic cancer cells express a truncated Smad4 protein upon PI3K and mTOR inhibition.
Co-Targeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer.
Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine.
Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer.
Complement component 1, q subcomponent binding protein (C1QBP) in lipid rafts mediates hepatic metastasis of pancreatic cancer by regulating IGF-1/IGF-1R signaling.
Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models.
Correction: Synergistic Effects of Concurrent Blockade of PI3K and MEK Pathways in Pancreatic Cancer Preclinical Models.
Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?
Dominant negative inhibitors of signalling through the phosphoinositol 3-kinase pathway for gene therapy of pancreatic cancer.
Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor.
Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer.
Dual PDK1/Aurora Kinase A Inhibitors Reduce Pancreatic Cancer Cell Proliferation and Colony Formation.
Dual roles of hemidesmosomal proteins in the pancreatic epithelium: the phosphoinositide 3-kinase decides.
Embigin is overexpressed in pancreatic ductal adenocarcinoma and regulates cell motility through epithelial to mesenchymal transition via the TGF-? pathway.
Emerging role of the KRAS-PDK1 axis in pancreatic cancer.
Enhanced antitumor efficacy of gemcitabine by evodiamine on pancreatic cancer via regulating PI3K/Akt pathway.
Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
Grape Proanthocyanidin Inhibit Pancreatic Cancer Cell Growth In Vitro and In Vivo through Induction of Apoptosis and by Targeting the PI3K/Akt Pathway.
Growth-inhibitory effect of phosphatidylinositol 3-kinase inhibitor on human pancreatic cancer cells and expression of Bcl-2 family.
HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer.
HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer.
HS-173, a selective PI3K inhibitor, induces cell death in head and neck squamous cell carcinoma cell lines.
Impaired insulin action on phosphatidylinositol 3-kinase activity and glucose transport in skeletal muscle of pancreatic cancer patients.
Implication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter?
Increase in PI3K signalling mimics mutated-Kras induction of pancreatic cancer.
Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells.
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.
Insulin Receptor and GPCR Crosstalk Stimulates YAP via PI3K and PKD in Pancreatic Cancer Cells.
Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells.
Insulin-like growth factor-I receptor in proliferation and motility of pancreatic cancer.
Integrin ?1 promotes gemcitabine resistance in pancreatic cancer through Cdc42 activation of PI3K p110? signaling.
Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer.
IRS-1 regulates proliferation, invasion and metastasis of pancreatic cancer cells through MAPK and PI3K signaling pathways.
Isoalantolactone inhibits pancreatic cancer proliferation by regulation of PI3K and Wnt signal pathway.
ITGA6 and RPSA synergistically promote pancreatic cancer invasion and metastasis via PI3K and MAPK signaling pathways.
K-RAS Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In Vivo.
Key role of phosphoinositide 3-kinase class IB in pancreatic cancer.
Kras, Pten, NF-?B, and inflammation: dangerous liaisons.
KRAS-related proteins in pancreatic cancer.
lncRNA MEG3 had anti-cancer effects to suppress pancreatic cancer activity.
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.
MiR-142-3p targeting NUCKS1 inhibits proliferation and invasion of pancreatic cancer cells.
miRNAs in insulin resistance and diabetes-associated pancreatic cancer: the 'minute and miracle' molecule moving as a monitor in the 'genomic galaxy'.
Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer.
Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells.
Molecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion?
Myricetin induces pancreatic cancer cell death via the induction of apoptosis and inhibition of the phosphatidylinositol 3-kinase (PI3K) signaling pathway.
Novel agents for the treatment of pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
PAK4 interacts with p85 alpha: implications for pancreatic cancer cell migration.
Pancreatic cancer cell proliferation is phosphatidylinositol 3-kinase dependent.
Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway.
Phase 1 study of rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
Phosphatidylinositol 3-kinase-dependent transcriptional silencing of the translational repressor 4E-BP1.
Phosphatidylinositol 3-Kinase: A Link Between Inflammation and Pancreatic Cancer.
Phosphoinositide 3-kinase inhibitor (wortmannin) inhibits pancreatic cancer cell motility and migration induced by hyaluronan in vitro and peritoneal metastasis in vivo.
Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics.
Phosphorylated Akt/PKB controls cell growth and apoptosis in intraductal papillary-mucinous tumor and invasive ductal adenocarcinoma of the pancreas.
Physiological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase and enhancing GLUT-1 expression.
PI-3' kinase and NF-kappaB cross-signaling in human pancreatic cancer cells.
PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells.
PI3K signaling maintains c-myc expression to regulate transcription of E2F1 in pancreatic cancer cells.
PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors.
Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer.
PREX2 promotes the proliferation, invasion and migration of pancreatic cancer cells by modulating the PI3K signaling pathway.
Radiosensitization of the PI3K inhibitor HS-173 through reduction of DNA damage repair in pancreatic cancer.
Signal transduction pathway mutations in gastrointestinal (GI) cancers: a systematic review and meta-analysis.
SWATH-MS proteomics of PANC-1 and MIA PaCa-2 pancreatic cancer cells allows identification of drug targets alternative to MEK and PI3K inhibition.
Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells.
Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models.
Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer.
Targeting PI3K Pathway in Pancreatic Ductal Adenocarcinoma: Rationale and Progress.
The effect of PI3K inhibitor LY294002 and gemcitabine hydrochloride combined with ionizing radiation on the formation of vasculogenic mimicry of Panc-1 cells in vitro and in vivo.
The outstanding role of miR-132-3p in carcinogenesis of solid tumors.
The role of phosphatidylinositol 3-kinase signaling pathways in pancreatic cancer.
Transcriptional co-factor Transducin beta-like (TBL) 1 acts as a checkpoint in pancreatic cancer malignancy.
Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice.
Pancreatitis
Ablation of phosphoinositide 3-kinase-gamma reduces the severity of acute pancreatitis.
Akt1 signalling supports acinar proliferation and limits acinar-to-ductal metaplasia formation upon induction of acute pancreatitis.
Expression of phosphatidylinositol-3 kinase and effects of inhibitor Wortmannin on expression of tumor necrosis factor-? in severe acute pancreatitis associated with acute lung injury.
LAP-like non-canonical autophagy and evolution of endocytic vacuoles in pancreatic acinar cells.
Phosphatidylinositide 3-kinase gamma regulates key pathologic responses to cholecystokinin in pancreatic acinar cells.
Phosphatidylinositol 3-kinase and trypsin activation in pancreatitis.
Phosphatidylinositol 3-kinase-dependent activation of trypsinogen modulates the severity of acute pancreatitis.
Role of phosphoinositide 3-kinase in the pathogenesis of acute pancreatitis.
Pancreatitis, Chronic
Dysregulation of PI3K and Hippo signaling pathways synergistically induces chronic pancreatitis via CTGF upregulation.
LY294002 enhances inhibitory effect of gemcitabine on proliferation of human pancreatic carcinoma PANC-1 cells.
Phosphatidylinositol 3-Kinase: A Link Between Inflammation and Pancreatic Cancer.
Papilloma
Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.
Loss of miR-143 and miR-145 in condyloma acuminatum promotes cellular proliferation and inhibits apoptosis by targeting NRAS.
Phosphatidylinositol 3-kinase regulates early differentiation in human laryngeal keratinocytes.
PTEN is a negative regulator of STAT3 activation in human papillomavirus-infected cells.
Paraganglioma
UPDATE ON THE CLINICOPATHOLOGY OF PITUITARY ADENOMAS.
Paralysis
Absence of metabotropic glutamate receptor homolog(s) accelerates acetylcholine neurotransmission in Caenorhabditis elegans.
Paramyxoviridae Infections
Emerging views of mitophagy in immunity and autoimmune diseases.
Paresthesia
PI3K mediated activation of GSK-3? reduces at-level primary afferent growth responses associated with excitotoxic spinal cord injury dysesthesias.
Parkinson Disease
A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers.
Autophagy and innate immunity: Insights from invertebrate model organisms.
Autophagy: a potential key contributor to the therapeutic action of mesenchymal stem cells.
Neuroprotection by marine-derived compound, 11-dehydrosinulariolide, in an in vitro Parkinson's model: a promising candidate for the treatment of Parkinson's disease.
Neuroprotective effect of Annona muricata-derived polysaccharides in neuronal HT22 cell damage induced by hydrogen peroxide.
Neurotrophic Effect of Asiatic acid, a Triterpene of Centella asiatica Against Chronic 1-Methyl 4-Phenyl 1, 2, 3, 6-Tetrahydropyridine Hydrochloride/Probenecid Mouse Model of Parkinson's disease: The Role of MAPK, PI3K-Akt-GSK3? and mTOR Signalling Pathways.
Regulation of PRKN-independent mitophagy.
Upstream regulators of phosphoinositide 3-kinase and their role in diseases.
Parkinsonian Disorders
Emerging views of mitophagy in immunity and autoimmune diseases.
Nerve growth factor prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced cell death via the Akt pathway by suppressing caspase-3-like activity using PC12 cells: relevance to therapeutical application for Parkinson's disease.
Sex differences in autophagy-mediated diseases: toward precision medicine.
Tumor suppressor PTEN affects tau phosphorylation: deficiency in the phosphatase activity of PTEN increases aggregation of an FTDP-17 mutant Tau.
Periodontitis
Effects of periodontitis on aortic insulin resistance in an obese rat model.
Increased visfatin expression is associated with nuclear factor-kappa B and phosphatidylinositol 3-kinase in periodontal inflammation.
Large-scale investigation of genomic markers for severe periodontitis.
Peripheral Nervous System Diseases
Genetic disruption of Pten in a novel mouse model of tomaculous neuropathy.
Mechanical allodynia and enhanced responses to capsaicin are mediated by PI3K in a paclitaxel model of peripheral neuropathy.
Persistent Infection
Genetic Defects in Phosphoinositide 3-Kinase ? Influence CD8+ T Cell Survival, Differentiation, and Function.
Human cytomegalovirus infection and atherothrombosis.
ICOS-deficient and ICOS YF mutant mice fail to control Toxoplasma gondii infection of the brain.
Peste-des-Petits-Ruminants
Autophagy in farm animals: current knowledge and future challenges.
Pheochromocytoma
Activation of phosphatidylinositol 3-kinase by epidermal growth factor, basic fibroblast growth factor, and nerve growth factor in PC12 pheochromocytoma cells.
Inhibition of the PI3K Pathway Suppresses Hormonal Secretion and Limits Growth in Pheochromocytoma Cells.
MiR-199a-5p regulates sirtuin1 and PI3K in the rat hippocampus with intrauterine growth restriction.
Mitogenic signaling by cyclic adenosine monophosphate in chromaffin cells involves phosphatidylinositol 3-kinase activation.
Nerve growth factor promotes the activation of phosphatidylinositol 3-kinase and its association with the trk tyrosine kinase.
Nuclear translocation of phosphatidylinositol 3-kinase in rat pheochromocytoma PC 12 cells after treatment with nerve growth factor.
Phosphatidylinositol 3-kinase is activated by nerve growth factor and epidermal growth factor in PC12 cells.
Secretin Receptor Promotes the Proliferation of Endocrine Tumor Cells Via the PI3K/AKT Pathway.
phosphatidylinositol 3-kinase deficiency
A dual role for the class III PI3K, Vps34, in platelet production and thrombus growth.
Active vacuolar H+ ATPase and functional cycle of Rab5 are required for the vacuolation defect triggered by PtdIns(3,5)P2 loss under PIKfyve or Vps34 deficiency.
Class III PI3K Positively Regulates Platelet Activation and Thrombosis via PI(3)P-Directed Function of NADPH Oxidase.
Deficiency in class III PI3-kinase confers postnatal lethality with IBD-like features in zebrafish.
Distinct roles of phosphoinositide-3 kinase and phospholipase Cgamma2 in B-cell receptor-mediated signal transduction.
Lens differentiation is controlled by the balance between PDGF and FGF signaling.
Pik3c3 deficiency in myeloid cells imparts partial resistance to experimental autoimmune encephalomyelitis associated with reduced IL-1? production.
Precision Therapy for the Treatment of Primary Immunodysregulatory Diseases.
Role of phosphatidylinositol-3 kinase in transcriptional regulation of TLR-induced IL-12 and IL-10 by Fc gamma receptor ligation in murine macrophages.
Vps34 Deficiency Reveals the Importance of Endocytosis for Podocyte Homeostasis.
phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase deficiency
SHIP-1 Regulates Phagocytosis and M2 Polarization Through the PI3K/Akt-STAT5-Trib1 Circuit in Pseudomonas aeruginosa Infection.
phosphatidylinositol-3,4-bisphosphate 4-phosphatase deficiency
The INPP4B Tumor Suppressor Modulates EGFR Trafficking and Promotes Triple-Negative Breast Cancer.
phosphoinositide phospholipase c deficiency
Distinct roles of phosphoinositide-3 kinase and phospholipase Cgamma2 in B-cell receptor-mediated signal transduction.
phospholipase d deficiency
Differential Roles of Phospholipase D Proteins in Fc?RI-Mediated Signaling and Mast Cell Function.
Role of phospholipase D1 in the regulation of mTOR activity by lysophosphatidic acid.
Pituitary ACTH Hypersecretion
Dual HDAC and PI3K Inhibitor: A Novel Potential Therapeutic Option in Cushing Disease.
Pituitary Neoplasms
Activation of phosphatidylinositol 3-kinase signaling promotes aberrant pituitary growth in a mouse model of thyroid-stimulating hormone-secreting pituitary tumors.
Combination of mTOR Inhibitors Augments Potency while Activating PI3K Signaling in Pituitary Tumors.
Differential effects of PI3K and dual PI3K/mTOR inhibition in rat prolactin-secreting pituitary tumors.
Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting.
MicroRNA-106b promotes pituitary tumor cell proliferation and invasion through PI3K/AKT signaling pathway by targeting PTEN.
Nerve growth factor restores p53 function in pituitary tumor cell lines via trkA-mediated activation of phosphatidylinositol 3-kinase.
Novel non-genomic signaling of thyroid hormone receptors in thyroid carcinogenesis.
Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression.
Targeting MAPK (Ras/ERK) and PI3K/Akt pathways in pituitary tumorigenesis.
UPDATE ON THE CLINICOPATHOLOGY OF PITUITARY ADENOMAS.
Pleural Effusion
Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo.
Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions.
Pleural Effusion, Malignant
Activation of calpain by renin-angiotensin system in pleural mesothelial cells mediates tuberculous pleural fibrosis.
Pleurisy
Phosphoinositide-3 kinases critically regulate the recruitment and survival of eosinophils in vivo: importance for the resolution of allergic inflammation.
Pneumococcal Infections
Importance of phosphoinositide 3-kinase gamma in the host defense against pneumococcal infection.
Submission for Special Issue: The Role of Platelet Activation in the Pathophysiology of HIV, Tuberculosis, and Pneumococcal Disease. Bedaquiline Suppresses ADP-Mediated Activation of Human Platelets In Vitro via Interference With Phosphatidylinositol 3-Kinase.
Pneumonia
Airway inflammation: chemokine-induced neutrophilia and the class I phosphoinositide 3-kinases.
Effects of phosphoinositide 3-kinase in protease-induced acute and chronic lung inflammation, remodeling and emphysema in rats.
Essential role of phosphoinositide 3-kinase gamma in eosinophil chemotaxis within acute pulmonary inflammation.
Highly pathogenic PRRSV induces IL-17 production via the activation of IRAK1-PI3K-p38MAPK-C/EBP?/CREB pathways.
Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis.
Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors.
Myeloid PTEN promotes inflammation but impairs bactericidal activities during murine pneumococcal pneumonia.
Olprinone and colforsin daropate alleviate septic lung inflammation and apoptosis through CREB-independent activation of the Akt pathway.
Platelet PI3K Modulates Innate Leukocyte Extravasation during Acid-Induced Acute Lung Inflammation.
Roles of PI3K pan-inhibitors and PI3K-? inhibitors in allergic lung inflammation: a systematic review and meta-analysis.
Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer: A Review.
SIGNALING PATHWAYS AND MEDIATORS IN LPS-INDUCED LUNG INFLAMMATION IN DIABETIC RATS: ROLE OF INSULIN.
Slit2 Regulates Attractive Eosinophil and Repulsive Neutrophil Chemotaxis through Differential srGAP1 Expression during Lung Inflammation.
Pneumonia, Pneumococcal
Myeloid PTEN promotes inflammation but impairs bactericidal activities during murine pneumococcal pneumonia.
Pneumonia, Pneumocystis
Risk of infection associated with targeted therapies for solid organ and hematological malignancies.
Pneumoperitoneum
TIMP-3 and Phosphatidylinositol 3-kinase genes were found to be related to the progression of colon cancer in a comparison of pneumoperitoneum and laparotomy in a murine model.
Polycystic Kidney Diseases
Folate-dactolisib conjugates for targeting tubular cells in polycystic kidneys.
PKD2/polycystin-2 induces autophagy by forming a complex with BECN1.
Polycystic Kidney, Autosomal Dominant
PKD2/polycystin-2 induces autophagy by forming a complex with BECN1.
Polycystic Ovary Syndrome
Altered aquaporin expression in women with polycystic ovary syndrome: hyperandrogenism in follicular fluid inhibits aquaporin-9 in granulosa cells through the phosphatidylinositol 3-kinase pathway.
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Defective Activation of Protein Kinase C-z in Muscle by Insulin and Phosphatidylinositol-3,4,5,-(PO(4))(3) in Obesity and Polycystic Ovary Syndrome.
Phosphatidylinositide 3-kinase inhibition: A new potential target for the treatment of polycystic ovarian syndrome.
Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene Met326Ile polymorphism in women with polycystic ovary syndrome.
Role of the PI3K-Akt Signaling Pathway in the Pathogenesis of Polycystic Ovary Syndrome.
[Activation and significance of the PI3K/Akt pathway in endometrium with polycystic ovary syndrome patients].
[Detection and significance of phosphatidylinositol 3-kinase in adipose tissue of polycystic ovary syndrome patients with insulin resistance]
Polymicrogyria
Characterisation of mutations of the phosphoinositide-3-kinase regulatory subunit, PIK3R2, in perisylvian polymicrogyria: a next-generation sequencing study.
Polymyalgia Rheumatica
Polymyalgia rheumatica development in a patient under PI3K inhibitor therapy for chronic lymphocytic leukaemia.
Polyomavirus Infections
Phosphoinositide 3'-Kinase ? Facilitates Polyomavirus Infection.
Porcine Reproductive and Respiratory Syndrome
Autophagy and innate immunity: Insights from invertebrate model organisms.
Role of phosphatidylinositol 3-kinase (PI3K) and Akt1 kinase in porcine reproductive and respiratory syndrome virus (PRRSV) replication.
Port-Wine Stain
Activation of PKC? and PI3K Kinases in Hypertrophic and Nodular Port Wine Stain Lesions.
The Pathogenesis of Port Wine Stain and Sturge Weber Syndrome: Complex Interactions between Genetic Alterations and Aberrant MAPK and PI3K Activation.
Pre-Eclampsia
Down-Regulation of Laminin (LN)- ?5 is Associated with Preeclampsia and Impairs Trophoblast Cell Viability and Invasiveness Through PI3K Signaling Pathway.
Inhibition of the PI3K-Akt pathway suppresses sFlt1 expression in human placental hypoxia models in vitro.
LncRNA MALAT1 regulates trophoblast cells migration and invasion via miR-206/IGF-1 axis.
miR-483 is downregulated in pre-eclampsia via targeting insulin-like growth factor 1 (IGF1) and regulates the PI3K/Akt/mTOR pathway of endothelial progenitor cells.
Nicotine Alleviates Cortical Neuronal Injury by Suppressing Neuroinflammation and Upregulating Neuronal PI3K-AKT Signaling in an Eclampsia-Like Seizure Model.
The significance of miR-145 in the prediction of preeclampsia.
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Suppression of c-Myc using 10058-F4 exerts caspase-3-dependent apoptosis and intensifies the antileukemic effect of vincristine in pre-B acute lymphoblastic leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells.
Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.
Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia.
Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen.
Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells.
Mometasone furoate inhibits growth of acute leukemia cells in childhood by regulating PI3K signaling pathway.
Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia.
PI3K inhibition synergizes with glucocorticoids but antagonizes with methotrexate in T-cell acute lymphoblastic leukemia.
PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines.
PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors.
PI3K-? inhibition using CAL-101 exerts apoptotic effects and increases doxorubicin-induced cell death in pre-B-acute lymphoblastic leukemia cells.
Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.
Regulation of PI3K signaling in T-cell acute lymphoblastic leukemia: a novel PTEN/Ikaros/miR-26b mechanism reveals a critical targetable role for PIK3CD.
Targeting PI3K Signaling in Acute Lymphoblastic Leukemia.
Targeting the MAPK/ERK and PI3K/AKT Signaling Pathways Affects NRF2, Trx and GSH Antioxidant Systems in Leukemia Cells.
Targeting the mTOR Pathway in Leukemia.
Targeting the MYC and PI3K pathways eliminates leukemia-initiating cells in T-cell acute lymphoblastic leukemia.
The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism.
The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
A copper chelate induces apoptosis and overcomes multidrug resistance in T-cell acute lymphoblastic leukemia through redox imbalance and inhibition of EGFR/PI3K/Akt expression.
Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells.
Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia.
Calming down T cell acute leukemia.
Clinical-Grade Peptide-Based Inhibition of CK2 Blocks Viability and Proliferation of T-ALL Cells and Counteracts IL-7 Stimulation and Stromal Support.
Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors.
Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.
Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.
Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen.
Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001.
IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia.
Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
Inactivation of LEF1 in T-cell acute lymphoblastic leukemia.
Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia.
Intracellular reactive oxygen species are essential for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells.
Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia.
NOTCH1 downregulation contributes to PI3K inhibitor resistance in T-ALL.
PI3K inhibition synergizes with glucocorticoids but antagonizes with methotrexate in T-cell acute lymphoblastic leukemia.
PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors.
PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response.
Preclinical testing of the AKT inhibitor triciribine in T-cell acute lymphoblastic leukemia.
PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability.
Single-cell profiling of pediatric T-cell acute lymphoblastic leukemia: Impact of PTEN exon 7 mutation on PI3K/Akt and JAK-STAT signaling pathways.
Targeting the MYC and PI3K pathways eliminates leukemia-initiating cells in T-cell acute lymphoblastic leukemia.
Targeting Wnt/?-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia.
Transcriptional Regulation of PIK3CD and PIKFYVE in T-Cell Acute Lymphoblastic Leukemia by IKAROS and Protein Kinase CK2.
[Reaserch Advances on the Role of PI3K/AKT Signaling Pathway and MiRNA in Acute T-Cell Lymphocytic Leukemia--Review].
Prediabetic State
Alpelisib-Induced Diabetic Ketoacidosis: A Case Report and Review of Literature.
Premature Birth
Hepatic Insulin Resistance and Altered Gluconeogenic Pathway in Premature Baboons.
IL-27 induces a pro-inflammatory response in human fetal membranes mediating preterm birth.
Primary Immunodeficiency Diseases
A human immunodeficiency caused by mutations in the PIK3R1 gene.
Activated phosphoinositide 3-kinase delta syndrome 1 and 2 (APDS 1 and APDS 2): similarities and differences based on clinical presentation in two boys.
Conformational disruption of PI3K? regulation by immunodeficiency mutations in PIK3CD and PIK3R1.
Phosphatase and tensin homolog (PTEN) mutation can cause activated phosphatidylinositol 3-kinase ? syndrome-like immunodeficiency.
PIK3R1 Mutation Associated with Hyper IgM (APDS2 Syndrome): A Case Report and Review of the Literature.
Primary Myelofibrosis
Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis.
VEGF Regulation of Angiogenic Factors via Inflammatory Signaling in Myeloproliferative Neoplasms.
Primary Ovarian Insufficiency
Functional roles of the phosphatidylinositol 3-kinases (PI3Ks) signaling in the mammalian ovary.
Hippo signaling in the ovary and polycystic ovarian syndrome.
Intraovarian control of early folliculogenesis.
New strategy for in vitro activation of primordial follicles with mTOR and PI3K stimulators.
Prolactinoma
The Balance of PI3K and ERK Signaling Is Dysregulated in Prolactinoma and Modulated by Dopamine.
prostaglandin-e synthase deficiency
Microsomal prostaglandin E synthase-1 deficiency is associated with elevated peroxisome proliferator-activated receptor gamma: regulation by prostaglandin E2 via the phosphatidylinositol 3-kinase and Akt pathway.
prostaglandin-endoperoxide synthase deficiency
Cyclooxygenase-2 deficiency in macrophages leads to defective p110? PI3K signaling and impairs cell adhesion and migration.
Prostatic Hyperplasia
miR-27b expression in diagnosis and evaluation prognosis of prostate cancer.
Over expression of PI3K-AkT reduces apoptosis and increases prostate size in benign prostatic hyperplasia.
Prostatic Intraepithelial Neoplasia
Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease.
Expression of phosphorylated-mTOR during the development of prostate cancer.
Prostatic Neoplasms
1,25-dihydroxyvitamin D(3) and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells.
A hormone-dependent feedback-loop controls androgen receptor levels by limiting MID1, a novel translation enhancer and promoter of oncogenic signaling.
A novel inhibitor of hypoxia-inducible factor-1alpha P3155 also modulates PI3K pathway and inhibits growth of prostate cancer cells.
A novel PI3K inhibitor displays potent preclinical activity against an androgen-independent and PTEN-deficient prostate cancer model established from the cell line PC3.
A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth.
A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer.
A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies.
A Phase II Trial of Temsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer.
A Tumor Suppressor Function for the Lipid Phosphatase INPP4B in Melanocytic Neoplasms.
Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes.
Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.
Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
Activation of the RalGEF/Ral Pathway Promotes Prostate Cancer Metastasis to Bone.
Active ?-catenin is regulated by the PTEN/PI3 kinase pathway: a role for protein phosphatase PP2A.
AKT and cytosolic phospholipase A2? form a positive loop in prostate cancer cells.
Akt in prostate cancer: possible role in androgen-independence.
Akt-regulated pathways in prostate cancer.
Aloe-emodin suppresses prostate cancer by targeting the mTOR complex 2.
An enzyme-responsive conjugate improves the delivery of a PI3K inhibitor to prostate cancer.
An inverted CAV1 (caveolin 1) topology defines novel autophagy-dependent exosome secretion from prostate cancer cells.
Androgen receptor-induced integrin ?6?1 and Bnip3 promote survival and resistance to PI3K inhibitors in castration-resistant prostate cancer.
Androgen-induced miR-27A acted as a tumor suppressor by targeting MAP2K4 and mediated prostate cancer progression.
Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins.
Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer.
AR Signaling and the PI3K Pathway in Prostate Cancer.
Arachidonic acid activates phosphatidylinositol 3-kinase signaling and induces gene expression in prostate cancer.
Arctigenin Triggers Apoptosis and Autophagy via PI3K/Akt/mTOR Inhibition in PC-3M Cells.
Aromatic Hydrocarbon Receptor Suppresses Prostate Cancer Bone Metastasis Cells-Induced Vasculogenesis of Endothelial Progenitor Cells under Hypoxia.
Assessment of Functional Phosphatidylinositol 3-Kinase Pathway Activity in Cancer Tissue Using Forkhead Box-O Target Gene Expression in a Knowledge-Based Computational Model.
Association between the Met326Ile polymorphism of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase and prostate cancer risk: a prospective study.
Association of polymorphisms of PTEN, AKT1, PI3K, AR, and AMACR genes in patients with prostate cancer.
AURKA suppression induces DU145 apoptosis and sensitizes DU145 to docetaxel treatment.
Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality.
B-Raf Activation Cooperates with PTEN Loss to Drive c-Myc Expression in Advanced Prostate Cancer.
BAD Dephosphorylation and Decreased Expression of MCL-1 Induce Rapid Apoptosis in Prostate Cancer Cells.
Bcl-xL mediates a survival mechanism independent of the phosphoinositide 3-kinase/Akt pathway in prostate cancer cells.
Behavioral stress accelerates prostate cancer development in mice.
BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer.
Cell type-specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors.
Clinical implications of genomic alterations in metastatic prostate cancer.
Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer.
Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3K?/?/? Inhibitor BAY1082439.
CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action.
Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism.
DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis.
Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers.
Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target?
Development of a three-dimensional culture model of prostatic epithelial cells and its use for the study of epithelial-mesenchymal transition and inhibition of PI3K pathway in prostate cancer.
Diarylpentanoid (1,5-bis(4-hydroxy-3-methoxyphenyl)-1,4-pentadiene-3-one) (MS13) Exhibits Anti-proliferative, Apoptosis Induction and Anti-migration Properties on Androgen-independent Human Prostate Cancer by Targeting Cell Cycle-Apoptosis and PI3K Signalling Pathways.
Diverse antiapoptotic signaling pathways activated by vasoactive intestinal polypeptide, epidermal growth factor, and phosphatidylinositol 3-kinase in prostate cancer cells converge on BAD.
Down-modulation of Bcl-2 sensitizes PTEN-mutated prostate cancer cells to starvation and taxanes.
Downregulation of mTOR by lentivirus inhibits prostate cancer cell growth.
Dual inhibition of BRD4 and PI3K by SF2523 suppresses human prostate cancer cell growth in vitro and in vivo.
Dual PI3K/mTOR Inhibitor NVP-BEZ235 Sensitizes Docetaxel in Castration Resistant Prostate Cancer.
Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models.
Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.
Effects of adipocytes on the proliferation and differentiation of prostate cancer cells in a 3-D culture model.
Enabling precision medicine by unravelling disease pathophysiology: quantifying signal transduction pathway activity across cell and tissue types.
Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells.
Eupafolin suppresses prostate cancer by targeting phosphatidylinositol 3-kinase-mediated Akt signaling.
Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (review).
Expression of phosphorylated-mTOR during the development of prostate cancer.
Feed Forward Cycle of Hypotonic Stress-induced ATP Release, Purinergic Receptor Activation, and Growth Stimulation of Prostate Cancer Cells.
Feedback suppression of PI3K? signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3K?.
FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer.
G-protein alpha-s and -12 subunits are involved in androgen-stimulated PI3K activation and androgen receptor transactivation in prostate cancer cells.
Gefitinib and bicalutamide show synergistic effects in primary cultures of prostate cancer derived from androgen-dependent naive patients.
Genetic Alterations in the PI3K Pathway in Prostate Cancer.
Gut Microbiota-Derived Short-Chain Fatty Acids Promote Prostate Cancer Growth via IGF1 Signaling.
HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer.
HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression.
Identification of Pik3ca mutation as a genetic driver of prostate cancer that cooperates with Pten loss to accelerate progression and castration-resistant growth.
Impact of E6-associated protein on the proliferation and invasion of prostate cancer cells in bone metastasis.
In Vitro Antimetastatic Effect of Phosphatidylinositol 3-Kinase Inhibitor ZSTK474 on Prostate Cancer PC3 Cells.
Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells.
Inhibition of phosphatidylinositol-3-kinase causes cell death through a protein kinase B (PKB)-dependent mechanism and growth arrest through a PKB-independent mechanism.
Inhibition of phosphatidylinositol-3-kinase causes increased sensitivity to radiation through a PKB-dependent mechanism.
Inhibition of the phosphatidylinositol 3'-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells.
Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer.
Interleukin-6 and oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase.
Interleukin-6 regulation of prostate cancer cell growth.
Invention of a novel photodynamic therapy for tumors using a photosensitizing PI3K inhibitor.
Involvement of intercellular adhesion molecule-1 up-regulation in bradykinin promotes cell motility in human prostate cancers.
Jab1/CSN5 mediates E2F dependent expression of mitotic and apoptotic but not DNA replication targets.
Leptin induces cell migration and the expression of growth factors in human prostate cancer cells.
Loss of PTEN stabilizes the lipid modifying enzyme cytosolic phospholipase A?? via AKT in prostate cancer cells.
Mammalian target of rapamycin and 3-phosphatidylinositol 3-kinase pathway inhibition enhances growth inhibition of transforming growth factor-beta1 in prostate cancer cells.
Mapping the Germline and Somatic Mutation Interaction Landscape in Indolent and Aggressive Prostate Cancers.
Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer.
Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24.
Microarray-based identification of differentially expressed genes associated with andrographolide derivatives-induced resistance in colon and prostate cancer cell lines.
MIIP inhibits the growth of prostate cancer via interaction with PP1? and negative modulation of AKT signaling.
miR-21 targets and inhibits tumor suppressor gene PTEN to promote prostate cancer cell proliferation and invasion: An experimental study.
miR-27b expression in diagnosis and evaluation prognosis of prostate cancer.
Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening.
Molecular alterations associated with prostate cancer.
Molecular biology of prostate-cancer pathogenesis.
Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy.
Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell-Level PI3K Pathway Activation.
MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2.
Nanomicellar TGX221 blocks xenograft tumor growth of prostate cancer in nude mice.
Negative cross talk between LIMK2 and PTEN promotes castration resistant prostate cancer pathogenesis in cells and in vivo.
No association between a polymorphic variant of the IRS-1 gene and prostate cancer risk.
Novel combination of docetaxel and thymoquinone induces synergistic cytotoxicity and apoptosis in DU-145 human prostate cancer cells by modulating PI3K-AKT pathway.
Novel strategies for molecular targeting to cancer.
NVP-BEZ235, a dual PI3K/mTOR inhibitor, induces cell death through alternate routes in prostate cancer cells depending on the PTEN genotype.
NVP-BEZ235, Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor, Prominently Enhances Radiosensitivity of Prostate Cancer Cell Line PC-3.
Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells.
Over expression of PI3K-AkT reduces apoptosis and increases prostate size in benign prostatic hyperplasia.
Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08).
Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.
Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells.
Phosphatidylinositol 3-kinase ? and ? isoforms play key roles in metastasis of prostate cancer DU145 cells.
Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers.
Phosphoinositide-3-kinase pathway activation in PTEN deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110{beta} and p110{delta} catalytic subunits.
Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients.
PI3 Kinase inhibition on TRAIL-induced apoptosis correlates with androgen-sensitivity and p21 expression in prostate cancer cells.
PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancer.
PI3K is required for insulin-stimulated but not EGF-stimulated ERK1/2 activation.
PI3K pathway and Bcl-2 family. Clinicopathological features in prostate cancer.
PI3K pathway in prostate cancer: All resistant roads lead to PI3K.
PI3K, Erk signaling in BMP7-induced epithelial-mesenchymal transition (EMT) of PC-3 prostate cancer cells in 2- and 3-dimensional cultures.
PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer.
PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer.
Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance.
Proinflammatory cytokine interleukin-6 in prostate carcinogenesis.
Prostate cancer, PI3K, PTEN and prognosis.
Prostate Power Play: Does Pik3ca Accelerate Pten-Deficient Cancer Progression?
Prostate specific membrane antigen knockdown impairs the tumorigenicity of LNCaP prostate cancer cells by inhibiting the phosphatidylinositol 3-kinase/Akt signaling pathway.
Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors.
Protein expression of PTEN, insulin-like growth factor I receptor (IGF1R), and lethal prostate cancer: a prospective study.
Proteomic analysis of extracellular vesicles identified PI3K pathway as a potential therapeutic target for cabazitaxel-resistant prostate cancer.
PSMA brings new flavors to PI3K signaling: A role for glutamate in prostate cancer.
PTEN genomic deletion defines favorable prognostic biomarkers in localized prostate cancer: a systematic review and meta-analysis.
Rac1-dependent lamellipodial motility in prostate cancer PC-3 cells revealed by optogenetic control of Rac1 activity.
Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.
Regulation of apoptosis by androgens in prostate cancer cells.
Regulation of cell survival by resveratrol involves inhibition of NFkappaB-regulated gene expression in prostate cancer cells.
Regulation of interleukin-6-mediated PI3K activation and neuroendocrine differentiation by androgen signaling in prostate cancer LNCaP cells.
Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA.
Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state.
Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer.
Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells.
Roles of androgen-dependent and -independent activation of signal transduction pathways for cell proliferation of prostate cancer cells.
Sanggenol L Induces Apoptosis and Cell Cycle Arrest via Activation of p53 and Suppression of PI3K/Akt/mTOR Signaling in Human Prostate Cancer Cells.
Saposin C promotes survival and prevents apoptosis via PI3K/Akt-dependent pathway in prostate cancer cells.
SB225002 inhibits prostate cancer invasion and attenuates the expression of BSP, OPN and MMP?2.
Selective growth regulatory and pro-apoptotic effects of DIM is mediated by AKT and NF-kappaB pathways in prostate cancer cells.
SGK3 is an androgen-inducible kinase promoting prostate cancer cell proliferation through activation of p70 S6 kinase and up-regulation of cyclin D1.
Structural and biophysical insights into the mode of covalent binding of rationally designed potent BMX inhibitors.
Structure-based assessment and network analysis of targeting 14-3-3 proteins in prostate cancer.
Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase.
Suppression of prometastatic phenotype of highly metastatic androgen-independent rat prostate cancer MLL cell line by PI3K inhibitor LY294002.
Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
Synthesis and Characterization of a Novel Prostate Cancer-Targeted Phosphatidylinositol-3-kinase Inhibitor Prodrug.
Synthesis and PI3 Kinase Inhibition Activity of a Wortmannin-Leucine Derivative.
Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor.
Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
TGF-?/PI3K/AKT/mTOR/NF-kB pathway. Clinicopathological features in prostate cancer.
The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation.
The Androgen Receptor Induces Integrin {alpha}6{beta}1 to Promote Prostate Tumor Cell Survival via NF-{kappa}B and Bcl-xL Independently of PI3K Signaling.
The long tail of oncogenic drivers in prostate cancer.
The Molecular Taxonomy of Primary Prostate Cancer.
The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects on TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity in Combination with PI3K Inhibition.
The outstanding role of miR-132-3p in carcinogenesis of solid tumors.
The phosphatidylinositol 3-kinase (PI3K) isoform dependence of tumor formation is determined by the genetic mode of PI3K pathway activation rather than by tissue type.
The PI3 Kinase Signaling Pathway in Prostate Cancer.
The PI3K regulatory subunit gene PIK3R1 is under direct control of androgens and repressed in prostate cancer cells.
The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations.
The Sex-determining region Y-box 4 and homeobox C6 transcriptional networks in prostate cancer progression: crosstalk with the Wnt, Notch, and PI3K pathways.
TIPE2 Overexpression Suppresses the Proliferation, Migration, and Invasion in Prostate Cancer Cells by Inhibiting PI3K/Akt Signaling Pathway.
Transcription factor AP-1 promotes growth and radioresistance in prostate cancer cells.
Tumours with PI3K activation are resistant to dietary restriction.
Vasculogenic Mimicry in Prostate Cancer: The Roles of EphA2 and PI3K.
Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K.
Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.
[Molecular subtypes and perspectives of targeted therapies in prostate cancer].
[PI3K/p110?-specific inhibitors in castration-resistant prostate cancer].
Protein Deficiency
Wiskott-Aldrich Syndrome Interacting Protein Deficiency Uncovers the Role of the Co-receptor CD19 as a Generic Hub for PI3 Kinase Signaling in B Cells.
Proteinuria
1,25-Dihydroxyvitamin D(3) Prevents Puromycin Aminonucleoside-Induced Apoptosis of Glomerular Podocytes by Activating the Phosphatidylinositol 3-Kinase/Akt-Signaling Pathway.
Vps34 Deficiency Reveals the Importance of Endocytosis for Podocyte Homeostasis.
Psoriasis
Autophagy-based unconventional secretion of HMGB1 by keratinocytes plays a pivotal role in psoriatic skin in?ammation.
Expression of PI3K Signaling Associated with T Cells in Psoriasis Is Inhibited by Seletalisib, a PI3K? Inhibitor, and Is Required for Functional Activity.
The role of PI3K/AKT/FOXO signaling in psoriasis.
Up-regulation of phosphatidylinositol 3-kinase in psoriatic lesions.
[Expressions of survivin, PI3K and AKT in keratinocytes in skin lesions and their pathogenic role in psoriasis vulgaris].
Psychomotor Agitation
Learning Deficits and Agenesis of Synapses and Myelinated Axons in Phosphoinositide-3 Kinase-Deficient Mice.
Puberty, Delayed
Loss of PI3K p110? in the Adipose Tissue Results in Infertility and Delayed Puberty Onset in Male Mice.
Pulmonary Adenomatosis, Ovine
A phosphatidylinositol 3-kinase docking site in the cytoplasmic tail of the Jaagsiekte sheep retrovirus transmembrane protein is essential for envelope-induced transformation of NIH 3T3 cells.
Transformation of mouse fibroblasts by Jaagsiekte sheep retrovirus envelope does not require phosphatidylinositol 3-kinase.
Pulmonary Arterial Hypertension
Reversal of the Warburg effect with DCA in PDGF?treated human PASMC is potentiated by pyruvate dehydrogenase kinase?1 inhibition mediated through blocking Akt/GSK?3? signalling.
SUMOylation of Vps34 by SUMO1 promotes phenotypic switching of vascular smooth muscle cells by activating autophagy in pulmonary arterial hypertension.
Suppression of Phosphatidylinositol 3-Kinase/Akt Signaling Attenuates Hypoxia-Induced Pulmonary Hypertension Through the Downregulation of Lysyl Oxidase.
Pulmonary Disease, Chronic Obstructive
Aberrant neutrophil functions in stable Chronic Obstructive Pulmonary Disease: The neutrophil as an immunotherapeutic target.
Asthma & COPD - SMi's sixth annual conference.
Bu-Shen-Fang-Chuan formula attenuates cigarette smoke-induced inflammation by modulating the PI3K/Akt-Nrf2 and NF-?B signalling pathways.
Combined Inhibition of PDE4 and PI3K? Modulates the Inflammatory Component Involved in the Progression of Chronic Obstructive Pulmonary Disease.
Decreased phosphatase PTEN amplifies PI3K signaling and enhances proinflammatory cytokine release in COPD.
Differential Effects of p38, MAPK, PI3K or Rho Kinase Inhibitors on Bacterial Phagocytosis and Efferocytosis by Macrophages in COPD.
Effective-component compatibility of Bufei Yishen formula II inhibits mucus hypersecretion of chronic obstructive pulmonary disease rats by regulating EGFR/PI3K/mTOR signaling.
Endoplasmic reticulum stress and unfolded protein response in diaphragm muscle dysfunction of patients with stable chronic obstructive pulmonary disease.
Extracellular matrix promotes proliferation, migration and adhesion of airway smooth muscle cells in a rat model of chronic obstructive pulmonary disease via upregulation of the PI3K/AKT signaling pathway.
Functional redundancy of class I phosphoinositide 3-kinase (PI3K) isoforms in signaling growth factor-mediated human neutrophil survival.
Ginsenoside Rg3 ameliorates acute exacerbation of COPD by suppressing neutrophil migration.
Inactivation of MTOR promotes autophagy-mediated epithelial injury in particulate matter-induced airway inflammation.
Oxidative stress dependent microRNA-34a activation via PI3K? reduces the expression of sirtuin-1 and sirtuin-6 in epithelial cells.
PI3K signaling in chronic obstructive pulmonary disease: mechanisms, targets, and therapy.
PI3K signalling in chronic obstructive pulmonary disease and opportunities for therapy.
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
The effect of phosphatidylinositol-3 kinase inhibition on matrix metalloproteinase-9 and reactive oxygen species release from chronic obstructive pulmonary disease neutrophils.
The phosphoinositide 3'-kinase p110? modulates contractile protein production and IL-6 release in human airway smooth muscle.
The PI3K/AKT/mTOR pathway regulates autophagy to induce apoptosis of alveolar epithelial cells in chronic obstructive pulmonary disease caused by PM2.5 particulate matter.
Upregulation of IL-17A/F from human lung tissue explants with cigarette smoke exposure: implications for COPD.
[Expression of mitogen-actived protein kinase, phosphatidylinositol 3-kinase and hypoxia-inducible factor-1alpha in pulmonary arteries of patients with chronic obstructive pulmonary disease]
Pulmonary Edema
17ß-estradiol suppresses lipopolysaccharide-induced acute lung injury through PI3K/Akt/SGK1 mediated up-regulation of epithelial sodium channel (ENaC) in vivo and in vitro.
Pulmonary Fibrosis
Dual Targeting of MEK and PI3K Pathways Attenuates Established and Progressive Pulmonary Fibrosis.
Inhibition of PI3K by PX-866 prevents transforming growth factor-alpha-induced pulmonary fibrosis.
Involvement of ER stress, PI3K/AKT activation, and lung fibroblast proliferation in bleomycin-induced pulmonary fibrosis.
Metformin ameliorates bleomycin-induced pulmonary fibrosis in mice by suppressing IGF-1.
MiR-503 modulates epithelial-mesenchymal transition in silica-induced pulmonary fibrosis by targeting PI3K p85 and is sponged by lncRNA MALAT1.
Sustained PI3K Activation exacerbates BLM-induced Lung Fibrosis via activation of pro-inflammatory and pro-fibrotic pathways.
[Preliminary study of exon sequence in pneumoconiosis using high-throughput and intervention of EGFR-TKIs on silicosis rats].
receptor protein-tyrosine kinase deficiency
p75NTR-dependent modulation of cellular handling of reactive oxygen species.
Rectal Neoplasms
A systematic approach introduced novel targets in rectal cancer by considering miRNA/mRNA interactions in response to radiotherapy.
CoA Synthase (COASY) Mediates Radiation Resistance via PI3K Signaling in Rectal Cancer.
Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1.
The Frequencies and Clinical Implications of Mutations in 33 Kinase-Related Genes in Locally Advanced Rectal Cancer: A Pilot Study.
Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: Opportunities for signaling-adapted therapies.
Relative Energy Deficiency in Sport
PI3K/AKT Pathway Involvement in the Osteogenic Effects of Osteoclast Culture Supernatants on Preosteoblast Cells.
Renal Insufficiency, Chronic
Investigation of the effects of indoxyl sulfate, a uremic toxin, on the intracellular oxidation level and phagocytic activity using an HL-60-differentiated human macrophage cell model.
Reperfusion Injury
Activation of cGMP/Protein Kinase G Pathway in Postconditioned Myocardium Depends on Reduced Oxidative Stress and Preserved Endothelial Nitric Oxide Synthase Coupling.
Apelin protects against ischemia-reperfusion injury in diabetic myocardium via inhibiting apoptosis and oxidative stress through PI3K and p38-MAPK signaling pathways.
Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts.
Cardioprotection of ischemic postconditioning and pharmacological post-treatment with adenosine or acetylcholine.
CTGF/CCN2 Postconditioning Increases Tolerance of Murine Hearts towards Ischemia-Reperfusion Injury.
Dexmedetomidine protects against lung ischemia-reperfusion injury by the PI3K/Akt/HIF-1? signaling pathway.
Discovery of 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol as an isozyme-selective inhibitor of PI3K for the treatment of ischemia reperfusion injury associated with myocardial infarction.
Enhanced recovery from ischemia-reperfusion injury in PI3K? dominant negative hearts: investigating the role of alternate PI3K isoforms, increased glucose oxidation and MAPK signaling.
Ginsenoside Rb1 preconditioning protects against myocardial infarction after regional ischemia and reperfusion by activation of phosphatidylinositol-3-kinase signal transduction.
Intestinal Epithelial Cell-Derived ?-Opioid Signaling Protects against Ischemia Reperfusion Injury through PI3K Signaling.
Ischemia-reperfusion injury and cardioprotection: investigating PTEN, the phosphatase that negatively regulates PI3K, using a congenital model of PTEN haploinsufficiency.
Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling.
MG53 constitutes a primary determinant of cardiac ischemic preconditioning.
Milrinone-induced postconditioning reduces hepatic ischemia-reperfusion injury in rats: the roles of phosphatidylinositol 3-kinase and nitric oxide.
Molecular aspects of ischaemic postconditioning.
Neuroprotective effects of bisperoxovanadium on cerebral ischemia by inflammation inhibition.
p42/p44-MAPK and PI3K are sufficient for IL-6 family cytokines/gp130 to signal to hypertrophy and survival in cardiomyocytes in the absence of JAK/STAT activation.
Pharmacological postconditioning with Neuregulin-1 mimics the cardioprotective effects of ischaemic postconditioning via ErbB4-dependent activation of reperfusion injury salvage kinase pathway.
Pharmacological postconditioning with tanshinone IIA attenuates myocardial ischemia-reperfusion injury in rats by activating the phosphatidylinositol 3-kinase pathway.
PI3K/Akt pathway contributes to neuroprotective effect of Tongxinluo against focal cerebral ischemia and reperfusion injury in rats.
Protective effect of urantide against ischemia-reperfusion injury via protein kinase C and phosphtidylinositol 3'-kinase - Akt pathway.
Relaxin Protects Rat Lungs from Ischemia-Reperfusion Injury via Inducible NO Synthase: Role of ERK-1/2, PI3K, and Forkhead Transcription Factor FKHRL1.
Remifentanil Preconditioning Reduces Postischemic Myocardial Infarction and Improves Left Ventricular Performance via Activation of the Janus Activated Kinase-2/Signal Transducers and Activators of Transcription-3 Signal Pathway and Subsequent Inhibition of Glycogen Synthase Kinase-3? in Rats.
Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium.
Role of Erk1/2, p70s6K, and eNOS in isoflurane-induced cardioprotection during early reperfusion in vivo: [Le role des Erk1/2, p70s6K et eNOS dans la cardioprotection induite par l'isoflurane pendant la reperfusion in vivo precoce].
The role of microRNA in modulating myocardial ischemia-reperfusion injury.
Therapeutic modulation of the phosphatidylinositol 3-kinases (PI3K) pathway in cerebral ischemic injury.
Respiratory Tract Infections
PIK3R1 Mutation Associated with Hyper IgM (APDS2 Syndrome): A Case Report and Review of the Literature.
Retinal Diseases
Activation of type 5 metabotropic glutamate receptor promotes the proliferation of rat retinal progenitor cell via activation of the PI-3-K and MAPK signaling pathways.
Retinal Neovascularization
Down-regulation of microRNA-155 attenuates retinal neovascularization via the PI3K/Akt pathway.
Effects of the phosphatidylinositol 3-kinase inhibitor in a mouse model of retinal neovascularization.
Inhibition of LY294002 in retinal neovascularization via down-regulation the PI3K/AKT-VEGF pathway in vivo and in vitro.
Retinitis Pigmentosa
Activation of type 5 metabotropic glutamate receptor promotes the proliferation of rat retinal progenitor cell via activation of the PI-3-K and MAPK signaling pathways.
Retinoblastoma
A peptide inhibitor derived from p55PIK phosphatidylinositol 3-kinase regulatory subunit: a novel cancer therapy.
Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins.
CB2R induces a protective response for epileptic seizure via the PI3K 110?-AKT signaling pathway.
Co-deleting Pten with Rb in retinal progenitor cells in mice results in fully penetrant bilateral retinoblastomas.
Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (review).
Identification and modulation of a caveolae-dependent signal pathway that regulates plasminogen activator inhibitor-1 in insulin-resistant adipocytes.
Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression.
Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes.
Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays.
Regulation of cancer metabolism by oncogenes and tumor suppressors.
Retinoblastoma cells activate the AKT pathway and are vulnerable to the PI3K/mTOR inhibitor NVP-BEZ235.
Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.
The botanical component p-hydroxycinnamic acid suppresses the growth and bone metastatic activity of human prostate cancer PC-3 cells in vitro.
The phytochemical p-hydroxycinnamic acid suppresses the growth and stimulates the death in human liver cancer HepG2 cells.
Transcriptional regulation of cellular ageing by the CCAAT box-binding factor CBF/NF-Y.
Rett Syndrome
Finding patients using similarity measures in a rare diseases-oriented clinical data warehouse: Dr. Warehouse and the needle in the needle stack.
Rhabdomyosarcoma
A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth.
Different Response of Ptch Mutant and Ptch Wildtype Rhabdomyosarcoma Toward SMO and PI3K Inhibitors.
Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.
Dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 synergizes with chloroquine to induce apoptosis in embryonal rhabdomyosarcoma.
DW09849, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110? (H1047R).
Effect of paraquat-induced oxidative stress on insulin regulation of insulin-like growth factor-binding protein-1 gene expression.
Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma.
Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways.
It takes two to tango: dual inhibition of PI3K & MAPK in rhabdomyosarcoma.
Regulation of hepatic insulin-like growth factor-binding protein-1 gene expression by insulin: central role for mammalian target of rapamycin independent of forkhead box O proteins.
Rhabdomyosarcoma, Alveolar
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Rheumatic Diseases
Recent findings on phosphoinositide-3 kinase in rheumatic diseases.
The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases.
Rhinitis, Allergic
Enhancement of allergic responses in vivo and in vitro by butylated hydroxytoluene.
PI3-Kinase Regulates Eosinophil and Neutrophil Degranulation in Patients with Allergic Rhinitis and Allergic Asthma Irrespective of Allergen Challenge Model.
Randomized phase 1 study of the phosphatidylinositol 3-kinase ? inhibitor idelalisib in patients with allergic rhinitis.
Rotavirus Infections
Activation of PI3K, Akt, and ERK during early rotavirus infection leads to V-ATPase-dependent endosomal acidification required for uncoating.
Death mechanisms in epithelial cells following rotavirus infection, exposure to inactivated rotavirus or genome transfection.
Molecular mechanism behind rotavirus NSP1-mediated PI3 kinase activation: interaction between NSP1 and the p85 subunit of PI3 kinase.
Rubella
Well begun is half done: Rubella virus perturbs autophagy signaling, thereby facilitating the construction of viral replication compartments.
Salivary Gland Neoplasms
The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation.
Salmonella Infections
Modulation of chloride secretory responses and barrier function of intestinal epithelial cells by the Salmonella effector protein SigD.
Sarcoidosis, Pulmonary
Phosphoinositide 3-kinase/protein kinase B inhibition restores regulatory T cell's function in pulmonary sarcoidosis.
Sarcoma
A systematic review of targeted agents for non-small cell lung cancer.
Advances in sarcoma gene mutations and therapeutic targets.
Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: A pattern distinct from other sarcomas with complex genomics.
Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell lines.
Biochemical and biological characterization of tumor-associated mutations of p110alpha.
Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment.
Clustered DNA lesion sites as a source of mutations during human colorectal tumourigenesis.
Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma.
Concordance of Predictive Markers for EGFR Inhibitors in Primary Tumors and Metastases in Colorectal Cancer: A Review.
Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay.
Diosgenin and 5-Methoxypsoralen Ameliorate Insulin Resistance through ER-?/PI3K/Akt-Signaling Pathways in HepG2 Cells.
Effects of PTEN Loss and Activated KRAS Overexpression on Mechanical Properties of Breast Epithelial Cells.
Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study.
Efficacy of phosphatidylinositol-3 kinase inhibitors in a primary mouse model of undifferentiated pleomorphic sarcoma.
ERK phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancer.
Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas.
Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma.
Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy.
High metastatic efficiency of human sarcoma cells in Rag2/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy.
Identification of dysregulated pathways associated with pancreatic cancer by survival analysis.
Molecular biology of lung cancer.
Multinuclear NMR and MRI Reveal an Early Metabolic Response to mTOR Inhibition in Sarcoma.
Novel role of microRNA-126 in digestive system cancers: From bench to bedside.
Oncogenes on my mind: ERK and MTOR signaling in cognitive diseases.
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.
PI3K inhibition enhances doxorubicin-induced apoptosis in sarcoma cells.
PIK3R3, part of the regulatory domain of PI3K, is upregulated in sarcoma stem-like cells and promotes invasion, migration, and chemotherapy resistance.
Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma.
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Protection from rapamycin-induced apoptosis by insulin-like growth factor-I is partially dependent on protein kinase C signaling.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Recurrent papillary thyroid carcinoma with pleural metastasis diagnosed by effusion cytology: a report of cases with clinicopathologic correlation.
Reelin induces the detachment of postnatal subventricular zone cells and the expression of the Egr-1 through Erk1/2 activation.
Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis.
Targeted genome-wide methylation and gene expression analyses reveal signaling pathways involved in ovarian dysfunction after developmental EDC exposure in rats.
Targeted therapies for advanced non-small cell lung cancer.
The Inhibition of PI3K-Akt Pathway Enhances Gamma-2 Herpesvirus Lytic Replication and Facilitates Reactivation from Latency.
The prognostic impact of Akt isoforms, PI3K and PTEN related to female steroid hormone receptors in soft tissue sarcomas.
Variable expression of PIK3R3 and PTEN in Ewing Sarcoma impacts oncogenic phenotypes.
Sarcoma, Avian
Initiation factor eIF2B not p70 S6 kinase is involved in the activation of the PI-3K signalling pathway induced by the v-src oncogene.
Stimulation of gene expression in neonatal rat ventricular myocytes by Ras is mediated by Ral guanine nucleotide dissociation stimulator (Ral.GDS) and phosphatidylinositol 3-kinase in addition to Raf.
The PPAR? agonist efatutazone impairs TGF-?2-induced motility of EGFR tyrosine kinase inhibitor-resistant lung cancer cells.
The SH3 domain of p56lck is involved in binding to phosphatidylinositol 3'-kinase from T lymphocytes.
Sarcoma, Ewing
Simultaneous inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways augment the sensitivity to actinomycin D in Ewing sarcoma.
Variable expression of PIK3R3 and PTEN in Ewing Sarcoma impacts oncogenic phenotypes.
Sarcoma, Synovial
Phosphatidylinositol-3'-kinase/AKT signalling is essential in synovial sarcoma.
Scleroderma, Diffuse
Analysis of PI3K Pathway Associated Molecules Reveals Dysregulated Innate and Adaptive Functions of B Cells in Early Diffuse Cutaneous Systemic Sclerosis.
Scleroderma, Systemic
Analysis of PI3K Pathway Associated Molecules Reveals Dysregulated Innate and Adaptive Functions of B Cells in Early Diffuse Cutaneous Systemic Sclerosis.
Seizures
Activation of Bcl-2-associated death protein and counter-response of Akt within cell populations during seizure-induced neuronal death.
CB2R induces a protective response for epileptic seizure via the PI3K 110?-AKT signaling pathway.
Effect of miR-124 on PI3K/Akt signal pathway in refractory epilepsy rats.
Nicotine Alleviates Cortical Neuronal Injury by Suppressing Neuroinflammation and Upregulating Neuronal PI3K-AKT Signaling in an Eclampsia-Like Seizure Model.
NMDA preconditioning protects against quinolinic acid-induced seizures via PKA, PI3K and MAPK/ERK signaling pathways.
Pentylenetetrazole-induced seizures cause acute, but not chronic, mTOR pathway activation in rat.
PIK3R2/Pik3r2 Activating Mutations Result in Brain Overgrowth and EEG Changes.
Role of Phosphatidylinositol-3 Kinase Pathway in NMDA Preconditioning: Different Mechanisms for Seizures and Hippocampal Neuronal Degeneration Induced by Quinolinic Acid.
The Putative Role of mTOR Inhibitors in Non-tuberous Sclerosis Complex-Related Epilepsy.
[Roles and mechanisms of traditional Chinese medicine and its active ingredients in treating epilepsy].
Seminoma
Genomic Characterization of Testicular Germ Cell Tumors Relapsing After Chemotherapy.
TDRG1 functions in testicular seminoma are dependent on the PI3K/Akt/mTOR signaling pathway.
Sepsis
A tetrahydroisoquinoline alkaloid THI-28 reduces LPS-induced HMGB1 and diminishes organ injury in septic mice through p38 and PI3K/Nrf2/HO-1 signals.
Activation of myocardial phosphoinositide-3-kinase p110? ameliorates cardiac dysfunction and improves survival in polymicrobial sepsis.
Artesunate ameliorates sepsis-induced acute lung injury by activating the mTOR/AKT/PI3K axis.
Deficiency of Phosphatidylinositol 3-Kinase ? Signaling Leads to Diminished Numbers of Regulatory T Cells and Increased Neutrophil Activity Resulting in Mortality Due to Endotoxic Shock.
Diacerhein attenuates the inflammatory response and improves survival in a model of severe sepsis.
Inhibition of the phosphoinositide 3-kinase pathway decreases innate resistance to lipopolysaccharide toxicity in TLR4 deficient mice.
Insulin hypersensitivity induced by hepatic PTEN gene ablation protects from murine endotoxemia.
Insulin inhibits LPS-induced signaling pathways in alveolar macrophages.
Insulin modulates the inflammatory granulocyte response to streptococci via phosphatidylinositol 3-kinase.
Melatonin attenuates sepsis-induced cardiac dysfunction via a PI3K/Akt-dependent mechanism.
Modulation of the phosphoinositide 3-kinase pathway alters innate resistance to polymicrobial sepsis.
Myeloid cell-specific inositol polyphosphate-4-phosphatase type I knockout mice impair bacteria clearance in a murine peritonitis model.
PKC and AKT Modulate cGMP/PKG Signaling Pathway on Platelet Aggregation in Experimental Sepsis.
Platelet activation and prothrombotic properties in a mouse model of peritoneal sepsis.
The phosphatidylinositol 3-kinase signaling pathway exerts protective effects during sepsis by controlling C5a-mediated activation of innate immune functions.
THE PHOSPHOINOSITIDE-3 KINASE SURVIVAL SIGNALING MECHANISM IN SEPSIS.
Severe Acute Respiratory Syndrome
Coronavirus interactions with the cellular autophagy machinery.
Targeting autophagy in disease: established and new strategies.
Severe Combined Immunodeficiency
DNA-PKcs mutations in dogs and horses: allele frequency and association with neoplasia.
Shock, Septic
Modulation of the phosphoinositide 3-kinase pathway alters innate resistance to polymicrobial sepsis.
Skin Diseases
IFN-gamma regulates the expression of B7-H1 in dermal fibroblast cells.
Skin Neoplasms
5-deoxykaempferol plays a potential therapeutic role by targeting multiple signaling pathways in skin cancer.
Negative feedback regulation of phosphatidylinositol 3-kinase/Akt pathway by over-expressed cyclooxygenase-2 in human epidermal cancer cells.
Small Cell Lung Carcinoma
Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer.
Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation.
Fibronectin enhances viability and alters cytoskeletal functions (with effects on the phosphatidylinositol 3-kinase pathway) in small cell lung cancer.
Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy.
Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
Retraction: Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216.
Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.
Targeting the phosphoinositide 3-kinase p110-? isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer.
Smith-Magenis Syndrome
Two Monogenetic Disorders, Activated PI3-Kinase-? Syndrome 2 and Smith-Magenis Syndrome, in One Patient: Case Report and a Literature Review of Neurodevelopmental Impact in Primary Immunodeficiencies Associated With Disturbed PI3K Signaling.
Spasm
Regulatory role of hippocampal PI3K and mTOR signaling pathway in NMDA-induced infant spasm rats.
Spastic Paraplegia, Hereditary
ZFYVE26/SPASTIZIN and SPG11/SPATACSIN mutations in hereditary spastic paraplegia types AR-SPG15 and AR-SPG11 have different effects on autophagy and endocytosis.
sphingosine kinase deficiency
Regulation of hepatic insulin signaling and glucose homeostasis by sphingosine kinase 2.
Spinal Cord Injuries
A retinoic acid receptor beta agonist (CD2019) overcomes inhibition of axonal outgrowth via phosphoinositide 3-kinase signalling in the injured adult spinal cord.
PI3 Kinase regulation of neural regeneration and muscle hypertrophy after spinal cord injury.
PI3K mediated activation of GSK-3? reduces at-level primary afferent growth responses associated with excitotoxic spinal cord injury dysesthesias.
Spinal cord injury causes insulin resistance associated with PI3K signaling pathway in hypothalamus.
The change tendency of PI3K/Akt pathway after spinal cord injury.
Triggering of Autophagy by Baicalein in Response to Apoptosis after Spinal Cord Injury: Possible Involvement of the PI3K Activation.
Spinal Dysraphism
Disruption of PDGFRalpha-initiated PI3K activation and migration of somite derivatives leads to spina bifida.
Squamous Cell Carcinoma of Head and Neck
A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.
A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3K? inhibition in controlling tumor growth.
A highway to carcinogenesis: the role of IQGAP1, a signaling scaffolding protein, in head and neck cancer development.
A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins.
A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma.
A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer.
Abnormal expression of PI3K isoforms in patients with tobacco-related oral squamous cell carcinoma.
Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin.
Akt-FOXO3a signaling axis dysregulation in human oral squamous cell carcinoma and potent efficacy of FOXO3a-targeted gene therapy.
AKT3 is a key regulator of head and neck squamous cell carcinoma.
Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer.
Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.
Antitumor activity of the dual PI3K/MTOR inhibitor, PF-04691502, in combination with radiation in head and neck cancer.
CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3K? Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma.
Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer.
Comprehensive Genomic Profiling of Patient-matched Head and Neck Cancer Cells: A Preclinical Pipeline for Metastatic and Recurrent Disease.
Cotargeting CHK1 and PI3K Synergistically Suppresses Tumor Growth of Oral Cavity Squamous Cell Carcinoma in Patient-Derived Xenografts.
Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.
Crosstalk signaling between HER3 and HPV16 E6 and E7 mediates resistance to PI3K inhibitors in head and neck cancer.
Differential compensation mechanisms define resistance to PI3K inhibitors in PIK3CA amplified HNSCC.
Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
Disruption of TP63-miR-27a* feedback loop by mutant TP53 in head and neck cancer.
Distinct roles of PIK3CA in the enrichment and maintenance of cancer stem cells in head and neck squamous cell carcinoma.
Dual Inhibition of Autophagy and PI3K/AKT/MTOR Pathway as a Therapeutic Strategy in Head and Neck Squamous Cell Carcinoma.
Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma.
Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines.
EGFR and PI3K Pathway Activities Might Guide Drug Repurposing in HPV-Negative Head and Neck Cancers.
Emerging Role of miR-372 and miR-101a in Head and Neck Squamous Cell Carcinoma.
Enhanced susceptibility to apoptosis of oral squamous cell carcinoma cells subjected to combined treatment with anticancer drugs and phosphatidylinositol 3-kinase inhibitors.
Enhanced susceptibility to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in oral squamous cell carcinoma cells treated with phosphatidylinositol 3-kinase inhibitors.
Enhancement of susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells by phosphatidylinositol 3-kinase inhibitor.
ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
Erratum to: Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
Exploring the importance of cancer pathways by meta-analysis of differential protein expression networks in three different cancers.
Expression Analysis of GRHL3 and PHLDA3 in Head and Neck Squamous Cell Carcinoma.
FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling.
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.
Functional kinomics identifies candidate therapeutic targets in head and neck cancer.
Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers.
Genomic landscape of human papillomavirus-associated cancers.
Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma.
HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma.
HS-173, a selective PI3K inhibitor, induces cell death in head and neck squamous cell carcinoma cell lines.
In-silico prediction of potential inhibitors against phosphatidylinositol 3-kinase catalytic subunit alpha involved in head and neck squamous cell carcinomas.
Inhibition of PI3K Isoform p110? Increases Both Anti-Tumor and Immunosuppressive Responses to Aggressive Murine Head and Neck Squamous Cell Carcinoma with Low Immunogenicity.
Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.
Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.
Long non-coding RNA CCAT1 is a prognostic biomarker for the progression of oral squamous cell carcinoma via miR-181a-mediated Wnt/?-catenin signaling pathway.
Low PTEN expression is associated with worse overall survival in head and neck squamous cell carcinoma patients treated with chemotherapy and cetuximab.
Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance.
Molecular landscape of head and neck cancer and implications for therapy.
Molecular pathways in head and neck cancer.
mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.
Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma.
Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation.
Omega-3 polyunsaturated fatty acids selectively inhibit growth in neoplastic oral keratinocytes by differentially activating ERK1/2.
Oncogenic driver mutations predict outcome in a cohort of head and neck squamous cell carcinoma (HNSCC) patients within a clinical trial.
Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.
Oral squamous cell carcinoma (OSCC)-derived exosomal MiR-221 targets and regulates phosphoinositide-3-kinase regulatory subunit 1 (PIK3R1) to promote human umbilical vein endothelial cells migration and tube formation.
Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway.
Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGF? signaling.
p120-catenin suppresses proliferation and tumor growth of oral squamous cell carcinoma via inhibiting nuclear phospholipase C-?1 signaling.
Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Phosphoinositide kinase-3 status associated with presence or absence of human papillomavirus in head and neck squamous cell carcinomas.
PI3k inhibitors (BKM120 and BYL719) as radiosensitizers for head and neck squamous cell carcinoma during radiotherapy.
PI3K inhibitors curtail MYC-dependent mutant p53 gain-of-function in head and neck squamous cell carcinoma.
PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer.
PIK3CA and p53 mutations promote 4NQO-initated head and neck tumor progression and metastasis in mice.
PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma.
PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
RAS/ PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma.
Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma.
Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2.
Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor.
Role of IQGAP1 in Papillomavirus-Associated Head and Neck Tumorigenesis.
Role of phosphatidylinositol-3-kinase pathway in head and neck squamous cell carcinoma.
Secretory Autophagy in Cancer-Associated Fibroblasts Promotes Head and Neck Cancer Progression and Offers a Novel Therapeutic Target.
Selective inhibition of PI3K110? as a novel therapeutic strategy for cetuximab?resistant oral squamous cell carcinoma.
Signaling pathways required for matrix metalloproteinase-9 induction by betacellulin in head-and-neck squamous carcinoma cells.
STAT3/HOTAIR signaling axis regulates HNSCC growth in an EZH2-dependent manner.
TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3K? inhibition in head and neck squamous cell carcinoma.
Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cells.
Targeted Therapy of Head and Neck Cancer.
Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.
Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC).
Targeting the PI3K Pathway in Head and Neck Squamous Cell Carcinoma.
Taselisib (GDC-0032), a Potent ?-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and anoikis in squamous cell carcinoma of the head and neck.
The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas.
The effect of LKB1 on the PI3K/Akt pathway activation in association with PTEN and PIK3CA in HNC.
The epithelial-mesenchymal transition mediator S100A4 maintains cancer-initiating cells in head and neck cancers.
The influence of PI3K inhibition on the radiotherapy response of head and neck cancer cells.
The inhibitors of KDM4 and KDM6 histone lysine demethylases enhance the anti-growth effects of erlotinib and HS-173 in head and neck cancer cells.
The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, crosstalk, and therapies.
The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies.
Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines.
Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma.
[Expression and significance of Ki-67, PI3K and Beclin1 in oral squamous cell carcinoma].
Starvation
14-3-3 Proteins are Regulators of Autophagy.
A fine-tuning mechanism underlying self-control for autophagy: deSUMOylation of BECN1 by SENP3.
AMPK connects energy stress to PIK3C3/VPS34 regulation.
Autophagy and signaling: their role in cell survival and cell death.
Bile salt-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent.
Biogenesis of autophagosomal precursors for LC3 lipidation from the ER-Golgi intermediate compartment.
Blockade of CCN6 (WISP3) activates growth factor-independent survival and resistance to anoikis in human mammary epithelial cells.
Branched-Chain Amino Acid Negatively Regulates KLF15 Expression via PI3K-AKT Pathway.
CD28-mediated regulation of multiple myeloma cell proliferation and survival.
Class III phosphoinositide 3-kinase--Beclin1 complex mediates the amino acid-dependent regulation of autophagy in C2C12 myotubes.
Cul3-KLHL20 Ubiquitin Ligase Governs the Turnover of ULK1 and VPS34 Complexes to Control Autophagy Termination.
Cyr61 is regulated by cAMP-dependent protein kinase with serum levels correlating with prostate cancer aggressiveness.
Cytokine-mediated FOXO3a phosphorylation suppresses FasL expression in hemopoietic cell lines: investigations of the role of Fas in apoptosis due to cytokine starvation.
DAPK3 inhibits gastric cancer progression via activation of ULK1-dependent autophagy.
Defect in skeletal muscle phosphatidylinositol-3-kinase in obese insulin-resistant mice.
Differential regulation of distinct Vps34 complexes by AMPK in nutrient stress and autophagy.
Dissection of autophagy in human platelets.
Drosophila Spidey/Kar Regulates Oenocyte Growth via PI3-Kinase Signaling.
Endonuclease G promotes autophagy by suppressing mTOR signaling and activating the DNA damage response.
Flavivirus NS4A-induced autophagy protects cells against death and enhances virus replication.
Foot-and-mouth disease virus induces autophagosomes during cell entry via a class III phosphatidylinositol 3-kinase-independent pathway.
Glutaminase Inhibitors Induce Thiol-Mediated Oxidative Stress and Radiosensitization in Treatment-Resistant Cervical Cancers.
hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase.
IL-10 inhibits the starvation induced autophagy in macrophages via class I phosphatidylinositol 3-kinase (PI3K) pathway.
Induction of Autophagy by Amino Acid Starvation in Fish Cells.
Integrated and comparative miRNA analysis of starvation-induced autophagy in mouse embryonic fibroblasts.
MAP1B-LC1 prevents autophagosome formation by linking syntaxin 17 to microtubules.
Modulating mitophagy in mitochondrial disease.
Negative feedback loops: nutrient starvation employs a new tr(IKK) to inhibit PI3K.
Negative regulation of miR-145 by C/EBP-? through the Akt pathway in cancer cells.
Nutritional control of gene expression in Drosophila larvae via TOR, Myc and a novel cis-regulatory element.
p85? SH2 Domain Phosphorylation by IKK Promotes Feedback Inhibition of PI3K and Akt in Response to Cellular Starvation.
PAQR3 controls autophagy by integrating AMPK signaling to enhance ATG14L-associated PI3K activity.
Phenotypic Identification of a Novel Autophagy Inhibitor Chemotype Targeting Lipid Kinase VPS34.
Phosphatidylinositol 3-kinase and COPII generate LC3 lipidation vesicles from the ER-Golgi intermediate compartment.
Phosphatidylinositol 3-kinase, Cdc42, and Rac1 act downstream of Ras in integrin-dependent neurite outgrowth in N1E-115 neuroblastoma cells.
Phosphorylated AKT inhibits the apoptosis induced by DRAM-mediated mitophagy in hepatocellular carcinoma by preventing the translocation of DRAM to mitochondria.
PI3K signaling of autophagy is required for starvation tolerance and virulenceof Cryptococcus neoformans.
Post-transcriptional regulation of autophagy in C2C12 myotubes following starvation and nutrient restoration.
Potassium starvation induces autophagy in yeast.
PRKAA/AMPK? phosphorylation switches the role of RASAL2 from a suppressor to an activator of autophagy.
Regulation of PIK3C3/VPS34 complexes by MTOR in nutrient stress-induced autophagy.
Regulation of V-ATPase Assembly in Nutrient Sensing and Function of V-ATPases in Breast Cancer Metastasis.
Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy.
The Ancient Phosphatidylinositol 3-Kinase Signaling System Is a Master Regulator of Energy and Carbon Metabolism in Algae.
TLR9 and beclin 1 crosstalk regulates muscle AMPK activation in exercise.
ULK1 induces autophagy by phosphorylating Beclin-1 and activating VPS34 lipid kinase.
ULK1 phosphorylates Ser30 of BECN1 in association with ATG14 to stimulate autophagy induction.
ULK1 targets Beclin-1 in autophagy.
Status Epilepticus
Peroxisome Proliferator-Activated Receptor ? Coactivator 1? Activates Vascular Endothelial Growth Factor That Protects Against Neuronal Cell Death Following Status Epilepticus through PI3K/AKT and MEK/ERK Signaling.
Stomach Neoplasms
2-Methoxyestradiol attenuates phosphatidylinositol 3-kinase/Akt pathway-mediated metastasis of gastric cancer.
A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer.
Aclidinium bromide inhibits the growth and metastasis of gastric cancer MKN?28 cells via the PI3K signaling pathway.
Activation of matrix metalloproteinase-9 (MMP-9) by neurotensin promotes cell invasion and migration through ERK pathway in gastric cancer.
Analysis of correlation between HP infection and activation of PI3K/Akt pathway in mucosal tissues of gastric cancer and precancerous lesions.
Analysis of PIK3CA mutations and PI3K pathway proteins in advanced gastric cancer.
Apatinib suppresses the Proliferation and Apoptosis of Gastric Cancer Cells via the PI3K/Akt Signaling Pathway.
Association of mast cell infiltration with gastric cancer progression.
Bcl-w promotes gastric cancer cell invasion by inducing matrix metalloproteinase-2 expression via phosphoinositide 3-kinase, Akt, and Sp1.
BMP2 accelerates the motility and invasiveness of gastric cancer cells via activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway.
Celastrol Induces Apoptosis of Gastric Cancer Cells by miR-21 Inhibiting PI3K/Akt-NF-?B Signaling Pathway.
Class I phosphatidylinositol 3-kinase inhibitor LY294002 activates autophagy and induces apoptosis through p53 pathway in gastric cancer cell line SGC7901.
Clinical value of CagA, c-Met, PI3K and Beclin-1 expressed in gastric cancer and their association with prognosis.
Clinicopathological significance of PI3K, Akt and survivin expression in gastric cancer.
Combination of cecropinXJ and LY294002 induces synergistic cytotoxicity, and apoptosis in human gastric cancer cells via inhibition of the PI3K/Akt signaling pathway.
Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells.
Combined effect of sCD40L and PI3K siRNA on transplanted tumours growth and microenvironment in nude mice with gastric cancer.
Combined treatment with PI3K inhibitor BKM120 and PARP inhibitor olaparib is effective in inhibiting the gastric cancer cells with ARID1A deficiency.
Curcumin regulates proliferation, autophagy and apoptosis in gastric cancer cells by affecting PI3K and P53 signaling.
Curcumol improves cisplatin sensitivity of human gastric cancer cells through inhibiting PI3K/AKT pathway.
Downregulation of HIF-1? inhibits the proliferation, migration and invasion of gastric cancer by inhibiting PI3K/AKT pathway and VEGF expression.
Dual inhibitor of PI3K and mTOR (NVP-BEZ235) augments the efficacy of fluorouracil on gastric cancer chemotherapy.
Effect of PI3K gene silencing on growth, migration and related proteins expression of CD40 signal-mediated gastric cancer cells.
Expression of Cyclooxygenase-2 Is Regulated by Glycogen Synthase Kinase-3beta in Gastric Cancer Cells.
Expression of PI3K/AKT pathway in gastric cancer and its blockade suppresses tumor growth and metastasis.
Genetic and bioinformatic analyses of the expression and function of PI3K regulatory subunit PIK3R3 in an Asian patient gastric cancer library.
GPER1 Silencing Suppresses the Proliferation, Migration, and Invasion of Gastric Cancer Cells by Inhibiting PI3K/AKT-Mediated EMT.
Helicobacter pylori regulates cellular migration and apoptosis by activation of phosphatidylinositol 3-kinase signaling.
HER-2-induced PI3K signaling pathway was involved in the pathogenesis of gastric cancer.
IL-1? promotes the nuclear translocaiton of S100A4 protein in gastric cancer cells MGC803 and the cell's stem-like properties through PI3K pathway.
Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine.
Intestinal trefoil factor confers colonic epithelial resistance to apoptosis.
Isorhamnetin Promotes MKN-45 Gastric Cancer Cell Apoptosis by Inhibiting PI3K-Mediated Adaptive Autophagy in a Hypoxic Environment.
Kaempferol suppresses human gastric cancer SNU-216 cell proliferation, promotes cell autophagy, but has no influence on cell apoptosis.
Luteolin exerts a marked antitumor effect in cMet-overexpressing patient-derived tumor xenograft models of gastric cancer.
Luteolin induces apoptosis in vitro through suppressing the MAPK and PI3K signaling pathways in gastric cancer.
LY294002 induces p53-dependent apoptosis of SGC7901 gastric cancer cells.
LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells.
Macroautophagy and ERK phosphorylation counteract the antiproliferative effect of proteasome inhibitor in gastric cancer cells.
Macrophage migration inhibitory factor regulates proliferation of gastric cancer cells via the PI3K/Akt pathway.
Markers CD40, VEGF, AKT, PI3K, and S100 Correlate with Tumor Stage in Gastric Cancer.
Metformin inhibits gastric cancer via the inhibition of HIF1?/PKM2 signaling.
MicroRNA-34A inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression.
MicroRNA?495 regulates human gastric cancer cell apoptosis and migration through Akt and mTOR signaling.
miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway.
Molecular changes in the phosphatidylinositide 3-kinase (PI3K) pathway are common in gastric cancer.
Mutation analysis of tumor suppressor gene PTEN in patients with gastric carcinomas and its impact on PI3K/AKT pathway.
Mutations of PIK3CA in gastric adenocarcinoma.
NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.
Osteopontin promotes the progression of gastric cancer through the NF-?B pathway regulated by the MAPK and PI3K.
Overexpression of PI3K p110? contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
Overexpression of the N-terminal end of the p55gamma regulatory subunit of phosphatidylinositol 3-kinase blocks cell cycle progression in gastric carcinoma cells.
Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-Fluorouracil in PIK3CA mutant gastric cancer cells.
Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: Meta-analysis, co-occurrence and ethnic variation.
Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death.
Piperine Inhibits Cell Proliferation and Induces Apoptosis of Human Gastric Cancer Cells by Downregulating Phosphatidylinositol 3-Kinase (PI3K)/Akt Pathway.
PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway.
PRL-3 promotes gastric cancer peritoneal metastasis via the PI3K/AKT signaling pathway in vitro and in vivo.
Rafoxanide promotes apoptosis and autophagy of gastric cancer cells by suppressing PI3K /Akt/mTOR pathway.
Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications.
Sh-MARCH8 Inhibits Tumorigenesis via PI3K Pathway in Gastric Cancer.
Signal transduction pathway mutations in gastrointestinal (GI) cancers: a systematic review and meta-analysis.
Significance of Akt phosphorylation on tumor growth and vascular endothelial growth factor expression in human gastric carcinoma.
Silencing of COL1A2, COL6A3, and THBS2 inhibits gastric cancer cell proliferation, migration, and invasion while promoting apoptosis through the PI3k-Akt signaling pathway.
Targeting AKT protein kinase in gastric cancer.
Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?
Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer.
The Effect of hsa-miR-451b Knockdown on Biological Functions of Gastric Cancer Stem-Like Cells.
The outstanding role of miR-132-3p in carcinogenesis of solid tumors.
Transcriptomic profiling and quantitative high-throughput (qHTS) drug screening of CDH1 deficient hereditary diffuse gastric cancer (HDGC) cells identify treatment leads for familial gastric cancer.
Up-regulation of PIK3CA promotes metastasis in gastric carcinoma.
VEGF promotes gastric cancer development by upregulating CRMP4.
VGLL1 phosphorylation and activation promotes gastric cancer malignancy via TGF-?/ERK/RSK2 signaling.
ZIC1 modulates cell-cycle distributions and cell migration through regulation of sonic hedgehog, PI3K and MAPK signaling pathways in gastric cancer.
[Effects of combined therapy of LY294002 and SN50 on nude mice model with gastric cancer].
[Impact of PI3K /Akt /mdm2 signaling pathway on the sensitivity of gastric cancer cell line SGC7901 to doxorubicin]
[Recombinant methioninase regulates PI3K/Akt/Glut-1 pathway and inhibits aerobic glycolysis to promote apoptosis of gastric cancer cells].
[The relationship of mTOR signaling pathway and histone acetylation in human gastric cancer cell lines]
Stomach Ulcer
Novel roles of local insulin-like growth factor-1 activation in gastric ulcer healing: promotes actin polymerization, cell proliferation, re-epithelialization, and induces cyclooxygenase-2 in a phosphatidylinositol 3-kinase-dependent manner.
Stomatitis
Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis.
Stroke
Application of nanostructured lipid carriers: the prolonged protective effects for sesamol in in vitro and in vivo models of ischemic stroke via activation of PI3K signalling pathway.
Ferulic acid-loaded nanostructured lipid carriers: A promising nanoformulation against the ischemic neural injuries.
Molecular and cellular mechanisms of neuroprotection by vascular endothelial growth factor.
NADPH Oxidase-2: Linking Glucose, Acidosis, and Excitotoxicity in Stroke.
Niaspan treatment induces neuroprotection after stroke.
Regulation of PI3K and Hand2 gene on physiological hypertrophy of heart following high-intensity interval, and endurance training.
The Role of the PI3K Pathway in the Regeneration of the Damaged Brain by Neural Stem Cells after Cerebral Infarction.
Thrombolysis by PLAT/tPA increases serum free IGF1 leading to a decrease of deleterious autophagy following brain ischemia.
Sturge-Weber Syndrome
The Pathogenesis of Port Wine Stain and Sturge Weber Syndrome: Complex Interactions between Genetic Alterations and Aberrant MAPK and PI3K Activation.
Subarachnoid Hemorrhage
Phosphatidylinositol 3-kinase inhibitor failed to reduce cerebral vasospasm in dog model of experimental subarachnoid hemorrhage.
The anti-apoptotic effect of PI3K-Akt signaling pathway after subarachnoid hemorrhage in rats.
Synovitis
PI3K/Akt inhibitor partly decreases TNF-?-induced activation of fibroblast-like synoviocytes in osteoarthritis.
Syphilis
Recombinant Treponema pallidum protein Tp0136 promotes fibroblast migration by modulating MCP-1/CCR2 through TLR4.
Tachycardia
Receptor-independent activation of GABAergic neurotransmission and receptor-dependent nontranscriptional activation of phosphatidylinositol 3-kinase/protein kinase Akt pathway in short-term cardiovascular actions of dexamethasone at the nucleus tractus solitarii of the rat.
Telangiectasia, Hereditary Hemorrhagic
ALK1 (Activin-Receptor Like Kinase 1) Loss Results in Vascular Hyperplasia in Mice and Humans Through PI3K (Phosphatidylinositol 3-Kinase) Activation.
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Telangiectasis
ALK1 (Activin-Receptor Like Kinase 1) Loss Results in Vascular Hyperplasia in Mice and Humans Through PI3K (Phosphatidylinositol 3-Kinase) Activation.
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Elongated telomeres in scid mice.
PI3 kinase inhibition improves vascular malformations in mouse models of hereditary haemorrhagic telangiectasia.
PI3K (Phosphatidylinositol 3-Kinase) Activation and Endothelial Cell Proliferation in Patients with Hemorrhagic Hereditary Telangiectasia Type 1.
Protective roles for ATM in cellular response to oxidative stress.
Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase.
Testicular Neoplasms
Essential role of the p110beta subunit of phosphoinositide 3-OH kinase in male fertility.
Tetanus
Estrogen enhances depolarization-induced glutamate release through activation of phosphatidylinositol 3-kinase and mitogen-activated protein kinase in cultured hippocampal neurons.
Morphine Prevents Lipopolysaccharide-Induced TNF Secretion in Mast Cells Blocking I?B Kinase Activation and SNAP-23 Phosphorylation: Correlation with the Formation of a ?-Arrestin/TRAF6 Complex.
Signalling mechanisms mediated by the phosphoinositide 3-kinase/Akt cascade in synaptic plasticity and memory in the rat.
Soluble ?Klotho downregulates Orai1-mediated store-operated Ca2+ entry via PI3K-dependent signaling.
The C-terminal domain of the heavy chain of tetanus toxin rescues cerebellar granule neurones from apoptotic death: involvement of phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways.
Thrombocythemia, Essential
IL6 inhibition of inflammatory S100A8/9 proteins is NF-?B mediated in essential thrombocythemia.
Thrombocytopenia
Mechanistically probing lipid-siRNA nanoparticle-associated toxicities identifies Jak inhibitors effective in mitigating multifaceted toxic responses.
Trp53 regulates platelets in bone marrow via the PI3K pathway.
Thromboembolism
PI3K pathway activation and thromboembolism in ovarian clear cell carcinomas.
Thrombosis
A dual role for the class III PI3K, Vps34, in platelet production and thrombus growth.
Active Micropump-Mixer for Rapid Antiplatelet Drug Screening in Whole Blood.
Advantages of a selective beta-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat.
Anti-thrombotic effects of ?-linolenic acid isolated from Zanthoxylum bungeanum Maxim seeds.
Class I PI 3-kinases signaling in platelet activation and thrombosis: PDK1/Akt/GSK3 axis and impact of PTEN and SHIP1.
Class III PI3K Positively Regulates Platelet Activation and Thrombosis via PI(3)P-Directed Function of NADPH Oxidase.
Continuous signaling via PI3K isoforms beta and gamma is required for platelet ADP receptor function in dynamic thrombus stabilization.
Differential Phosphoinositide 3-Kinase Signaling: Implications for PTCA?
Dual inhibition of PI3K and mTOR by VS-5584 suppresses thrombus formation.
Immune versus thrombotic stimulation of platelets differentially regulates signalling pathways, intracellular protein-protein interactions, and alpha-granule release.
Letter by Sonkar et al Regarding Article, "Class III PI3K Positively Regulates Platelet Activation and Thrombosis via PI(3)P-Directed Function of NADPH Oxidase".
Mechanisms of PI3K?-Selective Inhibition Revealed by Reciprocal Mutagenesis.
Modulation of platelet activation and thrombus formation using a pan-PI3K inhibitor S14161.
Non-redundant roles of phosphoinositide 3-kinase isoforms alpha and beta in glycoprotein VI-induced platelet signaling and thrombus formation.
Phosphoinositide 3-kinase p110 beta regulates integrin alpha IIb beta 3 avidity and the cellular transmission of contractile forces.
Phosphoinositide 3-kinases in platelets, thrombosis and therapeutics.
PI 3-kinase p110beta: a new target for antithrombotic therapy.
PI3K inhibitors in thrombosis and cardiovascular disease.
PI3K: From the Bench to the Clinic and Back.
Platelet CD40L Modulates Thrombus Growth Via Phosphatidylinositol 3-Kinase ?, and Not Via CD40 and I?B Kinase ?.
Recent patents of gene sequences relative to the phosphatidylinositol 3-kinase/Akt pathway and their relevance to drug discovery.
Repetitive progressive thermal preconditioning hinders thrombosis by reinforcing phosphatidylinositol 3-kinase/Akt-dependent heat-shock protein/endothelial nitric oxide synthase signaling.
Response by Liu and Hu to Letter Regarding Article, "Class III PI3K Positively Regulates Platelet Activation and Thrombosis via PI(3)P-Directed Function of NADPH Oxidase".
Salvianolic acid A inhibits platelet activation and arterial thrombosis via inhibition of PI3K.
Stimulation of mTORC2 by integrin ?IIb?3 is required for PI3K?-dependent activation of Akt but is dispensable for platelet spreading on fibrinogen.
The lipid products of phosphoinositide 3-kinase isoforms in cancer and thrombosis.
The PI3K? Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential.
The role of class I, II and III PI 3-kinases in platelet production and activation and their implication in thrombosis.
Tripeptide SQL Inhibits Platelet Aggregation and Thrombus Formation by Affecting PI3K/Akt Signaling.
Type I phosphoinositide 3-kinases: potential antithrombotic targets?
Thymoma
A common variation of the PTEN gene is associated with peripheral insulin resistance.
A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas.
A systematic review of targeted agents for non-small cell lung cancer.
A Targeted Next-Generation Sequencing Assay Detects a High Frequency of Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications for Clinical Practice.
Advances in the use of PARP inhibitor therapy for breast cancer.
Akt and mTORC1 Have Different Roles During Liver Tumorigenesis in Mice.
Akt as a therapeutic target in cancer.
Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt.
Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: A pattern distinct from other sarcomas with complex genomics.
Cell quality control mechanisms maintain stemness and differentiation potential of P19 embryonic carcinoma cells.
Deficient tyrosine phosphorylation of c-Cbl and associated proteins in phorbol ester-resistant EL4 mouse thymoma cells.
Effects of low-level laser irradiation on mesenchymal stem cell proliferation: a microarray analysis.
Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.
Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma.
Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy.
Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance.
Green tea polyphenols improve cardiac muscle mRNA and protein levels of signal pathways related to insulin and lipid metabolism and inflammation in insulin-resistant rats.
Hypoglycaemia induced by Trichinella infection is due to the increase of glucose uptake in infected muscle cells.
Interleukin-1 beta induced synthesis of protein kinase C-delta and protein kinase C-epsilon in EL4 thymoma cells: possible involvement of phosphatidylinositol 3-kinase.
Kif13b Regulates PNS and CNS Myelination through the Dlg1 Scaffold.
Megalencephaly and hemimegalencephaly: breakthroughs in molecular etiology.
Oncogene alterations in endometrial carcinosarcomas.
PAQR3 suppresses the growth of non-small cell lung cancer cells via modulation of EGFR-mediated autophagy.
Phosphatidylinositol 4,5-bisphosphate (PIP(2))-specific AKT1 is oncogenic.
Phosphoinositide 3-Kinase p110? Mediates Estrogen- and FSH-Stimulated Ovarian Follicle Growth.
Phosphorylation of AKT: a mutational analysis.
PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors.
PI3K/AKT, JNK, and ERK pathways are not crucial for the induction of cholesterol biosynthesis gene transcription in intestinal epithelial cells following treatment with the potato glycoalkaloid alpha-chaconine.
PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis.
Progress in targeted therapy for breast cancer.
Regulation of cumulus expansion and hyaluronan synthesis in porcine oocyte-cumulus complexes during in vitro maturation.
Role of Akt Isoforms Controlling Cancer Stem Cell Survival, Phenotype and Self-Renewal.
Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.
Targeting PI3K and RAD51 in Barrett's Adenocarcinoma: Impact on DNA Damage Checkpoints, Expression Profile and Tumor Growth.
The PPAR? agonist efatutazone impairs TGF-?2-induced motility of EGFR tyrosine kinase inhibitor-resistant lung cancer cells.
Therapeutic Inducers of Apoptosis in Ovarian Cancer.
Thrombolysis by PLAT/tPA increases serum free IGF1 leading to a decrease of deleterious autophagy following brain ischemia.
TP53 Tumor-suppressor Gene Plays a Key Role in IGF1 Signaling Pathway Related to the Aging of Human Melanocytes.
Transcriptomic differences of genes in the avian target of rapamycin (avTOR) pathway in a divergent line of meat-type chickens selected for feed efficiency.
Thyroid Cancer, Papillary
Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.
Downregulation of BANCR Promotes Aggressiveness in Papillary Thyroid Cancer via the MAPK and PI3K Pathways.
GPCR-mediated PI3K pathway mutations in pediatric and adult thyroid cancer.
Mammaliam target of rapamycin (mTOR) down-regulates iodide uptake in thyrocytes.
miRNA?148a inhibits cell growth of papillary thyroid cancer through STAT3 and PI3K/AKT signaling pathways.
Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells.
Resveratrol potentiates the anti-tumor effects of rapamycin in papillary thyroid cancer: PI3K/AKT/mTOR pathway involved.
Roles of phosphatidylinositol 3-kinase regulatory subunit alpha, activator protein-1, and programmed cell death 4 in diagnosis of papillary thyroid carcinoma.
The role of PI3K signaling pathway and its associated genes in papillary thyroid cancer.
Thyroid Carcinoma, Anaplastic
Deregulation of EGFR/PI3K and activation of PTEN by photodynamic therapy combined with carboplatin in human anaplastic thyroid cancer cells and xenograft tumors in nude mice.
Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer.
Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia.
Effects of a Phosphoinositide-3-Kinase Inhibitor on Anaplastic Thyroid Cancer Stem Cells
PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer.
Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer.
Thyroid Diseases
Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females.
Thyroid Neoplasms
A minireview: the role of MAPK/ERK and PI3K/Akt pathways in thyroid follicular cell-derived neoplasm.
Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002.
Biochemical and biological responses induced by coupling of Gab1 to phosphatidylinositol 3-kinase in RET-expressing cells.
Calcium-mediated activation of PI3K and p53 leads to apoptosis in thyroid carcinoma cells.
Diagnostic and prognostic markers in differentiated thyroid cancer.
Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer.
Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia.
Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer.
Evaluation of PTEN, PI3K, MTOR, and KRAS expression and their clinical and prognostic relevance to differentiated thyroid carcinoma.
Expression of hypoxia inducible factor 1{alpha} in thyroid carcinomas.
Gene expression correlation for cancer diagnosis: a pilot study.
Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.
GPCR-mediated PI3K pathway mutations in pediatric and adult thyroid cancer.
Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.
HPIP promotes thyroid cancer cell growth, migration and EMT through activating PI3K/AKT signaling pathway.
Hypoxia-inducible factor in thyroid carcinoma.
Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway.
Inhibiting the phosphatidylinositide 3-kinase pathway blocks radiation-induced metastasis associated with Rho-GTPase and Hypoxia-inducible factor-1 activity.
Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer.
Iodine promotes thyroid cancer development via SPANXA1 through the PI3K/AKT signalling pathway.
Key signaling pathways in thyroid cancer.
LPAR5 promotes thyroid carcinoma cell proliferation and migration by activating class IA PI3K catalytic subunit p110?.
MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.
Modulation of thyroidal radioiodide uptake by oncological pipeline inhibitors and Apigenin.
Molecular therapeutics for anaplastic thyroid cancer.
O-GlcNAcylation enhances the invasion of thyroid anaplastic cancer cells partially by PI3K/Akt1 pathway.
Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo.
Phosphatidylinositide 3-kinase (PI3K) and PI3K-related kinase (PIKK) activity contributes to radioresistance in thyroid carcinomas.
Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells.
PI3K inhibitors IC87114 inhibits the migration and invasion of thyroid cancer cell in vitro and in vivo.
Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways.
RAF-1 promotes survival of thyroid cancer cells harboring RET/PTC1 rearrangement independently of ERK activation.
REC8 is a novel tumor suppressor gene epigenetically robustly targeted by the PI3K pathway in thyroid cancer.
SASH1 inhibits proliferation and invasion of thyroid cancer cells through PI3K/Akt signaling pathway.
Signaling pathways in follicular cell-derived thyroid carcinomas (review).
Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer.
Synergistic action of a RAF inhibitor and a dual PI-3 Kinase / mTOR inhibitor in thyroid cancer.
Synergistic Antitumor Effect of BKM120 with Prima-1Met Via Inhibiting PI3K/AKT/mTOR and CPSF4/hTERT Signaling and Reactivating Mutant P53.
The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells.
The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.
The Transcriptional Regulation of FOXO Genes in Thyrocytes.
Thyroid Hormone Receptor Beta Inhibits PI3K-Akt-mTOR Signaling Axis in Anaplastic Thyroid Cancer via Genomic Mechanisms.
Treatment Directed To Signalling Molecules In Patients With Advanced Differentiated Thyroid Cancer.
ß-catenin signaling is required for RAS-driven thyroid cancer through PI3K activation.
Thyroid Nodule
HGF/C-MET system pathways in benign and malignant histotypes of thyroid nodules: an immunohistochemical characterization.
The tyrosine kinase receptor c-met, its cognate ligand HGF and the tyrosine kinase receptor trasducers STAT3, PI3K and RHO in thyroid nodules associated with Hashimoto's thyroiditis: an immunohistochemical characterization.
Thyroiditis
Edaravone ameliorates experimental autoimmune thyroiditis in rats through HO-1-dependent STAT3/PI3K/Akt pathway.
The tyrosine kinase receptor c-met, its cognate ligand HGF and the tyrosine kinase receptor trasducers STAT3, PI3K and RHO in thyroid nodules associated with Hashimoto's thyroiditis: an immunohistochemical characterization.
Tics
Cancer Stem Cell-Like Phenotype and Survival Are Coordinately Regulated by Akt/FoxO/Bim Pathway.
Tongue Neoplasms
In vitro antitumor effects of FGFR and PI3K inhibitors on human papillomavirus positive and negative tonsillar and base of tongue cancer cell lines.
LncRNA MALAT1 expression inhibition suppresses tongue squamous cell carcinoma proliferation, migration and invasion by inactivating PI3K/Akt pathway and downregulating MMP-9 expression.
Targeted Therapy With PI3K and FGFR Inhibitors on Human Papillomavirus Positive and Negative Tonsillar and Base of Tongue Cancer Lines With and Without Corresponding Mutations.
Tonsillar Neoplasms
Divergence of P53, PTEN, PI3K, Akt and mTOR expression in tonsillar cancer.
Tourette Syndrome
LY294002, a PI3K inhibitor, attenuates Tourette syndrome in rats.
Toxic Optic Neuropathy
Ocular Toxicity Profile of ST-162 and ST-168 as Novel Bifunctional MEK/PI3K Inhibitors.
Triple Negative Breast Neoplasms
Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer.
Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS 126 in models of triple-negative breast cancer.
BRCA1 subcellular localization regulated by PI3K signaling pathway in triple-negative breast cancer MDA-MB-231 cells and hormone-sensitive T47D cells.
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.
Closing escape routes: inhibition of IL-8 signaling enhances the anti-tumor efficacy of PI3K inhibitors.
Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT-mTOR pathway.
Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
Combined targeting of G protein-coupled receptor and EGF receptor signaling overcomes resistance to PI3K pathway inhibitors in PTEN-null triple negative breast cancer.
Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer.
Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer.
Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer.
Expression of Bioinformatically Candidate miRNAs including, miR-576-5p, miR-501-3p and miR-3143, Targeting PI3K Pathway in Triple-Negative Breast Cancer.
INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells.
Mass spectrometry-based proteomics reveals potential roles of NEK9 and MAP2K4 in resistance to PI3K inhibitors in triple negative breast cancers.
MEK and PI3K catalytic activity as predictor of the response to molecularly targeted agents in triple-negative breast cancer.
Molecular pathways: PI3K pathway targets in triple-negative breast cancers.
Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences.
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion.
PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer.
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA proficient triple negative breast cancer to PARP inhibition.
PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses.
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
PIPPing on AKT1: How Many Phosphatases Does It Take to Turn off PI3K?
Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models.
Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R.
Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway.
Targeting PI3K and AMPK? Signaling Alone or in Combination to Enhance Radiosensitivity of Triple Negative Breast Cancer.
TBCRC 032 IB/II Multicenter Study: Molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR+ metastatic triple-negative breast cancer.
The Interaction of PI3K Inhibition with Homologous Recombination Repair in Triple Negative Breast Cancer Cells.
Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells.
Vitamin C sensitizes triple negative breast cancer to PI3K inhibition therapy.
[Molecular mechanisms of resistance to phosphatidyl inositol 3-kinase inhibitors in triple-negative breast cancer cells].
Trophoblastic Neoplasms
Whole transcriptome analysis of gestational trophoblastic neoplasms reveals altered PI3K signaling pathway in epithelioid trophoblastic tumor.
Tuberculosis
B Cells and Programmed Death-Ligand 2 Signaling Are Required for Maximal Interferon-? Recall Response by Splenic CD4? Memory T Cells of Mice Vaccinated with Mycobacterium tuberculosis Ag85B.
Differential regulation of interleukin-12 and tumour necrosis factor-alpha by phosphatidylinositol 3-kinase and ERK 1/2 pathways during Mycobacterium tuberculosis infection.
Hydrogen sulfide-induced GAPDH sulfhydration disrupts the CCAR2-SIRT1 interaction to initiate autophagy.
Intracellular network of phosphatidylinositol 3-kinase, mammalian target of the rapamycin/70 kDa ribosomal S6 kinase 1, and mitogen-activated protein kinases pathways for regulating mycobacteria-induced IL-23 expression in human macrophages.
M. tuberculosis PknG manipulates host autophagy flux to promote pathogen intracellular survival.
Role of the phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways in the secretion of tumor necrosis factor-alpha and interleukin-10 by the PPD antigen of Mycobacterium tuberculosis.
Submission for Special Issue: The Role of Platelet Activation in the Pathophysiology of HIV, Tuberculosis, and Pneumococcal Disease. Bedaquiline Suppresses ADP-Mediated Activation of Human Platelets In Vitro via Interference With Phosphatidylinositol 3-Kinase.
Tuberculosis toxin blocking phagosome maturation inhibits a novel Ca2+/calmodulin-PI3K hVPS34 cascade.
Tuberous Sclerosis
A dynamic network model of mTOR signaling reveals TSC-independent mTORC2 regulation.
Akt and mTORC1 Have Different Roles During Liver Tumorigenesis in Mice.
AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor.
Critical role of arachidonic acid-activated mTOR signaling in breast carcinogenesis and angiogenesis.
Dally Proteoglycan Mediates the Autonomous and Nonautonomous Effects on Tissue Growth Caused by Activation of the PI3K and TOR Pathways.
Dexamethasone may inhibit placental growth by blocking glucocorticoid receptors via phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin and reactive oxygen species/AMP-activated protein kinase signalling pathways in human placental JEG-3 cells.
Effect of Sishen Pill on Memory T Cells From Experimental Colitis Induced by Dextran Sulfate Sodium.
Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway.
Neuropsychological Attention Skills and Related Behaviours in Adults with Tuberous Sclerosis Complex.
New Mechanisms of mTOR Pathway Activation in KIT-mutant Malignant GISTs.
p38? senses environmental stress to control innate immune responses via mechanistic target of rapamycin.
Restraining PI3K: mTOR signalling goes back to the membrane.
Signaling crosstalk between the mTOR complexes.
Significance of dynamic changes in gastric smooth muscle cell apoptosis, PI3K-AKT-mTOR and AMPK-mTOR signaling in a rat model of diabetic gastroparesis.
Targeting phosphoinositide 3-kinase: moving towards therapy.
Targeting the phosphatidylinositol 3-kinase pathway in airway smooth muscle: rationale and promise.
The anti-tumor activator sMEK1 and paclitaxel additively decrease expression of HIF-1? and VEGF via mTORC1-S6K/4E-BP-dependent signaling pathways.
The mitochondrial uncoupler DNP triggers brain cell mTOR signaling network reprogramming and CREB pathway up-regulation.
The Putative Role of mTOR Inhibitors in Non-tuberous Sclerosis Complex-Related Epilepsy.
The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins.
Transforming Growth Factor-? Signaling Participates in the Maintenance of the Primordial Follicle Pool in the Mouse Ovary.
United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling.
Ureteral Obstruction
Increased Phosphorylation of PI3K/Akt/mTOR in the Obstructed Kidney of Rats with Unilateral Ureteral Obstruction.
Urinary Bladder Neoplasms
Combination of Rapamycin and Resveratrol for Treatment of Bladder Cancer.
Dual Inhibition of PIK3C3 and FGFR as a New Therapeutic Approach to Treat Bladder Cancer.
Expression and Functions of Formyl Peptide Receptor 1 in Drug-Resistant Bladder Cancer.
Expression of proteins FGFR3, PI3K, AKT, p21Waf1/Cip1 and cyclins D1 and D3 in patients with T1 bladder tumours: clinical implications and prognostic significance.
Genome-Wide Screen of miRNAs and Targeting mRNAs Reveals the Negatively Regulatory Effect of miR-130b-3p on PTEN by PI3K and Integrin ?1 Signaling Pathways in Bladder Carcinoma.
Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.
Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer.
Matrine inhibits bladder cancer cell growth and invasion in vitro through PI3K/AKT signaling pathway: An experimental study.
Molecular pathways of urothelial development and bladder tumorigenesis.
Naproxen induces cell-cycle arrest and apoptosis in human urinary bladder cancer cell lines and chemically induced cancers by targeting PI3K.
Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy.
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer.
Phosphatidylinositol 3-Kinase Inhibitor LY294002 Suppresses Proliferation and Sensitizes Doxorubicin Chemotherapy in Bladder Cancer Cells.
Prediction of recurrence and progression in patients with T1G3 bladder cancer by gene expression of circulating tumor cells.
Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002.
Regulation of TLR4-induced IL-6 response in bladder cancer cells by opposing actions of MAPK and PI3K signaling.
Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer.
Suppressive effect of platycodin D on bladder cancer through microRNA-129-5p-mediated PABPC1/PI3K/AKT axis inactivation.
Targeting Autophagy by MPT0L145, a Highly Potent PIK3C3 Inhibitor, Provides Synergistic Interaction to Targeted or Chemotherapeutic Agents in Cancer Cells.
The oncogenic role of the cerebral endothelial cell adhesion molecule (CERCAM) in bladder cancer cells in vitro and in vivo.
The Phosphatidylinositol 3-kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.
Therapeutic Effects of Curcumin against Bladder Cancer: A Review of Possible Molecular Pathways.
Uterine Cervical Neoplasms
17?-Oestradiol activates proteolysis and increases invasion through phosphatidylinositol 3-kinase pathway in human cervical cancer cells.
?-hydroxyisovaleryl-shikonin induces human cervical cancer cell apoptosis via PI3K/AKT/mTOR signaling.
A triphenylethylene nonsteroidal SERM attenuates cervical cancer growth.
Astragaloside IV inhibits the invasion and metastasis of SiHa cervical cancer cells via the TGF??1?mediated PI3K and MAPK pathways.
Augmentation of Sodium Butyrate-induced Apoptosis by Phosphatidylinositol 3-kinase Inhibition in the Human Cervical Cancer Cell-line.
Butein suppresses cervical cancer growth through the PI3K/AKT/mTOR pathway.
CD38 is highly expressed and affects the PI3K/Akt signaling pathway in cervical cancer.
Chimeric Nanoparticle: A Platform for Simultaneous Targeting of Phosphatidylinositol-3-Kinase Signaling and Damaging DNA in Cancer Cells.
CLIC1 promotes the progression of cervical cancer through the PTEN / PI3K / AKT pathway.
Clinical outcomes and differential effects of PI3K pathway mutation in obese versus non-obese patients with cervical cancer.
Elevated phosphatidylinositol 3-kinase activation and its clinicopathological significance in cervical cancer.
Expression of PI3K and ERK in Uygur and Han patients with cervical squamous cancer.
Fucoxanthin and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Synergistically Promotes Apoptosis of Human Cervical Cancer Cells by Targeting PI3K/Akt/NF-?B Signaling Pathway.
Fucoxanthin induces apoptosis in human cervical cancer cell line HeLa via PI3K/Akt pathway.
Genetic alterations and PIK3CA gene mutations and amplifications analysis in cervical cancer by racial groups in the United States.
Genetic and methylation-induced loss of miR-181a2/181b2 within chr9q33.3 facilitate tumor growth of cervical cancer through PIK3R3/Akt/FoxO signaling pathway.
Glutaminase Inhibitors Induce Thiol-Mediated Oxidative Stress and Radiosensitization in Treatment-Resistant Cervical Cancers.
Hypoxia stimulates invasion and migration of human cervical cancer cell lines HeLa/SiHa through the Rab11 trafficking of integrin ?v?3/FAK/PI3K pathway-mediated Rac1 activation.
Identification and characterization of HPV-independent cervical cancers.
Inhibition of Phosphatidylinositol 3-kinase (PI3K) Signaling Synergistically Potentiates Antitumor Efficacy of Paclitaxel and Overcomes Paclitaxel-Mediated Resistance in Cervical Cancer.
INPP4B restrains cell proliferation and metastasis via regulation of the PI3K/AKT/SGK pathway.
Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19?784 Diverse Solid Tumors.
Lysophosphatidic Acid Inhibits Apoptosis Induced by Cisplatin in Cervical Cancer Cells.
MicroRNA-99b suppresses human cervical cancer cell activity by inhibiting the PI3K/AKT/mTOR signaling pathway.
MicroRNA?433 inhibits cell growth and induces apoptosis in human cervical cancer through PI3K/AKT signaling by targeting FAK.
Novel strategies for molecular targeting to cancer.
Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.
Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines.
Phosphatidylinositol 3-kinase Signaling as a Therapeutic Target for Cervical Cancer.
Phosphoinositide-3-kinase inhibition enhances radiosensitization of cervical cancer in vivo.
PI3K p110? inhibition sensitizes cervical cancer cells with aberrant PI3K signaling activation to PARP inhibitor BMN673.
PI3K/AKT activation induces PTEN ubiquitination and destabilization accelerating tumourigenesis.
PI3K/AKT pathway-mediated regulation of p27(Kip1) is associated with cell cycle arrest and apoptosis in cervical cancer.
RCE?4, a potential anti?cervical cancer drug isolated from Reineckia carnea, induces autophagy via the dual blockade of PI3K and ERK pathways in cervical cancer CaSki cells.
Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer.
S100A6 promotes the proliferation and migration of cervical cancer cells via the PI3K/Akt signaling pathway.
Stathmin is involved in arsenic trioxide-induced apoptosis in human cervical cancer cell lines via PI3K linked signal pathway.
STC1 promotes cell apoptosis via NF-?B phospho-P65 Ser536 in cervical cancer cells.
Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells.
TACC3 is essential for EGF-mediated EMT in cervical cancer.
Targeting the mutant PIK3CA gene by DNA-alkylating pyrrole-imidazole polyamide in cervical cancer.
The exosome-mediated PI3k/Akt/mTOR signaling pathway in cervical cancer.
The landscape of somatic mutations in Indonesian cervical cancer is predominated by the PI3K pathway.
The TLR3, PI3K, survivin, FasL, and Fas genes as major risk factors of occurrence and development of cervical cancer disease.
Vorinostat upregulates MICA via the PI3K/Akt pathway to enhance the ability of natural killer cells to kill tumor cells.
[Influce of lysophosphatidic acid on proliferation, adhesion, migration and apoptosis of cervical cancer HeLa cells.]
Uterine Hemorrhage
ARID1A and PI3-kinase pathway mutations in the endometrium drive epithelial transdifferentiation and collective invasion.
Uterine Neoplasms
Activated Mutant p110? Causes Endometrial Carcinoma in the Setting of Biallelic Pten Deletion.
The role of the phosphatidylinositol 3-kinase (PI3K) pathway in the development and treatment of uterine cancer.
Vaccinia
A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer.
Integrin ?1 mediates vaccinia virus entry through activation of PI3K/Akt signaling.
PI3K signaling regulates rapamycin-insensitive translation initiation complex formation in vaccinia virus-infected cells.
Varicocele
Human sperm anatomy: different expression and localization of phosphatidylinositol 3-kinase in normal and varicocele human spermatozoa.
Vascular Malformations
mTORc1 activity is necessary and sufficient for phosphorylation of eNOSS1177.
PI3 kinase inhibition improves vascular malformations in mouse models of hereditary haemorrhagic telangiectasia.
Prenatal diagnosis of CLOVES syndrome confirmed by detection of a mosaic PIK3CA mutation in cultured amniocytes.
Revisiting PI3-kinase signalling in angiogenesis.
Somatic Gain of KRAS Function in the Endothelium Is Sufficient to Cause Vascular Malformations That Require MEK but Not PI3K Signaling.
Vascular System Injuries
Differential Phosphoinositide 3-Kinase Signaling: Implications for PTCA?
Naringenin-induced HO-1 ameliorates high glucose or free fatty acids-associated apoptosis via PI3K and JNK/Nrf2 pathways in human umbilical vein endothelial cells.
Neutralizing interferon-? blocks inflammation-mediated vascular injury via PI3K and AMPK in systemic lupus erythematosus.
Vasculitis
A phosphatidylinositol 3-kinase inhibitor strongly suppressed pulmonary vascular remodeling of allergic vasculitis in a murine model.
Vasospasm, Intracranial
Phosphatidylinositol 3-kinase inhibitor failed to reduce cerebral vasospasm in dog model of experimental subarachnoid hemorrhage.
Simvastatin attenuation of cerebral vasospasm after subarachnoid hemorrhage in rats via increased phosphorylation of Akt and endothelial nitric oxide synthase.
Ventilator-Induced Lung Injury
Pulmonary-derived phosphoinositide 3-kinase gamma (PI3K?) contributes to ventilator-induced lung injury and edema.
Vesicular Stomatitis
Autophagy and innate immunity: Insights from invertebrate model organisms.
HIV-1 Nef counteracts autophagy restriction by enhancing the association between BECN1 and its inhibitor BCL2 in a PRKN-dependent manner.
Influenza M2 protein regulates MAVS-mediated signaling pathway through interacting with MAVS and increasing ROS production.
TLR4/CD14-mediated PI3K activation is an essential component of interferon-dependent VSV resistance in macrophages.
Viremia
A mutation in PIK3CD gene causing pediatric systemic lupus erythematosus: A case report.
Case Study: Mechanism for Increased Follicular Helper T Cell Development in Activated PI3K Delta Syndrome.
Early diagnosis of PI3K? syndrome in a 2 years old girl with recurrent otitis and enlarged spleen.
Mutations in PIK3CD Can Cause Hyper IgM Syndrome (HIGM) Associated with Increased Cancer Susceptibility.
Virus Diseases
Activation of the phosphatidylinositol 3-kinase/Akt signaling pathway during porcine circovirus type 2 infection facilitates cell survival and viral replication.
An essential role of PI3K in the control of West Nile virus infection.
Bivalent role of the phosphatidylinositol-3-kinase (PI3K) during influenza virus infection and host cell defence.
CATION CURRENTS IN HUMAN AIRWAY EPITHELIAL CELLS INDUCED BY INFECTION WITH INFLUENZA A VIRUS.
Crimean-Congo hemorrhagic fever virus entry into host cells occurs through the multivesicular body and requires ESCRT regulators.
Early events in the generation of autophagosomes are required for the formation of membrane structures involved in hepatitis C virus genome replication.
Expression of the RAE-1 family of stimulatory NK-cell ligands requires activation of the PI3K pathway during viral infection and transformation.
Flavivirus activates phosphatidylinositol 3-kinase signaling to block caspase-dependent apoptotic cell death at the early stage of virus infection.
Impaired B cell function during viral infections due to PTEN-mediated inhibition of the PI3K pathway.
Infectious bursal disease virus activates the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway by interaction of VP5 protein with the p85? subunit of PI3K.
Influenza A virus NS1 protein activates the phosphatidylinositol 3-kinase (PI3K)/Akt pathway by direct interaction with the p85 subunit of PI3K.
Influenza A virus NS1 protein activates the PI3K/Akt pathway to mediate antiapoptotic signaling responses.
Integrin ?1 mediates vaccinia virus entry through activation of PI3K/Akt signaling.
IRF-3 activation by sendai virus infection is required for cellular apoptosis and avoidance of persistence.
Mechanism of influenza A virus NS1 protein interaction with the p85beta, but not the p85alpha, subunit of phosphatidylinositol 3-kinase (PI3K) and up-regulation of PI3K activity.
Phosphatidylinositol 3-kinase regulates macrophage responses to double-stranded RNA and encephalomyocarditis virus.
Phosphatidylinositol-3-kinase and Akt are required for RIG-I-mediated anti-viral signalling through cross-talk with IPS-1.
PI3K signaling delays Sendai virus-induced apoptosis by preventing XIAP degradation.
PI3K signalling during influenza A virus infections.
PI3K/Akt/p53 pathway inhibits reovirus infection.
PI3K? Is Critical for Dendritic Cell-Mediated CD8+ T Cell Priming and Viral Clearance during Influenza Virus Infection.
Protein kinase B/Akt regulates coxsackievirus B3 replication through a mechanism which is not caspase dependent.
SH3 binding motif 1 in influenza A virus NS1 protein is essential for PI3K/Akt signaling pathway activation.
Suppression of Virulent Porcine Epidemic Diarrhea Virus Proliferation by the PI3K/Akt/GSK-3?/? Pathway.
Targeting the PI3K and MAPK pathways to treat Kaposi's-sarcoma-associated herpes virus infection and pathogenesis.
TLR4/CD14-mediated PI3K activation is an essential component of interferon-dependent VSV resistance in macrophages.
Transient activation of the PI3K/Akt pathway promotes Newcastle disease virus replication and enhances anti-apoptotic signaling responses.
Vitiligo
Aquaporin 3 and E-Cadherin Expression in Perilesional Vitiligo Skin.
Reduced Nrf2 activation in PI3K phosphorylation-impaired vitiliginous keratinocytes increases susceptibility to ROS-generating chemical-induced apoptosis.
Vitreoretinopathy, Proliferative
All-trans retinoic acid suppresses the adhering ability of ARPE-19 cells via mitogen-activated protein kinase and focal adhesion kinase.
Waldenstrom Macroglobulinemia
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.
Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib.
Wasting Syndrome
Impaired autophagy, defective T cell homeostasis, and a wasting syndrome in mice with a T cell-specific deletion of Vps34.
Werner Syndrome
Association of impaired phosphatidylinositol 3-kinase activity in GLUT1-containing vesicles with malinsertion of glucose transporters into the plasma membrane of fibroblasts from a patient with severe insulin resistance and clinical features of Werner syndrome.
West Nile Fever
An essential role of PI3K in the control of West Nile virus infection.
Whooping Cough
1?,25-dihydroxyvitamin D3 and resolvin D1 retune the balance between amyloid-? phagocytosis and inflammation in Alzheimer's disease patients.
5-HT receptors couple to activation of Akt, but not extracellular-regulated kinase (ERK), in cultured hippocampal neurons.
A dual role of protein kinase C in insulin signal transduction via adenylyl cyclase signaling system in muscle tissues of vertebrates and invertebrates.
A novel function of Goalpha: mediation of extracellular signal-regulated kinase activation by opioid receptors in neural cells.
A novel signaling pathway for beta-adrenergic receptor-mediated activation of phosphoinositide 3-kinase in H9c2 cardiomyocytes.
Activation of delta-, kappa-, and mu-opioid receptors induces phosphorylation of tuberin in transfected HEK 293 cells and native cells.
Activation of MAPK by TRH requires clathrin-dependent endocytosis and PKC but not receptor interaction with beta-arrestin or receptor endocytosis.
Activation of phosphatidylinositol 3-kinase by concanavalin A through dual signaling pathways, G-protein-coupled and phosphotyrosine-related, and an essential role of the G-protein-coupled signals for the lectin-induced respiratory burst in human monocytic THP-1 cells.
Activation of phosphatidylinositol 3-kinase/Akt signaling pathway and endogenous nitric oxide are needed for the antiarrhythmic effect of centrally administered rilmenidine.
Activation of the G(i) heterotrimeric G protein by ANCA IgG F(ab')2 fragments is necessary but not sufficient to stimulate the recruitment of those downstream mediators used by intact ANCA IgG.
Adenosine A3 receptor-mediated regulation of p38 and extracellular-regulated kinase ERK1/2 via phosphatidylinositol-3'-kinase.
Agonist stimulation of the serotonin1A receptor causes suppression of anoxia-induced apoptosis via mitogen-activated protein kinase in neuronal HN2-5 cells.
Allosteric modulation of metabotropic glutamate receptor 4 activates IDO1-dependent, immunoregulatory signaling in dendritic cells.
Anandamide-mediated CB1/CB2 cannabinoid receptor--independent nitric oxide production in rabbit aortic endothelial cells.
Antilipolytic effect of calcium-sensing receptor in human adipocytes.
Antimicrobial peptides human beta-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells.
Antineutrophil cytoplasm autoantibodies from patients with systemic vasculitis activate neutrophils through distinct signaling cascades: comparison with conventional Fcgamma receptor ligation.
Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1.
Autotaxin promotes motility via G protein-coupled phosphoinositide 3-kinase gamma in human melanoma cells.
Biphasic Erk1/2 activation sequentially involving Gs and Gi signaling is required in beta3-adrenergic receptor-induced primary smooth muscle cell proliferation.
Bombyx adipokinetic hormone receptor activates extracellular signal-regulated kinase 1 and 2 via G protein-dependent PKA and PKC but ?-arrestin-independent pathways.
Ca(2+)-permeable AMPA receptors induce phosphorylation of cAMP response element-binding protein through a phosphatidylinositol 3-kinase-dependent stimulation of the mitogen-activated protein kinase signaling cascade in neurons.
Carbachol-induced actin reorganization involves Gi activation of Rho in human airway smooth muscle cells.
Characterization of a G protein-activated phosphoinositide 3-kinase in vascular smooth muscle cell nuclei.
Characterization of rac and cdc42 activation in chemoattractant-stimulated human neutrophils using a novel assay for active GTPases.
Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells.
Coupling of serotonin 5-HT1B receptors to activation of mitogen-activated protein kinase (ERK-2) and p70 S6 kinase signaling systems.
CXC chemokine receptor 4 expression and function in human anaplastic thyroid cancer cells.
CXCL12 activation of CXCR4 regulates mucosal host defense through stimulation of epithelial cell migration and promotion of intestinal barrier integrity.
CXCL16 signals via Gi, phosphatidylinositol 3-kinase, Akt, I kappa B kinase, and nuclear factor-kappa B and induces cell-cell adhesion and aortic smooth muscle cell proliferation.
Dehydroepiandrosterone Activation of G-protein-coupled Estrogen Receptor Rapidly Stimulates MicroRNA-21 Transcription in Human Hepatocellular Carcinoma Cells.
Differential calcium regulation of proinflammatory activities in human neutrophils exposed to the neuropeptide pituitary adenylate cyclase-activating protein.
Differential fMet-Leu-Phe- and platelet-activating factor-induced signaling toward Ral activation in primary human neutrophils.
Dose-dependent activation of antiapoptotic and proapoptotic pathways by ethanol treatment in human vascular endothelial cells: differential involvement of adenosine.
Elastin peptides activate extracellular signal-regulated kinase 1/2 via a Ras-independent mechanism requiring both p110gamma/Raf-1 and protein kinase A/B-Raf signaling in human skin fibroblasts.
Eotaxin/CCL11 suppresses IL-8/CXCL8 secretion from human dermal microvascular endothelial cells.
Epidermal growth factor differentially augments G(i)-mediated stimulation of c-Jun N-terminal kinase activity.
fMLP-induced in vitro nitric oxide production and its regulation in murine peritoneal macrophages.
Functional and structural consequences of chemokine (C-X-C motif) receptor 4 activation with cognate and non-cognate agonists.
G protein-coupled APJ receptor signaling induces focal adhesion formation and cell motility.
Galanin and galanin receptor type 1 suppress proliferation in squamous carcinoma cells: activation of the extracellular signal regulated kinase pathway and induction of cyclin-dependent kinase inhibitors.
Galpha i2 enhances in vivo activation of and insulin signaling to GLUT4.
Ginsenoside Rb1 protects against 6-hydroxydopamine-induced oxidative stress by increasing heme oxygenase-1 expression through an estrogen receptor-related PI3K/Akt/Nrf2-dependent pathway in human dopaminergic cells.
HDL and sphingosine-1-phosphate activate stat3 in prostate cancer DU145 cells via ERK1/2 and S1P receptors, and promote cell migration and invasion.
Inhibition of chemokine (C-X-C motif) ligand 12/chemokine (C-X-C motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells.
Inhibition of neutrophil apoptosis by PAI-1.
Inhibitory phosphorylation of soluble guanylyl cyclase by muscarinic m2 receptors via Gbetagamma-dependent activation of c-Src kinase.
Insulin-like growth factor-I induces alpha(1B)-adrenergic receptor phosphorylation through G beta gamma and epidermal growth factor receptor transactivation.
Involvement of G(i) proteins and Src tyrosine kinase in TNFalpha production induced by lipopolysaccharide, group B Streptococci and Staphylococcus aureus.
Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor signals through multiple pathways in endothelial cells.
KATP channels in the nodose ganglia mediate the orexigenic actions of ghrelin.
Leptin Elicits LTC4 Synthesis by Eosinophils Mediated by Sequential Two-Step Autocrine Activation of CCR3 and PGD2 Receptors.
Leukotriene B4 mediates vascular smooth muscle cell migration through ?v?3 integrin transactivation.
Lysophosphatidic acid inhibits CC chemokine ligand 5/RANTES production by blocking IRF-1-mediated gene transcription in human bronchial epithelial cells.
Lysophosphatidic acid modulates alpha(1b)-adrenoceptor phosphorylation and function: roles of Gi and phosphoinositide 3-kinase.
Lysophosphatidic acid sensitizes mechanical stress-induced Ca2+ response via activation of phospholipase C and tyrosine kinase in cultured smooth muscle cells.
Lysophosphatidic Acid Triggers Apoptosis in HeLa Cells through the Upregulation of Tumor Necrosis Factor Receptor Superfamily Member 21.
Lysophosphatidylcholine activates p38 and p42/44 mitogen-activated protein kinases in monocytic THP-1 cells, but only p38 activation is involved in its stimulated chemotaxis.
Mechanism of phytoestrogen puerarin-mediated cytoprotection following oxidative injury: estrogen receptor-dependent up-regulation of PI3K/Akt and HO-1.
Mechanisms and modulation of pituitary adenylate cyclase-activating protein-induced calcium mobilization in human neutrophils.
Mechanisms of endothelin 1-stimulated proliferation in colorectal cancer cell lines.
Melanocortin-3 receptor activates MAP kinase via PI3 kinase.
Membrane electrical activity elicits inositol 1,4,5-trisphosphate-dependent slow Ca2+ signals through a Gbetagamma/phosphatidylinositol 3-kinase gamma pathway in skeletal myotubes.
Molecular pathways mediating activation by kainate of mitogen-activated protein kinase in oligodendrocyte progenitors.
Monocyte chemoattractant protein-1-induced activation of p42/44 MAPK and c-Jun in murine peritoneal macrophages: a potential pathway for macrophage activation.
Multiple Signaling Pathways Contribute to the Thrombin-induced Secretory Phenotype in Vascular Smooth Muscle Cells.
N-methyl D-aspartate receptor-mediated bidirectional control of extracellular signal-regulated kinase activity in cortical neuronal cultures.
Native group-III metabotropic glutamate receptors are coupled to the mitogen-activated protein kinase/phosphatidylinositol-3-kinase pathways.
Noradrenaline and alpha-adrenergic signaling induce the hsp70 gene promoter in mollusc immune cells.
Norepinephrine activates extracellular-regulated kinase in cortical neurons.
Orexin-A protects against oxygen-glucose deprivation/reoxygenation-induced cell damage by inhibiting endoplasmic reticulum stress-mediated apoptosis via the Gi and PI3K signaling pathways.
P2Y12 receptor stimulation inhibits beta-adrenergic receptor-induced differentiation by reversing the cyclic AMP-dependent inhibition of protein kinase B.
Permeabilization in a cerebral endothelial barrier model by pertussis toxin involves the PKC effector pathway and is abolished by elevated levels of cAMP.
Pertussis Toxin, an Inhibitor of G(?i) PCR, Inhibits Bile Acid- and Cytokine-Induced Apoptosis in Primary Rat Hepatocytes.
Pertussis toxin-sensitive and insensitive intracellular signalling pathways in undifferentiated 3T3-L1 cells stimulated by insulin converge with phosphatidylinositol 3-kinase upstream of the Ras mitogen-activated protein kinase cascade.
Phosphatidylinositol 3-kinase functionally compartmentalizes the concurrent G(s) signaling during beta2-adrenergic stimulation.
Platelet factor 4 induces human natural killer cells to synthesize and release interleukin-8.
Platelet-conditioned medium increases endothelial electrical resistance independently of cAMP/PKA and cGMP/PKG.
Possible involvement of C-C chemokines in functional augmentation of adhesion molecules in asthmatic patients.
Prostaglandin E2-EP3 signaling induces inflammatory swelling by mast cell activation.
Protective effects of morphine in peroxynitrite-induced apoptosis of primary rat neonatal astrocytes: potential involvement of G protein and phosphatidylinositol 3-kinase (PI3 kinase).
Rapid Remodeling of Invadosomes by Gi-coupled Receptors: DISSECTING THE ROLE OF Rho GTPases.
Rat white adipocytes activate p85/p110 PI3K and induce PM GLUT4 in response to adrenoceptor agonists or aluminum fluoride.
Regulation of expression of early growth response transcription factors in rat primary cortical neurons by extracellular ATP.
Regulation of STAT3 by mu-opioid receptors in human neuroblastoma SH-SY5Y cells.
Regulator of G-protein signalling 3 redirects prototypical Gi-coupled receptors from Rac1 to RhoA activation.
Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide.
Role of p38 mitogen-activated kinase and c-Jun terminal kinase in migration response to lysophosphatidic acid and sphingosine-1-phosphate in glioma cells.
Role of phosphatidylinositol 3-kinase in the binding of Bordetella pertussis to human monocytes.
Role of phosphatidylinositol 3-kinase in the development of hepatocyte preconditioning.
Saposin C promotes survival and prevents apoptosis via PI3K/Akt-dependent pathway in prostate cancer cells.
Secretory IgA-mediated basophil activation. II. Roles of GTP-binding regulatory proteins and phosphatidylinositol 3-kinase.
Selective ?1B- and ?1D-adrenoceptor antagonists suppress noradrenaline-induced activation, proliferation and ECM secretion of rat hepatic stellate cells in vitro.
Signal transduction pathways for activation of extracellular signal-regulated kinase by arachidonic acid in rat neutrophils.
Signaling pathways leading to phosphorylation of Akt and GSK-3{beta} by activation of cloned human and cerebral rat D2 and D3 receptors.
Signalling pathways involved in the chemotactic activity of CXCL12 in cultured rat cerebellar neurons and CHP100 neuroepithelioma cells.
Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1).
Sphingosine 1-phosphate triggers both apoptotic and survival signals for human hepatic myofibroblasts.
Sphingosine-1-phosphate activates the AKT pathway to inhibit chemotherapy induced human granulosa cell apoptosis.
Sphingosine-1-phosphate stimulates human glioma cell proliferation through Gi-coupled receptors: role of ERK MAP kinase and phosphatidylinositol 3-kinase beta.
Stimulation of human neutrophils by chemotactic factors is associated with the activation of phosphatidylinositol 3-kinase gamma.
Stimulation of the extracellular signal-regulated kinase 1/2 pathway by human beta-3 adrenergic receptor: new pharmacological profile and mechanism of activation.
Store-operated Ca2+ influx and stimulation of exocytosis in HL-60 granulocytes.
Study of the functional organization of a novel adenylate cyclase signaling mechanism of insulin action.
Synthesis of phosphatidylinositol 3,4,5-trisphosphate in permeabilized neutrophils regulated by receptors and G-proteins.
TG1019/OXE, a Galpha(i/o)-protein-coupled receptor, mediates 5-oxo-eicosatetraenoic acid-induced chemotaxis.
The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase.
The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt.
The chemokine CX3CL1 reduces migration and increases adhesion of neurons with mechanisms dependent on the beta1 integrin subunit.
The isoflavone Equol mediates rapid vascular relaxation: Ca2+-independent activation of endothelial nitric-oxide synthase/Hsp90 involving ERK1/2 and Akt phosphorylation in human endothelial cells.
The K+-ATP channel-independent pathway of regulation of insulin secretion by glucose: in search of the underlying mechanism.
Thrombin induces neoangiogenesis in the chick chorioallantoic membrane.
TIMP-1 inhibits apoptosis in breast carcinoma cells via a pathway involving pertussis toxin-sensitive G protein and c-Src.
Wnt-5a and G-protein signaling are required for collagen-induced DDR1 receptor activation and normal mammary cell adhesion.
[Influence of pertussis toxin on GPER-mediated activation of phosphatidylinositol 3-kinase/protein kinase B signaling induced by 17?-estradiol in endometrial carcinoma cells].
Wilms Tumor
Central role of PI3K in transcriptional activation of hTERT in HTLV-I-infected cells.
MiR-155-5p exerts tumor-suppressing functions in Wilms tumor by targeting IGF2 via the PI3K signaling pathway.
Wiskott-Aldrich Syndrome
The mechanism of CSF-1-induced Wiskott-Aldrich syndrome protein activation in vivo: a role for phosphatidylinositol 3-kinase and Cdc42.
Wiskott-Aldrich Syndrome Interacting Protein Deficiency Uncovers the Role of the Co-receptor CD19 as a Generic Hub for PI3 Kinase Signaling in B Cells.
Yellow Fever
Identification and characterization of the catalytic subunit of phosphatidylinositol 3-kinase in the yellow fever mosquito Aedes aegypti.
Zika Virus Infection
Mechanistic Target of Rapamycin (mTOR) Signaling Activation Antagonizes Autophagy to Facilitate Zika Virus Replication.
Zika virus infection differentially affects genome-wide transcription in neuronal cells and myeloid dendritic cells.